
The following have been reloaded with a version change:
  1) GCCcore/8.3.0 => GCCcore/9.3.0
  2) binutils/2.32-GCCcore-8.3.0 => binutils/2.34-GCCcore-9.3.0
  3) zlib/1.2.11-GCCcore-8.3.0 => zlib/1.2.11-GCCcore-9.3.0

2021-02-05 13:32:29 | INFO | fairseq_cli.generate | Namespace(all_gather_list_size=16384, beam=5, bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', cpu=False, criterion='cross_entropy', data='../../../data-bin/phrase4_0.5_EMEA/', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eval_bleu=True, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, force_anneal=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, left_pad_source='True', left_pad_target='False', lenpen=1, load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_sentences=128, max_source_positions=1024, max_target_positions=1024, max_tokens=None, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, momentum=0.99, nbest=1, no_beamable_mm=False, no_early_stop=False, no_progress_bar=False, no_repeat_ngram_size=0, no_seed_provided=True, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer='nag', path='../checkpoints/EMEA_p_4_1/checkpoint_best.pt', prefix_size=0, print_alignment=False, print_step=False, profile=False, quantization_config_path=None, quiet=False, remove_bpe='@@ ', replace_unk=None, required_batch_size_multiple=8, results_path=None, retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, score_reference=False, scoring='sacrebleu', seed=1, shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, target_lang=None, task='translation', temperature=1.0, tensorboard_logdir='', threshold_loss_scale=None, tokenizer=None, tpu=False, truncate_source=False, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, warmup_updates=0, weight_decay=0.0)
2021-02-05 13:32:30 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2021-02-05 13:32:30 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2021-02-05 13:32:30 | INFO | fairseq.data.data_utils | loaded 2001 examples from: ../../../data-bin/phrase4_0.5_EMEA/test.de-en.de
2021-02-05 13:32:30 | INFO | fairseq.data.data_utils | loaded 2001 examples from: ../../../data-bin/phrase4_0.5_EMEA/test.de-en.en
2021-02-05 13:32:30 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase4_0.5_EMEA/ test de-en 2001 examples
2021-02-05 13:32:30 | INFO | fairseq_cli.generate | loading model(s) from ../checkpoints/EMEA_p_4_1/checkpoint_best.pt
S-533	Welchen Nutzen hat Advate in diesen Studien gezeigt ?
T-533	What benefit has Advate shown during the studies ?
H-533	-0.423723965883255	What benefit has Advate shown in these trials ?
D-533	-0.423723965883255	What benefit has Advate shown in these trials ?
P-533	-0.1285 -1.0351 -0.6230 -0.4657 -0.0900 -0.3676 -0.1560 -0.1079 -1.0081 -0.5248 -0.1542
S-1044	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1044	- Use within three hours after reconstitution .
H-1044	-0.2850917875766754	- Use within three hours of reconstitution .
D-1044	-0.2850917875766754	- Use within three hours of reconstitution .
P-1044	-0.2927 -0.3625 -0.2080 -0.3889 -0.0725 -0.7649 -0.2022 -0.1635 -0.2366 -0.1592
S-263	Die Bedeutung dieser Beobachtung für den Menschen ist nicht bekannt .
T-263	The relevance to humans is unknown .
H-263	-0.44635874032974243	The significance of this observation for humans is unknown .
D-263	-0.44635874032974243	The significance of this observation for humans is unknown .
P-263	-0.2863 -1.1686 -0.2907 -0.2763 -0.5546 -0.0433 -0.3404 -1.0786 -0.1768 -0.8313 -0.1556 -0.1539
S-459	Die Bedeutung dieser Beobachtung für den Menschen ist nicht bekannt .
T-459	The relevance to humans is unknown .
H-459	-0.44635874032974243	The significance of this observation for humans is unknown .
D-459	-0.44635874032974243	The significance of this observation for humans is unknown .
P-459	-0.2863 -1.1686 -0.2907 -0.2763 -0.5546 -0.0433 -0.3404 -1.0786 -0.1768 -0.8313 -0.1556 -0.1539
S-868	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-868	- Use within three hours after reconstitution .
H-868	-0.2850917875766754	- Use within three hours of reconstitution .
D-868	-0.2850917875766754	- Use within three hours of reconstitution .
P-868	-0.2927 -0.3625 -0.2080 -0.3889 -0.0725 -0.7649 -0.2022 -0.1635 -0.2366 -0.1592
S-692	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-692	- Use within three hours after reconstitution .
H-692	-0.2850917875766754	- Use within three hours of reconstitution .
D-692	-0.2850917875766754	- Use within three hours of reconstitution .
P-692	-0.2927 -0.3625 -0.2080 -0.3889 -0.0725 -0.7649 -0.2022 -0.1635 -0.2366 -0.1592
S-1220	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1220	- Use within three hours after reconstitution .
H-1220	-0.2850917875766754	- Use within three hours of reconstitution .
D-1220	-0.2850917875766754	- Use within three hours of reconstitution .
P-1220	-0.2927 -0.3625 -0.2080 -0.3889 -0.0725 -0.7649 -0.2022 -0.1635 -0.2366 -0.1592
S-1396	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1396	- Use within three hours after reconstitution .
H-1396	-0.2850917875766754	- Use within three hours of reconstitution .
D-1396	-0.2850917875766754	- Use within three hours of reconstitution .
P-1396	-0.2927 -0.3625 -0.2080 -0.3889 -0.0725 -0.7649 -0.2022 -0.1635 -0.2366 -0.1592
S-1573	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1573	- Use within three hours after reconstitution .
H-1573	-0.2850917875766754	- Use within three hours of reconstitution .
D-1573	-0.2850917875766754	- Use within three hours of reconstitution .
P-1573	-0.2927 -0.3625 -0.2080 -0.3889 -0.0725 -0.7649 -0.2022 -0.1635 -0.2366 -0.1592
S-1883	Wie lautete die Empfehlung des CHMP zu diesem Zeitpunkt ?
T-1883	What was the recommendation of the CHMP at that time ?
H-1883	-0.47435635328292847	What was the CHMP recommendation at that time ?
D-1883	-0.47435635328292847	What was the CHMP recommendation at that time ?
P-1883	-0.1170 -0.4252 -0.3680 -0.2036 -0.0419 -0.9789 -0.1331 -0.2172 -1.2354 -1.2928 -0.5284 -0.1507
S-700	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-700	Place the vials on a flat clean surface .
H-700	-0.2990943491458893	Place the vials on a level surface .
D-700	-0.2990943491458893	Place the vials on a level surface .
P-700	-0.4746 -0.5374 -0.0304 -0.0813 -0.1746 -0.7593 -0.5032 -0.1040 -0.1700 -0.1562
S-1052	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1052	Place the vials on a flat clean surface .
H-1052	-0.2990943491458893	Place the vials on a level surface .
D-1052	-0.2990943491458893	Place the vials on a level surface .
P-1052	-0.4746 -0.5374 -0.0304 -0.0813 -0.1746 -0.7593 -0.5032 -0.1040 -0.1700 -0.1562
S-22	Reproduction is authorised provided the source is acknowledged .
T-22	Reproduction is authorised provided the source is acknowledged .
H-22	-0.30235373973846436	Reproduction is authorised provided the source is acknowledged .
D-22	-0.30235373973846436	Reproduction is authorised provided the source is acknowledged .
P-22	-0.3224 -0.2893 -0.1561 -0.4926 -0.2161 -0.0874 -0.1618 -0.0735 -0.1488 -1.3188 -0.2074 -0.1541
S-1228	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1228	Place the vials on a flat clean surface .
H-1228	-0.2990943491458893	Place the vials on a level surface .
D-1228	-0.2990943491458893	Place the vials on a level surface .
P-1228	-0.4746 -0.5374 -0.0304 -0.0813 -0.1746 -0.7593 -0.5032 -0.1040 -0.1700 -0.1562
S-1404	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1404	Place the vials on a flat clean surface .
H-1404	-0.2990943491458893	Place the vials on a level surface .
D-1404	-0.2990943491458893	Place the vials on a level surface .
P-1404	-0.4746 -0.5374 -0.0304 -0.0813 -0.1746 -0.7593 -0.5032 -0.1040 -0.1700 -0.1562
S-1581	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1581	Place the vials on a flat clean surface .
H-1581	-0.2990943491458893	Place the vials on a level surface .
D-1581	-0.2990943491458893	Place the vials on a level surface .
P-1581	-0.4746 -0.5374 -0.0304 -0.0813 -0.1746 -0.7593 -0.5032 -0.1040 -0.1700 -0.1562
S-876	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-876	Place the vials on a flat clean surface .
H-876	-0.2990943491458893	Place the vials on a level surface .
D-876	-0.2990943491458893	Place the vials on a level surface .
P-876	-0.4746 -0.5374 -0.0304 -0.0813 -0.1746 -0.7593 -0.5032 -0.1040 -0.1700 -0.1562
S-1875	Reproduction is authorised provided the source is acknowledged .
T-1875	Reproduction is authorised provided the source is acknowledged .
H-1875	-0.30235373973846436	Reproduction is authorised provided the source is acknowledged .
D-1875	-0.30235373973846436	Reproduction is authorised provided the source is acknowledged .
P-1875	-0.3224 -0.2893 -0.1561 -0.4926 -0.2161 -0.0874 -0.1618 -0.0735 -0.1488 -1.3188 -0.2074 -0.1541
S-35	Die zweite Studie erbrachte ähnliche Ergebnisse nach einem Jahr .
T-35	Similar results were seen in the second study after a year .
H-35	-0.4894125759601593	The second trial yielded similar results after one year .
D-35	-0.4894125759601593	The second trial yielded similar results after one year .
P-35	-0.2440 -0.0814 -1.6626 -1.9920 -0.0320 -0.1090 -0.1858 -0.1418 -1.2405 -0.1967 -0.1446 -0.1808 -0.1511
S-693	- Nach Rekonstitution nicht mehr kühlen .
T-693	- Do not refrigerate the preparation after reconstitution .
H-693	-0.613556444644928	- Do not cool after reconstitution .
D-693	-0.613556444644928	- Do not cool after reconstitution .
P-693	-0.6458 -0.2272 -0.1352 -3.1156 -0.6299 -0.2096 -0.2016 -0.1988 -0.1584
S-1045	- Nach Rekonstitution nicht mehr kühlen .
T-1045	- Do not refrigerate the preparation after reconstitution .
H-1045	-0.613556444644928	- Do not cool after reconstitution .
D-1045	-0.613556444644928	- Do not cool after reconstitution .
P-1045	-0.6458 -0.2272 -0.1352 -3.1156 -0.6299 -0.2096 -0.2016 -0.1988 -0.1584
S-1739	Im Zweifelsfall fragen Sie Ihren Arzt .
T-1739	If you are unsure about this , ask your doctor .
H-1739	-0.4401404559612274	If in doubt , ask your doctor .
D-1739	-0.4401404559612274	If in doubt , ask your doctor .
P-1739	-1.3337 -0.1362 -0.3489 -0.9577 -0.5791 -0.1531 -0.1069 -0.1865 -0.1592
S-869	- Nach Rekonstitution nicht mehr kühlen .
T-869	- Do not refrigerate the preparation after reconstitution .
H-869	-0.613556444644928	- Do not cool after reconstitution .
D-869	-0.613556444644928	- Do not cool after reconstitution .
P-869	-0.6458 -0.2272 -0.1352 -3.1156 -0.6299 -0.2096 -0.2016 -0.1988 -0.1584
S-288	Vitamin D einmal pro Tag wurde nicht untersucht .
T-288	The equivalence of intake of 5600 IU of vitamin D3 weekly in ADROVANCE to daily dosing of vitamin D 800 IU has not been studied .
H-288	-0.3749571144580841	vitamin D supplementation once a day has not been investigated .
D-288	-0.3749571144580841	vitamin D supplementation once a day has not been investigated .
P-288	-0.5055 -0.0678 -0.1441 -1.4129 -0.0301 -0.1375 -0.0378 -0.5744 -0.1048 -0.5990 -0.1153 -0.1339 -1.3639 -0.2433 -0.1540
S-1855	Wofür sollte Advexin angewendet werden ?
T-1855	What was Advexin expected to be used for ?
H-1855	-0.2520744204521179	What should Advexin be used for ?
D-1855	-0.2520744204521179	What should Advexin be used for ?
P-1855	-0.1192 -0.1969 -0.7661 -0.1740 -0.1395 -0.1082 -0.1563 -0.1277 -0.5757 -0.1571
S-1397	- Nach Rekonstitution nicht mehr kühlen .
T-1397	- Do not refrigerate the preparation after reconstitution .
H-1397	-0.613556444644928	- Do not cool after reconstitution .
D-1397	-0.613556444644928	- Do not cool after reconstitution .
P-1397	-0.6458 -0.2272 -0.1352 -3.1156 -0.6299 -0.2096 -0.2016 -0.1988 -0.1584
S-1221	- Nach Rekonstitution nicht mehr kühlen .
T-1221	- Do not refrigerate the preparation after reconstitution .
H-1221	-0.613556444644928	- Do not cool after reconstitution .
D-1221	-0.613556444644928	- Do not cool after reconstitution .
P-1221	-0.6458 -0.2272 -0.1352 -3.1156 -0.6299 -0.2096 -0.2016 -0.1988 -0.1584
S-1574	- Nach Rekonstitution nicht mehr kühlen .
T-1574	- Do not refrigerate the preparation after reconstitution .
H-1574	-0.613556444644928	- Do not cool after reconstitution .
D-1574	-0.613556444644928	- Do not cool after reconstitution .
P-1574	-0.6458 -0.2272 -0.1352 -3.1156 -0.6299 -0.2096 -0.2016 -0.1988 -0.1584
S-635	Verletzung , Vergiftung und durch Eingriffe
T-635	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-635	-0.6055084466934204	injury , poisoning and surgery
D-635	-0.6055084466934204	injury , poisoning and surgery
P-635	-0.5714 -0.1426 -0.5374 -0.1696 -0.4162 -2.2034 -0.1980
S-715	Nur klare , farblose Lösungen verwenden .
T-715	Only a clear and colourless solution should be used .
H-715	-0.31215623021125793	Use only clear , colourless solutions .
D-715	-0.31215623021125793	Use only clear , colourless solutions .
P-715	-0.3899 -1.3986 -0.1870 -0.3506 -0.0593 -0.1104 -0.0964 -0.1579 -0.2144 -0.1569
S-546	Die Genehmigung wurde am 2. März 2009 verlängert .
T-546	The marketing authorisation was renewed on 2 March 2009.
H-546	-0.3368927538394928	The authorisation was renewed on 2 March 2009 .
D-546	-0.3368927538394928	The authorisation was renewed on 2 March 2009 .
P-546	-0.5367 -0.6889 -0.0483 -0.3619 -1.1315 -0.1021 -0.1671 -0.1604 -0.1559 -0.2012 -0.1520
S-1067	Nur klare , farblose Lösungen verwenden .
T-1067	Only a clear and colourless solution should be used .
H-1067	-0.31215623021125793	Use only clear , colourless solutions .
D-1067	-0.31215623021125793	Use only clear , colourless solutions .
P-1067	-0.3899 -1.3986 -0.1870 -0.3506 -0.0593 -0.1104 -0.0964 -0.1579 -0.2144 -0.1569
S-1921	In der zweiten Studie wurden ähnliche Ergebnisse beobachtet .
T-1921	Similar results were seen in the second study .
H-1921	-0.3594281077384949	Similar results were observed in the second study .
D-1921	-0.3594281077384949	Similar results were observed in the second study .
P-1921	-0.7176 -0.0822 -0.4545 -0.2870 -0.5667 -0.1441 -0.1856 -0.0972 -1.1159 -0.1507 -0.1522
S-1885	Was waren die wesentlichen Bedenken des CHMP ?
T-1885	What were the main concerns of the CHMP ?
H-1885	-0.4579361379146576	What were the CHMP &apos;s main concerns ?
D-1885	-0.4579361379146576	What were the CHMP &apos;s main concerns ?
P-1885	-0.0789 -0.3809 -0.4952 -1.4027 -0.0423 -0.9188 -0.3584 -0.1778 -0.5728 -0.1516
S-891	Nur klare , farblose Lösungen verwenden .
T-891	Only a clear and colourless solution should be used .
H-891	-0.31215623021125793	Use only clear , colourless solutions .
D-891	-0.31215623021125793	Use only clear , colourless solutions .
P-891	-0.3899 -1.3986 -0.1870 -0.3506 -0.0593 -0.1104 -0.0964 -0.1579 -0.2144 -0.1569
S-1723	- Dieses Arzneimittel wurde Ihnen verschrieben .
T-1723	- This medicine has been prescribed for you .
H-1723	-0.4017469882965088	- This medicine has been prescribed to you .
D-1723	-0.4017469882965088	- This medicine has been prescribed to you .
P-1723	-0.5235 -0.2936 -1.0762 -0.8185 -0.1160 -0.1181 -0.0690 -0.9453 -0.0803 -0.2170 -0.1619
S-1243	Nur klare , farblose Lösungen verwenden .
T-1243	Only a clear and colourless solution should be used .
H-1243	-0.31215623021125793	Use only clear , colourless solutions .
D-1243	-0.31215623021125793	Use only clear , colourless solutions .
P-1243	-0.3899 -1.3986 -0.1870 -0.3506 -0.0593 -0.1104 -0.0964 -0.1579 -0.2144 -0.1569
S-1419	Nur klare , farblose Lösungen verwenden .
T-1419	Only a clear and colourless solution should be used .
H-1419	-0.31215623021125793	Use only clear , colourless solutions .
D-1419	-0.31215623021125793	Use only clear , colourless solutions .
P-1419	-0.3899 -1.3986 -0.1870 -0.3506 -0.0593 -0.1104 -0.0964 -0.1579 -0.2144 -0.1569
S-1596	Nur klare , farblose Lösungen verwenden .
T-1596	Only a clear and colourless solution should be used .
H-1596	-0.31215623021125793	Use only clear , colourless solutions .
D-1596	-0.31215623021125793	Use only clear , colourless solutions .
P-1596	-0.3899 -1.3986 -0.1870 -0.3506 -0.0593 -0.1104 -0.0964 -0.1579 -0.2144 -0.1569
S-1724	Es darf nicht an Dritte weitergegeben werden .
T-1724	Es darf nicht an Dritte weitergegeben werden . It may harm them , even
H-1724	-0.4294763207435608	Do not disclose it to third parties .
D-1724	-0.4294763207435608	Do not disclose it to third parties .
P-1724	-1.1122 -0.1366 -1.1019 -0.2232 -0.7176 -0.1635 -0.2811 -0.2218 -0.1796 -0.1572
S-633	Gelegentlich Gelegentlich Gelegentlich
T-633	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-633	-0.10281810909509659	Uncommon Uncommon Uncommon
D-633	-0.10281810909509659	Uncommon Uncommon Uncommon
P-633	-0.1248 -0.0841 -0.0881 -0.0964 -0.0842 -0.0759 -0.1661
S-629	Erkrankungen des Gastrointestinaltrakts
T-629	5 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-629	-0.1157950609922409	Gastrointestinal disorders
D-629	-0.1157950609922409	Gastrointestinal disorders
P-629	-0.0341 -0.0865 -0.1614 -0.1594 -0.0902 -0.0852 -0.0752 -0.2344
S-1793	Arzneimittel für Kinder unzugänglich aufbewahren .
T-1793	Keep out of the reach and sight of children .
H-1793	-0.3859097957611084	Keep out of the reach of children .
D-1793	-0.3859097957611084	Keep out of the reach of children .
P-1793	-1.2222 -0.8366 -0.1211 -0.6919 -0.0174 -0.1136 -0.1488 -0.1625 -0.1591
S-1406	Das Transfersystem nicht aus der Verpackung
T-1406	Do not remove the device from the package .
H-1406	-0.49376380443573	Do not take the transfer system out of the package
D-1406	-0.49376380443573	Do not take the transfer system out of the package
P-1406	-0.7128 -0.1357 -0.4680 -0.2332 -0.1074 -0.6451 -0.2085 -0.1277 -0.3688 -2.2644 -0.1596
S-1583	Das Transfersystem nicht aus der Verpackung
T-1583	Do not remove the device from the package .
H-1583	-0.49376380443573	Do not take the transfer system out of the package
D-1583	-0.49376380443573	Do not take the transfer system out of the package
P-1583	-0.7128 -0.1357 -0.4680 -0.2332 -0.1074 -0.6451 -0.2085 -0.1277 -0.3688 -2.2644 -0.1596
S-1666	Vor der Anwendung Gebrauchsinformation lesen .
T-1666	Vor der Anwendung Gebrauchsinformation lesen . Single use only .
H-1666	-0.6005427837371826	Read the leaflet before use .
D-1666	-0.6005427837371826	Read the leaflet before use .
P-1666	-0.9942 -1.9934 -1.3049 -0.0427 -0.1639 -0.4531 -0.1209 -0.1758 -0.1559
S-1230	Das Transfersystem nicht aus der Verpackung
T-1230	Do not remove the device from the package .
H-1230	-0.49376380443573	Do not take the transfer system out of the package
D-1230	-0.49376380443573	Do not take the transfer system out of the package
P-1230	-0.7128 -0.1357 -0.4680 -0.2332 -0.1074 -0.6451 -0.2085 -0.1277 -0.3688 -2.2644 -0.1596
S-1054	Das Transfersystem nicht aus der Verpackung
T-1054	Do not remove the device from the package .
H-1054	-0.49376380443573	Do not take the transfer system out of the package
D-1054	-0.49376380443573	Do not take the transfer system out of the package
P-1054	-0.7128 -0.1357 -0.4680 -0.2332 -0.1074 -0.6451 -0.2085 -0.1277 -0.3688 -2.2644 -0.1596
S-878	Das Transfersystem nicht aus der Verpackung
T-878	Do not remove the device from the package .
H-878	-0.49376380443573	Do not take the transfer system out of the package
D-878	-0.49376380443573	Do not take the transfer system out of the package
P-878	-0.7128 -0.1357 -0.4680 -0.2332 -0.1074 -0.6451 -0.2085 -0.1277 -0.3688 -2.2644 -0.1596
S-1804	Diese Maßnahme hilft die Umwelt zu schützen .
T-1804	These measures will help to protect the environment .
H-1804	-0.49024271965026855	These measures help to protect the environment .
D-1804	-0.49024271965026855	These measures help to protect the environment .
P-1804	-1.7704 -0.1060 -0.9444 -0.8465 -0.1162 -0.1509 -0.1714 -0.1500 -0.1563
S-702	Das Transfersystem nicht aus der Verpackung
T-702	Do not remove the device from the package .
H-702	-0.49376380443573	Do not take the transfer system out of the package
D-702	-0.49376380443573	Do not take the transfer system out of the package
P-702	-0.7128 -0.1357 -0.4680 -0.2332 -0.1074 -0.6451 -0.2085 -0.1277 -0.3688 -2.2644 -0.1596
S-1715	vor der Anwendung Gebrauchsinformation lesen .
T-1715	vor der Anwendung Gebrauchsinformation lesen . Single use only .
H-1715	-0.46919119358062744	read leaflets before use .
D-1715	-0.46919119358062744	read leaflets before use .
P-1715	-0.2483 -1.1645 -0.0373 -1.1982 -0.6609 -0.0922 -0.1952 -0.1569
S-1745	Sie sollten über frühe Anzeichen einer solchen
T-1745	Sie sollten über frühe Anzeichen einer solchen These symptoms can constitute an early
H-1745	-0.33358800411224365	You should be aware of early signs of such
D-1745	-0.33358800411224365	You should be aware of early signs of such
P-1745	-0.7039 -0.1464 -0.6112 -0.2577 -0.1370 -0.3541 -0.1108 -0.1876 -0.6704 -0.1568
S-806	0,85 0,43 0,43 0,43
T-806	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-806	-0.15031757950782776	0.85 0.43 0.43 0.43
D-806	-0.15031757950782776	0.85 0.43 0.43 0.43
P-806	-0.1925 -0.1318 -0.2234 -0.0736 -0.1948 -0.0761 -0.2329 -0.0769 -0.1509
S-982	0,85 0,43 0,43 0,43
T-982	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-982	-0.15031757950782776	0.85 0.43 0.43 0.43
D-982	-0.15031757950782776	0.85 0.43 0.43 0.43
P-982	-0.1925 -0.1318 -0.2234 -0.0736 -0.1948 -0.0761 -0.2329 -0.0769 -0.1509
S-1158	0,85 0,43 0,43 0,43
T-1158	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-1158	-0.15031757950782776	0.85 0.43 0.43 0.43
D-1158	-0.15031757950782776	0.85 0.43 0.43 0.43
P-1158	-0.1925 -0.1318 -0.2234 -0.0736 -0.1948 -0.0761 -0.2329 -0.0769 -0.1509
S-1334	0,85 0,43 0,43 0,43
T-1334	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-1334	-0.15031757950782776	0.85 0.43 0.43 0.43
D-1334	-0.15031757950782776	0.85 0.43 0.43 0.43
P-1334	-0.1925 -0.1318 -0.2234 -0.0736 -0.1948 -0.0761 -0.2329 -0.0769 -0.1509
S-1511	0,85 0,43 0,43 0,43
T-1511	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-1511	-0.15031757950782776	0.85 0.43 0.43 0.43
D-1511	-0.15031757950782776	0.85 0.43 0.43 0.43
P-1511	-0.1925 -0.1318 -0.2234 -0.0736 -0.1948 -0.0761 -0.2329 -0.0769 -0.1509
S-1506	Infektionen und parasitäre Erkrankungen
T-1506	( % patients<<unk>> a Infections and infestations Blood and lymphatic system disorders
H-1506	-0.3088950514793396	infections and parasitic disorders
D-1506	-0.3088950514793396	infections and parasitic disorders
P-1506	-0.7320 -0.0660 -0.1431 -0.1768 -0.1100 -0.1610 -1.0600 -0.0805 -0.2508
S-1708	Für Kinder unzugänglich aufbewahren .
T-1708	Keep out of the reach and sight of children .
H-1708	-0.2956223487854004	Store out of reach of children .
D-1708	-0.2956223487854004	Store out of reach of children .
P-1708	-1.1799 -0.2677 -0.1197 -0.2317 -0.1167 -0.1313 -0.1575 -0.1604
S-1676	Für Kinder unzugänglich aufbewahren .
T-1676	Keep out of the reach and sight of children .
H-1676	-0.2956223487854004	Store out of reach of children .
D-1676	-0.2956223487854004	Store out of reach of children .
P-1676	-1.1799 -0.2677 -0.1197 -0.2317 -0.1167 -0.1313 -0.1575 -0.1604
S-1941	Erwachsene und Jugendliche ab 12 Jahren :
T-1941	Adults and adolescents 12 years of age and over :
H-1941	-0.41432297229766846	Adults and adolescents aged 12 and over :
D-1941	-0.41432297229766846	Adults and adolescents aged 12 and over :
P-1941	-0.2081 -0.9640 -0.1420 -0.2823 -0.0493 -0.0314 -1.4145 -0.1308 -0.8963 -0.4524 -0.2469 -0.1541
S-1692	Für Kinder unzugänglich aufbewahren .
T-1692	Keep out of the reach and sight of children .
H-1692	-0.2956223487854004	Store out of reach of children .
D-1692	-0.2956223487854004	Store out of reach of children .
P-1692	-1.1799 -0.2677 -0.1197 -0.2317 -0.1167 -0.1313 -0.1575 -0.1604
S-1642	Für Kinder unzugänglich aufbewahren .
T-1642	Keep out of the reach and sight of children .
H-1642	-0.2956223487854004	Store out of reach of children .
D-1642	-0.2956223487854004	Store out of reach of children .
P-1642	-1.1799 -0.2677 -0.1197 -0.2317 -0.1167 -0.1313 -0.1575 -0.1604
S-1659	Für Kinder unzugänglich aufbewahren .
T-1659	Keep out of the reach and sight of children .
H-1659	-0.2956223487854004	Store out of reach of children .
D-1659	-0.2956223487854004	Store out of reach of children .
P-1659	-1.1799 -0.2677 -0.1197 -0.2317 -0.1167 -0.1313 -0.1575 -0.1604
S-1626	Für Kinder unzugänglich aufbewahren .
T-1626	Keep out of the reach and sight of children .
H-1626	-0.2956223487854004	Store out of reach of children .
D-1626	-0.2956223487854004	Store out of reach of children .
P-1626	-1.1799 -0.2677 -0.1197 -0.2317 -0.1167 -0.1313 -0.1575 -0.1604
S-654	Pharmakotherapeutische Gruppe :
T-654	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-654	-0.3208265006542206	Pharmacotherapeutic group :
D-654	-0.3208265006542206	Pharmacotherapeutic group :
P-654	-0.4950 -0.1061 -0.0862 -0.2178 -0.1902 -0.1438 -1.3170 -0.1737 -0.1576
S-1533	Pharmakotherapeutische Gruppe :
T-1533	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1533	-0.3208265006542206	Pharmacotherapeutic group :
D-1533	-0.3208265006542206	Pharmacotherapeutic group :
P-1533	-0.4950 -0.1061 -0.0862 -0.2178 -0.1902 -0.1438 -1.3170 -0.1737 -0.1576
S-1356	Pharmakotherapeutische Gruppe :
T-1356	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1356	-0.3208265006542206	Pharmacotherapeutic group :
D-1356	-0.3208265006542206	Pharmacotherapeutic group :
P-1356	-0.4950 -0.1061 -0.0862 -0.2178 -0.1902 -0.1438 -1.3170 -0.1737 -0.1576
S-1180	Pharmakotherapeutische Gruppe :
T-1180	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1180	-0.3208265006542206	Pharmacotherapeutic group :
D-1180	-0.3208265006542206	Pharmacotherapeutic group :
P-1180	-0.4950 -0.1061 -0.0862 -0.2178 -0.1902 -0.1438 -1.3170 -0.1737 -0.1576
S-1004	Pharmakotherapeutische Gruppe :
T-1004	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1004	-0.3208265006542206	Pharmacotherapeutic group :
D-1004	-0.3208265006542206	Pharmacotherapeutic group :
P-1004	-0.4950 -0.1061 -0.0862 -0.2178 -0.1902 -0.1438 -1.3170 -0.1737 -0.1576
S-828	Pharmakotherapeutische Gruppe :
T-828	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-828	-0.3208265006542206	Pharmacotherapeutic group :
D-828	-0.3208265006542206	Pharmacotherapeutic group :
P-828	-0.4950 -0.1061 -0.0862 -0.2178 -0.1902 -0.1438 -1.3170 -0.1737 -0.1576
S-632	0,43 0,43 0,43
T-632	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-632	-0.13645733892917633	0.43 0.43 0.43
D-632	-0.13645733892917633	0.43 0.43 0.43
P-632	-0.1681 -0.0890 -0.1951 -0.0794 -0.1877 -0.0840 -0.1517
S-495	ADROVANCE
T-495	You should not take ADROVANCE if you are or think you may be pregnant , or if you are breast-feeding .
H-495	-0.11199624836444855	ADROVANCE
D-495	-0.11199624836444855	ADROVANCE
P-495	-0.0805 -0.0657 -0.1238 -0.1025 -0.1141 -0.1854
S-494	Alendronat
T-494	Alendronate belongs to a group of non-hormonal medicines called bisphosphonates .
H-494	-0.15853635966777802	alendronate
D-494	-0.15853635966777802	alendronate
P-494	-0.2101 -0.1262 -0.1355 -0.1137 -0.2072
S-1023	PK-Parameter
T-1023	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1023	-0.3578144311904907	PK parameter
D-1023	-0.3578144311904907	PK parameter
P-1023	-0.2753 -0.1226 -0.5594 -0.6488 -0.1829
S-476	ADROVANCE
T-476	You should not take ADROVANCE if you are or think you may be pregnant , or if you are breast-feeding .
H-476	-0.11199624836444855	ADROVANCE
D-476	-0.11199624836444855	ADROVANCE
P-476	-0.0805 -0.0657 -0.1238 -0.1025 -0.1141 -0.1854
S-493	ADROVANCE
T-493	WHAT ADROVANCE IS AND WHAT IT IS USED FOR
H-493	-0.11199624836444855	ADROVANCE
D-493	-0.11199624836444855	ADROVANCE
P-493	-0.0805 -0.0657 -0.1238 -0.1025 -0.1141 -0.1854
S-474	Alendronat
T-474	Alendronate belongs to a group of non-hormonal medicines called bisphosphonates .
H-474	-0.15853635966777802	alendronate
D-474	-0.15853635966777802	alendronate
P-474	-0.2101 -0.1262 -0.1355 -0.1137 -0.2072
S-671	PK-Parameter
T-671	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-671	-0.3578144311904907	PK parameter
D-671	-0.3578144311904907	PK parameter
P-671	-0.2753 -0.1226 -0.5594 -0.6488 -0.1829
S-473	ADROVANCE
T-473	WHAT ADROVANCE IS AND WHAT IT IS USED FOR
H-473	-0.11199624836444855	ADROVANCE
D-473	-0.11199624836444855	ADROVANCE
P-473	-0.0805 -0.0657 -0.1238 -0.1025 -0.1141 -0.1854
S-1199	PK-Parameter
T-1199	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1199	-0.3578144311904907	PK parameter
D-1199	-0.3578144311904907	PK parameter
P-1199	-0.2753 -0.1226 -0.5594 -0.6488 -0.1829
S-1375	PK-Parameter
T-1375	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1375	-0.3578144311904907	PK parameter
D-1375	-0.3578144311904907	PK parameter
P-1375	-0.2753 -0.1226 -0.5594 -0.6488 -0.1829
S-847	PK-Parameter
T-847	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-847	-0.3578144311904907	PK parameter
D-847	-0.3578144311904907	PK parameter
P-847	-0.2753 -0.1226 -0.5594 -0.6488 -0.1829
S-475	ADROVANCE
T-475	Your doctor has prescribed ADROVANCE to treat your osteoporosis and because you are at risk of vitamin D insufficiency .
H-475	-0.11199624836444855	ADROVANCE
D-475	-0.11199624836444855	ADROVANCE
P-475	-0.0805 -0.0657 -0.1238 -0.1025 -0.1141 -0.1854
S-1552	PK-Parameter
T-1552	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1552	-0.3578144311904907	PK parameter
D-1552	-0.3578144311904907	PK parameter
P-1552	-0.2753 -0.1226 -0.5594 -0.6488 -0.1829
S-1931	2,5 mg / 120 mg
T-1931	2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg
H-1931	-0.28230538964271545	2.5 mg / 120 mg
D-1931	-0.28230538964271545	2.5 mg / 120 mg
P-1931	-1.1272 -0.0504 -0.1551 -0.1000 -0.0690 -0.1922
S-497	ADROVANCE
T-497	47 5 ) If you develop difficulty or pain upon swallowing , chest pain , or new or worsening heartburn , stop taking ADROVANCE and contact your doctor .
H-497	-0.11199624836444855	ADROVANCE
D-497	-0.11199624836444855	ADROVANCE
P-497	-0.0805 -0.0657 -0.1238 -0.1025 -0.1141 -0.1854
S-481	ADROVANCE
T-481	5 ) If you develop difficulty or pain upon swallowing , chest pain , or new or worsening heartburn , stop taking ADROVANCE and contact your doctor .
H-481	-0.11199624836444855	ADROVANCE
D-481	-0.11199624836444855	ADROVANCE
P-481	-0.0805 -0.0657 -0.1238 -0.1025 -0.1141 -0.1854
S-1510	2 1 1 1
T-1510	2 1 1 1 2 2 1 1 3 1
H-1510	-0.19785089790821075	2 1 1
D-1510	-0.19785089790821075	2 1 1
P-1510	-0.1903 -0.1545 -0.1373 -0.3093
S-981	2 1 1 1
T-981	2 1 1 1 2 2 1 1 3 1
H-981	-0.19785089790821075	2 1 1
D-981	-0.19785089790821075	2 1 1
P-981	-0.1903 -0.1545 -0.1373 -0.3093
S-805	2 1 1 1
T-805	2 1 1 1 2 2 1 1 3 1
H-805	-0.19785089790821075	2 1 1
D-805	-0.19785089790821075	2 1 1
P-805	-0.1903 -0.1545 -0.1373 -0.3093
S-1333	2 1 1 1
T-1333	2 1 1 1 2 2 1 1 3 1
H-1333	-0.19785089790821075	2 1 1
D-1333	-0.19785089790821075	2 1 1
P-1333	-0.1903 -0.1545 -0.1373 -0.3093
S-204	32 % ) .
T-204	32 % , respectively ) , through week 15.
H-204	-0.15522246062755585	32 % ) .
D-204	-0.15522246062755585	32 % ) .
P-204	-0.1924 -0.1444 -0.1336 -0.1545 -0.1513
S-484	Informieren Sie
T-484	Tell your doctor or pharmacist promptly about these or any other unusual symptoms .
H-484	-0.7220285534858704	Be sure to
D-484	-0.7220285534858704	Be sure to
P-484	-0.3656 -0.0537 -0.1451 -2.3238
S-1157	2 1 1 1
T-1157	2 1 1 1 2 2 1 1 3 1
H-1157	-0.19785089790821075	2 1 1
D-1157	-0.19785089790821075	2 1 1
P-1157	-0.1903 -0.1545 -0.1373 -0.3093
S-1935	14 Tabletten
T-1935	2 tablets 4 tablets 7 tablets 10 tablets 14 tablets 20 tablets
H-1935	-0.14793947339057922	14 tablets
D-1935	-0.14793947339057922	14 tablets
P-1935	-0.1606 -0.1337 -0.1257 -0.1717
S-500	Informieren Sie
T-500	Tell your doctor or pharmacist promptly about these or any other unusual symptoms .
H-500	-0.7220285534858704	Be sure to
D-500	-0.7220285534858704	Be sure to
P-500	-0.3656 -0.0537 -0.1451 -2.3238
S-630	Verabreichungsort
T-630	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-630	-0.578283429145813	site
D-630	-0.578283429145813	site
P-630	-0.9296 -0.2270
S-392	32 % ) .
T-392	32 % , respectively ) , through week 15.
H-392	-0.15522246062755585	32 % ) .
D-392	-0.15522246062755585	32 % ) .
P-392	-0.1924 -0.1444 -0.1336 -0.1545 -0.1513
S-499	Gelegentlich
T-499	Gelegentlich Very rare ( occurring in less than 1 of 10,000 patients treated ) .
H-499	-0.09656206518411636	Uncommon
D-499	-0.09656206518411636	Uncommon
P-499	-0.0841 -0.0557 -0.1499
S-498	Häufig :
T-498	The following terms are used to describe how often side effects have been reported :
H-498	-0.11559194326400757	Common :
D-498	-0.11559194326400757	Common :
P-498	-0.0645 -0.0965 -0.1440 -0.1574
S-483	Gelegentlich
T-483	Gelegentlich Very rare ( occurring in less than 1 of 10,000 patients treated ) .
H-483	-0.09656206518411636	Uncommon
D-483	-0.09656206518411636	Uncommon
P-483	-0.0841 -0.0557 -0.1499
S-631	1 1 1
T-631	2 1 1 1 2 2 1 1 3 1
H-631	-0.3668431043624878	1 1
D-631	-0.3668431043624878	1 1
P-631	-0.1562 -0.1349 -0.8095
S-488	Tel . :
T-488	Tel . : <<unk>> 36 1 888 53 00 hungary<<unk>> msd<<unk>> merck . com
H-488	-0.1596645563840866	Tel . :
D-488	-0.1596645563840866	Tel . :
P-488	-0.0438 -0.2747 -0.1633 -0.1568
S-504	Tel . :
T-504	Tel . : <<unk>> 36 1 888 53 00 hungary<<unk>> msd<<unk>> merck . com
H-504	-0.1596645563840866	Tel . :
D-504	-0.1596645563840866	Tel . :
P-504	-0.0438 -0.2747 -0.1633 -0.1568
S-492	Tel : +
T-492	Ireland Merck Sharp and Dohme Ireland ( Human Health ) Limited Tel : <<unk>> 353 ( 0<<unk>> 1 2998771 medinfo<<unk>> ireland<<unk>> merck . com
H-492	-0.10883509367704391	Tel : +
D-492	-0.10883509367704391	Tel : +
P-492	-0.0398 -0.1369 -0.1093 -0.1494
S-508	Tel : +
T-508	Ireland Merck Sharp and Dohme Ireland ( Human Health ) Limited Tel : <<unk>> 353 ( 0<<unk>> 1 2998771 medinfo<<unk>> ireland<<unk>> merck . com
H-508	-0.10883509367704391	Tel : +
D-508	-0.10883509367704391	Tel : +
P-508	-0.0398 -0.1369 -0.1093 -0.1494
S-482	Häufig :
T-482	The following terms are used to describe how often side effects have been reported :
H-482	-0.11559194326400757	Common :
D-482	-0.11559194326400757	Common :
P-482	-0.0645 -0.0965 -0.1440 -0.1574
S-506	Tel :
T-506	Tel . : <<unk>> 48 22 549 51 00 msdpolska<<unk>> merck . com
H-506	-0.11137733608484268	Tel :
D-506	-0.11137733608484268	Tel :
P-506	-0.0396 -0.1429 -0.1516
S-507	Tel :
T-507	Tel : <<unk>> 34 93 600 37 00 medicaldep<<unk>> ferrergrupo . com
H-507	-0.11137733608484268	Tel :
D-507	-0.11137733608484268	Tel :
P-507	-0.0396 -0.1429 -0.1516
S-490	Tel :
T-490	Tel . : <<unk>> 48 22 549 51 00 msdpolska<<unk>> merck . com
H-490	-0.11137733608484268	Tel :
D-490	-0.11137733608484268	Tel :
P-490	-0.0396 -0.1429 -0.1516
S-491	Tel :
T-491	Tel : <<unk>> 34 93 600 37 00 medicaldep<<unk>> ferrergrupo . com
H-491	-0.11137733608484268	Tel :
D-491	-0.11137733608484268	Tel :
P-491	-0.0396 -0.1429 -0.1516
S-489	Tel :
T-489	Eesti Österreich Merck Sharp <<unk>> Dohme OÜ Tel . : <<unk>> 372 613 9750 msdeesti<<unk>> merck . com
H-489	-0.11137733608484268	Tel :
D-489	-0.11137733608484268	Tel :
P-489	-0.0396 -0.1429 -0.1516
S-505	Tel :
T-505	50 Eesti Österreich Merck Sharp <<unk>> Dohme OÜ Tel . : <<unk>> 372 613 9750 msdeesti<<unk>> merck . com
H-505	-0.11137733608484268	Tel :
D-505	-0.11137733608484268	Tel :
P-505	-0.0396 -0.1429 -0.1516
S-628	0,43
T-628	Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-628	-0.16595913469791412	0.43
D-628	-0.16595913469791412	0.43
P-628	-0.2078 -0.0998 -0.1903
S-486	Die
T-486	The active substances are alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-486	-0.1733420044183731	The
D-486	-0.1733420044183731	The
P-486	-0.1918 -0.1549
S-479	(
T-479	40 3 ) Do not lie down stay fully upright ( sitting , standing or walking ) for at least 30 minutes after swallowing the tablet .
H-479	-0.15585824847221375	(
D-479	-0.15585824847221375	(
P-479	-0.1533 -0.1584
S-1952	2
T-1952	2 a history of haemorrhagic stroke or with risk factors which could increase the risk of haemorrhagic stroke .
H-1952	-0.16907338798046112	2
D-1952	-0.16907338798046112	2
P-1952	-0.1686 -0.1696
S-480	(
T-480	4 ) Do not take ADROVANCE at bedtime or before getting up for the day .
H-480	-0.15585824847221375	(
D-480	-0.15585824847221375	(
P-480	-0.1533 -0.1584
S-502	Die
T-502	The active substances are alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-502	-0.1733420044183731	The
D-502	-0.1733420044183731	The
P-502	-0.1918 -0.1549
S-501	Das
T-501	The expiry date refers to the last day of that month .
H-501	-0.1754222959280014	The
D-501	-0.1754222959280014	The
P-501	-0.1793 -0.1715
S-471	2.
T-471	ADROVANCE 70 mg/ 2800 IU tablets Alendronic acid as alendronate sodium trihydrate/ colecalciferol
H-471	-0.752857506275177	2.
D-471	-0.752857506275177	2.
P-471	-0.3145 -1.1912
S-472	2.
T-472	ADROVANCE 70 mg/ 2800 IU tablets Alendronic acid as alendronate sodium trihydrate/ colecalciferol
H-472	-0.752857506275177	2.
D-472	-0.752857506275177	2.
P-472	-0.3145 -1.1912
S-477	Sie
T-477	It is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .
H-477	-0.2522098124027252	you
D-477	-0.2522098124027252	you
P-477	-0.1974 -0.3071
S-496	Sie
T-496	It is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .
H-496	-0.2522098124027252	you
D-496	-0.2522098124027252	you
P-496	-0.1974 -0.3071
S-478	(
T-478	2 ) After getting up for the day and before taking any food , drink , or other medicine , swallow your ADROVANCE tablet with a full glass of water only ( not mineral water ) ( not less than 200 ml or 7 fl . oz . ) . Do not take with mineral water ( still or sparkling ) . Do not take with coffee or tea . Do not take with juice or milk .
H-478	-0.15585824847221375	(
D-478	-0.15585824847221375	(
P-478	-0.1533 -0.1584
S-485	Das
T-485	The expiry date refers to the last day of that month .
H-485	-0.1754222959280014	The
D-485	-0.1754222959280014	The
P-485	-0.1793 -0.1715
S-698	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-698	Wash your hands thoroughly using soap and warm water .
H-698	-0.29554012417793274	Wash hands carefully with soap and warm water .
D-698	-0.29554012417793274	Wash hands carefully with soap and warm water .
P-698	-1.2231 -0.0285 -0.1734 -0.6985 -0.1908 -0.1610 -0.1372 -0.1628 -0.1120 -0.1685 -0.1950
S-874	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-874	Wash your hands thoroughly using soap and warm water .
H-874	-0.29554012417793274	Wash hands carefully with soap and warm water .
D-874	-0.29554012417793274	Wash hands carefully with soap and warm water .
P-874	-1.2231 -0.0285 -0.1734 -0.6985 -0.1908 -0.1610 -0.1372 -0.1628 -0.1120 -0.1685 -0.1950
S-268	Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht .
T-268	Not all pack sizes may be marketed .
H-268	-0.3558407425880432	Not all pack sizes may be marketed .
D-268	-0.3558407425880432	Not all pack sizes may be marketed .
P-268	-1.0495 -0.0919 -1.0568 -0.0618 -0.1068 -0.2936 -0.2132 -0.5373 -0.0916 -0.2545 -0.1573
S-314	Bei den meisten Patienten gingen die Beschwerden nach dem Absetzen der Therapie zurück .
T-314	Most patients had relief of symptoms after stopping treatment .
H-314	-0.37257158756256104	In most patients , discomfort decreased after discontinuation of therapy .
D-314	-0.37257158756256104	In most patients , discomfort decreased after discontinuation of therapy .
P-314	-0.6254 -0.1217 -0.3803 -1.1026 -1.2097 -0.1167 -0.6406 -0.0593 -0.3393 -0.1101 -0.1016 -0.1016 -0.1507 -0.5922 -0.1572 -0.1521
S-57	Die empfohlene Dosis beträgt eine Tablette einmal wöchentlich .
T-57	The recommended dose is one tablet once a week .
H-57	-0.26003700494766235	The recommended dose is one tablet once weekly .
D-57	-0.26003700494766235	The recommended dose is one tablet once weekly .
P-57	-0.1399 -0.2105 -0.0717 -0.1658 -0.2701 -0.2452 -0.1245 -0.6723 -0.6573 -0.1494 -0.1536
S-547	Den vollständigen Wortlaut des EPAR für Advate finden Sie hier .
T-547	The full EPAR for Advate is available here .
H-547	-0.33301883935928345	The full EPAR for Advate is available here .
D-547	-0.33301883935928345	The full EPAR for Advate is available here .
P-547	-1.6609 -0.1386 -0.3504 -0.0573 -0.1606 -0.2609 -0.0791 -0.5564 -0.2795 -0.0968 -0.1991 -0.1567
S-250	Vor der Ausscheidung kommt es zu weiterer Hydroxylierung .
T-250	Further hydroxylation occurs prior to elimination .
H-250	-0.3464818596839905	Further hydroxylation occurs prior to excretion .
D-250	-0.3464818596839905	Further hydroxylation occurs prior to excretion .
P-250	-1.8222 -0.0677 -0.1125 -0.1641 -0.1152 -0.4600 -0.0530 -0.9090 -0.1283 -0.5209 -0.0243 -0.1211 -0.1979 -0.1545
S-446	Vor der Ausscheidung kommt es zu weiterer Hydroxylierung .
T-446	Further hydroxylation occurs prior to elimination .
H-446	-0.3464818596839905	Further hydroxylation occurs prior to excretion .
D-446	-0.3464818596839905	Further hydroxylation occurs prior to excretion .
P-446	-1.8222 -0.0677 -0.1125 -0.1641 -0.1152 -0.4600 -0.0530 -0.9090 -0.1283 -0.5209 -0.0243 -0.1211 -0.1979 -0.1545
S-464	Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht .
T-464	Not all pack sizes may be marketed .
H-464	-0.3558407425880432	Not all pack sizes may be marketed .
D-464	-0.3558407425880432	Not all pack sizes may be marketed .
P-464	-1.0495 -0.0919 -1.0568 -0.0618 -0.1068 -0.2936 -0.2132 -0.5373 -0.0916 -0.2545 -0.1573
S-596	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-596	For instructions for reconstitution prior to administration , see section 6.6 .
H-596	-0.4646434485912323	Reconstitution information prior to administration see section 6.6 .
D-596	-0.4646434485912323	Reconstitution information prior to administration see section 6.6 .
P-596	-2.1616 -0.0462 -1.1363 -0.2648 -0.1302 -0.0566 -1.1073 -0.1048 -0.0942 -0.1514 -0.1690 -0.1532
S-525	Advate wird angewendet , um den fehlenden Faktor VIII zu ersetzen .
T-525	Advate is used to replace the missing factor VIII .
H-525	-0.24060045182704926	Advate is used to replace the missing factor VIII .
D-525	-0.24060045182704926	Advate is used to replace the missing factor VIII .
P-525	-0.3910 -0.0944 -0.2064 -0.1364 -0.1448 -0.6744 -0.3369 -0.3423 -0.1436 -0.1699 -0.0907 -0.2348 -0.1623
S-1050	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1050	Wash your hands thoroughly using soap and warm water .
H-1050	-0.29554012417793274	Wash hands carefully with soap and warm water .
D-1050	-0.29554012417793274	Wash hands carefully with soap and warm water .
P-1050	-1.2231 -0.0285 -0.1734 -0.6985 -0.1908 -0.1610 -0.1372 -0.1628 -0.1120 -0.1685 -0.1950
S-1226	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1226	Wash your hands thoroughly using soap and warm water .
H-1226	-0.29554012417793274	Wash hands carefully with soap and warm water .
D-1226	-0.29554012417793274	Wash hands carefully with soap and warm water .
P-1226	-1.2231 -0.0285 -0.1734 -0.6985 -0.1908 -0.1610 -0.1372 -0.1628 -0.1120 -0.1685 -0.1950
S-1402	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1402	Wash your hands thoroughly using soap and warm water .
H-1402	-0.29554012417793274	Wash hands carefully with soap and warm water .
D-1402	-0.29554012417793274	Wash hands carefully with soap and warm water .
P-1402	-1.2231 -0.0285 -0.1734 -0.6985 -0.1908 -0.1610 -0.1372 -0.1628 -0.1120 -0.1685 -0.1950
S-1579	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1579	Wash your hands thoroughly using soap and warm water .
H-1579	-0.29554012417793274	Wash hands carefully with soap and warm water .
D-1579	-0.29554012417793274	Wash hands carefully with soap and warm water .
P-1579	-1.2231 -0.0285 -0.1734 -0.6985 -0.1908 -0.1610 -0.1372 -0.1628 -0.1120 -0.1685 -0.1950
S-198	Eine Ergänzung mit Vitamin D senkt diese Risiken und ihre Konsequenzen .
T-198	Supplemental vitamin D reduces these risks and their consequences .
H-198	-0.35839131474494934	Vitamin D supplementation reduces these risks and their consequences .
D-198	-0.35839131474494934	Vitamin D supplementation reduces these risks and their consequences .
P-198	-1.7988 -0.0567 -0.1386 -0.0119 -0.2553 -0.1100 -1.4871 -0.1011 -0.2247 -0.1341 -0.1419 -0.3578 -0.2261 -0.1770 -0.1545
S-211	5,0 , 5,8 % ) in der Gruppe mit 10 mg täglich .
T-211	5.0 , 5.8 % ) in the 10 mg daily group .
H-211	-0.18219861388206482	5.0 , 5.8 % ) in the 10 mg daily group .
D-211	-0.18219861388206482	5.0 , 5.8 % ) in the 10 mg daily group .
P-211	-0.0886 -0.0842 -0.1675 -0.0670 -0.1097 -0.1442 -0.1238 -0.1493 -0.1499 -0.4049 -0.0453 -0.2946 -0.5598 -0.1932 -0.1511
S-386	Eine Ergänzung mit Vitamin D senkt diese Risiken und ihre Konsequenzen .
T-386	Supplemental vitamin D reduces these risks and their consequences .
H-386	-0.35839131474494934	Vitamin D supplementation reduces these risks and their consequences .
D-386	-0.35839131474494934	Vitamin D supplementation reduces these risks and their consequences .
P-386	-1.7988 -0.0567 -0.1386 -0.0119 -0.2553 -0.1100 -1.4871 -0.1011 -0.2247 -0.1341 -0.1419 -0.3578 -0.2261 -0.1770 -0.1545
S-407	5,0 , 5,8 % ) in der Gruppe mit 10 mg täglich .
T-407	5.0 , 5.8 % ) in the 10 mg daily group .
H-407	-0.18219861388206482	5.0 , 5.8 % ) in the 10 mg daily group .
D-407	-0.18219861388206482	5.0 , 5.8 % ) in the 10 mg daily group .
P-407	-0.0886 -0.0842 -0.1675 -0.0670 -0.1097 -0.1442 -0.1238 -0.1493 -0.1499 -0.4049 -0.0453 -0.2946 -0.5598 -0.1932 -0.1511
S-126	Bei den meisten Patienten gingen die Beschwerden nach dem Absetzen der Therapie zurück .
T-126	Most patients had relief of symptoms after stopping treatment .
H-126	-0.37257158756256104	In most patients , discomfort decreased after discontinuation of therapy .
D-126	-0.37257158756256104	In most patients , discomfort decreased after discontinuation of therapy .
P-126	-0.6254 -0.1217 -0.3803 -1.1026 -1.2097 -0.1167 -0.6406 -0.0593 -0.3393 -0.1101 -0.1016 -0.1016 -0.1507 -0.5922 -0.1572 -0.1521
S-1125	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-1125	The product contains traces of mouse and hamster proteins .
H-1125	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
D-1125	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
P-1125	-1.3582 -0.0727 -0.1670 -0.2950 -0.1049 -0.1220 -0.1938 -0.0443 -0.1952 -0.1555 -0.0840 -0.3274 -0.0520 -0.2010 -0.1628
S-773	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-773	The product contains traces of mouse and hamster proteins .
H-773	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
D-773	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
P-773	-1.3582 -0.0727 -0.1670 -0.2950 -0.1049 -0.1220 -0.1938 -0.0443 -0.1952 -0.1555 -0.0840 -0.3274 -0.0520 -0.2010 -0.1628
S-1301	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-1301	The product contains traces of mouse and hamster proteins .
H-1301	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
D-1301	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
P-1301	-1.3582 -0.0727 -0.1670 -0.2950 -0.1049 -0.1220 -0.1938 -0.0443 -0.1952 -0.1555 -0.0840 -0.3274 -0.0520 -0.2010 -0.1628
S-1477	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-1477	The product contains traces of mouse and hamster proteins .
H-1477	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
D-1477	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
P-1477	-1.3582 -0.0727 -0.1670 -0.2950 -0.1049 -0.1220 -0.1938 -0.0443 -0.1952 -0.1555 -0.0840 -0.3274 -0.0520 -0.2010 -0.1628
S-1614	Zusammenfassung der Merkmale des Arzneimittels , Abschnitt 4.2 ) .
T-1614	Summary of Product Characteristics , section 4.2 )
H-1614	-0.3507736027240753	Summary of product characteristics , section 4.2 ) .
D-1614	-0.3507736027240753	Summary of product characteristics , section 4.2 ) .
P-1614	-0.2381 -0.0731 -0.2041 -2.1246 -0.7788 -0.1204 -0.1668 -0.1255 -0.1269 -0.1334 -0.1359 -0.1795 -0.1531
S-949	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-949	The product contains traces of mouse and hamster proteins .
H-949	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
D-949	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
P-949	-1.3582 -0.0727 -0.1670 -0.2950 -0.1049 -0.1220 -0.1938 -0.0443 -0.1952 -0.1555 -0.0840 -0.3274 -0.0520 -0.2010 -0.1628
S-102	Daher ist eine Dosisanpassung bei älteren Menschen nicht erforderlich .
T-102	Therefore no dosage adjustment is necessary for the elderly .
H-102	-0.3959740400314331	Dosage adjustment in elderly patients is therefore not necessary .
D-102	-0.3959740400314331	Dosage adjustment in elderly patients is therefore not necessary .
P-102	-0.7263 -0.7744 -0.1053 -0.0863 -0.0567 -0.2473 -1.1060 -0.9611 -0.3215 -0.2437 -0.2757 -0.5147 -0.1726 -0.1949 -0.1532
S-599	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-599	The product contains traces of mouse and hamster proteins .
H-599	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
D-599	-0.23571786284446716	This product contains traces of mouse and hamster proteins .
P-599	-1.3582 -0.0727 -0.1670 -0.2950 -0.1049 -0.1220 -0.1938 -0.0443 -0.1952 -0.1555 -0.0840 -0.3274 -0.0520 -0.2010 -0.1628
S-431	Die Proteinbindung im menschlichen Plasma beträgt ca. 78 <unk> .
T-431	Protein binding in human plasma is approximately 78 % .
H-431	-0.3261236846446991	The protein binding in human plasma is approximately 78 <unk> .
D-431	-0.3261236846446991	The protein binding in human plasma is approximately 78 <unk> .
P-431	-1.4758 -0.1052 -0.0559 -0.0955 -0.3978 -0.2747 -0.1378 -0.0650 -0.1309 -0.1498 -0.1296 -0.1138 -0.5988 -1.0109 -0.1504
S-235	Die Proteinbindung im menschlichen Plasma beträgt ca. 78 <unk> .
T-235	Protein binding in human plasma is approximately 78 % .
H-235	-0.3261236846446991	The protein binding in human plasma is approximately 78 <unk> .
D-235	-0.3261236846446991	The protein binding in human plasma is approximately 78 <unk> .
P-235	-1.4758 -0.1052 -0.0559 -0.0955 -0.3978 -0.2747 -0.1378 -0.0650 -0.1309 -0.1498 -0.1296 -0.1138 -0.5988 -1.0109 -0.1504
S-1917	Welchen Nutzen hat Aerinaze in diesen Studien gezeigt ?
T-1917	What benefit has Aerinaze shown during the studies ?
H-1917	-0.33931517601013184	What benefit has Aerinaze shown in these studies ?
D-1917	-0.33931517601013184	What benefit has Aerinaze shown in these studies ?
P-1917	-0.1182 -0.9575 -0.5311 -0.1619 -0.1284 -0.1432 -0.1188 -0.1204 -0.3638 -0.1577 -0.1264 -1.1571 -0.5122 -0.1536
S-74	Welchen Nutzen hat ADROVANCE in diesen Studien gezeigt ?
T-74	What benefit has ADROVANCE shown during the studies ?
H-74	-0.3413538336753845	What benefit has ADROVANCE shown in these studies ?
D-74	-0.3413538336753845	What benefit has ADROVANCE shown in these studies ?
P-74	-0.1815 -1.0161 -0.6871 -0.0291 -0.0623 -0.1289 -0.1131 -0.1130 -0.4721 -0.1718 -0.1089 -1.0181 -0.5219 -0.1551
S-1722	- Wenn Sie weitere Fragen haben , wenden Sie sich an Ihren Arzt .
T-1722	- If you have any further questions , ask your doctor .
H-1722	-0.4378108084201813	- If you have any further questions , contact your doctor .
D-1722	-0.4378108084201813	- If you have any further questions , contact your doctor .
P-1722	-0.5761 -0.4938 -0.1116 -0.2322 -0.2955 -1.5674 -0.5827 -0.3491 -0.8882 -0.1451 -0.1139 -0.1714 -0.1644
S-30	Der Harnsäurespiegel im Blut wurde jeden Monat bestimmt .
T-30	Blood uric acid levels were measured every month .
H-30	-0.38160523772239685	The uric acid level in the blood was determined each month .
D-30	-0.38160523772239685	The uric acid level in the blood was determined each month .
P-30	-0.4027 -0.7373 -0.0825 -0.0895 -0.3584 -0.4079 -0.2586 -0.0806 -0.1970 -0.9166 -1.3793 -0.1256 -0.1543 -0.1521
S-1315	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1315	4.5 Interaction with other medicinal products and other forms of interaction
H-1315	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
D-1315	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
P-1315	-0.1039 -0.1438 -0.9460 -0.1310 -1.0821 -0.5187 -0.2266 -0.0924 -0.8637 -0.1437 -1.4197 -0.3121 -0.1510 -0.1934
S-1828	Polska Baxter Poland Sp. z o.o. ul .
T-1828	Polska Baxter Poland Sp . z o. o. ul .
H-1828	-0.15188068151474	Polska Baxter Poland Sp. z o.o. ul .
D-1828	-0.15188068151474	Polska Baxter Poland Sp. z o.o. ul .
P-1828	-0.1335 -0.0782 -0.1496 -0.1631 -0.1426 -0.1725 -0.0883 -0.1274 -0.1328 -0.1536 -0.2543 -0.1085 -0.2728 -0.1552 -0.1458
S-11	Sie kann mit oder unabhängig von den Mahlzeiten eingenommen werden .
T-11	It can be taken with or without food .
H-11	-0.42814943194389343	It may be taken with or without meals .
D-11	-0.42814943194389343	It may be taken with or without meals .
P-11	-0.4672 -1.1981 -0.1420 -0.2346 -0.1917 -0.2252 -1.2999 -0.1718 -0.1897 -0.1615
S-1259	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1259	For a full list of excipients , see section 6.1 .
H-1259	-0.3957306146621704	For a full list of excipients see section 6.1 .
D-1259	-0.3957306146621704	For a full list of excipients see section 6.1 .
P-1259	-0.2004 -0.1393 -0.1357 -0.0743 -0.1296 -2.1743 -0.0553 -0.0326 -0.0936 -2.2052 -0.1193 -0.0969 -0.1413 -0.1841 -0.1542
S-1139	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1139	4.5 Interaction with other medicinal products and other forms of interaction
H-1139	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
D-1139	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
P-1139	-0.1039 -0.1438 -0.9460 -0.1310 -1.0821 -0.5187 -0.2266 -0.0924 -0.8637 -0.1437 -1.4197 -0.3121 -0.1510 -0.1934
S-1726	- Wenn eine der aufgeführten Nebenwirkungen Sie erheblich beeinträchtigt oder Sie
T-1726	- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
H-1726	-0.4036262035369873	- If any of the listed side effects significantly affect you or you
D-1726	-0.4036262035369873	- If any of the listed side effects significantly affect you or you
P-1726	-0.3173 -0.5660 -0.3306 -0.1251 -0.1969 -0.1397 -0.8455 -0.1327 -0.9322 -1.1042 -0.1031 -0.2743 -0.4194 -0.1637
S-286	Die Äquivalenz der Einnahme von 5.600 I.E.
T-286	ADROVANCE should not be taken at bedtime or before arising for the day .
H-286	-0.23430778086185455	The equivalent of taking 5,600 IU
D-286	-0.23430778086185455	The equivalent of taking 5,600 IU
P-286	-0.2168 -0.5364 -0.1700 -0.0802 -0.3201 -0.0867 -0.1077 -0.0621 -0.5286
S-1796	Im Kühlschrank lagern ( 2<unk> C-8<unk> C ) .
T-1796	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1796	-0.17319455742835999	Store in a refrigerator ( 2<unk> C-8<unk> C ) .
D-1796	-0.17319455742835999	Store in a refrigerator ( 2<unk> C-8<unk> C ) .
P-1796	-0.4594 -0.1650 -0.2307 -0.2901 -0.0336 -0.0618 -0.1521 -0.1944 -0.1634 -0.2351 -0.1947 -0.1259 -0.1439 -0.0956 -0.1088 -0.1399 -0.1698 -0.1534
S-1491	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1491	4.5 Interaction with other medicinal products and other forms of interaction
H-1491	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
D-1491	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
P-1491	-0.1039 -0.1438 -0.9460 -0.1310 -1.0821 -0.5187 -0.2266 -0.0924 -0.8637 -0.1437 -1.4197 -0.3121 -0.1510 -0.1934
S-1435	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1435	For a full list of excipients , see section 6.1 .
H-1435	-0.3957306146621704	For a full list of excipients see section 6.1 .
D-1435	-0.3957306146621704	For a full list of excipients see section 6.1 .
P-1435	-0.2004 -0.1393 -0.1357 -0.0743 -0.1296 -2.1743 -0.0553 -0.0326 -0.0936 -2.2052 -0.1193 -0.0969 -0.1413 -0.1841 -0.1542
S-290	Daher ist eine Dosisanpassung bei älteren Menschen nicht erforderlich .
T-290	Therefore no dosage adjustment is necessary for the elderly .
H-290	-0.3959740400314331	Dosage adjustment in elderly patients is therefore not necessary .
D-290	-0.3959740400314331	Dosage adjustment in elderly patients is therefore not necessary .
P-290	-0.7263 -0.7744 -0.1053 -0.0863 -0.0567 -0.2473 -1.1060 -0.9611 -0.3215 -0.2437 -0.2757 -0.5147 -0.1726 -0.1949 -0.1532
S-907	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-907	For a full list of excipients , see section 6.1 .
H-907	-0.3957306146621704	For a full list of excipients see section 6.1 .
D-907	-0.3957306146621704	For a full list of excipients see section 6.1 .
P-907	-0.2004 -0.1393 -0.1357 -0.0743 -0.1296 -2.1743 -0.0553 -0.0326 -0.0936 -2.2052 -0.1193 -0.0969 -0.1413 -0.1841 -0.1542
S-556	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-556	For a full list of excipients , see section 6.1 .
H-556	-0.3957306146621704	For a full list of excipients see section 6.1 .
D-556	-0.3957306146621704	For a full list of excipients see section 6.1 .
P-556	-0.2004 -0.1393 -0.1357 -0.0743 -0.1296 -2.1743 -0.0553 -0.0326 -0.0936 -2.2052 -0.1193 -0.0969 -0.1413 -0.1841 -0.1542
S-1083	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1083	For a full list of excipients , see section 6.1 .
H-1083	-0.3957306146621704	For a full list of excipients see section 6.1 .
D-1083	-0.3957306146621704	For a full list of excipients see section 6.1 .
P-1083	-0.2004 -0.1393 -0.1357 -0.0743 -0.1296 -2.1743 -0.0553 -0.0326 -0.0936 -2.2052 -0.1193 -0.0969 -0.1413 -0.1841 -0.1542
S-963	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-963	4.5 Interaction with other medicinal products and other forms of interaction
H-963	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
D-963	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
P-963	-0.1039 -0.1438 -0.9460 -0.1310 -1.0821 -0.5187 -0.2266 -0.0924 -0.8637 -0.1437 -1.4197 -0.3121 -0.1510 -0.1934
S-787	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-787	4.5 Interaction with other medicinal products and other forms of interaction
H-787	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
D-787	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
P-787	-0.1039 -0.1438 -0.9460 -0.1310 -1.0821 -0.5187 -0.2266 -0.0924 -0.8637 -0.1437 -1.4197 -0.3121 -0.1510 -0.1934
S-731	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-731	For a full list of excipients , see section 6.1 .
H-731	-0.3957306146621704	For a full list of excipients see section 6.1 .
D-731	-0.3957306146621704	For a full list of excipients see section 6.1 .
P-731	-0.2004 -0.1393 -0.1357 -0.0743 -0.1296 -2.1743 -0.0553 -0.0326 -0.0936 -2.2052 -0.1193 -0.0969 -0.1413 -0.1841 -0.1542
S-613	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-613	4.5 Interaction with other medicinal products and other forms of interaction
H-613	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
D-613	-0.45200639963150024	4.5 . Interactions with other medicines and other interactions
P-613	-0.1039 -0.1438 -0.9460 -0.1310 -1.0821 -0.5187 -0.2266 -0.0924 -0.8637 -0.1437 -1.4197 -0.3121 -0.1510 -0.1934
S-352	Für ADROVANCE wurden keine weiteren Nebenwirkungen festgestellt .
T-352	No additional adverse reactions have been identified for ADROVANCE .
H-352	-0.4291689395904541	No other undesirable effects were observed for ADROVANCE .
D-352	-0.4291689395904541	No other undesirable effects were observed for ADROVANCE .
P-352	-0.5346 -0.6488 -1.5217 -0.4227 -0.0529 -0.2561 -0.8336 -1.1929 -0.6309 -0.0820 -0.0662 -0.1257 -0.0987 -0.0843 -0.1622 -0.1535
S-856	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-856	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-856	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-856	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-856	-0.6048 -0.1749 -0.2098 -0.2771 -0.0343 -0.0643 -0.1534 -0.2259 -0.2353 -0.1364 -0.1812 -0.5743 -0.0655 -0.1176 -0.1347 -0.1881 -0.1544
S-164	Für ADROVANCE wurden keine weiteren Nebenwirkungen festgestellt .
T-164	No additional adverse reactions have been identified for ADROVANCE .
H-164	-0.4291689395904541	No other undesirable effects were observed for ADROVANCE .
D-164	-0.4291689395904541	No other undesirable effects were observed for ADROVANCE .
P-164	-0.5346 -0.6488 -1.5217 -0.4227 -0.0529 -0.2561 -0.8336 -1.1929 -0.6309 -0.0820 -0.0662 -0.1257 -0.0987 -0.0843 -0.1622 -0.1535
S-680	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-680	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-680	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-680	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-680	-0.6048 -0.1749 -0.2098 -0.2771 -0.0343 -0.0643 -0.1534 -0.2259 -0.2353 -0.1364 -0.1812 -0.5743 -0.0655 -0.1176 -0.1347 -0.1881 -0.1544
S-1806	Jede Pulver-Durchstechflasche enthält 250 I.E.
T-1806	Each powder vial contains 250 IU octocog alfa .
H-1806	-0.2529618740081787	Each vial contains 250 IU
D-1806	-0.2529618740081787	Each vial contains 250 IU
P-1806	-0.0365 -0.1351 -0.0311 -0.3513 -0.1338 -0.1192 -0.1012 -1.1155
S-1032	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1032	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1032	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-1032	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-1032	-0.6048 -0.1749 -0.2098 -0.2771 -0.0343 -0.0643 -0.1534 -0.2259 -0.2353 -0.1364 -0.1812 -0.5743 -0.0655 -0.1176 -0.1347 -0.1881 -0.1544
S-1208	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1208	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1208	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-1208	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-1208	-0.6048 -0.1749 -0.2098 -0.2771 -0.0343 -0.0643 -0.1534 -0.2259 -0.2353 -0.1364 -0.1812 -0.5743 -0.0655 -0.1176 -0.1347 -0.1881 -0.1544
S-1384	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1384	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1384	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-1384	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-1384	-0.6048 -0.1749 -0.2098 -0.2771 -0.0343 -0.0643 -0.1534 -0.2259 -0.2353 -0.1364 -0.1812 -0.5743 -0.0655 -0.1176 -0.1347 -0.1881 -0.1544
S-1561	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1561	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1561	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-1561	-0.20777924358844757	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-1561	-0.6048 -0.1749 -0.2098 -0.2771 -0.0343 -0.0643 -0.1534 -0.2259 -0.2353 -0.1364 -0.1812 -0.5743 -0.0655 -0.1176 -0.1347 -0.1881 -0.1544
S-1657	Nur zur einmaligen Anwendung Vor der Anwendung Gebrauchsinformation lesen .
T-1657	Nur zur einmaligen Anwendung Vor der Anwendung Gebrauchsinformation lesen . Read the package leaflet before use .
H-1657	-0.6868192553520203	ONLY USE Read leaflet prior to use .
D-1657	-0.6868192553520203	ONLY USE Read leaflet prior to use .
P-1657	-2.1474 -0.0290 -0.0664 -1.1970 -0.9463 -0.3979 -3.0063 -0.0311 -0.1999 -0.8846 -0.1215 -0.1173 -0.3106 -0.1601
S-1974	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1974	4.5 Interaction with other medicinal products and other forms of interaction
H-1974	-0.38505372405052185	4.5 Interactions with other medicines and other interactions
D-1974	-0.38505372405052185	4.5 Interactions with other medicines and other interactions
P-1974	-0.0995 -0.1450 -0.1531 -0.9036 -0.4666 -0.2315 -0.0943 -0.6984 -0.1438 -1.4454 -0.2864 -0.1452 -0.1928
S-331	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-331	4.5 Interaction with other medicinal products and other forms of interaction
H-331	-0.38505372405052185	4.5 Interactions with other medicines and other interactions
D-331	-0.38505372405052185	4.5 Interactions with other medicines and other interactions
P-331	-0.0995 -0.1450 -0.1531 -0.9036 -0.4666 -0.2315 -0.0943 -0.6984 -0.1438 -1.4454 -0.2864 -0.1452 -0.1928
S-1787	Häufige Nebenwirkungen Schwindel , Kopfschmerzen und Fieber
T-1787	Common side effects dizziness , headache and fever .
H-1787	-0.23365339636802673	Common side effects include dizziness , headache and fever
D-1787	-0.23365339636802673	Common side effects include dizziness , headache and fever
P-1787	-0.0536 -0.1017 -0.3260 -0.1030 -1.7009 -0.1477 -0.0345 -0.0473 -0.1402 -0.1152 -0.0511 -0.1865 -0.4015 -0.1074 -0.0630 -0.1590
S-1577	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1577	shows any sign of deterioration .
H-1577	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
D-1577	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
P-1577	-0.9870 -0.3921 -0.1065 -0.3179 -0.6792 -0.1915 -1.3121 -0.2638 -0.1219 -1.1278 -0.0704 -0.2553 -0.1564
S-1224	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1224	shows any sign of deterioration .
H-1224	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
D-1224	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
P-1224	-0.9870 -0.3921 -0.1065 -0.3179 -0.6792 -0.1915 -1.3121 -0.2638 -0.1219 -1.1278 -0.0704 -0.2553 -0.1564
S-1093	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-1093	The dose is determined using the following formula :
H-1093	-0.4267938733100891	The required dose is calculated using the following formula :
D-1093	-0.4267938733100891	The required dose is calculated using the following formula :
P-1093	-0.2866 -1.5803 -0.0581 -0.3047 -0.8246 -0.1159 -1.0380 -0.2010 -0.2444 -0.1189 -0.1924 -0.1565
S-917	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-917	The dose is determined using the following formula :
H-917	-0.4267938733100891	The required dose is calculated using the following formula :
D-917	-0.4267938733100891	The required dose is calculated using the following formula :
P-917	-0.2866 -1.5803 -0.0581 -0.3047 -0.8246 -0.1159 -1.0380 -0.2010 -0.2444 -0.1189 -0.1924 -0.1565
S-741	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-741	The dose is determined using the following formula :
H-741	-0.4267938733100891	The required dose is calculated using the following formula :
D-741	-0.4267938733100891	The required dose is calculated using the following formula :
P-741	-0.2866 -1.5803 -0.0581 -0.3047 -0.8246 -0.1159 -1.0380 -0.2010 -0.2444 -0.1189 -0.1924 -0.1565
S-1445	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-1445	The dose is determined using the following formula :
H-1445	-0.4267938733100891	The required dose is calculated using the following formula :
D-1445	-0.4267938733100891	The required dose is calculated using the following formula :
P-1445	-0.2866 -1.5803 -0.0581 -0.3047 -0.8246 -0.1159 -1.0380 -0.2010 -0.2444 -0.1189 -0.1924 -0.1565
S-1400	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1400	shows any sign of deterioration .
H-1400	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
D-1400	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
P-1400	-0.9870 -0.3921 -0.1065 -0.3179 -0.6792 -0.1915 -1.3121 -0.2638 -0.1219 -1.1278 -0.0704 -0.2553 -0.1564
S-1269	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-1269	The dose is determined using the following formula :
H-1269	-0.4267938733100891	The required dose is calculated using the following formula :
D-1269	-0.4267938733100891	The required dose is calculated using the following formula :
P-1269	-0.2866 -1.5803 -0.0581 -0.3047 -0.8246 -0.1159 -1.0380 -0.2010 -0.2444 -0.1189 -0.1924 -0.1565
S-1048	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1048	shows any sign of deterioration .
H-1048	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
D-1048	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
P-1048	-0.9870 -0.3921 -0.1065 -0.3179 -0.6792 -0.1915 -1.3121 -0.2638 -0.1219 -1.1278 -0.0704 -0.2553 -0.1564
S-872	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-872	shows any sign of deterioration .
H-872	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
D-872	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
P-872	-0.9870 -0.3921 -0.1065 -0.3179 -0.6792 -0.1915 -1.3121 -0.2638 -0.1219 -1.1278 -0.0704 -0.2553 -0.1564
S-696	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-696	shows any sign of deterioration .
H-696	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
D-696	-0.46014755964279175	its packaging is damaged or shows signs of manipulation .
P-696	-0.9870 -0.3921 -0.1065 -0.3179 -0.6792 -0.1915 -1.3121 -0.2638 -0.1219 -1.1278 -0.0704 -0.2553 -0.1564
S-567	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-567	The dose is determined using the following formula :
H-567	-0.4267938733100891	The required dose is calculated using the following formula :
D-567	-0.4267938733100891	The required dose is calculated using the following formula :
P-567	-0.2866 -1.5803 -0.0581 -0.3047 -0.8246 -0.1159 -1.0380 -0.2010 -0.2444 -0.1189 -0.1924 -0.1565
S-143	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-143	4.5 Interaction with other medicinal products and other forms of interaction
H-143	-0.38505372405052185	4.5 Interactions with other medicines and other interactions
D-143	-0.38505372405052185	4.5 Interactions with other medicines and other interactions
P-143	-0.0995 -0.1450 -0.1531 -0.9036 -0.4666 -0.2315 -0.0943 -0.6984 -0.1438 -1.4454 -0.2864 -0.1452 -0.1928
S-723	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-723	02 March 2004 Date of last renewal :
H-723	-0.3324633538722992	02 March 2004 Date of last renewal :
D-723	-0.3324633538722992	02 March 2004 Date of last renewal :
P-723	-0.3193 -0.2700 -0.1540 -0.9342 -0.1033 -0.2050 -0.2220 -0.3988 -0.1264 -0.7624 -0.1618
S-382	Vitamin D3 wird für eine normale Knochenbildung benötigt .
T-382	Vitamin D3 is required for normal bone formation .
H-382	-0.362935334444046	vitamin D3 is necessary for normal bone formation .
D-382	-0.362935334444046	vitamin D3 is necessary for normal bone formation .
P-382	-1.0775 -0.0853 -0.1727 -0.1336 -0.1817 -1.5468 -0.1818 -0.1832 -0.1643 -0.2436 -0.2275 -0.1573
S-1766	Dies ist besonders bei größeren , chirurgischen Eingriffen wichtig .
T-1766	This is particularly important if you are having major surgery .
H-1766	-0.3443419933319092	This is especially important for major surgery .
D-1766	-0.3443419933319092	This is especially important for major surgery .
P-1766	-0.1436 -0.2146 -0.6311 -0.0710 -1.1511 -0.1993 -0.3555 -0.1775 -0.1554
S-1795	Das Verfalldatum bezieht sich auf den letzten Tag des Monats .
T-1795	The expiry date refers to the last day of that month .
H-1795	-0.21327336132526398	The expiry date refers to the last day of the month .
D-1795	-0.21327336132526398	The expiry date refers to the last day of the month .
P-1795	-0.3691 -0.2096 -0.3902 -0.4353 -0.3416 -0.1136 -0.1334 -0.1534 -0.1167 -0.1397 -0.1447 -0.1931 -0.1273 -0.1760 -0.1554
S-1728	Was ist ADVATE und wofür wird es angewendet ?
T-1728	What ADVATE is and what it is used for 2.
H-1728	-0.2502334713935852	What is ADVATE and what it is used for ?
D-1728	-0.2502334713935852	What is ADVATE and what it is used for ?
P-1728	-0.0711 -0.3208 -0.0623 -0.1452 -0.0990 -0.1025 -0.1403 -0.1185 -0.9621 -0.1703 -0.2759 -0.1018 -0.7668 -0.1666
S-31	Welchen Nutzen hat Adenuric in diesen Studien gezeigt ?
T-31	What benefit has Adenuric shown during the studies ?
H-31	-0.33951419591903687	What benefit has Adenuric shown in these studies ?
D-31	-0.33951419591903687	What benefit has Adenuric shown in these studies ?
P-31	-0.1244 -0.5867 -0.6947 -0.1340 -0.1655 -0.0919 -0.1152 -0.4085 -0.1585 -0.1059 -1.1551 -0.5193 -0.1540
S-1075	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1075	02 March 2004 Date of last renewal :
H-1075	-0.3324633538722992	02 March 2004 Date of last renewal :
D-1075	-0.3324633538722992	02 March 2004 Date of last renewal :
P-1075	-0.3193 -0.2700 -0.1540 -0.9342 -0.1033 -0.2050 -0.2220 -0.3988 -0.1264 -0.7624 -0.1618
S-899	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-899	02 March 2004 Date of last renewal :
H-899	-0.3324633538722992	02 March 2004 Date of last renewal :
D-899	-0.3324633538722992	02 March 2004 Date of last renewal :
P-899	-0.3193 -0.2700 -0.1540 -0.9342 -0.1033 -0.2050 -0.2220 -0.3988 -0.1264 -0.7624 -0.1618
S-194	Vitamin D3 wird für eine normale Knochenbildung benötigt .
T-194	Vitamin D3 is required for normal bone formation .
H-194	-0.362935334444046	vitamin D3 is necessary for normal bone formation .
D-194	-0.362935334444046	vitamin D3 is necessary for normal bone formation .
P-194	-1.0775 -0.0853 -0.1727 -0.1336 -0.1817 -1.5468 -0.1818 -0.1832 -0.1643 -0.2436 -0.2275 -0.1573
S-1604	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1604	02 March 2004 Date of last renewal :
H-1604	-0.3324633538722992	02 March 2004 Date of last renewal :
D-1604	-0.3324633538722992	02 March 2004 Date of last renewal :
P-1604	-0.3193 -0.2700 -0.1540 -0.9342 -0.1033 -0.2050 -0.2220 -0.3988 -0.1264 -0.7624 -0.1618
S-1427	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1427	02 March 2004 Date of last renewal :
H-1427	-0.3324633538722992	02 March 2004 Date of last renewal :
D-1427	-0.3324633538722992	02 March 2004 Date of last renewal :
P-1427	-0.3193 -0.2700 -0.1540 -0.9342 -0.1033 -0.2050 -0.2220 -0.3988 -0.1264 -0.7624 -0.1618
S-1251	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1251	02 March 2004 Date of last renewal :
H-1251	-0.3324633538722992	02 March 2004 Date of last renewal :
D-1251	-0.3324633538722992	02 March 2004 Date of last renewal :
P-1251	-0.3193 -0.2700 -0.1540 -0.9342 -0.1033 -0.2050 -0.2220 -0.3988 -0.1264 -0.7624 -0.1618
S-1564	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1564	The product may not be returned to refrigerated storage again .
H-1564	-0.5699885487556458	Do not store the product in a refrigerated position .
D-1564	-0.5699885487556458	Do not store the product in a refrigerated position .
P-1564	-0.7222 -0.1388 -0.0725 -0.3262 -0.1175 -0.3578 -0.3651 -0.2843 -0.0257 -0.0748 -0.1322 -4.9465 -0.2614 -0.1549
S-1387	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1387	The product may not be returned to refrigerated storage again .
H-1387	-0.5699885487556458	Do not store the product in a refrigerated position .
D-1387	-0.5699885487556458	Do not store the product in a refrigerated position .
P-1387	-0.7222 -0.1388 -0.0725 -0.3262 -0.1175 -0.3578 -0.3651 -0.2843 -0.0257 -0.0748 -0.1322 -4.9465 -0.2614 -0.1549
S-1211	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1211	The product may not be returned to refrigerated storage again .
H-1211	-0.5699885487556458	Do not store the product in a refrigerated position .
D-1211	-0.5699885487556458	Do not store the product in a refrigerated position .
P-1211	-0.7222 -0.1388 -0.0725 -0.3262 -0.1175 -0.3578 -0.3651 -0.2843 -0.0257 -0.0748 -0.1322 -4.9465 -0.2614 -0.1549
S-1035	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1035	The product may not be returned to refrigerated storage again .
H-1035	-0.5699885487556458	Do not store the product in a refrigerated position .
D-1035	-0.5699885487556458	Do not store the product in a refrigerated position .
P-1035	-0.7222 -0.1388 -0.0725 -0.3262 -0.1175 -0.3578 -0.3651 -0.2843 -0.0257 -0.0748 -0.1322 -4.9465 -0.2614 -0.1549
S-859	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-859	The product may not be returned to refrigerated storage again .
H-859	-0.5699885487556458	Do not store the product in a refrigerated position .
D-859	-0.5699885487556458	Do not store the product in a refrigerated position .
P-859	-0.7222 -0.1388 -0.0725 -0.3262 -0.1175 -0.3578 -0.3651 -0.2843 -0.0257 -0.0748 -0.1322 -4.9465 -0.2614 -0.1549
S-683	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-683	The product may not be returned to refrigerated storage again .
H-683	-0.5699885487556458	Do not store the product in a refrigerated position .
D-683	-0.5699885487556458	Do not store the product in a refrigerated position .
P-683	-0.7222 -0.1388 -0.0725 -0.3262 -0.1175 -0.3578 -0.3651 -0.2843 -0.0257 -0.0748 -0.1322 -4.9465 -0.2614 -0.1549
S-808	Erkrankungen der Haut und des Unterhautzellgewebes
T-808	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-808	-0.2976169288158417	Skin and subcutaneous disorders
D-808	-0.2976169288158417	Skin and subcutaneous disorders
P-808	-0.5540 -0.1147 -0.1861 -0.1434 -0.0269 -0.0641 -0.1277 -0.1382 -1.6709 -0.0671 -0.1806
S-1775	Fragen Sie Ihren Arzt , wenn Sie nicht ganz sicher sind .
T-1775	You should check with your doctor if you are not sure .
H-1775	-0.2818048894405365	Ask your doctor if you are unsure .
D-1775	-0.2818048894405365	Ask your doctor if you are unsure .
P-1775	-0.1972 -0.0838 -0.1428 -0.1216 -0.0690 -0.0988 -0.1911 -1.6997 -0.1168 -0.2111 -0.1680
S-62	Weitere Informationen sind der Packungsbeilage zu entnehmen .
T-62	For more information , see the Package Leaflet .
H-62	-0.39391595125198364	For more information , see the Package Leaflet .
D-62	-0.39391595125198364	For more information , see the Package Leaflet .
P-62	-1.0444 -1.1123 -0.0899 -1.2795 -0.2056 -0.2221 -0.1639 -0.1307 -0.1915 -0.0196 -0.1053 -0.4024 -0.1537
S-1944	Die Einnahme kann unabhängig von den Mahlzeiten erfolgen .
T-1944	The tablet may be taken with or without food .
H-1944	-0.6217983365058899	You can take it independently of meals .
D-1944	-0.6217983365058899	You can take it independently of meals .
P-1944	-1.8448 -1.2695 -0.0307 -0.5335 -1.9877 -0.1406 -0.1545 -0.2477 -0.2987 -0.1677 -0.1645
S-1899	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-1899	The medicine can only be obtained with a prescription .
H-1899	-0.7479532957077026	This medicinal product is available only on prescription .
D-1899	-0.7479532957077026	This medicinal product is available only on prescription .
P-1899	-1.4055 -1.8176 -0.0729 -0.1144 -0.3801 -0.7905 -1.2287 -0.5455 -1.4219 -0.2915 -0.1589
S-516	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-516	The medicine can only be obtained with a prescription .
H-516	-0.7479532957077026	This medicinal product is available only on prescription .
D-516	-0.7479532957077026	This medicinal product is available only on prescription .
P-516	-1.4055 -1.8176 -0.0729 -0.1144 -0.3801 -0.7905 -1.2287 -0.5455 -1.4219 -0.2915 -0.1589
S-1514	Hämatokritabfall Auffällige Laborwerte
T-1514	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-1514	-0.7537031173706055	packed cell Abnormal laboratory values
D-1514	-0.7537031173706055	packed cell Abnormal laboratory values
P-1514	-3.2394 -0.2735 -1.1820 -0.3758 -0.2387 -0.0464 -0.5003 -0.1736
S-634	Positiver Test auf Antikörper gegen Faktor VIII
T-634	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-634	-0.29019051790237427	Positive test for antibodies to factor VIII
D-634	-0.29019051790237427	Positive test for antibodies to factor VIII
P-634	-0.5477 -0.1566 -0.1722 -0.1546 -0.3862 -0.0790 -0.6779 -0.6077 -0.1538 -0.0787 -0.1777
S-9	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-9	The medicine can only be obtained with a prescription .
H-9	-0.7479532957077026	This medicinal product is available only on prescription .
D-9	-0.7479532957077026	This medicinal product is available only on prescription .
P-9	-1.4055 -1.8176 -0.0729 -0.1144 -0.3801 -0.7905 -1.2287 -0.5455 -1.4219 -0.2915 -0.1589
S-809	Hämatokritabfall Auffällige Laborwerte
T-809	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-809	-0.7537031173706055	packed cell Abnormal laboratory values
D-809	-0.7537031173706055	packed cell Abnormal laboratory values
P-809	-3.2394 -0.2735 -1.1820 -0.3758 -0.2387 -0.0464 -0.5003 -0.1736
S-1159	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-1159	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-1159	-0.11854603886604309	Uncommon Uncommon Uncommon Uncommon
D-1159	-0.11854603886604309	Uncommon Uncommon Uncommon Uncommon
P-1159	-0.1566 -0.0899 -0.1246 -0.1259 -0.1073 -0.1240 -0.0928 -0.0764 -0.1695
S-1161	Hämatokritabfall Auffällige Laborwerte
T-1161	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-1161	-0.7537031173706055	packed cell Abnormal laboratory values
D-1161	-0.7537031173706055	packed cell Abnormal laboratory values
P-1161	-3.2394 -0.2735 -1.1820 -0.3758 -0.2387 -0.0464 -0.5003 -0.1736
S-1337	Hämatokritabfall Auffällige Laborwerte
T-1337	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-1337	-0.7537031173706055	packed cell Abnormal laboratory values
D-1337	-0.7537031173706055	packed cell Abnormal laboratory values
P-1337	-3.2394 -0.2735 -1.1820 -0.3758 -0.2387 -0.0464 -0.5003 -0.1736
S-1512	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-1512	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-1512	-0.11854603886604309	Uncommon Uncommon Uncommon Uncommon
D-1512	-0.11854603886604309	Uncommon Uncommon Uncommon Uncommon
P-1512	-0.1566 -0.0899 -0.1246 -0.1259 -0.1073 -0.1240 -0.0928 -0.0764 -0.1695
S-985	Hämatokritabfall Auffällige Laborwerte
T-985	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-985	-0.7537031173706055	packed cell Abnormal laboratory values
D-985	-0.7537031173706055	packed cell Abnormal laboratory values
P-985	-3.2394 -0.2735 -1.1820 -0.3758 -0.2387 -0.0464 -0.5003 -0.1736
S-984	Erkrankungen der Haut und des Unterhautzellgewebes
T-984	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-984	-0.2976169288158417	Skin and subcutaneous disorders
D-984	-0.2976169288158417	Skin and subcutaneous disorders
P-984	-0.5540 -0.1147 -0.1861 -0.1434 -0.0269 -0.0641 -0.1277 -0.1382 -1.6709 -0.0671 -0.1806
S-1335	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-1335	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-1335	-0.11854603886604309	Uncommon Uncommon Uncommon Uncommon
D-1335	-0.11854603886604309	Uncommon Uncommon Uncommon Uncommon
P-1335	-0.1566 -0.0899 -0.1246 -0.1259 -0.1073 -0.1240 -0.0928 -0.0764 -0.1695
S-1160	Erkrankungen der Haut und des Unterhautzellgewebes
T-1160	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-1160	-0.2976169288158417	Skin and subcutaneous disorders
D-1160	-0.2976169288158417	Skin and subcutaneous disorders
P-1160	-0.5540 -0.1147 -0.1861 -0.1434 -0.0269 -0.0641 -0.1277 -0.1382 -1.6709 -0.0671 -0.1806
S-983	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-983	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-983	-0.11854603886604309	Uncommon Uncommon Uncommon Uncommon
D-983	-0.11854603886604309	Uncommon Uncommon Uncommon Uncommon
P-983	-0.1566 -0.0899 -0.1246 -0.1259 -0.1073 -0.1240 -0.0928 -0.0764 -0.1695
S-807	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-807	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-807	-0.11854603886604309	Uncommon Uncommon Uncommon Uncommon
D-807	-0.11854603886604309	Uncommon Uncommon Uncommon Uncommon
P-807	-0.1566 -0.0899 -0.1246 -0.1259 -0.1073 -0.1240 -0.0928 -0.0764 -0.1695
S-1513	Erkrankungen der Haut und des Unterhautzellgewebes
T-1513	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-1513	-0.2976169288158417	Skin and subcutaneous disorders
D-1513	-0.2976169288158417	Skin and subcutaneous disorders
P-1513	-0.5540 -0.1147 -0.1861 -0.1434 -0.0269 -0.0641 -0.1277 -0.1382 -1.6709 -0.0671 -0.1806
S-1336	Erkrankungen der Haut und des Unterhautzellgewebes
T-1336	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-1336	-0.2976169288158417	Skin and subcutaneous disorders
D-1336	-0.2976169288158417	Skin and subcutaneous disorders
P-1336	-0.5540 -0.1147 -0.1861 -0.1434 -0.0269 -0.0641 -0.1277 -0.1382 -1.6709 -0.0671 -0.1806
S-56	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-56	The medicine can only be obtained with a prescription .
H-56	-0.7479532957077026	This medicinal product is available only on prescription .
D-56	-0.7479532957077026	This medicinal product is available only on prescription .
P-56	-1.4055 -1.8176 -0.0729 -0.1144 -0.3801 -0.7905 -1.2287 -0.5455 -1.4219 -0.2915 -0.1589
S-980	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-980	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-980	-0.33021634817123413	diarrhoea upper abdominal pain nausea vomiting
D-980	-0.33021634817123413	diarrhoea upper abdominal pain nausea vomiting
P-980	-0.3287 -0.0254 -0.0801 -0.0237 -3.4175 -0.3360 -0.0161 -0.0864 -0.0598 -0.1418 -0.0373 -0.1005 -0.0413 -0.1045 -0.1543
S-1932	Tablette mit veränderter Wirkstofffreisetzung
T-1932	Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet
H-1932	-0.8407373428344727	modified drug release tablet
D-1932	-0.8407373428344727	modified drug release tablet
P-1932	-1.4055 -0.1142 -2.8973 -0.7645 -0.4121 -0.1073 -0.1842
S-804	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-804	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-804	-0.33021634817123413	diarrhoea upper abdominal pain nausea vomiting
D-804	-0.33021634817123413	diarrhoea upper abdominal pain nausea vomiting
P-804	-0.3287 -0.0254 -0.0801 -0.0237 -3.4175 -0.3360 -0.0161 -0.0864 -0.0598 -0.1418 -0.0373 -0.1005 -0.0413 -0.1045 -0.1543
S-1933	Tablette mit veränderter Wirkstofffreisetzung
T-1933	Oral use Oral use Oral use Oral use Oral use Oral use
H-1933	-0.8407373428344727	modified drug release tablet
D-1933	-0.8407373428344727	modified drug release tablet
P-1933	-1.4055 -0.1142 -2.8973 -0.7645 -0.4121 -0.1073 -0.1842
S-1156	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-1156	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-1156	-0.33021634817123413	diarrhoea upper abdominal pain nausea vomiting
D-1156	-0.33021634817123413	diarrhoea upper abdominal pain nausea vomiting
P-1156	-0.3287 -0.0254 -0.0801 -0.0237 -3.4175 -0.3360 -0.0161 -0.0864 -0.0598 -0.1418 -0.0373 -0.1005 -0.0413 -0.1045 -0.1543
S-1332	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-1332	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-1332	-0.33021634817123413	diarrhoea upper abdominal pain nausea vomiting
D-1332	-0.33021634817123413	diarrhoea upper abdominal pain nausea vomiting
P-1332	-0.3287 -0.0254 -0.0801 -0.0237 -3.4175 -0.3360 -0.0161 -0.0864 -0.0598 -0.1418 -0.0373 -0.1005 -0.0413 -0.1045 -0.1543
S-1509	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-1509	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-1509	-0.33021634817123413	diarrhoea upper abdominal pain nausea vomiting
D-1509	-0.33021634817123413	diarrhoea upper abdominal pain nausea vomiting
P-1509	-0.3287 -0.0254 -0.0801 -0.0237 -3.4175 -0.3360 -0.0161 -0.0864 -0.0598 -0.1418 -0.0373 -0.1005 -0.0413 -0.1045 -0.1543
S-1930	Tablette mit veränderter Wirkstofffreisetzung
T-1930	EU/ 1/ 07/ 399/ 001 EU/ 1/ 07/ 399/ 002 EU/ 1/ 07/ 399/ 003 EU/ 1/ 07/ 399/ 004 EU/ 1/ 07/ 399/ 005 EU/ 1/ 07/ 399/ 006
H-1930	-0.8407373428344727	modified drug release tablet
D-1930	-0.8407373428344727	modified drug release tablet
P-1930	-1.4055 -0.1142 -2.8973 -0.7645 -0.4121 -0.1073 -0.1842
S-1889	Aus welchen Gründen hat das Unternehmen den Antrag zurückgenommen ?
T-1889	What were the reasons given by the company to withdraw the application ?
H-1889	-0.5276613235473633	What are the reasons why the company withdrew the application ?
D-1889	-0.5276613235473633	What are the reasons why the company withdrew the application ?
P-1889	-0.8065 -1.5925 -0.1782 -0.3480 -0.4259 -0.3069 -0.6883 -0.7846 -0.2456 -0.4083 -0.3304 -0.5940 -0.1504
S-615	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-615	Animal reproduction studies have not been conducted with factor VIII .
H-615	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
D-615	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
P-615	-0.6486 -0.6319 -1.0917 -0.1070 -0.0760 -0.9369 -0.9733 -0.3774 -0.2926 -0.1472 -0.0877 -0.2584 -0.1565
S-44	Den vollständigen Wortlaut des EPAR für Adenuric finden Sie hier .
T-44	The full EPAR for Adenuric can be found here .
H-44	-0.304220587015152	The full EPAR for Adenuric is available here .
D-44	-0.304220587015152	The full EPAR for Adenuric is available here .
P-44	-1.5370 -0.1783 -0.2474 -0.0617 -0.2235 -0.1195 -0.1439 -0.0908 -0.1204 -0.7942 -0.2544 -0.0912 -0.2407 -0.1561
S-748	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-748	Early haemarthrosis , muscle bleeding or oral bleeding .
H-748	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
D-748	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
P-748	-2.0614 -0.9768 -1.1126 -0.1711 -0.1400 -0.2329 -1.1257 -0.1754 -1.3407 -0.1557 -0.4402 -0.3943 -0.1105 -0.2740 -0.1544
S-789	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-789	Animal reproduction studies have not been conducted with factor VIII .
H-789	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
D-789	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
P-789	-0.6486 -0.6319 -1.0917 -0.1070 -0.0760 -0.9369 -0.9733 -0.3774 -0.2926 -0.1472 -0.0877 -0.2584 -0.1565
S-10	Die empfohlene Dosis von Adenuric beträgt 80 mg einmal täglich .
T-10	The recommended dose of Adenuric is 80 mg once a day .
H-10	-0.1593378484249115	The recommended dose of Adenuric is 80 mg once daily .
D-10	-0.1593378484249115	The recommended dose of Adenuric is 80 mg once daily .
P-10	-0.1170 -0.2555 -0.0866 -0.1154 -0.2341 -0.1629 -0.0846 -0.1299 -0.1526 -0.2559 -0.0441 -0.1417 -0.3093 -0.1460 -0.1545
S-1493	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-1493	Animal reproduction studies have not been conducted with factor VIII .
H-1493	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
D-1493	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
P-1493	-0.6486 -0.6319 -1.0917 -0.1070 -0.0760 -0.9369 -0.9733 -0.3774 -0.2926 -0.1472 -0.0877 -0.2584 -0.1565
S-1317	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-1317	Animal reproduction studies have not been conducted with factor VIII .
H-1317	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
D-1317	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
P-1317	-0.6486 -0.6319 -1.0917 -0.1070 -0.0760 -0.9369 -0.9733 -0.3774 -0.2926 -0.1472 -0.0877 -0.2584 -0.1565
S-1141	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-1141	Animal reproduction studies have not been conducted with factor VIII .
H-1141	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
D-1141	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
P-1141	-0.6486 -0.6319 -1.0917 -0.1070 -0.0760 -0.9369 -0.9733 -0.3774 -0.2926 -0.1472 -0.0877 -0.2584 -0.1565
S-965	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-965	Animal reproduction studies have not been conducted with factor VIII .
H-965	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
D-965	-0.44500207901000977	No animal reproduction studies were conducted with factor VIII .
P-965	-0.6486 -0.6319 -1.0917 -0.1070 -0.0760 -0.9369 -0.9733 -0.3774 -0.2926 -0.1472 -0.0877 -0.2584 -0.1565
S-801	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-801	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-801	-0.21623918414115906	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-801	-0.21623918414115906	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-801	-0.0481 -0.1592 -0.4773 -0.0436 -0.1350 -0.1245 -0.7221 -0.0197 -1.0778 -0.0194 -0.1461 -0.0631 -0.1103 -0.1038 -0.1316 -0.1359 -0.1413 -0.2899 -0.1597
S-574	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-574	Early haemarthrosis , muscle bleeding or oral bleeding .
H-574	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
D-574	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
P-574	-2.0614 -0.9768 -1.1126 -0.1711 -0.1400 -0.2329 -1.1257 -0.1754 -1.3407 -0.1557 -0.4402 -0.3943 -0.1105 -0.2740 -0.1544
S-1276	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-1276	Early haemarthrosis , muscle bleeding or oral bleeding .
H-1276	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
D-1276	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
P-1276	-2.0614 -0.9768 -1.1126 -0.1711 -0.1400 -0.2329 -1.1257 -0.1754 -1.3407 -0.1557 -0.4402 -0.3943 -0.1105 -0.2740 -0.1544
S-1994	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1994	4.7 Effects on ability to drive and use machines
H-1994	-0.334271103143692	4.7 Effects on ability to drive and use machines
D-1994	-0.334271103143692	4.7 Effects on ability to drive and use machines
P-1994	-0.1146 -0.1538 -0.0587 -0.0550 -0.1090 -0.4293 -0.5058 -0.7339 -0.1440 -0.6805 -0.8572 -0.1695
S-1610	Name und Anschrift des Herstellers , der für die Chargenfreigabe verantwortlich ist
T-1610	Name and address of the manufacturer responsible for batch release
H-1610	-0.39668533205986023	Name and address of the manufacturer responsible for batch approval
D-1610	-0.39668533205986023	Name and address of the manufacturer responsible for batch approval
P-1610	-0.3860 -0.1335 -0.1093 -0.1291 -0.2698 -0.5057 -0.1531 -0.1212 -1.1785 -0.0864 -1.4759 -0.2117
S-1496	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1496	4.7 Effects on ability to drive and use machines
H-1496	-0.334271103143692	4.7 Effects on ability to drive and use machines
D-1496	-0.334271103143692	4.7 Effects on ability to drive and use machines
P-1496	-0.1146 -0.1538 -0.0587 -0.0550 -0.1090 -0.4293 -0.5058 -0.7339 -0.1440 -0.6805 -0.8572 -0.1695
S-1320	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1320	4.7 Effects on ability to drive and use machines
H-1320	-0.334271103143692	4.7 Effects on ability to drive and use machines
D-1320	-0.334271103143692	4.7 Effects on ability to drive and use machines
P-1320	-0.1146 -0.1538 -0.0587 -0.0550 -0.1090 -0.4293 -0.5058 -0.7339 -0.1440 -0.6805 -0.8572 -0.1695
S-1144	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1144	4.7 Effects on ability to drive and use machines
H-1144	-0.334271103143692	4.7 Effects on ability to drive and use machines
D-1144	-0.334271103143692	4.7 Effects on ability to drive and use machines
P-1144	-0.1146 -0.1538 -0.0587 -0.0550 -0.1090 -0.4293 -0.5058 -0.7339 -0.1440 -0.6805 -0.8572 -0.1695
S-968	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-968	4.7 Effects on ability to drive and use machines
H-968	-0.334271103143692	4.7 Effects on ability to drive and use machines
D-968	-0.334271103143692	4.7 Effects on ability to drive and use machines
P-968	-0.1146 -0.1538 -0.0587 -0.0550 -0.1090 -0.4293 -0.5058 -0.7339 -0.1440 -0.6805 -0.8572 -0.1695
S-792	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-792	4.7 Effects on ability to drive and use machines
H-792	-0.334271103143692	4.7 Effects on ability to drive and use machines
D-792	-0.334271103143692	4.7 Effects on ability to drive and use machines
P-792	-0.1146 -0.1538 -0.0587 -0.0550 -0.1090 -0.4293 -0.5058 -0.7339 -0.1440 -0.6805 -0.8572 -0.1695
S-618	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-618	4.7 Effects on ability to drive and use machines
H-618	-0.334271103143692	4.7 Effects on ability to drive and use machines
D-618	-0.334271103143692	4.7 Effects on ability to drive and use machines
P-618	-0.1146 -0.1538 -0.0587 -0.0550 -0.1090 -0.4293 -0.5058 -0.7339 -0.1440 -0.6805 -0.8572 -0.1695
S-924	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-924	Early haemarthrosis , muscle bleeding or oral bleeding .
H-924	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
D-924	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
P-924	-2.0614 -0.9768 -1.1126 -0.1711 -0.1400 -0.2329 -1.1257 -0.1754 -1.3407 -0.1557 -0.4402 -0.3943 -0.1105 -0.2740 -0.1544
S-160	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-160	4.7 Effects on ability to drive and use machines
H-160	-0.334271103143692	4.7 Effects on ability to drive and use machines
D-160	-0.334271103143692	4.7 Effects on ability to drive and use machines
P-160	-0.1146 -0.1538 -0.0587 -0.0550 -0.1090 -0.4293 -0.5058 -0.7339 -0.1440 -0.6805 -0.8572 -0.1695
S-116	Viele dieser Patienten erhielten auch eine Chemotherapie und Kortikosteroide .
T-116	Many of these patients were also receiving chemotherapy and corticosteroids .
H-116	-0.1870611011981964	Many of these patients also received chemotherapy and corticosteroids .
D-116	-0.1870611011981964	Many of these patients also received chemotherapy and corticosteroids .
P-116	-0.1627 -0.1584 -0.1368 -0.1095 -0.9241 -0.3891 -0.1238 -0.0451 -0.0866 -0.1386 -0.2814 -0.1164 -0.0866 -0.0974 -0.1508 -0.0583 -0.1496 -0.1518
S-1454	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-1454	More extensive haemarthrosis , muscle bleeding or haematoma .
H-1454	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
D-1454	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
P-1454	-2.6307 -0.4945 -0.1438 -0.2130 -1.6123 -0.0892 -0.1325 -0.2836 -0.8644 -0.0867 -1.1718 -0.1424 -0.3655 -0.0410 -0.0554 -0.1170 -0.1873 -0.1533
S-780	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-780	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-780	-0.4121815264225006	In such cases , contact with a haemophilia centre is recommended .
D-780	-0.4121815264225006	In such cases , contact with a haemophilia centre is recommended .
P-780	-0.4119 -0.7026 -0.0842 -0.7687 -1.4011 -1.0422 -0.1303 -0.1836 -0.0766 -0.1227 -0.2623 -0.5271 -0.1886 -0.3830 -0.1566 -0.1533
S-627	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-627	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-627	-0.21623918414115906	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-627	-0.21623918414115906	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-627	-0.0481 -0.1592 -0.4773 -0.0436 -0.1350 -0.1245 -0.7221 -0.0197 -1.0778 -0.0194 -0.1461 -0.0631 -0.1103 -0.1038 -0.1316 -0.1359 -0.1413 -0.2899 -0.1597
S-606	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-606	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-606	-0.4121815264225006	In such cases , contact with a haemophilia centre is recommended .
D-606	-0.4121815264225006	In such cases , contact with a haemophilia centre is recommended .
P-606	-0.4119 -0.7026 -0.0842 -0.7687 -1.4011 -1.0422 -0.1303 -0.1836 -0.0766 -0.1227 -0.2623 -0.5271 -0.1886 -0.3830 -0.1566 -0.1533
S-447	Ein kleiner Anteil Vitamin D3 wird vor Ausscheidung glukuronidiert .
T-447	A small percentage of vitamin D3 undergoes glucuronidation prior to elimination .
H-447	-0.34755292534828186	A small amount of vitamin D3 is glucuronised prior to excretion .
D-447	-0.34755292534828186	A small amount of vitamin D3 is glucuronised prior to excretion .
P-447	-0.2748 -0.0688 -1.1904 -0.1229 -0.1502 -0.0825 -0.1606 -0.1373 -0.1652 -0.2652 -0.4716 -0.2697 -1.1580 -1.1758 -0.1292 -0.6296 -0.0281 -0.1302 -0.1876 -0.1535
S-272	Jede Tablette enthält 63 mg Lactose und 16 mg Sucrose .
T-272	Each tablet contains 63 mg lactose anhydrous and 16 mg sucrose .
H-272	-0.12315204739570618	Each tablet contains 63 mg lactose and 16 mg sucrose .
D-272	-0.12315204739570618	Each tablet contains 63 mg lactose and 16 mg sucrose .
P-272	-0.0435 -0.1743 -0.1161 -0.0876 -0.1344 -0.0581 -0.4614 -0.0417 -0.0994 -0.1472 -0.1210 -0.0562 -0.0836 -0.0857 -0.0515 -0.1768 -0.1553
S-251	Ein kleiner Anteil Vitamin D3 wird vor Ausscheidung glukuronidiert .
T-251	A small percentage of vitamin D3 undergoes glucuronidation prior to elimination .
H-251	-0.34755292534828186	A small amount of vitamin D3 is glucuronised prior to excretion .
D-251	-0.34755292534828186	A small amount of vitamin D3 is glucuronised prior to excretion .
P-251	-0.2748 -0.0688 -1.1904 -0.1229 -0.1502 -0.0825 -0.1606 -0.1373 -0.1652 -0.2652 -0.4716 -0.2697 -1.1580 -1.1758 -0.1292 -0.6296 -0.0281 -0.1302 -0.1876 -0.1535
S-85	Jede Tablette enthält 62 mg Lactose und 8 mg Sucrose .
T-85	Each tablet contains 62 mg lactose anhydrous and 8 mg sucrose .
H-85	-0.12495093792676926	Each tablet contains 62 mg lactose and 8 mg sucrose .
D-85	-0.12495093792676926	Each tablet contains 62 mg lactose and 8 mg sucrose .
P-85	-0.0564 -0.1782 -0.1152 -0.0940 -0.1462 -0.0556 -0.4541 -0.0416 -0.0971 -0.1477 -0.1333 -0.0528 -0.0824 -0.0878 -0.0521 -0.1757 -0.1539
S-304	Viele dieser Patienten erhielten auch eine Chemotherapie und Kortikosteroide .
T-304	Many of these patients were also receiving chemotherapy and corticosteroids .
H-304	-0.1870611011981964	Many of these patients also received chemotherapy and corticosteroids .
D-304	-0.1870611011981964	Many of these patients also received chemotherapy and corticosteroids .
P-304	-0.1627 -0.1584 -0.1368 -0.1095 -0.9241 -0.3891 -0.1238 -0.0451 -0.0866 -0.1386 -0.2814 -0.1164 -0.0866 -0.0974 -0.1508 -0.0583 -0.1496 -0.1518
S-1100	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-1100	Early haemarthrosis , muscle bleeding or oral bleeding .
H-1100	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
D-1100	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
P-1100	-2.0614 -0.9768 -1.1126 -0.1711 -0.1400 -0.2329 -1.1257 -0.1754 -1.3407 -0.1557 -0.4402 -0.3943 -0.1105 -0.2740 -0.1544
S-1452	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-1452	Early haemarthrosis , muscle bleeding or oral bleeding .
H-1452	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
D-1452	-0.5910477638244629	early joint bleeding , muscle bleeding , or mouth bleeding .
P-1452	-2.0614 -0.9768 -1.1126 -0.1711 -0.1400 -0.2329 -1.1257 -0.1754 -1.3407 -0.1557 -0.4402 -0.3943 -0.1105 -0.2740 -0.1544
S-1278	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-1278	More extensive haemarthrosis , muscle bleeding or haematoma .
H-1278	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
D-1278	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
P-1278	-2.6307 -0.4945 -0.1438 -0.2130 -1.6123 -0.0892 -0.1325 -0.2836 -0.8644 -0.0867 -1.1718 -0.1424 -0.3655 -0.0410 -0.0554 -0.1170 -0.1873 -0.1533
S-1102	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-1102	More extensive haemarthrosis , muscle bleeding or haematoma .
H-1102	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
D-1102	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
P-1102	-2.6307 -0.4945 -0.1438 -0.2130 -1.6123 -0.0892 -0.1325 -0.2836 -0.8644 -0.0867 -1.1718 -0.1424 -0.3655 -0.0410 -0.0554 -0.1170 -0.1873 -0.1533
S-926	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-926	More extensive haemarthrosis , muscle bleeding or haematoma .
H-926	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
D-926	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
P-926	-2.6307 -0.4945 -0.1438 -0.2130 -1.6123 -0.0892 -0.1325 -0.2836 -0.8644 -0.0867 -1.1718 -0.1424 -0.3655 -0.0410 -0.0554 -0.1170 -0.1873 -0.1533
S-750	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-750	More extensive haemarthrosis , muscle bleeding or haematoma .
H-750	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
D-750	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
P-750	-2.6307 -0.4945 -0.1438 -0.2130 -1.6123 -0.0892 -0.1325 -0.2836 -0.8644 -0.0867 -1.1718 -0.1424 -0.3655 -0.0410 -0.0554 -0.1170 -0.1873 -0.1533
S-576	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-576	More extensive haemarthrosis , muscle bleeding or haematoma .
H-576	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
D-576	-0.4880276024341583	More pronounced joint bleeding , muscle bleeding , or haematoma .
P-576	-2.6307 -0.4945 -0.1438 -0.2130 -1.6123 -0.0892 -0.1325 -0.2836 -0.8644 -0.0867 -1.1718 -0.1424 -0.3655 -0.0410 -0.0554 -0.1170 -0.1873 -0.1533
S-327	Bei diesen Patienten sind Urin und Serum-Calcium zu überwachen .
T-327	Urine and serum calcium should be monitored in these patients .
H-327	-0.26231878995895386	In these patients urine and serum calcium should be monitored .
D-327	-0.26231878995895386	In these patients urine and serum calcium should be monitored .
P-327	-1.5363 -0.2007 -0.1040 -0.3653 -0.0705 -0.1439 -0.2016 -0.1057 -0.2000 -0.1120 -0.0966 -0.6467 -0.1415 -0.1132 -0.0932 -0.1737 -0.1545
S-139	Bei diesen Patienten sind Urin und Serum-Calcium zu überwachen .
T-139	Urine and serum calcium should be monitored in these patients .
H-139	-0.26231878995895386	In these patients urine and serum calcium should be monitored .
D-139	-0.26231878995895386	In these patients urine and serum calcium should be monitored .
P-139	-1.5363 -0.2007 -0.1040 -0.3653 -0.0705 -0.1439 -0.2016 -0.1057 -0.2000 -0.1120 -0.0966 -0.6467 -0.1415 -0.1132 -0.0932 -0.1737 -0.1545
S-1818	eská republika Baxter Czech spol.s.r.o .
T-1818	eská republika Baxter Czech spol . s. r. o.
H-1818	-0.16602930426597595	eská republika Baxter Czech spol.s.r.o .
D-1818	-0.16602930426597595	eská republika Baxter Czech spol.s.r.o .
P-1818	-0.0708 -0.1717 -0.0764 -0.0252 -0.0739 -0.1301 -0.1652 -0.1471 -0.0504 -0.1162 -0.0562 -0.2909 -0.8657 -0.0655 -0.2156 -0.1489 -0.1708 -0.1478
S-549	1 Durchstechflasche + 1 Durchstechflasche + Gerät zur Rekonstitution
T-549	1 vial + 1 vial + reconstitution device
H-549	-0.24782389402389526	1 vial + 1 vial + reconstitution device
D-549	-0.24782389402389526	1 vial + 1 vial + reconstitution device
P-549	-0.1682 -0.0456 -0.1098 -0.1308 -0.1476 -0.0370 -0.1495 -0.1157 -0.4975 -0.1574 -1.2497 -0.1650
S-1566	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1566	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1566	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
D-1566	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
P-1566	-1.3454 -0.5761 -0.5825 -0.2813 -0.7193 -0.0026 -0.0747 -0.1556 -0.7079 -0.1201 -0.0865 -0.1251 -0.1887 -0.1529
S-329	Sonstige Bestandteile Dieses Arzneimittel enthält Lactose und Sucrose .
T-329	14 Excipients This medicinal product contains lactose and sucrose .
H-329	-0.1738165020942688	Other ingredients This medicinal product contains lactose and sucrose .
D-329	-0.1738165020942688	Other ingredients This medicinal product contains lactose and sucrose .
P-329	-1.4037 -0.0543 -0.1542 -0.0094 -0.0899 -0.1378 -0.0826 -0.0701 -0.0322 -0.0769 -0.1371 -0.0654 -0.0903 -0.0652 -0.1558 -0.1563
S-141	Sonstige Bestandteile Dieses Arzneimittel enthält Lactose und Sucrose .
T-141	4 Excipients This medicinal product contains lactose and sucrose .
H-141	-0.1738165020942688	Other ingredients This medicinal product contains lactose and sucrose .
D-141	-0.1738165020942688	Other ingredients This medicinal product contains lactose and sucrose .
P-141	-1.4037 -0.0543 -0.1542 -0.0094 -0.0899 -0.1378 -0.0826 -0.0701 -0.0322 -0.0769 -0.1371 -0.0654 -0.0903 -0.0652 -0.1558 -0.1563
S-1993	Deshalb sollte Aerinaze in der Stillzeit nicht angewendet werden .
T-1993	Therefore Aerinaze should not be used in breast-feeding women .
H-1993	-0.38886862993240356	Aerinaze should therefore not be used while breast-feeding .
D-1993	-0.38886862993240356	Aerinaze should therefore not be used while breast-feeding .
P-1993	-1.9329 -0.1283 -0.1443 -0.1186 -0.0887 -0.1652 -1.2195 -0.1639 -0.1356 -0.3398 -0.8222 -0.9057 -0.0334 -0.0254 -0.0450 -0.1863 -0.1557
S-1389	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1389	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1389	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
D-1389	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
P-1389	-1.3454 -0.5761 -0.5825 -0.2813 -0.7193 -0.0026 -0.0747 -0.1556 -0.7079 -0.1201 -0.0865 -0.1251 -0.1887 -0.1529
S-1213	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1213	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1213	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
D-1213	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
P-1213	-1.3454 -0.5761 -0.5825 -0.2813 -0.7193 -0.0026 -0.0747 -0.1556 -0.7079 -0.1201 -0.0865 -0.1251 -0.1887 -0.1529
S-1037	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1037	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1037	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
D-1037	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
P-1037	-1.3454 -0.5761 -0.5825 -0.2813 -0.7193 -0.0026 -0.0747 -0.1556 -0.7079 -0.1201 -0.0865 -0.1251 -0.1887 -0.1529
S-861	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-861	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-861	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
D-861	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
P-861	-1.3454 -0.5761 -0.5825 -0.2813 -0.7193 -0.0026 -0.0747 -0.1556 -0.7079 -0.1201 -0.0865 -0.1251 -0.1887 -0.1529
S-1848	ADVATE darf nicht mit anderen Arzneimitteln oder Lösungen gemischt werden .
T-1848	ADVATE must not be mixed with other medicinal products or solvents .
H-1848	-0.3100898861885071	ADVATE should not be mixed with other medicines or solutions .
D-1848	-0.3100898861885071	ADVATE should not be mixed with other medicines or solutions .
P-1848	-0.7110 -0.1532 -0.0939 -0.0987 -0.8494 -0.1468 -0.1473 -0.2197 -0.1772 -0.2801 -0.3956 -0.9527 -0.1663 -0.2052 -0.2054 -0.1590
S-328	Patienten mit einer Malabsorption nehmen möglicherweise nicht ausreichend Vitamin D3 auf .
T-328	Patients with malabsorption may not adequately absorb vitamin D3 .
H-328	-0.47247424721717834	Malabsorption patients may not be receiving adequate vitamin D3 .
D-328	-0.47247424721717834	Malabsorption patients may not be receiving adequate vitamin D3 .
P-328	-0.3154 -0.0743 -0.4255 -0.2541 -0.2056 -0.1778 -1.1644 -1.6610 -0.8770 -0.6194 -0.0662 -0.1731 -0.1443 -0.7747 -0.1543
S-172	Nach Markteinführung wurden folgende Reaktionen berichtet ( Häufigkeit nicht bekannt ) :
T-172	During post-marketing experience the following reactions have been reported ( frequency not known ) :
H-172	-0.5788997411727905	Following reactions have been reported ( frequency unknown ) :
D-172	-0.5788997411727905	Following reactions have been reported ( frequency unknown ) :
P-172	-0.9351 -0.2867 -0.0381 -1.8956 -0.1083 -0.1139 -0.4877 -1.2736 -0.0651 -0.2727 -0.1425 -1.7495 -0.1570
S-360	Nach Markteinführung wurden folgende Reaktionen berichtet ( Häufigkeit nicht bekannt ) :
T-360	During post-marketing experience the following reactions have been reported ( frequency not known ) :
H-360	-0.5788997411727905	Following reactions have been reported ( frequency unknown ) :
D-360	-0.5788997411727905	Following reactions have been reported ( frequency unknown ) :
P-360	-0.9351 -0.2867 -0.0381 -1.8956 -0.1083 -0.1139 -0.4877 -1.2736 -0.0651 -0.2727 -0.1425 -1.7495 -0.1570
S-592	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-592	Method of administration ADVATE should be administered via the intravenous route .
H-592	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
D-592	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
P-592	-0.1985 -0.1176 -0.0861 -0.1236 -0.1570 -0.0883 -0.0907 -0.8378 -0.1330 -0.6920 -0.0992 -0.2032 -0.0787 -0.0745 -0.0926 -0.2120 -0.1577
S-766	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-766	Method of administration ADVATE should be administered via the intravenous route .
H-766	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
D-766	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
P-766	-0.1985 -0.1176 -0.0861 -0.1236 -0.1570 -0.0883 -0.0907 -0.8378 -0.1330 -0.6920 -0.0992 -0.2032 -0.0787 -0.0745 -0.0926 -0.2120 -0.1577
S-942	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-942	Method of administration ADVATE should be administered via the intravenous route .
H-942	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
D-942	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
P-942	-0.1985 -0.1176 -0.0861 -0.1236 -0.1570 -0.0883 -0.0907 -0.8378 -0.1330 -0.6920 -0.0992 -0.2032 -0.0787 -0.0745 -0.0926 -0.2120 -0.1577
S-1118	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-1118	Method of administration ADVATE should be administered via the intravenous route .
H-1118	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
D-1118	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
P-1118	-0.1985 -0.1176 -0.0861 -0.1236 -0.1570 -0.0883 -0.0907 -0.8378 -0.1330 -0.6920 -0.0992 -0.2032 -0.0787 -0.0745 -0.0926 -0.2120 -0.1577
S-1294	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-1294	Method of administration ADVATE should be administered via the intravenous route .
H-1294	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
D-1294	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
P-1294	-0.1985 -0.1176 -0.0861 -0.1236 -0.1570 -0.0883 -0.0907 -0.8378 -0.1330 -0.6920 -0.0992 -0.2032 -0.0787 -0.0745 -0.0926 -0.2120 -0.1577
S-1470	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-1470	Method of administration ADVATE should be administered via the intravenous route .
H-1470	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
D-1470	-0.2024994194507599	method of administration ADVATE should be administered intravenously .
P-1470	-0.1985 -0.1176 -0.0861 -0.1236 -0.1570 -0.0883 -0.0907 -0.8378 -0.1330 -0.6920 -0.0992 -0.2032 -0.0787 -0.0745 -0.0926 -0.2120 -0.1577
S-45	Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-45	EU/ 1/ 08/ 447/ 001 EU/ 1/ 08/ 447/ 002 EU/ 1/ 08/ 447/ 003 EU/ 1/ 08/ 447/ 004
H-45	-0.2445519119501114	Blister ( Aclar/ PVC/ aluminium )
D-45	-0.2445519119501114	Blister ( Aclar/ PVC/ aluminium )
P-45	-1.2556 -0.0917 -0.1863 -0.1838 -0.2158 -0.1776 -0.1415 -0.1155 -0.1385 -0.1359 -0.1709 -0.3924 -0.1407 -0.1527 -0.1694
S-685	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-685	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-685	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
D-685	-0.36562028527259827	storage conditions of the reconstituted product see section 6.3 .
P-685	-1.3454 -0.5761 -0.5825 -0.2813 -0.7193 -0.0026 -0.0747 -0.1556 -0.7079 -0.1201 -0.0865 -0.1251 -0.1887 -0.1529
S-60	Die Tablette darf nicht gekaut werden und nicht im Mund zergehen .
T-60	The tablet should not be chewed or allowed to dissolve in the mouth .
H-60	-0.45972535014152527	Do not chew or dissolve in the mouth .
D-60	-0.45972535014152527	Do not chew or dissolve in the mouth .
P-60	-0.4635 -0.1333 -0.0467 -0.1234 -0.8835 -1.5178 -0.1344 -0.5076 -1.2090 -0.1111 -0.2241 -0.1624
S-140	Patienten mit einer Malabsorption nehmen möglicherweise nicht ausreichend Vitamin D3 auf .
T-140	Patients with malabsorption may not adequately absorb vitamin D3 .
H-140	-0.47247424721717834	Malabsorption patients may not be receiving adequate vitamin D3 .
D-140	-0.47247424721717834	Malabsorption patients may not be receiving adequate vitamin D3 .
P-140	-0.3154 -0.0743 -0.4255 -0.2541 -0.2056 -0.1778 -1.1644 -1.6610 -0.8770 -0.6194 -0.0662 -0.1731 -0.1443 -0.7747 -0.1543
S-1801	Das Arzneimittel unmittelbar nach dem vollständigen Lösen des Pulvers verbrauchen .
T-1801	Use the product immediately once the powder is completely dissolved .
H-1801	-0.4148085117340088	Use immediately after dissolving the powder .
D-1801	-0.4148085117340088	Use immediately after dissolving the powder .
P-1801	-1.1561 -0.3848 -0.3580 -0.7586 -0.3882 -0.1471 -0.3840 -0.1897 -0.1991 -0.1824
S-1608	Name und Anschrift des Herstellers des Wirkstoffs biologischen Ursprungs
T-1608	Name and address of the manufacturer of the biological active substance
H-1608	-0.3371426463127136	Name and address of the manufacturer of the active substance of biological origin
D-1608	-0.3371426463127136	Name and address of the manufacturer of the active substance of biological origin
P-1608	-0.9065 -0.1354 -0.1687 -0.1341 -0.5820 -0.7449 -0.1423 -0.2505 -0.9512 -0.0451 -0.4955 -0.3916 -0.0960 -0.0843 -0.1029 -0.1633
S-152	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell erwogen werden .
T-152	Additional vitamin D supplements may be considered on an individual basis .
H-152	-0.3288305401802063	Additional vitamin D supplementation should be considered individually .
D-152	-0.3288305401802063	Additional vitamin D supplementation should be considered individually .
P-152	-1.7178 -0.7441 -0.0564 -0.1293 -0.0516 -0.1166 -0.1061 -0.1443 -0.1376 -0.1474 -0.7690 -0.1583 -0.1697 -0.1555
S-1768	99 Inhibitoren liegen . Dies wird von Ihrem Arzt abgeklärt werden .
T-1768	This will be checked by your doctor .
H-1768	-0.3604394197463989	99 inhibitors , this will be determined by your doctor .
D-1768	-0.3604394197463989	99 inhibitors , this will be determined by your doctor .
P-1768	-0.2990 -0.1806 -0.0635 -0.0522 -0.1458 -1.5100 -0.8010 -0.5753 -0.1637 -0.8582 -0.1544 -0.1498 -0.1139 -0.1824 -0.1569
S-1858	Li-Fraumeni-Krebs kann in vielen Teilen des Körpers auftreten .
T-1858	People who have this mutation are more likely to develop cancer .
H-1858	-0.40796932578086853	Li-Fraumeni cancer can occur in many parts of the body .
D-1858	-0.40796932578086853	Li-Fraumeni cancer can occur in many parts of the body .
P-1858	-1.7739 -0.4189 -0.4423 -0.0507 -0.3385 -1.1059 -0.4529 -0.4894 -0.1372 -0.2050 -0.3810 -0.1196 -0.1726 -0.1060 -0.1785 -0.1551
S-340	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell erwogen werden .
T-340	Additional vitamin D supplements may be considered on an individual basis .
H-340	-0.3288305401802063	Additional vitamin D supplementation should be considered individually .
D-340	-0.3288305401802063	Additional vitamin D supplementation should be considered individually .
P-340	-1.7178 -0.7441 -0.0564 -0.1293 -0.0516 -0.1166 -0.1061 -0.1443 -0.1376 -0.1474 -0.7690 -0.1583 -0.1697 -0.1555
S-146	Andere klinisch relevante Wechselwirkungen mit Arzneimitteln sind nicht zu erwarten .
T-146	No other clinically significant interactions with medicinal products are anticipated .
H-146	-0.4414524435997009	No other clinically relevant interactions with medicines are expected .
D-146	-0.4414524435997009	No other clinically relevant interactions with medicines are expected .
P-146	-0.8323 -0.0992 -0.0952 -0.0969 -0.7157 -0.1790 -0.9470 -0.2282 -0.5647 -0.8097 -0.2262 -1.0260 -0.2066 -0.1538
S-1725	Es kann anderen Menschen schaden , auch wenn diese die gleichen Beschwerden haben wie Sie .
T-1725	if their symptoms are the same as yours .
H-1725	-0.4490659534931183	It can harm other people , even if they have the same discomfort as you .
D-1725	-0.4490659534931183	It can harm other people , even if they have the same discomfort as you .
P-1725	-0.3041 -0.6401 -1.2410 -0.2265 -0.4231 -0.7729 -0.2202 -0.2841 -0.1733 -0.4078 -0.1663 -0.3660 -1.4747 -0.3583 -0.4208 -0.0830 -0.3631 -0.1579
S-412	Die BMD des Gesamtskeletts stieg ebenfalls signifikant an .
T-412	Total body BMD also increased significantly .
H-412	-0.4530068635940552	The BMD of the total skeleton also increased significantly .
D-412	-0.4530068635940552	The BMD of the total skeleton also increased significantly .
P-412	-1.4748 -0.4124 -0.1290 -0.1685 -0.1553 -1.3603 -0.5425 -0.7552 -0.0458 -0.7046 -0.1281 -0.1590 -0.1545 -0.1522
S-216	Die BMD des Gesamtskeletts stieg ebenfalls signifikant an .
T-216	Total body BMD also increased significantly .
H-216	-0.4530068635940552	The BMD of the total skeleton also increased significantly .
D-216	-0.4530068635940552	The BMD of the total skeleton also increased significantly .
P-216	-1.4748 -0.4124 -0.1290 -0.1685 -0.1553 -1.3603 -0.5425 -0.7552 -0.0458 -0.7046 -0.1281 -0.1590 -0.1545 -0.1522
S-334	Andere klinisch relevante Wechselwirkungen mit Arzneimitteln sind nicht zu erwarten .
T-334	No other clinically significant interactions with medicinal products are anticipated .
H-334	-0.4414524435997009	No other clinically relevant interactions with medicines are expected .
D-334	-0.4414524435997009	No other clinically relevant interactions with medicines are expected .
P-334	-0.8323 -0.0992 -0.0952 -0.0969 -0.7157 -0.1790 -0.9470 -0.2282 -0.5647 -0.8097 -0.2262 -1.0260 -0.2066 -0.1538
S-1869	Welche Unterlagen hat das Unternehmen dem CHMP zur Stützung seines Antrags vorgelegt ?
T-1869	What documentation did the company present to support its application to the CHMP ?
H-1869	-0.47364339232444763	What documents has the company submitted to CHMP in support of its application ?
D-1869	-0.47364339232444763	What documents has the company submitted to CHMP in support of its application ?
P-1869	-0.1032 -1.0648 -0.8484 -0.3774 -0.6845 -1.2399 -0.1644 -0.6954 -0.0468 -0.3350 -0.1048 -0.1406 -0.2463 -0.7386 -0.6365 -0.1517
S-1043	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1043	For administration the use of a luer-lock syringe is required .
H-1043	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
D-1043	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
P-1043	-0.9413 -0.4555 -0.2370 -0.4142 -1.1691 -0.1027 -0.1638 -0.0662 -0.0128 -0.1541 -0.3334 -0.7398 -0.5513 -0.1855 -0.1549
S-1395	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1395	For administration the use of a luer-lock syringe is required .
H-1395	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
D-1395	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
P-1395	-0.9413 -0.4555 -0.2370 -0.4142 -1.1691 -0.1027 -0.1638 -0.0662 -0.0128 -0.1541 -0.3334 -0.7398 -0.5513 -0.1855 -0.1549
S-1572	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1572	For administration the use of a luer-lock syringe is required .
H-1572	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
D-1572	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
P-1572	-0.9413 -0.4555 -0.2370 -0.4142 -1.1691 -0.1027 -0.1638 -0.0662 -0.0128 -0.1541 -0.3334 -0.7398 -0.5513 -0.1855 -0.1549
S-86	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-86	For a full list of excipients , see section 6.1 .
H-86	-0.3900008499622345	For a full list of other ingredients , see section 6.1 .
D-86	-0.3900008499622345	For a full list of other ingredients , see section 6.1 .
P-86	-0.1772 -0.1502 -0.1245 -0.1047 -0.1343 -3.2156 -0.0271 -0.6215 -0.2076 -0.1194 -0.0957 -0.1406 -0.1872 -0.1543
S-1219	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1219	For administration the use of a luer-lock syringe is required .
H-1219	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
D-1219	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
P-1219	-0.9413 -0.4555 -0.2370 -0.4142 -1.1691 -0.1027 -0.1638 -0.0662 -0.0128 -0.1541 -0.3334 -0.7398 -0.5513 -0.1855 -0.1549
S-1738	- wenn Sie allergisch gegen Maus- oder Hamsterprotein sind .
T-1738	- if you are allergic to mouse or hamster proteins
H-1738	-0.2146112322807312	- if you are allergic to mouse or hamster protein .
D-1738	-0.2146112322807312	- if you are allergic to mouse or hamster protein .
P-1738	-1.2854 -0.1157 -0.1427 -0.1306 -0.0759 -0.0507 -0.1421 -0.1802 -0.0520 -0.1789 -0.1324 -0.0862 -0.2231 -0.2676 -0.1558
S-867	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-867	For administration the use of a luer-lock syringe is required .
H-867	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
D-867	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
P-867	-0.9413 -0.4555 -0.2370 -0.4142 -1.1691 -0.1027 -0.1638 -0.0662 -0.0128 -0.1541 -0.3334 -0.7398 -0.5513 -0.1855 -0.1549
S-1938	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1938	For a full list of excipients , see section 6.1 .
H-1938	-0.3900008499622345	For a full list of other ingredients , see section 6.1 .
D-1938	-0.3900008499622345	For a full list of other ingredients , see section 6.1 .
P-1938	-0.1772 -0.1502 -0.1245 -0.1047 -0.1343 -3.2156 -0.0271 -0.6215 -0.2076 -0.1194 -0.0957 -0.1406 -0.1872 -0.1543
S-273	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-273	For a full list of excipients , see section 6.1 .
H-273	-0.3900008499622345	For a full list of other ingredients , see section 6.1 .
D-273	-0.3900008499622345	For a full list of other ingredients , see section 6.1 .
P-273	-0.1772 -0.1502 -0.1245 -0.1047 -0.1343 -3.2156 -0.0271 -0.6215 -0.2076 -0.1194 -0.0957 -0.1406 -0.1872 -0.1543
S-691	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-691	For administration the use of a luer-lock syringe is required .
H-691	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
D-691	-0.3787706792354584	A Luer-Lock-Syringe is necessary for administration .
P-691	-0.9413 -0.4555 -0.2370 -0.4142 -1.1691 -0.1027 -0.1638 -0.0662 -0.0128 -0.1541 -0.3334 -0.7398 -0.5513 -0.1855 -0.1549
S-1802	Arzneimittel dürfen nicht im Abwasser oder Haushaltsabfall entsorgt werden .
T-1802	Medicines should not be disposed of via waste water or household waste .
H-1802	-0.3996250629425049	Medicines should not be disposed of in sewage or household waste .
D-1802	-0.3996250629425049	Medicines should not be disposed of in sewage or household waste .
P-1802	-2.1492 -0.1754 -0.6815 -0.1595 -0.1447 -0.0913 -0.0803 -0.1712 -0.4479 -1.1205 -0.2599 -0.2014 -0.2220 -0.1663 -0.1712 -0.1518
S-1416	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1416	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1416	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
D-1416	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
P-1416	-0.3816 -0.0817 -0.5639 -0.1262 -0.1010 -0.9442 -0.1749 -0.2950 -0.3810 -0.2959 -0.1104 -0.2690 -0.1902 -0.1458 -0.1815 -0.1554
S-1593	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1593	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1593	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
D-1593	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
P-1593	-0.3816 -0.0817 -0.5639 -0.1262 -0.1010 -0.9442 -0.1749 -0.2950 -0.3810 -0.2959 -0.1104 -0.2690 -0.1902 -0.1458 -0.1815 -0.1554
S-706	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-706	Do not remove the blue cap from the BAXJECT II device .
H-706	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
D-706	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
P-706	-0.0636 -0.1323 -0.1315 -0.2512 -0.3014 -0.3891 -0.1809 -0.6881 -0.4012 -0.1766 -0.2151 -0.1199 -0.1197 -0.1143 -0.2620 -0.1577
S-1817	H-1123 Budapest Tel . : <unk> 361 202 19 80
T-1817	H-1123 Budapest Tel . : <<unk>> 361 202 19 80
H-1817	-0.14781048893928528	H-1123 Budapest Tel . : <unk> 361 202 19 80
D-1817	-0.14781048893928528	H-1123 Budapest Tel . : <unk> 361 202 19 80
P-1817	-0.2080 -0.1179 -0.1134 -0.1364 -0.1124 -0.0584 -0.4633 -0.1410 -0.0298 -0.1468 -0.0578 -0.1740 -0.1261 -0.1450 -0.1744 -0.1603
S-1846	Beim Auflösen und bei der Anwendung sind aseptische Techniken erforderlich .
T-1846	Aseptic technique is required during preparation of the solution and administration .
H-1846	-0.6743931770324707	Aseptic techniques are necessary for dissolution and administration .
D-1846	-0.6743931770324707	Aseptic techniques are necessary for dissolution and administration .
P-1846	-2.2542 -1.2975 -0.6392 -0.0592 -0.1440 -0.3028 -0.8002 -1.4903 -0.3100 -1.0218 -0.1342 -0.5521 -0.2815 -0.1545
S-882	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-882	Do not remove the blue cap from the BAXJECT II device .
H-882	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
D-882	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
P-882	-0.0636 -0.1323 -0.1315 -0.2512 -0.3014 -0.3891 -0.1809 -0.6881 -0.4012 -0.1766 -0.2151 -0.1199 -0.1197 -0.1143 -0.2620 -0.1577
S-1058	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1058	Do not remove the blue cap from the BAXJECT II device .
H-1058	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
D-1058	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
P-1058	-0.0636 -0.1323 -0.1315 -0.2512 -0.3014 -0.3891 -0.1809 -0.6881 -0.4012 -0.1766 -0.2151 -0.1199 -0.1197 -0.1143 -0.2620 -0.1577
S-1240	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1240	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1240	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
D-1240	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
P-1240	-0.3816 -0.0817 -0.5639 -0.1262 -0.1010 -0.9442 -0.1749 -0.2950 -0.3810 -0.2959 -0.1104 -0.2690 -0.1902 -0.1458 -0.1815 -0.1554
S-1410	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1410	Do not remove the blue cap from the BAXJECT II device .
H-1410	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
D-1410	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
P-1410	-0.0636 -0.1323 -0.1315 -0.2512 -0.3014 -0.3891 -0.1809 -0.6881 -0.4012 -0.1766 -0.2151 -0.1199 -0.1197 -0.1143 -0.2620 -0.1577
S-1064	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1064	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1064	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
D-1064	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
P-1064	-0.3816 -0.0817 -0.5639 -0.1262 -0.1010 -0.9442 -0.1749 -0.2950 -0.3810 -0.2959 -0.1104 -0.2690 -0.1902 -0.1458 -0.1815 -0.1554
S-888	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-888	The product dissolves rapidly ( usually in less than 1 minute ) .
H-888	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
D-888	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
P-888	-0.3816 -0.0817 -0.5639 -0.1262 -0.1010 -0.9442 -0.1749 -0.2950 -0.3810 -0.2959 -0.1104 -0.2690 -0.1902 -0.1458 -0.1815 -0.1554
S-712	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-712	The product dissolves rapidly ( usually in less than 1 minute ) .
H-712	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
D-712	-0.2748520076274872	The product dissolves rapidly ( usually in less than 1 minute ) .
P-712	-0.3816 -0.0817 -0.5639 -0.1262 -0.1010 -0.9442 -0.1749 -0.2950 -0.3810 -0.2959 -0.1104 -0.2690 -0.1902 -0.1458 -0.1815 -0.1554
S-515	Advate ist sowohl zur kurz- als auch zur langfristigen Anwendung angezeigt .
T-515	Advate is intended for either short-term or long-term use .
H-515	-0.3849432170391083	Advate is indicated for both short- and long @-@ term use .
D-515	-0.3849432170391083	Advate is indicated for both short- and long @-@ term use .
P-515	-0.8515 -0.0795 -0.2096 -0.2268 -0.1957 -0.6669 -0.1224 -0.2357 -0.1428 -1.2252 -0.9126 -0.2251 -0.3573 -0.1659 -0.1571
S-1613	Arzneimittel auf eingeschränkte ärztliche Verschreibung ( siehe Anhang I :
T-1613	Medicinal product subject to restricted medical prescription ( See Annex I :
H-1613	-0.6022515892982483	restricted prescription ( see Annex I :
D-1613	-0.6022515892982483	restricted prescription ( see Annex I :
P-1613	-1.9709 -0.7481 -1.4662 -0.1462 -0.1574 -0.1039 -0.1789 -0.4868 -0.1619
S-1474	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-1474	For instructions for reconstitution prior to administration , see section 6.6 .
H-1474	-0.4655490219593048	Reconstitution information prior to administration see section 6.6 .
D-1474	-0.4655490219593048	Reconstitution information prior to administration see section 6.6 .
P-1474	-2.1653 -0.0463 -1.1351 -0.2655 -0.1291 -0.0566 -1.1139 -0.1048 -0.0943 -0.1536 -0.1690 -0.1531
S-1298	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-1298	For instructions for reconstitution prior to administration , see section 6.6 .
H-1298	-0.4655490219593048	Reconstitution information prior to administration see section 6.6 .
D-1298	-0.4655490219593048	Reconstitution information prior to administration see section 6.6 .
P-1298	-2.1653 -0.0463 -1.1351 -0.2655 -0.1291 -0.0566 -1.1139 -0.1048 -0.0943 -0.1536 -0.1690 -0.1531
S-1122	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-1122	For instructions for reconstitution prior to administration , see section 6.6 .
H-1122	-0.4655490219593048	Reconstitution information prior to administration see section 6.6 .
D-1122	-0.4655490219593048	Reconstitution information prior to administration see section 6.6 .
P-1122	-2.1653 -0.0463 -1.1351 -0.2655 -0.1291 -0.0566 -1.1139 -0.1048 -0.0943 -0.1536 -0.1690 -0.1531
S-923	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-923	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-923	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
D-923	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
P-923	-1.0608 -0.1415 -0.1164 -0.2717 -0.0708 -0.1495 -0.0933 -0.1363 -0.1652 -0.1000 -0.1133 -0.1613 -0.2514 -0.1342 -0.1112 -0.1328 -0.1557
S-1234	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1234	Do not remove the blue cap from the BAXJECT II device .
H-1234	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
D-1234	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
P-1234	-0.0636 -0.1323 -0.1315 -0.2512 -0.3014 -0.3891 -0.1809 -0.6881 -0.4012 -0.1766 -0.2151 -0.1199 -0.1197 -0.1143 -0.2620 -0.1577
S-946	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-946	For instructions for reconstitution prior to administration , see section 6.6 .
H-946	-0.4655490219593048	Reconstitution information prior to administration see section 6.6 .
D-946	-0.4655490219593048	Reconstitution information prior to administration see section 6.6 .
P-946	-2.1653 -0.0463 -1.1351 -0.2655 -0.1291 -0.0566 -1.1139 -0.1048 -0.0943 -0.1536 -0.1690 -0.1531
S-1099	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-1099	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-1099	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
D-1099	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
P-1099	-1.0608 -0.1415 -0.1164 -0.2717 -0.0708 -0.1495 -0.0933 -0.1363 -0.1652 -0.1000 -0.1133 -0.1613 -0.2514 -0.1342 -0.1112 -0.1328 -0.1557
S-573	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-573	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-573	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
D-573	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
P-573	-1.0608 -0.1415 -0.1164 -0.2717 -0.0708 -0.1495 -0.0933 -0.1363 -0.1652 -0.1000 -0.1133 -0.1613 -0.2514 -0.1342 -0.1112 -0.1328 -0.1557
S-1934	Blister ( PCTFE<unk> PVC<unk> Alu )
T-1934	Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu )
H-1934	-0.2330949604511261	blister ( PCTFE/ PVC/ alu )
D-1934	-0.2330949604511261	blister ( PCTFE/ PVC/ alu )
P-1934	-0.9776 -0.1582 -0.1515 -0.1938 -0.1218 -0.1296 -0.1918 -0.2663 -0.1276 -0.1275 -0.1178 -0.1338 -0.4602 -0.2389 -0.1491 -0.1840
S-1951	Aerinaze ist ebenfalls kontraindiziert bei Patienten mit :
T-1951	Aerinaze is also contraindicated in patients with : narrow-angle glaucoma , urinary retention , cardiovascular diseases such as ischaemic heart disease , tachyarrhythmia and severe hypertension , hyperthyroidism ,
H-1951	-0.3647547662258148	Aerinaze is also contraindicated in patients with
D-1951	-0.3647547662258148	Aerinaze is also contraindicated in patients with
P-1951	-0.1667 -0.1247 -0.1507 -0.1301 -0.0973 -0.1754 -0.1678 -0.0678 -0.0358 -0.1849 -0.2194 -0.2733 -2.9479
S-1904	Aerinaze enthält zwei arzneilich wirksame Bestandteile :
T-1904	Aerinaze contains two active substances : desloratadine , an antihistamine , and pseudoephedrine , which is a nasal decongestant .
H-1904	-0.17296914756298065	Aerinaze contains two active ingredients :
D-1904	-0.17296914756298065	Aerinaze contains two active ingredients :
P-1904	-0.1363 -0.1394 -0.1520 -0.1273 -0.1043 -0.2112 -0.1946 -0.0323 -0.4567 -0.1886 -0.1600
S-1773	Am Ende der Packungsbeilage finden Sie genaue Informationen zur Selbstbehandlung .
T-1773	Detailed instructions for self-administration are given at the end of this package leaflet .
H-1773	-0.5392816066741943	Detailed information on self @-@ treatment can be found at the end of the leaflet .
D-1773	-0.5392816066741943	Detailed information on self @-@ treatment can be found at the end of the leaflet .
P-1773	-3.3971 -0.0561 -0.3630 -0.2222 -0.1865 -1.2415 -0.4438 -0.5360 -0.1321 -0.1614 -0.3632 -0.1537 -0.2464 -0.1239 -0.4784 -2.0875 -0.0296 -0.1312 -0.2785 -0.1537
S-1758	Normalerweise wird die Ersatztherapie mit ADVATE lebenslang durchgeführt .
T-1758	Usually , the replacement therapy with ADVATE is a life-long treatment .
H-1758	-0.4562559425830841	Replacement therapy with ADVATE is usually lifelong .
D-1758	-0.4562559425830841	Replacement therapy with ADVATE is usually lifelong .
P-1758	-2.6472 -0.1839 -0.0786 -0.1975 -0.2419 -0.0898 -0.1449 -0.1043 -0.0902 -0.2868 -0.4598 -1.9217 -0.0544 -0.1871 -0.1558
S-1451	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-1451	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-1451	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
D-1451	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
P-1451	-1.0608 -0.1415 -0.1164 -0.2717 -0.0708 -0.1495 -0.0933 -0.1363 -0.1652 -0.1000 -0.1133 -0.1613 -0.2514 -0.1342 -0.1112 -0.1328 -0.1557
S-1275	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-1275	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-1275	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
D-1275	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
P-1275	-1.0608 -0.1415 -0.1164 -0.2717 -0.0708 -0.1495 -0.0933 -0.1363 -0.1652 -0.1000 -0.1133 -0.1613 -0.2514 -0.1342 -0.1112 -0.1328 -0.1557
S-1587	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1587	Do not remove the blue cap from the BAXJECT II device .
H-1587	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
D-1587	-0.23153731226921082	Do not remove the blue cap from the BAXJECT II .
P-1587	-0.0636 -0.1323 -0.1315 -0.2512 -0.3014 -0.3891 -0.1809 -0.6881 -0.4012 -0.1766 -0.2151 -0.1199 -0.1197 -0.1143 -0.2620 -0.1577
S-747	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-747	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-747	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
D-747	-0.19796757400035858	dosage frequency ( hours ) / duration of treatment ( days )
P-747	-1.0608 -0.1415 -0.1164 -0.2717 -0.0708 -0.1495 -0.0933 -0.1363 -0.1652 -0.1000 -0.1133 -0.1613 -0.2514 -0.1342 -0.1112 -0.1328 -0.1557
S-1983	Die Wechselwirkung zwischen Aerinaze und Alkohol wurde nicht untersucht .
T-1983	The interaction with Aerinaze and alcohol has not been studied .
H-1983	-0.307422935962677	The interaction between Aerinaze and alcohol was not investigated .
D-1983	-0.307422935962677	The interaction between Aerinaze and alcohol was not investigated .
P-1983	-0.9195 -0.2386 -0.0922 -0.2936 -0.2521 -0.1279 -0.1427 -0.1280 -0.0835 -0.1387 -0.1366 -1.1700 -0.1328 -0.7366 -0.1704 -0.1555
S-1800	Im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1800	Keep the vial in the outer carton in order to protect from light .
H-1800	-0.48322799801826477	Store in a carton to protect from light .
D-1800	-0.48322799801826477	Store in a carton to protect from light .
P-1800	-0.0844 -0.3625 -0.3604 -2.4555 -0.0236 -0.1866 -0.1479 -1.1866 -0.1042 -0.1958 -0.2079
S-1575	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1575	- Dispose any unused product or waste material in accordance with local requirements .
H-1575	-0.38744792342185974	- Any unused product or waste material should be disposed
D-1575	-0.38744792342185974	- Any unused product or waste material should be disposed
P-1575	-0.6612 -0.1085 -0.2028 -0.1317 -0.3872 -0.1664 -0.7062 -0.1361 -0.6362 -0.2017 -0.9431 -0.0210 -0.7347
S-1398	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1398	- Dispose any unused product or waste material in accordance with local requirements .
H-1398	-0.38744792342185974	- Any unused product or waste material should be disposed
D-1398	-0.38744792342185974	- Any unused product or waste material should be disposed
P-1398	-0.6612 -0.1085 -0.2028 -0.1317 -0.3872 -0.1664 -0.7062 -0.1361 -0.6362 -0.2017 -0.9431 -0.0210 -0.7347
S-1222	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1222	- Dispose any unused product or waste material in accordance with local requirements .
H-1222	-0.38744792342185974	- Any unused product or waste material should be disposed
D-1222	-0.38744792342185974	- Any unused product or waste material should be disposed
P-1222	-0.6612 -0.1085 -0.2028 -0.1317 -0.3872 -0.1664 -0.7062 -0.1361 -0.6362 -0.2017 -0.9431 -0.0210 -0.7347
S-1046	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1046	- Dispose any unused product or waste material in accordance with local requirements .
H-1046	-0.38744792342185974	- Any unused product or waste material should be disposed
D-1046	-0.38744792342185974	- Any unused product or waste material should be disposed
P-1046	-0.6612 -0.1085 -0.2028 -0.1317 -0.3872 -0.1664 -0.7062 -0.1361 -0.6362 -0.2017 -0.9431 -0.0210 -0.7347
S-870	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-870	- Dispose any unused product or waste material in accordance with local requirements .
H-870	-0.38744792342185974	- Any unused product or waste material should be disposed
D-870	-0.38744792342185974	- Any unused product or waste material should be disposed
P-870	-0.6612 -0.1085 -0.2028 -0.1317 -0.3872 -0.1664 -0.7062 -0.1361 -0.6362 -0.2017 -0.9431 -0.0210 -0.7347
S-694	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-694	- Dispose any unused product or waste material in accordance with local requirements .
H-694	-0.38744792342185974	- Any unused product or waste material should be disposed
D-694	-0.38744792342185974	- Any unused product or waste material should be disposed
P-694	-0.6612 -0.1085 -0.2028 -0.1317 -0.3872 -0.1664 -0.7062 -0.1361 -0.6362 -0.2017 -0.9431 -0.0210 -0.7347
S-770	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-770	For instructions for reconstitution prior to administration , see section 6.6 .
H-770	-0.4655490219593048	Reconstitution information prior to administration see section 6.6 .
D-770	-0.4655490219593048	Reconstitution information prior to administration see section 6.6 .
P-770	-2.1653 -0.0463 -1.1351 -0.2655 -0.1291 -0.0566 -1.1139 -0.1048 -0.0943 -0.1536 -0.1690 -0.1531
S-1138	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-1138	To be taken into consideration by patients on a controlled sodium diet .
H-1138	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
D-1138	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
P-1138	-0.3387 -1.4602 -0.1567 -0.5312 -0.4708 -0.2627 -0.5092 -0.2128 -0.0980 -0.2081 -0.5180 -0.0457 -0.1702 -0.1554
S-786	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-786	To be taken into consideration by patients on a controlled sodium diet .
H-786	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
D-786	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
P-786	-0.3387 -1.4602 -0.1567 -0.5312 -0.4708 -0.2627 -0.5092 -0.2128 -0.0980 -0.2081 -0.5180 -0.0457 -0.1702 -0.1554
S-179	Spezifische Erfahrungen zur Behandlung einer Überdosis mit Alendronat liegen nicht vor .
T-179	No specific information is available on the treatment of overdose with alendronate .
H-179	-0.4442588686943054	No specific experience exists in the treatment of alendronate overdose .
D-179	-0.4442588686943054	No specific experience exists in the treatment of alendronate overdose .
P-179	-0.6821 -0.2470 -0.3822 -0.9100 -1.6318 -1.3075 -0.1504 -0.1226 -0.6988 -0.1136 -0.1499 -0.1196 -0.0927 -0.0677 -0.2796 -0.1526
S-90	Die empfohlene Dosierung beträgt eine ADROVANCE Tablette einmal wöchentlich .
T-90	The recommended dosage is one ADROVANCE tablet once weekly .
H-90	-0.27318111062049866	The recommended dose is one ADROVANCE tablet weekly .
D-90	-0.27318111062049866	The recommended dose is one ADROVANCE tablet weekly .
P-90	-0.1552 -0.1913 -0.9216 -0.1659 -0.2598 -0.0997 -0.0632 -0.1256 -0.1030 -0.1002 -0.2346 -0.1289 -1.2330 -0.1602 -0.1556
S-1850	Fragen und Antworten zur Rücknahme des Antrags auf Genehmigung für das Inverkehrbringen von Advexin
T-1850	Questions and answers on the withdrawal of the marketing application for Advexin
H-1850	-0.39396053552627563	Q &amp; A on the withdrawal of the marketing authorisation application for Advexin
D-1850	-0.39396053552627563	Q &amp; A on the withdrawal of the marketing authorisation application for Advexin
P-1850	-2.6719 -0.2347 -0.1604 -0.1539 -0.8928 -0.1126 -0.1178 -0.7687 -0.3040 -0.0177 -0.0464 -0.2094 -0.2157 -0.3372 -0.1601 -0.1306 -0.1633
S-863	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-863	19 6.6 Special precautions for disposal and other handling
H-863	-0.21872763335704803	6.6 Special precautions for disposal and other handling
D-863	-0.21872763335704803	6.6 Special precautions for disposal and other handling
P-863	-0.1135 -0.1496 -0.2163 -0.3553 -0.0584 -0.1101 -0.1845 -0.0583 -0.1134 -0.1372 -0.6802 -0.0919 -0.5748
S-1314	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-1314	To be taken into consideration by patients on a controlled sodium diet .
H-1314	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
D-1314	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
P-1314	-0.3387 -1.4602 -0.1567 -0.5312 -0.4708 -0.2627 -0.5092 -0.2128 -0.0980 -0.2081 -0.5180 -0.0457 -0.1702 -0.1554
S-367	Spezifische Erfahrungen zur Behandlung einer Überdosis mit Alendronat liegen nicht vor .
T-367	No specific information is available on the treatment of overdose with alendronate .
H-367	-0.4442588686943054	No specific experience exists in the treatment of alendronate overdose .
D-367	-0.4442588686943054	No specific experience exists in the treatment of alendronate overdose .
P-367	-0.6821 -0.2470 -0.3822 -0.9100 -1.6318 -1.3075 -0.1504 -0.1226 -0.6988 -0.1136 -0.1499 -0.1196 -0.0927 -0.0677 -0.2796 -0.1526
S-962	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-962	To be taken into consideration by patients on a controlled sodium diet .
H-962	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
D-962	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
P-962	-0.3387 -1.4602 -0.1567 -0.5312 -0.4708 -0.2627 -0.5092 -0.2128 -0.0980 -0.2081 -0.5180 -0.0457 -0.1702 -0.1554
S-684	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-684	Keep the vial in the outer carton in order to protect from light .
H-684	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
D-684	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
P-684	-0.5159 -0.3321 -0.1310 -0.0940 -0.1951 -0.4526 -2.2961 -0.0268 -0.3528 -0.1588 -2.0043 -0.0682 -0.0994 -0.1428 -0.1351 -0.1718 -0.1637
S-612	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-612	To be taken into consideration by patients on a controlled sodium diet .
H-612	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
D-612	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
P-612	-0.3387 -1.4602 -0.1567 -0.5312 -0.4708 -0.2627 -0.5092 -0.2128 -0.0980 -0.2081 -0.5180 -0.0457 -0.1702 -0.1554
S-1215	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1215	39 6.6 Special precautions for disposal and other handling
H-1215	-0.21872763335704803	6.6 Special precautions for disposal and other handling
D-1215	-0.21872763335704803	6.6 Special precautions for disposal and other handling
P-1215	-0.1135 -0.1496 -0.2163 -0.3553 -0.0584 -0.1101 -0.1845 -0.0583 -0.1134 -0.1372 -0.6802 -0.0919 -0.5748
S-1039	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1039	29 6.6 Special precautions for disposal and other handling
H-1039	-0.21872763335704803	6.6 Special precautions for disposal and other handling
D-1039	-0.21872763335704803	6.6 Special precautions for disposal and other handling
P-1039	-0.1135 -0.1496 -0.2163 -0.3553 -0.0584 -0.1101 -0.1845 -0.0583 -0.1134 -0.1372 -0.6802 -0.0919 -0.5748
S-158	5 Es ist nicht bekannt , ob Alendronat in die Muttermilch übergeht .
T-158	It is not known whether alendronate is excreted into human breast milk .
H-158	-0.42795172333717346	Alendronate is not known to be metabolised into breast milk .
D-158	-0.42795172333717346	Alendronate is not known to be metabolised into breast milk .
P-158	-1.5988 -0.1286 -0.1215 -0.0915 -0.3247 -0.2361 -0.1783 -0.1845 -0.7055 -2.6169 -0.0255 -0.0621 -0.3282 -0.1755 -0.1559 -0.1897 -0.1518
S-1568	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1568	6.6 Special precautions for disposal and other handling
H-1568	-0.21872763335704803	6.6 Special precautions for disposal and other handling
D-1568	-0.21872763335704803	6.6 Special precautions for disposal and other handling
P-1568	-0.1135 -0.1496 -0.2163 -0.3553 -0.0584 -0.1101 -0.1845 -0.0583 -0.1134 -0.1372 -0.6802 -0.0919 -0.5748
S-1490	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-1490	To be taken into consideration by patients on a controlled sodium diet .
H-1490	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
D-1490	-0.3669919967651367	This should be considered in patients on a sodium controlled diet .
P-1490	-0.3387 -1.4602 -0.1567 -0.5312 -0.4708 -0.2627 -0.5092 -0.2128 -0.0980 -0.2081 -0.5180 -0.0457 -0.1702 -0.1554
S-687	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-687	6.6 Special precautions for disposal and other handling
H-687	-0.21872763335704803	6.6 Special precautions for disposal and other handling
D-687	-0.21872763335704803	6.6 Special precautions for disposal and other handling
P-687	-0.1135 -0.1496 -0.2163 -0.3553 -0.0584 -0.1101 -0.1845 -0.0583 -0.1134 -0.1372 -0.6802 -0.0919 -0.5748
S-277	Die empfohlene Dosierung beträgt eine ADROVANCE Tablette einmal wöchentlich .
T-277	The recommended dosage is one ADROVANCE tablet once weekly .
H-277	-0.27318111062049866	The recommended dose is one ADROVANCE tablet weekly .
D-277	-0.27318111062049866	The recommended dose is one ADROVANCE tablet weekly .
P-277	-0.1552 -0.1913 -0.9216 -0.1659 -0.2598 -0.0997 -0.0632 -0.1256 -0.1030 -0.1002 -0.2346 -0.1289 -1.2330 -0.1602 -0.1556
S-1486	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-1486	Rarely , inhibitors may develop after the first 100 exposure days.
H-1486	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
D-1486	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
P-1486	-0.2078 -0.0416 -0.0704 -0.3495 -0.2440 -0.0628 -0.0604 -0.1533 -0.6074 -0.8093 -0.1379 -0.1888 -0.0626 -0.1088 -0.2194 -0.1658 -0.0477 -0.1683 -0.1522
S-1310	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-1310	Rarely , inhibitors may develop after the first 100 exposure days.
H-1310	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
D-1310	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
P-1310	-0.2078 -0.0416 -0.0704 -0.3495 -0.2440 -0.0628 -0.0604 -0.1533 -0.6074 -0.8093 -0.1379 -0.1888 -0.0626 -0.1088 -0.2194 -0.1658 -0.0477 -0.1683 -0.1522
S-154	Es liegen keine geeigneten Daten zur Anwendung von ADROVANCE bei schwangeren Frauen vor .
T-154	There are no adequate data from the use of ADROVANCE in pregnant women .
H-154	-0.31632259488105774	There are no adequate data on the use of ADROVANCE in pregnant women .
D-154	-0.31632259488105774	There are no adequate data on the use of ADROVANCE in pregnant women .
P-154	-1.3460 -0.5264 -0.0619 -0.9700 -0.2120 -0.5446 -0.5080 -0.6086 -0.1204 -0.0682 -0.0629 -0.1219 -0.1092 -0.0742 -0.1356 -0.1165 -0.0967 -0.1718 -0.1554
S-3	Adenuric ist ein Arzneimittel , das den Wirkstoff Febuxostat enthält .
T-3	Adenuric is a medicine containing the active substance febuxostat .
H-3	-0.22985193133354187	Adenuric is a medicinal product containing the active substance Febuxostat .
D-3	-0.22985193133354187	Adenuric is a medicinal product containing the active substance Febuxostat .
P-3	-0.0906 -0.1422 -0.0816 -0.1312 -0.1689 -0.1380 -1.2686 -0.0961 -0.1086 -0.7074 -0.4081 -0.0526 -0.1055 -0.3049 -0.1486 -0.1264 -0.0476 -0.1436 -0.1689 -0.1579
S-1942	Die empfohlene Dosierung von Aerinaze beträgt eine Tablette zweimal täglich .
T-1942	The recommended dose of Aerinaze is one tablet twice a day .
H-1942	-0.19992731511592865	The recommended dose of Aerinaze is one tablet 2 times daily .
D-1942	-0.19992731511592865	The recommended dose of Aerinaze is one tablet 2 times daily .
P-1942	-0.1538 -0.3078 -0.5416 -0.1377 -0.1488 -0.1413 -0.1504 -0.1298 -0.0926 -0.1452 -0.2515 -0.1743 -0.1136 -0.2219 -0.3110 -0.2747 -0.1486 -0.1542
S-1732	Faktor VIII ist notwendig um im Blut Gerinnsel zu bilden und so Blutungen zu stoppen .
T-1732	Factor VIII is necessary for the blood to form clots and stop bleedings .
H-1732	-0.5171725749969482	Factor VIII is necessary for clots to form in the blood to stop bleeding .
D-1732	-0.5171725749969482	Factor VIII is necessary for clots to form in the blood to stop bleeding .
P-1732	-0.1842 -0.1445 -0.0861 -0.2087 -0.2795 -3.4639 -1.1543 -0.2444 -0.3262 -0.1994 -0.1596 -0.1823 -0.0942 -1.7974 -0.5723 -0.2917 -0.0800 -0.2001 -0.1577
S-1565	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1565	Keep the vial in the outer carton in order to protect from light .
H-1565	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
D-1565	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
P-1565	-0.5159 -0.3321 -0.1310 -0.0940 -0.1951 -0.4526 -2.2961 -0.0268 -0.3528 -0.1588 -2.0043 -0.0682 -0.0994 -0.1428 -0.1351 -0.1718 -0.1637
S-608	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-608	Rarely , inhibitors may develop after the first 100 exposure days.
H-608	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
D-608	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
P-608	-0.2078 -0.0416 -0.0704 -0.3495 -0.2440 -0.0628 -0.0604 -0.1533 -0.6074 -0.8093 -0.1379 -0.1888 -0.0626 -0.1088 -0.2194 -0.1658 -0.0477 -0.1683 -0.1522
S-1388	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1388	Keep the vial in the outer carton in order to protect from light .
H-1388	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
D-1388	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
P-1388	-0.5159 -0.3321 -0.1310 -0.0940 -0.1951 -0.4526 -2.2961 -0.0268 -0.3528 -0.1588 -2.0043 -0.0682 -0.0994 -0.1428 -0.1351 -0.1718 -0.1637
S-782	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-782	Rarely , inhibitors may develop after the first 100 exposure days.
H-782	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
D-782	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
P-782	-0.2078 -0.0416 -0.0704 -0.3495 -0.2440 -0.0628 -0.0604 -0.1533 -0.6074 -0.8093 -0.1379 -0.1888 -0.0626 -0.1088 -0.2194 -0.1658 -0.0477 -0.1683 -0.1522
S-1212	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1212	Keep the vial in the outer carton in order to protect from light .
H-1212	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
D-1212	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
P-1212	-0.5159 -0.3321 -0.1310 -0.0940 -0.1951 -0.4526 -2.2961 -0.0268 -0.3528 -0.1588 -2.0043 -0.0682 -0.0994 -0.1428 -0.1351 -0.1718 -0.1637
S-1134	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-1134	Rarely , inhibitors may develop after the first 100 exposure days.
H-1134	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
D-1134	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
P-1134	-0.2078 -0.0416 -0.0704 -0.3495 -0.2440 -0.0628 -0.0604 -0.1533 -0.6074 -0.8093 -0.1379 -0.1888 -0.0626 -0.1088 -0.2194 -0.1658 -0.0477 -0.1683 -0.1522
S-1036	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1036	Keep the vial in the outer carton in order to protect from light .
H-1036	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
D-1036	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
P-1036	-0.5159 -0.3321 -0.1310 -0.0940 -0.1951 -0.4526 -2.2961 -0.0268 -0.3528 -0.1588 -2.0043 -0.0682 -0.0994 -0.1428 -0.1351 -0.1718 -0.1637
S-958	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-958	Rarely , inhibitors may develop after the first 100 exposure days.
H-958	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
D-958	-0.2030406892299652	In rare cases , inhibitors may form after the first 100 days of exposure .
P-958	-0.2078 -0.0416 -0.0704 -0.3495 -0.2440 -0.0628 -0.0604 -0.1533 -0.6074 -0.8093 -0.1379 -0.1888 -0.0626 -0.1088 -0.2194 -0.1658 -0.0477 -0.1683 -0.1522
S-860	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-860	Keep the vial in the outer carton in order to protect from light .
H-860	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
D-860	-0.4317975342273712	Store the vial in a carton to protect the contents from light .
P-860	-0.5159 -0.3321 -0.1310 -0.0940 -0.1951 -0.4526 -2.2961 -0.0268 -0.3528 -0.1588 -2.0043 -0.0682 -0.0994 -0.1428 -0.1351 -0.1718 -0.1637
S-1391	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1391	6.6 Special precautions for disposal and other handling
H-1391	-0.21872763335704803	6.6 Special precautions for disposal and other handling
D-1391	-0.21872763335704803	6.6 Special precautions for disposal and other handling
P-1391	-0.1135 -0.1496 -0.2163 -0.3553 -0.0584 -0.1101 -0.1845 -0.0583 -0.1134 -0.1372 -0.6802 -0.0919 -0.5748
S-346	Es ist nicht bekannt , ob Alendronat in die Muttermilch übergeht .
T-346	It is not known whether alendronate is excreted into human breast milk .
H-346	-0.4465121030807495	It is not known whether alendronate is absorbed into breast milk .
D-346	-0.4465121030807495	It is not known whether alendronate is absorbed into breast milk .
P-346	-0.7960 -0.1719 -0.5137 -0.1007 -0.5770 -0.0915 -0.1226 -0.1017 -0.0933 -0.9207 -3.0007 -0.0669 -0.2725 -0.2754 -0.1460 -0.1881 -0.1520
S-336	Unerwünschte Reaktionen , die auf diese kombinierte Anwendung zurückzuführen waren , wurden nicht beobachtet .
T-336	No adverse reactions attributable to their concomitant use were identified .
H-336	-0.5600237250328064	No adverse reactions resulting from this combined use were observed .
D-336	-0.5600237250328064	No adverse reactions resulting from this combined use were observed .
P-336	-0.8070 -0.1135 -0.0163 -0.2261 -0.0282 -1.7169 -0.1510 -0.5712 -0.6956 -1.7178 -1.1730 -0.2966 -0.1711 -0.1562
S-349	Es wurden keine Studien zur Verkehrstüchtigkeit oder zur Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-349	No studies on the effects on the ability to drive and use machines have been performed .
H-349	-0.5877919793128967	No studies have been carried out on ability to drive or use machines .
D-349	-0.5877919793128967	No studies have been carried out on ability to drive or use machines .
P-349	-0.1437 -0.1862 -1.4927 -0.1223 -1.0045 -0.1328 -0.9854 -1.4630 -0.4591 -0.4601 -0.1613 -1.0429 -0.7944 -0.2132 -0.1554
S-1966	Ebenfalls zur Vorsicht geraten wird bei Patienten , die mit anderen Sympathomimetika behandelt werden .
T-1966	Caution should also be exercised in patients being treated with other sympathomimetics .
H-1966	-0.2773023843765259	Caution should also be exercised in patients receiving other sympathomimetics .
D-1966	-0.2773023843765259	Caution should also be exercised in patients receiving other sympathomimetics .
P-1966	-0.2499 -0.0854 -0.6965 -0.1605 -0.1588 -0.1017 -0.1454 -0.7655 -0.3692 -1.0505 -0.2561 -0.0891 -0.0686 -0.0792 -0.1277 -0.1575 -0.1525
S-1611	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgien
T-1611	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
H-1611	-0.16343125700950623	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
D-1611	-0.16343125700950623	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
P-1611	-0.2090 -0.1584 -0.1465 -0.0749 -0.1692 -0.0779 -0.1076 -0.0993 -0.0767 -0.0863 -0.1416 -0.1388 -0.0970 -0.0675 -0.1035 -0.1182 -0.0642 -0.0741 -1.1041 -0.1537
S-148	Unerwünschte Reaktionen , die auf diese kombinierte Anwendung zurückzuführen waren , wurden nicht beobachtet .
T-148	No adverse reactions attributable to their concomitant use were identified .
H-148	-0.5600237250328064	No adverse reactions resulting from this combined use were observed .
D-148	-0.5600237250328064	No adverse reactions resulting from this combined use were observed .
P-148	-0.8070 -0.1135 -0.0163 -0.2261 -0.0282 -1.7169 -0.1510 -0.5712 -0.6956 -1.7178 -1.1730 -0.2966 -0.1711 -0.1562
S-815	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-815	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-815	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-815	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-815	-0.4127 -0.2137 -0.1467 -0.1199 -0.0321 -0.4720 -0.6267 -0.3385 -0.1292 -0.1808 -0.4653 -0.1693 -0.0987 -0.2969 -0.1777 -0.8352 -0.3030 -0.0678 -0.1791 -0.1516
S-161	Es wurden keine Studien zur Verkehrstüchtigkeit oder zur Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-161	No studies on the effects on the ability to drive and use machines have been performed .
H-161	-0.5877919793128967	No studies have been carried out on ability to drive or use machines .
D-161	-0.5877919793128967	No studies have been carried out on ability to drive or use machines .
P-161	-0.1437 -0.1862 -1.4927 -0.1223 -1.0045 -0.1328 -0.9854 -1.4630 -0.4591 -0.4601 -0.1613 -1.0429 -0.7944 -0.2132 -0.1554
S-1903	Sobald die Nase wieder frei ist , können die Patienten Desloratadin allein einnehmen .
T-1903	Once the nose has cleared , patients can use desloratadine alone .
H-1903	-0.36923947930336	Once the nose is clear , patients can take desloratadine alone .
D-1903	-0.36923947930336	Once the nose is clear , patients can take desloratadine alone .
P-1903	-1.0719 -0.2918 -0.4018 -0.2333 -0.5631 -0.3400 -0.1677 -0.7824 -0.1061 -0.2037 -0.0541 -0.1040 -0.1787 -1.0860 -0.3855 -0.1521 -0.1548
S-1879	Zur Beurteilung eines neuen Antrags benötigt der CHMP in der Regel bis zu 210 Tage .
T-1879	The CHMP normally takes up to 210 days to evaluate a new application .
H-1879	-0.49888700246810913	The CHMP usually takes up to 210 days to evaluate a new application .
D-1879	-0.49888700246810913	The CHMP usually takes up to 210 days to evaluate a new application .
P-1879	-1.3933 -0.1229 -0.0455 -1.7902 -1.2142 -0.3600 -0.1263 -0.0654 -0.1328 -0.1546 -1.8207 -0.1065 -0.1899 -0.2461 -0.3503 -0.2095 -0.1530
S-307	Während der Behandlung sollten diese Patienten kieferchirurgische Eingriffe soweit möglich vermeiden .
T-307	While on treatment , these patients should avoid invasive dental procedures if possible .
H-307	-0.45249059796333313	During treatment , these patients should avoid maxillofacial surgery as far as possible .
D-307	-0.45249059796333313	During treatment , these patients should avoid maxillofacial surgery as far as possible .
P-307	-0.7871 -0.4328 -0.5246 -0.8946 -0.1003 -0.1007 -0.3167 -1.2188 -0.1879 -0.5321 -0.2853 -0.0248 -0.1526 -1.0221 -1.2916 -0.1436 -0.2760 -0.1536 -0.1522
S-119	Während der Behandlung sollten diese Patienten kieferchirurgische Eingriffe soweit möglich vermeiden .
T-119	While on treatment , these patients should avoid invasive dental procedures if possible .
H-119	-0.45249059796333313	During treatment , these patients should avoid maxillofacial surgery as far as possible .
D-119	-0.45249059796333313	During treatment , these patients should avoid maxillofacial surgery as far as possible .
P-119	-0.7871 -0.4328 -0.5246 -0.8946 -0.1003 -0.1007 -0.3167 -1.2188 -0.1879 -0.5321 -0.2853 -0.0248 -0.1526 -1.0221 -1.2916 -0.1436 -0.2760 -0.1536 -0.1522
S-376	Der unter Therapie mit Alendronat gebildete Knochen ist von normaler Qualität .
T-376	The bone formed during treatment with alendronate is of normal quality .
H-376	-0.4291197657585144	The bone formed during alendronate therapy is of normal quality .
D-376	-0.4291197657585144	The bone formed during alendronate therapy is of normal quality .
P-376	-0.7041 -0.1173 -2.1068 -1.5181 -0.3021 -0.1154 -0.1661 -0.0992 -0.2968 -0.1942 -0.2086 -0.1226 -0.1447 -0.1856 -0.1554
S-641	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-641	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-641	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-641	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-641	-0.4127 -0.2137 -0.1467 -0.1199 -0.0321 -0.4720 -0.6267 -0.3385 -0.1292 -0.1808 -0.4653 -0.1693 -0.0987 -0.2969 -0.1777 -0.8352 -0.3030 -0.0678 -0.1791 -0.1516
S-1877	Als das Unternehmen seinen Antrag zurücknahm , war in dem Antragsverfahren Tag 179 erreicht .
T-1877	The application was at day 179 when the company withdrew .
H-1877	-0.4345376789569855	When the company withdrew its application , day 179 was reached in the application procedure .
D-1877	-0.4345376789569855	When the company withdrew its application , day 179 was reached in the application procedure .
P-1877	-0.3752 -0.2558 -0.6286 -0.0603 -0.1291 -0.3487 -0.3919 -0.3085 -1.9664 -0.0983 -0.1330 -1.0280 -0.3141 -0.3129 -0.1996 -0.6575 -0.7268 -0.1700 -0.1516
S-1245	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1245	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1245	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
D-1245	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
P-1245	-0.8920 -0.1428 -0.4352 -0.3601 -0.3101 -1.0461 -0.2708 -0.8578 -0.1801 -2.0072 -0.0360 -0.0871 -0.3143 -0.1769 -0.1567
S-1069	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1069	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1069	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
D-1069	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
P-1069	-0.8920 -0.1428 -0.4352 -0.3601 -0.3101 -1.0461 -0.2708 -0.8578 -0.1801 -2.0072 -0.0360 -0.0871 -0.3143 -0.1769 -0.1567
S-287	Vitamin D3 einmal pro Woche in ADROVANCE und von 800 I.E.
T-287	Patients should receive supplemental calcium if intake from diet is inadequate ( see section 4.4 ) .
H-287	-0.26859578490257263	vitamin D3 once a week in ADROVANCE and 800 IU
D-287	-0.26859578490257263	vitamin D3 once a week in ADROVANCE and 800 IU
P-287	-1.5044 -0.0858 -0.1585 -0.1464 -0.2475 -0.4794 -0.0829 -0.1634 -0.0677 -0.0730 -0.1312 -0.0954 -0.0865 -0.1441 -0.7523 -0.1192 -0.0981 -0.3990
S-1851	Internationaler Freiname ( INN ) : Contusugene Ladenovec
T-1851	International non-proprietary name ( INN ) : contusugene ladenovec
H-1851	-0.45002132654190063	International name ( INN ) : Contusugene Ladenovec
D-1851	-0.45002132654190063	International name ( INN ) : Contusugene Ladenovec
P-1851	-0.2234 -4.7196 -0.1537 -0.0945 -0.1463 -0.1254 -0.1502 -0.1637 -0.1770 -0.1062 -0.2463 -0.3581 -0.1332 -0.1086 -0.1356 -0.1587
S-1808	Trometamol , Polysorbat 80 , Glutathion ( reduziert ) .
T-1808	trometamol , polysorbate 80 , and glutathione ( reduced ) .
H-1808	-0.15414966642856598	trometamol , polysorbate 80 , glutathione ( reduced ) .
D-1808	-0.15414966642856598	trometamol , polysorbate 80 , glutathione ( reduced ) .
P-1808	-0.4521 -0.1257 -0.1278 -0.1173 -0.1459 -0.1299 -0.0650 -0.1563 -0.0936 -0.1628 -0.1453 -0.3376 -0.0738 -0.0672 -0.1264 -0.1750 -0.1544 -0.0838 -0.1383 -0.2026 -0.1565
S-1598	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1598	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1598	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
D-1598	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
P-1598	-0.8920 -0.1428 -0.4352 -0.3601 -0.3101 -1.0461 -0.2708 -0.8578 -0.1801 -2.0072 -0.0360 -0.0871 -0.3143 -0.1769 -0.1567
S-1421	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1421	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1421	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
D-1421	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
P-1421	-0.8920 -0.1428 -0.4352 -0.3601 -0.3101 -1.0461 -0.2708 -0.8578 -0.1801 -2.0072 -0.0360 -0.0871 -0.3143 -0.1769 -0.1567
S-991	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-991	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-991	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-991	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-991	-0.4127 -0.2137 -0.1467 -0.1199 -0.0321 -0.4720 -0.6267 -0.3385 -0.1292 -0.1808 -0.4653 -0.1693 -0.0987 -0.2969 -0.1777 -0.8352 -0.3030 -0.0678 -0.1791 -0.1516
S-1167	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-1167	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-1167	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-1167	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-1167	-0.4127 -0.2137 -0.1467 -0.1199 -0.0321 -0.4720 -0.6267 -0.3385 -0.1292 -0.1808 -0.4653 -0.1693 -0.0987 -0.2969 -0.1777 -0.8352 -0.3030 -0.0678 -0.1791 -0.1516
S-893	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-893	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-893	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
D-893	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
P-893	-0.8920 -0.1428 -0.4352 -0.3601 -0.3101 -1.0461 -0.2708 -0.8578 -0.1801 -2.0072 -0.0360 -0.0871 -0.3143 -0.1769 -0.1567
S-717	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-717	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-717	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
D-717	-0.4848935008049011	Turn the system upwards ( with the concentrate vial ) .
P-717	-0.8920 -0.1428 -0.4352 -0.3601 -0.3101 -1.0461 -0.2708 -0.8578 -0.1801 -2.0072 -0.0360 -0.0871 -0.3143 -0.1769 -0.1567
S-1812	Pharmazeutischer Unternehmer Baxter AG Industriestrasse 67 A-1221 Wien , Österreich
T-1812	95 Marketing Authorisation Holder Baxter AG Industriestrasse 67 A-1221 Vienna
H-1812	-0.31458425521850586	Authorisation Holder Baxter AG Industriestrasse 67 A-1221 Vienna , Austria
D-1812	-0.31458425521850586	Authorisation Holder Baxter AG Industriestrasse 67 A-1221 Vienna , Austria
P-1812	-2.9713 -0.1162 -0.1064 -0.4433 -0.0728 -0.1670 -0.1470 -0.1610 -0.1043 -0.0558 -0.0705 -0.2212 -0.1073 -0.1124 -0.1070 -0.1456 -0.1185 -0.8488 -0.1422 -0.2295 -0.1581
S-1520	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-1520	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-1520	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-1520	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-1520	-0.4127 -0.2137 -0.1467 -0.1199 -0.0321 -0.4720 -0.6267 -0.3385 -0.1292 -0.1808 -0.4653 -0.1693 -0.0987 -0.2969 -0.1777 -0.8352 -0.3030 -0.0678 -0.1791 -0.1516
S-1343	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-1343	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-1343	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-1343	-0.2708408236503601	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-1343	-0.4127 -0.2137 -0.1467 -0.1199 -0.0321 -0.4720 -0.6267 -0.3385 -0.1292 -0.1808 -0.4653 -0.1693 -0.0987 -0.2969 -0.1777 -0.8352 -0.3030 -0.0678 -0.1791 -0.1516
S-188	Der unter Therapie mit Alendronat gebildete Knochen ist von normaler Qualität .
T-188	The bone formed during treatment with alendronate is of normal quality .
H-188	-0.4291197657585144	The bone formed during alendronate therapy is of normal quality .
D-188	-0.4291197657585144	The bone formed during alendronate therapy is of normal quality .
P-188	-0.7041 -0.1173 -2.1068 -1.5181 -0.3021 -0.1154 -0.1661 -0.0992 -0.2968 -0.1942 -0.2086 -0.1226 -0.1447 -0.1856 -0.1554
S-1881	Sobald das Unternehmen Antworten auf diese Fragen übermittelt hat , werden diese vom CHMP geprüft .
T-1881	Once the company has supplied responses to the questions , the CHMP reviews them and may , before giving an opinion , ask any remaining questions at day 180.
H-1881	-0.6052284836769104	Once the company has provided answers to these questions , they will be considered by the CHMP .
D-1881	-0.6052284836769104	Once the company has provided answers to these questions , they will be considered by the CHMP .
P-1881	-1.2953 -0.7959 -0.6636 -0.5388 -1.7083 -1.0607 -0.2427 -0.2155 -0.4880 -0.2159 -1.2305 -0.3292 -0.1453 -1.8196 -0.1680 -0.6978 -0.1048 -0.0439 -0.1876 -0.1533
S-1508	60 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1508	55 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1508	-0.2197342962026596	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1508	-0.2197342962026596	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1508	-0.0438 -0.1609 -0.4610 -0.0445 -0.1311 -0.1219 -0.6671 -0.0202 -1.2265 -0.0198 -0.1443 -0.0667 -0.1125 -0.1008 -0.1309 -0.1336 -0.1326 -0.3009 -0.1558
S-1403	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1403	Remove caps from powder and solvent vials .
H-1403	-0.4319283664226532	Remove caps from vials with powder and solvent .
D-1403	-0.4319283664226532	Remove caps from vials with powder and solvent .
P-1403	-0.3327 -0.0576 -0.1185 -1.4658 -0.2006 -0.0300 -0.0961 -1.5478 -0.6595 -0.1895 -0.1792 -0.8253 -0.1845 -0.1599
S-1492	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-1492	54 No interaction studies have been performed with ADVATE .
H-1492	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
D-1492	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
P-1492	-0.1125 -0.9531 -1.5564 -0.1565 -1.1019 -0.1370 -1.5403 -0.5274 -0.1763 -0.1224 -0.1749 -0.0813 -0.1444 -0.0885 -0.0875 -0.1881 -0.2890 -0.2511 -0.9807 -0.0922 -0.1685 -0.1546
S-614	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-614	No interaction studies have been performed with ADVATE. .
H-614	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
D-614	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
P-614	-0.1125 -0.9531 -1.5564 -0.1565 -1.1019 -0.1370 -1.5403 -0.5274 -0.1763 -0.1224 -0.1749 -0.0813 -0.1444 -0.0885 -0.0875 -0.1881 -0.2890 -0.2511 -0.9807 -0.0922 -0.1685 -0.1546
S-1140	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-1140	34 No interaction studies have been performed with ADVATE .
H-1140	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
D-1140	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
P-1140	-0.1125 -0.9531 -1.5564 -0.1565 -1.1019 -0.1370 -1.5403 -0.5274 -0.1763 -0.1224 -0.1749 -0.0813 -0.1444 -0.0885 -0.0875 -0.1881 -0.2890 -0.2511 -0.9807 -0.0922 -0.1685 -0.1546
S-964	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-964	24 No interaction studies have been performed with ADVATE .
H-964	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
D-964	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
P-964	-0.1125 -0.9531 -1.5564 -0.1565 -1.1019 -0.1370 -1.5403 -0.5274 -0.1763 -0.1224 -0.1749 -0.0813 -0.1444 -0.0885 -0.0875 -0.1881 -0.2890 -0.2511 -0.9807 -0.0922 -0.1685 -0.1546
S-788	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-788	14 No interaction studies have been performed with ADVATE .
H-788	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
D-788	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
P-788	-0.1125 -0.9531 -1.5564 -0.1565 -1.1019 -0.1370 -1.5403 -0.5274 -0.1763 -0.1224 -0.1749 -0.0813 -0.1444 -0.0885 -0.0875 -0.1881 -0.2890 -0.2511 -0.9807 -0.0922 -0.1685 -0.1546
S-83	Den vollständigen Wortlaut des EPAR für ADROVANCE finden Sie hier .
T-83	The full EPAR for ADROVANCE is available here .
H-83	-0.29957738518714905	The full EPAR for ADROVANCE is available here .
D-83	-0.29957738518714905	The full EPAR for ADROVANCE is available here .
P-83	-1.7935 -0.1894 -0.3257 -0.0728 -0.1809 -0.0916 -0.0667 -0.1261 -0.1012 -0.0958 -0.7144 -0.2382 -0.0996 -0.2403 -0.1577
S-43	Der Inhaber der Genehmigung für das Inverkehrbringen ist Beaufour Ipsen Pharma .
T-43	The marketing authorisation holder is Beaufour Ipsen Pharma .
H-43	-0.2912139594554901	The marketing authorisation holder is Beaufour Ipsen Pharma .
D-43	-0.2912139594554901	The marketing authorisation holder is Beaufour Ipsen Pharma .
P-43	-0.3669 -2.6479 -0.0268 -0.0489 -0.1007 -0.1582 -0.1174 -0.1095 -0.1545 -0.0800 -0.0858 -0.0527 -0.0905 -0.1735 -0.1550
S-1316	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-1316	44 No interaction studies have been performed with ADVATE .
H-1316	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
D-1316	-0.4129359722137451	No studies have been carried out into the interaction of ADVATE with other medicinal products .
P-1316	-0.1125 -0.9531 -1.5564 -0.1565 -1.1019 -0.1370 -1.5403 -0.5274 -0.1763 -0.1224 -0.1749 -0.0813 -0.1444 -0.0885 -0.0875 -0.1881 -0.2890 -0.2511 -0.9807 -0.0922 -0.1685 -0.1546
S-1580	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1580	Remove caps from powder and solvent vials .
H-1580	-0.4319283664226532	Remove caps from vials with powder and solvent .
D-1580	-0.4319283664226532	Remove caps from vials with powder and solvent .
P-1580	-0.3327 -0.0576 -0.1185 -1.4658 -0.2006 -0.0300 -0.0961 -1.5478 -0.6595 -0.1895 -0.1792 -0.8253 -0.1845 -0.1599
S-1010	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1010	Activated Factor X converts prothrombin to thrombin .
H-1010	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
D-1010	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
P-1010	-1.0890 -0.1683 -0.0987 -0.1179 -0.1128 -0.1973 -0.1786 -0.0907 -0.0220 -0.1743 -0.1198 -0.7108 -0.0668 -0.1565 -0.1164 -0.1764 -0.1576
S-1227	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1227	Remove caps from powder and solvent vials .
H-1227	-0.4319283664226532	Remove caps from vials with powder and solvent .
D-1227	-0.4319283664226532	Remove caps from vials with powder and solvent .
P-1227	-0.3327 -0.0576 -0.1185 -1.4658 -0.2006 -0.0300 -0.0961 -1.5478 -0.6595 -0.1895 -0.1792 -0.8253 -0.1845 -0.1599
S-1051	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1051	Remove caps from powder and solvent vials .
H-1051	-0.4319283664226532	Remove caps from vials with powder and solvent .
D-1051	-0.4319283664226532	Remove caps from vials with powder and solvent .
P-1051	-0.3327 -0.0576 -0.1185 -1.4658 -0.2006 -0.0300 -0.0961 -1.5478 -0.6595 -0.1895 -0.1792 -0.8253 -0.1845 -0.1599
S-875	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-875	Remove caps from powder and solvent vials .
H-875	-0.4319283664226532	Remove caps from vials with powder and solvent .
D-875	-0.4319283664226532	Remove caps from vials with powder and solvent .
P-875	-0.3327 -0.0576 -0.1185 -1.4658 -0.2006 -0.0300 -0.0961 -1.5478 -0.6595 -0.1895 -0.1792 -0.8253 -0.1845 -0.1599
S-699	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-699	Remove caps from powder and solvent vials .
H-699	-0.4319283664226532	Remove caps from vials with powder and solvent .
D-699	-0.4319283664226532	Remove caps from vials with powder and solvent .
P-699	-0.3327 -0.0576 -0.1185 -1.4658 -0.2006 -0.0300 -0.0961 -1.5478 -0.6595 -0.1895 -0.1792 -0.8253 -0.1845 -0.1599
S-539	Falls sich Antikörper entwickeln , ist die Wirksamkeit von Advate nicht gewährleistet .
T-539	If antibodies develop , Advate will not work effectively .
H-539	-0.39799150824546814	If antibodies develop , the efficacy of Advate is not assured .
D-539	-0.39799150824546814	If antibodies develop , the efficacy of Advate is not assured .
P-539	-1.7012 -0.1128 -0.0693 -1.3921 -0.1718 -0.5295 -0.6413 -0.0683 -0.0960 -0.1176 -0.3283 -0.0812 -0.3958 -0.2255 -0.5050 -0.1717 -0.1584
S-279	Hinweise , um eine ausreichende Resorption von Alendronat zu gewährleisten :
T-279	To permit adequate absorption of alendronate :
H-279	-0.5748298168182373	Notes to ensure adequate absorption of alendronate include
D-279	-0.5748298168182373	Notes to ensure adequate absorption of alendronate include
P-279	-3.7110 -0.1464 -1.1841 -0.2530 -0.2635 -0.1972 -0.0635 -0.1307 -0.1121 -0.1204 -0.1259 -0.0758 -0.8748 -0.7891
S-92	Hinweise , um eine ausreichende Resorption von Alendronat zu gewährleisten :
T-92	To permit adequate absorption of alendronate :
H-92	-0.5748298168182373	Notes to ensure adequate absorption of alendronate include
D-92	-0.5748298168182373	Notes to ensure adequate absorption of alendronate include
P-92	-3.7110 -0.1464 -1.1841 -0.2530 -0.2635 -0.1972 -0.0635 -0.1307 -0.1121 -0.1204 -0.1259 -0.0758 -0.8748 -0.7891
S-1929	Den vollständigen Wortlaut des EPAR für Aerinaze finden Sie hier .
T-1929	The full EPAR for Aerinaze can be found here .
H-1929	-0.2933802902698517	The full EPAR for Aerinaze is available here .
D-1929	-0.2933802902698517	The full EPAR for Aerinaze is available here .
P-1929	-1.6452 -0.1603 -0.2935 -0.0602 -0.1858 -0.1419 -0.1220 -0.1458 -0.1294 -0.1001 -0.6695 -0.2531 -0.0988 -0.2383 -0.1568
S-348	16 4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-348	4.7 Effects on ability to drive and use machines
H-348	-0.3209627568721771	4.7 Effects on ability to drive and use machines
D-348	-0.3209627568721771	4.7 Effects on ability to drive and use machines
P-348	-0.0858 -0.1459 -0.0575 -0.0614 -0.1094 -0.3088 -0.4705 -0.8046 -0.1456 -0.6449 -0.8557 -0.1615
S-834	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-834	Activated Factor X converts prothrombin to thrombin .
H-834	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
D-834	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
P-834	-1.0890 -0.1683 -0.0987 -0.1179 -0.1128 -0.1973 -0.1786 -0.0907 -0.0220 -0.1743 -0.1198 -0.7108 -0.0668 -0.1565 -0.1164 -0.1764 -0.1576
S-1504	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-1504	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-1504	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
D-1504	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
P-1504	-1.0773 -0.1435 -1.9612 -0.4530 -1.0765 -0.1205 -0.1361 -0.6634 -0.0224 -1.1795 -0.1267 -0.0820 -0.1837 -0.1973 -0.1551
S-1152	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-1152	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-1152	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
D-1152	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
P-1152	-1.0773 -0.1435 -1.9612 -0.4530 -1.0765 -0.1205 -0.1361 -0.6634 -0.0224 -1.1795 -0.1267 -0.0820 -0.1837 -0.1973 -0.1551
S-1331	49 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1331	45 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1331	-0.2200758159160614	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1331	-0.2200758159160614	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1331	-0.0530 -0.1986 -0.4269 -0.0473 -0.1317 -0.1233 -0.6866 -0.0208 -1.1976 -0.0203 -0.1454 -0.0663 -0.1123 -0.1009 -0.1320 -0.1347 -0.1363 -0.2911 -0.1564
S-1155	38 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1155	35 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1155	-0.22305476665496826	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1155	-0.22305476665496826	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1155	-0.0703 -0.1601 -0.4552 -0.0481 -0.1351 -0.1227 -0.6912 -0.0199 -1.2377 -0.0199 -0.1452 -0.0660 -0.1135 -0.1010 -0.1321 -0.1337 -0.1333 -0.2958 -0.1573
S-979	27 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-979	25 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-979	-0.2245631366968155	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-979	-0.2245631366968155	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-979	-0.0582 -0.2033 -0.4123 -0.0459 -0.1364 -0.1224 -0.7320 -0.0212 -1.2194 -0.0194 -0.1448 -0.0651 -0.1131 -0.1011 -0.1316 -0.1347 -0.1396 -0.3104 -0.1558
S-803	16 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-803	15 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-803	-0.22288697957992554	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-803	-0.22288697957992554	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-803	-0.0539 -0.1633 -0.4661 -0.0436 -0.1365 -0.1232 -0.7012 -0.0206 -1.2155 -0.0200 -0.1453 -0.0676 -0.1129 -0.1013 -0.1314 -0.1344 -0.1362 -0.3044 -0.1573
S-1840	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
T-1840	34 <<unk>> GR-163 41 . : <<unk>> 30-210-99 87 000
H-1840	-0.18741923570632935	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
D-1840	-0.18741923570632935	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
P-1840	-0.5461 -0.0613 -0.0929 -0.1316 -0.1382 -0.1492 -0.1576 -0.4280 -0.1618 -0.0546 -0.2508 -0.0858 -0.2401 -0.2800 -0.0905 -0.0377 -0.3611 -0.1349 -0.1588
S-1827	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
T-1827	34 <<unk>> GR-163 41 . : <<unk>> 30-210-99 87 000
H-1827	-0.18741923570632935	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
D-1827	-0.18741923570632935	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
P-1827	-0.5461 -0.0613 -0.0929 -0.1316 -0.1382 -0.1492 -0.1576 -0.4280 -0.1618 -0.0546 -0.2508 -0.0858 -0.2401 -0.2800 -0.0905 -0.0377 -0.3611 -0.1349 -0.1588
S-1823	4 D-85716 Unterschleißheim Tel : <unk> 49 89 31 701
T-1823	4 D-85716 Unterschleißheim Tel : <<unk>> 49 89 31 701
H-1823	-0.1949656754732132	4 D-85716 Unterschleissheim Tel : <unk> 49 89 31 701
D-1823	-0.1949656754732132	4 D-85716 Unterschleissheim Tel : <unk> 49 89 31 701
P-1823	-0.3855 -0.1821 -0.1003 -0.1453 -0.1427 -0.1159 -0.9297 -0.0571 -0.2857 -0.4773 -0.0615 -0.1388 -0.0292 -0.0679 -0.0882 -0.1000 -0.1504 -0.0890 -0.1575
S-659	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-659	Activated Factor X converts prothrombin to thrombin .
H-659	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
D-659	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
P-659	-1.0890 -0.1683 -0.0987 -0.1179 -0.1128 -0.1973 -0.1786 -0.0907 -0.0220 -0.1743 -0.1198 -0.7108 -0.0668 -0.1565 -0.1164 -0.1764 -0.1576
S-1328	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-1328	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-1328	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
D-1328	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
P-1328	-1.0773 -0.1435 -1.9612 -0.4530 -1.0765 -0.1205 -0.1361 -0.6634 -0.0224 -1.1795 -0.1267 -0.0820 -0.1837 -0.1973 -0.1551
S-1186	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1186	Activated Factor X converts prothrombin to thrombin .
H-1186	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
D-1186	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
P-1186	-1.0890 -0.1683 -0.0987 -0.1179 -0.1128 -0.1973 -0.1786 -0.0907 -0.0220 -0.1743 -0.1198 -0.7108 -0.0668 -0.1565 -0.1164 -0.1764 -0.1576
S-976	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-976	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-976	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
D-976	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
P-976	-1.0773 -0.1435 -1.9612 -0.4530 -1.0765 -0.1205 -0.1361 -0.6634 -0.0224 -1.1795 -0.1267 -0.0820 -0.1837 -0.1973 -0.1551
S-800	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-800	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-800	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
D-800	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
P-800	-1.0773 -0.1435 -1.9612 -0.4530 -1.0765 -0.1205 -0.1361 -0.6634 -0.0224 -1.1795 -0.1267 -0.0820 -0.1837 -0.1973 -0.1551
S-626	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-626	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-626	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
D-626	-0.505210280418396	Table 2 shows the frequency of adverse events in clinical trials :
P-626	-1.0773 -0.1435 -1.9612 -0.4530 -1.0765 -0.1205 -0.1361 -0.6634 -0.0224 -1.1795 -0.1267 -0.0820 -0.1837 -0.1973 -0.1551
S-1780	Sollten Sie weitere Fragen zur Anwendung dieses Arzneimittels haben , wenden Sie sich an Ihren Arzt .
T-1780	If you have any further questions on the use of this product , ask your doctor .
H-1780	-0.4728456437587738	If you have any further questions about the use of this product , contact your doctor .
D-1780	-0.4728456437587738	If you have any further questions about the use of this product , contact your doctor .
P-1780	-0.6385 -0.1066 -0.2490 -0.3592 -1.3165 -0.3829 -0.5040 -1.4767 -0.1657 -0.1181 -0.1156 -1.3425 -0.2279 -0.9593 -0.1349 -0.0999 -0.1558 -0.1583
S-1784	- Atembeschwerden , pfeifendes Atmen , Engegefühl in der Brust ,
T-1784	- difficulty in breathing , wheezing , tightness in the chest ,
H-1784	-0.36772292852401733	- difficulty breathing , whistling , tightness in the chest ,
D-1784	-0.36772292852401733	- difficulty breathing , whistling , tightness in the chest ,
P-1784	-0.7698 -0.5158 -0.0994 -0.1441 -1.1936 -0.2700 -0.3007 -0.9071 -0.1513 -0.0688 -0.1983 -0.4828 -0.0766 -0.1846 -0.1530
S-1539	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1539	Activated Factor X converts prothrombin to thrombin .
H-1539	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
D-1539	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
P-1539	-1.0890 -0.1683 -0.0987 -0.1179 -0.1128 -0.1973 -0.1786 -0.0907 -0.0220 -0.1743 -0.1198 -0.7108 -0.0668 -0.1565 -0.1164 -0.1764 -0.1576
S-1362	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1362	Activated Factor X converts prothrombin to thrombin .
H-1362	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
D-1362	-0.22081811726093292	The activated factor X converts prothrombin into thrombin .
P-1362	-1.0890 -0.1683 -0.0987 -0.1179 -0.1128 -0.1973 -0.1786 -0.0907 -0.0220 -0.1743 -0.1198 -0.7108 -0.0668 -0.1565 -0.1164 -0.1764 -0.1576
S-1778	Fahren Sie sofort mit der nächsten vorgesehenen Anwendung fort , wie von Ihrem Arzt angewiesen .
T-1778	Proceed with the next injection as scheduled immediately and continue as advised by your doctor .
H-1778	-0.5811740159988403	Carry on with the next scheduled administration immediately as advised by your doctor .
D-1778	-0.5811740159988403	Carry on with the next scheduled administration immediately as advised by your doctor .
P-1778	-1.5619 -0.0807 -0.1614 -0.7008 -0.8479 -0.3102 -1.0555 -1.8151 -1.0495 -0.2361 -0.7924 -0.1560 -0.1216 -0.1020 -0.1520 -0.1558
S-1484	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-1484	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-1484	-0.4131746292114258	In such cases , contact with a haemophilia centre is recommended .
D-1484	-0.4131746292114258	In such cases , contact with a haemophilia centre is recommended .
P-1484	-0.4120 -0.7032 -0.0849 -0.7705 -1.4050 -1.0518 -0.1303 -0.1834 -0.0766 -0.1227 -0.2624 -0.5252 -0.1887 -0.3844 -0.1578 -0.1521
S-625	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-625	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-625	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
D-625	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
P-625	-3.1341 -0.0103 -0.4936 -0.0249 -1.3684 -0.7477 -0.4094 -0.1698 -0.1271 -0.2292 -0.4549 -0.2506 -0.9183 -1.0428 -0.2701 -0.1117 -0.3131 -0.1524
S-1505	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1505	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1505	-0.21631217002868652	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1505	-0.21631217002868652	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1505	-0.0481 -0.1594 -0.4749 -0.0433 -0.1341 -0.1246 -0.7213 -0.0198 -1.0836 -0.0194 -0.1449 -0.0636 -0.1112 -0.1038 -0.1315 -0.1360 -0.1403 -0.2904 -0.1597
S-975	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-975	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-975	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
D-975	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
P-975	-3.1341 -0.0103 -0.4936 -0.0249 -1.3684 -0.7477 -0.4094 -0.1698 -0.1271 -0.2292 -0.4549 -0.2506 -0.9183 -1.0428 -0.2701 -0.1117 -0.3131 -0.1524
S-1329	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1329	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1329	-0.21631217002868652	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1329	-0.21631217002868652	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1329	-0.0481 -0.1594 -0.4749 -0.0433 -0.1341 -0.1246 -0.7213 -0.0198 -1.0836 -0.0194 -0.1449 -0.0636 -0.1112 -0.1038 -0.1315 -0.1360 -0.1403 -0.2904 -0.1597
S-1308	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-1308	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-1308	-0.4131746292114258	In such cases , contact with a haemophilia centre is recommended .
D-1308	-0.4131746292114258	In such cases , contact with a haemophilia centre is recommended .
P-1308	-0.4120 -0.7032 -0.0849 -0.7705 -1.4050 -1.0518 -0.1303 -0.1834 -0.0766 -0.1227 -0.2624 -0.5252 -0.1887 -0.3844 -0.1578 -0.1521
S-1153	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1153	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1153	-0.21631217002868652	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1153	-0.21631217002868652	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1153	-0.0481 -0.1594 -0.4749 -0.0433 -0.1341 -0.1246 -0.7213 -0.0198 -1.0836 -0.0194 -0.1449 -0.0636 -0.1112 -0.1038 -0.1315 -0.1360 -0.1403 -0.2904 -0.1597
S-1132	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-1132	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-1132	-0.4131746292114258	In such cases , contact with a haemophilia centre is recommended .
D-1132	-0.4131746292114258	In such cases , contact with a haemophilia centre is recommended .
P-1132	-0.4120 -0.7032 -0.0849 -0.7705 -1.4050 -1.0518 -0.1303 -0.1834 -0.0766 -0.1227 -0.2624 -0.5252 -0.1887 -0.3844 -0.1578 -0.1521
S-799	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-799	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-799	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
D-799	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
P-799	-3.1341 -0.0103 -0.4936 -0.0249 -1.3684 -0.7477 -0.4094 -0.1698 -0.1271 -0.2292 -0.4549 -0.2506 -0.9183 -1.0428 -0.2701 -0.1117 -0.3131 -0.1524
S-977	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-977	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-977	-0.21631217002868652	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-977	-0.21631217002868652	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-977	-0.0481 -0.1594 -0.4749 -0.0433 -0.1341 -0.1246 -0.7213 -0.0198 -1.0836 -0.0194 -0.1449 -0.0636 -0.1112 -0.1038 -0.1315 -0.1360 -0.1403 -0.2904 -0.1597
S-1672	300 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1672	300 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1672	-0.2386782020330429	300 IU/ ml after reconstitution Specific activity : approximately
D-1672	-0.2386782020330429	300 IU/ ml after reconstitution Specific activity : approximately
P-1672	-0.0434 -0.1250 -0.1488 -0.1102 -0.0482 -0.4245 -0.2015 -0.1243 -0.8535 -0.0295 -0.3489 -0.1852 -0.5429 -0.1555
S-1654	200 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1654	200 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1654	-0.2528851628303528	200 IU/ ml after reconstitution Specific activity : approximately
D-1654	-0.2528851628303528	200 IU/ ml after reconstitution Specific activity : approximately
P-1654	-0.2792 -0.1201 -0.1602 -0.1187 -0.0523 -0.4291 -0.1989 -0.1171 -0.8440 -0.0290 -0.3365 -0.1831 -0.5178 -0.1544
S-19	Durch die Verminderung der Harnsäureproduktion kann Adenuric die
T-19	By reducing the production of uric acid , Adenuric can reduce levels of uric acid in the blood and keep them low , stopping crystals from building up .
H-19	-0.4778856635093689	By decreasing uric acid production , Adenuric may
D-19	-0.4778856635093689	By decreasing uric acid production , Adenuric may
P-19	-1.8481 -0.9039 -0.2930 -0.0748 -0.0811 -0.0609 -0.1087 -0.3008 -0.2502 -0.1803 -0.0749 -0.1268 -1.0138 -1.3730
S-1704	600 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1704	600 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1704	-0.2502070367336273	600 IU/ ml after reconstitution Specific activity : approximately
D-1704	-0.2502070367336273	600 IU/ ml after reconstitution Specific activity : approximately
P-1704	-0.1547 -0.1188 -0.1339 -0.1152 -0.0514 -0.4459 -0.2037 -0.1231 -0.8706 -0.0308 -0.3540 -0.1837 -0.5615 -0.1556
S-1688	400 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1688	400 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1688	-0.24260295927524567	400 IU/ ml after reconstitution Specific activity : approximately
D-1688	-0.24260295927524567	400 IU/ ml after reconstitution Specific activity : approximately
P-1688	-0.1148 -0.1218 -0.1444 -0.1159 -0.0504 -0.4188 -0.1990 -0.1230 -0.8804 -0.0298 -0.3523 -0.1830 -0.5072 -0.1557
S-1151	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-1151	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-1151	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
D-1151	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
P-1151	-3.1341 -0.0103 -0.4936 -0.0249 -1.3684 -0.7477 -0.4094 -0.1698 -0.1271 -0.2292 -0.4549 -0.2506 -0.9183 -1.0428 -0.2701 -0.1117 -0.3131 -0.1524
S-1327	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-1327	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-1327	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
D-1327	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
P-1327	-3.1341 -0.0103 -0.4936 -0.0249 -1.3684 -0.7477 -0.4094 -0.1698 -0.1271 -0.2292 -0.4549 -0.2506 -0.9183 -1.0428 -0.2701 -0.1117 -0.3131 -0.1524
S-1638	100 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1638	100 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1638	-0.2497454434633255	100 IU/ ml after reconstitution Specific activity : approximately
D-1638	-0.2497454434633255	100 IU/ ml after reconstitution Specific activity : approximately
P-1638	-0.1321 -0.1218 -0.1571 -0.1164 -0.0493 -0.4394 -0.1889 -0.1210 -0.9264 -0.0299 -0.3491 -0.1860 -0.5244 -0.1546
S-1622	50 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1622	50 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1622	-0.23866493999958038	50 IU/ ml after reconstitution Specific activity : approximately
D-1622	-0.23866493999958038	50 IU/ ml after reconstitution Specific activity : approximately
P-1622	-0.0793 -0.1299 -0.1413 -0.1124 -0.0482 -0.4141 -0.1913 -0.1202 -0.8702 -0.0290 -0.3428 -0.1830 -0.5251 -0.1545
S-1503	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-1503	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-1503	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
D-1503	-0.5682533979415894	Adverse reactions after decreasing severity are listed within the frequencies .
P-1503	-3.1341 -0.0103 -0.4936 -0.0249 -1.3684 -0.7477 -0.4094 -0.1698 -0.1271 -0.2292 -0.4549 -0.2506 -0.9183 -1.0428 -0.2701 -0.1117 -0.3131 -0.1524
S-956	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-956	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-956	-0.4131746292114258	In such cases , contact with a haemophilia centre is recommended .
D-956	-0.4131746292114258	In such cases , contact with a haemophilia centre is recommended .
P-956	-0.4120 -0.7032 -0.0849 -0.7705 -1.4050 -1.0518 -0.1303 -0.1834 -0.0766 -0.1227 -0.2624 -0.5252 -0.1887 -0.3844 -0.1578 -0.1521
S-969	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-969	ADVATE has no influence on the ability to drive and use machines .
H-969	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
D-969	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
P-969	-0.1126 -0.1586 -0.0916 -0.0949 -0.4258 -0.0972 -1.2313 -0.1226 -1.3634 -0.3008 -0.6842 -1.1476 -0.8959 -0.7400 -0.2367 -0.1659
S-1969	Eine fortgesetzte Anwendung kann zu einer Toleranz führen , die ein erhöhtes Risiko für eine Überdosierung bedingt .
T-1969	Continuous use can lead to tolerance resulting in an increased risk of overdosing .
H-1969	-0.4116440415382385	Continued use may result in tolerance resulting in an increased risk of overdose .
D-1969	-0.4116440415382385	Continued use may result in tolerance resulting in an increased risk of overdose .
P-1969	-0.8650 -1.3251 -0.1050 -0.3850 -0.4235 -0.7422 -0.1301 -0.5104 -0.1678 -1.9154 -0.1328 -0.2381 -0.0498 -0.1254 -0.2103 -0.1122 -0.0551 -0.1726 -0.1554
S-1497	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-1497	ADVATE has no influence on the ability to drive and use machines .
H-1497	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
D-1497	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
P-1497	-0.1126 -0.1586 -0.0916 -0.0949 -0.4258 -0.0972 -1.2313 -0.1226 -1.3634 -0.3008 -0.6842 -1.1476 -0.8959 -0.7400 -0.2367 -0.1659
S-1321	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-1321	ADVATE has no influence on the ability to drive and use machines .
H-1321	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
D-1321	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
P-1321	-0.1126 -0.1586 -0.0916 -0.0949 -0.4258 -0.0972 -1.2313 -0.1226 -1.3634 -0.3008 -0.6842 -1.1476 -0.8959 -0.7400 -0.2367 -0.1659
S-1145	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-1145	ADVATE has no influence on the ability to drive and use machines .
H-1145	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
D-1145	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
P-1145	-0.1126 -0.1586 -0.0916 -0.0949 -0.4258 -0.0972 -1.2313 -0.1226 -1.3634 -0.3008 -0.6842 -1.1476 -0.8959 -0.7400 -0.2367 -0.1659
S-125	Der Zeitpunkt des Auftretens dieser Symptome variierte von einem Tag bis zu mehreren Monaten nach Therapiebeginn .
T-125	The time to onset of symptoms varied from one day to several months after starting treatment .
H-125	-0.3052321672439575	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
D-125	-0.3052321672439575	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
P-125	-0.5185 -0.6065 -0.2124 -1.3509 -0.1112 -0.1216 -0.1445 -0.0917 -0.0881 -0.1311 -0.2187 -0.1723 -0.1486 -0.1537 -0.0596 -0.1455 -0.4804 -0.8801 -0.2364 -0.2146 -0.6218 -0.1599 -0.1522
S-793	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-793	ADVATE has no influence on the ability to drive and use machines .
H-793	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
D-793	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
P-793	-0.1126 -0.1586 -0.0916 -0.0949 -0.4258 -0.0972 -1.2313 -0.1226 -1.3634 -0.3008 -0.6842 -1.1476 -0.8959 -0.7400 -0.2367 -0.1659
S-619	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-619	ADVATE has no influence on the ability to drive and use machines .
H-619	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
D-619	-0.49182385206222534	ADVATE has no impact on ability to drive or use machines .
P-619	-0.1126 -0.1586 -0.0916 -0.0949 -0.4258 -0.0972 -1.2313 -0.1226 -1.3634 -0.3008 -0.6842 -1.1476 -0.8959 -0.7400 -0.2367 -0.1659
S-1073	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1073	The pulse rate should be determined before and during administration of ADVATE .
H-1073	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
D-1073	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
P-1073	-1.9378 -0.1268 -0.0989 -0.1077 -0.1437 -0.4875 -1.3702 -0.1407 -0.3103 -1.4723 -0.0488 -0.1225 -0.0771 -0.1488 -0.0928 -0.0896 -0.1867 -0.1563
S-1249	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1249	The pulse rate should be determined before and during administration of ADVATE .
H-1249	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
D-1249	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
P-1249	-1.9378 -0.1268 -0.0989 -0.1077 -0.1437 -0.4875 -1.3702 -0.1407 -0.3103 -1.4723 -0.0488 -0.1225 -0.0771 -0.1488 -0.0928 -0.0896 -0.1867 -0.1563
S-901	ADVATE 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-901	ADVATE 1000 IU powder and solvent for solution for injection .
H-901	-0.3329548239707947	ADVATE 1000 IU powder and solvent for the preparation of a solution for injection
D-901	-0.3329548239707947	ADVATE 1000 IU powder and solvent for the preparation of a solution for injection
P-901	-0.0745 -0.1499 -0.0949 -0.0882 -0.0717 -0.1229 -0.0894 -0.7609 -0.1782 -0.1549 -0.2727 -0.4929 -1.9599 -0.6686 -0.1304 -1.0188 -0.1439 -0.1402 -0.1289 -0.0770 -0.1731
S-269	Hertford Road , Hoddesdon Hertfordshire EN11 9BU Vereinigtes Königreich
T-269	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
H-269	-0.12894406914710999	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
D-269	-0.12894406914710999	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
P-269	-0.2479 -0.1374 -0.1032 -0.0600 -0.1447 -0.1413 -0.1357 -0.1050 -0.1729 -0.1530 -0.1305 -0.1143 -0.0514 -0.1226 -0.1262 -0.1436 -0.0861 -0.1308 -0.1213 -0.1509
S-1077	ADVATE 1500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-1077	ADVATE 1500 IU powder and solvent for solution for injection .
H-1077	-0.35001352429389954	ADVATE 1500 IU powder and solvent for the preparation of a solution for injection
D-1077	-0.35001352429389954	ADVATE 1500 IU powder and solvent for the preparation of a solution for injection
P-1077	-0.0556 -0.1482 -0.0963 -0.0894 -0.1033 -0.1213 -0.0957 -1.1117 -0.1787 -0.1525 -0.2817 -0.5076 -1.9495 -0.6694 -0.1287 -0.9996 -0.1478 -0.1372 -0.1268 -0.0771 -0.1722
S-725	ADVATE 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-725	ADVATE 500 IU powder and solvent for solution for injection .
H-725	-0.3489453196525574	ADVATE 500 IU powder and solvent for preparation of solution for injection
D-725	-0.3489453196525574	ADVATE 500 IU powder and solvent for preparation of solution for injection
P-725	-0.0757 -0.1476 -0.0984 -0.0913 -0.0822 -0.1228 -0.0884 -1.0869 -0.1773 -0.1542 -0.2794 -0.5160 -2.3339 -0.1416 -0.7603 -0.1079 -0.1293 -0.0601 -0.1766
S-1253	ADVATE 2000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-1253	ADVATE 2000 IU powder and solvent for solution for injection .
H-1253	-0.33298560976982117	ADVATE 2000 IU powder and solvent for the preparation of a solution for injection
D-1253	-0.33298560976982117	ADVATE 2000 IU powder and solvent for the preparation of a solution for injection
P-1253	-0.0734 -0.1508 -0.0973 -0.0942 -0.0985 -0.1333 -0.0830 -0.8204 -0.1772 -0.1538 -0.2640 -0.4752 -1.8623 -0.6742 -0.1296 -1.0606 -0.1312 -0.1330 -0.1284 -0.0794 -0.1728
S-1429	ADVATE 3000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-1429	ADVATE 3000 IU powder and solvent for solution for injection .
H-1429	-0.3395588994026184	ADVATE 3000 IU powder and solvent for the preparation of a solution for injection
D-1429	-0.3395588994026184	ADVATE 3000 IU powder and solvent for the preparation of a solution for injection
P-1429	-0.0777 -0.1498 -0.0966 -0.0900 -0.0451 -0.1232 -0.0940 -0.8470 -0.1774 -0.1591 -0.2875 -0.5173 -1.9717 -0.6891 -0.1295 -1.0152 -0.1430 -0.1376 -0.1300 -0.0764 -0.1735
S-1743	Falls Ihre Blutungen mit ADVATE nicht kontrolliert werden können , wenden Sie sich umgehend an Ihren Arzt
T-1743	If your bleeding is not controlled with ADVATE , tell your doctor immediately .
H-1743	-0.2539293169975281	If your bleeding cannot be controlled with ADVATE , contact your doctor immediately
D-1743	-0.2539293169975281	If your bleeding cannot be controlled with ADVATE , contact your doctor immediately
P-1743	-0.2155 -0.4422 -0.6955 -0.1186 -0.6447 -0.1340 -0.3781 -0.3463 -0.1034 -0.1487 -0.0954 -0.0870 -0.1926 -0.4896 -0.1149 -0.1016 -0.0787 -0.1840
S-159	Colecalciferol und einige seiner aktiven Metaboliten gehen in die Muttermilch über .
T-159	Colecalciferol and some of its active metabolites pass into breast milk .
H-159	-0.2817595899105072	Colecalciferol and some of its active metabolites are released into breast milk .
D-159	-0.2817595899105072	Colecalciferol and some of its active metabolites are released into breast milk .
P-159	-0.2402 -0.1164 -0.1947 -0.1246 -0.1315 -0.1333 -0.1417 -0.2331 -0.1395 -0.1124 -0.0451 -0.1608 -0.0379 -0.1070 -0.4809 -2.4588 -0.2259 -0.3602 -0.1527 -0.1665 -0.1535
S-1210	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1210	The beginning of storage at room temperature should be recorded on the product carton .
H-1210	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
D-1210	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
P-1210	-0.4555 -1.1838 -0.1388 -0.5445 -0.1276 -1.2798 -0.1084 -0.1477 -0.1480 -0.1357 -1.4376 -0.1194 -0.1635 -0.2779 -0.0714 -0.1826 -0.0176 -0.1886 -0.1550
S-897	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-897	The pulse rate should be determined before and during administration of ADVATE .
H-897	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
D-897	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
P-897	-1.9378 -0.1268 -0.0989 -0.1077 -0.1437 -0.4875 -1.3702 -0.1407 -0.3103 -1.4723 -0.0488 -0.1225 -0.0771 -0.1488 -0.0928 -0.0896 -0.1867 -0.1563
S-465	Hertford Road , Hoddesdon Hertfordshire EN11 9BU Vereinigtes Königreich
T-465	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
H-465	-0.12894406914710999	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
D-465	-0.12894406914710999	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
P-465	-0.2479 -0.1374 -0.1032 -0.0600 -0.1447 -0.1413 -0.1357 -0.1050 -0.1729 -0.1530 -0.1305 -0.1143 -0.0514 -0.1226 -0.1262 -0.1436 -0.0861 -0.1308 -0.1213 -0.1509
S-721	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-721	The pulse rate should be determined before and during administration of ADVATE .
H-721	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
D-721	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
P-721	-1.9378 -0.1268 -0.0989 -0.1077 -0.1437 -0.4875 -1.3702 -0.1407 -0.3103 -1.4723 -0.0488 -0.1225 -0.0771 -0.1488 -0.0928 -0.0896 -0.1867 -0.1563
S-550	ADVATE 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-550	ADVATE 250 IU powder and solvent for solution for injection
H-550	-0.34572580456733704	ADVATE 250 IU powder and solvent for preparation of solution for injection
D-550	-0.34572580456733704	ADVATE 250 IU powder and solvent for preparation of solution for injection
P-550	-0.0615 -0.1456 -0.0960 -0.0905 -0.0872 -0.1228 -0.0810 -1.0863 -0.1779 -0.1497 -0.2825 -0.4911 -2.2960 -0.1414 -0.7883 -0.1072 -0.1291 -0.0595 -0.1753
S-682	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-682	The beginning of storage at room temperature should be recorded on the product carton .
H-682	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
D-682	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
P-682	-0.4555 -1.1838 -0.1388 -0.5445 -0.1276 -1.2798 -0.1084 -0.1477 -0.1480 -0.1357 -1.4376 -0.1194 -0.1635 -0.2779 -0.0714 -0.1826 -0.0176 -0.1886 -0.1550
S-1471	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-1471	In case of administration by a non health care professional appropriate training is needed .
H-1471	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-1471	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-1471	-1.1267 -0.9663 -0.7463 -0.1940 -0.2605 -0.1281 -0.1331 -0.1055 -0.1254 -1.4283 -0.3294 -0.4379 -0.5103 -2.4366 -0.2639 -0.5126 -0.6923 -0.1847 -0.1549
S-1783	- Hautrötung , Ausschlag , Quaddelbildung , Juckreiz am ganzen Körper ,
T-1783	- rash , hives , wheals , generalised itching ,
H-1783	-0.46277129650115967	- redness , rash , wheezing , itching all over the body ,
D-1783	-0.46277129650115967	- redness , rash , wheezing , itching all over the body ,
P-1783	-0.3773 -1.3243 -0.0810 -0.1424 -0.1336 -0.0585 -0.1392 -0.2198 -2.2859 -0.5259 -0.1383 -1.2000 -0.0644 -0.6433 -0.0812 -0.9136 -0.0905 -0.2141 -0.1594
S-1798	Bitte notieren Sie den Beginn und das Ende der Raumtemperaturlagerung auf dem Umkarton .
T-1798	Please record the beginning of storage at room temperature on the product carton .
H-1798	-0.4509872496128082	Write down the start and end of room temperature storage on the outer carton .
D-1798	-0.4509872496128082	Write down the start and end of room temperature storage on the outer carton .
P-1798	-2.5166 -0.0696 -0.2719 -0.3155 -1.3832 -0.1423 -0.5864 -0.1562 -1.6053 -0.0993 -0.1304 -0.1273 -0.1847 -0.2610 -0.0649 -0.2490 -0.0155 -0.2329 -0.1566
S-548	Pulver : Durchstechflasche ( Glas ) Lösungsmittel : Durchstechflasche ( Glas )
T-548	powder : vial ( glass ) ; solvent : vial ( glass )
H-548	-0.26137956976890564	powder : vial ( glass ) solvent : vial ( glass )
D-548	-0.26137956976890564	powder : vial ( glass ) solvent : vial ( glass )
P-548	-1.6741 -0.1433 -0.6336 -0.0732 -0.1459 -0.0431 -0.1296 -0.4039 -0.1786 -0.1443 -0.0275 -0.1033 -0.1255 -0.0624 -0.1299 -0.1640
S-1803	Fragen Sie Ihren Apotheker wie das Arzneimittel zu entsorgen ist , wenn Sie es nicht mehr benötigen .
T-1803	Ask your pharmacist how to dispose of medicines no longer required .
H-1803	-0.2756200134754181	Ask your pharmacist how to dispose of the medicine if you no longer need it .
D-1803	-0.2756200134754181	Ask your pharmacist how to dispose of the medicine if you no longer need it .
P-1803	-0.1509 -0.0770 -0.2023 -0.1185 -0.1203 -0.1382 -0.2431 -0.0942 -0.0691 -0.3529 -0.6222 -1.2542 -0.8070 -0.1060 -0.2588 -0.1158 -0.2871 -0.1242 -0.2027 -0.1683
S-1563	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1563	The beginning of storage at room temperature should be recorded on the product carton .
H-1563	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
D-1563	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
P-1563	-0.4555 -1.1838 -0.1388 -0.5445 -0.1276 -1.2798 -0.1084 -0.1477 -0.1480 -0.1357 -1.4376 -0.1194 -0.1635 -0.2779 -0.0714 -0.1826 -0.0176 -0.1886 -0.1550
S-858	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-858	The beginning of storage at room temperature should be recorded on the product carton .
H-858	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
D-858	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
P-858	-0.4555 -1.1838 -0.1388 -0.5445 -0.1276 -1.2798 -0.1084 -0.1477 -0.1480 -0.1357 -1.4376 -0.1194 -0.1635 -0.2779 -0.0714 -0.1826 -0.0176 -0.1886 -0.1550
S-1034	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1034	The beginning of storage at room temperature should be recorded on the product carton .
H-1034	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
D-1034	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
P-1034	-0.4555 -1.1838 -0.1388 -0.5445 -0.1276 -1.2798 -0.1084 -0.1477 -0.1480 -0.1357 -1.4376 -0.1194 -0.1635 -0.2779 -0.0714 -0.1826 -0.0176 -0.1886 -0.1550
S-1393	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1393	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1393	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-1393	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-1393	-1.0035 -0.2232 -0.1125 -0.7534 -0.1620 -0.1191 -0.2049 -0.1526 -0.1452 -0.0414 -0.1187 -0.1063 -0.3878 -0.2366 -0.6022 -0.3560 -0.1377 -0.0868 -0.1650 -0.1535
S-1386	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1386	The beginning of storage at room temperature should be recorded on the product carton .
H-1386	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
D-1386	-0.3622835874557495	The beginning and end of room temperature storage should be noted on the outer carton .
P-1386	-0.4555 -1.1838 -0.1388 -0.5445 -0.1276 -1.2798 -0.1084 -0.1477 -0.1480 -0.1357 -1.4376 -0.1194 -0.1635 -0.2779 -0.0714 -0.1826 -0.0176 -0.1886 -0.1550
S-347	Colecalciferol und einige seiner aktiven Metaboliten gehen in die Muttermilch über .
T-347	Colecalciferol and some of its active metabolites pass into breast milk .
H-347	-0.2817595899105072	Colecalciferol and some of its active metabolites are released into breast milk .
D-347	-0.2817595899105072	Colecalciferol and some of its active metabolites are released into breast milk .
P-347	-0.2402 -0.1164 -0.1947 -0.1246 -0.1315 -0.1333 -0.1417 -0.2331 -0.1395 -0.1124 -0.0451 -0.1608 -0.0379 -0.1070 -0.4809 -2.4588 -0.2259 -0.3602 -0.1527 -0.1665 -0.1535
S-1295	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-1295	In case of administration by a non health care professional appropriate training is needed .
H-1295	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-1295	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-1295	-1.1267 -0.9663 -0.7463 -0.1940 -0.2605 -0.1281 -0.1331 -0.1055 -0.1254 -1.4283 -0.3294 -0.4379 -0.5103 -2.4366 -0.2639 -0.5126 -0.6923 -0.1847 -0.1549
S-1660	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1660	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1660	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1660	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1660	-1.0186 -0.9701 -0.0828 -0.0639 -0.1789 -0.7495 -0.1246 -0.3650 -0.2242 -0.1633 -0.1408 -0.1459 -0.4690 -0.0369 -0.1480 -0.1558 -0.1484 -0.3108 -0.1592
S-1677	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1677	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1677	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1677	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1677	-1.0186 -0.9701 -0.0828 -0.0639 -0.1789 -0.7495 -0.1246 -0.3650 -0.2242 -0.1633 -0.1408 -0.1459 -0.4690 -0.0369 -0.1480 -0.1558 -0.1484 -0.3108 -0.1592
S-1844	29-1 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
T-1844	29-1 LT-09129 Vilnius Tel : <<unk>> 370 5 269 16 91
H-1844	-0.1251017451286316	29-1 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
D-1844	-0.1251017451286316	29-1 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
P-1844	-0.2153 -0.1944 -0.1224 -0.1499 -0.1883 -0.1379 -0.0932 -0.1545 -0.1145 -0.1644 -0.1171 -0.1576 -0.0706 -0.1419 -0.0330 -0.0455 -0.1385 -0.0628 -0.1179 -0.1135 -0.0639 -0.1550
S-1750	Schwangerschaft und Stillzeit Informieren Sie Ihren Arzt , wenn Sie schwanger sind oder stillen .
T-1750	Pregnancy and breast-feeding Tell your doctor if you are pregnant or breast-feeding .
H-1750	-0.31688690185546875	Be sure to tell your doctor if you are pregnant or breast-feeding .
D-1750	-0.31688690185546875	Be sure to tell your doctor if you are pregnant or breast-feeding .
P-1750	-3.2338 -0.0485 -0.1292 -0.1045 -0.1352 -0.0865 -0.0825 -0.1003 -0.1058 -0.1225 -0.1362 -0.6347 -0.0290 -0.0616 -0.0351 -0.1678 -0.1739
S-1627	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1627	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1627	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1627	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1627	-1.0186 -0.9701 -0.0828 -0.0639 -0.1789 -0.7495 -0.1246 -0.3650 -0.2242 -0.1633 -0.1408 -0.1459 -0.4690 -0.0369 -0.1480 -0.1558 -0.1484 -0.3108 -0.1592
S-1643	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1643	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1643	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1643	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1643	-1.0186 -0.9701 -0.0828 -0.0639 -0.1789 -0.7495 -0.1246 -0.3650 -0.2242 -0.1633 -0.1408 -0.1459 -0.4690 -0.0369 -0.1480 -0.1558 -0.1484 -0.3108 -0.1592
S-1781	Wie alle Arzneimittel kann ADVATE Nebenwirkungen haben , die aber nicht bei jedem auftreten müssen .
T-1781	Like all medicines , ADVATE can cause side effects , although not everybody gets them .
H-1781	-0.5750551819801331	Like all medicines , ADVATE may have side effects , but these may not be evident in everyone .
D-1781	-0.5750551819801331	Like all medicines , ADVATE may have side effects , but these may not be evident in everyone .
P-1781	-0.3302 -0.1073 -0.3080 -0.2015 -0.2157 -0.1335 -0.1530 -0.1059 -0.0982 -1.1506 -0.7476 -0.2282 -0.1535 -1.2415 -0.3079 -1.3822 -0.9749 -0.1507 -0.7044 -3.9104 -0.0311 -0.4346 -0.9657 -0.1806 -0.1592
S-1742	Die Entwicklung von Inhibitoren ist eine bekannte Komplikation der Hämophilie A Behandlung .
T-1742	Development of inhibitors is a known complication in the treatment of haemophilia A.
H-1742	-0.2662707269191742	The development of inhibitors is a known complication of haemophilia A treatment .
D-1742	-0.2662707269191742	The development of inhibitors is a known complication of haemophilia A treatment .
P-1742	-1.9647 -0.1243 -0.1247 -0.1739 -0.0789 -0.0604 -0.1427 -0.1832 -0.1282 -0.7007 -0.0675 -0.1466 -0.1522 -0.5047 -0.1195 -0.0696 -0.0799 -0.1548 -0.2925 -0.1702 -0.1522
S-1693	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1693	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1693	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1693	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1693	-1.0186 -0.9701 -0.0828 -0.0639 -0.1789 -0.7495 -0.1246 -0.3650 -0.2242 -0.1633 -0.1408 -0.1459 -0.4690 -0.0369 -0.1480 -0.1558 -0.1484 -0.3108 -0.1592
S-1709	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1709	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1709	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1709	-0.2976659834384918	Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1709	-1.0186 -0.9701 -0.0828 -0.0639 -0.1789 -0.7495 -0.1246 -0.3650 -0.2242 -0.1633 -0.1408 -0.1459 -0.4690 -0.0369 -0.1480 -0.1558 -0.1484 -0.3108 -0.1592
S-1425	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1425	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden . The pulse rate should be determined before and during administration of ADVATE .
H-1425	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
D-1425	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
P-1425	-1.9378 -0.1268 -0.0989 -0.1077 -0.1437 -0.4875 -1.3702 -0.1407 -0.3103 -1.4723 -0.0488 -0.1225 -0.0771 -0.1488 -0.0928 -0.0896 -0.1867 -0.1563
S-1602	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1602	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden . The pulse rate should be determined before and during administration of ADVATE .
H-1602	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
D-1602	-0.3954596519470215	s pulse should be measured before and during the administration of ADVATE .
P-1602	-1.9378 -0.1268 -0.0989 -0.1077 -0.1437 -0.4875 -1.3702 -0.1407 -0.3103 -1.4723 -0.0488 -0.1225 -0.0771 -0.1488 -0.0928 -0.0896 -0.1867 -0.1563
S-1748	B. Atembeschwerden und ( Beinahe<unk> -Ohnmacht benötigen eine sofortige Notfallbehandlung .
T-1748	Severe symptoms , including difficulty in breathing and ( near ) fainting , require prompt emergency treatment .
H-1748	-0.39611852169036865	difficulty breathing and ( near fainting ) need immediate emergency treatment .
D-1748	-0.39611852169036865	difficulty breathing and ( near fainting ) need immediate emergency treatment .
P-1748	-1.9461 -0.1496 -0.1647 -0.4047 -0.0666 -0.9422 -0.1667 -0.1260 -0.5260 -0.3356 -0.2339 -0.1946 -0.2570 -0.2765 -0.1517
S-689	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-689	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-689	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-689	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-689	-1.0035 -0.2232 -0.1125 -0.7534 -0.1620 -0.1191 -0.2049 -0.1526 -0.1452 -0.0414 -0.1187 -0.1063 -0.3878 -0.2366 -0.6022 -0.3560 -0.1377 -0.0868 -0.1650 -0.1535
S-1810	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1810	After reconstitution , the solution is clear , colourless and free from foreign particles .
H-1810	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-1810	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-1810	-1.0035 -0.2232 -0.1125 -0.7534 -0.1620 -0.1191 -0.2049 -0.1526 -0.1452 -0.0414 -0.1187 -0.1063 -0.3878 -0.2366 -0.6022 -0.3560 -0.1377 -0.0868 -0.1650 -0.1535
S-570	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-570	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-570	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
D-570	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
P-570	-0.9155 -0.1130 -0.7712 -0.1515 -2.4754 -0.1074 -0.4291 -0.4360 -0.1992 -1.5958 -0.8160 -1.0698 -0.0651 -0.6741 -0.1257 -0.1027 -0.1791 -0.1567
S-1041	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1041	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1041	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-1041	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-1041	-1.0035 -0.2232 -0.1125 -0.7534 -0.1620 -0.1191 -0.2049 -0.1526 -0.1452 -0.0414 -0.1187 -0.1063 -0.3878 -0.2366 -0.6022 -0.3560 -0.1377 -0.0868 -0.1650 -0.1535
S-1217	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1217	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1217	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-1217	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-1217	-1.0035 -0.2232 -0.1125 -0.7534 -0.1620 -0.1191 -0.2049 -0.1526 -0.1452 -0.0414 -0.1187 -0.1063 -0.3878 -0.2366 -0.6022 -0.3560 -0.1377 -0.0868 -0.1650 -0.1535
S-1570	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1570	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1570	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-1570	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-1570	-1.0035 -0.2232 -0.1125 -0.7534 -0.1620 -0.1191 -0.2049 -0.1526 -0.1452 -0.0414 -0.1187 -0.1063 -0.3878 -0.2366 -0.6022 -0.3560 -0.1377 -0.0868 -0.1650 -0.1535
S-1757	Die Einnahmehäufigkeit hängt davon ab , wie gut ADVATE bei Ihnen wirkt .
T-1757	The frequency of administration will depend on how well ADVATE is working for you .
H-1757	-0.26471009850502014	The frequency depends on how well ADVATE works in you .
D-1757	-0.26471009850502014	The frequency depends on how well ADVATE works in you .
P-1757	-0.7140 -0.1550 -0.0894 -1.1040 -0.1211 -0.0958 -0.1929 -0.0437 -0.1443 -0.0891 -0.0939 -0.4831 -0.4028 -0.1841 -0.1590 -0.1631
S-865	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-865	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-865	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-865	-0.26341909170150757	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-865	-1.0035 -0.2232 -0.1125 -0.7534 -0.1620 -0.1191 -0.2049 -0.1526 -0.1452 -0.0414 -0.1187 -0.1063 -0.3878 -0.2366 -0.6022 -0.3560 -0.1377 -0.0868 -0.1650 -0.1535
S-1448	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-1448	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-1448	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
D-1448	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
P-1448	-0.9155 -0.1130 -0.7712 -0.1515 -2.4754 -0.1074 -0.4291 -0.4360 -0.1992 -1.5958 -0.8160 -1.0698 -0.0651 -0.6741 -0.1257 -0.1027 -0.1791 -0.1567
S-744	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-744	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-744	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
D-744	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
P-744	-0.9155 -0.1130 -0.7712 -0.1515 -2.4754 -0.1074 -0.4291 -0.4360 -0.1992 -1.5958 -0.8160 -1.0698 -0.0651 -0.6741 -0.1257 -0.1027 -0.1791 -0.1567
S-920	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-920	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-920	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
D-920	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
P-920	-0.9155 -0.1130 -0.7712 -0.1515 -2.4754 -0.1074 -0.4291 -0.4360 -0.1992 -1.5958 -0.8160 -1.0698 -0.0651 -0.6741 -0.1257 -0.1027 -0.1791 -0.1567
S-1096	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-1096	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-1096	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
D-1096	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
P-1096	-0.9155 -0.1130 -0.7712 -0.1515 -2.4754 -0.1074 -0.4291 -0.4360 -0.1992 -1.5958 -0.8160 -1.0698 -0.0651 -0.6741 -0.1257 -0.1027 -0.1791 -0.1567
S-1272	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-1272	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-1272	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
D-1272	-0.5768421292304993	The following Table 1 indicates dosage in haemorrhage and surgery :
P-1272	-0.9155 -0.1130 -0.7712 -0.1515 -2.4754 -0.1074 -0.4291 -0.4360 -0.1992 -1.5958 -0.8160 -1.0698 -0.0651 -0.6741 -0.1257 -0.1027 -0.1791 -0.1567
S-1434	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-1434	0.45 mmol sodium ( 10 mg ) per vial .
H-1434	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-1434	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-1434	-0.1650 -0.1658 -0.1025 -0.2093 -0.0997 -0.5784 -0.1008 -0.1338 -0.0818 -0.0561 -0.0797 -0.1469 -0.1654 -0.0448 -0.1432 -0.0670 -0.0096 -0.0685 -0.3915 -0.1539
S-1119	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-1119	In case of administration by a non health care professional appropriate training is needed .
H-1119	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-1119	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-1119	-1.1267 -0.9663 -0.7463 -0.1940 -0.2605 -0.1281 -0.1331 -0.1055 -0.1254 -1.4283 -0.3294 -0.4379 -0.5103 -2.4366 -0.2639 -0.5126 -0.6923 -0.1847 -0.1549
S-1258	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-1258	0.45 mmol sodium ( 10 mg ) per vial .
H-1258	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-1258	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-1258	-0.1650 -0.1658 -0.1025 -0.2093 -0.0997 -0.5784 -0.1008 -0.1338 -0.0818 -0.0561 -0.0797 -0.1469 -0.1654 -0.0448 -0.1432 -0.0670 -0.0096 -0.0685 -0.3915 -0.1539
S-1710	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1710	Store in the original package in order to protect from light .
H-1710	-0.45664846897125244	Store the container in its original packaging to protect from light .
D-1710	-0.45664846897125244	Store the container in its original packaging to protect from light .
P-1710	-0.4213 -0.8181 -1.3097 -0.1406 -0.3335 -0.2120 -0.9472 -0.1149 -0.2521 -0.2268 -1.1070 -0.1130 -0.1886 -0.2082
S-14	Die Behandlung mit Adenuric darf nicht abgesetzt werden , wenn ein Gichtanfall auftritt .
T-14	Adenuric treatment should not be stopped if an attack happens .
H-14	-0.3324975073337555	Treatment with Adenuric should not be discontinued if an attack of gout occurs .
D-14	-0.3324975073337555	Treatment with Adenuric should not be discontinued if an attack of gout occurs .
P-14	-2.2100 -0.0629 -0.1074 -0.2022 -0.2039 -0.1950 -0.1010 -0.1307 -0.4843 -0.1548 -0.1042 -0.1117 -0.0105 -0.7920 -1.5655 -0.0863 -0.1267 -0.0822 -0.1248 -0.4136 -0.0554 -0.1716 -0.1507
S-1727	Nebenwirkungen bemerken , die nicht in dieser Gebrauchsinformation angegeben sind , informieren Sie bitte Ihren Arzt .
T-1727	please tell your doctor .
H-1727	-0.4662739336490631	If you notice any undesirable effects not listed in this leaflet , tell your doctor .
D-1727	-0.4662739336490631	If you notice any undesirable effects not listed in this leaflet , tell your doctor .
P-1727	-0.8228 -0.1333 -1.0523 -0.7527 -1.4076 -0.1957 -0.0448 -0.2837 -0.7052 -1.5812 -0.1499 -0.1817 -0.0879 -0.0442 -0.0568 -0.1378 -1.5663 -0.1342 -0.1002 -0.1955 -0.1582
S-1628	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1628	Store in the original package in order to protect from light .
H-1628	-0.45664846897125244	Store the container in its original packaging to protect from light .
D-1628	-0.45664846897125244	Store the container in its original packaging to protect from light .
P-1628	-0.4213 -0.8181 -1.3097 -0.1406 -0.3335 -0.2120 -0.9472 -0.1149 -0.2521 -0.2268 -1.1070 -0.1130 -0.1886 -0.2082
S-1644	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1644	Store in the original package in order to protect from light .
H-1644	-0.45664846897125244	Store the container in its original packaging to protect from light .
D-1644	-0.45664846897125244	Store the container in its original packaging to protect from light .
P-1644	-0.4213 -0.8181 -1.3097 -0.1406 -0.3335 -0.2120 -0.9472 -0.1149 -0.2521 -0.2268 -1.1070 -0.1130 -0.1886 -0.2082
S-1678	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1678	Store in the original package in order to protect from light .
H-1678	-0.45664846897125244	Store the container in its original packaging to protect from light .
D-1678	-0.45664846897125244	Store the container in its original packaging to protect from light .
P-1678	-0.4213 -0.8181 -1.3097 -0.1406 -0.3335 -0.2120 -0.9472 -0.1149 -0.2521 -0.2268 -1.1070 -0.1130 -0.1886 -0.2082
S-1694	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1694	Store in the original package in order to protect from light .
H-1694	-0.45664846897125244	Store the container in its original packaging to protect from light .
D-1694	-0.45664846897125244	Store the container in its original packaging to protect from light .
P-1694	-0.4213 -0.8181 -1.3097 -0.1406 -0.3335 -0.2120 -0.9472 -0.1149 -0.2521 -0.2268 -1.1070 -0.1130 -0.1886 -0.2082
S-1082	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-1082	0.45 mmol sodium ( 10 mg ) per vial .
H-1082	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-1082	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-1082	-0.1650 -0.1658 -0.1025 -0.2093 -0.0997 -0.5784 -0.1008 -0.1338 -0.0818 -0.0561 -0.0797 -0.1469 -0.1654 -0.0448 -0.1432 -0.0670 -0.0096 -0.0685 -0.3915 -0.1539
S-1661	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1661	Store in the original package in order to protect from light .
H-1661	-0.45664846897125244	Store the container in its original packaging to protect from light .
D-1661	-0.45664846897125244	Store the container in its original packaging to protect from light .
P-1661	-0.4213 -0.8181 -1.3097 -0.1406 -0.3335 -0.2120 -0.9472 -0.1149 -0.2521 -0.2268 -1.1070 -0.1130 -0.1886 -0.2082
S-555	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-555	0.45 mmol sodium ( 10 mg ) per vial .
H-555	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-555	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-555	-0.1650 -0.1658 -0.1025 -0.2093 -0.0997 -0.5784 -0.1008 -0.1338 -0.0818 -0.0561 -0.0797 -0.1469 -0.1654 -0.0448 -0.1432 -0.0670 -0.0096 -0.0685 -0.3915 -0.1539
S-593	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-593	In case of administration by a non health care professional appropriate training is needed .
H-593	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-593	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-593	-1.1267 -0.9663 -0.7463 -0.1940 -0.2605 -0.1281 -0.1331 -0.1055 -0.1254 -1.4283 -0.3294 -0.4379 -0.5103 -2.4366 -0.2639 -0.5126 -0.6923 -0.1847 -0.1549
S-730	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-730	0.45 mmol sodium ( 10 mg ) per vial .
H-730	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-730	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-730	-0.1650 -0.1658 -0.1025 -0.2093 -0.0997 -0.5784 -0.1008 -0.1338 -0.0818 -0.0561 -0.0797 -0.1469 -0.1654 -0.0448 -0.1432 -0.0670 -0.0096 -0.0685 -0.3915 -0.1539
S-767	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-767	In case of administration by a non health care professional appropriate training is needed .
H-767	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-767	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-767	-1.1267 -0.9663 -0.7463 -0.1940 -0.2605 -0.1281 -0.1331 -0.1055 -0.1254 -1.4283 -0.3294 -0.4379 -0.5103 -2.4366 -0.2639 -0.5126 -0.6923 -0.1847 -0.1549
S-906	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-906	0.45 mmol sodium ( 10 mg ) per vial .
H-906	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-906	-0.14817453920841217	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-906	-0.1650 -0.1658 -0.1025 -0.2093 -0.0997 -0.5784 -0.1008 -0.1338 -0.0818 -0.0561 -0.0797 -0.1469 -0.1654 -0.0448 -0.1432 -0.0670 -0.0096 -0.0685 -0.3915 -0.1539
S-943	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-943	In case of administration by a non health care professional appropriate training is needed .
H-943	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-943	-0.5650933980941772	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-943	-1.1267 -0.9663 -0.7463 -0.1940 -0.2605 -0.1281 -0.1331 -0.1055 -0.1254 -1.4283 -0.3294 -0.4379 -0.5103 -2.4366 -0.2639 -0.5126 -0.6923 -0.1847 -0.1549
S-1207	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1207	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1207	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1207	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1207	-0.5414 -0.2760 -0.0958 -0.0761 -0.1362 -1.1676 -0.1277 -0.0939 -0.2848 -0.6080 -0.0665 -0.0923 -0.1345 -0.5735 -0.1201 -0.0400 -0.6459 -0.2389 -0.1229 -0.1605 -0.1525
S-1383	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1383	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1383	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1383	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1383	-0.5414 -0.2760 -0.0958 -0.0761 -0.1362 -1.1676 -0.1277 -0.0939 -0.2848 -0.6080 -0.0665 -0.0923 -0.1345 -0.5735 -0.1201 -0.0400 -0.6459 -0.2389 -0.1229 -0.1605 -0.1525
S-1560	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1560	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1560	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1560	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1560	-0.5414 -0.2760 -0.0958 -0.0761 -0.1362 -1.1676 -0.1277 -0.0939 -0.2848 -0.6080 -0.0665 -0.0923 -0.1345 -0.5735 -0.1201 -0.0400 -0.6459 -0.2389 -0.1229 -0.1605 -0.1525
S-855	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-855	From a microbiological point of view , the product should be used immediately after reconstitution .
H-855	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-855	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-855	-0.5414 -0.2760 -0.0958 -0.0761 -0.1362 -1.1676 -0.1277 -0.0939 -0.2848 -0.6080 -0.0665 -0.0923 -0.1345 -0.5735 -0.1201 -0.0400 -0.6459 -0.2389 -0.1229 -0.1605 -0.1525
S-1853	Advexin wurde am 23 . Oktober 2006 als Arzneimittel für seltene Leiden ausgewiesen .
T-1853	Advexin was designated as an orphan medicinal product on 23 October 2006.
H-1853	-0.32042932510375977	Advexin was designated an orphan medicine on 23 October 2006 .
D-1853	-0.32042932510375977	Advexin was designated an orphan medicine on 23 October 2006 .
P-1853	-0.7579 -0.1554 -0.1319 -0.2645 -0.8142 -0.1098 -0.3155 -0.7870 -0.2098 -0.3925 -0.6735 -0.1061 -0.1594 -0.1183 -0.1227 -0.1765 -0.1525
S-1977	Die gleichzeitige Anwendung von Sympathomimetika kann zu kritischen hypertonen Reaktionen führen .
T-1977	Concurrent administration with sympathomimetic medicines may result in critical hypertension reactions .
H-1977	-0.3513951003551483	Co-administration of sympathomimetics may result in critical hypertonic reactions .
D-1977	-0.3513951003551483	Co-administration of sympathomimetics may result in critical hypertonic reactions .
P-1977	-1.2698 -0.2770 -0.0154 -0.1520 -0.0297 -0.0421 -0.0632 -0.0969 -0.5087 -1.7251 -0.1264 -0.0862 -0.0265 -1.5023 -0.0450 -0.3148 -0.0435 -0.1974 -0.1545
S-4	Es ist als gelbe , kapselförmige Tabletten ( 80 und 120 mg ) erhältlich .
T-4	It is available as yellow , capsule- shaped tablets ( 80 and 120 mg ) .
H-4	-0.352321058511734	It is available as yellow capsule tablets ( 80 and 120 mg ) .
D-4	-0.352321058511734	It is available as yellow capsule tablets ( 80 and 120 mg ) .
P-4	-0.4878 -0.1952 -0.3340 -1.0342 -0.1206 -1.0783 -0.1056 -0.5792 -0.8769 -0.1595 -0.1878 -0.2500 -0.2828 -0.1154 -0.0561 -0.1429 -0.1783 -0.1571
S-598	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-598	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-598	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-598	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-598	-0.7880 -0.2999 -0.1354 -0.2249 -0.0873 -0.0770 -0.1069 -0.0837 -0.0590 -0.2059 -1.3853 -0.0719 -0.0646 -0.0471 -0.0469 -0.0742 -0.0538 -0.9803 -0.0763 -0.1504 -0.1537
S-1114	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-1114	Patients should be monitored for the development of factor VIII inhibitors .
H-1114	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
D-1114	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
P-1114	-0.3817 -0.0929 -0.1278 -0.1658 -0.7742 -0.1243 -1.0242 -0.1740 -1.1518 -0.1255 -0.5717 -0.1926 -0.0750 -0.1117 -0.0698 -0.0604 -0.1581 -0.1720 -0.1524
S-1031	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1031	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1031	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1031	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1031	-0.5414 -0.2760 -0.0958 -0.0761 -0.1362 -1.1676 -0.1277 -0.0939 -0.2848 -0.6080 -0.0665 -0.0923 -0.1345 -0.5735 -0.1201 -0.0400 -0.6459 -0.2389 -0.1229 -0.1605 -0.1525
S-948	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-948	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-948	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-948	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-948	-0.7880 -0.2999 -0.1354 -0.2249 -0.0873 -0.0770 -0.1069 -0.0837 -0.0590 -0.2059 -1.3853 -0.0719 -0.0646 -0.0471 -0.0469 -0.0742 -0.0538 -0.9803 -0.0763 -0.1504 -0.1537
S-679	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-679	From a microbiological point of view , the product should be used immediately after reconstitution .
H-679	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-679	-0.2740527093410492	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-679	-0.5414 -0.2760 -0.0958 -0.0761 -0.1362 -1.1676 -0.1277 -0.0939 -0.2848 -0.6080 -0.0665 -0.0923 -0.1345 -0.5735 -0.1201 -0.0400 -0.6459 -0.2389 -0.1229 -0.1605 -0.1525
S-1290	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-1290	Patients should be monitored for the development of factor VIII inhibitors .
H-1290	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
D-1290	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
P-1290	-0.3817 -0.0929 -0.1278 -0.1658 -0.7742 -0.1243 -1.0242 -0.1740 -1.1518 -0.1255 -0.5717 -0.1926 -0.0750 -0.1117 -0.0698 -0.0604 -0.1581 -0.1720 -0.1524
S-1466	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-1466	Patients should be monitored for the development of factor VIII inhibitors .
H-1466	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
D-1466	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
P-1466	-0.3817 -0.0929 -0.1278 -0.1658 -0.7742 -0.1243 -1.0242 -0.1740 -1.1518 -0.1255 -0.5717 -0.1926 -0.0750 -0.1117 -0.0698 -0.0604 -0.1581 -0.1720 -0.1524
S-762	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-762	Patients should be monitored for the development of factor VIII inhibitors .
H-762	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
D-762	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
P-762	-0.3817 -0.0929 -0.1278 -0.1658 -0.7742 -0.1243 -1.0242 -0.1740 -1.1518 -0.1255 -0.5717 -0.1926 -0.0750 -0.1117 -0.0698 -0.0604 -0.1581 -0.1720 -0.1524
S-938	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-938	Patients should be monitored for the development of factor VIII inhibitors .
H-938	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
D-938	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
P-938	-0.3817 -0.0929 -0.1278 -0.1658 -0.7742 -0.1243 -1.0242 -0.1740 -1.1518 -0.1255 -0.5717 -0.1926 -0.0750 -0.1117 -0.0698 -0.0604 -0.1581 -0.1720 -0.1524
S-1363	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1363	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1363	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
D-1363	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
P-1363	-0.8063 -1.6940 -0.5436 -0.0429 -0.0896 -0.2342 -0.1201 -0.1669 -0.2192 -0.2895 -0.2495 -0.4192 -1.8404 -0.5921 -0.2194 -0.6240 -0.9464 -0.1528 -0.1525
S-276	ADROVANCE vermindert das Risiko für Wirbel- und Hüftfrakturen .
T-276	ADROVANCE reduces the risk of vertebral and hip fractures .
H-276	-0.20890823006629944	ADROVANCE reduces the risk of vertebral and hip fractures .
D-276	-0.20890823006629944	ADROVANCE reduces the risk of vertebral and hip fractures .
P-276	-0.0415 -0.0660 -0.1264 -0.1011 -0.1074 -1.2123 -0.1002 -0.2063 -0.1432 -0.3124 -0.4051 -0.0645 -0.0727 -0.2491 -0.1593 -0.0582 -0.3110 -0.0865 -0.1981 -0.1570
S-89	ADROVANCE vermindert das Risiko für Wirbel- und Hüftfrakturen .
T-89	ADROVANCE reduces the risk of vertebral and hip fractures .
H-89	-0.20890823006629944	ADROVANCE reduces the risk of vertebral and hip fractures .
D-89	-0.20890823006629944	ADROVANCE reduces the risk of vertebral and hip fractures .
P-89	-0.0415 -0.0660 -0.1264 -0.1011 -0.1074 -1.2123 -0.1002 -0.2063 -0.1432 -0.3124 -0.4051 -0.0645 -0.0727 -0.2491 -0.1593 -0.0582 -0.3110 -0.0865 -0.1981 -0.1570
S-1799	Das Produkt darf nach der Lagerung bei Raumtemperatur nicht wieder gekühlt gelagert werden .
T-1799	The product may not be returned to refrigerated storage after storage at room temperature .
H-1799	-0.5495944023132324	Do not store the product in a refrigerated position after storage at room temperature .
D-1799	-0.5495944023132324	Do not store the product in a refrigerated position after storage at room temperature .
P-1799	-1.9676 -0.1318 -0.0874 -0.3486 -0.1066 -0.9747 -0.3336 -0.4529 -0.0209 -0.0743 -0.1243 -3.1784 -0.8023 -1.1748 -0.1744 -0.1021 -0.0683 -0.1647 -0.1547
S-1957	Deshalb ist bei der Anwendung des Kombinationspräparats bei Patienten über 60 Jahren Vorsicht geboten .
T-1957	Therefore the combination product should be used with caution in patients above 60 years of age .
H-1957	-0.39791831374168396	Caution should therefore be exercised when using the combination in patients over 60 years of age .
D-1957	-0.39791831374168396	Caution should therefore be exercised when using the combination in patients over 60 years of age .
P-1957	-1.6184 -0.0867 -0.3173 -0.2492 -0.1398 -0.0292 -0.1205 -0.3327 -0.8057 -0.8779 -0.5143 -0.1847 -0.1833 -0.2001 -0.2253 -1.3014 -0.3641 -0.1051 -0.1496 -0.1530
S-72	Die Patienten erhielten einmal pro Woche entweder ADROVANCE oder nur Alendronat .
T-72	Patients received either ADROVANCE or alendronate only once a week .
H-72	-0.2969084680080414	Patients received either ADROVANCE or alendronate once a week .
D-72	-0.2969084680080414	Patients received either ADROVANCE or alendronate once a week .
P-72	-1.5662 -0.0977 -1.2325 -0.0942 -0.0641 -0.0627 -0.1255 -0.1127 -0.0711 -0.2336 -0.2021 -0.1098 -0.1477 -0.1042 -0.2776 -0.7411 -0.0789 -0.1673 -0.1522
S-772	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-772	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-772	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-772	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-772	-0.7880 -0.2999 -0.1354 -0.2249 -0.0873 -0.0770 -0.1069 -0.0837 -0.0590 -0.2059 -1.3853 -0.0719 -0.0646 -0.0471 -0.0469 -0.0742 -0.0538 -0.9803 -0.0763 -0.1504 -0.1537
S-588	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-588	Patients should be monitored for the development of factor VIII inhibitors .
H-588	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
D-588	-0.30029532313346863	Patients should be monitored regularly for formation of factor VIII inhibitors .
P-588	-0.3817 -0.0929 -0.1278 -0.1658 -0.7742 -0.1243 -1.0242 -0.1740 -1.1518 -0.1255 -0.5717 -0.1926 -0.0750 -0.1117 -0.0698 -0.0604 -0.1581 -0.1720 -0.1524
S-1124	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-1124	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-1124	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-1124	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-1124	-0.7880 -0.2999 -0.1354 -0.2249 -0.0873 -0.0770 -0.1069 -0.0837 -0.0590 -0.2059 -1.3853 -0.0719 -0.0646 -0.0471 -0.0469 -0.0742 -0.0538 -0.9803 -0.0763 -0.1504 -0.1537
S-881	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-881	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-881	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
D-881	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
P-881	-1.5737 -0.0282 -0.1097 -0.6539 -1.8564 -0.2009 -1.2909 -0.1670 -0.1985 -0.1111 -0.1160 -0.1155 -0.1670 -1.8139 -0.0884 -0.1414 -0.1685 -0.1300 -0.1808 -0.1591
S-1057	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1057	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1057	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
D-1057	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
P-1057	-1.5737 -0.0282 -0.1097 -0.6539 -1.8564 -0.2009 -1.2909 -0.1670 -0.1985 -0.1111 -0.1160 -0.1155 -0.1670 -1.8139 -0.0884 -0.1414 -0.1685 -0.1300 -0.1808 -0.1591
S-1303	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-1303	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-1303	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-1303	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-1303	-1.0446 -0.3707 -0.0697 -1.0279 -0.2359 -0.2172 -0.1397 -1.9086 -0.1287 -0.2382 -0.0181 -0.1369 -0.2032 -0.2241 -0.2741 -0.1719 -0.1557
S-1479	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-1479	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-1479	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-1479	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-1479	-1.0446 -0.3707 -0.0697 -1.0279 -0.2359 -0.2172 -0.1397 -1.9086 -0.1287 -0.2382 -0.0181 -0.1369 -0.2032 -0.2241 -0.2741 -0.1719 -0.1557
S-705	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-705	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-705	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
D-705	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
P-705	-1.5737 -0.0282 -0.1097 -0.6539 -1.8564 -0.2009 -1.2909 -0.1670 -0.1985 -0.1111 -0.1160 -0.1155 -0.1670 -1.8139 -0.0884 -0.1414 -0.1685 -0.1300 -0.1808 -0.1591
S-951	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-951	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-951	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-951	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-951	-1.0446 -0.3707 -0.0697 -1.0279 -0.2359 -0.2172 -0.1397 -1.9086 -0.1287 -0.2382 -0.0181 -0.1369 -0.2032 -0.2241 -0.2741 -0.1719 -0.1557
S-775	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-775	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-775	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-775	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-775	-1.0446 -0.3707 -0.0697 -1.0279 -0.2359 -0.2172 -0.1397 -1.9086 -0.1287 -0.2382 -0.0181 -0.1369 -0.2032 -0.2241 -0.2741 -0.1719 -0.1557
S-1233	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1233	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1233	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
D-1233	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
P-1233	-1.5737 -0.0282 -0.1097 -0.6539 -1.8564 -0.2009 -1.2909 -0.1670 -0.1985 -0.1111 -0.1160 -0.1155 -0.1670 -1.8139 -0.0884 -0.1414 -0.1685 -0.1300 -0.1808 -0.1591
S-1409	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1409	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1409	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
D-1409	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
P-1409	-1.5737 -0.0282 -0.1097 -0.6539 -1.8564 -0.2009 -1.2909 -0.1670 -0.1985 -0.1111 -0.1160 -0.1155 -0.1670 -1.8139 -0.0884 -0.1414 -0.1685 -0.1300 -0.1808 -0.1591
S-1586	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1586	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1586	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
D-1586	-0.4635511040687561	Remove the package from BAXJECT II ( Fig . B ) .
P-1586	-1.5737 -0.0282 -0.1097 -0.6539 -1.8564 -0.2009 -1.2909 -0.1670 -0.1985 -0.1111 -0.1160 -0.1155 -0.1670 -1.8139 -0.0884 -0.1414 -0.1685 -0.1300 -0.1808 -0.1591
S-1127	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-1127	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-1127	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-1127	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-1127	-1.0446 -0.3707 -0.0697 -1.0279 -0.2359 -0.2172 -0.1397 -1.9086 -0.1287 -0.2382 -0.0181 -0.1369 -0.2032 -0.2241 -0.2741 -0.1719 -0.1557
S-1300	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-1300	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-1300	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-1300	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-1300	-0.7880 -0.2999 -0.1354 -0.2249 -0.0873 -0.0770 -0.1069 -0.0837 -0.0590 -0.2059 -1.3853 -0.0719 -0.0646 -0.0471 -0.0469 -0.0742 -0.0538 -0.9803 -0.0763 -0.1504 -0.1537
S-1011	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1011	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1011	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
D-1011	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
P-1011	-0.8063 -1.6940 -0.5436 -0.0429 -0.0896 -0.2342 -0.1201 -0.1669 -0.2192 -0.2895 -0.2495 -0.4192 -1.8404 -0.5921 -0.2194 -0.6240 -0.9464 -0.1528 -0.1525
S-1187	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1187	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1187	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
D-1187	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
P-1187	-0.8063 -1.6940 -0.5436 -0.0429 -0.0896 -0.2342 -0.1201 -0.1669 -0.2192 -0.2895 -0.2495 -0.4192 -1.8404 -0.5921 -0.2194 -0.6240 -0.9464 -0.1528 -0.1525
S-1776	Sollten Sie eine größere Menge angewendet haben , wenden Sie sich bitte schnellstmöglich an Ihren Arzt .
T-1776	If you inject more ADVATE than recommended , tell your doctor as soon as possible .
H-1776	-0.44894909858703613	If you have used a larger amount , please contact your doctor as soon as possible .
D-1776	-0.44894909858703613	If you have used a larger amount , please contact your doctor as soon as possible .
P-1776	-0.2948 -0.1383 -0.4076 -0.8909 -0.6726 -1.4224 -0.9401 -0.3818 -1.0203 -0.6416 -0.1389 -0.1226 -0.2713 -0.0837 -0.1495 -0.1916 -0.1555 -0.1576
S-660	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-660	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-660	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
D-660	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
P-660	-0.8063 -1.6940 -0.5436 -0.0429 -0.0896 -0.2342 -0.1201 -0.1669 -0.2192 -0.2895 -0.2495 -0.4192 -1.8404 -0.5921 -0.2194 -0.6240 -0.9464 -0.1528 -0.1525
S-835	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-835	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-835	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
D-835	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
P-835	-0.8063 -1.6940 -0.5436 -0.0429 -0.0896 -0.2342 -0.1201 -0.1669 -0.2192 -0.2895 -0.2495 -0.4192 -1.8404 -0.5921 -0.2194 -0.6240 -0.9464 -0.1528 -0.1525
S-1476	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-1476	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-1476	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-1476	-0.2463027387857437	As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-1476	-0.7880 -0.2999 -0.1354 -0.2249 -0.0873 -0.0770 -0.1069 -0.0837 -0.0590 -0.2059 -1.3853 -0.0719 -0.0646 -0.0471 -0.0469 -0.0742 -0.0538 -0.9803 -0.0763 -0.1504 -0.1537
S-601	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-601	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-601	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-601	-0.38618966937065125	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-601	-1.0446 -0.3707 -0.0697 -1.0279 -0.2359 -0.2172 -0.1397 -1.9086 -0.1287 -0.2382 -0.0181 -0.1369 -0.2032 -0.2241 -0.2741 -0.1719 -0.1557
S-1540	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1540	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1540	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
D-1540	-0.49488961696624756	This then releases fibrin from fibrinogen and clot formation can occur .
P-1540	-0.8063 -1.6940 -0.5436 -0.0429 -0.0896 -0.2342 -0.1201 -0.1669 -0.2192 -0.2895 -0.2495 -0.4192 -1.8404 -0.5921 -0.2194 -0.6240 -0.9464 -0.1528 -0.1525
S-1918	Aerinaze linderte die Symptome wirksamer als die beiden Wirkstoffe jeweils allein .
T-1918	Aerinaze was more effective in reducing symptoms than either of the two active substances taken alone .
H-1918	-0.340576708316803	Aerinaze relieved symptoms more effectively than both agents alone .
D-1918	-0.340576708316803	Aerinaze relieved symptoms more effectively than both agents alone .
P-1918	-0.1482 -0.1269 -0.1506 -0.1213 -0.0989 -1.1214 -0.0874 -0.3086 -0.1865 -0.3038 -0.0927 -1.8981 -0.3246 -0.1586 -0.1655 -0.1560
S-1991	Desloratadin und Pseudoephedrin gehen in die Muttermilch über .
T-1991	Desloratadine and pseudoephedrine are both excreted in breast milk .
H-1991	-0.33845284581184387	Desloratadine and pseudoephedrine are added to breast milk .
D-1991	-0.33845284581184387	Desloratadine and pseudoephedrine are added to breast milk .
P-1991	-0.7231 -0.0417 -0.1153 -0.3112 -0.4892 -0.1404 -0.1115 -0.1296 -0.1452 -0.0603 -0.1129 -0.0925 -0.0998 -0.6370 -2.3942 -0.1793 -0.5032 -0.1635 -0.1670 -0.1523
S-342	Es liegen keine geeigneten Daten zur Anwendung von ADROVANCE bei schwangeren Frauen vor .
T-342	There are no adequate data from the use of ADROVANCE in pregnant women .
H-342	-0.31610336899757385	There are no adequate data on the use of ADROVANCE in pregnant women .
D-342	-0.31610336899757385	There are no adequate data on the use of ADROVANCE in pregnant women .
P-342	-1.3460 -0.5264 -0.0614 -0.9700 -0.2120 -0.5448 -0.5062 -0.6086 -0.1204 -0.0682 -0.0629 -0.1219 -0.1084 -0.0742 -0.1356 -0.1165 -0.0967 -0.1704 -0.1554
S-1833	78 sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
T-1833	78 sector 4 Bucure ti 041836-RO Tel . : <<unk>> 40-21-321 16 40
H-1833	-0.14479386806488037	78 sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
D-1833	-0.14479386806488037	78 sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
P-1833	-0.7410 -0.1111 -0.1290 -0.1260 -0.0500 -0.1857 -0.0778 -0.1234 -0.1712 -0.0568 -0.1510 -0.1277 -0.0689 -0.1783 -0.1484 -0.0432 -0.2093 -0.0935 -0.1645 -0.0597 -0.1368 -0.0964 -0.1017 -0.1097 -0.1587
S-1319	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-1319	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-1319	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
D-1319	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
P-1319	-2.1604 -0.1458 -0.0726 -0.1629 -0.4598 -0.4502 -0.1370 -0.2178 -1.1101 -0.0832 -0.1622 -0.7592 -0.0071 -0.1252 -0.8481 -1.1999 -0.2700 -0.7350 -0.3541 -0.0153 -0.6571 -0.1537
S-967	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-967	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-967	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
D-967	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
P-967	-2.1604 -0.1458 -0.0726 -0.1629 -0.4598 -0.4502 -0.1370 -0.2178 -1.1101 -0.0832 -0.1622 -0.7592 -0.0071 -0.1252 -0.8481 -1.1999 -0.2700 -0.7350 -0.3541 -0.0153 -0.6571 -0.1537
S-1003	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1003	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1003	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
D-1003	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
P-1003	-1.3829 -0.9839 -0.0349 -0.1301 -0.7172 -0.1431 -0.0837 -0.0792 -0.1391 -1.3149 -0.6191 -0.0407 -0.0856 -0.0925 -0.1487 -0.0822 -0.2797 -0.6212 -0.1842 -0.1538
S-1143	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-1143	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-1143	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
D-1143	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
P-1143	-2.1604 -0.1458 -0.0726 -0.1629 -0.4598 -0.4502 -0.1370 -0.2178 -1.1101 -0.0832 -0.1622 -0.7592 -0.0071 -0.1252 -0.8481 -1.1999 -0.2700 -0.7350 -0.3541 -0.0153 -0.6571 -0.1537
S-791	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-791	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-791	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
D-791	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
P-791	-2.1604 -0.1458 -0.0726 -0.1629 -0.4598 -0.4502 -0.1370 -0.2178 -1.1101 -0.0832 -0.1622 -0.7592 -0.0071 -0.1252 -0.8481 -1.1999 -0.2700 -0.7350 -0.3541 -0.0153 -0.6571 -0.1537
S-617	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-617	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-617	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
D-617	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
P-617	-2.1604 -0.1458 -0.0726 -0.1629 -0.4598 -0.4502 -0.1370 -0.2178 -1.1101 -0.0832 -0.1622 -0.7592 -0.0071 -0.1252 -0.8481 -1.1999 -0.2700 -0.7350 -0.3541 -0.0153 -0.6571 -0.1537
S-1355	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1355	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1355	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
D-1355	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
P-1355	-1.3829 -0.9839 -0.0349 -0.1301 -0.7172 -0.1431 -0.0837 -0.0792 -0.1391 -1.3149 -0.6191 -0.0407 -0.0856 -0.0925 -0.1487 -0.0822 -0.2797 -0.6212 -0.1842 -0.1538
S-1495	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-1495	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-1495	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
D-1495	-0.467581570148468	Factor VIII should therefore only be used during pregnancy and lactation if there is a clear indication .
P-1495	-2.1604 -0.1458 -0.0726 -0.1629 -0.4598 -0.4502 -0.1370 -0.2178 -1.1101 -0.0832 -0.1622 -0.7592 -0.0071 -0.1252 -0.8481 -1.1999 -0.2700 -0.7350 -0.3541 -0.0153 -0.6571 -0.1537
S-1179	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1179	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1179	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
D-1179	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
P-1179	-1.3829 -0.9839 -0.0349 -0.1301 -0.7172 -0.1431 -0.0837 -0.0792 -0.1391 -1.3149 -0.6191 -0.0407 -0.0856 -0.0925 -0.1487 -0.0822 -0.2797 -0.6212 -0.1842 -0.1538
S-827	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-827	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-827	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
D-827	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
P-827	-1.3829 -0.9839 -0.0349 -0.1301 -0.7172 -0.1431 -0.0837 -0.0792 -0.1391 -1.3149 -0.6191 -0.0407 -0.0856 -0.0925 -0.1487 -0.0822 -0.2797 -0.6212 -0.1842 -0.1538
S-1532	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1532	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1532	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
D-1532	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
P-1532	-1.3829 -0.9839 -0.0349 -0.1301 -0.7172 -0.1431 -0.0837 -0.0792 -0.1391 -1.3149 -0.6191 -0.0407 -0.0856 -0.0925 -0.1487 -0.0822 -0.2797 -0.6212 -0.1842 -0.1538
S-653	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-653	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-653	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
D-653	-0.3658367991447449	human overdose symptoms of recombinant blood clotting factor VIII are unknown .
P-653	-1.3829 -0.9839 -0.0349 -0.1301 -0.7172 -0.1431 -0.0837 -0.0792 -0.1391 -1.3149 -0.6191 -0.0407 -0.0856 -0.0925 -0.1487 -0.0822 -0.2797 -0.6212 -0.1842 -0.1538
S-1274	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-1274	Factor VIII level required ( % or IU/ dl )
H-1274	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
D-1274	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
P-1274	-1.9637 -0.1619 -0.1015 -0.9348 -0.3505 -1.5691 -1.1813 -0.9097 -0.1004 -0.2509 -0.1297 -0.1562 -0.0804 -0.0257 -0.1618 -0.2841
S-1450	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-1450	Factor VIII level required ( % or IU/ dl )
H-1450	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
D-1450	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
P-1450	-1.9637 -0.1619 -0.1015 -0.9348 -0.3505 -1.5691 -1.1813 -0.9097 -0.1004 -0.2509 -0.1297 -0.1562 -0.0804 -0.0257 -0.1618 -0.2841
S-746	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-746	Factor VIII level required ( % or IU/ dl )
H-746	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
D-746	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
P-746	-1.9637 -0.1619 -0.1015 -0.9348 -0.3505 -1.5691 -1.1813 -0.9097 -0.1004 -0.2509 -0.1297 -0.1562 -0.0804 -0.0257 -0.1618 -0.2841
S-922	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-922	Factor VIII level required ( % or IU/ dl )
H-922	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
D-922	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
P-922	-1.9637 -0.1619 -0.1015 -0.9348 -0.3505 -1.5691 -1.1813 -0.9097 -0.1004 -0.2509 -0.1297 -0.1562 -0.0804 -0.0257 -0.1618 -0.2841
S-1098	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-1098	Factor VIII level required ( % or IU/ dl )
H-1098	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
D-1098	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
P-1098	-1.9637 -0.1619 -0.1015 -0.9348 -0.3505 -1.5691 -1.1813 -0.9097 -0.1004 -0.2509 -0.1297 -0.1562 -0.0804 -0.0257 -0.1618 -0.2841
S-1648	ADVATE 500 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1648	ADVATE 500 IU powder for solution for injection Octocog alfa IV use
H-1648	-0.3153039813041687	ADVATE 500 IU powder for preparation of a solution for injection .
D-1648	-0.3153039813041687	ADVATE 500 IU powder for preparation of a solution for injection .
P-1648	-0.1253 -0.1504 -0.0993 -0.0940 -0.0973 -0.1206 -0.1482 -0.2812 -0.2559 -1.0424 -0.1346 -1.2158 -0.0541 -0.1080 -0.0990 -0.0898 -0.4725 -1.0870
S-521	Ausführliche Erläuterungen zur Berechnung der Dosierungen sind der Packungsbeilage zu entnehmen .
T-521	Full details on how to calculate the doses are included in the Package Leaflet .
H-521	-0.35657328367233276	Detailed information on the calculation of doses can be found in the Package Leaflet .
D-521	-0.35657328367233276	Detailed information on the calculation of doses can be found in the Package Leaflet .
P-521	-0.8061 -0.0678 -0.9357 -0.1982 -1.0722 -0.1507 -0.1212 -0.1048 -0.1366 -0.2057 -0.7689 -1.4469 -0.1415 -0.2521 -0.1825 -0.1559 -0.4499 -0.1500 -0.3087 -0.0277 -0.1312 -0.2336 -0.1533
S-444	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden .
T-444	Circulating vitamin D3 is bound to vitamin D-binding protein .
H-444	-0.213578462600708	Circulating vitamin D3 is bound to vitamin D binding protein .
D-444	-0.213578462600708	Circulating vitamin D3 is bound to vitamin D binding protein .
P-444	-0.5087 -0.1670 -0.0900 -0.1044 -0.0864 -0.1602 -0.1387 -0.1774 -0.4880 -0.1675 -0.6051 -0.0516 -0.3002 -0.2676 -0.1107 -0.0662 -0.1981 -0.1566
S-1870	Die Wirkungen von Advexin wurden zunächst in Versuchsmodellen getestet , bevor sie an Menschen untersucht wurden .
T-1870	The effects of Advexin were first tested in experimental models before being studied in humans .
H-1870	-0.47463259100914	The effects of Advexin were first evaluated in experimental models before being evaluated in humans .
D-1870	-0.47463259100914	The effects of Advexin were first evaluated in experimental models before being evaluated in humans .
P-1870	-0.5498 -0.2794 -0.1227 -0.4936 -0.1536 -0.1339 -0.2892 -1.5228 -1.6297 -0.1107 -0.1464 -1.4779 -0.0671 -0.2463 -0.8049 -0.3362 -1.3883 -0.1066 -0.1286 -0.1511 -0.1488 -0.1544
S-2000	Diese und andere unerwünschte Ereignisse , die in klinischen Prüfungen auftraten , sind in der nachfolgenden Tabelle aufgeführt .
T-2000	These and other undesirable effects reported during the clinical trials are listed in the following table .
H-2000	-0.2999621331691742	These and other adverse events that occurred in clinical trials are listed in the following table .
D-2000	-0.2999621331691742	These and other adverse events that occurred in clinical trials are listed in the following table .
P-2000	-0.3077 -0.1558 -0.1784 -0.0382 -0.0293 -0.0848 -1.6958 -0.2876 -0.2577 -0.1115 -0.0888 -0.2556 -0.3580 -0.1868 -0.1738 -0.8438 -0.2885 -0.1993 -0.1579
S-537	Patienten mit Hämophilie A können Antikörper ( Inhibitoren ) gegenüber Faktor VIII bilden .
T-537	Haemophilia A patients may develop antibodies ( inhibitors ) to factor VIII .
H-537	-0.32341131567955017	Patients with haemophilia A may form antibodies ( inhibitors ) to factor VIII .
D-537	-0.32341131567955017	Patients with haemophilia A may form antibodies ( inhibitors ) to factor VIII .
P-537	-1.0452 -0.0985 -0.1300 -0.2171 -0.0584 -0.0500 -0.0469 -0.1595 -0.4788 -2.4452 -0.1532 -0.0832 -0.2288 -0.1190 -0.0804 -0.0457 -0.1633 -0.1502 -0.7770 -0.5999 -0.1615 -0.0831 -0.2343 -0.1526
S-1729	2. Was müssen Sie vor der Anwendung von ADVATE beachten ? 3. Wie ist ADVATE anzuwenden ?
T-1729	Before you use ADVATE 3.
H-1729	-0.4839582145214081	2 . What should be considered before using ADVATE ? 3 . How should ADVATE be used ?
D-1729	-0.4839582145214081	2 . What should be considered before using ADVATE ? 3 . How should ADVATE be used ?
P-1729	-1.9131 -0.2141 -0.1137 -0.7300 -1.8571 -0.9055 -0.4243 -1.4069 -0.0904 -0.1471 -0.0938 -0.0956 -0.7913 -0.1885 -0.1372 -0.5502 -0.7172 -0.0903 -0.1434 -0.0977 -0.0926 -0.1083 -0.3279 -0.6991 -0.1635
S-1716	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1716	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1716	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1716	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1716	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-1719	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1719	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1719	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1719	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1719	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-1686	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1686	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1686	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1686	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1686	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-1699	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1699	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1699	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1699	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1699	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-1702	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1702	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1702	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1702	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1702	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-1670	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1670	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1670	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1670	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1670	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-1652	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1652	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1652	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1652	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1652	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-131	Andere mögliche Ursachen einer Osteoporose neben Östrogen-Mangel und Alter sollten in Betracht gezogen werden .
T-131	Causes of osteoporosis other than oestrogen deficiency and ageing should be considered .
H-131	-0.20369037985801697	Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
D-131	-0.20369037985801697	Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
P-131	-0.2698 -0.6647 -0.0613 -0.1483 -0.1223 -0.0907 -0.1067 -0.1339 -0.0878 -0.0771 -0.8864 -0.1024 -0.6738 -0.2320 -0.0386 -0.0413 -0.0932 -0.0339 -0.1277 -0.1298 -0.3668 -0.1900 -0.1778 -0.1125 -0.1743 -0.1528
S-319	Andere mögliche Ursachen einer Osteoporose neben Östrogen-Mangel und Alter sollten in Betracht gezogen werden .
T-319	Causes of osteoporosis other than oestrogen deficiency and ageing should be considered .
H-319	-0.20369037985801697	Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
D-319	-0.20369037985801697	Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
P-319	-0.2698 -0.6647 -0.0613 -0.1483 -0.1223 -0.0907 -0.1067 -0.1339 -0.0878 -0.0771 -0.8864 -0.1024 -0.6738 -0.2320 -0.0386 -0.0413 -0.0932 -0.0339 -0.1277 -0.1298 -0.3668 -0.1900 -0.1778 -0.1125 -0.1743 -0.1528
S-1819	Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
T-1819	Opletalova 55 CZ-110 00 Praha 1 Tel . : <<unk>> 420 225774111
H-1819	-0.13993333280086517	Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
D-1819	-0.13993333280086517	Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
P-1819	-0.1249 -0.1056 -0.1893 -0.0723 -0.1185 -0.1315 -0.2027 -0.1110 -0.1741 -0.1078 -0.2159 -0.1236 -0.1365 -0.0557 -0.4561 -0.1419 -0.0248 -0.2086 -0.1226 -0.0945 -0.0842 -0.0968 -0.1672 -0.0730 -0.1592
S-1683	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1683	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1683	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1683	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1683	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-1632	ADVATE 250 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1632	ADVATE 250 IU powder for solution for injection Octocog alfa IV use
H-1632	-0.30563464760780334	ADVATE 250 IU powder for preparation of a solution for injection .
D-1632	-0.30563464760780334	ADVATE 250 IU powder for preparation of a solution for injection .
P-1632	-0.1005 -0.1492 -0.0978 -0.0918 -0.1234 -0.1196 -0.1332 -0.3224 -0.2502 -0.9812 -0.1335 -1.1932 -0.0556 -0.1077 -0.0968 -0.0860 -0.4514 -1.0076
S-1667	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1667	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1667	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1667	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1667	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-1959	Das Kombinationspräparat wird für die Anwendung bei Patienten mit eingeschränkter Nieren- oder Leberfunktion nicht empfohlen .
T-1959	The combination product is not recommended for use in patients with impaired renal or hepatic function .
H-1959	-0.2740060091018677	The combination is not recommended for use in patients with impaired renal or hepatic impairment .
D-1959	-0.2740060091018677	The combination is not recommended for use in patients with impaired renal or hepatic impairment .
P-1959	-0.8163 -0.3821 -1.6804 -0.1653 -0.0954 -0.1355 -0.0726 -0.1289 -0.3435 -0.1417 -0.2802 -0.3664 -0.2575 -0.1230 -0.2276 -0.7174 -0.0290 -0.0884 -0.0554 -0.0214 -0.0322 -0.0945 -0.1657 -0.1557
S-1770	Steigern Sie die Dosierung von ADVATE zur Kontrolle Ihrer Blutung nicht ohne Ihren Arzt zu befragen .
T-1770	Do not increase the total dose of ADVATE to control your bleeding without consulting your doctor .
H-1770	-0.23936299979686737	Do not increase the dosage of ADVATE to control your bleeding without asking your doctor .
D-1770	-0.23936299979686737	Do not increase the dosage of ADVATE to control your bleeding without asking your doctor .
P-1770	-0.2748 -0.1307 -0.0965 -0.3518 -0.5011 -0.0860 -0.1049 -0.1188 -0.0930 -0.1516 -0.0957 -0.0916 -0.1924 -0.2283 -0.1290 -0.3255 -0.1137 -0.1942 -1.6939 -0.1382 -0.0713 -0.1596 -0.1629
S-1682	ADVATE 1500 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1682	ADVATE 1500 IU powder for solution for injection Octocog alfa IV use
H-1682	-0.3101142346858978	ADVATE 1500 IU powder for preparation of a solution for injection .
D-1682	-0.3101142346858978	ADVATE 1500 IU powder for preparation of a solution for injection .
P-1682	-0.0824 -0.1520 -0.0972 -0.0904 -0.1526 -0.1194 -0.1391 -0.3164 -0.2343 -1.0918 -0.1344 -1.1531 -0.0582 -0.1089 -0.0965 -0.0918 -0.4701 -0.9935
S-1698	ADVATE 2000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1698	ADVATE 2000 IU powder for solution for injection Octocog alfa IV use
H-1698	-0.31141167879104614	ADVATE 2000 IU powder for preparation of a solution for injection .
D-1698	-0.31141167879104614	ADVATE 2000 IU powder for preparation of a solution for injection .
P-1698	-0.1092 -0.1535 -0.0973 -0.0957 -0.0934 -0.1331 -0.1440 -0.2266 -0.2311 -1.0688 -0.1331 -1.2115 -0.0538 -0.1078 -0.0978 -0.0958 -0.5165 -1.0367
S-1714	ADVATE 3000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1714	ADVATE 3000 IU powder for solution for injection Octocog alfa IV use
H-1714	-0.30665087699890137	ADVATE 3000 IU powder for preparation of a solution for injection .
D-1714	-0.30665087699890137	ADVATE 3000 IU powder for preparation of a solution for injection .
P-1714	-0.1216 -0.1521 -0.0975 -0.0914 -0.0480 -0.1206 -0.1483 -0.2455 -0.2416 -1.1227 -0.1352 -1.1636 -0.0562 -0.1081 -0.0989 -0.0921 -0.4878 -0.9885
S-1665	ADVATE 1000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1665	ADVATE 1000 IU powder for solution for injection Octocog alfa IV use
H-1665	-0.29849421977996826	ADVATE 1000 IU powder for preparation of a solution for injection .
D-1665	-0.29849421977996826	ADVATE 1000 IU powder for preparation of a solution for injection .
P-1665	-0.1170 -0.1514 -0.0957 -0.0901 -0.0737 -0.1200 -0.1308 -0.2118 -0.2362 -1.1272 -0.1336 -1.1675 -0.0567 -0.1085 -0.0990 -0.0935 -0.4823 -0.8778
S-1649	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1649	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1649	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1649	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1649	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-1882	Bevor der CHMP ein Gutachten abgibt , kann er dem Unternehmen an Tag 180 etwaig verbleibende Fragen stellen .
T-1882	Following the CHMP s opinion , it usually takes around two months for the European Commission to grant a licence .
H-1882	-0.49662935733795166	Before issuing an opinion , the CHMP may ask the company any remaining questions on day 180 .
D-1882	-0.49662935733795166	Before issuing an opinion , the CHMP may ask the company any remaining questions on day 180 .
P-1882	-0.6336 -1.7824 -0.1368 -1.1143 -0.9498 -0.2433 -0.6430 -0.0873 -0.0439 -0.4202 -0.2422 -0.3695 -1.2060 -0.1564 -0.1207 -0.4424 -0.4041 -0.9169 -0.0866 -0.2748 -0.1550
S-1633	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1633	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1633	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1633	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1633	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-1636	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1636	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1636	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
D-1636	-0.14423565566539764	CONTENTS BY WEIGHT , VOLUME OR BY UNIT
P-1636	-0.1529 -0.1738 -0.2275 -0.0844 -0.5366 -0.0051 -0.0553 -0.0665 -0.0889 -0.0528 -0.1442 -0.1200 -0.0558 -0.0965 -0.0454 -0.1424 -0.0634 -0.4963 -0.1272 -0.2284 -0.0544 -0.1554
S-572	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-572	Factor VIII level required ( % or IU/ dl )
H-572	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
D-572	-0.5226026177406311	Required factor VIII ( % or IU/ dl )
P-572	-1.9637 -0.1619 -0.1015 -0.9348 -0.3505 -1.5691 -1.1813 -0.9097 -0.1004 -0.2509 -0.1297 -0.1562 -0.0804 -0.0257 -0.1618 -0.2841
S-1263	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-1263	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-1263	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
D-1263	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
P-1263	-0.2757 -0.0478 -0.1174 -1.2308 -0.1879 -3.3458 -0.1397 -0.2016 -0.2063 -0.0823 -0.0489 -0.1187 -0.1220 -0.9486 -1.4941 -0.1522 -0.9132 -0.2083 -0.1285 -0.1559 -0.0845 -0.0684 -0.1322 -0.1633 -0.1536
S-1439	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-1439	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-1439	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
D-1439	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
P-1439	-0.2757 -0.0478 -0.1174 -1.2308 -0.1879 -3.3458 -0.1397 -0.2016 -0.2063 -0.0823 -0.0489 -0.1187 -0.1220 -0.9486 -1.4941 -0.1522 -0.9132 -0.2083 -0.1285 -0.1559 -0.0845 -0.0684 -0.1322 -0.1633 -0.1536
S-47	Filmtablette Zum Einnehmen Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-47	Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu )
H-47	-0.4319089353084564	film-coated tablet Blister ( Aclar/ PVC/ aluminium )
D-47	-0.4319089353084564	film-coated tablet Blister ( Aclar/ PVC/ aluminium )
P-47	-3.6524 -0.0937 -0.8475 -0.0701 -0.6967 -0.1548 -1.2923 -0.0836 -0.1595 -0.2463 -0.2080 -0.1953 -0.1256 -0.1164 -0.2485 -0.1290 -0.1681 -0.1815 -0.0767 -0.1498 -0.1743
S-1087	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-1087	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-1087	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
D-1087	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
P-1087	-0.2757 -0.0478 -0.1174 -1.2308 -0.1879 -3.3458 -0.1397 -0.2016 -0.2063 -0.0823 -0.0489 -0.1187 -0.1220 -0.9486 -1.4941 -0.1522 -0.9132 -0.2083 -0.1285 -0.1559 -0.0845 -0.0684 -0.1322 -0.1633 -0.1536
S-911	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-911	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-911	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
D-911	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
P-911	-0.2757 -0.0478 -0.1174 -1.2308 -0.1879 -3.3458 -0.1397 -0.2016 -0.2063 -0.0823 -0.0489 -0.1187 -0.1220 -0.9486 -1.4941 -0.1522 -0.9132 -0.2083 -0.1285 -0.1559 -0.0845 -0.0684 -0.1322 -0.1633 -0.1536
S-529	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-529	The study went on to look at the number 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-529	-0.13689033687114716	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-529	-0.13689033687114716	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-529	-0.1643 -0.1133 -0.0890 -0.0601 -0.1967 -0.0539 -0.1342 -0.1196 -0.1150 -0.1166 -0.1132 -0.1184 -0.1348 -0.1062 -0.1284 -0.0925 -0.1961 -0.1722 -0.1119 -0.1365 -0.1267 -0.3661 -0.1725 -0.1471
S-560	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-560	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-560	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
D-560	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
P-560	-0.2757 -0.0478 -0.1174 -1.2308 -0.1879 -3.3458 -0.1397 -0.2016 -0.2063 -0.0823 -0.0489 -0.1187 -0.1220 -0.9486 -1.4941 -0.1522 -0.9132 -0.2083 -0.1285 -0.1559 -0.0845 -0.0684 -0.1322 -0.1633 -0.1536
S-552	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 50 I.E.<unk> ml Octocog alfa .
T-552	After reconstitution , each ml solution for injection contains approximately 50 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-552	-0.24092860519886017	After reconstitution , each ml of solution contains approximately 50 IU/ ml of Octocog alfa .
D-552	-0.24092860519886017	After reconstitution , each ml of solution contains approximately 50 IU/ ml of Octocog alfa .
P-552	-1.1989 -0.2628 -0.2064 -0.2583 -0.4005 -0.0952 -0.2655 -0.0785 -0.0766 -0.2600 -0.1657 -0.1012 -0.0551 -0.0984 -0.0451 -0.5986 -0.6069 -0.1284 -0.1285 -0.2205 -0.1233 -0.0638 -0.1935 -0.1506
S-727	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 100 I.E.<unk> ml Octocog alfa .
T-727	After reconstitution , each ml solution for injection contains approximately 100 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-727	-0.23375262320041656	After reconstitution , each ml of solution contains approximately 100 IU/ ml of Octocog alfa .
D-727	-0.23375262320041656	After reconstitution , each ml of solution contains approximately 100 IU/ ml of Octocog alfa .
P-727	-1.2200 -0.2647 -0.2095 -0.2482 -0.3964 -0.0974 -0.2601 -0.0815 -0.0782 -0.1846 -0.1303 -0.1011 -0.0512 -0.0997 -0.0444 -0.5845 -0.5506 -0.1290 -0.1289 -0.2196 -0.1222 -0.0639 -0.1924 -0.1518
S-903	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 200 I.E.<unk> ml Octocog alfa .
T-903	After reconstitution , each ml solution for injection contains approximately 200 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-903	-0.23318737745285034	After reconstitution , each ml of solution contains approximately 200 IU/ ml of Octocog alfa .
D-903	-0.23318737745285034	After reconstitution , each ml of solution contains approximately 200 IU/ ml of Octocog alfa .
P-903	-1.2104 -0.2687 -0.2062 -0.2548 -0.3761 -0.0980 -0.2599 -0.0825 -0.0796 -0.1939 -0.1696 -0.0969 -0.0509 -0.1061 -0.0494 -0.5279 -0.5587 -0.1294 -0.1280 -0.2212 -0.1209 -0.0629 -0.1929 -0.1517
S-1079	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 300 I.E.<unk> ml Octocog alfa .
T-1079	After reconstitution , each ml solution for injection contains approximately 300 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-1079	-0.228571817278862	After reconstitution , each ml of solution contains approximately 300 IU/ ml of Octocog alfa .
D-1079	-0.228571817278862	After reconstitution , each ml of solution contains approximately 300 IU/ ml of Octocog alfa .
P-1079	-1.2175 -0.2696 -0.2083 -0.2519 -0.3480 -0.0961 -0.2576 -0.0818 -0.0757 -0.2028 -0.0749 -0.0988 -0.0445 -0.0996 -0.0476 -0.5613 -0.5473 -0.1291 -0.1291 -0.2208 -0.1212 -0.0637 -0.1863 -0.1522
S-1255	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 400 I.E.<unk> ml Octocog alfa .
T-1255	After reconstitution , each ml solution for injection contains approximately 400 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-1255	-0.2308489978313446	After reconstitution , each ml of solution contains approximately 400 IU/ ml of Octocog alfa .
D-1255	-0.2308489978313446	After reconstitution , each ml of solution contains approximately 400 IU/ ml of Octocog alfa .
P-1255	-1.2294 -0.2682 -0.2124 -0.2548 -0.3625 -0.0959 -0.2574 -0.0825 -0.0782 -0.2123 -0.0874 -0.1019 -0.0482 -0.1020 -0.0492 -0.5475 -0.5494 -0.1285 -0.1281 -0.2190 -0.1215 -0.0636 -0.1885 -0.1519
S-1431	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 600 I.E.<unk> ml Octocog alfa .
T-1431	After reconstitution , each ml solution for injection contains approximately 600 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-1431	-0.2286454290151596	After reconstitution , each ml of solution contains approximately 600 IU/ ml of Octocog alfa .
D-1431	-0.2286454290151596	After reconstitution , each ml of solution contains approximately 600 IU/ ml of Octocog alfa .
P-1431	-1.1887 -0.2712 -0.2124 -0.2463 -0.3479 -0.0940 -0.2515 -0.0788 -0.0731 -0.2079 -0.1019 -0.1001 -0.0461 -0.1032 -0.0500 -0.5413 -0.5715 -0.1287 -0.1280 -0.2192 -0.1207 -0.0641 -0.1899 -0.1512
S-735	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-735	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-735	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
D-735	-0.4291165769100189	Treatment must be carried out under the supervision of a doctor familiar with the treatment of haemophilia .
P-735	-0.2757 -0.0478 -0.1174 -1.2308 -0.1879 -3.3458 -0.1397 -0.2016 -0.2063 -0.0823 -0.0489 -0.1187 -0.1220 -0.9486 -1.4941 -0.1522 -0.9132 -0.2083 -0.1285 -0.1559 -0.0845 -0.0684 -0.1322 -0.1633 -0.1536
S-1772	Wenn Sie selbst oder eine andere Person ADVATE verabreichen , darf dies nur nach einem entsprechenden Training geschehen .
T-1772	You or someone else might also administer ADVATE as an injection , but only after receiving adequate training .
H-1772	-0.5720358490943909	If you or someone else is administering ADVATE , this should only be done after appropriate training .
D-1772	-0.5720358490943909	If you or someone else is administering ADVATE , this should only be done after appropriate training .
P-1772	-0.5154 -0.2146 -0.2725 -1.3801 -0.3964 -0.9206 -2.2284 -0.1255 -0.0740 -0.1553 -0.1040 -0.0910 -0.3112 -1.8062 -0.4338 -0.7394 -0.2429 -0.5747 -0.2349 -1.6163 -0.2598 -0.3023 -0.1575
S-186	Studien zur Präklinik zeigten , dass Alendronat sich bevorzugt an den Stellen der aktiven Resorption
T-186	Preclinical studies have shown preferential localisation of alendronate to sites of active resorption .
H-186	-0.5044988989830017	Preclinical studies have shown that alendronate is preferred at sites of active absorption
D-186	-0.5044988989830017	Preclinical studies have shown that alendronate is preferred at sites of active absorption
P-186	-1.0956 -0.6510 -0.0409 -0.5093 -0.3861 -0.8656 -0.2392 -0.1738 -0.1125 -0.1117 -0.1246 -0.0760 -2.9184 -0.8494 -1.2420 -0.3324 -0.3184 -0.0713 -0.1637 -0.0690 -0.2436
S-462	In der Original-Blisterpackung aufbewahren , um den Inhalt vor Feuchtigkeit und Licht zu schützen .
T-462	Store in the original blister in order to protect from moisture and light .
H-462	-0.3090588450431824	Store in their original blister to protect from moisture and light .
D-462	-0.3090588450431824	Store in their original blister to protect from moisture and light .
P-462	-0.1173 -0.2598 -1.5612 -0.2138 -0.4341 -0.0981 -0.2295 -0.1612 -0.3838 -0.6817 -0.0577 -0.0477 -0.1776 -0.1372 -0.1715 -0.2127
S-266	In der Original-Blisterpackung aufbewahren , um den Inhalt vor Feuchtigkeit und Licht zu schützen .
T-266	Store in the original blister in order to protect from moisture and light .
H-266	-0.3090588450431824	Store in their original blister to protect from moisture and light .
D-266	-0.3090588450431824	Store in their original blister to protect from moisture and light .
P-266	-0.1173 -0.2598 -1.5612 -0.2138 -0.4341 -0.0981 -0.2295 -0.1612 -0.3838 -0.6817 -0.0577 -0.0477 -0.1776 -0.1372 -0.1715 -0.2127
S-690	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-690	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-690	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
D-690	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
P-690	-0.4262 -1.5060 -0.2274 -0.2217 -0.8414 -0.4645 -1.5227 -0.1510 -0.3075 -0.2531 -0.9896 -0.1831 -0.1194 -0.1607 -1.1202 -0.2005
S-536	In den zusätzlichen Studien , einschließlich der Studie mit Kindern unter sechs Jahren , wurde die Wirksamkeit von Advate bestätigt .
T-536	The additional studies confirmed Advate s effectiveness , including in children under six years of age .
H-536	-0.462280809879303	Additional studies , including the trial in children under six , confirmed the efficacy of Advate .
D-536	-0.462280809879303	Additional studies , including the trial in children under six , confirmed the efficacy of Advate .
P-536	-0.3713 -0.7679 -0.3359 -0.0609 -0.9334 -1.2614 -0.3884 -0.2116 -0.3963 -0.5944 -1.0767 -1.5752 -0.4745 -0.2064 -0.0587 -0.0782 -0.1193 -0.3372 -0.0939 -0.2058 -0.1606
S-535	Darüber hinaus war bei 81 % dieser Blutungsepisoden nur eine einzige Behandlung mit Advate erforderlich .
T-535	In addition , 81 % of these bleeding episodes required only a single treatment with Advate .
H-535	-0.41687214374542236	Moreover , in 81 % of these bleeding episodes , only one treatment with Advate was necessary .
D-535	-0.41687214374542236	Moreover , in 81 % of these bleeding episodes , only one treatment with Advate was necessary .
P-535	-1.6159 -0.1382 -1.2118 -0.1373 -0.1255 -0.1366 -0.1988 -0.6281 -0.1911 -0.0074 -0.4283 -0.5625 -0.4683 -0.7104 -0.7139 -0.2275 -0.0886 -0.1495 -0.6970 -0.1632 -0.1543
S-1811	Jede Packung beinhaltet des Weiteren ein Gerät zur Rekonstitution ( BAXJECTII ) .
T-1811	Each pack also contains a device for reconstitution ( BAXJECT II ) .
H-1811	-0.3040870428085327	Each pack also contains a reconstitution device ( BAXJECTII ) .
D-1811	-0.3040870428085327	Each pack also contains a reconstitution device ( BAXJECTII ) .
P-1811	-0.0939 -0.9026 -0.4295 -0.7696 -0.1968 -0.4869 -0.1439 -0.8638 -0.1429 -0.2500 -0.1733 -0.1820 -0.1093 -0.1511 -0.1247 -0.1274 -0.1680 -0.1579
S-1042	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1042	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1042	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
D-1042	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
P-1042	-0.4262 -1.5060 -0.2274 -0.2217 -0.8414 -0.4645 -1.5227 -0.1510 -0.3075 -0.2531 -0.9896 -0.1831 -0.1194 -0.1607 -1.1202 -0.2005
S-1218	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1218	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1218	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
D-1218	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
P-1218	-0.4262 -1.5060 -0.2274 -0.2217 -0.8414 -0.4645 -1.5227 -0.1510 -0.3075 -0.2531 -0.9896 -0.1831 -0.1194 -0.1607 -1.1202 -0.2005
S-1721	Lesen Sie die gesamte Packungsbeilage sorgfältig durch , bevor Sie mit der Anwendung dieses Arzneimittels beginnen .
T-1721	Read all of this leaflet carefully before you start using this medicine .
H-1721	-0.4802728593349457	Read all of the Package Leaflet carefully before starting to use this medicine .
D-1721	-0.4802728593349457	Read all of the Package Leaflet carefully before starting to use this medicine .
P-1721	-0.9841 -1.2213 -1.0989 -0.3931 -0.3464 -0.1331 -0.3036 -0.0285 -0.1865 -0.1227 -0.2192 -1.2891 -0.8390 -0.1751 -0.1229 -0.8729 -0.1530 -0.1558
S-1754	Dies muss bei Patienten , die einer natriumkontollierten Diät unterliegen , berücksichtigt werden .
T-1754	To be taken into consideration by patients on a controlled sodium diet .
H-1754	-0.5667349100112915	This should be considered in patients on a sodium restricted diet .
D-1754	-0.5667349100112915	This should be considered in patients on a sodium restricted diet .
P-1754	-0.3622 -1.5079 -0.1601 -0.5981 -0.4925 -0.2772 -0.4270 -0.2105 -0.2577 -0.2454 -3.0132 -0.0553 -0.1718 -0.1554
S-356	Häufig : muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen .
T-356	Musculoskeletal and connective tissue disorders :
H-356	-0.23356546461582184	Common : musculoskeletal ( bone , muscle or joint ) pain .
D-356	-0.23356546461582184	Common : musculoskeletal ( bone , muscle or joint ) pain .
P-356	-0.1528 -0.1039 -0.1656 -0.0692 -0.3836 -0.0702 -0.1199 -0.2432 -0.1156 -0.2580 -0.1107 -0.1340 -0.1310 -1.0237 -0.7644 -0.1419 -0.0901 -0.2017 -0.1583
S-168	Häufig : muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen .
T-168	Musculoskeletal and connective tissue disorders :
H-168	-0.23356546461582184	Common : musculoskeletal ( bone , muscle or joint ) pain .
D-168	-0.23356546461582184	Common : musculoskeletal ( bone , muscle or joint ) pain .
P-168	-0.1528 -0.1039 -0.1656 -0.0692 -0.3836 -0.0702 -0.1199 -0.2432 -0.1156 -0.2580 -0.1107 -0.1340 -0.1310 -1.0237 -0.7644 -0.1419 -0.0901 -0.2017 -0.1583
S-7	Wenn derartige Ablagerungen in den Gelenken entstehen und Schmerzen verursachen , spricht man von einer Gicht .
T-7	When this happens in the joints and causes pain , it is known as gout .
H-7	-0.4327232241630554	When such deposits form in the joints and cause pain , it is called gout .
D-7	-0.4327232241630554	When such deposits form in the joints and cause pain , it is called gout .
P-7	-0.3539 -0.9310 -0.9595 -0.1729 -2.1838 -0.1472 -0.2784 -0.0639 -0.0290 -0.4096 -0.1797 -0.0717 -0.1779 -1.3082 -0.1632 -0.6898 -0.0955 -0.1314 -0.1510 -0.1569
S-1911	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-1911	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-1911	-0.13689033687114716	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-1911	-0.13689033687114716	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-1911	-0.1643 -0.1133 -0.0890 -0.0601 -0.1967 -0.0539 -0.1342 -0.1196 -0.1150 -0.1166 -0.1132 -0.1184 -0.1348 -0.1062 -0.1284 -0.0925 -0.1961 -0.1722 -0.1119 -0.1365 -0.1267 -0.3661 -0.1725 -0.1471
S-866	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-866	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-866	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
D-866	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
P-866	-0.4262 -1.5060 -0.2274 -0.2217 -0.8414 -0.4645 -1.5227 -0.1510 -0.3075 -0.2531 -0.9896 -0.1831 -0.1194 -0.1607 -1.1202 -0.2005
S-311	Knochen- , Gelenk- und<unk> oder Muskelschmerzen wurden bei Patienten unter Bisphosphonaten berichtet .
T-311	Bone , joint , and/ or muscle pain has been reported in patients taking bisphosphonates .
H-311	-0.3656056225299835	bone , joint , or muscle pain have been reported in patients receiving bisphosphonates .
D-311	-0.3656056225299835	bone , joint , or muscle pain have been reported in patients receiving bisphosphonates .
P-311	-0.9806 -0.1486 -0.4682 -1.1537 -0.4642 -0.0467 -0.0793 -1.3267 -0.1682 -0.1026 -0.1571 -1.2227 -0.2551 -0.0867 -0.0376 -0.0567 -0.1394 -0.0575 -0.2087 -0.1517
S-123	Knochen- , Gelenk- und<unk> oder Muskelschmerzen wurden bei Patienten unter Bisphosphonaten berichtet .
T-123	Bone , joint , and/ or muscle pain has been reported in patients taking bisphosphonates .
H-123	-0.3656056225299835	bone , joint , or muscle pain have been reported in patients receiving bisphosphonates .
D-123	-0.3656056225299835	bone , joint , or muscle pain have been reported in patients receiving bisphosphonates .
P-123	-0.9806 -0.1486 -0.4682 -1.1537 -0.4642 -0.0467 -0.0793 -1.3267 -0.1682 -0.1026 -0.1571 -1.2227 -0.2551 -0.0867 -0.0376 -0.0567 -0.1394 -0.0575 -0.2087 -0.1517
S-20	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-20	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-20	-0.13689033687114716	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-20	-0.13689033687114716	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-20	-0.1643 -0.1133 -0.0890 -0.0601 -0.1967 -0.0539 -0.1342 -0.1196 -0.1150 -0.1166 -0.1132 -0.1184 -0.1348 -0.1062 -0.1284 -0.0925 -0.1961 -0.1722 -0.1119 -0.1365 -0.1267 -0.3661 -0.1725 -0.1471
S-1972	Sportler müssen darauf hingewiesen werden , dass unter der Therapie mit Pseudoephedrin positive Dopingtests möglich sind .
T-1972	Athletes should be informed that treatment with pseudoephedrine could lead to positive doping tests .
H-1972	-0.36192643642425537	Athletes should be advised that pseudoephedrine therapy may result in positive doping tests .
D-1972	-0.36192643642425537	Athletes should be advised that pseudoephedrine therapy may result in positive doping tests .
P-1972	-0.4123 -0.1139 -0.9110 -0.1515 -1.5540 -0.1842 -1.0208 -0.2468 -0.1497 -0.0795 -0.1310 -0.2436 -0.1066 -0.1313 -0.3914 -0.7213 -0.1413 -0.4049 -0.4201 -0.1130 -0.1803 -0.1538
S-513	Advate enthält den Wirkstoff Octocog alfa ( menschlicher Gerinnungsfaktor VIII ) .
T-513	Advate contains the active substance octocog alfa ( human coagulation factor VIII ) .
H-513	-0.24960963428020477	Advate contains the active substance octocog alfa ( human coagulation factor VIII ) .
D-513	-0.24960963428020477	Advate contains the active substance octocog alfa ( human coagulation factor VIII ) .
P-513	-0.4822 -0.0981 -0.0668 -1.1959 -0.0572 -0.1004 -0.8891 -0.1174 -0.1257 -0.2491 -0.1174 -0.0667 -0.1468 -0.1404 -0.8736 -0.0452 -0.2385 -0.0364 -0.1547 -0.0800 -0.1281 -0.1761 -0.1550
S-1760	In einigen Fällen jedoch können , besonders bei jüngeren Patienten , häufigere Injektionen oder höhere Dosen erforderlich sein .
T-1760	However , in some cases , especially in younger patients , more frequent injections or higher doses may be necessary .
H-1760	-0.26343217492103577	However , in some cases , especially in younger patients , more frequent injections or higher doses may be necessary .
D-1760	-0.26343217492103577	However , in some cases , especially in younger patients , more frequent injections or higher doses may be necessary .
P-1760	-0.9997 -0.2818 -0.1691 -0.1096 -0.0799 -0.3570 -0.8529 -0.5647 -0.0817 -0.0996 -0.1282 -0.4799 -0.0672 -0.2215 -0.0400 -0.1923 -0.3883 -0.2474 -0.0729 -0.0879 -0.1641 -0.2920 -0.1904 -0.1540
S-1571	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1571	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1571	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
D-1571	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
P-1571	-0.4262 -1.5060 -0.2274 -0.2217 -0.8414 -0.4645 -1.5227 -0.1510 -0.3075 -0.2531 -0.9896 -0.1831 -0.1194 -0.1607 -1.1202 -0.2005
S-1394	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1394	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1394	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
D-1394	-0.5434458255767822	- For reconstitution only the sterilised water for injections and the
P-1394	-0.4262 -1.5060 -0.2274 -0.2217 -0.8414 -0.4645 -1.5227 -0.1510 -0.3075 -0.2531 -0.9896 -0.1831 -0.1194 -0.1607 -1.1202 -0.2005
S-449	In beiden Fällen wurde die Radioaktivität fast ausschließlich als Metaboliten der Ausgangssubstanz ausgeschieden .
T-449	In both cases , the excreted radioactivity was almost exclusively as metabolites of the parent .
H-449	-0.35407352447509766	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
D-449	-0.35407352447509766	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
P-449	-0.2621 -0.0854 -0.1121 -0.5738 -0.8731 -0.0971 -0.2225 -1.4947 -0.0399 -0.0650 -0.1442 -0.4425 -0.2086 -1.1583 -0.0430 -0.0630 -0.4859 -0.1745 -0.8447 -0.0925 -0.1536 -0.1532
S-409	Die zwei Behandlungsgruppen waren auch hinsichtlich der BMD-Zunahmen an anderen Skelettstellen vergleichbar .
T-409	The two treatment groups were also similar with regard to BMD increases at other skeletal sites .
H-409	-0.3505569100379944	The two treatment arms were also comparable in BMD increases at other skeletal sites .
D-409	-0.3505569100379944	The two treatment arms were also comparable in BMD increases at other skeletal sites .
P-409	-0.2793 -0.2345 -0.3388 -0.8727 -0.1641 -0.2601 -0.6272 -0.1306 -0.3966 -0.4475 -0.2193 -0.6594 -1.0111 -0.3948 -0.5567 -0.0594 -0.1557 -0.1071 -0.1380 -0.1574 -0.1513
S-253	In beiden Fällen wurde die Radioaktivität fast ausschließlich als Metaboliten der Ausgangssubstanz ausgeschieden .
T-253	In both cases , the excreted radioactivity was almost exclusively as metabolites of the parent .
H-253	-0.35407352447509766	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
D-253	-0.35407352447509766	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
P-253	-0.2621 -0.0854 -0.1121 -0.5738 -0.8731 -0.0971 -0.2225 -1.4947 -0.0399 -0.0650 -0.1442 -0.4425 -0.2086 -1.1583 -0.0430 -0.0630 -0.4859 -0.1745 -0.8447 -0.0925 -0.1536 -0.1532
S-52	Dieses Arzneimittel ist identisch mit FOSAVANCE , das bereits in der Europäischen Union zugelassen ist .
T-52	This medicine is the same as FOSAVANCE , which is already authorised in the European Union .
H-52	-0.2987780272960663	This medicine is identical to FOSAVANCE , which is already authorised in the European Union .
D-52	-0.2987780272960663	This medicine is identical to FOSAVANCE , which is already authorised in the European Union .
P-52	-0.3627 -1.4343 -0.1581 -0.4257 -0.1216 -0.2938 -0.2178 -0.1155 -0.1238 -0.1294 -0.1082 -0.1002 -0.7082 -0.3057 -0.3353 -0.3545 -0.5536 -0.1994 -0.2124 -0.1535 -0.2384 -0.1815 -0.1788 -0.1586
S-716	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-716	Connect the syringe to BAXJECT II ( Fig . d ) .
H-716	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-716	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-716	-0.9691 -0.0981 -0.1048 -0.2986 -0.1409 -0.0298 -0.0126 -0.1419 -1.1182 -0.1620 -0.1597 -0.2081 -0.1133 -0.1167 -0.1335 -0.6267 -1.8174 -0.4255 -0.1081 -0.1267 -0.1624 -0.1575
S-892	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-892	Connect the syringe to BAXJECT II ( Fig . d ) .
H-892	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-892	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-892	-0.9691 -0.0981 -0.1048 -0.2986 -0.1409 -0.0298 -0.0126 -0.1419 -1.1182 -0.1620 -0.1597 -0.2081 -0.1133 -0.1167 -0.1335 -0.6267 -1.8174 -0.4255 -0.1081 -0.1267 -0.1624 -0.1575
S-1751	Ihr Arzt wird entscheiden , ob Sie ADVATE in der Schwangerschaft und Stillzeit anwenden können .
T-1751	Your doctor will decide if ADVATE may be used during pregnancy and breast-feeding .
H-1751	-0.28641262650489807	Your doctor will decide whether you can use ADVATE during pregnancy and lactation .
D-1751	-0.28641262650489807	Your doctor will decide whether you can use ADVATE during pregnancy and lactation .
P-1751	-0.1451 -0.1002 -0.1527 -0.2134 -0.8176 -0.5482 -0.4499 -0.0992 -0.0735 -0.1575 -0.1072 -0.0860 -1.3813 -0.0914 -0.1608 -0.7015 -0.0105 -0.1051 -0.1664 -0.1607
S-1068	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1068	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1068	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-1068	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-1068	-0.9691 -0.0981 -0.1048 -0.2986 -0.1409 -0.0298 -0.0126 -0.1419 -1.1182 -0.1620 -0.1597 -0.2081 -0.1133 -0.1167 -0.1335 -0.6267 -1.8174 -0.4255 -0.1081 -0.1267 -0.1624 -0.1575
S-1244	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1244	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1244	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-1244	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-1244	-0.9691 -0.0981 -0.1048 -0.2986 -0.1409 -0.0298 -0.0126 -0.1419 -1.1182 -0.1620 -0.1597 -0.2081 -0.1133 -0.1167 -0.1335 -0.6267 -1.8174 -0.4255 -0.1081 -0.1267 -0.1624 -0.1575
S-1420	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1420	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1420	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-1420	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-1420	-0.9691 -0.0981 -0.1048 -0.2986 -0.1409 -0.0298 -0.0126 -0.1419 -1.1182 -0.1620 -0.1597 -0.2081 -0.1133 -0.1167 -0.1335 -0.6267 -1.8174 -0.4255 -0.1081 -0.1267 -0.1624 -0.1575
S-213	8 Behandlungsgruppen waren auch hinsichtlich der BMD-Zunahmen an anderen Skelettstellen vergleichbar .
T-213	The two treatment groups were also similar with regard to BMD increases at other skeletal sites .
H-213	-0.44105806946754456	8 treatment groups were also comparable in BMD increases at other skeletal sites .
D-213	-0.44105806946754456	8 treatment groups were also comparable in BMD increases at other skeletal sites .
P-213	-1.2327 -0.4292 -1.2423 -0.2235 -0.3568 -0.7142 -0.1390 -0.4773 -0.4175 -0.2301 -0.7317 -0.9536 -0.3142 -0.5837 -0.0591 -0.1588 -0.1063 -0.1296 -0.1702 -0.1513
S-1992	Verminderte Milchproduktion wurde von stillenden Müttern im Zusammenhang mit Pseudoephedrin berichtet .
T-1992	Decreased milk production in nursing mothers has been reported with pseudoephedrine .
H-1992	-0.3395729064941406	Decreased milk production has been reported in nursing mothers associated with pseudoephedrine .
D-1992	-0.3395729064941406	Decreased milk production has been reported in nursing mothers associated with pseudoephedrine .
P-1992	-1.2753 -0.0458 -0.0363 -0.0946 -0.1032 -0.5528 -0.1226 -0.0628 -0.9705 -0.4607 -0.1526 -0.7377 -1.7964 -0.1443 -0.1582 -0.1668 -0.1504 -0.0661 -0.1383 -0.1451 -0.0978 -0.1786 -0.1531
S-526	Es korrigiert den Faktor VIII-Mangel und ermöglicht eine vorübergehende Kontrolle der Blutungsstörung .
T-526	It corrects the factor VIII deficiency and gives temporary control of the bleeding disorder .
H-526	-0.5520012378692627	It corrects factor VIII deficiency and enables temporary control of bleeding disorder .
D-526	-0.5520012378692627	It corrects factor VIII deficiency and enables temporary control of bleeding disorder .
P-526	-1.3683 -0.1183 -0.2306 -0.6871 -0.5271 -1.5786 -0.0452 -0.0497 -0.0962 -0.2329 -1.7364 -0.1285 -1.2091 -0.2693 -0.1359 -1.6566 -0.1481 -0.4652 -0.2001 -0.1567
S-1762	Der erforderliche Faktor VIII-Spiegel hängt von der Schwere und dem Ort der Blutung ab .
T-1762	The target factor VIII levels will depend on the severity and location of the bleeding .
H-1762	-0.6382754445075989	The factor VIII level required varies with the severity and site of bleeding .
D-1762	-0.6382754445075989	The factor VIII level required varies with the severity and site of bleeding .
P-1762	-0.6660 -2.0822 -0.6537 -1.4650 -0.4284 -1.2014 -1.3532 -0.1610 -0.2005 -0.3271 -0.0907 -0.1176 -0.1663 -1.2529 -0.1470 -1.3548 -0.1017 -0.2051 -0.1527
S-1594	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1594	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1594	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-1594	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-1594	-1.0459 -0.2515 -0.1325 -0.7510 -0.2092 -0.1081 -0.1241 -0.1411 -0.1398 -0.1436 -0.0444 -0.1225 -0.1093 -0.4052 -0.2409 -0.6595 -0.3735 -0.1284 -0.0854 -0.1647 -0.1528
S-1417	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1417	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1417	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-1417	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-1417	-1.0459 -0.2515 -0.1325 -0.7510 -0.2092 -0.1081 -0.1241 -0.1411 -0.1398 -0.1436 -0.0444 -0.1225 -0.1093 -0.4052 -0.2409 -0.6595 -0.3735 -0.1284 -0.0854 -0.1647 -0.1528
S-1241	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1241	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1241	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-1241	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-1241	-1.0459 -0.2515 -0.1325 -0.7510 -0.2092 -0.1081 -0.1241 -0.1411 -0.1398 -0.1436 -0.0444 -0.1225 -0.1093 -0.4052 -0.2409 -0.6595 -0.3735 -0.1284 -0.0854 -0.1647 -0.1528
S-1065	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1065	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1065	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-1065	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-1065	-1.0459 -0.2515 -0.1325 -0.7510 -0.2092 -0.1081 -0.1241 -0.1411 -0.1398 -0.1436 -0.0444 -0.1225 -0.1093 -0.4052 -0.2409 -0.6595 -0.3735 -0.1284 -0.0854 -0.1647 -0.1528
S-889	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-889	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-889	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-889	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-889	-1.0459 -0.2515 -0.1325 -0.7510 -0.2092 -0.1081 -0.1241 -0.1411 -0.1398 -0.1436 -0.0444 -0.1225 -0.1093 -0.4052 -0.2409 -0.6595 -0.3735 -0.1284 -0.0854 -0.1647 -0.1528
S-1960	Aerinaze darf nicht bei Kindern unter 12 Jahren angewendet werden ( siehe Abschnitt 4.2 ) .
T-1960	Aerinaze should not be used in children below the age of 12 years ( see section 4.2 ) .
H-1960	-0.23315326869487762	Do not use Aerinaze in children under 12 years of age ( see section 4.2 ) .
D-1960	-0.23315326869487762	Do not use Aerinaze in children under 12 years of age ( see section 4.2 ) .
P-1960	-1.1268 -0.1353 -0.0424 -0.1226 -0.1317 -0.1465 -0.1300 -0.0916 -0.3688 -0.1149 -0.3844 -0.1686 -0.5657 -0.6405 -0.1160 -0.1579 -0.1222 -0.0712 -0.1175 -0.1320 -0.1369 -0.1818 -0.1570
S-1597	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1597	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1597	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-1597	-0.32871145009994507	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-1597	-0.9691 -0.0981 -0.1048 -0.2986 -0.1409 -0.0298 -0.0126 -0.1419 -1.1182 -0.1620 -0.1597 -0.2081 -0.1133 -0.1167 -0.1335 -0.6267 -1.8174 -0.4255 -0.1081 -0.1267 -0.1624 -0.1575
S-713	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-713	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-713	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-713	-0.26349374651908875	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-713	-1.0459 -0.2515 -0.1325 -0.7510 -0.2092 -0.1081 -0.1241 -0.1411 -0.1398 -0.1436 -0.0444 -0.1225 -0.1093 -0.4052 -0.2409 -0.6595 -0.3735 -0.1284 -0.0854 -0.1647 -0.1528
S-470	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
T-470	Via Complutense , 140 ES-28805 Alcalá de Henares Madrid , Spain
H-470	-0.1141020804643631	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
D-470	-0.1141020804643631	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
P-470	-0.1680 -0.1367 -0.2289 -0.1351 -0.0810 -0.0280 -0.1387 -0.1358 -0.1332 -0.1051 -0.0890 -0.1255 -0.0930 -0.0911 -0.1169 -0.0709 -0.1224 -0.1204 -0.0440 -0.0787 -0.1397 -0.0931 -0.1490
S-1019	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1019	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1019	-0.2525270879268646	AUC0- ( IU h/ dl ) t 1/ 2 ( h )
D-1019	-0.2525270879268646	AUC0- ( IU h/ dl ) t 1/ 2 ( h )
P-1019	-0.0582 -0.1411 -1.0592 -0.1498 -0.1457 -0.1338 -1.0558 -0.1704 -0.1021 -0.0299 -0.1288 -0.1691 -0.1130 -0.1917 -0.1223 -0.1495 -0.3068 -0.1283 -0.4421
S-843	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-843	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-843	-0.2525270879268646	AUC0- ( IU h/ dl ) t 1/ 2 ( h )
D-843	-0.2525270879268646	AUC0- ( IU h/ dl ) t 1/ 2 ( h )
P-843	-0.0582 -0.1411 -1.0592 -0.1498 -0.1457 -0.1338 -1.0558 -0.1704 -0.1021 -0.0299 -0.1288 -0.1691 -0.1130 -0.1917 -0.1223 -0.1495 -0.3068 -0.1283 -0.4421
S-278	Angesichts des Krankheitsverlaufs bei Osteoporose ist ADROVANCE zur Langzeittherapie vorgesehen .
T-278	Due to the nature of the disease process in osteoporosis , ADROVANCE is intended for long-term use .
H-278	-0.42669519782066345	In view of the course of osteoporosis , ADROVANCE is intended for long @-@ term therapy .
D-278	-0.42669519782066345	In view of the course of osteoporosis , ADROVANCE is intended for long @-@ term therapy .
P-278	-2.6464 -0.1720 -0.1287 -0.4408 -0.7041 -0.1697 -0.3941 -0.0848 -0.1005 -0.1315 -0.0824 -0.0813 -0.5070 -0.0657 -0.0645 -0.1268 -0.1013 -0.1019 -0.4101 -1.6156 -0.2892 -1.1476 -1.1307 -0.2702 -0.2399 -0.1601 -0.1540
S-91	Angesichts des Krankheitsverlaufs bei Osteoporose ist ADROVANCE zur Langzeittherapie vorgesehen .
T-91	Due to the nature of the disease process in osteoporosis , ADROVANCE is intended for long-term use .
H-91	-0.42669519782066345	In view of the course of osteoporosis , ADROVANCE is intended for long @-@ term therapy .
D-91	-0.42669519782066345	In view of the course of osteoporosis , ADROVANCE is intended for long @-@ term therapy .
P-91	-2.6464 -0.1720 -0.1287 -0.4408 -0.7041 -0.1697 -0.3941 -0.0848 -0.1005 -0.1315 -0.0824 -0.0813 -0.5070 -0.0657 -0.0645 -0.1268 -0.1013 -0.1019 -0.4101 -1.6156 -0.2892 -1.1476 -1.1307 -0.2702 -0.2399 -0.1601 -0.1540
S-300	Es ist sehr wichtig , dass alle Dosierungsanweisungen an den Patienten weitergegeben werden und vom Patienten verstanden
T-300	It is very important that the full dosing instructions are provided to , and are understood by the patient ( see section 4.2 ) .
H-300	-0.3981666564941406	It is very important that all dosage instructions are communicated to the patient and understood by the patient
D-300	-0.3981666564941406	It is very important that all dosage instructions are communicated to the patient and understood by the patient
P-300	-0.2993 -0.1639 -0.9954 -0.0684 -0.2854 -0.2379 -0.3982 -1.1707 -0.1015 -0.9386 -0.2483 -1.4964 -0.1142 -0.1771 -0.3151 -0.0777 -0.1317 -0.5098 -0.3606 -0.3688 -0.1162 -0.1846
S-1548	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1548	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1548	-0.2525270879268646	AUC0- ( IU h/ dl ) t 1/ 2 ( h )
D-1548	-0.2525270879268646	AUC0- ( IU h/ dl ) t 1/ 2 ( h )
P-1548	-0.0582 -0.1411 -1.0592 -0.1498 -0.1457 -0.1338 -1.0558 -0.1704 -0.1021 -0.0299 -0.1288 -0.1691 -0.1130 -0.1917 -0.1223 -0.1495 -0.3068 -0.1283 -0.4421
S-1371	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1371	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1371	-0.2525270879268646	AUC0- ( IU h/ dl ) t 1/ 2 ( h )
D-1371	-0.2525270879268646	AUC0- ( IU h/ dl ) t 1/ 2 ( h )
P-1371	-0.0582 -0.1411 -1.0592 -0.1498 -0.1457 -0.1338 -1.0558 -0.1704 -0.1021 -0.0299 -0.1288 -0.1691 -0.1130 -0.1917 -0.1223 -0.1495 -0.3068 -0.1283 -0.4421
S-1195	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1195	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1195	-0.2525270879268646	AUC0- ( IU h/ dl ) t 1/ 2 ( h )
D-1195	-0.2525270879268646	AUC0- ( IU h/ dl ) t 1/ 2 ( h )
P-1195	-0.0582 -0.1411 -1.0592 -0.1498 -0.1457 -0.1338 -1.0558 -0.1704 -0.1021 -0.0299 -0.1288 -0.1691 -0.1130 -0.1917 -0.1223 -0.1495 -0.3068 -0.1283 -0.4421
S-1822	Kobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
T-1822	Kobaltweg 49 NL-3542 CE Utrecht Tel : <<unk>> 31 30 2488911
H-1822	-0.12620846927165985	Cobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
D-1822	-0.12620846927165985	Cobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
P-1822	-0.5195 -0.3272 -0.0374 -0.0707 -0.1209 -0.1933 -0.1147 -0.0948 -0.0888 -0.0285 -0.0987 -0.0782 -0.0567 -0.0577 -0.1372 -0.0247 -0.0895 -0.1422 -0.1204 -0.1218 -0.1162 -0.1057 -0.1580
S-1838	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
T-1838	Viale Tiziano , 25 I-00196 Roma Tel : <<unk>> 39 06 324911
H-1838	-0.1256663203239441	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
D-1838	-0.1256663203239441	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
P-1838	-0.2016 -0.0720 -0.2094 -0.0535 -0.1108 -0.1381 -0.1258 -0.1514 -0.1071 -0.0717 -0.2587 -0.1421 -0.1953 -0.0575 -0.1384 -0.0304 -0.0813 -0.0944 -0.1375 -0.1319 -0.1183 -0.1067 -0.1564
S-293	ADROVANCE wurde bei Kindern und Jugendlichen nicht untersucht und sollte daher bei ihnen nicht angewendet werden .
T-293	ADROVANCE has not been studied in children and adolescents and therefore should not be given to them .
H-293	-0.2645685076713562	ADROVANCE has not been studied in children and adolescents and should therefore not be used in them .
D-293	-0.2645685076713562	ADROVANCE has not been studied in children and adolescents and should therefore not be used in them .
P-293	-0.0472 -0.0596 -0.1287 -0.1087 -0.0745 -0.2334 -0.1335 -0.1305 -1.4506 -0.1258 -0.2945 -0.2084 -0.0645 -0.0632 -0.0308 -0.2934 -0.3905 -1.1022 -0.1515 -0.1284 -0.4952 -0.2779 -0.3009 -0.1603 -0.1600
S-105	ADROVANCE wurde bei Kindern und Jugendlichen nicht untersucht und sollte daher bei ihnen nicht angewendet werden .
T-105	ADROVANCE has not been studied in children and adolescents and therefore should not be given to them .
H-105	-0.2645685076713562	ADROVANCE has not been studied in children and adolescents and should therefore not be used in them .
D-105	-0.2645685076713562	ADROVANCE has not been studied in children and adolescents and should therefore not be used in them .
P-105	-0.0472 -0.0596 -0.1287 -0.1087 -0.0745 -0.2334 -0.1335 -0.1305 -1.4506 -0.1258 -0.2945 -0.2084 -0.0645 -0.0632 -0.0308 -0.2934 -0.3905 -1.1022 -0.1515 -0.1284 -0.4952 -0.2779 -0.3009 -0.1603 -0.1600
S-1946	Die Dauer der Anwendung ist so kurz wie möglich zu halten und sollte nach Abklingen der Symptome nicht fortgesetzt werden .
T-1946	The duration of treatment should be kept as short as possible and should not be continued after the symptoms have disappeared .
H-1946	-0.41162317991256714	Use should be kept as short as possible and should not be continued after symptoms subside .
D-1946	-0.41162317991256714	Use should be kept as short as possible and should not be continued after symptoms subside .
P-1946	-1.2110 -0.4846 -0.1706 -1.7527 -0.2847 -0.5357 -0.1766 -0.1731 -0.2210 -0.2187 -0.1888 -0.1186 -0.3555 -0.3885 -0.1829 -1.0313 -0.0120 -0.1612 -0.1533
S-1813	Hersteller Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgien
T-1813	Manufacturer Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
H-1813	-0.12551464140415192	Manufacturer Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgium
D-1813	-0.12551464140415192	Manufacturer Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgium
P-1813	-0.1138 -0.0517 -0.0726 -0.1055 -0.2256 -0.1446 -0.1626 -0.1451 -0.0836 -0.1313 -0.0777 -0.0946 -0.1098 -0.0739 -0.0895 -0.1361 -0.1391 -0.0972 -0.0647 -0.1059 -0.1195 -0.0569 -0.0930 -0.1458 -0.4723 -0.1510
S-61	Die Patientinnen sollen außerdem zusätzlich Calcium einnehmen , falls über die Nahrung nicht genügend aufgenommen wird .
T-61	Patients should also take calcium supplements if they are not getting enough calcium from their diet .
H-61	-0.5181819796562195	Patients should also take additional calcium if food intake is insufficient .
D-61	-0.5181819796562195	Patients should also take additional calcium if food intake is insufficient .
P-61	-0.2519 -0.1010 -0.2937 -0.2654 -0.0556 -0.7811 -0.1876 -0.1122 -0.1180 -0.3650 -2.4317 -0.8850 -1.1250 -0.5860 -0.9586 -0.4953 -0.1582 -0.1563
S-1954	Die empfohlene Dosierung und die Dauer der Behandlung dürfen nicht überschritten werden ( siehe Abschnitt 4.2 ) .
T-1954	Do not exceed the recommended dosage and the duration of treatment ( see section 4.2 ) .
H-1954	-0.18337103724479675	Do not exceed the recommended dosage and duration of treatment ( see section 4.2 ) .
D-1954	-0.18337103724479675	Do not exceed the recommended dosage and duration of treatment ( see section 4.2 ) .
P-1954	-0.1322 -0.1278 -0.0806 -0.0949 -0.2308 -0.1459 -1.0991 -0.0852 -0.1025 -0.3385 -0.0766 -0.1114 -0.1381 -0.1999 -0.1513 -0.1091 -0.0856 -0.1188 -0.1316 -0.1368 -0.1816 -0.1559
S-313	Der Zeitpunkt des Auftretens dieser Symptome variierte von einem Tag bis zu mehreren Monaten nach Therapiebeginn .
T-313	The time to onset of symptoms varied from one day to several months after starting treatment .
H-313	-0.30542975664138794	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
D-313	-0.30542975664138794	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
P-313	-0.5177 -0.6044 -0.2141 -1.3560 -0.1112 -0.1227 -0.1445 -0.0915 -0.0894 -0.1311 -0.2170 -0.1724 -0.1495 -0.1523 -0.0597 -0.1445 -0.4825 -0.8794 -0.2364 -0.2152 -0.6205 -0.1611 -0.1521
S-704	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-704	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-704	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-704	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-704	-1.3794 -0.1560 -0.2883 -0.5138 -0.4963 -0.3253 -0.1797 -1.4921 -0.2804 -0.5311 -0.5019 -1.4571 -0.0975 -0.2321 -0.1609 -0.8033 -0.0628 -0.0933 -1.4455 -0.1771 -0.6688 -0.0689 -0.1926 -0.1500 -0.1570
S-581	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-581	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-581	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
D-581	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
P-581	-0.4941 -0.1329 -0.1500 -0.1339 -0.0734 -0.2501 -0.0506 -0.1708 -0.1148 -0.1406 -1.3398 -1.9500 -0.1470 -0.3280 -0.4519 -0.1250 -0.0641 -0.1021 -0.1223 -0.1688 -0.1227 -0.8668 -1.0162 -0.1387 -0.1722 -0.1536
S-1232	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1232	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1232	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-1232	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-1232	-1.3794 -0.1560 -0.2883 -0.5138 -0.4963 -0.3253 -0.1797 -1.4921 -0.2804 -0.5311 -0.5019 -1.4571 -0.0975 -0.2321 -0.1609 -0.8033 -0.0628 -0.0933 -1.4455 -0.1771 -0.6688 -0.0689 -0.1926 -0.1500 -0.1570
S-1107	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-1107	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-1107	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
D-1107	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
P-1107	-0.4941 -0.1329 -0.1500 -0.1339 -0.0734 -0.2501 -0.0506 -0.1708 -0.1148 -0.1406 -1.3398 -1.9500 -0.1470 -0.3280 -0.4519 -0.1250 -0.0641 -0.1021 -0.1223 -0.1688 -0.1227 -0.8668 -1.0162 -0.1387 -0.1722 -0.1536
S-1413	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1413	Insert the white plastic spike through the ADVATE stopper .
H-1413	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
D-1413	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
P-1413	-0.7878 -0.2142 -0.3479 -1.9574 -0.8748 -0.2138 -1.2687 -0.2193 -0.1710 -0.1802 -0.0673 -0.1223 -0.1333 -0.2605 -0.1607 -0.3546 -0.0909 -0.0807 -1.0225 -0.1567 -0.1994 -0.1667 -0.1611 -0.1990 -0.2857 -0.1645 -0.1576
S-931	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-931	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-931	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
D-931	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
P-931	-0.4941 -0.1329 -0.1500 -0.1339 -0.0734 -0.2501 -0.0506 -0.1708 -0.1148 -0.1406 -1.3398 -1.9500 -0.1470 -0.3280 -0.4519 -0.1250 -0.0641 -0.1021 -0.1223 -0.1688 -0.1227 -0.8668 -1.0162 -0.1387 -0.1722 -0.1536
S-880	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-880	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-880	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-880	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-880	-1.3794 -0.1560 -0.2883 -0.5138 -0.4963 -0.3253 -0.1797 -1.4921 -0.2804 -0.5311 -0.5019 -1.4571 -0.0975 -0.2321 -0.1609 -0.8033 -0.0628 -0.0933 -1.4455 -0.1771 -0.6688 -0.0689 -0.1926 -0.1500 -0.1570
S-755	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-755	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-755	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
D-755	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
P-755	-0.4941 -0.1329 -0.1500 -0.1339 -0.0734 -0.2501 -0.0506 -0.1708 -0.1148 -0.1406 -1.3398 -1.9500 -0.1470 -0.3280 -0.4519 -0.1250 -0.0641 -0.1021 -0.1223 -0.1688 -0.1227 -0.8668 -1.0162 -0.1387 -0.1722 -0.1536
S-1056	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1056	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1056	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-1056	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-1056	-1.3794 -0.1560 -0.2883 -0.5138 -0.4963 -0.3253 -0.1797 -1.4921 -0.2804 -0.5311 -0.5019 -1.4571 -0.0975 -0.2321 -0.1609 -0.8033 -0.0628 -0.0933 -1.4455 -0.1771 -0.6688 -0.0689 -0.1926 -0.1500 -0.1570
S-1585	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1585	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1585	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-1585	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-1585	-1.3794 -0.1560 -0.2883 -0.5138 -0.4963 -0.3253 -0.1797 -1.4921 -0.2804 -0.5311 -0.5019 -1.4571 -0.0975 -0.2321 -0.1609 -0.8033 -0.0628 -0.0933 -1.4455 -0.1771 -0.6688 -0.0689 -0.1926 -0.1500 -0.1570
S-285	Die Patienten sollten ergänzend Calcium erhalten , sofern die Versorgung über die Nahrung nicht ausreichend ist ( siehe Abschnitt 4.4 ) .
T-285	12 Patients should not lie down for at least 30 minutes after taking ADROVANCE .
H-285	-0.5351423025131226	Patients should be supplemented with calcium if food is not sufficient ( see section 4.4 ) .
D-285	-0.5351423025131226	Patients should be supplemented with calcium if food is not sufficient ( see section 4.4 ) .
P-285	-1.2894 -0.1023 -0.1822 -0.7364 -2.0840 -0.0816 -0.1491 -0.1848 -0.2006 -0.1081 -0.1252 -1.1821 -1.8556 -2.3716 -0.4824 -0.6488 -0.1692 -0.1007 -0.0921 -0.1149 -0.1318 -0.1350 -0.1590 -0.1565
S-1590	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1590	Insert the white plastic spike through the ADVATE stopper .
H-1590	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
D-1590	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
P-1590	-0.7878 -0.2142 -0.3479 -1.9574 -0.8748 -0.2138 -1.2687 -0.2193 -0.1710 -0.1802 -0.0673 -0.1223 -0.1333 -0.2605 -0.1607 -0.3546 -0.0909 -0.0807 -1.0225 -0.1567 -0.1994 -0.1667 -0.1611 -0.1990 -0.2857 -0.1645 -0.1576
S-1131	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-1131	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-1131	-0.38158902525901794	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
D-1131	-0.38158902525901794	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
P-1131	-1.1393 -0.0998 -1.0690 -0.2619 -0.6689 -0.2075 -0.0782 -0.1262 -0.0662 -0.0699 -0.1470 -0.1080 -0.9936 -1.0477 -0.1035 -0.4854 -0.1755 -0.4148 -0.2119 -0.1574
S-1237	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1237	Insert the white plastic spike through the ADVATE stopper .
H-1237	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
D-1237	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
P-1237	-0.7878 -0.2142 -0.3479 -1.9574 -0.8748 -0.2138 -1.2687 -0.2193 -0.1710 -0.1802 -0.0673 -0.1223 -0.1333 -0.2605 -0.1607 -0.3546 -0.0909 -0.0807 -1.0225 -0.1567 -0.1994 -0.1667 -0.1611 -0.1990 -0.2857 -0.1645 -0.1576
S-1061	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1061	Insert the white plastic spike through the ADVATE stopper .
H-1061	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
D-1061	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
P-1061	-0.7878 -0.2142 -0.3479 -1.9574 -0.8748 -0.2138 -1.2687 -0.2193 -0.1710 -0.1802 -0.0673 -0.1223 -0.1333 -0.2605 -0.1607 -0.3546 -0.0909 -0.0807 -1.0225 -0.1567 -0.1994 -0.1667 -0.1611 -0.1990 -0.2857 -0.1645 -0.1576
S-885	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-885	Insert the white plastic spike through the ADVATE stopper .
H-885	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
D-885	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
P-885	-0.7878 -0.2142 -0.3479 -1.9574 -0.8748 -0.2138 -1.2687 -0.2193 -0.1710 -0.1802 -0.0673 -0.1223 -0.1333 -0.2605 -0.1607 -0.3546 -0.0909 -0.0807 -1.0225 -0.1567 -0.1994 -0.1667 -0.1611 -0.1990 -0.2857 -0.1645 -0.1576
S-1283	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-1283	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-1283	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
D-1283	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
P-1283	-0.4941 -0.1329 -0.1500 -0.1339 -0.0734 -0.2501 -0.0506 -0.1708 -0.1148 -0.1406 -1.3398 -1.9500 -0.1470 -0.3280 -0.4519 -0.1250 -0.0641 -0.1021 -0.1223 -0.1688 -0.1227 -0.8668 -1.0162 -0.1387 -0.1722 -0.1536
S-709	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-709	Insert the white plastic spike through the ADVATE stopper .
H-709	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
D-709	-0.37106332182884216	Press the white spine of the BAXJECT II through the rubber stopper of the ADVATE bottle .
P-709	-0.7878 -0.2142 -0.3479 -1.9574 -0.8748 -0.2138 -1.2687 -0.2193 -0.1710 -0.1802 -0.0673 -0.1223 -0.1333 -0.2605 -0.1607 -0.3546 -0.0909 -0.0807 -1.0225 -0.1567 -0.1994 -0.1667 -0.1611 -0.1990 -0.2857 -0.1645 -0.1576
S-1459	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-1459	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-1459	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
D-1459	-0.34540286660194397	The dose and frequency of administration should be adjusted in line with the clinical efficacy of the product in individual cases .
P-1459	-0.4941 -0.1329 -0.1500 -0.1339 -0.0734 -0.2501 -0.0506 -0.1708 -0.1148 -0.1406 -1.3398 -1.9500 -0.1470 -0.3280 -0.4519 -0.1250 -0.0641 -0.1021 -0.1223 -0.1688 -0.1227 -0.8668 -1.0162 -0.1387 -0.1722 -0.1536
S-98	Die Patienten sollten ergänzend Calcium erhalten , sofern die Versorgung über die Nahrung nicht ausreichend ist ( siehe Abschnitt 4.4 ) .
T-98	Patients should receive supplemental calcium if intake from diet is inadequate ( see section 4.4 ) .
H-98	-0.5351423025131226	Patients should be supplemented with calcium if food is not sufficient ( see section 4.4 ) .
D-98	-0.5351423025131226	Patients should be supplemented with calcium if food is not sufficient ( see section 4.4 ) .
P-98	-1.2894 -0.1023 -0.1822 -0.7364 -2.0840 -0.0816 -0.1491 -0.1848 -0.2006 -0.1081 -0.1252 -1.1821 -1.8556 -2.3716 -0.4824 -0.6488 -0.1692 -0.1007 -0.0921 -0.1149 -0.1318 -0.1350 -0.1590 -0.1565
S-17	Der in Adenuric enthaltene Wirkstoff Feboxustat vermindert die Bildung von Harnsäure .
T-17	The active substance in Adenuric , feboxustat , reduces the formation of uric acid .
H-17	-0.33090442419052124	The active substance feboxustat in Adenuric decreases the formation of uric acid .
D-17	-0.33090442419052124	The active substance feboxustat in Adenuric decreases the formation of uric acid .
P-17	-2.5704 -0.1159 -0.1203 -0.5199 -0.4725 -0.1406 -0.1872 -0.1745 -0.1262 -0.7901 -0.2423 -0.1229 -0.0986 -0.1403 -0.5895 -0.0800 -0.5112 -0.2713 -0.1210 -0.0405 -0.0865 -0.0946 -0.1667 -0.1586
S-955	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-955	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-955	-0.38158902525901794	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
D-955	-0.38158902525901794	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
P-955	-1.1393 -0.0998 -1.0690 -0.2619 -0.6689 -0.2075 -0.0782 -0.1262 -0.0662 -0.0699 -0.1470 -0.1080 -0.9936 -1.0477 -0.1035 -0.4854 -0.1755 -0.4148 -0.2119 -0.1574
S-779	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-779	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-779	-0.38158902525901794	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
D-779	-0.38158902525901794	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
P-779	-1.1393 -0.0998 -1.0690 -0.2619 -0.6689 -0.2075 -0.0782 -0.1262 -0.0662 -0.0699 -0.1470 -0.1080 -0.9936 -1.0477 -0.1035 -0.4854 -0.1755 -0.4148 -0.2119 -0.1574
S-605	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-605	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-605	-0.38158902525901794	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
D-605	-0.38158902525901794	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
P-605	-1.1393 -0.0998 -1.0690 -0.2619 -0.6689 -0.2075 -0.0782 -0.1262 -0.0662 -0.0699 -0.1470 -0.1080 -0.9936 -1.0477 -0.1035 -0.4854 -0.1755 -0.4148 -0.2119 -0.1574
S-1856	Advexin hätte zur Behandlung von Li-Fraumeni-Krebs bei Patienten ab einem Alter von 18 Jahren angewendet werden sollen .
T-1856	Advexin was expected to be used to treat Li-Fraumeni cancer in patients from the age of 18 years .
H-1856	-0.42768439650535583	Advexin should have been used to treat Li-Fraumeni cancer in patients aged 18 years and over .
D-1856	-0.42768439650535583	Advexin should have been used to treat Li-Fraumeni cancer in patients aged 18 years and over .
P-1856	-0.6427 -0.1627 -0.1362 -0.1564 -0.2321 -0.0991 -0.3292 -0.2841 -0.1334 -2.0071 -0.2404 -0.2159 -0.0406 -0.2414 -1.4952 -0.1399 -0.3339 -1.6563 -0.1024 -0.6675 -0.2420 -0.3700 -0.1780 -0.1580
S-429	Das mittlere Steady-State-Volumen der Verteilung beträgt , den Knochen ausgenommen , mindestens 28 Liter beim Menschen .
T-429	The mean steady-state volume of distribution , exclusive of bone , is at least 28 litres in humans .
H-429	-0.4504147171974182	The mean steady-state volume of the distribution is at least 28 litres in humans , excluding bones .
D-429	-0.4504147171974182	The mean steady-state volume of the distribution is at least 28 litres in humans , excluding bones .
P-429	-0.2429 -0.2373 -0.4202 -0.3143 -0.1552 -0.9076 -0.1486 -0.0849 -0.4828 -1.0678 -0.1167 -1.2528 -0.6496 -0.1057 -0.0879 -0.3437 -1.0387 -0.1170 -0.3823 -0.4045 -0.4015 -1.1435 -0.1695 -1.1094 -0.1730 -0.1534
S-233	Das mittlere Steady-State-Volumen der Verteilung beträgt , den Knochen ausgenommen , mindestens 28 Liter beim Menschen .
T-233	The mean steady-state volume of distribution , exclusive of bone , is at least 28 litres in humans .
H-233	-0.4504147171974182	The mean steady-state volume of the distribution is at least 28 litres in humans , excluding bones .
D-233	-0.4504147171974182	The mean steady-state volume of the distribution is at least 28 litres in humans , excluding bones .
P-233	-0.2429 -0.2373 -0.4202 -0.3143 -0.1552 -0.9076 -0.1486 -0.0849 -0.4828 -1.0678 -0.1167 -1.2528 -0.6496 -0.1057 -0.0879 -0.3437 -1.0387 -0.1170 -0.3823 -0.4045 -0.4015 -1.1435 -0.1695 -1.1094 -0.1730 -0.1534
S-1408	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1408	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1408	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-1408	-0.476447731256485	Turn the opening downwards and press the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-1408	-1.3794 -0.1560 -0.2883 -0.5138 -0.4963 -0.3253 -0.1797 -1.4921 -0.2804 -0.5311 -0.5019 -1.4571 -0.0975 -0.2321 -0.1609 -0.8033 -0.0628 -0.0933 -1.4455 -0.1771 -0.6688 -0.0689 -0.1926 -0.1500 -0.1570
S-190	Bei unzureichender Sonnenbestrahlung ist es essenziell , dass Vitamin D3 ein Bestandteil der Nahrung ist .
T-190	In the absence of adequate sunlight exposure , vitamin D3 is an essential dietary nutrient .
H-190	-0.6019495129585266	In cases of insufficient sunlight , it is essential that vitamin D3 is a component of food .
D-190	-0.6019495129585266	In cases of insufficient sunlight , it is essential that vitamin D3 is a component of food .
P-190	-1.9163 -0.8643 -0.9358 -0.2270 -1.0291 -1.5979 -0.3706 -0.4696 -0.9907 -0.1637 -0.1715 -0.2911 -0.0734 -0.0795 -0.1618 -0.1357 -0.6767 -1.3264 -1.1902 -0.0991 -0.3635 -0.9693 -0.1889 -0.1547
S-42	Am 21.April 2008 erteilte die Europäische Kommission eine Genehmigung für das Inverkehrbringen von Adenuric in der gesamten Europäischen Union .
T-42	The European Commission granted a marketing authorisation valid throughout the European Union for Adenuric on 21 April 2008.
H-42	-0.33037814497947693	On 21 April 2008 , the European Commission authorised Adenuric to be marketed throughout the European Union .
D-42	-0.33037814497947693	On 21 April 2008 , the European Commission authorised Adenuric to be marketed throughout the European Union .
P-42	-0.4630 -0.8849 -0.1785 -0.1527 -0.4425 -0.1596 -0.1833 -0.1302 -1.3189 -0.1963 -1.6541 -0.1528 -0.0836 -0.1242 -0.2741 -0.1930 -0.1045 -0.0859 -0.2570 -0.1546 -0.2589 -0.1662 -0.1558 -0.1545
S-432	Biotransformation Es gibt keine Hinweise darauf , dass Alendronat beim Tier oder beim Menschen metabolisiert wird .
T-432	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
H-432	-0.18196998536586761	biotransformation There is no evidence that alendronate is metabolised in animals or humans .
D-432	-0.18196998536586761	biotransformation There is no evidence that alendronate is metabolised in animals or humans .
P-432	-0.5182 -0.0841 -0.0352 -0.1406 -0.0568 -0.4587 -0.3758 -0.0979 -0.0324 -0.3805 -0.0539 -0.1037 -0.1243 -0.0688 -0.2115 -0.1476 -0.0447 -0.0702 -0.1928 -0.4605 -0.1863 -0.1331 -0.2303 -0.1593
S-236	Biotransformation Es gibt keine Hinweise darauf , dass Alendronat beim Tier oder beim Menschen metabolisiert wird .
T-236	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
H-236	-0.18196998536586761	biotransformation There is no evidence that alendronate is metabolised in animals or humans .
D-236	-0.18196998536586761	biotransformation There is no evidence that alendronate is metabolised in animals or humans .
P-236	-0.5182 -0.0841 -0.0352 -0.1406 -0.0568 -0.4587 -0.3758 -0.0979 -0.0324 -0.3805 -0.0539 -0.1037 -0.1243 -0.0688 -0.2115 -0.1476 -0.0447 -0.0702 -0.1928 -0.4605 -0.1863 -0.1331 -0.2303 -0.1593
S-38	Die vollständige Auflistung der im Zusammenhang mit Adenuric berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-38	For the full list of all side effects reported with Adenuric , see the Package Leaflet .
H-38	-0.3108786344528198	For a full list of adverse reactions reported with Adenuric , see the Package Leaflet .
D-38	-0.3108786344528198	For a full list of adverse reactions reported with Adenuric , see the Package Leaflet .
P-38	-0.9118 -0.1277 -0.1131 -0.1015 -0.1284 -2.9615 -0.0276 -0.2925 -0.0200 -0.2300 -0.4246 -0.1113 -0.1587 -0.0868 -0.1245 -0.4168 -0.2145 -0.1922 -0.1731 -0.1401 -0.1770 -0.0293 -0.1246 -0.3314 -0.1529
S-1785	Schwere Nebenwirkungen einschließlich Atmenot , und ( Beinahe<unk> -Ohnmachten erfordern eine sofortige Notfallbehandlung .
T-1785	Severe symptoms , including difficulty in breathing and ( nearly ) fainting , require prompt emergency treatment .
H-1785	-0.41880372166633606	Severe side effects including shortness of breath , and ( near fainting require immediate emergency treatment .
D-1785	-0.41880372166633606	Severe side effects including shortness of breath , and ( near fainting require immediate emergency treatment .
P-1785	-0.5563 -0.1350 -0.9417 -0.1434 -0.1238 -3.1850 -0.0330 -0.1191 -0.0514 -0.4279 -0.1335 -0.2329 -0.0788 -0.5405 -0.1960 -0.1193 -0.9749 -0.3056 -0.1480 -0.3557 -0.2594 -0.1524
S-378	Bei unzureichender Sonnenbestrahlung ist es essenziell , dass Vitamin D3 ein Bestandteil der Nahrung ist .
T-378	In the absence of adequate sunlight exposure , vitamin D3 is an essential dietary nutrient .
H-378	-0.6019495129585266	In cases of insufficient sunlight , it is essential that vitamin D3 is a component of food .
D-378	-0.6019495129585266	In cases of insufficient sunlight , it is essential that vitamin D3 is a component of food .
P-378	-1.9163 -0.8643 -0.9358 -0.2270 -1.0291 -1.5979 -0.3706 -0.4696 -0.9907 -0.1637 -0.1715 -0.2911 -0.0734 -0.0795 -0.1618 -0.1357 -0.6767 -1.3264 -1.1902 -0.0991 -0.3635 -0.9693 -0.1889 -0.1547
S-406	4,8 , 5,4 % ) in der Gruppe mit 70 mg einmal wöchentlich und 5,4 % ( 95 % CI :
T-406	4.8 , 5.4 % ) in the 70 mg once-weekly group and 5.4 % ( 95 % CI :
H-406	-0.17067120969295502	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % ( 95 % CI :
D-406	-0.17067120969295502	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % ( 95 % CI :
P-406	-0.1366 -0.1312 -0.1715 -0.0639 -0.1516 -0.1205 -0.1349 -0.1603 -0.1533 -0.2608 -0.0290 -0.7872 -0.3687 -0.0973 -0.1469 -0.0868 -0.1360 -0.0645 -0.0928 -0.1108 -0.1538 -0.2125 -0.1545
S-1805	- Der arzneilich wirksame Bestandteil ist Octocog alfa ( Blutgerinnungsfaktor VIII vom Menschen ,
T-1805	- The active substance is octocog alfa ( human coagulation Factor VIII produced by recombinant
H-1805	-0.35655611753463745	- Octocog alfa ( human coagulation factor VIII ,
D-1805	-0.35655611753463745	- Octocog alfa ( human coagulation factor VIII ,
P-1805	-0.3753 -1.8163 -0.1163 -0.1178 -0.2373 -0.1288 -0.0675 -0.2376 -0.2292 -1.2646 -0.0618 -0.2816 -0.0442 -0.1706 -0.0751 -0.4611 -0.3764
S-1829	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
T-1829	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <<unk>> 48 22 4883 777
H-1829	-0.11821796745061874	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
D-1829	-0.11821796745061874	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
P-1829	-0.1282 -0.1213 -0.2280 -0.0796 -0.0595 -0.1003 -0.1067 -0.0627 -0.0966 -0.1282 -0.0618 -0.1452 -0.0794 -0.1908 -0.2033 -0.0782 -0.0661 -0.2863 -0.1386 -0.0316 -0.0871 -0.0938 -0.1392 -0.0771 -0.1339 -0.1115 -0.1569
S-1733	Bei Patienten mit Hämophilie A ( angeborenem Faktor VIII-Mangel ) fehlt er oder funktioniert nicht korrekt .
T-1733	In patients with haemophilia A ( inborn factor VIII deficiency ) , it is missing or not working properly .
H-1733	-0.3822595179080963	In patients with haemophilia A ( congenital factor VIII deficiency ) , it is absent or not functioning correctly .
D-1733	-0.3822595179080963	In patients with haemophilia A ( congenital factor VIII deficiency ) , it is absent or not functioning correctly .
P-1733	-0.6798 -0.6754 -0.1250 -0.1213 -0.0671 -0.0684 -0.0637 -0.1473 -0.1458 -0.3072 -0.1157 -0.1545 -0.1803 -0.4428 -0.5594 -0.9335 -0.0352 -0.0789 -0.0934 -0.1383 -1.2810 -0.4349 -0.1861 -1.1037 -0.4958 -0.1905 -1.2511 -1.1977 -0.1544 -0.6326 -0.2205 -0.1811 -0.1521
S-210	4,8 , 5,4 % ) in der Gruppe mit 70 mg einmal wöchentlich und 5,4 % ( 95 % CI :
T-210	4.8 , 5.4 % ) in the 70 mg once-weekly group and 5.4 % ( 95 % CI :
H-210	-0.17067120969295502	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % ( 95 % CI :
D-210	-0.17067120969295502	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % ( 95 % CI :
P-210	-0.1366 -0.1312 -0.1715 -0.0639 -0.1516 -0.1205 -0.1349 -0.1603 -0.1533 -0.2608 -0.0290 -0.7872 -0.3687 -0.0973 -0.1469 -0.0868 -0.1360 -0.0645 -0.0928 -0.1108 -0.1538 -0.2125 -0.1545
S-88	Therapie der postmenopausalen Osteoporose bei Patienten mit Risiko für einen Vitamin-D-Mangel .
T-88	Treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency .
H-88	-0.2631061375141144	therapy of post-menopausal osteoporosis in patients at risk of vitamin D deficiency .
D-88	-0.2631061375141144	therapy of post-menopausal osteoporosis in patients at risk of vitamin D deficiency .
P-88	-2.1601 -0.4580 -0.0782 -0.5434 -0.0784 -0.0906 -0.0313 -0.1227 -0.1800 -0.0972 -0.1033 -0.1302 -0.0886 -0.0809 -0.1351 -0.2642 -0.1364 -0.1023 -1.0378 -0.1490 -0.0436 -0.1472 -0.0390 -0.0489 -0.1511 -0.4518 -0.1547
S-565	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E.
T-565	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU
H-565	-0.2966974675655365	The calculation of the necessary Factor VIII dose is based on the empirical finding that 1 IU
D-565	-0.2966974675655365	The calculation of the necessary Factor VIII dose is based on the empirical finding that 1 IU
P-565	-0.8881 -0.3762 -0.1062 -0.0857 -0.1451 -0.3607 -1.4182 -0.6553 -0.1444 -0.0793 -0.0486 -0.1867 -0.1047 -0.1615 -0.7545 -0.1016 -0.1298 -0.1994 -0.1058 -0.3092 -0.2092 -0.1616 -0.1271 -0.0654 -0.4929
S-1591	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1591	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1591	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1591	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1591	-0.4585 -1.0442 -0.0882 -0.1936 -1.6690 -0.4855 -0.1629 -0.2880 -0.1603 -0.1235 -0.2072 -0.6146 -1.3369 -1.2228 -0.0697 -0.1870 -0.1433 -0.1230 -0.7866 -0.1593
S-1414	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1414	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1414	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1414	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1414	-0.4585 -1.0442 -0.0882 -0.1936 -1.6690 -0.4855 -0.1629 -0.2880 -0.1603 -0.1235 -0.2072 -0.6146 -1.3369 -1.2228 -0.0697 -0.1870 -0.1433 -0.1230 -0.7866 -0.1593
S-1238	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1238	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1238	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1238	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1238	-0.4585 -1.0442 -0.0882 -0.1936 -1.6690 -0.4855 -0.1629 -0.2880 -0.1603 -0.1235 -0.2072 -0.6146 -1.3369 -1.2228 -0.0697 -0.1870 -0.1433 -0.1230 -0.7866 -0.1593
S-1062	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1062	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1062	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1062	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1062	-0.4585 -1.0442 -0.0882 -0.1936 -1.6690 -0.4855 -0.1629 -0.2880 -0.1603 -0.1235 -0.2072 -0.6146 -1.3369 -1.2228 -0.0697 -0.1870 -0.1433 -0.1230 -0.7866 -0.1593
S-886	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-886	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-886	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-886	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-886	-0.4585 -1.0442 -0.0882 -0.1936 -1.6690 -0.4855 -0.1629 -0.2880 -0.1603 -0.1235 -0.2072 -0.6146 -1.3369 -1.2228 -0.0697 -0.1870 -0.1433 -0.1230 -0.7866 -0.1593
S-1963	Diese Wirkungen sind bei Kindern , älteren Patienten oder im Falle einer Überdosierung wahrscheinlicher ( siehe Abschnitt 4.9 ) .
T-1963	These effects may be more likely to occur in children , elderly patients , or in cases of overdose ( see section 4.9 ) .
H-1963	-0.3130810260772705	These effects are more likely in paediatric , elderly patients , or in case of overdose ( see section 4.9 ) .
D-1963	-0.3130810260772705	These effects are more likely in paediatric , elderly patients , or in case of overdose ( see section 4.9 ) .
P-1963	-0.5251 -0.1191 -0.1619 -0.1848 -0.5905 -0.1748 -0.9859 -0.0103 -0.0315 -0.1237 -0.1661 -0.0854 -0.2837 -0.9549 -0.2185 -0.4616 -2.2439 -0.1203 -0.2433 -0.0515 -0.1636 -0.0984 -0.0841 -0.1132 -0.1164 -0.1343 -0.1657 -0.1537
S-455	Es wurden keine nicht-klinischen Studien mit der Kombination von Alendronat und Colecalciferol durchgeführt .
T-455	Non-clinical studies with the combination of alendronate and colecalciferol have not been conducted .
H-455	-0.2992127239704132	No non-clinical trials of the combination of alendronate and colecalciferol were conducted .
D-455	-0.2992127239704132	No non-clinical trials of the combination of alendronate and colecalciferol were conducted .
P-455	-0.1926 -0.8309 -0.4311 -0.0867 -0.7586 -0.8359 -0.6162 -0.3050 -0.1411 -0.1801 -0.1011 -0.1103 -0.0597 -0.1546 -0.1167 -0.1338 -0.1804 -0.1216 -0.1217 -0.1387 -0.8163 -0.4302 -0.1625 -0.1551
S-1373	52 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1373	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1373	-0.44739535450935364	52 data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
D-1373	-0.44739535450935364	52 data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
P-1373	-1.3203 -0.9021 -0.7340 -0.4289 -0.7803 -0.9464 -0.9446 -0.8587 -0.1280 -0.0714 -0.1482 -0.0889 -0.0839 -0.1708 -0.1033 -0.2008 -0.3215 -0.2496 -0.1242 -0.5239 -0.0764 -0.3712 -0.1688 -0.3032 -2.2305 -0.3404 -0.1429 -0.3092 -0.1951 -0.1542
S-1197	41 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1197	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1197	-0.39700427651405334	Data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
D-1197	-0.39700427651405334	Data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
P-1197	-1.0400 -0.4718 -0.3319 -0.5763 -0.9231 -0.9552 -0.8826 -0.1269 -0.0729 -0.1483 -0.0886 -0.0850 -0.1634 -0.1089 -0.1942 -0.3328 -0.2627 -0.1106 -0.4318 -0.0770 -0.3451 -0.2045 -0.2607 -2.2274 -0.3501 -0.1434 -0.2713 -0.1733 -0.1532
S-1984	In einer klinisch- pharmakologischen Studie wurde bei gleichzeitiger Einnahme von Desloratadin und Alkohol die
T-1984	However , in a clinical pharmacology trial desloratadine taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol .
H-1984	-0.44473031163215637	In a clinical pharmacological trial , the concomitant administration of desloratadine and alcohol
D-1984	-0.44473031163215637	In a clinical pharmacological trial , the concomitant administration of desloratadine and alcohol
P-1984	-0.8716 -0.1471 -0.1379 -0.2201 -0.3578 -1.1861 -0.9435 -1.3370 -1.1726 -0.0216 -0.0166 -0.2058 -0.3774 -0.1267 -0.2820 -0.0553 -0.1102 -0.1853 -0.6235 -0.1738 -0.3163 -0.9159
S-1600	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1600	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1600	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
D-1600	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
P-1600	-2.5878 -0.0568 -0.1013 -0.2851 -0.5511 -0.0683 -1.1033 -0.1259 -0.1969 -0.1468 -0.1765 -0.0875 -0.0378 -0.0132 -0.1430 -0.1791 -0.6635 -0.7684 -0.2057 -1.0360 -0.0844 -0.1147 -0.0848 -0.1528 -0.1553
S-1550	63 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1550	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1550	-0.41789087653160095	63 data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
D-1550	-0.41789087653160095	63 data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
P-1550	-0.4462 -0.9144 -0.8160 -0.4607 -0.6946 -0.9612 -0.9322 -0.8479 -0.1278 -0.0710 -0.1496 -0.0900 -0.0837 -0.1729 -0.1016 -0.2010 -0.3166 -0.2570 -0.1276 -0.5349 -0.0775 -0.3786 -0.1808 -0.3061 -2.1450 -0.3444 -0.1425 -0.3130 -0.1887 -0.1535
S-1423	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1423	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1423	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
D-1423	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
P-1423	-2.5878 -0.0568 -0.1013 -0.2851 -0.5511 -0.0683 -1.1033 -0.1259 -0.1969 -0.1468 -0.1765 -0.0875 -0.0378 -0.0132 -0.1430 -0.1791 -0.6635 -0.7684 -0.2057 -1.0360 -0.0844 -0.1147 -0.0848 -0.1528 -0.1553
S-669	8 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-669	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-669	-0.40923693776130676	Data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
D-669	-0.40923693776130676	Data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
P-669	-1.0890 -0.6331 -0.3765 -0.6540 -0.9296 -0.9493 -0.7701 -0.1283 -0.0735 -0.1488 -0.0881 -0.0837 -0.1670 -0.1117 -0.2026 -0.3390 -0.2687 -0.1091 -0.4446 -0.0771 -0.3570 -0.2119 -0.2870 -2.2383 -0.3614 -0.1457 -0.2915 -0.1772 -0.1537
S-1247	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1247	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1247	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
D-1247	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
P-1247	-2.5878 -0.0568 -0.1013 -0.2851 -0.5511 -0.0683 -1.1033 -0.1259 -0.1969 -0.1468 -0.1765 -0.0875 -0.0378 -0.0132 -0.1430 -0.1791 -0.6635 -0.7684 -0.2057 -1.0360 -0.0844 -0.1147 -0.0848 -0.1528 -0.1553
S-719	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-719	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-719	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
D-719	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
P-719	-2.5878 -0.0568 -0.1013 -0.2851 -0.5511 -0.0683 -1.1033 -0.1259 -0.1969 -0.1468 -0.1765 -0.0875 -0.0378 -0.0132 -0.1430 -0.1791 -0.6635 -0.7684 -0.2057 -1.0360 -0.0844 -0.1147 -0.0848 -0.1528 -0.1553
S-1071	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1071	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1071	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
D-1071	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
P-1071	-2.5878 -0.0568 -0.1013 -0.2851 -0.5511 -0.0683 -1.1033 -0.1259 -0.1969 -0.1468 -0.1765 -0.0875 -0.0378 -0.0132 -0.1430 -0.1791 -0.6635 -0.7684 -0.2057 -1.0360 -0.0844 -0.1147 -0.0848 -0.1528 -0.1553
S-1021	30 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1021	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1021	-0.4501816928386688	30 data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
D-1021	-0.4501816928386688	30 data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
P-1021	-0.6995 -1.3290 -0.8509 -0.4970 -0.7472 -0.9674 -0.9764 -0.8533 -0.1278 -0.0714 -0.1494 -0.0898 -0.0843 -0.1716 -0.1056 -0.2025 -0.3437 -0.2595 -0.1264 -0.5347 -0.0777 -0.3892 -0.1885 -0.2956 -2.1904 -0.3482 -0.1435 -0.3264 -0.2059 -0.1526
S-895	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-895	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-895	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
D-895	-0.36504799127578735	Connect the perfusion cutlery to the syringe and inject the product intravenously .
P-895	-2.5878 -0.0568 -0.1013 -0.2851 -0.5511 -0.0683 -1.1033 -0.1259 -0.1969 -0.1468 -0.1765 -0.0875 -0.0378 -0.0132 -0.1430 -0.1791 -0.6635 -0.7684 -0.2057 -1.0360 -0.0844 -0.1147 -0.0848 -0.1528 -0.1553
S-845	19 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-845	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-845	-0.43713587522506714	Data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
D-845	-0.43713587522506714	Data from a one @-@ time administration of ADVATE in 53 children under 6 years of age were used to compile this table .
P-845	-1.9091 -0.5853 -0.4027 -0.6220 -0.9324 -0.9311 -0.7746 -0.1277 -0.0710 -0.1498 -0.0879 -0.0838 -0.1616 -0.1096 -0.1994 -0.3320 -0.2779 -0.1130 -0.4653 -0.0780 -0.3969 -0.2038 -0.2805 -2.2474 -0.3617 -0.1441 -0.2981 -0.1768 -0.1531
S-710	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-710	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-710	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-710	-0.4762090742588043	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-710	-0.4585 -1.0442 -0.0882 -0.1936 -1.6690 -0.4855 -0.1629 -0.2880 -0.1603 -0.1235 -0.2072 -0.6146 -1.3369 -1.2228 -0.0697 -0.1870 -0.1433 -0.1230 -0.7866 -0.1593
S-522	Der Wirkstoff in Advate , Octocog alfa , ist ein Protein des Blutgerinnungsfaktors .
T-522	The active substance in Advate , octocog alfa , is a blood coagulation factor protein .
H-522	-0.311033695936203	The active substance in Advate , Octocog alfa , is a protein in the blood clotting factor .
D-522	-0.311033695936203	The active substance in Advate , Octocog alfa , is a protein in the blood clotting factor .
P-522	-0.2355 -0.1026 -0.1385 -0.1605 -0.5065 -0.0960 -0.1702 -0.8743 -0.1052 -0.1216 -0.2290 -0.1247 -0.0656 -0.2249 -0.1500 -0.1293 -0.7556 -1.3420 -0.2513 -0.3968 -1.2890 -0.0252 -0.0823 -0.1685 -0.1885 -0.1531
S-259	Es wurden keine nicht-klinischen Studien mit der Kombination von Alendronat und Colecalciferol durchgeführt .
T-259	Non-clinical studies with the combination of alendronate and colecalciferol have not been conducted .
H-259	-0.2992127239704132	No non-clinical trials of the combination of alendronate and colecalciferol were conducted .
D-259	-0.2992127239704132	No non-clinical trials of the combination of alendronate and colecalciferol were conducted .
P-259	-0.1926 -0.8309 -0.4311 -0.0867 -0.7586 -0.8359 -0.6162 -0.3050 -0.1411 -0.1801 -0.1011 -0.1103 -0.0597 -0.1546 -0.1167 -0.1338 -0.1804 -0.1216 -0.1217 -0.1387 -0.8163 -0.4302 -0.1625 -0.1551
S-520	Die Dosierung wird darüber hinaus je nach Schweregrad der Blutung und Art des chirurgischen Eingriffes angepasst .
T-520	The dose is also adjusted depending on the severity of the haemorrhage or the type of surgery .
H-520	-0.52716463804245	The dosage is also adjusted according to the severity of the bleeding and type of surgery .
D-520	-0.52716463804245	The dosage is also adjusted according to the severity of the bleeding and type of surgery .
P-520	-1.2369 -0.7027 -0.0876 -0.1020 -0.6791 -0.8028 -0.1573 -2.5874 -0.1310 -0.3590 -0.3121 -0.1209 -0.1319 -0.8471 -0.7034 -0.2238 -0.1249 -1.4472 -0.1169 -0.1501 -0.4196 -0.1537
S-1026	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1026	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1026	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1026	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1026	-1.2211 -0.5271 -0.0571 -0.2115 -0.0634 -0.0777 -0.2371 -0.2781 -0.6006 -0.5411 -0.2169 -0.1224 -0.0681 -0.1464 -0.0806 -0.0835 -0.1356 -0.1191 -0.0839 -0.0786 -0.1720 -0.1680 -0.1542
S-239	Die Plasmakonzentrationen fielen um mehr als 95 % innerhalb von sechs Stunden nach intravenöser Gabe .
T-239	Plasma concentrations fell by more than 95 % within six hours following intravenous administration .
H-239	-0.3413933515548706	plasma concentrations decreased by more than 95 % within six hours after intravenous administration .
D-239	-0.3413933515548706	plasma concentrations decreased by more than 95 % within six hours after intravenous administration .
P-239	-0.8276 -0.0502 -0.0816 -0.0732 -0.0566 -0.0567 -2.0218 -0.0702 -0.1770 -0.5123 -0.1138 -0.1029 -0.1440 -0.3225 -0.3190 -0.0836 -1.0035 -1.4774 -0.0727 -0.0766 -0.1312 -0.0452 -0.2210 -0.1530
S-435	Die Plasmakonzentrationen fielen um mehr als 95 % innerhalb von sechs Stunden nach intravenöser Gabe .
T-435	Plasma concentrations fell by more than 95 % within six hours following intravenous administration .
H-435	-0.3413933515548706	plasma concentrations decreased by more than 95 % within six hours after intravenous administration .
D-435	-0.3413933515548706	plasma concentrations decreased by more than 95 % within six hours after intravenous administration .
P-435	-0.8276 -0.0502 -0.0816 -0.0732 -0.0566 -0.0567 -2.0218 -0.0702 -0.1770 -0.5123 -0.1138 -0.1029 -0.1440 -0.3225 -0.3190 -0.0836 -1.0035 -1.4774 -0.0727 -0.0766 -0.1312 -0.0452 -0.2210 -0.1530
S-383	Ein Vitamin-D-Mangel entsteht , wenn Sonnenbestrahlung und Aufnahme aus der Nahrung unzureichend sind .
T-383	Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate .
H-383	-0.4638102948665619	D deficiency occurs when insufficient exposure to the sun and food intake .
D-383	-0.4638102948665619	D deficiency occurs when insufficient exposure to the sun and food intake .
P-383	-0.3088 -0.0387 -0.0299 -0.1250 -1.1878 -0.0624 -0.1978 -0.7876 -0.9030 -1.8057 -0.1898 -0.8758 -0.1304 -0.1392 -0.8317 -0.3516 -0.0924 -0.6003 -0.1545
S-674	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-674	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-674	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-674	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-674	-1.2211 -0.5271 -0.0571 -0.2115 -0.0634 -0.0777 -0.2371 -0.2781 -0.6006 -0.5411 -0.2169 -0.1224 -0.0681 -0.1464 -0.0806 -0.0835 -0.1356 -0.1191 -0.0839 -0.0786 -0.1720 -0.1680 -0.1542
S-73	Hauptindikator der Wirksamkeit war der Prozentsatz der Patienten mit geringem Vitamin-D-Spiegel .
T-73	The main measure of effectiveness was the percentage of patients with low vitamin D levels .
H-73	-0.503904402256012	The main measure of efficacy was the percentage of patients with low D levels .
D-73	-0.503904402256012	The main measure of efficacy was the percentage of patients with low D levels .
P-73	-0.3086 -1.5567 -1.0538 -0.1330 -0.3078 -0.0798 -0.0855 -0.2069 -0.3001 -0.3610 -0.1310 -0.2619 -0.2628 -0.8805 -0.7777 -1.5526 -0.6577 -0.1529
S-850	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-850	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-850	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-850	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-850	-1.2211 -0.5271 -0.0571 -0.2115 -0.0634 -0.0777 -0.2371 -0.2781 -0.6006 -0.5411 -0.2169 -0.1224 -0.0681 -0.1464 -0.0806 -0.0835 -0.1356 -0.1191 -0.0839 -0.0786 -0.1720 -0.1680 -0.1542
S-1202	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1202	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1202	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1202	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1202	-1.2211 -0.5271 -0.0571 -0.2115 -0.0634 -0.0777 -0.2371 -0.2781 -0.6006 -0.5411 -0.2169 -0.1224 -0.0681 -0.1464 -0.0806 -0.0835 -0.1356 -0.1191 -0.0839 -0.0786 -0.1720 -0.1680 -0.1542
S-1378	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1378	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1378	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1378	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1378	-1.2211 -0.5271 -0.0571 -0.2115 -0.0634 -0.0777 -0.2371 -0.2781 -0.6006 -0.5411 -0.2169 -0.1224 -0.0681 -0.1464 -0.0806 -0.0835 -0.1356 -0.1191 -0.0839 -0.0786 -0.1720 -0.1680 -0.1542
S-1555	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1555	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1555	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1555	-0.2367030531167984	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1555	-1.2211 -0.5271 -0.0571 -0.2115 -0.0634 -0.0777 -0.2371 -0.2781 -0.6006 -0.5411 -0.2169 -0.1224 -0.0681 -0.1464 -0.0806 -0.0835 -0.1356 -0.1191 -0.0839 -0.0786 -0.1720 -0.1680 -0.1542
S-195	Ein Vitamin-D-Mangel entsteht , wenn Sonnenbestrahlung und Aufnahme aus der Nahrung unzureichend sind .
T-195	Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate .
H-195	-0.4638102948665619	D deficiency occurs when insufficient exposure to the sun and food intake .
D-195	-0.4638102948665619	D deficiency occurs when insufficient exposure to the sun and food intake .
P-195	-0.3088 -0.0387 -0.0299 -0.1250 -1.1878 -0.0624 -0.1978 -0.7876 -0.9030 -1.8057 -0.1898 -0.8758 -0.1304 -0.1392 -0.8317 -0.3516 -0.0924 -0.6003 -0.1545
S-1939	Ovale Tablette mit einer blauen und einer weißen Schicht , die blaue Schicht trägt die Prägung D12 .
T-1939	Blue and white bilayer oval tablet with D12 branded to blue layer .
H-1939	-0.36148491501808167	Oval tablet with a blue and a white layer , the blue layer is marked D12 .
D-1939	-0.36148491501808167	Oval tablet with a blue and a white layer , the blue layer is marked D12 .
P-1939	-0.1699 -0.2604 -0.1159 -0.2522 -0.3080 -0.1095 -0.1916 -0.5749 -0.0707 -0.7853 -0.2742 -0.2364 -0.0960 -0.5904 -1.5883 -0.1527 -0.9720 -0.1260 -0.1892 -0.1661
S-1206	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1206	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1206	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1206	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1206	-1.5975 -0.2764 -0.1830 -1.5176 -0.4111 -0.1622 -0.1538 -0.2088 -1.0790 -0.8173 -0.2798 -0.2605 -0.6327 -0.1682 -0.1143 -0.2186 -0.2717 -0.1158 -0.1535 -0.4063 -0.1616
S-1030	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1030	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1030	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1030	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1030	-1.5975 -0.2764 -0.1830 -1.5176 -0.4111 -0.1622 -0.1538 -0.2088 -1.0790 -0.8173 -0.2798 -0.2605 -0.6327 -0.1682 -0.1143 -0.2186 -0.2717 -0.1158 -0.1535 -0.4063 -0.1616
S-678	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-678	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-678	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-678	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-678	-1.5975 -0.2764 -0.1830 -1.5176 -0.4111 -0.1622 -0.1538 -0.2088 -1.0790 -0.8173 -0.2798 -0.2605 -0.6327 -0.1682 -0.1143 -0.2186 -0.2717 -0.1158 -0.1535 -0.4063 -0.1616
S-1382	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1382	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1382	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1382	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1382	-1.5975 -0.2764 -0.1830 -1.5176 -0.4111 -0.1622 -0.1538 -0.2088 -1.0790 -0.8173 -0.2798 -0.2605 -0.6327 -0.1682 -0.1143 -0.2186 -0.2717 -0.1158 -0.1535 -0.4063 -0.1616
S-1559	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1559	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1559	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1559	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1559	-1.5975 -0.2764 -0.1830 -1.5176 -0.4111 -0.1622 -0.1538 -0.2088 -1.0790 -0.8173 -0.2798 -0.2605 -0.6327 -0.1682 -0.1143 -0.2186 -0.2717 -0.1158 -0.1535 -0.4063 -0.1616
S-1764	Wenn Sie den Eindruck haben , dass die Wirkung von ADVATE unzureichend ist , informieren Sie Ihren Arzt .
T-1764	If you have the impression that the effect of ADVATE is insufficient , talk to your doctor .
H-1764	-0.3713259696960449	If you feel that the effect of ADVATE is inadequate , tell your doctor .
D-1764	-0.3713259696960449	If you feel that the effect of ADVATE is inadequate , tell your doctor .
P-1764	-0.1911 -0.1329 -1.4572 -0.9883 -0.9004 -0.4890 -0.1300 -0.0924 -0.1455 -0.0893 -0.0894 -0.2093 -0.2638 -1.0448 -0.1940 -0.3881 -0.1369 -0.1174 -0.2003 -0.1663
S-854	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-854	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-854	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-854	-0.43759685754776	After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-854	-1.5975 -0.2764 -0.1830 -1.5176 -0.4111 -0.1622 -0.1538 -0.2088 -1.0790 -0.8173 -0.2798 -0.2605 -0.6327 -0.1682 -0.1143 -0.2186 -0.2717 -0.1158 -0.1535 -0.4063 -0.1616
S-512	Advate besteht aus einem Pulver und einem Lösungsmittel , die zur Herstellung einer Injektionslösung gemischt werden .
T-512	Advate is a powder and solvent that are mixed together to make a solution for injection .
H-512	-0.2980623245239258	Advate consists of a powder and a solvent mixed to produce a solution for injection .
D-512	-0.2980623245239258	Advate consists of a powder and a solvent mixed to produce a solution for injection .
P-512	-0.4262 -0.0966 -0.1294 -0.1100 -0.1331 -0.1370 -0.1307 -0.1545 -0.3297 -0.1705 -0.1760 -1.6142 -0.3305 -1.2973 -0.3196 -0.0549 -0.1100 -0.1123 -0.0664 -0.2002 -0.1602
S-518	Advate wird durch eine Injektion in eine Vene mit einer Geschwindigkeit von bis zu 10 ml pro Minute verabreicht .
T-518	Advate is given by injection into a vein at a rate of up to 10 ml per minute .
H-518	-0.23878265917301178	Advate is administered by injection into a vein at a rate of up to 10 ml per minute .
D-518	-0.23878265917301178	Advate is administered by injection into a vein at a rate of up to 10 ml per minute .
P-518	-0.4064 -0.0893 -0.1488 -1.1540 -0.1218 -0.2093 -0.1940 -0.0825 -0.1311 -0.1282 -0.0625 -0.0576 -0.1766 -0.4910 -0.7150 -0.1529 -0.3536 -0.1208 -0.1933 -0.1005 -0.1224 -0.1766 -0.1817 -0.1607
S-1890	Das Schreiben , in dem das Unternehmen die EMEA über die Rücknahme des Antrags informiert , kann hier aufgerufen werden .
T-1890	The letter from the company notifying the EMEA of the withdrawal of the application is available here .
H-1890	-0.49001243710517883	The letter informing EMEA of the withdrawal of the application can be found here .
D-1890	-0.49001243710517883	The letter informing EMEA of the withdrawal of the application can be found here .
P-1890	-0.4781 -0.6104 -2.0210 -0.2158 -0.3639 -0.0599 -0.1197 -1.1452 -0.4503 -0.3072 -0.2431 -0.3184 -0.4197 -1.0413 -0.1630 -0.7727 -0.1219 -0.3037 -0.1550
S-1769	Möglicherweise werden Sie höhere ADVATE-Dosen oder sogar ein anderes Produkt benötigen , um die Blutungen zu kontrollieren .
T-1769	You might need a higher dose of ADVATE or even a different product to control bleedings .
H-1769	-0.37448805570602417	You may need higher ADVATE doses or even another product to control bleeding .
D-1769	-0.37448805570602417	You may need higher ADVATE doses or even another product to control bleeding .
P-1769	-0.9952 -0.2073 -0.3358 -0.2480 -0.8725 -0.1609 -0.1177 -0.1714 -0.2770 -0.0786 -1.1155 -0.1737 -0.9230 -0.1056 -0.1656 -0.2704 -0.8215 -0.1244 -0.1673 -0.1583
S-542	Die vollständige Auflistung der im Zusammenhang mit Advate berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-542	For the full list of all side effects reported with Advate , see the Package Leaflet .
H-542	-0.30732694268226624	For a full list of reported adverse reactions associated with Advate , see the Package Leaflet .
D-542	-0.30732694268226624	For a full list of reported adverse reactions associated with Advate , see the Package Leaflet .
P-542	-1.0032 -0.1309 -0.1287 -0.1230 -0.1281 -0.1464 -1.2256 -0.0138 -0.3615 -0.0236 -1.5443 -0.1408 -0.3686 -0.0829 -0.4329 -0.2378 -0.2261 -0.1839 -0.1377 -0.1432 -0.0227 -0.1222 -0.2955 -0.1525
S-639	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-639	6 The immunogenicity of ADVATE was evaluated in previously treated patients .
H-639	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-639	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-639	-1.0211 -0.0557 -0.0885 -0.1998 -0.2655 -1.1419 -0.4083 -0.1838 -0.1274 -0.0676 -0.0893 -0.1347 -0.1234 -0.0842 -0.1461 -0.0836 -0.0983 -0.9414 -0.5087 -0.1124 -0.1143 -0.1479 -0.1588 -0.2358 -0.2117 -0.1548
S-517	Die Behandlung mit Advate sollte von einem Arzt eingeleitet werden , der über Erfahrung in der Behandlung von Hämophilie verfügt .
T-517	Advate should be started by a doctor who has experience in the treatment of haemophilia .
H-517	-0.26175224781036377	Treatment with Advate should be initiated by a doctor with experience in the treatment of haemophilia .
D-517	-0.26175224781036377	Treatment with Advate should be initiated by a doctor with experience in the treatment of haemophilia .
P-517	-0.9134 -0.0590 -0.1137 -0.1786 -0.3336 -0.0901 -0.1321 -0.1205 -0.0739 -0.0940 -0.1601 -0.1421 -0.9919 -0.4325 -0.2395 -0.3035 -1.0426 -0.2231 -0.1183 -0.1572 -0.0874 -0.0721 -0.1379 -0.1684 -0.1582
S-1341	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-1341	46 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-1341	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-1341	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-1341	-1.0211 -0.0557 -0.0885 -0.1998 -0.2655 -1.1419 -0.4083 -0.1838 -0.1274 -0.0676 -0.0893 -0.1347 -0.1234 -0.0842 -0.1461 -0.0836 -0.0983 -0.9414 -0.5087 -0.1124 -0.1143 -0.1479 -0.1588 -0.2358 -0.2117 -0.1548
S-245	Verteilung Nach der Resorption geht Vitamin D3 als Bestandteil von Chylomikronen ins Blut über .
T-245	Distribution Following absorption , vitamin D3 enters the blood as part of chylomicrons .
H-245	-0.28461340069770813	Distribution After absorption , vitamin D3 is absorbed into the blood as a component of chylomicrons .
D-245	-0.28461340069770813	Distribution After absorption , vitamin D3 is absorbed into the blood as a component of chylomicrons .
P-245	-0.8286 -0.0988 -1.0190 -0.0979 -0.0913 -0.5263 -0.1053 -0.0781 -0.1541 -0.1402 -0.5990 -0.7321 -0.0569 -0.6147 -0.1501 -0.1281 -0.1902 -0.1994 -0.7252 -0.1062 -0.2100 -0.1496 -0.1625 -0.1363 -0.1118 -0.1892 -0.3055 -0.1937 -0.1537
S-1730	WAS IST ADVATE UND WOFÜR WIRD ES ANGEWENDET ?
T-1730	WHAT ADVATE IS AND WHAT IT IS USED FOR
H-1730	-0.37574833631515503	WHAT ADVATE IS AND WHAT IT IS USED FOR
D-1730	-0.37574833631515503	WHAT ADVATE IS AND WHAT IT IS USED FOR
P-1730	-1.0126 -0.0233 -0.4362 -0.1851 -0.1607 -0.1030 -0.2326 -1.4112 -0.3121 -0.2118 -0.8477 -0.0971 -0.0715 -0.0415 -0.1930 -0.0724 -0.9759
S-1998	Es wird nicht erwartet , dass Pseudoephedrinsulfat die psychomotorische Leistungsfähigkeit beeinträchtigt .
T-1998	It is not expected that pseudoephedrine sulphate impairs psychomotor performance .
H-1998	-0.3584425747394562	Pseudoephedrine sulphate is not expected to affect psychomotor performance .
D-1998	-0.3584425747394562	Pseudoephedrine sulphate is not expected to affect psychomotor performance .
P-1998	-0.3673 -0.0789 -0.1501 -0.4514 -0.1323 -0.1376 -0.1524 -0.0891 -0.5729 -0.0946 -0.2244 -0.1481 -0.3066 -0.1317 -1.1718 -0.6278 -0.1880 -0.2103 -0.4263 -1.8689 -0.2013 -0.1541
S-695	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-695	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-695	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
D-695	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
P-695	-0.3322 -0.1261 -0.1251 -0.0486 -0.4525 -0.1370 -0.1540 -0.2029 -0.1187 -0.1130 -0.1984 -1.0660 -1.0317 -0.8621 -0.2193 -0.1657 -0.0344 -0.0944 -1.0707 -0.4735 -1.2688 -0.0823 -0.4752 -0.1778
S-1835	elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
T-1835	elezna cesta 14 SI-1000 Ljubljana Tel . : <<unk>> 386 1 420 16 80
H-1835	-0.11469321697950363	elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
D-1835	-0.11469321697950363	elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
P-1835	-0.1133 -0.0927 -0.1017 -0.1432 -0.0875 -0.1367 -0.0990 -0.1220 -0.0886 -0.0634 -0.1273 -0.0678 -0.1178 -0.0902 -0.0650 -0.2053 -0.1405 -0.0405 -0.1078 -0.1335 -0.1290 -0.1761 -0.1154 -0.1087 -0.1511 -0.1579
S-1737	- wenn Sie allergisch ( überempfindlich ) gegen Octocog alfa oder einem der sonstigen Bestandteile
T-1737	- if you are allergic ( hypersensitive ) to octocog alfa or any of the other ingredients of ADVATE
H-1737	-0.21961502730846405	- if you are allergic ( hypersensitive ) to Octocog alfa or any of the ingredients
D-1737	-0.21961502730846405	- if you are allergic ( hypersensitive ) to Octocog alfa or any of the ingredients
P-1737	-0.4898 -0.1077 -0.1084 -0.1369 -0.1429 -0.0346 -0.2314 -0.1357 -0.2235 -0.1507 -0.1351 -1.0940 -0.1230 -0.1183 -0.2674 -0.1168 -0.0569 -0.1979 -0.3723 -0.1308 -0.2539 -0.2689 -0.1541
S-1576	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1576	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1576	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
D-1576	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
P-1576	-0.3322 -0.1261 -0.1251 -0.0486 -0.4525 -0.1370 -0.1540 -0.2029 -0.1187 -0.1130 -0.1984 -1.0660 -1.0317 -0.8621 -0.2193 -0.1657 -0.0344 -0.0944 -1.0707 -0.4735 -1.2688 -0.0823 -0.4752 -0.1778
S-1399	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1399	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1399	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
D-1399	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
P-1399	-0.3322 -0.1261 -0.1251 -0.0486 -0.4525 -0.1370 -0.1540 -0.2029 -0.1187 -0.1130 -0.1984 -1.0660 -1.0317 -0.8621 -0.2193 -0.1657 -0.0344 -0.0944 -1.0707 -0.4735 -1.2688 -0.0823 -0.4752 -0.1778
S-1223	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1223	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1223	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
D-1223	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
P-1223	-0.3322 -0.1261 -0.1251 -0.0486 -0.4525 -0.1370 -0.1540 -0.2029 -0.1187 -0.1130 -0.1984 -1.0660 -1.0317 -0.8621 -0.2193 -0.1657 -0.0344 -0.0944 -1.0707 -0.4735 -1.2688 -0.0823 -0.4752 -0.1778
S-1047	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1047	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1047	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
D-1047	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
P-1047	-0.3322 -0.1261 -0.1251 -0.0486 -0.4525 -0.1370 -0.1540 -0.2029 -0.1187 -0.1130 -0.1984 -1.0660 -1.0317 -0.8621 -0.2193 -0.1657 -0.0344 -0.0944 -1.0707 -0.4735 -1.2688 -0.0823 -0.4752 -0.1778
S-871	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-871	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-871	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
D-871	-0.37626442313194275	- Do not use the BAXJECT II unit set if its sterile barrier has been breached ,
P-871	-0.3322 -0.1261 -0.1251 -0.0486 -0.4525 -0.1370 -0.1540 -0.2029 -0.1187 -0.1130 -0.1984 -1.0660 -1.0317 -0.8621 -0.2193 -0.1657 -0.0344 -0.0944 -1.0707 -0.4735 -1.2688 -0.0823 -0.4752 -0.1778
S-15	Die Wirksamkeit und Sicherheit von Adenuric wurden bei Patienten mit schweren Nieren- oder Leberproblemen nicht untersucht .
T-15	The safety and effectiveness of Adenuric have not been studied in patients with severe kidney or liver problems .
H-15	-0.21637959778308868	The efficacy and safety of Adenuric have not been evaluated in patients with severe renal or liver problems .
D-15	-0.21637959778308868	The efficacy and safety of Adenuric have not been evaluated in patients with severe renal or liver problems .
P-15	-0.4347 -0.0423 -0.0663 -0.0821 -0.1566 -0.0344 -0.1235 -0.1329 -0.1661 -0.0927 -0.1317 -0.7767 -0.1099 -0.1089 -0.4050 -0.1227 -0.1325 -0.3031 -0.1721 -0.3835 -0.2025 -0.1108 -0.2053 -0.7587 -0.2672 -0.1663 -0.1537
S-1860	Der Wirkstoff in Advexin , Contusugene Ladenovec , ist ein viraler Vektor .
T-1860	The active substance in Advexin , contusugene ladenovec , is a viral vector .
H-1860	-0.19451811909675598	The active substance in Advexin , Contusugene Ladenovec , is a viral vector .
D-1860	-0.19451811909675598	The active substance in Advexin , Contusugene Ladenovec , is a viral vector .
P-1860	-0.2380 -0.1313 -0.1591 -0.1608 -0.6952 -0.1299 -0.1370 -0.1549 -0.1533 -0.1760 -0.1152 -0.1301 -0.7049 -0.1329 -0.0988 -0.1408 -0.1807 -0.1508 -0.1117 -0.2422 -0.0561 -0.1176 -0.1962 -0.1551
S-1518	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-1518	56 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-1518	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-1518	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-1518	-1.0211 -0.0557 -0.0885 -0.1998 -0.2655 -1.1419 -0.4083 -0.1838 -0.1274 -0.0676 -0.0893 -0.1347 -0.1234 -0.0842 -0.1461 -0.0836 -0.0983 -0.9414 -0.5087 -0.1124 -0.1143 -0.1479 -0.1588 -0.2358 -0.2117 -0.1548
S-1165	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-1165	36 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-1165	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-1165	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-1165	-1.0211 -0.0557 -0.0885 -0.1998 -0.2655 -1.1419 -0.4083 -0.1838 -0.1274 -0.0676 -0.0893 -0.1347 -0.1234 -0.0842 -0.1461 -0.0836 -0.0983 -0.9414 -0.5087 -0.1124 -0.1143 -0.1479 -0.1588 -0.2358 -0.2117 -0.1548
S-813	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-813	16 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-813	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-813	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-813	-1.0211 -0.0557 -0.0885 -0.1998 -0.2655 -1.1419 -0.4083 -0.1838 -0.1274 -0.0676 -0.0893 -0.1347 -0.1234 -0.0842 -0.1461 -0.0836 -0.0983 -0.9414 -0.5087 -0.1124 -0.1143 -0.1479 -0.1588 -0.2358 -0.2117 -0.1548
S-989	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-989	26 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-989	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-989	-0.2655653953552246	inhibitor development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-989	-1.0211 -0.0557 -0.0885 -0.1998 -0.2655 -1.1419 -0.4083 -0.1838 -0.1274 -0.0676 -0.0893 -0.1347 -0.1234 -0.0842 -0.1461 -0.0836 -0.0983 -0.9414 -0.5087 -0.1124 -0.1143 -0.1479 -0.1588 -0.2358 -0.2117 -0.1548
S-441	Verteilung Nach der Resorption geht Vitamin D3 als Bestandteil von Chylomikronen ins Blut über .
T-441	Distribution Following absorption , vitamin D3 enters the blood as part of chylomicrons .
H-441	-0.28461340069770813	Distribution After absorption , vitamin D3 is absorbed into the blood as a component of chylomicrons .
D-441	-0.28461340069770813	Distribution After absorption , vitamin D3 is absorbed into the blood as a component of chylomicrons .
P-441	-0.8286 -0.0988 -1.0190 -0.0979 -0.0913 -0.5263 -0.1053 -0.0781 -0.1541 -0.1402 -0.5990 -0.7321 -0.0569 -0.6147 -0.1501 -0.1281 -0.1902 -0.1994 -0.7252 -0.1062 -0.2100 -0.1496 -0.1625 -0.1363 -0.1118 -0.1892 -0.3055 -0.1937 -0.1537
S-374	Studien zur Präklinik zeigten , dass Alendronat sich bevorzugt an den Stellen der aktiven Resorption konzentriert .
T-374	Preclinical studies have shown preferential localisation of alendronate to sites of active resorption .
H-374	-0.4107990860939026	Preclinical studies have shown that alendronate primarily concentrates at sites of active absorption .
D-374	-0.4107990860939026	Preclinical studies have shown that alendronate primarily concentrates at sites of active absorption .
P-374	-0.9803 -0.8057 -0.0384 -0.5213 -0.3434 -0.8858 -0.2498 -0.1669 -0.1156 -0.1158 -0.1222 -0.0891 -2.4988 -0.4260 -0.1758 -0.5980 -0.4334 -0.3303 -0.0582 -0.1021 -0.0661 -0.1722 -0.1531
S-24	Die Wirkungen von Adenuric wurden zunächst in Versuchsmodellen getestet , bevor sie an Menschen untersucht wurden .
T-24	The effects of Adenuric were first tested in experimental models before being studied in humans .
H-24	-0.42991918325424194	The effects of Adenuric were first tested in experimental models before being studied in humans .
D-24	-0.42991918325424194	The effects of Adenuric were first tested in experimental models before being studied in humans .
P-24	-0.8357 -0.2901 -0.1229 -0.1403 -0.1543 -0.0881 -0.1285 -0.2690 -1.4041 -1.2283 -0.1417 -1.1082 -0.0559 -0.2326 -0.7823 -0.4219 -0.9861 -0.1288 -0.2091 -0.1473 -0.1531
S-1755	Die Behandlung mit ADVATE wird von einem in der Behandlung von Hämophilie A erfahrenen Arzt eingeleitet .
T-1755	Treatment with ADVATE will be started by a doctor who is experienced in the care of patients with haemophilia A.
H-1755	-0.340072363615036	ADVATE treatment is initiated by a doctor with experience in the treatment of haemophilia A .
D-1755	-0.340072363615036	ADVATE treatment is initiated by a doctor with experience in the treatment of haemophilia A .
P-1755	-0.3021 -0.1614 -0.1022 -0.0865 -1.3606 -0.2154 -0.1209 -0.0981 -0.1464 -0.2492 -1.3513 -0.6819 -0.7838 -0.2488 -0.9426 -0.2146 -0.1185 -0.1391 -0.0921 -0.0735 -0.0712 -0.1732 -0.2709 -0.1574
S-1630	74 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1630	68 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1630	-0.20929887890815735	MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-1630	-0.20929887890815735	MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-1630	-3.6872 -0.0715 -0.0440 -0.0576 -0.0425 -0.1229 -0.1380 -0.0653 -0.0693 -0.0385 -0.0575 -0.8873 -0.0506 -0.0331 -0.0176 -0.0223 -0.1518 -0.0429 -0.0398 -0.0830 -0.0141 -0.0165 -0.0583 -0.0453 -0.3725 -0.0992 -0.0832 -0.0540 -0.0518 -0.0702 -0.1491 -0.0235 -0.1467
S-1663	82 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1663	76 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1663	-0.1961510330438614	82 MINIMUM PARTICULARS ON SMALL IMMEDIATE PACKAGING UNITS
D-1663	-0.1961510330438614	82 MINIMUM PARTICULARS ON SMALL IMMEDIATE PACKAGING UNITS
P-1663	-0.2942 -0.1152 -0.0706 -0.0547 -0.0517 -0.0438 -0.0895 -0.1363 -0.0558 -0.0870 -0.0410 -0.0573 -3.3825 -0.0425 -0.0516 -0.1253 -0.0123 -0.0180 -0.0546 -0.0605 -0.1447 -0.1194 -0.0780 -0.0689 -0.0456 -0.0471 -0.1296 -0.0256 -0.1852
S-523	Faktor VIII ist eine der Substanzen ( Faktoren ) im Körper , die an der Blutgerinnung beteiligt sind .
T-523	In the body , factor VIII is one of the substances ( factors ) involved in blood coagulation ( clotting ) .
H-523	-0.2293877750635147	Factor VIII is one of the substances ( factors ) in the body involved in blood clotting .
D-523	-0.2293877750635147	Factor VIII is one of the substances ( factors ) in the body involved in blood clotting .
P-523	-0.2022 -0.1564 -0.0826 -0.1591 -0.1642 -0.1313 -0.2339 -0.7646 -0.1067 -0.2223 -0.1369 -0.1379 -0.3583 -0.1809 -0.1083 -0.8812 -0.1316 -0.3207 -0.2713 -0.0614 -0.1363 -0.1707 -0.1569
S-1878	Nachdem der CHMP die Antworten des Unternehmens auf die ihm gestellten Fragen geprüft hatte , waren immer noch einige Fragen ungeklärt .
T-1878	After the CHMP had assessed the responses from the company to a list of questions , there were still some unresolved issues outstanding .
H-1878	-0.8018974661827087	After the CHMP reviewed the company &apos;s replies to the questions put to it , a number of questions remained unresolved .
D-1878	-0.8018974661827087	After the CHMP reviewed the company &apos;s replies to the questions put to it , a number of questions remained unresolved .
P-1878	-1.0763 -2.1427 -0.0661 -0.0459 -2.4566 -0.4139 -0.7983 -0.5422 -1.9811 -0.1451 -0.1918 -0.4296 -0.5441 -2.7876 -0.1420 -0.2311 -0.1425 -1.9445 -0.2554 -0.1188 -1.4322 -1.1922 -0.4007 -1.0571 -0.1588 -0.1528
S-1646	78 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1646	72 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1646	-0.18627314269542694	78 MINIMUM PARTICULARS ON SMALL IMMEDIATE PACKAGING UNITS
D-1646	-0.18627314269542694	78 MINIMUM PARTICULARS ON SMALL IMMEDIATE PACKAGING UNITS
P-1646	-0.4654 -0.0920 -0.0661 -0.0530 -0.0549 -0.0455 -0.1046 -0.1061 -0.0544 -0.0709 -0.0402 -0.0518 -2.9569 -0.0460 -0.0549 -0.1240 -0.0122 -0.0200 -0.0544 -0.0627 -0.1512 -0.1250 -0.0734 -0.0761 -0.0468 -0.0553 -0.1264 -0.0248 -0.1870
S-351	Folgende Nebenwirkungen wurden während klinischer Studien und<unk> oder nach Markteinführung von Alendronat berichtet .
T-351	The following adverse reactions have been reported during clinical studies and/ or post-marketing use with alendronate .
H-351	-0.34489595890045166	The following adverse reactions were reported during clinical trials and/ or after the marketing of alendronate .
D-351	-0.34489595890045166	The following adverse reactions were reported during clinical trials and/ or after the marketing of alendronate .
P-351	-0.5708 -0.0611 -1.2131 -0.0596 -0.6125 -0.0209 -1.0821 -0.0794 -0.1418 -0.2451 -0.3786 -0.0834 -0.2049 -0.2482 -0.7331 -0.3000 -1.1599 -0.2931 -0.1496 -0.1042 -0.0935 -0.0588 -0.2312 -0.1524
S-1680	86 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1680	80 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1680	-0.20275519788265228	86 MINIMUM PARTICULARS ON SMALL IMMEDIATE PACKAGING UNITS
D-1680	-0.20275519788265228	86 MINIMUM PARTICULARS ON SMALL IMMEDIATE PACKAGING UNITS
P-1680	-0.5679 -0.1092 -0.0707 -0.0435 -0.0529 -0.0491 -0.0641 -0.1213 -0.0611 -0.0803 -0.0421 -0.0555 -3.3432 -0.0394 -0.0567 -0.1178 -0.0121 -0.0172 -0.0536 -0.0642 -0.1482 -0.1298 -0.0730 -0.0725 -0.0478 -0.0406 -0.1275 -0.0248 -0.1936
S-1696	90 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1696	84 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1696	-0.19751378893852234	90 MINIMUM PARTICULARS ON SMALL IMMEDIATE PACKAGING UNITS
D-1696	-0.19751378893852234	90 MINIMUM PARTICULARS ON SMALL IMMEDIATE PACKAGING UNITS
P-1696	-0.5957 -0.1350 -0.0555 -0.0386 -0.0530 -0.0463 -0.0763 -0.0831 -0.0494 -0.0686 -0.0396 -0.0446 -3.1970 -0.0424 -0.0564 -0.1292 -0.0129 -0.0175 -0.0533 -0.0624 -0.1556 -0.1219 -0.0755 -0.0777 -0.0446 -0.0507 -0.1172 -0.0258 -0.2022
S-1712	94 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1712	88 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1712	-0.2258533537387848	94 MINIMUM PARTICULARS ON SMALL IMMEDIATE PACKAGING UNITS
D-1712	-0.2258533537387848	94 MINIMUM PARTICULARS ON SMALL IMMEDIATE PACKAGING UNITS
P-1712	-1.6127 -0.1047 -0.0661 -0.0582 -0.0505 -0.0458 -0.0811 -0.1187 -0.0567 -0.0771 -0.0388 -0.0567 -2.9699 -0.0457 -0.0530 -0.1198 -0.0122 -0.0183 -0.0534 -0.0695 -0.1378 -0.1217 -0.0748 -0.0794 -0.0462 -0.0443 -0.1197 -0.0244 -0.1924
S-248	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden .
T-248	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden . Circulating vitamin D3 is bound to vitamin D-binding protein .
H-248	-0.213658407330513	Circulating vitamin D3 is bound to vitamin D binding protein .
D-248	-0.213658407330513	Circulating vitamin D3 is bound to vitamin D binding protein .
P-248	-0.5119 -0.1670 -0.0900 -0.1043 -0.0865 -0.1602 -0.1396 -0.1773 -0.4854 -0.1674 -0.6043 -0.0519 -0.3011 -0.2677 -0.1099 -0.0666 -0.1982 -0.1565
S-1873	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-1873	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel. 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-1873	-0.15487931668758392	The 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-1873	-0.15487931668758392	The 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-1873	-0.6347 -0.1691 -0.1351 -0.0882 -0.0660 -0.1971 -0.0577 -0.1347 -0.1123 -0.1154 -0.1168 -0.1138 -0.1178 -0.1351 -0.1044 -0.1244 -0.0934 -0.2006 -0.1691 -0.1086 -0.1373 -0.1081 -0.3236 -0.1610 -0.1474
S-150	B. Cholestyramin , Colestipol ) können die Resorption von Vitamin D beeinträchtigen .
T-150	Colecalciferol Olestra , mineral oils , orlistat , and bile acid sequestrants ( e. g. cholestyramine , colestipol ) may impair the absorption of vitamin D.
H-150	-0.3245718479156494	cholestyramine , colestipol ) may impair the absorption of vitamin D .
D-150	-0.3245718479156494	cholestyramine , colestipol ) may impair the absorption of vitamin D .
P-150	-0.5229 -0.0671 -0.1355 -0.0927 -0.2097 -0.1833 -0.1385 -0.0457 -0.7110 -0.1468 -0.6837 -2.2894 -0.0248 -0.6779 -0.0543 -0.0586 -0.1233 -0.1711 -0.0627 -0.2008 -0.3839 -0.1571
S-338	B. Cholestyramin , Colestipol ) können die Resorption von Vitamin D beeinträchtigen .
T-338	Colecalciferol Olestra , mineral oils , orlistat , and bile acid sequestrants ( e. g. cholestyramine , colestipol ) may impair the absorption of vitamin D.
H-338	-0.3245718479156494	cholestyramine , colestipol ) may impair the absorption of vitamin D .
D-338	-0.3245718479156494	cholestyramine , colestipol ) may impair the absorption of vitamin D .
P-338	-0.5229 -0.0671 -0.1355 -0.0927 -0.2097 -0.1833 -0.1385 -0.0457 -0.7110 -0.1468 -0.6837 -2.2894 -0.0248 -0.6779 -0.0543 -0.0586 -0.1233 -0.1711 -0.0627 -0.2008 -0.3839 -0.1571
S-163	Folgende Nebenwirkungen wurden während klinischer Studien und<unk> oder nach Markteinführung von Alendronat berichtet .
T-163	The following adverse reactions have been reported during clinical studies and/ or post-marketing use with alendronate .
H-163	-0.34489595890045166	The following adverse reactions were reported during clinical trials and/ or after the marketing of alendronate .
D-163	-0.34489595890045166	The following adverse reactions were reported during clinical trials and/ or after the marketing of alendronate .
P-163	-0.5708 -0.0611 -1.2131 -0.0596 -0.6125 -0.0209 -1.0821 -0.0794 -0.1418 -0.2451 -0.3786 -0.0834 -0.2049 -0.2482 -0.7331 -0.3000 -1.1599 -0.2931 -0.1496 -0.1042 -0.0935 -0.0588 -0.2312 -0.1524
S-426	Die gemeinsame Einnahme von Alendronat mit Kaffee oder Orangensaft reduzierte die Bioverfügbarkeit um etwa 60 <unk> .
T-426	Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60 % .
H-426	-0.26216238737106323	Taking alendronate concomitantly with coffee or orange juice reduced bioavailability by approximately 60 % .
D-426	-0.26216238737106323	Taking alendronate concomitantly with coffee or orange juice reduced bioavailability by approximately 60 % .
P-426	-0.8276 -0.1536 -0.1230 -0.1259 -0.1037 -1.1415 -0.1763 -0.0041 -0.1702 -0.1434 -0.0723 -0.1696 -0.1701 -0.1078 -0.3215 -0.2186 -0.0928 -0.1559 -0.6034 -0.1182 -0.6936 -0.1844 -0.1522
S-1779	Wenn Sie die Anwendung von ADVATE abbrechen Brechen Sie die Anwendung von ADVATE nicht ab ohne Ihren Arzt zu befragen .
T-1779	If you stop using ADVATE Do not stop using ADVATE without consulting your doctor .
H-1779	-0.5079349875450134	If you wish to discontinue use of ADVATE , do not discontinue use of ADVATE without consulting your doctor .
D-1779	-0.5079349875450134	If you wish to discontinue use of ADVATE , do not discontinue use of ADVATE without consulting your doctor .
P-1779	-0.4754 -0.0973 -4.3131 -0.1279 -0.3867 -0.1494 -1.7783 -0.1350 -0.1071 -0.1548 -0.1024 -0.0943 -0.4646 -0.2971 -0.1397 -0.6565 -0.1617 -1.1347 -0.7567 -0.0992 -0.1502 -0.1018 -0.0954 -0.1925 -2.3467 -0.1255 -0.1454 -0.1300 -0.1531 -0.1656
S-819	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-819	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-819	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
D-819	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
P-819	-0.4430 -2.5198 -0.1185 -1.1691 -0.0738 -0.6196 -0.2546 -0.1482 -0.2259 -0.9446 -0.1139 -0.0411 -0.0578 -0.1379 -2.0342 -0.1062 -1.0187 -0.6903 -0.0776 -0.1388 -0.1271 -0.1520 -1.2621 -0.4453 -0.3100 -1.6267 -0.3432 -0.1925 -0.1555
S-1752	Verkehrstüchtigkeit und das Bedienen von Maschinen ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und das Bedienen von Maschinen .
T-1752	Driving and using machines ADVATE has no influence on your ability to drive or to use machines .
H-1752	-0.49840468168258667	ability to drive and use machines ADVATE has no effect on ability to drive and use machines .
D-1752	-0.49840468168258667	ability to drive and use machines ADVATE has no effect on ability to drive and use machines .
P-1752	-3.2675 -0.2608 -0.3897 -0.1711 -0.2697 -0.7011 -0.1230 -0.1508 -0.0798 -0.0853 -0.3031 -0.1172 -1.6235 -0.1296 -0.7812 -0.8769 -0.1603 -0.3471 -0.2640 -0.2421 -0.4561 -0.1652
S-1794	Verwenden Sie ADVATE nicht mehr nach dem Verfalldatum , das auf dem Etikett nach verwendbar bis angegeben ist . .
T-1794	Do not use ADVATE after the expiry date , which is stated on the label after EXP .
H-1794	-0.3218638598918915	Do not use ADVATE after the expiry date indicated on the label .
D-1794	-0.3218638598918915	Do not use ADVATE after the expiry date indicated on the label .
P-1794	-0.0867 -0.1535 -0.1365 -0.1230 -0.1445 -0.0953 -0.0991 -0.6217 -0.2946 -0.1863 -0.5772 -0.2254 -0.9544 -0.1467 -0.1666 -0.0204 -1.0805 -0.6809
S-645	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-645	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-645	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
D-645	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
P-645	-0.4430 -2.5198 -0.1185 -1.1691 -0.0738 -0.6196 -0.2546 -0.1482 -0.2259 -0.9446 -0.1139 -0.0411 -0.0578 -0.1379 -2.0342 -0.1062 -1.0187 -0.6903 -0.0776 -0.1388 -0.1271 -0.1520 -1.2621 -0.4453 -0.3100 -1.6267 -0.3432 -0.1925 -0.1555
S-230	Die gemeinsame Einnahme von Alendronat mit Kaffee oder Orangensaft reduzierte die Bioverfügbarkeit um etwa 60 <unk> .
T-230	Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60 % .
H-230	-0.26216238737106323	Taking alendronate concomitantly with coffee or orange juice reduced bioavailability by approximately 60 % .
D-230	-0.26216238737106323	Taking alendronate concomitantly with coffee or orange juice reduced bioavailability by approximately 60 % .
P-230	-0.8276 -0.1536 -0.1230 -0.1259 -0.1037 -1.1415 -0.1763 -0.0041 -0.1702 -0.1434 -0.0723 -0.1696 -0.1701 -0.1078 -0.3215 -0.2186 -0.0928 -0.1559 -0.6034 -0.1182 -0.6936 -0.1844 -0.1522
S-1347	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-1347	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-1347	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
D-1347	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
P-1347	-0.4430 -2.5198 -0.1185 -1.1691 -0.0738 -0.6196 -0.2546 -0.1482 -0.2259 -0.9446 -0.1139 -0.0411 -0.0578 -0.1379 -2.0342 -0.1062 -1.0187 -0.6903 -0.0776 -0.1388 -0.1271 -0.1520 -1.2621 -0.4453 -0.3100 -1.6267 -0.3432 -0.1925 -0.1555
S-638	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-638	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-638	-0.5161653161048889	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-638	-0.5161653161048889	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-638	-2.0832 -0.2375 -1.3624 -0.1261 -0.7394 -0.5866 -0.1191 -0.1975 -0.1402 -0.4150 -0.2633 -0.3427 -0.6178 -1.5744 -0.5282 -0.1352 -0.0558 -0.0560 -0.1371 -0.1728 -2.4817 -0.2080 -0.7089 -0.4955 -0.1642 -0.3155 -0.1416 -0.1800 -1.0944 -0.1688 -0.1521
S-469	Name und Anschrift des ( der ) Hersteller<unk> s ) , der ( die ) für die Chargenfreigabe verantwortlich ist ( sind )
T-469	Name and address of the manufacturer<<unk>> s ) responsible for batch release
H-469	-0.5664924383163452	Name and address of the manufacturer ( s ) responsible for batch release ( s )
D-469	-0.5664924383163452	Name and address of the manufacturer ( s ) responsible for batch release ( s )
P-469	-1.3918 -0.1417 -0.0959 -0.1426 -0.6060 -1.0730 -0.1720 -0.1292 -0.1179 -0.2301 -0.1627 -2.5776 -0.1048 -1.7152 -0.9318 -0.2031 -0.1249 -0.2765
S-1736	WAS MÜSSEN SIE VOR DER ANWENDUNG VON ADVATE BEACHTEN ?
T-1736	BEFORE YOU USE ADVATE
H-1736	-0.5577592253684998	WHAT YOU MUST REGARD TO ADVATE BEFORE USE
D-1736	-0.5577592253684998	WHAT YOU MUST REGARD TO ADVATE BEFORE USE
P-1736	-1.0753 -0.0155 -0.2341 -0.1394 -0.1130 -1.3858 -0.0606 -0.1550 -2.2459 -0.4621 -0.0898 -0.8792 -1.7373 -0.1186 -0.1456 -0.0924 -1.6435 -0.0147 -0.0091 -0.0267 -0.5235 -1.1037
S-995	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-995	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-995	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
D-995	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
P-995	-0.4430 -2.5198 -0.1185 -1.1691 -0.0738 -0.6196 -0.2546 -0.1482 -0.2259 -0.9446 -0.1139 -0.0411 -0.0578 -0.1379 -2.0342 -0.1062 -1.0187 -0.6903 -0.0776 -0.1388 -0.1271 -0.1520 -1.2621 -0.4453 -0.3100 -1.6267 -0.3432 -0.1925 -0.1555
S-169	Selten : starke muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen ( siehe Abschnitt 4.4 ) .
T-169	Metabolism and nutrition disorders :
H-169	-0.22523736953735352	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
D-169	-0.22523736953735352	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
P-169	-0.6569 -0.1134 -0.1617 -0.2191 -0.0787 -0.3233 -0.0767 -0.1100 -0.2622 -0.1134 -0.2511 -0.1177 -0.1364 -0.1547 -1.0483 -0.7261 -0.1471 -0.0850 -0.1477 -0.1194 -0.0953 -0.1189 -0.1349 -0.1332 -0.1689 -0.1560
S-1368	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1368	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1368	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
D-1368	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
P-1368	-1.5749 -1.9221 -0.0565 -0.2184 -0.0510 -0.1672 -0.2321 -0.1189 -0.2151 -0.1293 -0.2102 -0.1880 -0.0535 -0.6217 -0.1250 -1.0025 -1.4518 -1.1077 -0.8386 -0.0620 -0.0914 -0.1554 -0.1494 -0.1510
S-1016	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1016	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1016	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
D-1016	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
P-1016	-1.5749 -1.9221 -0.0565 -0.2184 -0.0510 -0.1672 -0.2321 -0.1189 -0.2151 -0.1293 -0.2102 -0.1880 -0.0535 -0.6217 -0.1250 -1.0025 -1.4518 -1.1077 -0.8386 -0.0620 -0.0914 -0.1554 -0.1494 -0.1510
S-53	Der Hersteller von FOSAVANCE hat zugestimmt , dass die wissenschaftlichen Daten dieses Produkts auch für ADROVANCE verwendet werden können .
T-53	The company that makes FOSAVANCE has agreed that its scientific data can be used for ADROVANCE .
H-53	-0.3196357190608978	The manufacturer of FOSAVANCE has agreed that the scientific data on this product may also be used for ADROVANCE .
D-53	-0.3196357190608978	The manufacturer of FOSAVANCE has agreed that the scientific data on this product may also be used for ADROVANCE .
P-53	-0.4599 -0.4338 -0.1457 -0.1590 -0.0907 -0.1280 -0.1242 -0.1142 -0.0975 -0.3323 -1.2715 -0.2949 -0.4144 -0.2339 -0.2809 -1.5419 -0.1906 -0.1452 -0.6802 -0.4506 -0.1225 -0.2754 -0.5833 -0.2579 -0.0645 -0.1197 -0.1195 -0.0903 -0.2033 -0.1632
S-1996	In klinischen Studien zur Beurteilung der Verkehrstüchtigkeit wurde bei Patienten , die Desloratadin erhielten , keine Beeinträchtigung festgestellt .
T-1996	In clinical trials that assessed the driving ability , no impairment occurred in patients receiving desloratadine .
H-1996	-0.45241579413414	No impairment was observed in roadworthiness clinical trials in patients receiving desloratadine .
D-1996	-0.45241579413414	No impairment was observed in roadworthiness clinical trials in patients receiving desloratadine .
P-1996	-0.7521 -0.8898 -0.0163 -0.0335 -0.0977 -0.6697 -1.6412 -0.1338 -2.6770 -0.4861 -0.0548 -0.0480 -0.3533 -0.3247 -0.6039 -0.6209 -0.0172 -0.2362 -0.0456 -0.1004 -0.2651 -0.4637 -0.1735 -0.1535
S-1545	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1545	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1545	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
D-1545	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
P-1545	-1.5749 -1.9221 -0.0565 -0.2184 -0.0510 -0.1672 -0.2321 -0.1189 -0.2151 -0.1293 -0.2102 -0.1880 -0.0535 -0.6217 -0.1250 -1.0025 -1.4518 -1.1077 -0.8386 -0.0620 -0.0914 -0.1554 -0.1494 -0.1510
S-1171	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-1171	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-1171	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
D-1171	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
P-1171	-0.4430 -2.5198 -0.1185 -1.1691 -0.0738 -0.6196 -0.2546 -0.1482 -0.2259 -0.9446 -0.1139 -0.0411 -0.0578 -0.1379 -2.0342 -0.1062 -1.0187 -0.6903 -0.0776 -0.1388 -0.1271 -0.1520 -1.2621 -0.4453 -0.3100 -1.6267 -0.3432 -0.1925 -0.1555
S-1192	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1192	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1192	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
D-1192	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
P-1192	-1.5749 -1.9221 -0.0565 -0.2184 -0.0510 -0.1672 -0.2321 -0.1189 -0.2151 -0.1293 -0.2102 -0.1880 -0.0535 -0.6217 -0.1250 -1.0025 -1.4518 -1.1077 -0.8386 -0.0620 -0.0914 -0.1554 -0.1494 -0.1510
S-1524	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-1524	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-1524	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
D-1524	-0.5361294150352478	The detection frequency of FVIII inhibitors to date is in line with expectations and in the range already observed .
P-1524	-0.4430 -2.5198 -0.1185 -1.1691 -0.0738 -0.6196 -0.2546 -0.1482 -0.2259 -0.9446 -0.1139 -0.0411 -0.0578 -0.1379 -2.0342 -0.1062 -1.0187 -0.6903 -0.0776 -0.1388 -0.1271 -0.1520 -1.2621 -0.4453 -0.3100 -1.6267 -0.3432 -0.1925 -0.1555
S-840	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-840	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-840	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
D-840	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
P-840	-1.5749 -1.9221 -0.0565 -0.2184 -0.0510 -0.1672 -0.2321 -0.1189 -0.2151 -0.1293 -0.2102 -0.1880 -0.0535 -0.6217 -0.1250 -1.0025 -1.4518 -1.1077 -0.8386 -0.0620 -0.0914 -0.1554 -0.1494 -0.1510
S-665	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-665	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-665	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
D-665	-0.4538993537425995	The plasma samples were evaluated in a central laboratory using a one @-@ stage clotting test .
P-665	-1.5749 -1.9221 -0.0565 -0.2184 -0.0510 -0.1672 -0.2321 -0.1189 -0.2151 -0.1293 -0.2102 -0.1880 -0.0535 -0.6217 -0.1250 -1.0025 -1.4518 -1.1077 -0.8386 -0.0620 -0.0914 -0.1554 -0.1494 -0.1510
S-1866	Da Krebszellen beschädigte DNA enthalten , hilft das p53-Protein , die DNA wiederherzustellen oder verursacht , dass die Zellen absterben .
T-1866	Because cancer cells contain damaged DNA , the p53 protein either helps to repair the DNA or causes the cells to die .
H-1866	-0.3886670172214508	Since cancer cells contain damaged DNA , the p53 protein helps to restore DNA or causes cells to die .
D-1866	-0.3886670172214508	Since cancer cells contain damaged DNA , the p53 protein helps to restore DNA or causes cells to die .
P-1866	-1.3249 -0.1665 -0.0711 -0.0898 -0.4434 -0.0478 -0.1433 -0.4791 -0.1513 -0.0552 -0.0834 -0.9416 -0.8297 -0.4908 -1.0746 -0.4733 -0.2003 -0.8715 -0.1322 -0.1446 -0.1765 -0.1597
S-357	Selten : starke muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen ( siehe Abschnitt 4.4 ) .
T-357	Metabolism and nutrition disorders :
H-357	-0.22523736953735352	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
D-357	-0.22523736953735352	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
P-357	-0.6569 -0.1134 -0.1617 -0.2191 -0.0787 -0.3233 -0.0767 -0.1100 -0.2622 -0.1134 -0.2511 -0.1177 -0.1364 -0.1547 -1.0483 -0.7261 -0.1471 -0.0850 -0.1477 -0.1194 -0.0953 -0.1189 -0.1349 -0.1332 -0.1689 -0.1560
S-1422	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1422	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1422	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
D-1422	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
P-1422	-3.3708 -0.4230 -0.3864 -0.0831 -0.0486 -0.1333 -0.1245 -0.6357 -0.1778 -0.0690 -0.0472 -0.0132 -0.3778 -0.1930 -1.6654 -0.2961 -0.1432 -0.1640 -1.2238 -0.0973 -0.1751 -1.3625 -0.9261 -0.1227 -0.1278 -0.1648 -0.1557
S-1246	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1246	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1246	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
D-1246	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
P-1246	-3.3708 -0.4230 -0.3864 -0.0831 -0.0486 -0.1333 -0.1245 -0.6357 -0.1778 -0.0690 -0.0472 -0.0132 -0.3778 -0.1930 -1.6654 -0.2961 -0.1432 -0.1640 -1.2238 -0.0973 -0.1751 -1.3625 -0.9261 -0.1227 -0.1278 -0.1648 -0.1557
S-894	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-894	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-894	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
D-894	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
P-894	-3.3708 -0.4230 -0.3864 -0.0831 -0.0486 -0.1333 -0.1245 -0.6357 -0.1778 -0.0690 -0.0472 -0.0132 -0.3778 -0.1930 -1.6654 -0.2961 -0.1432 -0.1640 -1.2238 -0.0973 -0.1751 -1.3625 -0.9261 -0.1227 -0.1278 -0.1648 -0.1557
S-1424	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1424	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml
H-1424	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
D-1424	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
P-1424	-0.6377 -0.1214 -0.0978 -0.1363 -1.4496 -0.1271 -0.6581 -0.1963 -0.1424 -0.6868 -1.6174 -0.1180 -0.3260 -0.1557 -0.0862 -0.3094 -1.4655 -0.2098 -0.1691 -0.1608 -0.1609 -0.1643 -0.5991 -0.1822 -0.1542
S-1599	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1599	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1599	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
D-1599	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
P-1599	-3.3708 -0.4230 -0.3864 -0.0831 -0.0486 -0.1333 -0.1245 -0.6357 -0.1778 -0.0690 -0.0472 -0.0132 -0.3778 -0.1930 -1.6654 -0.2961 -0.1432 -0.1640 -1.2238 -0.0973 -0.1751 -1.3625 -0.9261 -0.1227 -0.1278 -0.1648 -0.1557
S-1601	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1601	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml
H-1601	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
D-1601	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
P-1601	-0.6377 -0.1214 -0.0978 -0.1363 -1.4496 -0.1271 -0.6581 -0.1963 -0.1424 -0.6868 -1.6174 -0.1180 -0.3260 -0.1557 -0.0862 -0.3094 -1.4655 -0.2098 -0.1691 -0.1608 -0.1609 -0.1643 -0.5991 -0.1822 -0.1542
S-1887	Der Ausschuss hatte ferner Bedenken bezüglich der Verarbeitung des Arzneimittels im Körper , der Art der Verabreichung sowie der Sicherheit des Arzneimittels .
T-1887	The Committee also had concerns over what happens to the medicine in the body , how it should be given and how safe it is .
H-1887	-0.49806463718414307	The Committee also had concerns about how the product is processed in the body , how it is administered and the safety of the product .
D-1887	-0.49806463718414307	The Committee also had concerns about how the product is processed in the body , how it is administered and the safety of the product .
P-1887	-0.2792 -0.6139 -0.3678 -0.5853 -0.2442 -1.0494 -3.1496 -0.1891 -0.7999 -0.5107 -0.5953 -0.2401 -0.3018 -0.1574 -0.1650 -0.1844 -1.3843 -0.1261 -0.1775 -0.5470 -0.0961 -0.6160 -1.0561 -0.0526 -0.1174 -0.2379 -0.2658 -0.1805 -0.1532
S-1070	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1070	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1070	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
D-1070	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
P-1070	-3.3708 -0.4230 -0.3864 -0.0831 -0.0486 -0.1333 -0.1245 -0.6357 -0.1778 -0.0690 -0.0472 -0.0132 -0.3778 -0.1930 -1.6654 -0.2961 -0.1432 -0.1640 -1.2238 -0.0973 -0.1751 -1.3625 -0.9261 -0.1227 -0.1278 -0.1648 -0.1557
S-720	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-720	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-720	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
D-720	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
P-720	-0.6377 -0.1214 -0.0978 -0.1363 -1.4496 -0.1271 -0.6581 -0.1963 -0.1424 -0.6868 -1.6174 -0.1180 -0.3260 -0.1557 -0.0862 -0.3094 -1.4655 -0.2098 -0.1691 -0.1608 -0.1609 -0.1643 -0.5991 -0.1822 -0.1542
S-718	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-718	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-718	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
D-718	-0.4706513285636902	Pull the reconstituted solution into the syringe by slowly retracting the piston ( Fig.e ) .
P-718	-3.3708 -0.4230 -0.3864 -0.0831 -0.0486 -0.1333 -0.1245 -0.6357 -0.1778 -0.0690 -0.0472 -0.0132 -0.3778 -0.1930 -1.6654 -0.2961 -0.1432 -0.1640 -1.2238 -0.0973 -0.1751 -1.3625 -0.9261 -0.1227 -0.1278 -0.1648 -0.1557
S-322	Der Vitamin-D-Gehalt von ADROVANCE ist nicht zur Behandlung eines Vitamin-D-Mangels geeignet .
T-322	The content of vitamin D in ADROVANCE is not suitable for correction of vitamin D deficiency .
H-322	-0.38309258222579956	The D vitamin content of ADROVANCE is not suitable for the treatment of vitamin D deficiency .
D-322	-0.38309258222579956	The D vitamin content of ADROVANCE is not suitable for the treatment of vitamin D deficiency .
P-322	-1.8569 -0.5352 -1.6097 -0.0799 -0.7321 -0.2027 -0.0784 -0.0648 -0.1249 -0.0981 -0.0889 -0.2832 -0.1898 -1.2215 -0.4546 -0.4381 -0.2111 -0.1177 -0.8323 -0.0459 -0.1554 -0.0354 -0.0304 -0.1393 -0.1762 -0.1579
S-134	Der Vitamin-D-Gehalt von ADROVANCE ist nicht zur Behandlung eines Vitamin-D-Mangels geeignet .
T-134	The content of vitamin D in ADROVANCE is not suitable for correction of vitamin D deficiency .
H-134	-0.38309258222579956	The D vitamin content of ADROVANCE is not suitable for the treatment of vitamin D deficiency .
D-134	-0.38309258222579956	The D vitamin content of ADROVANCE is not suitable for the treatment of vitamin D deficiency .
P-134	-1.8569 -0.5352 -1.6097 -0.0799 -0.7321 -0.2027 -0.0784 -0.0648 -0.1249 -0.0981 -0.0889 -0.2832 -0.1898 -1.2215 -0.4546 -0.4381 -0.2111 -0.1177 -0.8323 -0.0459 -0.1554 -0.0354 -0.0304 -0.1393 -0.1762 -0.1579
S-55	ADROVANCE vermindert das Risiko für Wirbel<unk> säulen<unk> - und Hüftfrakturen ( Brüche ) .
T-55	ADROVANCE reduces the risk of vertebral ( spine ) and hip fractures ( breaks ) .
H-55	-0.26494070887565613	ADROVANCE reduces the risk of spinal and hip fractures ( fractures ) .
D-55	-0.26494070887565613	ADROVANCE reduces the risk of spinal and hip fractures ( fractures ) .
P-55	-0.0349 -0.0581 -0.1269 -0.1198 -0.0826 -1.1714 -0.1050 -0.2497 -0.1593 -0.3259 -0.2582 -0.2272 -0.1689 -0.0513 -0.3509 -0.0771 -0.6143 -1.0768 -0.0681 -0.1374 -0.2110 -0.1539
S-1971	Deshalb ist es im Falle eines operativen Eingriffs vorzuziehen , die Behandlung 24 Stunden vor der Einleitung der Narkose abzusetzen .
T-1971	Therefore , if surgery is scheduled , it is preferable to discontinue treatment 24 hours before anaesthesia .
H-1971	-0.5571020245552063	Therefore , in the event of surgery , it is preferable to discontinue treatment 24 hours prior to the start of anaesthesia .
D-1971	-0.5571020245552063	Therefore , in the event of surgery , it is preferable to discontinue treatment 24 hours prior to the start of anaesthesia .
P-1971	-2.1088 -0.0689 -0.2831 -1.1275 -0.7255 -1.0357 -0.1219 -0.9799 -0.4607 -1.1104 -0.2457 -0.3464 -0.1100 -0.2032 -0.3865 -0.1265 -0.2416 -0.2031 -0.0966 -0.7514 -0.1226 -1.3692 -2.9179 -0.1232 -0.5102 -0.2087 -0.3248 -0.0851 -0.1636 -0.1544
S-113	Die Patienten sollen darüber informiert werden , dass das Risiko ösophagealer Probleme erhöht sein kann , wenn sie diese Anweisungen nicht einhalten .
T-113	Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems .
H-113	-0.3454452157020569	Patients should be advised that failure to follow these instructions may result in an increased risk of oesophageal problems .
D-113	-0.3454452157020569	Patients should be advised that failure to follow these instructions may result in an increased risk of oesophageal problems .
P-113	-0.2158 -0.0937 -0.2748 -0.1333 -1.4078 -0.1597 -1.8308 -0.1370 -0.7062 -0.0767 -0.5452 -0.3374 -1.1127 -0.1247 -0.3111 -0.0648 -0.1181 -0.1457 -0.1772 -0.0377 -0.3900 -0.0643 -0.0553 -0.1254 -0.3265 -0.2001 -0.1548
S-1995	Es wurden keine Studien zu den Auswirkungen von Aerinaze auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-1995	No studies on the effects on the ability to drive and use machines have been performed with Aerinaze .
H-1995	-0.4651796221733093	No studies have been carried out on the impact of Aerinaze on ability to drive and use machines .
D-1995	-0.4651796221733093	No studies have been carried out on the impact of Aerinaze on ability to drive and use machines .
P-1995	-0.1074 -0.0667 -0.8398 -0.1112 -0.8733 -0.1355 -1.1652 -0.5010 -0.9059 -0.1405 -0.1512 -0.1260 -0.1480 -0.1336 -0.0900 -0.1020 -1.0150 -0.3747 -1.2737 -0.6539 -0.6403 -1.2596 -0.1931 -0.1567
S-769	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-769	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-769	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
D-769	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
P-769	-1.6751 -0.2961 -0.2293 -0.1233 -0.4473 -0.2480 -0.7165 -0.1899 -0.2625 -0.2461 -1.5768 -2.5418 -0.1294 -0.0820 -0.1370 -0.0889 -0.0886 -1.0531 -0.2148 -0.2327 -0.2431 -0.1277 -0.0590 -0.1178 -0.2596 -0.1456 -0.1632 -0.1266 -0.1892 -0.1572
S-68	Alendronat ist ein Biphosphonat , das seit Mitte der 1990er Jahre gegen Osteoporose eingesetzt wird .
T-68	Vitamin D3 , along with other forms of vitamin D , is required for calcium absorption and normal bone formation .
H-68	-0.2727302312850952	Alendronate is a biphosphonate used since the mid 1990s to treat osteoporosis .
D-68	-0.2727302312850952	Alendronate is a biphosphonate used since the mid 1990s to treat osteoporosis .
P-68	-0.3294 -0.1301 -0.0868 -0.0935 -0.1702 -0.1223 -0.0678 -0.1790 -0.0655 -0.1277 -0.9888 -0.6677 -0.1657 -0.2125 -1.7938 -0.4327 -0.2294 -0.1323 -0.0992 -0.0976 -0.1186 -0.0910 -0.0800 -0.1771 -0.1595
S-1814	102 Falls weitere Informationen über das Arzneimittel gewünscht werden , setzen Sie sich bitte mit dem örtlichen Vertreter des Zulassungsinhabers in Verbindung .
T-1814	96 For any information about this medicine , please contact the local representative of the Marketing Authorisation Holder :
H-1814	-0.5398494005203247	For more information on the product , please contact the marketing authorisation holder &apos;s local representative .
D-1814	-0.5398494005203247	For more information on the product , please contact the marketing authorisation holder &apos;s local representative .
P-1814	-1.5079 -2.1834 -0.0743 -1.0082 -0.4724 -0.8196 -0.2371 -0.7273 -0.0411 -0.2730 -1.4458 -0.0502 -0.0514 -0.1313 -0.6473 -0.1118 -0.0493 -0.2702 -0.1555
S-896	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-896	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-896	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
D-896	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
P-896	-0.6377 -0.1214 -0.0978 -0.1363 -1.4496 -0.1271 -0.6581 -0.1963 -0.1424 -0.6868 -1.6174 -0.1180 -0.3260 -0.1557 -0.0862 -0.3094 -1.4655 -0.2098 -0.1691 -0.1608 -0.1609 -0.1643 -0.5991 -0.1822 -0.1542
S-1988	In Tierversuchen war weder Desloratadin noch die Kombination von Loratadin und Pseudoephedrin teratogen .
T-1988	Neither desloratadine nor the combination of loratadine and pseudoephedrine were teratogenic in animal studies .
H-1988	-0.2949539124965668	In animal experiments , neither desloratadine nor the combination of loratadine and pseudoephedrine was teratogenous .
D-1988	-0.2949539124965668	In animal experiments , neither desloratadine nor the combination of loratadine and pseudoephedrine was teratogenous .
P-1988	-0.3188 -0.0908 -1.7102 -0.1485 -0.3814 -0.4907 -0.1382 -0.0402 -0.1163 -0.3857 -0.2452 -0.1342 -0.2220 -0.0497 -0.1231 -0.1601 -0.1220 -0.3018 -0.2933 -0.1791 -0.1147 -0.1535 -0.1471 -0.0556 -0.1173 -0.1530 -0.1446 -0.8450 -0.0612 -0.1027 -0.6711 -1.5036 -0.1559 -0.1519
S-305	Osteonekrose des Kiefers wurde auch bei Osteoporosepatienten unter oralen Bisphosphonaten berichtet .
T-305	Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates .
H-305	-0.17207098007202148	jaw osteonecrosis has also been reported in osteoporosis patients receiving oral bisphosphonates .
D-305	-0.17207098007202148	jaw osteonecrosis has also been reported in osteoporosis patients receiving oral bisphosphonates .
P-305	-0.5272 -0.3147 -0.1452 -0.0671 -0.1191 -0.0579 -0.0645 -0.0908 -0.7599 -0.1951 -0.1270 -0.0985 -0.3404 -0.4217 -0.0672 -0.1124 -0.1410 -0.1011 -0.0727 -0.1930 -0.2688 -0.0448 -0.0844 -0.0225 -0.0780 -0.0836 -0.0738 -0.1653 -0.1522
S-1872	Der Patient erhielt über einen Zeitraum von fünf Monaten 12 Advexin-Injektionen , die in einige der Tumore gespritzt wurden .
T-1872	Der Patient erhielt über einen Zeitraum von fünf Monaten 12 Advexin-Injektionen , die in einige der Tumore gespritzt wurden . The effectiveness of the medicine was assessed by using scans to look at how the tumours responded to treatment .
H-1872	-0.30587831139564514	The patient received 12 Advexin injections over five months , which were injected into some of the tumours .
D-1872	-0.30587831139564514	The patient received 12 Advexin injections over five months , which were injected into some of the tumours .
P-1872	-0.7975 -0.1000 -0.5464 -0.1207 -0.6561 -0.2355 -0.1277 -0.2007 -0.0483 -0.5638 -0.5937 -0.1895 -0.6675 -1.1648 -0.1076 -0.3709 -0.0683 -0.1447 -0.1858 -0.1275 -0.1654 -0.0519 -0.0831 -0.1754 -0.1541
S-1473	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-1473	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-1473	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
D-1473	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
P-1473	-1.6751 -0.2961 -0.2293 -0.1233 -0.4473 -0.2480 -0.7165 -0.1899 -0.2625 -0.2461 -1.5768 -2.5418 -0.1294 -0.0820 -0.1370 -0.0889 -0.0886 -1.0531 -0.2148 -0.2327 -0.2431 -0.1277 -0.0590 -0.1178 -0.2596 -0.1456 -0.1632 -0.1266 -0.1892 -0.1572
S-1297	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-1297	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-1297	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
D-1297	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
P-1297	-1.6751 -0.2961 -0.2293 -0.1233 -0.4473 -0.2480 -0.7165 -0.1899 -0.2625 -0.2461 -1.5768 -2.5418 -0.1294 -0.0820 -0.1370 -0.0889 -0.0886 -1.0531 -0.2148 -0.2327 -0.2431 -0.1277 -0.0590 -0.1178 -0.2596 -0.1456 -0.1632 -0.1266 -0.1892 -0.1572
S-1121	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-1121	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-1121	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
D-1121	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
P-1121	-1.6751 -0.2961 -0.2293 -0.1233 -0.4473 -0.2480 -0.7165 -0.1899 -0.2625 -0.2461 -1.5768 -2.5418 -0.1294 -0.0820 -0.1370 -0.0889 -0.0886 -1.0531 -0.2148 -0.2327 -0.2431 -0.1277 -0.0590 -0.1178 -0.2596 -0.1456 -0.1632 -0.1266 -0.1892 -0.1572
S-945	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-945	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-945	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
D-945	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
P-945	-1.6751 -0.2961 -0.2293 -0.1233 -0.4473 -0.2480 -0.7165 -0.1899 -0.2625 -0.2461 -1.5768 -2.5418 -0.1294 -0.0820 -0.1370 -0.0889 -0.0886 -1.0531 -0.2148 -0.2327 -0.2431 -0.1277 -0.0590 -0.1178 -0.2596 -0.1456 -0.1632 -0.1266 -0.1892 -0.1572
S-595	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-595	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-595	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
D-595	-0.4056006073951721	For the benefit of patients , it is recommended that each administration of ADVATE should include the name and batch number of the product .
P-595	-1.6751 -0.2961 -0.2293 -0.1233 -0.4473 -0.2480 -0.7165 -0.1899 -0.2625 -0.2461 -1.5768 -2.5418 -0.1294 -0.0820 -0.1370 -0.0889 -0.0886 -1.0531 -0.2148 -0.2327 -0.2431 -0.1277 -0.0590 -0.1178 -0.2596 -0.1456 -0.1632 -0.1266 -0.1892 -0.1572
S-1072	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1072	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-1072	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
D-1072	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
P-1072	-0.6377 -0.1214 -0.0978 -0.1363 -1.4496 -0.1271 -0.6581 -0.1963 -0.1424 -0.6868 -1.6174 -0.1180 -0.3260 -0.1557 -0.0862 -0.3094 -1.4655 -0.2098 -0.1691 -0.1608 -0.1609 -0.1643 -0.5991 -0.1822 -0.1542
S-1771	Wie ADVATE angewendet wird ADVATE wird normalerweise vom Arzt in eine Vene ( intravenös ) verabreicht .
T-1771	How ADVATE is given ADVATE is usually injected into a vein ( intravenously ) by your doctor or nurse .
H-1771	-0.3094359040260315	How ADVATE is administered ADVATE is usually given by the doctor into a vein ( intravenously ) .
D-1771	-0.3094359040260315	How ADVATE is administered ADVATE is usually given by the doctor into a vein ( intravenously ) .
P-1771	-1.1550 -0.0656 -0.1605 -0.1062 -0.0930 -0.1455 -0.3913 -0.1027 -0.1027 -0.1473 -0.1057 -0.1024 -0.1452 -0.4829 -2.0050 -0.4143 -0.2477 -0.4286 -0.8725 -0.2848 -0.2295 -0.0364 -0.1615 -0.3192 -0.0829 -0.0941 -0.2723 -0.1373 -0.2303 -0.1608
S-1248	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1248	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-1248	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
D-1248	-0.4052780270576477	The solution should be given slowly , at a rate convenient to the patient and maximum of 10 ml/ minute .
P-1248	-0.6377 -0.1214 -0.0978 -0.1363 -1.4496 -0.1271 -0.6581 -0.1963 -0.1424 -0.6868 -1.6174 -0.1180 -0.3260 -0.1557 -0.0862 -0.3094 -1.4655 -0.2098 -0.1691 -0.1608 -0.1609 -0.1643 -0.5991 -0.1822 -0.1542
S-117	Osteonekrose des Kiefers wurde auch bei Osteoporosepatienten unter oralen Bisphosphonaten berichtet .
T-117	Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates .
H-117	-0.17207098007202148	jaw osteonecrosis has also been reported in osteoporosis patients receiving oral bisphosphonates .
D-117	-0.17207098007202148	jaw osteonecrosis has also been reported in osteoporosis patients receiving oral bisphosphonates .
P-117	-0.5272 -0.3147 -0.1452 -0.0671 -0.1191 -0.0579 -0.0645 -0.0908 -0.7599 -0.1951 -0.1270 -0.0985 -0.3404 -0.4217 -0.0672 -0.1124 -0.1410 -0.1011 -0.0727 -0.1930 -0.2688 -0.0448 -0.0844 -0.0225 -0.0780 -0.0836 -0.0738 -0.1653 -0.1522
S-1913	Die Wirksamkeit von Aerinaze wurde in zwei Hauptstudien mit insgesamt 1 248 erwachsenen und jugendlichen Patienten untersucht .
T-1913	The effectiveness of Aerinaze was assessed in two main studies involving a total of 1,248 adult and adolescent patients .
H-1913	-0.31955191493034363	The efficacy of Aerinaze has been evaluated in two main studies involving a total of 1,248 adult and adolescent patients .
D-1913	-0.31955191493034363	The efficacy of Aerinaze has been evaluated in two main studies involving a total of 1,248 adult and adolescent patients .
P-1913	-1.1717 -0.1168 -0.0657 -0.0854 -0.1174 -0.1322 -0.1275 -0.1485 -0.1385 -0.0911 -1.1384 -0.1496 -0.7162 -0.1171 -0.1216 -0.2081 -1.1113 -0.7079 -1.2644 -0.2725 -0.2152 -0.1238 -0.8198 -0.1054 -0.1187 -0.0755 -0.1505 -0.2100 -0.1547 -0.1369 -0.1177 -0.1614 -0.1538
S-1895	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-1895	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-1895	-0.3597107529640198	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of EPAR ) .
D-1895	-0.3597107529640198	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of EPAR ) .
P-1895	-0.9571 -0.8976 -0.0803 -0.4259 -0.4143 -0.2662 -0.3780 -0.9622 -0.2933 -0.0418 -0.2623 -0.2588 -1.1320 -0.2986 -0.7936 -0.0562 -0.1058 -0.1571 -0.0760 -0.2240 -0.2403 -0.3236 -0.1235 -0.7657 -0.0424 -0.1248 -0.2122 -0.1583
S-511	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-511	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-511	-0.3597107529640198	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of EPAR ) .
D-511	-0.3597107529640198	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of EPAR ) .
P-511	-0.9571 -0.8976 -0.0803 -0.4259 -0.4143 -0.2662 -0.3780 -0.9622 -0.2933 -0.0418 -0.2623 -0.2588 -1.1320 -0.2986 -0.7936 -0.0562 -0.1058 -0.1571 -0.0760 -0.2240 -0.2403 -0.3236 -0.1235 -0.7657 -0.0424 -0.1248 -0.2122 -0.1583
S-50	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-50	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-50	-0.3597107529640198	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of EPAR ) .
D-50	-0.3597107529640198	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of EPAR ) .
P-50	-0.9571 -0.8976 -0.0803 -0.4259 -0.4143 -0.2662 -0.3780 -0.9622 -0.2933 -0.0418 -0.2623 -0.2588 -1.1320 -0.2986 -0.7936 -0.0562 -0.1058 -0.1571 -0.0760 -0.2240 -0.2403 -0.3236 -0.1235 -0.7657 -0.0424 -0.1248 -0.2122 -0.1583
S-2	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-2	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-2	-0.3597107529640198	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of EPAR ) .
D-2	-0.3597107529640198	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of EPAR ) .
P-2	-0.9571 -0.8976 -0.0803 -0.4259 -0.4143 -0.2662 -0.3780 -0.9622 -0.2933 -0.0418 -0.2623 -0.2588 -1.1320 -0.2986 -0.7936 -0.0562 -0.1058 -0.1571 -0.0760 -0.2240 -0.2403 -0.3236 -0.1235 -0.7657 -0.0424 -0.1248 -0.2122 -0.1583
S-1868	Advexin hätte die Krankheit heilen oder deren Fortschreiten verlangsamen sollen , indem die normale Schutzfunktion der Zellen wiederhergestellt wird .
T-1868	Advexin was expected to cure or slow down the disease by restoring the normal protective function of the cells .
H-1868	-0.45151418447494507	Advexin should have cured the disease or slowed its progression by restoring the normal protective function of the cells .
D-1868	-0.45151418447494507	Advexin should have cured the disease or slowed its progression by restoring the normal protective function of the cells .
P-1868	-0.6767 -0.1536 -0.1353 -0.4042 -0.2149 -1.3954 -0.1047 -1.9721 -0.3362 -0.2507 -0.3386 -0.0505 -0.2096 -0.2200 -0.1675 -0.2038 -0.3979 -0.1275 -1.5897 -1.2367 -0.2909 -0.4719 -0.1340 -0.6775 -0.1003 -0.1726 -0.1582
S-1411	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1411	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1411	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-1411	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-1411	-2.1817 -0.7190 -0.2061 -1.9401 -0.1942 -0.0850 -0.1331 -0.1938 -0.2494 -0.1489 -0.1550 -0.1903 -0.0977 -1.4743 -0.1299 -0.5891 -0.1649 -0.2171 -0.1355 -0.0739 -0.1655 -0.1625
S-1588	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1588	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1588	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-1588	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-1588	-2.1817 -0.7190 -0.2061 -1.9401 -0.1942 -0.0850 -0.1331 -0.1938 -0.2494 -0.1489 -0.1550 -0.1903 -0.0977 -1.4743 -0.1299 -0.5891 -0.1649 -0.2171 -0.1355 -0.0739 -0.1655 -0.1625
S-400	3,2 % in der 5.600-I.E.-Vitamin-D3-Gruppe . Der Anteil an Patientinnen mit
T-400	3.2 % in the Vitamin D3 5600 group through the 24-week extension .
H-400	-0.42101553082466125	3.2 % in the 5,600 IU vitamin D 3 group . The proportion of
D-400	-0.42101553082466125	3.2 % in the 5,600 IU vitamin D 3 group . The proportion of
P-400	-0.1998 -0.1570 -0.1266 -0.1728 -0.1964 -0.7433 -0.0758 -0.1610 -0.3697 -0.5238 -0.0943 -0.4354 -0.7589 -0.5135 -0.9564 -1.3749 -0.4135 -0.3005 -0.4258
S-458	In Studien verursachten hohe Dosen bei Ratten ein vermehrtes Auftreten von unvollständiger Ossifikation bei den Feten .
T-458	In studies , rats given high doses showed an increased incidence of incomplete foetal ossification .
H-458	-0.4250737726688385	In studies , high doses in rats caused an increased occurrence of incomplete ossification in the fetus .
D-458	-0.4250737726688385	In studies , high doses in rats caused an increased occurrence of incomplete ossification in the fetus .
P-458	-0.2803 -0.5070 -0.3132 -0.7339 -0.1551 -0.0514 -0.1601 -0.0378 -2.1517 -0.4435 -0.0709 -1.6964 -0.0494 -0.1119 -0.1005 -0.1241 -0.2837 -0.3362 -0.5782 -0.1361 -0.1691 -0.2266 -1.0682 -0.9621 -0.1520 -0.1527
S-1747	Treten irgendwelche dieser Symptome auf , brechen Sie die Injektion sofort ab und kontaktieren Sie Ihren Arzt . Schwere Symptome wie z.
T-1747	If any of these symptoms occur , stop the injection immediately and contact your doctor .
H-1747	-0.2654522657394409	If any of these symptoms occur , discontinue the injection immediately and contact your doctor . Severe symptoms such as
D-1747	-0.2654522657394409	If any of these symptoms occur , discontinue the injection immediately and contact your doctor . Severe symptoms such as
P-1747	-0.2670 -0.3732 -0.1329 -0.1092 -0.0503 -0.5340 -0.1236 -1.6293 -0.0899 -0.8039 -0.2057 -0.1226 -0.0188 -0.1276 -0.3544 -0.1172 -0.1186 -0.1581 -0.2156 -0.1650 -0.0695 -0.2632 -0.1572 -0.1636
S-262	In Studien verursachten hohe Dosen bei Ratten ein vermehrtes Auftreten von unvollständiger Ossifikation bei den Feten .
T-262	In studies , rats given high doses showed an increased incidence of incomplete foetal ossification .
H-262	-0.4250737726688385	In studies , high doses in rats caused an increased occurrence of incomplete ossification in the fetus .
D-262	-0.4250737726688385	In studies , high doses in rats caused an increased occurrence of incomplete ossification in the fetus .
P-262	-0.2803 -0.5070 -0.3132 -0.7339 -0.1551 -0.0514 -0.1601 -0.0378 -2.1517 -0.4435 -0.0709 -1.6964 -0.0494 -0.1119 -0.1005 -0.1241 -0.2837 -0.3362 -0.5782 -0.1361 -0.1691 -0.2266 -1.0682 -0.9621 -0.1520 -0.1527
S-1235	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1235	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1235	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-1235	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-1235	-2.1817 -0.7190 -0.2061 -1.9401 -0.1942 -0.0850 -0.1331 -0.1938 -0.2494 -0.1489 -0.1550 -0.1903 -0.0977 -1.4743 -0.1299 -0.5891 -0.1649 -0.2171 -0.1355 -0.0739 -0.1655 -0.1625
S-707	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-707	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-707	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-707	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-707	-2.1817 -0.7190 -0.2061 -1.9401 -0.1942 -0.0850 -0.1331 -0.1938 -0.2494 -0.1489 -0.1550 -0.1903 -0.0977 -1.4743 -0.1299 -0.5891 -0.1649 -0.2171 -0.1355 -0.0739 -0.1655 -0.1625
S-883	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-883	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-883	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-883	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-883	-2.1817 -0.7190 -0.2061 -1.9401 -0.1942 -0.0850 -0.1331 -0.1938 -0.2494 -0.1489 -0.1550 -0.1903 -0.0977 -1.4743 -0.1299 -0.5891 -0.1649 -0.2171 -0.1355 -0.0739 -0.1655 -0.1625
S-1059	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1059	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1059	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-1059	-0.4366875886917114	Use only the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-1059	-2.1817 -0.7190 -0.2061 -1.9401 -0.1942 -0.0850 -0.1331 -0.1938 -0.2494 -0.1489 -0.1550 -0.1903 -0.0977 -1.4743 -0.1299 -0.5891 -0.1649 -0.2171 -0.1355 -0.0739 -0.1655 -0.1625
S-1066	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1066	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1066	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
D-1066	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
P-1066	-0.9477 -0.7257 -0.1721 -0.2047 -0.0538 -0.1769 -1.6350 -0.0743 -0.1668 -2.0678 -0.0442 -0.7508 -0.4205 -0.5481 -0.1422 -0.6113 -0.1290 -0.8243 -0.5655 -0.0935 -0.7032 -0.0954 -0.1583 -0.1524
S-1242	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1242	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1242	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
D-1242	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
P-1242	-0.9477 -0.7257 -0.1721 -0.2047 -0.0538 -0.1769 -1.6350 -0.0743 -0.1668 -2.0678 -0.0442 -0.7508 -0.4205 -0.5481 -0.1422 -0.6113 -0.1290 -0.8243 -0.5655 -0.0935 -0.7032 -0.0954 -0.1583 -0.1524
S-1418	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1418	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1418	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
D-1418	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
P-1418	-0.9477 -0.7257 -0.1721 -0.2047 -0.0538 -0.1769 -1.6350 -0.0743 -0.1668 -2.0678 -0.0442 -0.7508 -0.4205 -0.5481 -0.1422 -0.6113 -0.1290 -0.8243 -0.5655 -0.0935 -0.7032 -0.0954 -0.1583 -0.1524
S-714	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-714	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-714	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
D-714	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
P-714	-0.9477 -0.7257 -0.1721 -0.2047 -0.0538 -0.1769 -1.6350 -0.0743 -0.1668 -2.0678 -0.0442 -0.7508 -0.4205 -0.5481 -0.1422 -0.6113 -0.1290 -0.8243 -0.5655 -0.0935 -0.7032 -0.0954 -0.1583 -0.1524
S-1595	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1595	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1595	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
D-1595	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
P-1595	-0.9477 -0.7257 -0.1721 -0.2047 -0.0538 -0.1769 -1.6350 -0.0743 -0.1668 -2.0678 -0.0442 -0.7508 -0.4205 -0.5481 -0.1422 -0.6113 -0.1290 -0.8243 -0.5655 -0.0935 -0.7032 -0.0954 -0.1583 -0.1524
S-339	Antikonvulsiva , Cimetidin und Thiazide können den Abbaustoffwechsel von Vitamin D verstärken .
T-339	Anticonvulsants , cimetidine and thiazides may increase the catabolism of vitamin D.
H-339	-0.3182770311832428	Anticonvulsants , cimetidine and thiazides can increase the metabolism of vitamin D .
D-339	-0.3182770311832428	Anticonvulsants , cimetidine and thiazides can increase the metabolism of vitamin D .
P-339	-0.7337 -0.1294 -0.0155 -0.1918 -0.3117 -0.1386 -0.2870 -0.1172 -0.1581 -0.1145 -0.2068 -0.3776 -0.0497 -0.1282 -0.0776 -0.1858 -0.9002 -1.2497 -0.4008 -1.8675 -0.0334 -0.0543 -0.1280 -0.1505 -0.0757 -0.2616 -0.4113 -0.1557
S-1863	Das Gen , welches das Virus in Advexin trägt , ist das normale ( nicht defekte ) p53-Gen .
T-1863	The gene carried by the virus in Advexin is the normal ( non-defective ) p53 gene .
H-1863	-0.39970552921295166	The gene that carries the virus in Advexin is the normal ( not defective ) p53 gene .
D-1863	-0.39970552921295166	The gene that carries the virus in Advexin is the normal ( not defective ) p53 gene .
P-1863	-0.2102 -0.2381 -1.4530 -0.8034 -0.2227 -0.1135 -0.2057 -0.9048 -0.1706 -0.1366 -0.1537 -0.3331 -0.0954 -0.3099 -2.3037 -0.5038 -0.1037 -0.1330 -0.1185 -0.0280 -0.3155 -0.1810 -0.1551
S-890	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-890	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-890	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
D-890	-0.4776404798030853	If solution and containers permit , parenterals should always be checked for suspended particles before administration .
P-890	-0.9477 -0.7257 -0.1721 -0.2047 -0.0538 -0.1769 -1.6350 -0.0743 -0.1668 -2.0678 -0.0442 -0.7508 -0.4205 -0.5481 -0.1422 -0.6113 -0.1290 -0.8243 -0.5655 -0.0935 -0.7032 -0.0954 -0.1583 -0.1524
S-541	Bei einigen Patienten , die mit Arzneimitteln behandelt wurden , welche Faktor VIII enthalten , wurde Überempfindlichkeit ( allergische Reaktion ) beobachtet .
T-541	Hypersensitivity ( allergic reactions ) has sometimes been seen in patients treated with factor VIII-containing products .
H-541	-0.4199814200401306	Hypersensitivity ( allergic reaction ) has been observed in some patients treated with medicines containing factor VIII .
D-541	-0.4199814200401306	Hypersensitivity ( allergic reaction ) has been observed in some patients treated with medicines containing factor VIII .
P-541	-1.9669 -0.0710 -0.0246 -0.0632 -0.1578 -0.2046 -0.0602 -0.0505 -0.1390 -1.2853 -0.1491 -0.1533 -0.1415 -0.2726 -0.2166 -1.4787 -0.1725 -2.2081 -0.4509 -0.2760 -0.3258 -0.1664 -0.0872 -0.2207 -0.1571
S-1923	Die vollständige Auflistung der im Zusammenhang mit Aerinaze berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-1923	For the full list of all side effects reported with Aerinaze , see the Package Leaflet .
H-1923	-0.3089401423931122	For a full list of reported Aerinaze side effects , see the Package Leaflet .
D-1923	-0.3089401423931122	For a full list of reported Aerinaze side effects , see the Package Leaflet .
P-1923	-0.9309 -0.1296 -0.1160 -0.1164 -0.1284 -0.2706 -1.2969 -0.1658 -0.1395 -0.1277 -0.1024 -1.2645 -0.1322 -0.5691 -0.2689 -0.2125 -0.1844 -0.1297 -0.1796 -0.0337 -0.1242 -0.3285 -0.1543
S-566	Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-566	2 factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-566	-0.3534933924674988	Factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
D-566	-0.3534933924674988	Factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
P-566	-0.6986 -0.1631 -0.0890 -0.1075 -0.0964 -0.9921 -0.0554 -0.6133 -0.5593 -0.6418 -0.7228 -1.7822 -0.2147 -0.1387 -0.5362 -0.0576 -0.0823 -0.1237 -0.1173 -0.1370 -0.1917 -0.0935 -0.0280 -0.4383 -0.1568
S-78	Die vollständige Auflistung der im Zusammenhang mit ADROVANCE berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-78	For the full list of all side effects reported with ADROVANCE , see the Package Leaflet .
H-78	-0.3479754626750946	See the Package Leaflet for a full list of reported adverse reactions associated with ADROVANCE .
D-78	-0.3479754626750946	See the Package Leaflet for a full list of reported adverse reactions associated with ADROVANCE .
P-78	-2.1086 -0.2039 -1.1949 -0.1268 -0.2046 -0.0241 -0.1341 -0.1467 -0.1280 -0.1323 -0.1264 -0.1218 -0.7663 -1.7242 -0.0220 -0.2678 -0.0205 -0.5997 -0.1383 -0.0792 -0.0754 -0.1237 -0.1035 -0.0614 -0.2600 -0.1532
S-1940	Symptomatische Behandlung der saisonalen allergischen Rhinitis mit begleitender Nasenschleimhautschwellung .
T-1940	Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion .
H-1940	-0.27726396918296814	Symptomatic treatment of seasonal allergic rhinitis with accompanying nasal swelling .
D-1940	-0.27726396918296814	Symptomatic treatment of seasonal allergic rhinitis with accompanying nasal swelling .
P-1940	-1.7645 -0.0858 -0.0857 -0.2499 -0.2029 -0.2047 -0.0920 -0.0649 -0.0801 -0.1085 -0.0708 -0.0993 -0.0731 -0.3453 -1.8627 -0.0999 -0.1463 -0.0802 -0.0191 -0.2205 -0.1657 -0.1016 -0.2731 -0.1576
S-1381	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1381	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1381	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-1381	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-1381	-1.7971 -0.4714 -0.4658 -0.0919 -0.0907 -0.1309 -0.3475 -0.1472 -0.6327 -0.1492 -0.1669 -0.4858 -1.0144 -0.0481 -0.1003 -0.9003 -0.1383 -0.1525 -0.1716 -0.1623 -0.1847 -0.2371 -0.1242 -0.0903 -0.1543 -0.2135 -0.0790 -0.1030 -0.1583 -0.1535
S-1489	59 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1489	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1489	-0.2640884518623352	After reconstitution , this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
D-1489	-0.2640884518623352	After reconstitution , this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
P-1489	-2.3450 -0.3095 -0.1652 -0.5155 -0.1187 -0.1117 -0.0530 -0.0921 -0.0597 -0.1130 -0.1534 -0.0979 -0.2234 -0.0901 -1.0396 -0.0680 -0.1344 -0.1712 -0.0530 -0.1580 -0.0677 -0.0147 -0.0621 -0.2299 -0.1554
S-1313	48 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1313	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1313	-0.2726319432258606	48 This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
D-1313	-0.2726319432258606	48 This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
P-1313	-1.1148 -0.6774 -0.1405 -0.0629 -0.0898 -0.2619 -0.8538 -0.1575 -0.0981 -0.2259 -0.0933 -0.6569 -0.0764 -0.1382 -0.1637 -0.0565 -0.1508 -0.0690 -0.0147 -0.0590 -0.7601 -0.3608 -0.1775 -0.2020 -0.1543
S-1137	37 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1137	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1137	-0.27816829085350037	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
D-1137	-0.27816829085350037	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
P-1137	-1.6808 -0.0812 -0.0590 -0.0963 -0.1966 -0.8243 -0.1583 -0.1012 -0.2254 -0.0925 -0.7861 -0.0763 -0.1378 -0.1674 -0.0579 -0.1424 -0.0680 -0.0149 -0.0587 -0.7577 -0.3585 -0.1849 -0.1932 -0.1567
S-961	26 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-961	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-961	-0.27149146795272827	Following reconstitution , this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
D-961	-0.27149146795272827	Following reconstitution , this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
P-961	-2.7358 -0.3274 -0.1457 -0.3777 -0.1088 -0.0727 -0.0508 -0.0837 -0.0572 -0.1116 -0.1542 -0.0987 -0.2249 -0.0896 -1.0374 -0.0683 -0.1336 -0.1691 -0.0559 -0.1691 -0.0666 -0.0141 -0.0606 -0.2185 -0.1553
S-538	Ein Antikörper ist ein Protein , das vom Körper aufgrund seines natürlichen Schutzmechanismus als Reaktion auf unbekannte Stoffe gebildet wird .
T-538	An antibody is a protein produced by the body in reaction to unknown agents as part of the natural defence system of the body .
H-538	-0.3799753189086914	An antibody is a protein produced by the body by its natural protective mechanism in response to unknown substances .
D-538	-0.3799753189086914	An antibody is a protein produced by the body by its natural protective mechanism in response to unknown substances .
P-538	-0.4494 -0.1321 -0.1365 -0.1500 -0.1356 -0.0565 -0.7097 -0.2035 -0.1501 -0.1345 -2.5788 -0.1472 -0.4092 -1.6786 -0.1322 -0.1236 -0.2704 -0.3557 -0.1328 -0.1686 -0.4520 -0.0913 -0.1654 -0.1560
S-611	4 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-611	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-611	-0.2835134267807007	After reconstitution , this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
D-611	-0.2835134267807007	After reconstitution , this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
P-611	-2.7855 -0.3089 -0.1750 -0.4902 -0.1091 -0.1098 -0.0537 -0.0844 -0.0591 -0.1140 -0.1595 -0.0978 -0.2277 -0.0916 -1.1225 -0.0711 -0.1345 -0.1680 -0.0531 -0.1576 -0.0665 -0.0144 -0.0611 -0.2189 -0.1535
S-1281	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-1281	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-1281	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
D-1281	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
P-1281	-1.4472 -0.2159 -0.0955 -0.1651 -0.3779 -0.8460 -0.1940 -0.1193 -0.4131 -0.2037 -0.3964 -0.2249 -0.1199 -0.9888 -0.1381 -0.1971 -0.1046 -0.3946 -0.1362 -0.3800 -0.8424 -0.1876 -0.1135 -0.6957 -0.3131 -0.5330 -0.1600
S-929	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-929	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-929	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
D-929	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
P-929	-1.4472 -0.2159 -0.0955 -0.1651 -0.3779 -0.8460 -0.1940 -0.1193 -0.4131 -0.2037 -0.3964 -0.2249 -0.1199 -0.9888 -0.1381 -0.1971 -0.1046 -0.3946 -0.1362 -0.3800 -0.8424 -0.1876 -0.1135 -0.6957 -0.3131 -0.5330 -0.1600
S-371	Vitamin D3 über bis zu 5 Monate nicht mit Hypercalciurie oder Hypercalcämie assoziiert .
T-371	In a clinical study of healthy adults a 4000 IU daily dose of vitamin D3 for up to five months was not associated with hypercalciuria or hypercalcaemia .
H-371	-0.19223496317863464	vitamin D3 for up to 5 months is not associated with hypercalciuria or hypercalcaemia .
D-371	-0.19223496317863464	vitamin D3 for up to 5 months is not associated with hypercalciuria or hypercalcaemia .
P-371	-0.1842 -0.0735 -0.1651 -0.1438 -0.7678 -0.2899 -0.1301 -0.1637 -0.1513 -1.0263 -0.1559 -0.1449 -0.1732 -0.0352 -0.1257 -0.1165 -0.0606 -0.1441 -0.1443 -0.0689 -0.1249 -0.0467 -0.0254 -0.1313 -0.2486 -0.1562
S-183	Vitamin D3 über bis zu 5 Monate nicht mit Hypercalciurie oder Hypercalcämie assoziiert .
T-183	In a clinical study of healthy adults a 4000 IU daily dose of vitamin D3 for up to five months was not associated with hypercalciuria or hypercalcaemia .
H-183	-0.19223496317863464	vitamin D3 for up to 5 months is not associated with hypercalciuria or hypercalcaemia .
D-183	-0.19223496317863464	vitamin D3 for up to 5 months is not associated with hypercalciuria or hypercalcaemia .
P-183	-0.1842 -0.0735 -0.1651 -0.1438 -0.7678 -0.2899 -0.1301 -0.1637 -0.1513 -1.0263 -0.1559 -0.1449 -0.1732 -0.0352 -0.1257 -0.1165 -0.0606 -0.1441 -0.1443 -0.0689 -0.1249 -0.0467 -0.0254 -0.1313 -0.2486 -0.1562
S-1914	In beiden Studien wurde Aerinaze mit Desloratadin allein und mit Pseudoephedrin allein verglichen .
T-1914	In both studies , Aerinaze was compared with desloratadine alone and with pseudoephedrine alone .
H-1914	-0.25291943550109863	In both studies , Aerinaze was compared to desloratadine alone and to pseudoephedrine alone .
D-1914	-0.25291943550109863	In both studies , Aerinaze was compared to desloratadine alone and to pseudoephedrine alone .
P-1914	-0.3713 -0.0866 -0.9137 -0.2804 -0.2664 -0.1337 -0.1476 -0.1075 -0.0926 -0.3084 -0.2076 -1.1447 -0.4468 -0.0637 -0.1162 -0.2911 -0.5564 -0.1572 -0.1784 -0.5164 -0.1016 -0.1705 -0.1511 -0.0672 -0.1119 -0.1258 -0.1137 -0.0551 -0.1498 -0.1542
S-1836	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
T-1836	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <<unk>> 354 533 6100
H-1836	-0.28997355699539185	Suðurlandsbrau/ 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
D-1836	-0.28997355699539185	Suðurlandsbrau/ 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
P-1836	-0.2809 -0.0881 -0.0974 -0.2545 -2.9517 -1.6914 -0.2391 -0.2374 -0.1181 -0.1155 -0.1145 -0.1592 -0.1727 -0.2011 -0.0827 -0.0577 -0.0973 -0.1334 -0.0448 -0.0587 -0.1515 -0.0667 -0.1468 -0.0738 -0.1816 -0.1227 -0.1818 -0.1248 -0.1631
S-1825	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
T-1825	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <<unk>> 372 6 515 100
H-1825	-0.12450423836708069	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
D-1825	-0.12450423836708069	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
P-1825	-0.1790 -0.0849 -0.1389 -0.0443 -0.1374 -0.1284 -0.1508 -0.0410 -0.2133 -0.1366 -0.1409 -0.1391 -0.0811 -0.0822 -0.1026 -0.1314 -0.0411 -0.1204 -0.0991 -0.2303 -0.1383 -0.0335 -0.1492 -0.1151 -0.1335 -0.1837 -0.1585 -0.1195 -0.1567
S-1824	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
T-1824	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <<unk>> 47 22 58 4800
H-1824	-0.11624044179916382	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
D-1824	-0.11624044179916382	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
P-1824	-0.0921 -0.1057 -0.1315 -0.1495 -0.1543 -0.0553 -0.1445 -0.1384 -0.1719 -0.1842 -0.1115 -0.0705 -0.1236 -0.1175 -0.1277 -0.0791 -0.0873 -0.1022 -0.1558 -0.1151 -0.1123 -0.1375 -0.0377 -0.0603 -0.0854 -0.1075 -0.1776 -0.0777 -0.1574
S-1457	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-1457	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-1457	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
D-1457	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
P-1457	-1.4472 -0.2159 -0.0955 -0.1651 -0.3779 -0.8460 -0.1940 -0.1193 -0.4131 -0.2037 -0.3964 -0.2249 -0.1199 -0.9888 -0.1381 -0.1971 -0.1046 -0.3946 -0.1362 -0.3800 -0.8424 -0.1876 -0.1135 -0.6957 -0.3131 -0.5330 -0.1600
S-677	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-677	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-677	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-677	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-677	-1.7971 -0.4714 -0.4658 -0.0919 -0.0907 -0.1309 -0.3475 -0.1472 -0.6327 -0.1492 -0.1669 -0.4858 -1.0144 -0.0481 -0.1003 -0.9003 -0.1383 -0.1525 -0.1716 -0.1623 -0.1847 -0.2371 -0.1242 -0.0903 -0.1543 -0.2135 -0.0790 -0.1030 -0.1583 -0.1535
S-1105	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-1105	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-1105	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
D-1105	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
P-1105	-1.4472 -0.2159 -0.0955 -0.1651 -0.3779 -0.8460 -0.1940 -0.1193 -0.4131 -0.2037 -0.3964 -0.2249 -0.1199 -0.9888 -0.1381 -0.1971 -0.1046 -0.3946 -0.1362 -0.3800 -0.8424 -0.1876 -0.1135 -0.6957 -0.3131 -0.5330 -0.1600
S-151	Antikonvulsiva , Cimetidin und Thiazide können den Abbaustoffwechsel von Vitamin D verstärken .
T-151	Anticonvulsants , cimetidine and thiazides may increase the catabolism of vitamin D.
H-151	-0.3182770311832428	Anticonvulsants , cimetidine and thiazides can increase the metabolism of vitamin D .
D-151	-0.3182770311832428	Anticonvulsants , cimetidine and thiazides can increase the metabolism of vitamin D .
P-151	-0.7337 -0.1294 -0.0155 -0.1918 -0.3117 -0.1386 -0.2870 -0.1172 -0.1581 -0.1145 -0.2068 -0.3776 -0.0497 -0.1282 -0.0776 -0.1858 -0.9002 -1.2497 -0.4008 -1.8675 -0.0334 -0.0543 -0.1280 -0.1505 -0.0757 -0.2616 -0.4113 -0.1557
S-753	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-753	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-753	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
D-753	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
P-753	-1.4472 -0.2159 -0.0955 -0.1651 -0.3779 -0.8460 -0.1940 -0.1193 -0.4131 -0.2037 -0.3964 -0.2249 -0.1199 -0.9888 -0.1381 -0.1971 -0.1046 -0.3946 -0.1362 -0.3800 -0.8424 -0.1876 -0.1135 -0.6957 -0.3131 -0.5330 -0.1600
S-579	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-579	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-579	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
D-579	-0.3705100119113922	Every 24 hours ( 12 -24 hours in patients under 6 years ) for at least 1 day until wound healing is achieved .
P-579	-1.4472 -0.2159 -0.0955 -0.1651 -0.3779 -0.8460 -0.1940 -0.1193 -0.4131 -0.2037 -0.3964 -0.2249 -0.1199 -0.9888 -0.1381 -0.1971 -0.1046 -0.3946 -0.1362 -0.3800 -0.8424 -0.1876 -0.1135 -0.6957 -0.3131 -0.5330 -0.1600
S-16	Das Arzneimittel wird nicht empfohlen bei Kindern und bei Patienten , die eine Organtransplantation hatten , da es für diese Gruppen nicht untersucht wurde .
T-16	It is not recommended for use in children or in patients who have had an organ transplant because it has not been studied in these groups .
H-16	-0.419821172952652	This medicine is not recommended in paediatric and organ transplant patients as it has not been evaluated for these groups .
D-16	-0.419821172952652	This medicine is not recommended in paediatric and organ transplant patients as it has not been evaluated for these groups .
P-16	-1.3103 -0.9800 -0.2001 -0.1678 -0.1340 -0.2553 -1.3261 -0.0095 -0.0191 -0.1340 -0.2616 -0.6936 -0.1146 -0.2031 -0.0528 -0.8735 -0.1811 -0.2697 -0.1193 -0.1099 -1.8082 -0.1188 -0.8839 -0.2275 -0.5419 -0.1793 -0.1603
S-1558	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1558	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1558	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-1558	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-1558	-1.7971 -0.4714 -0.4658 -0.0919 -0.0907 -0.1309 -0.3475 -0.1472 -0.6327 -0.1492 -0.1669 -0.4858 -1.0144 -0.0481 -0.1003 -0.9003 -0.1383 -0.1525 -0.1716 -0.1623 -0.1847 -0.2371 -0.1242 -0.0903 -0.1543 -0.2135 -0.0790 -0.1030 -0.1583 -0.1535
S-1205	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1205	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1205	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-1205	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-1205	-1.7971 -0.4714 -0.4658 -0.0919 -0.0907 -0.1309 -0.3475 -0.1472 -0.6327 -0.1492 -0.1669 -0.4858 -1.0144 -0.0481 -0.1003 -0.9003 -0.1383 -0.1525 -0.1716 -0.1623 -0.1847 -0.2371 -0.1242 -0.0903 -0.1543 -0.2135 -0.0790 -0.1030 -0.1583 -0.1535
S-853	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-853	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-853	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-853	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-853	-1.7971 -0.4714 -0.4658 -0.0919 -0.0907 -0.1309 -0.3475 -0.1472 -0.6327 -0.1492 -0.1669 -0.4858 -1.0144 -0.0481 -0.1003 -0.9003 -0.1383 -0.1525 -0.1716 -0.1623 -0.1847 -0.2371 -0.1242 -0.0903 -0.1543 -0.2135 -0.0790 -0.1030 -0.1583 -0.1535
S-1029	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1029	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1029	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-1029	-0.30543091893196106	As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-1029	-1.7971 -0.4714 -0.4658 -0.0919 -0.0907 -0.1309 -0.3475 -0.1472 -0.6327 -0.1492 -0.1669 -0.4858 -1.0144 -0.0481 -0.1003 -0.9003 -0.1383 -0.1525 -0.1716 -0.1623 -0.1847 -0.2371 -0.1242 -0.0903 -0.1543 -0.2135 -0.0790 -0.1030 -0.1583 -0.1535
S-785	15 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-785	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-785	-0.27229297161102295	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
D-785	-0.27229297161102295	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
P-785	-1.4002 -0.0838 -0.0611 -0.0958 -0.2241 -0.8328 -0.1602 -0.1017 -0.2267 -0.0936 -0.8215 -0.0750 -0.1385 -0.1676 -0.0569 -0.1436 -0.0694 -0.0155 -0.0580 -0.8104 -0.3654 -0.1874 -0.1916 -0.1543
S-312	Nach Markteinführung waren diese Symptome selten schwerwiegend und<unk> oder mit Einschränkungen der Beweglichkeit verbunden ( siehe Abschnitt 4.8 ) .
T-312	In post-marketing experience , these symptoms have rarely been severe and/ or incapacitating ( see section 4.8 ) .
H-312	-0.5219282507896423	Following marketing , these symptoms were rarely severe and/ or associated with impairment of mobility ( see section 4.8 ) .
D-312	-0.5219282507896423	Following marketing , these symptoms were rarely severe and/ or associated with impairment of mobility ( see section 4.8 ) .
P-312	-2.6897 -1.3052 -0.5176 -0.1359 -0.1150 -0.2343 -1.2564 -0.6662 -1.7356 -0.3065 -0.1888 -0.8274 -0.1340 -2.1831 -0.0742 -0.0353 -0.1420 -0.2424 -0.5952 -0.1836 -0.1584 -0.1061 -0.0883 -0.1062 -0.1269 -0.1469 -0.1593 -0.1535
S-384	Ein Mangel steht in Verbindung mit einer negativen Calciumbilanz , Knochenverlust und einem erhöhten Risiko für Skelettfrakturen .
T-384	Insufficiency is associated with negative calcium balance , bone loss , and increased risk of skeletal fracture .
H-384	-0.28790009021759033	Deficiency is associated with negative calcium balance , bone loss , and an increased risk of skeletal fractures .
D-384	-0.28790009021759033	Deficiency is associated with negative calcium balance , bone loss , and an increased risk of skeletal fractures .
P-384	-0.3141 -0.0488 -0.1768 -0.8780 -0.1675 -0.1463 -1.0487 -0.0618 -0.1254 -0.1126 -0.2397 -0.1510 -0.0782 -0.2139 -0.8944 -0.1382 -0.8288 -0.0437 -0.1695 -0.4899 -0.0899 -0.0486 -0.1320 -0.1168 -0.9012 -0.1230 -0.1679 -0.1547
S-1937	Jede Tablette enthält 2,5 mg Desloratadin und 120 mg Pseudoephedrin ( als Sulfat ) .
T-1937	Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
H-1937	-0.18368329107761383	Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
D-1937	-0.18368329107761383	Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
P-1937	-0.0503 -0.1751 -0.1212 -0.0964 -0.3268 -0.0430 -0.7424 -0.0710 -0.1099 -0.2349 -0.4152 -0.1505 -0.0824 -0.0398 -0.1825 -0.2317 -0.1497 -0.0486 -0.1317 -0.1699 -0.1274 -0.1493 -0.3569 -0.0968 -0.4667 -0.0945 -0.1370 -0.1692 -0.1560
S-196	Ein Mangel steht in Verbindung mit einer negativen Calciumbilanz , Knochenverlust und einem erhöhten Risiko für Skelettfrakturen .
T-196	Insufficiency is associated with negative calcium balance , bone loss , and increased risk of skeletal fracture .
H-196	-0.28790009021759033	Deficiency is associated with negative calcium balance , bone loss , and an increased risk of skeletal fractures .
D-196	-0.28790009021759033	Deficiency is associated with negative calcium balance , bone loss , and an increased risk of skeletal fractures .
P-196	-0.3141 -0.0488 -0.1768 -0.8780 -0.1675 -0.1463 -1.0487 -0.0618 -0.1254 -0.1126 -0.2397 -0.1510 -0.0782 -0.2139 -0.8944 -0.1382 -0.8288 -0.0437 -0.1695 -0.4899 -0.0899 -0.0486 -0.1320 -0.1168 -0.9012 -0.1230 -0.1679 -0.1547
S-124	Nach Markteinführung waren diese Symptome selten schwerwiegend und<unk> oder mit Einschränkungen der Beweglichkeit verbunden ( siehe Abschnitt 4.8 ) .
T-124	In post-marketing experience , these symptoms have rarely been severe and/ or incapacitating ( see section 4.8 ) .
H-124	-0.5219282507896423	Following marketing , these symptoms were rarely severe and/ or associated with impairment of mobility ( see section 4.8 ) .
D-124	-0.5219282507896423	Following marketing , these symptoms were rarely severe and/ or associated with impairment of mobility ( see section 4.8 ) .
P-124	-2.6897 -1.3052 -0.5176 -0.1359 -0.1150 -0.2343 -1.2564 -0.6662 -1.7356 -0.3065 -0.1888 -0.8274 -0.1340 -2.1831 -0.0742 -0.0353 -0.1420 -0.2424 -0.5952 -0.1836 -0.1584 -0.1061 -0.0883 -0.1062 -0.1269 -0.1469 -0.1593 -0.1535
S-6	Bei der Hyperurikämie können sich Uratkristalle bilden und in den Gelenken und Nieren ablagern .
T-6	Hyperuricaemia can lead to urate crystals forming and building up in the joints and the kidneys .
H-6	-0.4711383283138275	In hyperuricaemia , urine crystals may form and deposit in the joints and kidneys .
D-6	-0.4711383283138275	In hyperuricaemia , urine crystals may form and deposit in the joints and kidneys .
P-6	-2.7492 -0.0847 -0.0738 -0.3277 -0.0142 -0.1318 -0.3851 -1.4203 -0.9180 -0.2360 -0.0220 -0.1605 -1.3219 -0.5010 -0.1756 -1.4542 -0.2202 -0.9406 -0.0375 -0.0210 -0.1407 -0.2753 -0.2935 -0.0370 -0.1534 -0.1545
S-1483	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-1483	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-1483	-0.3819096088409424	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
D-1483	-0.3819096088409424	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
P-1483	-1.1436 -0.1005 -1.0692 -0.2614 -0.6648 -0.2059 -0.0775 -0.1262 -0.0667 -0.0695 -0.1481 -0.1079 -0.9934 -1.0505 -0.1034 -0.4885 -0.1755 -0.4148 -0.2136 -0.1573
S-681	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-681	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-681	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
D-681	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
P-681	-1.4745 -1.6251 -0.2031 -0.5254 -0.3406 -0.0759 -0.9213 -0.1568 -0.2810 -0.1179 -1.0966 -0.1002 -0.0755 -0.1581 -0.7138 -0.1247 -0.2802 -0.6357 -0.2057 -0.1592 -0.2419 -0.2516 -0.0453 -0.1459 -0.3821 -0.1525 -0.1862 -0.1531
S-857	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-857	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-857	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
D-857	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
P-857	-1.4745 -1.6251 -0.2031 -0.5254 -0.3406 -0.0759 -0.9213 -0.1568 -0.2810 -0.1179 -1.0966 -0.1002 -0.0755 -0.1581 -0.7138 -0.1247 -0.2802 -0.6357 -0.2057 -0.1592 -0.2419 -0.2516 -0.0453 -0.1459 -0.3821 -0.1525 -0.1862 -0.1531
S-1033	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-1033	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1033	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
D-1033	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
P-1033	-1.4745 -1.6251 -0.2031 -0.5254 -0.3406 -0.0759 -0.9213 -0.1568 -0.2810 -0.1179 -1.0966 -0.1002 -0.0755 -0.1581 -0.7138 -0.1247 -0.2802 -0.6357 -0.2057 -0.1592 -0.2419 -0.2516 -0.0453 -0.1459 -0.3821 -0.1525 -0.1862 -0.1531
S-1209	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-1209	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1209	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
D-1209	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
P-1209	-1.4745 -1.6251 -0.2031 -0.5254 -0.3406 -0.0759 -0.9213 -0.1568 -0.2810 -0.1179 -1.0966 -0.1002 -0.0755 -0.1581 -0.7138 -0.1247 -0.2802 -0.6357 -0.2057 -0.1592 -0.2419 -0.2516 -0.0453 -0.1459 -0.3821 -0.1525 -0.1862 -0.1531
S-1385	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-1385	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1385	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
D-1385	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
P-1385	-1.4745 -1.6251 -0.2031 -0.5254 -0.3406 -0.0759 -0.9213 -0.1568 -0.2810 -0.1179 -1.0966 -0.1002 -0.0755 -0.1581 -0.7138 -0.1247 -0.2802 -0.6357 -0.2057 -0.1592 -0.2419 -0.2516 -0.0453 -0.1459 -0.3821 -0.1525 -0.1862 -0.1531
S-1562	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-1562	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1562	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
D-1562	-0.38677778840065	During runtime , the product can be stored at room temperature ( up to 25<unk> C ) for a maximum of 2 months .
P-1562	-1.4745 -1.6251 -0.2031 -0.5254 -0.3406 -0.0759 -0.9213 -0.1568 -0.2810 -0.1179 -1.0966 -0.1002 -0.0755 -0.1581 -0.7138 -0.1247 -0.2802 -0.6357 -0.2057 -0.1592 -0.2419 -0.2516 -0.0453 -0.1459 -0.3821 -0.1525 -0.1862 -0.1531
S-1949	Überempfindlichkeit gegen den Wirkstoff , einen der sonstigen Bestandteile , adrenergen Wirkstoffen oder Loratadin .
T-1949	Hypersensitivity to the active substance , to any of the excipients , to adrenergic agents or to loratadine .
H-1949	-0.34842583537101746	Hypersensitivity to the active substance , any of the other ingredients , adrenergic agents or loratadine .
D-1949	-0.34842583537101746	Hypersensitivity to the active substance , any of the other ingredients , adrenergic agents or loratadine .
P-1949	-0.4381 -0.0540 -0.0414 -0.0624 -0.1580 -0.3077 -0.1804 -0.0515 -0.1671 -0.8583 -0.2487 -0.2327 -1.0644 -0.1660 -0.1428 -0.0772 -0.0941 -0.1186 -0.0604 -0.0704 -0.8222 -0.0903 -0.1043 -0.3354 -3.0001 -0.3063 -0.1548
S-1307	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-1307	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-1307	-0.3819096088409424	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
D-1307	-0.3819096088409424	Patients who develop factor VIII inhibitors may experience an inadequate clinical response .
P-1307	-1.1436 -0.1005 -1.0692 -0.2614 -0.6648 -0.2059 -0.0775 -0.1262 -0.0667 -0.0695 -0.1481 -0.1079 -0.9934 -1.0505 -0.1034 -0.4885 -0.1755 -0.4148 -0.2136 -0.1573
S-742	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-742	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-742	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-742	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-742	-1.0580 -0.0998 -0.1108 -0.2243 -0.1469 -0.1576 -0.0475 -0.1360 -0.1826 -0.9478 -0.0594 -0.1392 -0.0655 -0.1336 -0.1166 -0.2957 -0.0834 -0.1256 -0.0331 -1.8578 -0.3932 -0.1376 -0.1644 -0.1354 -0.1506 -0.0542 -0.1548
S-568	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-568	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-568	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-568	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-568	-1.0580 -0.0998 -0.1108 -0.2243 -0.1469 -0.1576 -0.0475 -0.1360 -0.1826 -0.9478 -0.0594 -0.1392 -0.0655 -0.1336 -0.1166 -0.2957 -0.0834 -0.1256 -0.0331 -1.8578 -0.3932 -0.1376 -0.1644 -0.1354 -0.1506 -0.0542 -0.1548
S-644	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-644	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-644	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-644	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-644	-2.1692 -0.2304 -0.2726 -0.3160 -1.0491 -0.3435 -0.5865 -0.0962 -0.6669 -0.1442 -0.1579 -0.1943 -0.0880 -0.2571 -0.1211 -0.1340 -0.2554 -0.1308 -0.6830 -0.5649 -0.0756 -0.3685 -0.1411 -0.4506 -0.1261 -0.1779 -0.1041 -0.3081 -0.1147 -0.1223 -0.1667 -0.1546
S-1446	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-1446	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-1446	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-1446	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-1446	-1.0580 -0.0998 -0.1108 -0.2243 -0.1469 -0.1576 -0.0475 -0.1360 -0.1826 -0.9478 -0.0594 -0.1392 -0.0655 -0.1336 -0.1166 -0.2957 -0.0834 -0.1256 -0.0331 -1.8578 -0.3932 -0.1376 -0.1644 -0.1354 -0.1506 -0.0542 -0.1548
S-1270	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-1270	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-1270	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-1270	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-1270	-1.0580 -0.0998 -0.1108 -0.2243 -0.1469 -0.1576 -0.0475 -0.1360 -0.1826 -0.9478 -0.0594 -0.1392 -0.0655 -0.1336 -0.1166 -0.2957 -0.0834 -0.1256 -0.0331 -1.8578 -0.3932 -0.1376 -0.1644 -0.1354 -0.1506 -0.0542 -0.1548
S-107	Alendronat Alendronat kann lokale Irritationen der Schleimhäute des oberen Gastrointestinaltraktes verursachen .
T-107	Alendronate Alendronate can cause local irritation of the upper gastrointestinal mucosa .
H-107	-0.30349239706993103	Alendronate Alendronate may cause local irritation of the upper gastrointestinal mucosae .
D-107	-0.30349239706993103	Alendronate Alendronate may cause local irritation of the upper gastrointestinal mucosae .
P-107	-0.2576 -0.1259 -0.1421 -0.1293 -0.3453 -0.1233 -0.1355 -0.0979 -0.8471 -0.1951 -0.6189 -0.1023 -0.1640 -0.4483 -0.3439 -1.0100 -0.2246 -0.1297 -0.5814 -0.0943 -0.0677 -0.1173 -0.0421 -1.1716 -0.2138 -0.1619
S-918	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-918	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-918	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-918	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-918	-1.0580 -0.0998 -0.1108 -0.2243 -0.1469 -0.1576 -0.0475 -0.1360 -0.1826 -0.9478 -0.0594 -0.1392 -0.0655 -0.1336 -0.1166 -0.2957 -0.0834 -0.1256 -0.0331 -1.8578 -0.3932 -0.1376 -0.1644 -0.1354 -0.1506 -0.0542 -0.1548
S-994	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-994	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-994	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-994	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-994	-2.1692 -0.2304 -0.2726 -0.3160 -1.0491 -0.3435 -0.5865 -0.0962 -0.6669 -0.1442 -0.1579 -0.1943 -0.0880 -0.2571 -0.1211 -0.1340 -0.2554 -0.1308 -0.6830 -0.5649 -0.0756 -0.3685 -0.1411 -0.4506 -0.1261 -0.1779 -0.1041 -0.3081 -0.1147 -0.1223 -0.1667 -0.1546
S-1346	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-1346	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-1346	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-1346	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-1346	-2.1692 -0.2304 -0.2726 -0.3160 -1.0491 -0.3435 -0.5865 -0.0962 -0.6669 -0.1442 -0.1579 -0.1943 -0.0880 -0.2571 -0.1211 -0.1340 -0.2554 -0.1308 -0.6830 -0.5649 -0.0756 -0.3685 -0.1411 -0.4506 -0.1261 -0.1779 -0.1041 -0.3081 -0.1147 -0.1223 -0.1667 -0.1546
S-379	Vitamin D3 wird in der Leber zu 25-Hydroxyvitamin D3 umgewandelt und gespeichert , bis es gebraucht wird .
T-379	Vitamin D3 is converted to 25-hydroxyvitamin D3 in the liver , and stored until needed .
H-379	-0.3230082392692566	Vitamin D3 is converted into 25-hydroxyvitamin D3 in the liver and stored until it is needed .
D-379	-0.3230082392692566	Vitamin D3 is converted into 25-hydroxyvitamin D3 in the liver and stored until it is needed .
P-379	-0.9944 -0.0614 -0.1605 -0.1392 -0.1658 -0.7015 -1.7240 -0.5957 -0.0894 -0.0539 -0.1218 -0.1092 -0.1120 -0.0821 -0.1626 -0.1428 -0.6448 -0.1584 -0.1264 -0.2945 -0.3846 -0.1259 -0.2491 -0.5617 -0.1965 -0.5286 -0.1967 -0.1606
S-310	Die klinische Einschätzung durch den behandelnden Arzt ist maßgebend für die Therapieplanung bei jedem Patienten auf Basis einer individuellen Nutzen-Risiko-Bewertung .
T-310	Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/ risk assessment .
H-310	-0.4439854919910431	The clinical assessment by the attending physician is decisive for the therapy planning in each patient on the basis of an individual benefit-risk assessment .
D-310	-0.4439854919910431	The clinical assessment by the attending physician is decisive for the therapy planning in each patient on the basis of an individual benefit-risk assessment .
P-310	-0.3142 -0.1995 -0.2851 -0.7089 -0.2183 -0.6283 -0.5137 -0.0988 -0.2306 -1.9975 -0.2157 -0.7650 -1.8881 -0.3141 -1.1810 -0.3908 -0.0721 -0.3100 -0.1536 -0.1566 -0.1228 -0.2482 -0.0974 -1.1030 -0.1221 -0.0355 -0.3722 -0.2531 -0.1708 -0.1526
S-191	Vitamin D3 wird in der Leber zu 25-Hydroxyvitamin D3 umgewandelt und gespeichert , bis es gebraucht wird .
T-191	Vitamin D3 is converted to 25-hydroxyvitamin D3 in the liver , and stored until needed .
H-191	-0.3230082392692566	Vitamin D3 is converted into 25-hydroxyvitamin D3 in the liver and stored until it is needed .
D-191	-0.3230082392692566	Vitamin D3 is converted into 25-hydroxyvitamin D3 in the liver and stored until it is needed .
P-191	-0.9944 -0.0614 -0.1605 -0.1392 -0.1658 -0.7015 -1.7240 -0.5957 -0.0894 -0.0539 -0.1218 -0.1092 -0.1120 -0.0821 -0.1626 -0.1428 -0.6448 -0.1584 -0.1264 -0.2945 -0.3846 -0.1259 -0.2491 -0.5617 -0.1965 -0.5286 -0.1967 -0.1606
S-122	Die klinische Einschätzung durch den behandelnden Arzt ist maßgebend für die Therapieplanung bei jedem Patienten auf Basis einer individuellen Nutzen-Risiko-Bewertung .
T-122	Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/ risk assessment .
H-122	-0.4439854919910431	The clinical assessment by the attending physician is decisive for the therapy planning in each patient on the basis of an individual benefit-risk assessment .
D-122	-0.4439854919910431	The clinical assessment by the attending physician is decisive for the therapy planning in each patient on the basis of an individual benefit-risk assessment .
P-122	-0.3142 -0.1995 -0.2851 -0.7089 -0.2183 -0.6283 -0.5137 -0.0988 -0.2306 -1.9975 -0.2157 -0.7650 -1.8881 -0.3141 -1.1810 -0.3908 -0.0721 -0.3100 -0.1536 -0.1566 -0.1228 -0.2482 -0.0974 -1.1030 -0.1221 -0.0355 -0.3722 -0.2531 -0.1708 -0.1526
S-295	Alendronat Alendronat kann lokale Irritationen der Schleimhäute des oberen Gastrointestinaltraktes verursachen .
T-295	Alendronate Alendronate can cause local irritation of the upper gastrointestinal mucosa .
H-295	-0.30349239706993103	Alendronate Alendronate may cause local irritation of the upper gastrointestinal mucosae .
D-295	-0.30349239706993103	Alendronate Alendronate may cause local irritation of the upper gastrointestinal mucosae .
P-295	-0.2576 -0.1259 -0.1421 -0.1293 -0.3453 -0.1233 -0.1355 -0.0979 -0.8471 -0.1951 -0.6189 -0.1023 -0.1640 -0.4483 -0.3439 -1.0100 -0.2246 -0.1297 -0.5814 -0.0943 -0.0677 -0.1173 -0.0421 -1.1716 -0.2138 -0.1619
S-1094	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-1094	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-1094	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-1094	-0.26708507537841797	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-1094	-1.0580 -0.0998 -0.1108 -0.2243 -0.1469 -0.1576 -0.0475 -0.1360 -0.1826 -0.9478 -0.0594 -0.1392 -0.0655 -0.1336 -0.1166 -0.2957 -0.0834 -0.1256 -0.0331 -1.8578 -0.3932 -0.1376 -0.1644 -0.1354 -0.1506 -0.0542 -0.1548
S-1777	Wenn Sie die Anwendung von ADVATE vergessen haben Injizieren Sie nicht die doppelte Dosis , wenn Sie die vorherige Anwendung vergessen haben .
T-1777	If you forget to use ADVATE Do not inject a double dose to make up for a forgotten dose .
H-1777	-0.5171415209770203	If you have forgotten to use ADVATE Do not inject twice the dose if you have missed the previous dose .
D-1777	-0.5171415209770203	If you have forgotten to use ADVATE Do not inject twice the dose if you have missed the previous dose .
P-1777	-0.3875 -0.1004 -0.9658 -1.0095 -0.1686 -0.9970 -0.0971 -0.1547 -0.0923 -0.0939 -0.8965 -0.1314 -1.0819 -0.0619 -1.8620 -0.2882 -0.3542 -0.1057 -0.0987 -0.4865 -1.3249 -0.7223 -0.1455 -1.4443 -0.1964 -0.1787
S-818	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-818	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-818	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-818	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-818	-2.1692 -0.2304 -0.2726 -0.3160 -1.0491 -0.3435 -0.5865 -0.0962 -0.6669 -0.1442 -0.1579 -0.1943 -0.0880 -0.2571 -0.1211 -0.1340 -0.2554 -0.1308 -0.6830 -0.5649 -0.0756 -0.3685 -0.1411 -0.4506 -0.1261 -0.1779 -0.1041 -0.3081 -0.1147 -0.1223 -0.1667 -0.1546
S-921	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-921	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-921	-0.43301457166671753	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
D-921	-0.43301457166671753	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
P-921	-0.0633 -0.1472 -0.1431 -0.3325 -0.1310 -0.0957 -1.1966 -0.5540 -1.5234 -0.1628 -0.2019 -0.1429 -1.4420 -1.1160 -0.1673 -0.1153 -0.2932 -0.1564 -0.1533 -0.4216 -0.1181 -0.1394 -1.6671 -0.1788 -0.1624
S-833	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-833	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-833	-0.22422285377979279	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-833	-0.22422285377979279	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-833	-0.9459 -0.1838 -0.1034 -0.0717 -0.1992 -0.1065 -0.1650 -0.1427 -0.2793 -0.1772 -0.0532 -0.1633 -0.6976 -0.0665 -0.1012 -0.0596 -0.1403 -0.1256 -0.2976 -0.5460 -0.0964 -0.1918 -0.1745 -0.1288 -0.1418 -0.1056 -0.0903 -0.0755 -0.2537 -0.2489 -0.9390 -0.1583 -0.1691
S-1273	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-1273	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-1273	-0.43301457166671753	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
D-1273	-0.43301457166671753	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
P-1273	-0.0633 -0.1472 -0.1431 -0.3325 -0.1310 -0.0957 -1.1966 -0.5540 -1.5234 -0.1628 -0.2019 -0.1429 -1.4420 -1.1160 -0.1673 -0.1153 -0.2932 -0.1564 -0.1533 -0.4216 -0.1181 -0.1394 -1.6671 -0.1788 -0.1624
S-1185	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-1185	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-1185	-0.22422285377979279	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-1185	-0.22422285377979279	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-1185	-0.9459 -0.1838 -0.1034 -0.0717 -0.1992 -0.1065 -0.1650 -0.1427 -0.2793 -0.1772 -0.0532 -0.1633 -0.6976 -0.0665 -0.1012 -0.0596 -0.1403 -0.1256 -0.2976 -0.5460 -0.0964 -0.1918 -0.1745 -0.1288 -0.1418 -0.1056 -0.0903 -0.0755 -0.2537 -0.2489 -0.9390 -0.1583 -0.1691
S-1097	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-1097	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-1097	-0.43301457166671753	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
D-1097	-0.43301457166671753	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
P-1097	-0.0633 -0.1472 -0.1431 -0.3325 -0.1310 -0.0957 -1.1966 -0.5540 -1.5234 -0.1628 -0.2019 -0.1429 -1.4420 -1.1160 -0.1673 -0.1153 -0.2932 -0.1564 -0.1533 -0.4216 -0.1181 -0.1394 -1.6671 -0.1788 -0.1624
S-1009	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-1009	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-1009	-0.22422285377979279	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-1009	-0.22422285377979279	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-1009	-0.9459 -0.1838 -0.1034 -0.0717 -0.1992 -0.1065 -0.1650 -0.1427 -0.2793 -0.1772 -0.0532 -0.1633 -0.6976 -0.0665 -0.1012 -0.0596 -0.1403 -0.1256 -0.2976 -0.5460 -0.0964 -0.1918 -0.1745 -0.1288 -0.1418 -0.1056 -0.0903 -0.0755 -0.2537 -0.2489 -0.9390 -0.1583 -0.1691
S-932	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-932	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-932	-0.3280516266822815	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-932	-0.3280516266822815	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-932	-0.7125 -1.2512 -0.2435 -0.1629 -0.3563 -0.0865 -0.0606 -1.1305 -0.1265 -0.2697 -0.6107 -0.1396 -0.0981 -0.0627 -0.5268 -0.1303 -0.7490 -0.1354 -0.7427 -0.1724 -0.1955 -0.4408 -0.1157 -0.4017 -0.1045 -0.6706 -0.2563 -0.2152 -0.0832 -0.1410 -0.0598 -0.2192 -0.1539
S-1170	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-1170	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-1170	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-1170	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-1170	-2.1692 -0.2304 -0.2726 -0.3160 -1.0491 -0.3435 -0.5865 -0.0962 -0.6669 -0.1442 -0.1579 -0.1943 -0.0880 -0.2571 -0.1211 -0.1340 -0.2554 -0.1308 -0.6830 -0.5649 -0.0756 -0.3685 -0.1411 -0.4506 -0.1261 -0.1779 -0.1041 -0.3081 -0.1147 -0.1223 -0.1667 -0.1546
S-1523	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-1523	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-1523	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-1523	-0.336618036031723	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-1523	-2.1692 -0.2304 -0.2726 -0.3160 -1.0491 -0.3435 -0.5865 -0.0962 -0.6669 -0.1442 -0.1579 -0.1943 -0.0880 -0.2571 -0.1211 -0.1340 -0.2554 -0.1308 -0.6830 -0.5649 -0.0756 -0.3685 -0.1411 -0.4506 -0.1261 -0.1779 -0.1041 -0.3081 -0.1147 -0.1223 -0.1667 -0.1546
S-756	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-756	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-756	-0.3280516266822815	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-756	-0.3280516266822815	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-756	-0.7125 -1.2512 -0.2435 -0.1629 -0.3563 -0.0865 -0.0606 -1.1305 -0.1265 -0.2697 -0.6107 -0.1396 -0.0981 -0.0627 -0.5268 -0.1303 -0.7490 -0.1354 -0.7427 -0.1724 -0.1955 -0.4408 -0.1157 -0.4017 -0.1045 -0.6706 -0.2563 -0.2152 -0.0832 -0.1410 -0.0598 -0.2192 -0.1539
S-745	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-745	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-745	-0.43301457166671753	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
D-745	-0.43301457166671753	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
P-745	-0.0633 -0.1472 -0.1431 -0.3325 -0.1310 -0.0957 -1.1966 -0.5540 -1.5234 -0.1628 -0.2019 -0.1429 -1.4420 -1.1160 -0.1673 -0.1153 -0.2932 -0.1564 -0.1533 -0.4216 -0.1181 -0.1394 -1.6671 -0.1788 -0.1624
S-658	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-658	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-658	-0.22422285377979279	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-658	-0.22422285377979279	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-658	-0.9459 -0.1838 -0.1034 -0.0717 -0.1992 -0.1065 -0.1650 -0.1427 -0.2793 -0.1772 -0.0532 -0.1633 -0.6976 -0.0665 -0.1012 -0.0596 -0.1403 -0.1256 -0.2976 -0.5460 -0.0964 -0.1918 -0.1745 -0.1288 -0.1418 -0.1056 -0.0903 -0.0755 -0.2537 -0.2489 -0.9390 -0.1583 -0.1691
S-571	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-571	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-571	-0.43301457166671753	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
D-571	-0.43301457166671753	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
P-571	-0.0633 -0.1472 -0.1431 -0.3325 -0.1310 -0.0957 -1.1966 -0.5540 -1.5234 -0.1628 -0.2019 -0.1429 -1.4420 -1.1160 -0.1673 -0.1153 -0.2932 -0.1564 -0.1533 -0.4216 -0.1181 -0.1394 -1.6671 -0.1788 -0.1624
S-1928	Am 30 Juli 2007 erteilte die Europäische Kommission dem Unternehmen SP Europe eine Genehmigung für das Inverkehrbringen von Aerinaze in der gesamten Europäischen Union .
T-1928	The European Commission granted a marketing authorisation valid throughout the European Union for Aerinaze to SP Europe on 30 July 2007.
H-1928	-0.2634957432746887	On 30 July 2007 , the European Commission authorised SP Europe to market Aerinaze throughout the European Union .
D-1928	-0.2634957432746887	On 30 July 2007 , the European Commission authorised SP Europe to market Aerinaze throughout the European Union .
P-1928	-0.4051 -0.1729 -0.2450 -0.1148 -0.5154 -0.1588 -0.2172 -0.1330 -1.0939 -0.1770 -0.0503 -0.1271 -0.2612 -1.0587 -0.1470 -0.1272 -0.1430 -0.1488 -0.0947 -0.2815 -0.1569 -0.2600 -0.1708 -0.1703 -0.1567
S-1284	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-1284	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-1284	-0.3280516266822815	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-1284	-0.3280516266822815	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-1284	-0.7125 -1.2512 -0.2435 -0.1629 -0.3563 -0.0865 -0.0606 -1.1305 -0.1265 -0.2697 -0.6107 -0.1396 -0.0981 -0.0627 -0.5268 -0.1303 -0.7490 -0.1354 -0.7427 -0.1724 -0.1955 -0.4408 -0.1157 -0.4017 -0.1045 -0.6706 -0.2563 -0.2152 -0.0832 -0.1410 -0.0598 -0.2192 -0.1539
S-1111	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-1111	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-1111	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
D-1111	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
P-1111	-0.5345 -0.1313 -0.1147 -0.1487 -1.0357 -0.0984 -0.1037 -0.3218 -0.8815 -0.1499 -0.4409 -0.1581 -0.0894 -0.1578 -1.3148 -0.7320 -0.2188 -0.0784 -0.0572 -0.0828 -1.3804 -1.3342 -0.4713 -0.0553 -0.0974 -0.6336 -0.1634 -0.1578
S-941	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-941	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-941	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-941	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-941	-0.5638 -0.7989 -0.1371 -0.1484 -0.7794 -0.1233 -0.6982 -0.1039 -0.1676 -0.8308 -0.0760 -1.0438 -0.2097 -0.5488 -0.4605 -0.3817 -0.1416 -0.1839 -0.0718 -0.0637 -0.1032 -0.2946 -0.2052 -0.0748 -0.1224 -0.1409 -0.1791 -0.1572
S-765	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-765	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-765	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-765	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-765	-0.5638 -0.7989 -0.1371 -0.1484 -0.7794 -0.1233 -0.6982 -0.1039 -0.1676 -0.8308 -0.0760 -1.0438 -0.2097 -0.5488 -0.4605 -0.3817 -0.1416 -0.1839 -0.0718 -0.0637 -0.1032 -0.2946 -0.2052 -0.0748 -0.1224 -0.1409 -0.1791 -0.1572
S-1117	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-1117	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-1117	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-1117	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-1117	-0.5638 -0.7989 -0.1371 -0.1484 -0.7794 -0.1233 -0.6982 -0.1039 -0.1676 -0.8308 -0.0760 -1.0438 -0.2097 -0.5488 -0.4605 -0.3817 -0.1416 -0.1839 -0.0718 -0.0637 -0.1032 -0.2946 -0.2052 -0.0748 -0.1224 -0.1409 -0.1791 -0.1572
S-1287	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-1287	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-1287	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
D-1287	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
P-1287	-0.5345 -0.1313 -0.1147 -0.1487 -1.0357 -0.0984 -0.1037 -0.3218 -0.8815 -0.1499 -0.4409 -0.1581 -0.0894 -0.1578 -1.3148 -0.7320 -0.2188 -0.0784 -0.0572 -0.0828 -1.3804 -1.3342 -0.4713 -0.0553 -0.0974 -0.6336 -0.1634 -0.1578
S-935	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-935	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-935	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
D-935	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
P-935	-0.5345 -0.1313 -0.1147 -0.1487 -1.0357 -0.0984 -0.1037 -0.3218 -0.8815 -0.1499 -0.4409 -0.1581 -0.0894 -0.1578 -1.3148 -0.7320 -0.2188 -0.0784 -0.0572 -0.0828 -1.3804 -1.3342 -0.4713 -0.0553 -0.0974 -0.6336 -0.1634 -0.1578
S-1463	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-1463	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-1463	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
D-1463	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
P-1463	-0.5345 -0.1313 -0.1147 -0.1487 -1.0357 -0.0984 -0.1037 -0.3218 -0.8815 -0.1499 -0.4409 -0.1581 -0.0894 -0.1578 -1.3148 -0.7320 -0.2188 -0.0784 -0.0572 -0.0828 -1.3804 -1.3342 -0.4713 -0.0553 -0.0974 -0.6336 -0.1634 -0.1578
S-759	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-759	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-759	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
D-759	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
P-759	-0.5345 -0.1313 -0.1147 -0.1487 -1.0357 -0.0984 -0.1037 -0.3218 -0.8815 -0.1499 -0.4409 -0.1581 -0.0894 -0.1578 -1.3148 -0.7320 -0.2188 -0.0784 -0.0572 -0.0828 -1.3804 -1.3342 -0.4713 -0.0553 -0.0974 -0.6336 -0.1634 -0.1578
S-591	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-591	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-591	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-591	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-591	-0.5638 -0.7989 -0.1371 -0.1484 -0.7794 -0.1233 -0.6982 -0.1039 -0.1676 -0.8308 -0.0760 -1.0438 -0.2097 -0.5488 -0.4605 -0.3817 -0.1416 -0.1839 -0.0718 -0.0637 -0.1032 -0.2946 -0.2052 -0.0748 -0.1224 -0.1409 -0.1791 -0.1572
S-585	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-585	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-585	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
D-585	-0.3979963958263397	Individual patients may differ in their response to factor VIII , achieve different in vivo recovery and have different half-lives .
P-585	-0.5345 -0.1313 -0.1147 -0.1487 -1.0357 -0.0984 -0.1037 -0.3218 -0.8815 -0.1499 -0.4409 -0.1581 -0.0894 -0.1578 -1.3148 -0.7320 -0.2188 -0.0784 -0.0572 -0.0828 -1.3804 -1.3342 -0.4713 -0.0553 -0.0974 -0.6336 -0.1634 -0.1578
S-375	Die Aktivität der Osteoklasten wird gehemmt , Rekrutierung und Anbindung der Osteoklasten sind jedoch nicht betroffen .
T-375	Activity of osteoclasts is inhibited , but recruitment or attachment of osteoclasts is not affected .
H-375	-0.42289239168167114	The activity of osteoclasts is inhibited , but recruitment and bonding of osteoclasts are not affected .
D-375	-0.42289239168167114	The activity of osteoclasts is inhibited , but recruitment and bonding of osteoclasts are not affected .
P-375	-1.5243 -0.7345 -0.1300 -0.6019 -0.0854 -0.1683 -0.0271 -0.1179 -0.1678 -0.5220 -0.0850 -0.1048 -0.4799 -0.3571 -1.8670 -0.1349 -1.6457 -0.0977 -0.4056 -0.5311 -0.0896 -0.1616 -0.0514 -0.1223 -0.9602 -0.4823 -0.2747 -0.1790 -0.1550
S-1456	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-1456	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-1456	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
D-1456	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
P-1456	-1.5590 -0.1332 -0.2876 -2.5558 -0.2292 -0.1700 -0.1058 -0.1671 -0.3277 -0.0809 -0.1015 -0.1330 -0.4662 -0.3150 -0.5309 -0.2583 -0.1140 -0.8495 -0.0950 -0.1340 -0.6106 -0.2538 -0.9333 -0.7050 -0.1517 -0.0693 -0.6110 -0.9239 -0.3366 -0.1599
S-1280	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-1280	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-1280	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
D-1280	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
P-1280	-1.5590 -0.1332 -0.2876 -2.5558 -0.2292 -0.1700 -0.1058 -0.1671 -0.3277 -0.0809 -0.1015 -0.1330 -0.4662 -0.3150 -0.5309 -0.2583 -0.1140 -0.8495 -0.0950 -0.1340 -0.6106 -0.2538 -0.9333 -0.7050 -0.1517 -0.0693 -0.6110 -0.9239 -0.3366 -0.1599
S-1293	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-1293	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-1293	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-1293	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-1293	-0.5638 -0.7989 -0.1371 -0.1484 -0.7794 -0.1233 -0.6982 -0.1039 -0.1676 -0.8308 -0.0760 -1.0438 -0.2097 -0.5488 -0.4605 -0.3817 -0.1416 -0.1839 -0.0718 -0.0637 -0.1032 -0.2946 -0.2052 -0.0748 -0.1224 -0.1409 -0.1791 -0.1572
S-928	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-928	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-928	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
D-928	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
P-928	-1.5590 -0.1332 -0.2876 -2.5558 -0.2292 -0.1700 -0.1058 -0.1671 -0.3277 -0.0809 -0.1015 -0.1330 -0.4662 -0.3150 -0.5309 -0.2583 -0.1140 -0.8495 -0.0950 -0.1340 -0.6106 -0.2538 -0.9333 -0.7050 -0.1517 -0.0693 -0.6110 -0.9239 -0.3366 -0.1599
S-1469	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-1469	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-1469	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-1469	-0.31464728713035583	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-1469	-0.5638 -0.7989 -0.1371 -0.1484 -0.7794 -0.1233 -0.6982 -0.1039 -0.1676 -0.8308 -0.0760 -1.0438 -0.2097 -0.5488 -0.4605 -0.3817 -0.1416 -0.1839 -0.0718 -0.0637 -0.1032 -0.2946 -0.2052 -0.0748 -0.1224 -0.1409 -0.1791 -0.1572
S-1717	95 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1717	89 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1717	-0.2528693974018097	95 PARTICULARS ON THE ROUTE<unk> S BOTTLE WITH THE SOLUTION
D-1717	-0.2528693974018097	95 PARTICULARS ON THE ROUTE<unk> S BOTTLE WITH THE SOLUTION
P-1717	-1.1249 -0.1728 -0.3203 -0.0692 -0.1371 -0.0278 -0.1348 -1.0743 -0.1150 -0.6805 -0.4098 -0.0519 -0.1226 -0.0855 -0.1612 -0.0823 -0.1032 -0.0217 -0.1138 -0.1547 -0.0868 -0.6015 -0.3339 -0.1643 -0.0888 -0.0288 -0.3114 -0.3015
S-1700	91 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1700	85 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1700	-0.3346136808395386	91 PARTICULARS ON THE DISPOSAL BOTTLE WITH THE SOLUTION
D-1700	-0.3346136808395386	91 PARTICULARS ON THE DISPOSAL BOTTLE WITH THE SOLUTION
P-1700	-0.9890 -0.1833 -0.3756 -0.0532 -0.1767 -0.0289 -0.1274 -1.2078 -0.1040 -3.0367 -0.0052 -0.0137 -0.0346 -0.1737 -0.0957 -0.1080 -0.0203 -0.0679 -0.1598 -0.0805 -0.6463 -0.4421 -0.1903 -0.0944 -0.0312 -0.3133 -0.2749
S-1907	Wenn die Rezeptoren blockiert sind , kann Histamin seine Wirkung nicht entfalten , und dies führt zur Linderung der Allergiesymptome .
T-1907	Wenn die Rezeptoren blockiert sind , kann Histamin seine Wirkung nicht entfalten , und dies führt zur Linderung der Allergiesymptome . This reduces the amount of fluid released from the vessels , resulting in less swelling and less mucus production in the nose .
H-1907	-0.47314679622650146	When the receptors are blocked , histamine is unable to act and this relieves allergy symptoms .
D-1907	-0.47314679622650146	When the receptors are blocked , histamine is unable to act and this relieves allergy symptoms .
P-1907	-0.7372 -0.8581 -0.1448 -0.0522 -0.0653 -0.2042 -0.1894 -0.2173 -0.1253 -0.0391 -1.8441 -0.1562 -0.1308 -1.5138 -0.8202 -0.4875 -1.7556 -0.1022 -1.2377 -0.0951 -0.2283 -0.0342 -0.1570 -0.1600
S-503	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium<unk> info<unk> merck.com
T-503	Succursale belge/ Belgisch bijhuis Tél/ Tel : <<unk>> 32 ( 0 ) 800 38693 MSDBelgium<<unk>> info<<unk>> merck . com
H-503	-0.3347594141960144	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693
D-503	-0.3347594141960144	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693
P-503	-0.1549 -0.0420 -0.1574 -0.0754 -0.1039 -0.0827 -0.1348 -0.0584 -0.1182 -0.1409 -0.0502 -0.0954 -0.1341 -0.1205 -0.1205 -0.0706 -0.0764 -0.1736 -0.0877 -4.6974
S-487	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium<unk> info<unk> merck.com
T-487	Succursale belge/ Belgisch bijhuis Tél/ Tel : <<unk>> 32 ( 0 ) 800 38693 MSDBelgium<<unk>> info<<unk>> merck . com
H-487	-0.3347594141960144	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693
D-487	-0.3347594141960144	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693
P-487	-0.1549 -0.0420 -0.1574 -0.0754 -0.1039 -0.0827 -0.1348 -0.0584 -0.1182 -0.1409 -0.0502 -0.0954 -0.1341 -0.1205 -0.1205 -0.0706 -0.0764 -0.1736 -0.0877 -4.6974
S-292	ADROVANCE wird für Patienten mit eingeschränkter Nierenfunktion mit einer GFR unter 35 ml<unk> min aufgrund mangelnder Erfahrung nicht empfohlen .
T-292	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min , due to lack of experience .
H-292	-0.3155991733074188	ADROVANCE is not recommended in patients with impaired renal function with a GFR below 35 ml/ min due to lack of experience .
D-292	-0.3155991733074188	ADROVANCE is not recommended in patients with impaired renal function with a GFR below 35 ml/ min due to lack of experience .
P-292	-0.0369 -0.0596 -0.1316 -0.0935 -0.0764 -0.2140 -0.1435 -0.1343 -1.1925 -1.4635 -0.1361 -0.5783 -0.3521 -0.1438 -0.1597 -0.0647 -0.3444 -1.0244 -0.0715 -0.0738 -0.4782 -0.1307 -0.1595 -0.1795 -0.1450 -0.1604 -0.3925 -0.1245 -1.3573 -0.1213 -0.1222 -0.3935 -0.1555
S-104	ADROVANCE wird für Patienten mit eingeschränkter Nierenfunktion mit einer GFR unter 35 ml<unk> min aufgrund mangelnder Erfahrung nicht empfohlen .
T-104	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min , due to lack of experience .
H-104	-0.3155991733074188	ADROVANCE is not recommended in patients with impaired renal function with a GFR below 35 ml/ min due to lack of experience .
D-104	-0.3155991733074188	ADROVANCE is not recommended in patients with impaired renal function with a GFR below 35 ml/ min due to lack of experience .
P-104	-0.0369 -0.0596 -0.1316 -0.0935 -0.0764 -0.2140 -0.1435 -0.1343 -1.1925 -1.4635 -0.1361 -0.5783 -0.3521 -0.1438 -0.1597 -0.0647 -0.3444 -1.0244 -0.0715 -0.0738 -0.4782 -0.1307 -0.1595 -0.1795 -0.1450 -0.1604 -0.3925 -0.1245 -1.3573 -0.1213 -0.1222 -0.3935 -0.1555
S-229	Die Bioverfügbarkeit war minimal , wenn Alendronat mit oder bis zu zwei Stunden nach einem standardisierten Frühstück angewendet wurde .
T-229	Bioavailability was negligible whether alendronate was administered with , or up to two hours after , a standardised breakfast .
H-229	-0.3392637372016907	Bioavailability was minimal when alendronate was used with or up to two hours after a standardized breakfast .
D-229	-0.3392637372016907	Bioavailability was minimal when alendronate was used with or up to two hours after a standardized breakfast .
P-229	-0.7007 -0.0995 -0.2321 -0.0506 -0.3130 -0.1527 -0.1195 -0.1164 -0.0931 -0.1343 -2.2247 -0.2637 -0.3172 -0.9534 -0.1280 -0.2710 -0.0708 -0.2862 -0.2524 -0.6396 -0.2477 -0.3038 -0.1820 -0.1727 -0.1567
S-425	Die Bioverfügbarkeit war minimal , wenn Alendronat mit oder bis zu zwei Stunden nach einem standardisierten Frühstück angewendet wurde .
T-425	Bioavailability was negligible whether alendronate was administered with , or up to two hours after , a standardised breakfast .
H-425	-0.3392637372016907	Bioavailability was minimal when alendronate was used with or up to two hours after a standardized breakfast .
D-425	-0.3392637372016907	Bioavailability was minimal when alendronate was used with or up to two hours after a standardized breakfast .
P-425	-0.7007 -0.0995 -0.2321 -0.0506 -0.3130 -0.1527 -0.1195 -0.1164 -0.0931 -0.1343 -2.2247 -0.2637 -0.3172 -0.9534 -0.1280 -0.2710 -0.0708 -0.2862 -0.2524 -0.6396 -0.2477 -0.3038 -0.1820 -0.1727 -0.1567
S-1684	87 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1684	81 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1684	-0.231151282787323	87 PARTICULARS ON THE ROUTE<unk> S BOTTLE WITH THE SOLUTION
D-1684	-0.231151282787323	87 PARTICULARS ON THE ROUTE<unk> S BOTTLE WITH THE SOLUTION
P-1684	-0.5286 -0.1203 -0.1980 -0.0443 -0.1395 -0.0252 -0.1224 -1.1169 -0.1571 -0.7585 -0.4121 -0.0452 -0.1205 -0.0800 -0.1572 -0.0806 -0.1064 -0.0214 -0.1327 -0.1605 -0.0913 -0.6415 -0.3313 -0.1640 -0.0906 -0.0276 -0.3192 -0.2795
S-1668	83 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1668	77 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1668	-0.27036070823669434	83 PARTICULARS ON THE ROUTE<unk> S BOTTLE WITH THE SOLUTION
D-1668	-0.27036070823669434	83 PARTICULARS ON THE ROUTE<unk> S BOTTLE WITH THE SOLUTION
P-1668	-1.2698 -0.1975 -0.3415 -0.0584 -0.1471 -0.0266 -0.1283 -1.1336 -0.1134 -0.9368 -0.3703 -0.0475 -0.1512 -0.0833 -0.1533 -0.0794 -0.1085 -0.0208 -0.1136 -0.1548 -0.0885 -0.6292 -0.3079 -0.1698 -0.0920 -0.0267 -0.3105 -0.3098
S-1650	79 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1650	73 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1650	-0.2922860383987427	79 PARTICULARS ON THE ROUTE<unk> S BOTTLE WITH THE SOLUTION
D-1650	-0.2922860383987427	79 PARTICULARS ON THE ROUTE<unk> S BOTTLE WITH THE SOLUTION
P-1650	-1.6010 -0.1825 -0.2648 -0.0556 -0.1482 -0.0237 -0.1202 -1.5152 -0.1064 -0.9195 -0.4306 -0.0447 -0.1345 -0.0781 -0.1642 -0.0750 -0.0986 -0.0208 -0.1220 -0.1508 -0.0874 -0.5790 -0.3380 -0.1790 -0.0882 -0.0273 -0.3246 -0.3042
S-1634	75 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1634	69 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1634	-0.24962477385997772	75 PARTICULARS ON THE ROUTE<unk> S BOTTLE WITH THE SOLUTION
D-1634	-0.24962477385997772	75 PARTICULARS ON THE ROUTE<unk> S BOTTLE WITH THE SOLUTION
P-1634	-0.8331 -0.2978 -0.2218 -0.0579 -0.1311 -0.0254 -0.1234 -1.0401 -0.1267 -0.8220 -0.4247 -0.0495 -0.1330 -0.0835 -0.1672 -0.0791 -0.0998 -0.0221 -0.1070 -0.1531 -0.0874 -0.6372 -0.3583 -0.1691 -0.0914 -0.0281 -0.3239 -0.2959
S-25	Die Wirksamkeit von Adenuric wurde in zwei Hauptstudien an insgesamt 1 834 Patienten mit Hyperurikämie und Gicht untersucht .
T-25	The effectiveness of Adenuric has been studied in two main studies involving a total of 1,834 patients with hyperuricaemia and gout .
H-25	-0.31047242879867554	The efficacy of Adenuric was evaluated in two main studies involving a total of 1 834 patients with hyperuricaemia and gout .
D-25	-0.31047242879867554	The efficacy of Adenuric was evaluated in two main studies involving a total of 1 834 patients with hyperuricaemia and gout .
P-25	-1.2985 -0.1076 -0.0649 -0.0854 -0.1156 -0.1265 -0.1658 -0.1029 -0.1385 -0.8647 -0.8764 -0.1162 -0.1211 -0.2046 -0.9124 -0.7749 -1.0625 -0.2653 -0.2040 -0.1251 -0.9213 -0.1044 -0.0914 -0.4323 -0.1577 -0.0509 -0.0605 -0.5229 -0.0177 -0.1270 -0.1296 -0.0738 -0.1409 -0.1505 -0.1531
S-1104	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-1104	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-1104	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
D-1104	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
P-1104	-1.5590 -0.1332 -0.2876 -2.5558 -0.2292 -0.1700 -0.1058 -0.1671 -0.3277 -0.0809 -0.1015 -0.1330 -0.4662 -0.3150 -0.5309 -0.2583 -0.1140 -0.8495 -0.0950 -0.1340 -0.6106 -0.2538 -0.9333 -0.7050 -0.1517 -0.0693 -0.6110 -0.9239 -0.3366 -0.1599
S-578	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-578	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-578	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
D-578	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
P-578	-1.5590 -0.1332 -0.2876 -2.5558 -0.2292 -0.1700 -0.1058 -0.1671 -0.3277 -0.0809 -0.1015 -0.1330 -0.4662 -0.3150 -0.5309 -0.2583 -0.1140 -0.8495 -0.0950 -0.1340 -0.6106 -0.2538 -0.9333 -0.7050 -0.1517 -0.0693 -0.6110 -0.9239 -0.3366 -0.1599
S-752	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-752	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-752	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
D-752	-0.4456355571746826	injection every 8-24 hours ( 6-12 hours in patients under 6 years of age ) until the risk to the patient is over .
P-752	-1.5590 -0.1332 -0.2876 -2.5558 -0.2292 -0.1700 -0.1058 -0.1671 -0.3277 -0.0809 -0.1015 -0.1330 -0.4662 -0.3150 -0.5309 -0.2583 -0.1140 -0.8495 -0.0950 -0.1340 -0.6106 -0.2538 -0.9333 -0.7050 -0.1517 -0.0693 -0.6110 -0.9239 -0.3366 -0.1599
S-289	In klinischen Studien gab es keinen altersabhängigen Unterschied bei dem Wirksamkeits- oder Sicherheitsprofil von Alendronat .
T-289	In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate .
H-289	-0.3050105571746826	In clinical trials , there was no age @-@ related difference in the efficacy or safety profile of alendronate .
D-289	-0.3050105571746826	In clinical trials , there was no age @-@ related difference in the efficacy or safety profile of alendronate .
P-289	-0.5227 -0.1133 -0.2352 -0.6665 -0.5413 -0.4193 -0.0858 -0.0527 -1.2636 -1.9091 -0.1424 -0.1749 -0.3437 -0.0202 -0.0730 -0.1055 -0.1468 -0.0447 -0.1753 -0.1246 -0.1480 -0.1070 -0.1121 -0.0669 -0.1834 -0.1523
S-952	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-952	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-952	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
D-952	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
P-952	-0.3568 -0.6727 -0.5760 -0.1187 -0.3298 -0.1202 -0.1123 -0.1078 -0.1192 -0.0421 -0.4018 -0.1793 -0.1867 -0.1596 -0.1223 -2.1405 -0.1377 -1.3333 -0.7426 -0.1192 -0.1545 -0.8740 -0.2140 -0.7047 -0.1720 -0.1113 -0.0836 -0.1087 -0.1243 -0.1372 -0.1587 -0.1518
S-1891	Welche Konsequenzen hat die Rücknahme für Patienten , die derzeit an klinischen Studien bzw. Compassionate-Use -Programmen mit Advexin teilnehmen ?
T-1891	What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Advexin ?
H-1891	-0.5931686758995056	What consequences does the withdrawal have for patients currently participating in clinical trials and / or Compassion Use Programmes with Advexin ?
D-1891	-0.5931686758995056	What consequences does the withdrawal have for patients currently participating in clinical trials and / or Compassion Use Programmes with Advexin ?
P-1891	-0.1327 -0.7203 -1.3743 -1.5394 -0.4157 -0.2724 -0.1639 -0.7093 -0.6642 -1.0829 -0.0932 -0.1282 -0.2885 -0.0803 -1.8140 -0.3014 -0.1307 -0.7933 -0.9608 -0.1947 -2.0717 -0.0862 -0.9669 -0.5367 -0.1620 -0.1305 -0.6411 -0.1535
S-101	In klinischen Studien gab es keinen altersabhängigen Unterschied bei dem Wirksamkeits- oder Sicherheitsprofil von Alendronat .
T-101	In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate .
H-101	-0.3050105571746826	In clinical trials , there was no age @-@ related difference in the efficacy or safety profile of alendronate .
D-101	-0.3050105571746826	In clinical trials , there was no age @-@ related difference in the efficacy or safety profile of alendronate .
P-101	-0.5227 -0.1133 -0.2352 -0.6665 -0.5413 -0.4193 -0.0858 -0.0527 -1.2636 -1.9091 -0.1424 -0.1749 -0.3437 -0.0202 -0.0730 -0.1055 -0.1468 -0.0447 -0.1753 -0.1246 -0.1480 -0.1070 -0.1121 -0.0669 -0.1834 -0.1523
S-545	Am 2. März 2004 erteilte die Europäische Kommission dem Unternehmen Baxter AG eine Genehmigung für das Inverkehrbringen von Advate in der gesamten Europäischen Union .
T-545	The European Commission granted a marketing authorisation valid throughout the EU for Advate to Baxter AG on 2 March 2004.
H-545	-0.28801658749580383	On 2 March 2004 , the European Commission authorised Baxter AG to market Advate throughout the European Union .
D-545	-0.28801658749580383	On 2 March 2004 , the European Commission authorised Baxter AG to market Advate throughout the European Union .
P-545	-0.4996 -0.2554 -0.1924 -0.1592 -0.5916 -0.1697 -0.2283 -0.1326 -1.1282 -0.1728 -0.2873 -0.1434 -0.1523 -0.2453 -0.2473 -0.7306 -0.3188 -0.0911 -0.2682 -0.1565 -0.2348 -0.1763 -0.1721 -0.1589
S-602	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-602	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-602	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
D-602	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
P-602	-0.3568 -0.6727 -0.5760 -0.1187 -0.3298 -0.1202 -0.1123 -0.1078 -0.1192 -0.0421 -0.4018 -0.1793 -0.1867 -0.1596 -0.1223 -2.1405 -0.1377 -1.3333 -0.7426 -0.1192 -0.1545 -0.8740 -0.2140 -0.7047 -0.1720 -0.1113 -0.0836 -0.1087 -0.1243 -0.1372 -0.1587 -0.1518
S-776	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-776	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-776	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
D-776	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
P-776	-0.3568 -0.6727 -0.5760 -0.1187 -0.3298 -0.1202 -0.1123 -0.1078 -0.1192 -0.0421 -0.4018 -0.1793 -0.1867 -0.1596 -0.1223 -2.1405 -0.1377 -1.3333 -0.7426 -0.1192 -0.1545 -0.8740 -0.2140 -0.7047 -0.1720 -0.1113 -0.0836 -0.1087 -0.1243 -0.1372 -0.1587 -0.1518
S-315	Bei einem Teil der Patienten traten die Symptome erneut auf , wenn die Therapie mit demselben Arzneimittel oder einem anderen Bisphosphonat wieder aufgenommen wurde .
T-315	A subset had recurrence of symptoms when rechallenged with the same medicinal product or another bisphosphonate .
H-315	-0.5717017650604248	In some patients , symptoms recurred when resumed therapy with the same medicine or another bisphosphonate .
D-315	-0.5717017650604248	In some patients , symptoms recurred when resumed therapy with the same medicine or another bisphosphonate .
P-315	-0.8536 -0.3370 -0.9027 -0.5148 -0.7214 -1.6737 -0.2093 -0.4685 -2.2013 -0.4118 -0.6184 -0.9997 -0.1916 -0.1513 -0.2933 -1.9172 -0.1783 -0.5307 -0.0959 -0.0346 -0.0375 -0.0537 -0.1695 -0.1553
S-1128	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-1128	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-1128	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
D-1128	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
P-1128	-0.3568 -0.6727 -0.5760 -0.1187 -0.3298 -0.1202 -0.1123 -0.1078 -0.1192 -0.0421 -0.4018 -0.1793 -0.1867 -0.1596 -0.1223 -2.1405 -0.1377 -1.3333 -0.7426 -0.1192 -0.1545 -0.8740 -0.2140 -0.7047 -0.1720 -0.1113 -0.0836 -0.1087 -0.1243 -0.1372 -0.1587 -0.1518
S-1304	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-1304	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-1304	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
D-1304	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
P-1304	-0.3568 -0.6727 -0.5760 -0.1187 -0.3298 -0.1202 -0.1123 -0.1078 -0.1192 -0.0421 -0.4018 -0.1793 -0.1867 -0.1596 -0.1223 -2.1405 -0.1377 -1.3333 -0.7426 -0.1192 -0.1545 -0.8740 -0.2140 -0.7047 -0.1720 -0.1113 -0.0836 -0.1087 -0.1243 -0.1372 -0.1587 -0.1518
S-1480	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-1480	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-1480	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
D-1480	-0.34604668617248535	In the event of anaphylactic shock , shock therapy should be carried out in accordance with current medical standards ( see section 4.8 ) .
P-1480	-0.3568 -0.6727 -0.5760 -0.1187 -0.3298 -0.1202 -0.1123 -0.1078 -0.1192 -0.0421 -0.4018 -0.1793 -0.1867 -0.1596 -0.1223 -2.1405 -0.1377 -1.3333 -0.7426 -0.1192 -0.1545 -0.8740 -0.2140 -0.7047 -0.1720 -0.1113 -0.0836 -0.1087 -0.1243 -0.1372 -0.1587 -0.1518
S-1861	Dabei handelt es sich um eine Art von Virus , das genetisch so verändert wurde , dass es ein Gen in die Zellen des Körpers tragen kann .
T-1861	This is a type of virus that has been altered genetically so that it can carry a gene into the cells of the body .
H-1861	-0.4081432819366455	This is a type of virus that has been genetically modified to carry a gene into the cells of the body .
D-1861	-0.4081432819366455	This is a type of virus that has been genetically modified to carry a gene into the cells of the body .
P-1861	-1.4729 -0.2925 -0.1488 -0.1686 -0.1211 -0.1740 -1.0810 -0.3455 -0.1392 -0.8577 -0.3740 -0.6790 -0.0834 -0.4096 -0.5277 -0.2361 -0.1744 -0.3485 -0.8526 -0.3295 -0.6033 -0.2509 -0.1923 -0.1777 -0.1634
S-1982	Die Resorptionsrate von Pseudoephedrinsulfat wird durch Antazida erhöht und durch Kaolin gemindert .
T-1982	Antacids increase the rate of pseudoephedrine sulphate absorption , kaolin decreases it .
H-1982	-0.2147625833749771	The absorption rate of pseudoephedrine sulphate is increased by antacids and decreased by kaolin .
D-1982	-0.2147625833749771	The absorption rate of pseudoephedrine sulphate is increased by antacids and decreased by kaolin .
P-1982	-0.2223 -1.0410 -0.0624 -0.3911 -0.1390 -0.1673 -0.1070 -0.1444 -0.1490 -0.1156 -0.2589 -0.1871 -0.1297 -0.5983 -0.0932 -0.1799 -0.0670 -0.1646 -0.1147 -0.0736 -0.3407 -0.1878 -0.6117 -0.0631 -0.1338 -0.1818 -0.0862 -0.1167 -0.1604 -0.1548
S-127	Bei einem Teil der Patienten traten die Symptome erneut auf , wenn die Therapie mit demselben Arzneimittel oder einem anderen Bisphosphonat wieder aufgenommen wurde .
T-127	A subset had recurrence of symptoms when rechallenged with the same medicinal product or another bisphosphonate .
H-127	-0.5717017650604248	In some patients , symptoms recurred when resumed therapy with the same medicine or another bisphosphonate .
D-127	-0.5717017650604248	In some patients , symptoms recurred when resumed therapy with the same medicine or another bisphosphonate .
P-127	-0.8536 -0.3370 -0.9027 -0.5148 -0.7214 -1.6737 -0.2093 -0.4685 -2.2013 -0.4118 -0.6184 -0.9997 -0.1916 -0.1513 -0.2933 -1.9172 -0.1783 -0.5307 -0.0959 -0.0346 -0.0375 -0.0537 -0.1695 -0.1553
S-368	Bei einer Überdosis mit ADROVANCE sollten Milch oder Antazida gegeben werden , um Alendronat zu binden .
T-368	In case of overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
H-368	-0.302083820104599	In case of an overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
D-368	-0.302083820104599	In case of an overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
P-368	-0.8125 -1.2484 -0.1212 -1.1708 -0.2687 -0.0501 -0.5351 -0.0798 -0.0668 -0.1245 -0.1086 -0.0936 -0.2564 -0.0965 -0.1610 -0.0895 -0.0703 -0.2486 -0.1481 -0.1332 -1.2934 -0.3644 -0.0747 -0.0348 -0.7850 -0.1025 -0.1302 -0.0647 -0.1734 -0.1559
S-564	2 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-564	One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-564	-0.30871620774269104	2 IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
D-564	-0.30871620774269104	2 IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
P-564	-0.7880 -1.0942 -0.0268 -0.1386 -0.2780 -0.2681 -0.2270 -1.6229 -0.3219 -0.3631 -0.3847 -0.1059 -0.1337 -0.1936 -0.1512 -0.1356 -0.1125 -0.1692 -0.0989 -0.1811 -1.0678 -0.1400 -0.2928 -0.1436 -0.1856 -0.1180 -0.0624 -0.1228 -0.1821 -0.1515
S-1809	101 Wie ADVATE aussieht und Inhalt der Packung ADVATE liegt als weiße bis gelbliche , pulvrige Substanz vor .
T-1809	What ADVATE looks like and contents of the pack ADVATE is a white to off-white friable powder .
H-1809	-0.3775765597820282	What ADVATE looks like and contents of the pack ADVATE is available as a white to yellowish , powdery substance .
D-1809	-0.3775765597820282	What ADVATE looks like and contents of the pack ADVATE is available as a white to yellowish , powdery substance .
P-1809	-0.7982 -0.0892 -0.1486 -0.1031 -0.1004 -0.2298 -0.2757 -0.1690 -2.2402 -0.0900 -0.1935 -0.2320 -1.1843 -0.5663 -0.1543 -0.0881 -0.0959 -0.9671 -0.6795 -0.8188 -0.9040 -0.1312 -0.1802 -0.3713 -0.0412 -0.1629 -0.0231 -0.6763 -0.1112 -0.2973 -0.1893 -0.0426 -0.3240 -0.1593
S-739	13 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-739	12 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-739	-0.3280693590641022	One IU of factor VIII-activity corresponds to the amount of factor VIII in one ml of normal human plasma .
D-739	-0.3280693590641022	One IU of factor VIII-activity corresponds to the amount of factor VIII in one ml of normal human plasma .
P-739	-2.3289 -0.1460 -0.0380 -0.1364 -0.2774 -0.2845 -0.2423 -1.6908 -0.3772 -0.3297 -0.2637 -0.1104 -0.1342 -0.1833 -0.1475 -0.1355 -0.1091 -0.1666 -0.0937 -0.1770 -1.1845 -0.0883 -0.2322 -0.1424 -0.1904 -0.1192 -0.0625 -0.1233 -0.1754 -0.1518
S-1475	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-1475	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-1475	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
D-1475	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
P-1475	-0.3142 -0.0600 -0.0460 -0.0810 -0.1749 -0.1041 -0.9042 -0.3959 -1.4320 -0.2155 -0.3861 -1.3554 -1.1213 -0.4188 -0.2129 -0.0852 -0.0410 -0.2087 -0.2398 -0.0787 -0.1710 -0.0511 -0.5733 -0.1560
S-915	24 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-915	22 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-915	-0.3176341652870178	One IU of factor VIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
D-915	-0.3176341652870178	One IU of factor VIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
P-915	-1.9203 -0.1420 -0.0383 -0.1392 -0.2918 -0.2733 -0.2751 -1.5939 -0.5376 -0.2884 -0.1058 -0.1321 -0.1839 -0.1483 -0.1353 -0.1123 -0.1741 -0.0910 -0.1827 -1.2050 -0.0972 -0.1821 -0.1446 -0.1937 -0.1183 -0.0615 -0.1216 -0.1688 -0.1531
S-1091	35 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-1091	32 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-1091	-0.3032349646091461	35 IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
D-1091	-0.3032349646091461	35 IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
P-1091	-0.8971 -0.8684 -0.0267 -0.1370 -0.2842 -0.2783 -0.2273 -1.5699 -0.3124 -0.3550 -0.3973 -0.1056 -0.1345 -0.1967 -0.1571 -0.1357 -0.1137 -0.1684 -0.0936 -0.1803 -1.0708 -0.1431 -0.2763 -0.1434 -0.1872 -0.1177 -0.0613 -0.1219 -0.1842 -0.1520
S-1267	46 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-1267	42 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-1267	-0.31257104873657227	One IU of factor VIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
D-1267	-0.31257104873657227	One IU of factor VIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
P-1267	-1.7637 -0.1359 -0.0358 -0.1385 -0.3290 -0.2655 -0.2823 -1.5786 -0.5371 -0.2858 -0.1045 -0.1322 -0.1837 -0.1413 -0.1347 -0.1117 -0.1712 -0.0913 -0.1808 -1.2115 -0.0988 -0.1826 -0.1504 -0.1915 -0.1180 -0.0612 -0.1237 -0.1691 -0.1543
S-1443	57 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-1443	52 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-1443	-0.3082391917705536	57 IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
D-1443	-0.3082391917705536	57 IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
P-1443	-1.1573 -0.7468 -0.0244 -0.1378 -0.2750 -0.2840 -0.2375 -1.5820 -0.3382 -0.3703 -0.3711 -0.1036 -0.1337 -0.1935 -0.1553 -0.1355 -0.1100 -0.1679 -0.0949 -0.1810 -1.0679 -0.1411 -0.2698 -0.1416 -0.1858 -0.1181 -0.0616 -0.1244 -0.1839 -0.1532
S-112	Es ist sehr wichtig , dass alle Dosierungsanweisungen an den Patienten weitergegeben werden und vom Patienten verstanden werden ( siehe Abschnitt 4.2 ) .
T-112	It is very important that the full dosing instructions are provided to , and are understood by the patient ( see section 4.2 ) .
H-112	-0.35171985626220703	It is very important that all dosage instructions are communicated to the patient and understood by the patient ( see section 4.2 ) .
D-112	-0.35171985626220703	It is very important that all dosage instructions are communicated to the patient and understood by the patient ( see section 4.2 ) .
P-112	-0.2936 -0.1680 -1.2118 -0.0561 -0.2665 -0.2497 -0.5226 -1.2050 -0.0980 -1.2319 -0.2152 -1.1454 -0.1118 -0.2162 -0.5106 -0.0847 -0.1432 -0.7326 -0.3048 -0.2909 -0.0949 -0.1564 -0.1068 -0.0807 -0.1180 -0.1330 -0.1362 -0.1611 -0.1540
S-180	Bei einer Überdosis mit ADROVANCE sollten Milch oder Antazida gegeben werden , um Alendronat zu binden .
T-180	In case of overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
H-180	-0.302083820104599	In case of an overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
D-180	-0.302083820104599	In case of an overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
P-180	-0.8125 -1.2484 -0.1212 -1.1708 -0.2687 -0.0501 -0.5351 -0.0798 -0.0668 -0.1245 -0.1086 -0.0936 -0.2564 -0.0965 -0.1610 -0.0895 -0.0703 -0.2486 -0.1481 -0.1332 -1.2934 -0.3644 -0.0747 -0.0348 -0.7850 -0.1025 -0.1302 -0.0647 -0.1734 -0.1559
S-1609	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Schweiz
T-1609	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Switzerland
H-1609	-0.16355514526367188	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Schweiz
D-1609	-0.16355514526367188	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Schweiz
P-1609	-0.2218 -0.1583 -0.1482 -0.1173 -0.0736 -0.0622 -0.0820 -0.1706 -0.1302 -0.1396 -0.0647 -0.1180 -0.0871 -0.1519 -0.1282 -0.1443 -0.0608 -0.8319 -0.0651 -0.1678 -0.1175 -0.1123 -0.0739 -0.0881 -0.0916 -0.1308 -0.1115 -0.0738 -0.1107 -0.8711 -0.1653
S-1437	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-1437	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-1437	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-1437	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-1437	-0.0707 -0.1014 -0.1144 -0.1285 -0.1270 -0.0689 -0.1313 -0.0949 -0.0942 -0.1236 -0.8211 -0.1511 -0.1186 -0.5927 -0.1344 -0.1149 -0.0674 -0.0785 -0.0728 -0.1555 -0.1437 -0.3970 -0.0888 -0.1456 -0.1126 -0.2970 -0.6426 -0.0352 -0.0618 -0.0943 -0.1309 -0.2557 -0.1516
S-320	Eine bestehende Hypocalcämie muss ausgeglichen werden , bevor die Therapie mit ADROVANCE begonnen wird ( siehe Abschnitt 4.3 ) .
T-320	Hypocalcaemia must be corrected before initiating therapy with ADROVANCE ( see section 4.3 ) .
H-320	-0.366667777299881	Existing hypocalcaemia must be corrected before ADROVANCE therapy is initiated ( see section 4.3 ) .
D-320	-0.366667777299881	Existing hypocalcaemia must be corrected before ADROVANCE therapy is initiated ( see section 4.3 ) .
P-320	-0.8530 -0.1187 -0.0986 -0.1079 -0.0300 -0.0397 -0.1318 -1.2553 -0.1209 -1.4701 -0.0664 -0.3252 -1.1318 -0.0645 -0.1304 -0.1012 -0.0848 -0.9055 -2.0121 -0.4270 -0.1013 -0.1577 -0.1083 -0.0981 -0.1194 -0.1231 -0.1365 -0.1586 -0.1551
S-1164	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-1164	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-1164	-0.5156458616256714	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-1164	-0.5156458616256714	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-1164	-2.0723 -0.2377 -1.3639 -0.1262 -0.7412 -0.5869 -0.1191 -0.1962 -0.1402 -0.4160 -0.2633 -0.3416 -0.6207 -1.5818 -0.5271 -0.1363 -0.0558 -0.0560 -0.1370 -0.1730 -2.4734 -0.2080 -0.7077 -0.4926 -0.1630 -0.3159 -0.1405 -0.1812 -1.0894 -0.1688 -0.1522
S-1340	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-1340	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-1340	-0.5156458616256714	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-1340	-0.5156458616256714	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-1340	-2.0723 -0.2377 -1.3639 -0.1262 -0.7412 -0.5869 -0.1191 -0.1962 -0.1402 -0.4160 -0.2633 -0.3416 -0.6207 -1.5818 -0.5271 -0.1363 -0.0558 -0.0560 -0.1370 -0.1730 -2.4734 -0.2080 -0.7077 -0.4926 -0.1630 -0.3159 -0.1405 -0.1812 -1.0894 -0.1688 -0.1522
S-1517	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-1517	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-1517	-0.5156458616256714	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-1517	-0.5156458616256714	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-1517	-2.0723 -0.2377 -1.3639 -0.1262 -0.7412 -0.5869 -0.1191 -0.1962 -0.1402 -0.4160 -0.2633 -0.3416 -0.6207 -1.5818 -0.5271 -0.1363 -0.0558 -0.0560 -0.1370 -0.1730 -2.4734 -0.2080 -0.7077 -0.4926 -0.1630 -0.3159 -0.1405 -0.1812 -1.0894 -0.1688 -0.1522
S-1299	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-1299	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-1299	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
D-1299	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
P-1299	-0.3142 -0.0600 -0.0460 -0.0810 -0.1749 -0.1041 -0.9042 -0.3959 -1.4320 -0.2155 -0.3861 -1.3554 -1.1213 -0.4188 -0.2129 -0.0852 -0.0410 -0.2087 -0.2398 -0.0787 -0.1710 -0.0511 -0.5733 -0.1560
S-132	Eine bestehende Hypocalcämie muss ausgeglichen werden , bevor die Therapie mit ADROVANCE begonnen wird ( siehe Abschnitt 4.3 ) .
T-132	Hypocalcaemia must be corrected before initiating therapy with ADROVANCE ( see section 4.3 ) .
H-132	-0.366667777299881	Existing hypocalcaemia must be corrected before ADROVANCE therapy is initiated ( see section 4.3 ) .
D-132	-0.366667777299881	Existing hypocalcaemia must be corrected before ADROVANCE therapy is initiated ( see section 4.3 ) .
P-132	-0.8530 -0.1187 -0.0986 -0.1079 -0.0300 -0.0397 -0.1318 -1.2553 -0.1209 -1.4701 -0.0664 -0.3252 -1.1318 -0.0645 -0.1304 -0.1012 -0.0848 -0.9055 -2.0121 -0.4270 -0.1013 -0.1577 -0.1083 -0.0981 -0.1194 -0.1231 -0.1365 -0.1586 -0.1551
S-1123	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-1123	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-1123	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
D-1123	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
P-1123	-0.3142 -0.0600 -0.0460 -0.0810 -0.1749 -0.1041 -0.9042 -0.3959 -1.4320 -0.2155 -0.3861 -1.3554 -1.1213 -0.4188 -0.2129 -0.0852 -0.0410 -0.2087 -0.2398 -0.0787 -0.1710 -0.0511 -0.5733 -0.1560
S-597	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-597	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-597	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
D-597	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
P-597	-0.3142 -0.0600 -0.0460 -0.0810 -0.1749 -0.1041 -0.9042 -0.3959 -1.4320 -0.2155 -0.3861 -1.3554 -1.1213 -0.4188 -0.2129 -0.0852 -0.0410 -0.2087 -0.2398 -0.0787 -0.1710 -0.0511 -0.5733 -0.1560
S-771	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-771	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-771	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
D-771	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
P-771	-0.3142 -0.0600 -0.0460 -0.0810 -0.1749 -0.1041 -0.9042 -0.3959 -1.4320 -0.2155 -0.3861 -1.3554 -1.1213 -0.4188 -0.2129 -0.0852 -0.0410 -0.2087 -0.2398 -0.0787 -0.1710 -0.0511 -0.5733 -0.1560
S-947	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-947	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-947	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
D-947	-0.36779090762138367	Hypersensitivity to active ingredients or any of the ingredients , or to mouse or hamster proteins .
P-947	-0.3142 -0.0600 -0.0460 -0.0810 -0.1749 -0.1041 -0.9042 -0.3959 -1.4320 -0.2155 -0.3861 -1.3554 -1.1213 -0.4188 -0.2129 -0.0852 -0.0410 -0.2087 -0.2398 -0.0787 -0.1710 -0.0511 -0.5733 -0.1560
S-1902	Eine Behandlungsdauer von mehr als 10 Tagen wird nicht empfohlen , weil die Wirkungen des Arzneimittels auf die Verstopfung der Nase nachlassen können .
T-1902	Treatment for more than 10 days is not advisable , as the medicine s effects on nasal congestion may wear off .
H-1902	-0.5069085955619812	Duration of treatment of more than 10 days is not recommended , as the effects of the drug on nose constipation may decrease .
D-1902	-0.5069085955619812	Duration of treatment of more than 10 days is not recommended , as the effects of the drug on nose constipation may decrease .
P-1902	-1.3392 -0.1129 -0.2177 -0.7766 -1.6332 -0.6568 -0.1036 -0.1756 -0.1280 -0.1517 -0.1769 -0.1041 -1.4798 -0.8610 -0.2555 -0.2941 -0.1839 -0.2054 -1.8120 -0.1172 -1.3635 -0.5886 -0.2012 -0.0454 -0.1324 -0.2405 -1.4054 -0.1154 -0.1745 -0.1554
S-988	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-988	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-988	-0.5156458616256714	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-988	-0.5156458616256714	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-988	-2.0723 -0.2377 -1.3639 -0.1262 -0.7412 -0.5869 -0.1191 -0.1962 -0.1402 -0.4160 -0.2633 -0.3416 -0.6207 -1.5818 -0.5271 -0.1363 -0.0558 -0.0560 -0.1370 -0.1730 -2.4734 -0.2080 -0.7077 -0.4926 -0.1630 -0.3159 -0.1405 -0.1812 -1.0894 -0.1688 -0.1522
S-1551	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-1551	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-1551	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-1551	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-1551	-0.0712 -0.1441 -0.1237 -0.0617 -0.1292 -1.5947 -0.1564 -0.0817 -0.0826 -0.6852 -0.0789 -0.0545 -0.2215 -0.1804 -0.0485 -0.1279 -0.1769 -0.1149 -0.8359 -0.1074 -0.0699 -0.2327 -0.0383 -0.4317 -0.0841 -0.0557 -0.0591 -0.1920 -0.1577
S-1965	Bei der Anwendung bei Patienten mit stenosierenden Magengeschwüren und pyloroduodenaler Obstruktion ist Vorsicht geboten .
T-1965	Use with caution in patients with stenosing peptic ulcer , pyloroduodenal obstruction , and obstruction of the vesical cervix .
H-1965	-0.42567920684814453	Caution should be exercised when using in patients with stenosis and pyloroduodenal obstruction .
D-1965	-0.42567920684814453	Caution should be exercised when using in patients with stenosis and pyloroduodenal obstruction .
P-1965	-0.7566 -0.0656 -0.3307 -0.1665 -0.0764 -0.1473 -0.3068 -2.1513 -0.4574 -0.1980 -0.1659 -0.0301 -0.3160 -3.8977 -0.5829 -0.0780 -0.0522 -0.1399 -0.1933 -0.1063 -0.0668 -0.2450 -0.1175 -0.0627 -0.2013 -0.1554
S-1022	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-1022	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-1022	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-1022	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-1022	-0.0712 -0.1441 -0.1237 -0.0617 -0.1292 -1.5947 -0.1564 -0.0817 -0.0826 -0.6852 -0.0789 -0.0545 -0.2215 -0.1804 -0.0485 -0.1279 -0.1769 -0.1149 -0.8359 -0.1074 -0.0699 -0.2327 -0.0383 -0.4317 -0.0841 -0.0557 -0.0591 -0.1920 -0.1577
S-1198	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-1198	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-1198	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-1198	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-1198	-0.0712 -0.1441 -0.1237 -0.0617 -0.1292 -1.5947 -0.1564 -0.0817 -0.0826 -0.6852 -0.0789 -0.0545 -0.2215 -0.1804 -0.0485 -0.1279 -0.1769 -0.1149 -0.8359 -0.1074 -0.0699 -0.2327 -0.0383 -0.4317 -0.0841 -0.0557 -0.0591 -0.1920 -0.1577
S-1374	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-1374	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-1374	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-1374	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-1374	-0.0712 -0.1441 -0.1237 -0.0617 -0.1292 -1.5947 -0.1564 -0.0817 -0.0826 -0.6852 -0.0789 -0.0545 -0.2215 -0.1804 -0.0485 -0.1279 -0.1769 -0.1149 -0.8359 -0.1074 -0.0699 -0.2327 -0.0383 -0.4317 -0.0841 -0.0557 -0.0591 -0.1920 -0.1577
S-670	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-670	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-670	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-670	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-670	-0.0712 -0.1441 -0.1237 -0.0617 -0.1292 -1.5947 -0.1564 -0.0817 -0.0826 -0.6852 -0.0789 -0.0545 -0.2215 -0.1804 -0.0485 -0.1279 -0.1769 -0.1149 -0.8359 -0.1074 -0.0699 -0.2327 -0.0383 -0.4317 -0.0841 -0.0557 -0.0591 -0.1920 -0.1577
S-1323	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-1323	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-1323	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
D-1323	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
P-1323	-1.3623 -0.1267 -0.1209 -0.0845 -0.5507 -0.0287 -0.6857 -0.0165 -0.1579 -0.0947 -0.1169 -0.0999 -0.1333 -0.3988 -0.1620 -0.2087 -0.0908 -0.7190 -0.3260 -0.0587 -0.5031 -1.6310 -0.2171 -0.3241 -0.7595 -0.5125 -0.1350 -0.3272 -0.0897 -0.1590 -0.0915 -0.1033 -0.1879 -0.1538
S-65	Dies tritt dann ein , wenn nicht genug neues Knochengewebe nachwächst , um die natürlich abgebaute Knochensubstanz zu ersetzen .
T-65	Dies tritt dann ein , wenn nicht genug neues Knochengewebe nachwächst , um die natürlich abgebaute Knochensubstanz zu ersetzen . The active substances in ADROVANCE are alendronate and vitamin D3 .
H-65	-0.30512329936027527	This occurs when not enough new bone tissue grows to replace the naturally broken down bone .
D-65	-0.30512329936027527	This occurs when not enough new bone tissue grows to replace the naturally broken down bone .
P-65	-0.1801 -0.2777 -0.0645 -0.4473 -0.6389 -0.2341 -0.2765 -0.0817 -0.1141 -0.5587 -0.1369 -0.1741 -0.5773 -0.3920 -0.0902 -0.7479 -0.2999 -0.0614 -0.5920 -0.1572
S-170	Selten : symptomatische Hypocalcämie , meist bei Patienten mit entsprechenden prädisponierenden Faktoren ( siehe Abschnitt 4.4 ) .
T-170	Common : musculoskeletal ( bone , muscle or joint ) pain Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) Rare : symptomatic hypocalcaemia , often in association with predisposing conditions .
H-170	-0.21167497336864471	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
D-170	-0.21167497336864471	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
P-170	-0.3557 -0.1068 -0.1413 -0.0814 -0.0774 -0.1045 -0.0283 -0.1008 -0.0449 -0.0402 -0.1297 -0.2046 -0.7647 -0.5221 -0.2445 -0.2093 -0.9485 -0.1088 -0.4307 -0.4494 -0.0866 -0.1086 -0.1575 -0.1037 -0.0859 -0.1191 -0.1355 -0.1341 -0.1724 -0.1533
S-358	Selten : symptomatische Hypocalcämie , meist bei Patienten mit entsprechenden prädisponierenden Faktoren ( siehe Abschnitt 4.4 ) .
T-358	Common : musculoskeletal ( bone , muscle or joint ) pain Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) Rare : symptomatic hypocalcaemia , often in association with predisposing conditions .
H-358	-0.21167497336864471	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
D-358	-0.21167497336864471	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
P-358	-0.3557 -0.1068 -0.1413 -0.0814 -0.0774 -0.1045 -0.0283 -0.1008 -0.0449 -0.0402 -0.1297 -0.2046 -0.7647 -0.5221 -0.2445 -0.2093 -0.9485 -0.1088 -0.4307 -0.4494 -0.0866 -0.1086 -0.1575 -0.1037 -0.0859 -0.1191 -0.1355 -0.1341 -0.1724 -0.1533
S-846	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-846	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-846	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-846	-0.22063617408275604	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-846	-0.0712 -0.1441 -0.1237 -0.0617 -0.1292 -1.5947 -0.1564 -0.0817 -0.0826 -0.6852 -0.0789 -0.0545 -0.2215 -0.1804 -0.0485 -0.1279 -0.1769 -0.1149 -0.8359 -0.1074 -0.0699 -0.2327 -0.0383 -0.4317 -0.0841 -0.0557 -0.0591 -0.1920 -0.1577
S-1821	Danmark Baxter A<unk> S Gydevang 43 DK-3450 Allerød Tlf : <unk> 45 48 16 64 00
T-1821	Danmark Baxter A/ S Gydevang 43 DK-3450 Allerød Tlf : <<unk>> 45 48 16 64 00
H-1821	-0.11624566465616226	Danmark Baxter A/ S Gydevang 43 DK-3450 Allerød Tlf : <unk> 45 48 16 64 00
D-1821	-0.11624566465616226	Danmark Baxter A/ S Gydevang 43 DK-3450 Allerød Tlf : <unk> 45 48 16 64 00
P-1821	-0.2577 -0.1108 -0.1189 -0.1443 -0.1769 -0.0924 -0.1140 -0.1067 -0.0514 -0.0486 -0.0783 -0.0940 -0.1556 -0.1611 -0.1265 -0.0676 -0.1226 -0.1272 -0.1217 -0.1189 -0.1379 -0.1144 -0.1152 -0.1387 -0.0304 -0.0945 -0.1191 -0.1404 -0.0459 -0.1139 -0.1581
S-1499	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-1499	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-1499	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
D-1499	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
P-1499	-1.3623 -0.1267 -0.1209 -0.0845 -0.5507 -0.0287 -0.6857 -0.0165 -0.1579 -0.0947 -0.1169 -0.0999 -0.1333 -0.3988 -0.1620 -0.2087 -0.0908 -0.7190 -0.3260 -0.0587 -0.5031 -1.6310 -0.2171 -0.3241 -0.7595 -0.5125 -0.1350 -0.3272 -0.0897 -0.1590 -0.0915 -0.1033 -0.1879 -0.1538
S-1085	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-1085	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-1085	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-1085	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-1085	-0.0707 -0.1014 -0.1144 -0.1285 -0.1270 -0.0689 -0.1313 -0.0949 -0.0942 -0.1236 -0.8211 -0.1511 -0.1186 -0.5927 -0.1344 -0.1149 -0.0674 -0.0785 -0.0728 -0.1555 -0.1437 -0.3970 -0.0888 -0.1456 -0.1126 -0.2970 -0.6426 -0.0352 -0.0618 -0.0943 -0.1309 -0.2557 -0.1516
S-1261	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-1261	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-1261	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-1261	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-1261	-0.0707 -0.1014 -0.1144 -0.1285 -0.1270 -0.0689 -0.1313 -0.0949 -0.0942 -0.1236 -0.8211 -0.1511 -0.1186 -0.5927 -0.1344 -0.1149 -0.0674 -0.0785 -0.0728 -0.1555 -0.1437 -0.3970 -0.0888 -0.1456 -0.1126 -0.2970 -0.6426 -0.0352 -0.0618 -0.0943 -0.1309 -0.2557 -0.1516
S-558	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-558	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-558	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-558	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-558	-0.0707 -0.1014 -0.1144 -0.1285 -0.1270 -0.0689 -0.1313 -0.0949 -0.0942 -0.1236 -0.8211 -0.1511 -0.1186 -0.5927 -0.1344 -0.1149 -0.0674 -0.0785 -0.0728 -0.1555 -0.1437 -0.3970 -0.0888 -0.1456 -0.1126 -0.2970 -0.6426 -0.0352 -0.0618 -0.0943 -0.1309 -0.2557 -0.1516
S-733	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-733	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-733	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-733	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-733	-0.0707 -0.1014 -0.1144 -0.1285 -0.1270 -0.0689 -0.1313 -0.0949 -0.0942 -0.1236 -0.8211 -0.1511 -0.1186 -0.5927 -0.1344 -0.1149 -0.0674 -0.0785 -0.0728 -0.1555 -0.1437 -0.3970 -0.0888 -0.1456 -0.1126 -0.2970 -0.6426 -0.0352 -0.0618 -0.0943 -0.1309 -0.2557 -0.1516
S-909	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-909	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-909	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-909	-0.17936038970947266	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-909	-0.0707 -0.1014 -0.1144 -0.1285 -0.1270 -0.0689 -0.1313 -0.0949 -0.0942 -0.1236 -0.8211 -0.1511 -0.1186 -0.5927 -0.1344 -0.1149 -0.0674 -0.0785 -0.0728 -0.1555 -0.1437 -0.3970 -0.0888 -0.1456 -0.1126 -0.2970 -0.6426 -0.0352 -0.0618 -0.0943 -0.1309 -0.2557 -0.1516
S-1837	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <unk> 421 2 59418455
T-1837	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <<unk>> 421 2 59418455
H-1837	-0.12140128016471863	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <unk> 421 2 59418455
D-1837	-0.12140128016471863	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <unk> 421 2 59418455
P-1837	-0.1941 -0.1691 -0.0541 -0.1052 -0.1182 -0.0513 -0.1209 -0.0918 -0.1289 -0.1495 -0.1151 -0.0830 -0.1339 -0.1026 -0.0940 -0.1354 -0.1142 -0.1433 -0.0689 -0.0758 -0.1464 -0.0266 -0.2105 -0.1095 -0.1305 -0.1396 -0.1908 -0.1221 -0.1834 -0.0930 -0.1616
S-1147	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-1147	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-1147	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
D-1147	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
P-1147	-1.3623 -0.1267 -0.1209 -0.0845 -0.5507 -0.0287 -0.6857 -0.0165 -0.1579 -0.0947 -0.1169 -0.0999 -0.1333 -0.3988 -0.1620 -0.2087 -0.0908 -0.7190 -0.3260 -0.0587 -0.5031 -1.6310 -0.2171 -0.3241 -0.7595 -0.5125 -0.1350 -0.3272 -0.0897 -0.1590 -0.0915 -0.1033 -0.1879 -0.1538
S-621	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-621	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-621	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
D-621	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
P-621	-1.3623 -0.1267 -0.1209 -0.0845 -0.5507 -0.0287 -0.6857 -0.0165 -0.1579 -0.0947 -0.1169 -0.0999 -0.1333 -0.3988 -0.1620 -0.2087 -0.0908 -0.7190 -0.3260 -0.0587 -0.5031 -1.6310 -0.2171 -0.3241 -0.7595 -0.5125 -0.1350 -0.3272 -0.0897 -0.1590 -0.0915 -0.1033 -0.1879 -0.1538
S-795	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-795	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-795	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
D-795	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
P-795	-1.3623 -0.1267 -0.1209 -0.0845 -0.5507 -0.0287 -0.6857 -0.0165 -0.1579 -0.0947 -0.1169 -0.0999 -0.1333 -0.3988 -0.1620 -0.2087 -0.0908 -0.7190 -0.3260 -0.0587 -0.5031 -1.6310 -0.2171 -0.3241 -0.7595 -0.5125 -0.1350 -0.3272 -0.0897 -0.1590 -0.0915 -0.1033 -0.1879 -0.1538
S-971	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-971	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-971	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
D-971	-0.31581053137779236	A total of 56 adverse reactions ( ADRs ) were reported in 27 of 234 once @-@ treated patients during clinical trials of ADVATE .
P-971	-1.3623 -0.1267 -0.1209 -0.0845 -0.5507 -0.0287 -0.6857 -0.0165 -0.1579 -0.0947 -0.1169 -0.0999 -0.1333 -0.3988 -0.1620 -0.2087 -0.0908 -0.7190 -0.3260 -0.0587 -0.5031 -1.6310 -0.2171 -0.3241 -0.7595 -0.5125 -0.1350 -0.3272 -0.0897 -0.1590 -0.0915 -0.1033 -0.1879 -0.1538
S-812	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-812	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-812	-0.5156458616256714	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-812	-0.5156458616256714	At the end of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-812	-2.0723 -0.2377 -1.3639 -0.1262 -0.7412 -0.5869 -0.1191 -0.1962 -0.1402 -0.4160 -0.2633 -0.3416 -0.6207 -1.5818 -0.5271 -0.1363 -0.0558 -0.0560 -0.1370 -0.1730 -2.4734 -0.2080 -0.7077 -0.4926 -0.1630 -0.3159 -0.1405 -0.1812 -1.0894 -0.1688 -0.1522
S-135	Bei Patienten mit diesen Erkrankungen sollten unter der Therapie mit ADROVANCE das Serum-Calcium sowie Symptome einer Hypocalcämie überwacht werden .
T-135	In patients with these conditions , serum calcium and symptoms of hypocalcaemia should be monitored during therapy with ADROVANCE .
H-135	-0.32831212878227234	Patients with these disorders should be monitored for serum calcium and symptoms of hypocalcaemia when receiving ADROVANCE .
D-135	-0.32831212878227234	Patients with these disorders should be monitored for serum calcium and symptoms of hypocalcaemia when receiving ADROVANCE .
P-135	-1.2716 -0.0884 -0.1254 -0.1400 -0.5169 -0.0798 -0.1359 -0.3174 -0.3512 -0.1283 -0.9979 -0.4637 -0.1174 -0.1941 -0.1323 -0.0812 -0.8966 -1.3898 -0.1176 -0.0430 -0.1233 -0.0817 -0.0407 -0.1262 -1.2155 -0.4579 -0.1052 -0.0668 -0.1304 -0.1073 -0.0935 -0.5394 -0.1578
S-1436	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-1436	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-1436	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-1436	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-1436	-1.0020 -0.2200 -0.1329 -0.6690 -0.1642 -0.1104 -0.1929 -0.1615 -0.1488 -0.0292 -0.1168 -0.1064 -0.1639 -0.2254 -0.5210 -0.4056 -0.1163 -0.0885 -0.4708 -1.1682 -0.1444 -0.0740 -0.0881 -0.4432 -0.0903 -0.1214 -0.1429 -0.0941 -0.1301 -0.1645 -0.1553
S-247	Kleinere Mengen verteilen sich in Fett- und Muskelgewebe und werden dort als Vitamin D3 gespeichert , um später in den Kreislauf abgegeben zu werden .
T-247	Lesser amounts are distributed to adipose and muscle tissue and stored as vitamin D3 at
H-247	-0.45506832003593445	Smaller amounts are distributed in fat and muscle tissue and are stored there as vitamin D3 before being released into the circulation .
D-247	-0.45506832003593445	Smaller amounts are distributed in fat and muscle tissue and are stored there as vitamin D3 before being released into the circulation .
P-247	-0.7587 -0.1280 -0.3080 -0.4954 -1.5217 -0.1387 -0.4463 -0.4153 -0.1574 -0.0383 -0.2888 -0.9392 -0.8678 -0.1728 -0.1219 -0.9042 -0.2073 -0.1538 -0.0634 -0.1570 -0.1388 -1.6249 -0.4199 -0.9888 -0.1940 -0.1818 -0.6206 -0.0655 -0.9781 -0.1558
S-557	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-557	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-557	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-557	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-557	-1.0020 -0.2200 -0.1329 -0.6690 -0.1642 -0.1104 -0.1929 -0.1615 -0.1488 -0.0292 -0.1168 -0.1064 -0.1639 -0.2254 -0.5210 -0.4056 -0.1163 -0.0885 -0.4708 -1.1682 -0.1444 -0.0740 -0.0881 -0.4432 -0.0903 -0.1214 -0.1429 -0.0941 -0.1301 -0.1645 -0.1553
S-732	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-732	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-732	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-732	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-732	-1.0020 -0.2200 -0.1329 -0.6690 -0.1642 -0.1104 -0.1929 -0.1615 -0.1488 -0.0292 -0.1168 -0.1064 -0.1639 -0.2254 -0.5210 -0.4056 -0.1163 -0.0885 -0.4708 -1.1682 -0.1444 -0.0740 -0.0881 -0.4432 -0.0903 -0.1214 -0.1429 -0.0941 -0.1301 -0.1645 -0.1553
S-908	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-908	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-908	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-908	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-908	-1.0020 -0.2200 -0.1329 -0.6690 -0.1642 -0.1104 -0.1929 -0.1615 -0.1488 -0.0292 -0.1168 -0.1064 -0.1639 -0.2254 -0.5210 -0.4056 -0.1163 -0.0885 -0.4708 -1.1682 -0.1444 -0.0740 -0.0881 -0.4432 -0.0903 -0.1214 -0.1429 -0.0941 -0.1301 -0.1645 -0.1553
S-1084	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-1084	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-1084	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-1084	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-1084	-1.0020 -0.2200 -0.1329 -0.6690 -0.1642 -0.1104 -0.1929 -0.1615 -0.1488 -0.0292 -0.1168 -0.1064 -0.1639 -0.2254 -0.5210 -0.4056 -0.1163 -0.0885 -0.4708 -1.1682 -0.1444 -0.0740 -0.0881 -0.4432 -0.0903 -0.1214 -0.1429 -0.0941 -0.1301 -0.1645 -0.1553
S-1260	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-1260	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-1260	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-1260	-0.25360924005508423	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-1260	-1.0020 -0.2200 -0.1329 -0.6690 -0.1642 -0.1104 -0.1929 -0.1615 -0.1488 -0.0292 -0.1168 -0.1064 -0.1639 -0.2254 -0.5210 -0.4056 -0.1163 -0.0885 -0.4708 -1.1682 -0.1444 -0.0740 -0.0881 -0.4432 -0.0903 -0.1214 -0.1429 -0.0941 -0.1301 -0.1645 -0.1553
S-403	Es gab keinen statistisch signifikanten Unterschied zwischen den Behandlungsgruppen beim Anteil der Patientinnen mit Hypercalciurie am Ende der 24-wöchigen Verlängerung .
T-403	The percentage of patients with hypercalciuria at the end of the 24-week extension was not statistically different between treatment groups .
H-403	-0.31615567207336426	There was no statistically significant difference between treatment arms in the proportion of patients with hypercalciuria at the end of the 24 week extension .
D-403	-0.31615567207336426	There was no statistically significant difference between treatment arms in the proportion of patients with hypercalciuria at the end of the 24 week extension .
P-403	-0.2868 -0.2292 -0.0849 -0.2232 -0.0976 -0.0831 -0.1140 -0.0652 -0.2345 -0.8640 -0.4892 -0.4625 -0.2387 -0.3924 -0.1268 -1.0254 -0.1451 -0.0306 -0.1126 -0.1243 -0.0597 -0.1655 -0.2748 -0.2003 -0.2006 -0.1196 -1.5149 -0.4593 -1.1047 -0.2582 -0.1767 -0.1527
S-443	Kleinere Mengen verteilen sich in Fett- und Muskelgewebe und werden dort als Vitamin D3 gespeichert , um später in den Kreislauf abgegeben zu werden .
T-443	Lesser amounts are distributed to adipose and muscle tissue and stored as vitamin D3 at these sites for later release into the circulation .
H-443	-0.45506832003593445	Smaller amounts are distributed in fat and muscle tissue and are stored there as vitamin D3 before being released into the circulation .
D-443	-0.45506832003593445	Smaller amounts are distributed in fat and muscle tissue and are stored there as vitamin D3 before being released into the circulation .
P-443	-0.7587 -0.1280 -0.3080 -0.4954 -1.5217 -0.1387 -0.4463 -0.4153 -0.1574 -0.0383 -0.2888 -0.9392 -0.8678 -0.1728 -0.1219 -0.9042 -0.2073 -0.1538 -0.0634 -0.1570 -0.1388 -1.6249 -0.4199 -0.9888 -0.1940 -0.1818 -0.6206 -0.0655 -0.9781 -0.1558
S-1905	Desloratadin , ein Antihistaminikum , und Pseudoephedrin , ein die Nasenschleimhaut abschwellendes Mittel .
T-1905	Desloratadine works by blocking the receptors on which histamine , a substance in the body that causes allergic symptoms , normally fixes itself .
H-1905	-0.29094868898391724	desloratadine , an antihistamine , and pseudoephedrine , a decongestant .
D-1905	-0.29094868898391724	desloratadine , an antihistamine , and pseudoephedrine , a decongestant .
P-1905	-1.1931 -0.0398 -0.1078 -0.3123 -0.3180 -0.1479 -0.1842 -0.1371 -0.0545 -0.0579 -0.1785 -0.1319 -0.1168 -0.1737 -0.1587 -0.0467 -0.1306 -0.1291 -0.0889 -0.1436 -0.2394 -2.4315 -0.0933 -0.0597 -0.1383 -0.8839 -0.1585
S-323	Bei Patienten mit diesen Erkrankungen sollten unter der Therapie mit ADROVANCE das Serum-Calcium sowie Symptome einer Hypocalcämie überwacht werden .
T-323	In patients with these conditions , serum calcium and symptoms of hypocalcaemia should be monitored during therapy with ADROVANCE .
H-323	-0.32831212878227234	Patients with these disorders should be monitored for serum calcium and symptoms of hypocalcaemia when receiving ADROVANCE .
D-323	-0.32831212878227234	Patients with these disorders should be monitored for serum calcium and symptoms of hypocalcaemia when receiving ADROVANCE .
P-323	-1.2716 -0.0884 -0.1254 -0.1400 -0.5169 -0.0798 -0.1359 -0.3174 -0.3512 -0.1283 -0.9979 -0.4637 -0.1174 -0.1941 -0.1323 -0.0812 -0.8966 -1.3898 -0.1176 -0.0430 -0.1233 -0.0817 -0.0407 -0.1262 -1.2155 -0.4579 -0.1052 -0.0668 -0.1304 -0.1073 -0.0935 -0.5394 -0.1578
S-1761	Behandlung von Blutungen Die Dosis von Octocog alfa wird in Abhängigkeit vom Körpergewicht und den angestrebten Faktor VIII-Spiegeln errechnet .
T-1761	Treatment of bleeding The dose of octocog alfa is calculated depending on you body weight and the factor VIII levels to be achieved .
H-1761	-0.472065806388855	Treatment of bleeding The dose of Octocog alfa is determined by body weight and target factor VIII-levels .
D-1761	-0.472065806388855	Treatment of bleeding The dose of Octocog alfa is determined by body weight and target factor VIII-levels .
P-1761	-0.1249 -0.1580 -0.0961 -0.1180 -0.9030 -0.1897 -1.1848 -0.2348 -0.1278 -1.0304 -0.1126 -0.1253 -0.2440 -0.1227 -0.0601 -0.2358 -1.1087 -1.7394 -0.2861 -0.0635 -0.1243 -1.6813 -0.4651 -0.2490 -0.5923 -1.8164 -0.3314 -0.2552 -0.2240 -0.1574
S-1254	Jede Flasche enthält nominal 2000 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-1254	Each vial contains nominally 2000 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-1254	-0.2997167706489563	Each bottle contains a nominal 2000 IU/ recombinant clotting factor VIII ( rDNA ) Octocog alfa/ * .
D-1254	-0.2997167706489563	Each bottle contains a nominal 2000 IU/ recombinant clotting factor VIII ( rDNA ) Octocog alfa/ * .
P-1254	-0.0918 -0.2087 -0.4415 -1.2899 -0.0599 -0.0594 -0.4498 -0.0932 -0.6794 -0.7275 -0.1718 -0.1066 -0.0864 -0.1307 -1.8587 -0.0494 -0.0633 -0.0452 -0.1409 -0.0682 -0.1412 -0.0739 -0.0572 -0.1333 -1.3131 -0.1181 -0.1210 -0.2386 -0.0958 -0.1777 -0.2139 -0.0947 -0.4351 -0.1545
S-726	Jede Flasche enthält nominal 500 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-726	Each vial contains nominally 500 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-726	-0.29400718212127686	Each bottle contains a nominal 500 IU/ recombinant clotting factor VIII ( rDNA ) Octocog alfa/ * .
D-726	-0.29400718212127686	Each bottle contains a nominal 500 IU/ recombinant clotting factor VIII ( rDNA ) Octocog alfa/ * .
P-726	-0.0866 -0.2187 -0.4783 -1.2232 -0.0831 -0.0615 -0.3980 -0.1013 -0.5257 -0.7012 -0.1680 -0.1065 -0.0895 -0.1264 -1.9170 -0.0493 -0.0626 -0.0447 -0.1347 -0.0684 -0.1421 -0.0744 -0.0568 -0.1339 -1.2961 -0.1181 -0.1218 -0.2405 -0.0968 -0.1683 -0.2077 -0.0968 -0.4429 -0.1551
S-902	Jede Flasche enthält nominal 1000 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-902	Each vial contains nominally 1000 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-902	-0.2906199097633362	Each bottle contains a nominal 1000 IU/ recombinant clotting factor VIII ( rDNA ) Octocog alfa/ * .
D-902	-0.2906199097633362	Each bottle contains a nominal 1000 IU/ recombinant clotting factor VIII ( rDNA ) Octocog alfa/ * .
P-902	-0.0796 -0.2650 -0.5523 -0.8776 -0.0508 -0.0568 -0.5562 -0.0990 -0.5876 -0.7591 -0.1632 -0.1062 -0.0881 -0.1304 -1.8332 -0.0487 -0.0621 -0.0436 -0.1433 -0.0694 -0.1426 -0.0740 -0.0573 -0.1336 -1.2651 -0.1178 -0.1216 -0.2414 -0.0957 -0.1724 -0.2067 -0.0947 -0.4311 -0.1547
S-1078	Jede Flasche enthält nominal 1500 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-1078	Each vial contains nominally 1500 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-1078	-0.31637871265411377	Each bottle contains a nominal 1,500 IU/ recombinant blood clotting factor VIII ( rDNA ) Octocog alfa/ * .
D-1078	-0.31637871265411377	Each bottle contains a nominal 1,500 IU/ recombinant blood clotting factor VIII ( rDNA ) Octocog alfa/ * .
P-1078	-0.1115 -0.2101 -0.5792 -0.7778 -0.0623 -0.0655 -1.2403 -0.1011 -0.7355 -0.8273 -0.1993 -0.1082 -0.0888 -0.1319 -1.2163 -1.1639 -0.0365 -0.0754 -0.0597 -0.1369 -0.0707 -0.1439 -0.0728 -0.0551 -0.1315 -1.0624 -0.1181 -0.1222 -0.2394 -0.0955 -0.1735 -0.2172 -0.0919 -0.3976 -0.1538
S-324	Aufgrund der Stimulation der Knochenmineralisation durch Alendronat können Abnahmen des Serum-Calciums und -Phosphats auftreten .
T-324	Due to the positive effects of alendronate in increasing bone mineral , decreases in serum calcium and phosphate may occur .
H-324	-0.3335628807544708	Due to the stimulation of bone mineralisation by alendronate , decreases in serum calcium and phosphate may occur .
D-324	-0.3335628807544708	Due to the stimulation of bone mineralisation by alendronate , decreases in serum calcium and phosphate may occur .
P-324	-2.2449 -0.0766 -0.1276 -2.0601 -0.4381 -0.1230 -0.1361 -0.1298 -0.1753 -0.1467 -0.8272 -0.3177 -0.1166 -0.1033 -0.1448 -0.0826 -0.2746 -0.8282 -0.2607 -0.2248 -0.1614 -0.1023 -0.1554 -0.1168 -0.1071 -0.1398 -0.1719 -0.0884 -0.0967 -0.6293 -0.0923 -0.1529 -0.1546
S-1430	Jede Flasche enthält nominal 3000 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-1430	Each vial contains nominally 3000 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-1430	-0.2828287184238434	Each bottle contains a nominal 3000 IU/ recombinant clotting factor VIII ( rDNA ) Octocog alfa/ * .
D-1430	-0.2828287184238434	Each bottle contains a nominal 3000 IU/ recombinant clotting factor VIII ( rDNA ) Octocog alfa/ * .
P-1430	-0.0686 -0.2186 -0.4337 -1.1414 -0.0636 -0.0661 -0.2750 -0.0900 -0.5844 -0.6930 -0.2002 -0.1061 -0.0889 -0.1291 -1.8527 -0.0491 -0.0633 -0.0447 -0.1407 -0.0683 -0.1436 -0.0736 -0.0568 -0.1329 -1.1965 -0.1189 -0.1210 -0.2400 -0.0960 -0.1693 -0.2101 -0.0953 -0.4296 -0.1551
S-227	In Osteoporosestudien war Alendronat wirksam , wenn es mindestens 30 Minuten vor dem ersten Essen oder Trinken des Tages eingenommen wurde .
T-227	In osteoporosis studies , alendronate was effective when administered at least 30 minutes before the first food or beverage of the day .
H-227	-0.24566392600536346	In osteoporosis studies , alendronate was effective when taken at least 30 minutes before the first meal or drink of the day .
D-227	-0.24566392600536346	In osteoporosis studies , alendronate was effective when taken at least 30 minutes before the first meal or drink of the day .
P-227	-0.2452 -0.1363 -0.0792 -0.0999 -0.1509 -0.1210 -0.0977 -0.2078 -0.3949 -0.1347 -0.1126 -0.1010 -0.0691 -0.2182 -0.0843 -0.7520 -0.6524 -0.1486 -0.1191 -0.1261 -0.1710 -0.9028 -0.6261 -0.0800 -0.9754 -0.1436 -0.1681 -0.1289 -0.1658 -0.1058 -0.1869 -0.1560
S-551	Jede Flasche enthält nominal 250 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-551	Each vial contains nominally 250 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-551	-0.2855728268623352	Each bottle contains a nominal 250 IU/ recombinant clotting factor VIII ( rDNA ) Octocog alfa/ * .
D-551	-0.2855728268623352	Each bottle contains a nominal 250 IU/ recombinant clotting factor VIII ( rDNA ) Octocog alfa/ * .
P-551	-0.0811 -0.2668 -0.5180 -0.7561 -0.0942 -0.0677 -0.6136 -0.1124 -0.5333 -0.6836 -0.1928 -0.1057 -0.0873 -0.1277 -1.7923 -0.0480 -0.0616 -0.0458 -0.1388 -0.0678 -0.1434 -0.0737 -0.0570 -0.1331 -1.2793 -0.1179 -0.1219 -0.2376 -0.0961 -0.1661 -0.2045 -0.0971 -0.4326 -0.1546
S-436	Die terminale Halbwertszeit beim Menschen wird unter Berücksichtigung der Freisetzung von Alendronat aus dem Skelett auf über zehn Jahre geschätzt .
T-436	The terminal half-life in humans is estimated to exceed ten years , reflecting release of alendronate from the skeleton .
H-436	-0.34731432795524597	The human terminal half-life is estimated at over ten years , taking into account the release of alendronate from the skeleton .
D-436	-0.34731432795524597	The human terminal half-life is estimated at over ten years , taking into account the release of alendronate from the skeleton .
P-436	-0.6165 -0.8709 -0.0697 -0.0871 -0.1765 -0.0742 -0.9173 -0.1970 -0.7231 -0.9220 -0.5520 -0.0917 -1.4119 -0.8406 -0.3412 -0.1914 -0.5975 -0.1606 -0.1416 -0.1092 -0.1284 -0.1712 -0.0994 -0.1855 -0.1632 -0.0797 -0.0851 -0.0840 -0.1781 -0.1528
S-187	7 konzentriert . Die Aktivität der Osteoklasten wird gehemmt , Rekrutierung und Anbindung der Osteoklasten sind jedoch nicht betroffen .
T-187	Activity of osteoclasts is inhibited , but recruitment or attachment of osteoclasts is not affected .
H-187	-0.4806166887283325	7 . Osteoclastic activity is inhibited , but osteoclastic recruitment and attachment are not affected .
D-187	-0.4806166887283325	7 . Osteoclastic activity is inhibited , but osteoclastic recruitment and attachment are not affected .
P-187	-1.8246 -0.6868 -0.5634 -0.1114 -0.1558 -0.0128 -1.4441 -0.3879 -0.1996 -0.4816 -0.0925 -0.1007 -0.5937 -0.4522 -0.5112 -0.0901 -0.1758 -0.0146 -0.5453 -0.7883 -0.1340 -2.1121 -0.1084 -0.0801 -0.8639 -0.6962 -0.3598 -0.1949 -0.1562
S-240	Die terminale Halbwertszeit beim Menschen wird unter Berücksichtigung der Freisetzung von Alendronat aus dem Skelett auf über zehn Jahre geschätzt .
T-240	The terminal half-life in humans is estimated to exceed ten years , reflecting release of alendronate from the skeleton .
H-240	-0.34731432795524597	The human terminal half-life is estimated at over ten years , taking into account the release of alendronate from the skeleton .
D-240	-0.34731432795524597	The human terminal half-life is estimated at over ten years , taking into account the release of alendronate from the skeleton .
P-240	-0.6165 -0.8709 -0.0697 -0.0871 -0.1765 -0.0742 -0.9173 -0.1970 -0.7231 -0.9220 -0.5520 -0.0917 -1.4119 -0.8406 -0.3412 -0.1914 -0.5975 -0.1606 -0.1416 -0.1092 -0.1284 -0.1712 -0.0994 -0.1855 -0.1632 -0.0797 -0.0851 -0.0840 -0.1781 -0.1528
S-1909	Dies führt dazu , dass weniger Flüssigkeit aus den Gefäßen austritt , sodass die Schwellung abnimmt und die Nase weniger Schleim absondert .
T-1909	Aerinaze tablets have two layers , one containing desloratadine , and the other containing pseudoephedrine .
H-1909	-0.438639760017395	This results in less fluid escaping from the vessels , so that the swelling decreases and the nose secretes less mucus .
D-1909	-0.438639760017395	This results in less fluid escaping from the vessels , so that the swelling decreases and the nose secretes less mucus .
P-1909	-0.7871 -1.3860 -0.1338 -0.1716 -0.2830 -0.4018 -1.1632 -0.1424 -0.2565 -0.3976 -0.2087 -0.0794 -0.4449 -1.9628 -0.6697 -1.1533 -0.1210 -0.0852 -0.5439 -0.0495 -0.1721 -0.3655 -0.1766 -0.7880 -0.4099 -0.1942 -0.2221 -0.0810 -0.1500 -0.1583
S-264	Colecalciferol In Tierstudien wurden bei weit höheren Dosen als der therapeutischen Dosis beim Menschen reproduktionstoxische Wirkungen beobachtet .
T-264	Colecalciferol At doses far higher than the human therapeutic range , reproductive toxicity has been observed in animal studies .
H-264	-0.39934492111206055	Colecalciferol In animal studies , reproductive toxicity effects were observed at doses far greater than the therapeutic dose in humans .
D-264	-0.39934492111206055	Colecalciferol In animal studies , reproductive toxicity effects were observed at doses far greater than the therapeutic dose in humans .
P-264	-0.2667 -0.1245 -0.1658 -0.1332 -0.1359 -0.1920 -1.2642 -0.0367 -0.1552 -0.6632 -0.1727 -1.1573 -0.1686 -0.3407 -0.1767 -0.7839 -0.7457 -0.2618 -0.2270 -0.6805 -0.0587 -1.6576 -1.1647 -0.1130 -0.5329 -0.2748 -0.0914 -0.1649 -0.3060 -0.2517 -0.1582 -0.1530
S-460	Colecalciferol In Tierstudien wurden bei weit höheren Dosen als der therapeutischen Dosis beim Menschen reproduktionstoxische Wirkungen beobachtet .
T-460	Colecalciferol At doses far higher than the human therapeutic range , reproductive toxicity has been observed in animal studies .
H-460	-0.39934492111206055	Colecalciferol In animal studies , reproductive toxicity effects were observed at doses far greater than the therapeutic dose in humans .
D-460	-0.39934492111206055	Colecalciferol In animal studies , reproductive toxicity effects were observed at doses far greater than the therapeutic dose in humans .
P-460	-0.2667 -0.1245 -0.1658 -0.1332 -0.1359 -0.1920 -1.2642 -0.0367 -0.1552 -0.6632 -0.1727 -1.1573 -0.1686 -0.3407 -0.1767 -0.7839 -0.7457 -0.2618 -0.2270 -0.6805 -0.0587 -1.6576 -1.1647 -0.1130 -0.5329 -0.2748 -0.0914 -0.1649 -0.3060 -0.2517 -0.1582 -0.1530
S-1744	Es besteht die geringe Möglichkeit , dass Sie eine anaphylaktische Reaktion ( eine plötzliche , schwere , allergische Reaktion ) auf ADVATE entwickeln .
T-1744	There is a rare chance that you may experience an anaphylactic reaction ( a severe , sudden allergic reaction ) to ADVATE .
H-1744	-0.29005497694015503	There is a small possibility that you will develop an anaphylactic reaction ( a sudden , severe , allergic reaction ) to ADVATE .
D-1744	-0.29005497694015503	There is a small possibility that you will develop an anaphylactic reaction ( a sudden , severe , allergic reaction ) to ADVATE .
P-1744	-0.4411 -0.1868 -0.6919 -0.7614 -1.2569 -0.7937 -0.1178 -0.8827 -0.2042 -0.8654 -0.1523 -0.1161 -0.1169 -0.1291 -0.0595 -0.0757 -0.1912 -0.7186 -0.0744 -0.1608 -0.0870 -0.2457 -0.0832 -0.0368 -0.0680 -0.1373 -0.1554 -0.0643 -0.1479 -0.1030 -0.0885 -0.1951 -0.1632
S-37	Insbesondere bei Patienten mit Herzbeschwerden in der Vorgeschichte besteht möglicherweise auch ein erhöhtes Risiko bestimmter Nebenwirkungen , die das Herz und die Blutgefäße betreffen .
T-37	There may also be an increased risk of certain side effects affecting the heart and blood vessels , particularly in patients with a history of heart problems .
H-37	-0.5480229258537292	Especially in patients with a history of heart problems , there may also be an increased risk of certain cardiac and vascular side effects .
D-37	-0.5480229258537292	Especially in patients with a history of heart problems , there may also be an increased risk of certain cardiac and vascular side effects .
P-37	-1.4697 -0.1262 -0.9650 -1.0248 -0.1421 -0.7373 -0.9123 -0.1276 -0.3543 -2.6630 -0.3370 -0.3803 -0.3226 -0.3403 -0.1420 -0.1543 -0.0538 -0.1470 -0.1708 -0.4414 -1.2546 -0.9487 -0.1867 -0.6889 -0.1094 -0.0336 -1.7598 -0.1254 -0.1655 -0.1564
S-153	ADROVANCE ist nur für die Anwendung bei postmenopausalen Frauen vorgesehen und ist daher weder während der Schwangerschaft noch von stillenden Frauen anzuwenden .
T-153	ADROVANCE is only intended for use in postmenopausal women and therefore it should not be used during pregnancy or in breast-feeding women .
H-153	-0.4368261694908142	ADROVANCE is designed only for use in post-menopausal women and should therefore not be used during pregnancy or by nursing women .
D-153	-0.4368261694908142	ADROVANCE is designed only for use in post-menopausal women and should therefore not be used during pregnancy or by nursing women .
P-153	-0.0467 -0.0567 -0.1293 -0.1135 -0.0803 -0.2268 -1.5560 -1.9170 -0.3438 -0.0581 -0.1352 -0.2184 -0.2982 -0.0969 -0.0811 -0.0415 -0.1164 -0.1218 -0.4141 -2.4833 -0.6965 -0.2953 -0.1203 -0.4200 -0.3228 -0.0583 -0.3177 -1.4552 -1.3918 -0.1383 -0.3430 -0.1611 -0.1601
S-1529	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-1529	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-1529	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
D-1529	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
P-1529	-0.4911 -0.1310 -1.1567 -0.0879 -0.2552 -0.1827 -0.1164 -0.0821 -0.0738 -0.0852 -0.1271 -1.4718 -0.2437 -0.2566 -0.8385 -0.0383 -0.0170 -0.3898 -0.1288 -0.1469 -0.1633 -1.4281 -0.0246 -0.1787 -0.0540 -0.1075 -0.1608 -0.1543
S-1352	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-1352	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-1352	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
D-1352	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
P-1352	-0.4911 -0.1310 -1.1567 -0.0879 -0.2552 -0.1827 -0.1164 -0.0821 -0.0738 -0.0852 -0.1271 -1.4718 -0.2437 -0.2566 -0.8385 -0.0383 -0.0170 -0.3898 -0.1288 -0.1469 -0.1633 -1.4281 -0.0246 -0.1787 -0.0540 -0.1075 -0.1608 -0.1543
S-1176	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-1176	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-1176	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
D-1176	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
P-1176	-0.4911 -0.1310 -1.1567 -0.0879 -0.2552 -0.1827 -0.1164 -0.0821 -0.0738 -0.0852 -0.1271 -1.4718 -0.2437 -0.2566 -0.8385 -0.0383 -0.0170 -0.3898 -0.1288 -0.1469 -0.1633 -1.4281 -0.0246 -0.1787 -0.0540 -0.1075 -0.1608 -0.1543
S-1000	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-1000	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-1000	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
D-1000	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
P-1000	-0.4911 -0.1310 -1.1567 -0.0879 -0.2552 -0.1827 -0.1164 -0.0821 -0.0738 -0.0852 -0.1271 -1.4718 -0.2437 -0.2566 -0.8385 -0.0383 -0.0170 -0.3898 -0.1288 -0.1469 -0.1633 -1.4281 -0.0246 -0.1787 -0.0540 -0.1075 -0.1608 -0.1543
S-824	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-824	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-824	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
D-824	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
P-824	-0.4911 -0.1310 -1.1567 -0.0879 -0.2552 -0.1827 -0.1164 -0.0821 -0.0738 -0.0852 -0.1271 -1.4718 -0.2437 -0.2566 -0.8385 -0.0383 -0.0170 -0.3898 -0.1288 -0.1469 -0.1633 -1.4281 -0.0246 -0.1787 -0.0540 -0.1075 -0.1608 -0.1543
S-650	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-650	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-650	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
D-650	-0.3068544566631317	One patient exhibited both a statistically significant upward trend and a sustained peak in antibody levels against murine IgG .
P-650	-0.4911 -0.1310 -1.1567 -0.0879 -0.2552 -0.1827 -0.1164 -0.0821 -0.0738 -0.0852 -0.1271 -1.4718 -0.2437 -0.2566 -0.8385 -0.0383 -0.0170 -0.3898 -0.1288 -0.1469 -0.1633 -1.4281 -0.0246 -0.1787 -0.0540 -0.1075 -0.1608 -0.1543
S-1620	Der Inhaber dieser Arzneimittelzulassung wird PSURs im Abstand von 6 Monaten vorlegen , es sei denn , dass der CHMP andere Zeiträume festlegt .
T-1620	The holder of this marketing authorisation holder will submit PSURs every 6 months unless otherwise specified by the CHMP .
H-1620	-0.4758293330669403	Holder of this marketing authorisation will submit PSURs 6 months apart , unless otherwise specified by the CHMP .
D-1620	-0.4758293330669403	Holder of this marketing authorisation will submit PSURs 6 months apart , unless otherwise specified by the CHMP .
P-1620	-1.1632 -0.5728 -0.2138 -0.6488 -1.5504 -0.0089 -0.0458 -0.3167 -0.6951 -0.0549 -0.1105 -0.1554 -0.0767 -0.1097 -1.9321 -0.2026 -0.1216 -0.5426 -0.1605 -1.2685 -1.6927 -0.0642 -0.2138 -0.8145 -0.1246 -0.0506 -0.2556 -0.1564
S-1472	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-1472	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-1472	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-1472	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-1472	-1.5107 -1.0585 -0.5400 -0.1875 -0.2207 -1.2871 -0.0840 -0.5896 -0.3541 -1.8283 -0.1461 -0.1565 -0.1013 -1.6585 -0.7174 -0.0755 -0.3744 -0.0689 -0.2544 -0.1651 -0.1471 -0.1370 -0.1492 -0.1656 -0.1249 -0.0769 -0.1530 -0.1481 -0.0385 -0.0984 -0.2115 -0.1520
S-1296	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-1296	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-1296	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-1296	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-1296	-1.5107 -1.0585 -0.5400 -0.1875 -0.2207 -1.2871 -0.0840 -0.5896 -0.3541 -1.8283 -0.1461 -0.1565 -0.1013 -1.6585 -0.7174 -0.0755 -0.3744 -0.0689 -0.2544 -0.1651 -0.1471 -0.1370 -0.1492 -0.1656 -0.1249 -0.0769 -0.1530 -0.1481 -0.0385 -0.0984 -0.2115 -0.1520
S-1142	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-1142	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-1142	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
D-1142	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
P-1142	-3.6239 -0.0666 -0.1266 -0.5487 -0.3868 -0.3329 -0.0337 -0.0872 -0.0954 -0.1310 -0.2627 -0.0793 -0.0589 -0.0814 -0.1511 -0.1490 -0.1272 -0.3028 -0.6433 -0.4978 -1.0642 -1.2093 -1.1278 -0.9295 -0.1204 -0.6269 -0.1456 -0.0848 -0.1769 -0.0590 -0.2169 -1.1795 -0.0117 -0.1358 -0.1689 -0.1537
S-28	In beiden Studien wurde Allopurinol in einer Dosis von einmal täglich 300 mg angewendet ; Patienten mit Nierenproblemen erhielten nur 100 mg pro Tag .
T-28	In both studies , allopurinol was used at a dose of 300 mg once a day , except for patients with kidney problems , who took 100 mg .
H-28	-0.40303006768226624	In both trials , allopurinol was given at a once @-@ daily dose of 300 mg ; patients with renal problems received only 100 mg per day .
D-28	-0.40303006768226624	In both trials , allopurinol was given at a once @-@ daily dose of 300 mg ; patients with renal problems received only 100 mg per day .
P-28	-0.4150 -0.0819 -0.9947 -0.3804 -1.5005 -0.1041 -0.1648 -0.1287 -0.1375 -0.7183 -1.0643 -0.3903 -1.1393 -1.6881 -0.1087 -0.1567 -0.1234 -0.1660 -0.0477 -0.8048 -0.3337 -0.1510 -0.3056 -0.1181 -0.3577 -0.4409 -0.3959 -0.1600 -0.0326 -0.2749 -0.1011 -0.1583 -0.1550
S-944	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-944	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-944	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-944	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-944	-1.5107 -1.0585 -0.5400 -0.1875 -0.2207 -1.2871 -0.0840 -0.5896 -0.3541 -1.8283 -0.1461 -0.1565 -0.1013 -1.6585 -0.7174 -0.0755 -0.3744 -0.0689 -0.2544 -0.1651 -0.1471 -0.1370 -0.1492 -0.1656 -0.1249 -0.0769 -0.1530 -0.1481 -0.0385 -0.0984 -0.2115 -0.1520
S-341	ADROVANCE ist nur für die Anwendung bei postmenopausalen Frauen vorgesehen und ist daher weder während der Schwangerschaft noch von stillenden Frauen anzuwenden .
T-341	ADROVANCE is only intended for use in postmenopausal women and therefore it should not be used during pregnancy or in breast-feeding women .
H-341	-0.4368261694908142	ADROVANCE is designed only for use in post-menopausal women and should therefore not be used during pregnancy or by nursing women .
D-341	-0.4368261694908142	ADROVANCE is designed only for use in post-menopausal women and should therefore not be used during pregnancy or by nursing women .
P-341	-0.0467 -0.0567 -0.1293 -0.1135 -0.0803 -0.2268 -1.5560 -1.9170 -0.3438 -0.0581 -0.1352 -0.2184 -0.2982 -0.0969 -0.0811 -0.0415 -0.1164 -0.1218 -0.4141 -2.4833 -0.6965 -0.2953 -0.1203 -0.4200 -0.3228 -0.0583 -0.3177 -1.4552 -1.3918 -0.1383 -0.3430 -0.1611 -0.1601
S-1494	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-1494	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-1494	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
D-1494	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
P-1494	-3.6239 -0.0666 -0.1266 -0.5487 -0.3868 -0.3329 -0.0337 -0.0872 -0.0954 -0.1310 -0.2627 -0.0793 -0.0589 -0.0814 -0.1511 -0.1490 -0.1272 -0.3028 -0.6433 -0.4978 -1.0642 -1.2093 -1.1278 -0.9295 -0.1204 -0.6269 -0.1456 -0.0848 -0.1769 -0.0590 -0.2169 -1.1795 -0.0117 -0.1358 -0.1689 -0.1537
S-966	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-966	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-966	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
D-966	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
P-966	-3.6239 -0.0666 -0.1266 -0.5487 -0.3868 -0.3329 -0.0337 -0.0872 -0.0954 -0.1310 -0.2627 -0.0793 -0.0589 -0.0814 -0.1511 -0.1490 -0.1272 -0.3028 -0.6433 -0.4978 -1.0642 -1.2093 -1.1278 -0.9295 -0.1204 -0.6269 -0.1456 -0.0848 -0.1769 -0.0590 -0.2169 -1.1795 -0.0117 -0.1358 -0.1689 -0.1537
S-416	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<unk> Kompressions-<unk> Fraktur .
T-416	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<<unk>> Kompressions-<<unk>> Fraktur . A three-year study of 2,027 patients who had at least one baseline vertebral ( compression ) fracture .
H-416	-0.4882719814777374	FIT 1 : a three @-@ year trial of 2,027 patients with at least one pre-existing vertebral compression fracture .
D-416	-0.4882719814777374	FIT 1 : a three @-@ year trial of 2,027 patients with at least one pre-existing vertebral compression fracture .
P-416	-0.1856 -0.1265 -0.1511 -0.1825 -0.1447 -0.4869 -1.5252 -0.1071 -0.4670 -1.4375 -0.1251 -0.0563 -0.1050 -1.2853 -0.1427 -0.1439 -0.1058 -0.1328 -1.5396 -0.2666 -0.0530 -1.4384 -0.1141 -0.0469 -0.4531 -3.0507 -0.0834 -0.0914 -0.9581 -0.0500 -0.4168 -0.1516
S-220	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<unk> Kompressions-<unk> Fraktur .
T-220	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<<unk>> Kompressions-<<unk>> Fraktur . A three-year study of 2,027 patients who had at least one baseline vertebral ( compression ) fracture .
H-220	-0.4882719814777374	FIT 1 : a three @-@ year trial of 2,027 patients with at least one pre-existing vertebral compression fracture .
D-220	-0.4882719814777374	FIT 1 : a three @-@ year trial of 2,027 patients with at least one pre-existing vertebral compression fracture .
P-220	-0.1856 -0.1265 -0.1511 -0.1825 -0.1447 -0.4869 -1.5252 -0.1071 -0.4670 -1.4375 -0.1251 -0.0563 -0.1050 -1.2853 -0.1427 -0.1439 -0.1058 -0.1328 -1.5396 -0.2666 -0.0530 -1.4384 -0.1141 -0.0469 -0.4531 -3.0507 -0.0834 -0.0914 -0.9581 -0.0500 -0.4168 -0.1516
S-419	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur .
T-419	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur . A four-year study of 4,432 patients with low bone mass but without a baseline vertebral fracture .
H-419	-0.4547075033187866	FIT 2 : a four year trial of 4,432 patients with low bone mass but without pre-existing vertebral fracture .
D-419	-0.4547075033187866	FIT 2 : a four year trial of 4,432 patients with low bone mass but without pre-existing vertebral fracture .
P-419	-0.2227 -0.1120 -0.1491 -0.1881 -0.1415 -0.6512 -1.1827 -0.6374 -1.6849 -0.5040 -0.1553 -0.1279 -1.9984 -0.1657 -0.5824 -0.0694 -0.0381 -0.2083 -0.9267 -2.0581 -0.2146 -0.1160 -0.4098 -0.1557 -0.0601 -0.1227 -0.0949 -0.0688 -0.4413 -0.1533
S-223	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur .
T-223	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur . A four-year study of 4,432 patients with low bone mass but without a baseline vertebral fracture .
H-223	-0.4547075033187866	FIT 2 : a four year trial of 4,432 patients with low bone mass but without pre-existing vertebral fracture .
D-223	-0.4547075033187866	FIT 2 : a four year trial of 4,432 patients with low bone mass but without pre-existing vertebral fracture .
P-223	-0.2227 -0.1120 -0.1491 -0.1881 -0.1415 -0.6512 -1.1827 -0.6374 -1.6849 -0.5040 -0.1553 -0.1279 -1.9984 -0.1657 -0.5824 -0.0694 -0.0381 -0.2083 -0.9267 -2.0581 -0.2146 -0.1160 -0.4098 -0.1557 -0.0601 -0.1227 -0.0949 -0.0688 -0.4413 -0.1533
S-418	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt .
T-418	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt . 2.2 % , a reduction of 51 % ) .
H-418	-0.3099452555179596	In addition , a significant reduction in the incidence of hip fractures ( 1.1 % vs. 2.2 % ; reduction of 51 % ) was observed .
D-418	-0.3099452555179596	In addition , a significant reduction in the incidence of hip fractures ( 1.1 % vs. 2.2 % ; reduction of 51 % ) was observed .
P-418	-1.1178 -0.0645 -0.1985 -0.3808 -0.1313 -0.1316 -0.2587 -0.7337 -0.0358 -0.0807 -0.1283 -0.0625 -0.7739 -0.1205 -0.9715 -0.0428 -0.1108 -1.1120 -0.1518 -0.1390 -0.1197 -0.2303 -0.7315 -0.1451 -0.0845 -0.1175 -0.1461 -0.2785 -0.6801 -0.1755 -0.1529
S-222	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt .
T-222	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt . 2.2 % , a reduction of 51 % ) .
H-222	-0.3099452555179596	In addition , a significant reduction in the incidence of hip fractures ( 1.1 % vs. 2.2 % ; reduction of 51 % ) was observed .
D-222	-0.3099452555179596	In addition , a significant reduction in the incidence of hip fractures ( 1.1 % vs. 2.2 % ; reduction of 51 % ) was observed .
P-222	-1.1178 -0.0645 -0.1985 -0.3808 -0.1313 -0.1316 -0.2587 -0.7337 -0.0358 -0.0807 -0.1283 -0.0625 -0.7739 -0.1205 -0.9715 -0.0428 -0.1108 -1.1120 -0.1518 -0.1390 -0.1197 -0.2303 -0.7315 -0.1451 -0.0845 -0.1175 -0.1461 -0.2785 -0.6801 -0.1755 -0.1529
S-274	Rechteckartige , weiße bis gebrochen weiße Tabletten , gekennzeichnet mit dem Umriss eines Knochens auf der einen Seite und 270 auf der anderen Seite .
T-274	Modified rectangle-shaped , white to off-white tablets , marked with an outline of a bone image on one side , and <<unk>> 270 <<unk>> on the other .
H-274	-0.24060069024562836	Rectangular , white to broken white tablets marked with the outline of a bone on one side and 270 on the other .
D-274	-0.24060069024562836	Rectangular , white to broken white tablets marked with the outline of a bone on one side and 270 on the other .
P-274	-0.4484 -0.0515 -0.0785 -0.0895 -1.2367 -0.0561 -0.1559 -0.7829 -0.0872 -0.1079 -0.0959 -0.9016 -0.1908 -0.3588 -0.2544 -0.0919 -0.1387 -0.2128 -0.0776 -0.1259 -0.1646 -0.1022 -0.1747 -0.1252 -0.1206 -0.1511 -0.1378 -0.2949 -0.1635
S-1735	ADVATE wird ohne Zusatz eines menschlichen oder tierischen Proteins während des Zellkultur- Prozesses , der Reinigung und der Endformulierung hergestellt .
T-1735	ADVATE is prepared without the addition of any human- or animal-derived protein in the cell culture process , purification or final formulation .
H-1735	-0.32721513509750366	ADVATE is produced without the addition of a human or animal protein during cell culture , purification and final formulation .
D-1735	-0.32721513509750366	ADVATE is produced without the addition of a human or animal protein during cell culture , purification and final formulation .
P-1735	-0.0711 -0.1552 -0.0981 -0.0946 -0.2038 -0.6779 -0.2486 -1.1301 -0.0802 -0.1277 -1.7358 -0.1561 -0.1510 -0.0558 -0.0563 -0.1890 -1.2214 -0.1845 -0.2073 -0.5260 -0.0979 -0.1299 -0.8615 -0.2144 -0.0354 -0.0915 -0.2002 -0.1607
S-1318	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-1318	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-1318	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
D-1318	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
P-1318	-3.6239 -0.0666 -0.1266 -0.5487 -0.3868 -0.3329 -0.0337 -0.0872 -0.0954 -0.1310 -0.2627 -0.0793 -0.0589 -0.0814 -0.1511 -0.1490 -0.1272 -0.3028 -0.6433 -0.4978 -1.0642 -1.2093 -1.1278 -0.9295 -0.1204 -0.6269 -0.1456 -0.0848 -0.1769 -0.0590 -0.2169 -1.1795 -0.0117 -0.1358 -0.1689 -0.1537
S-1826	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 <unk> Top 2A A-1031 Wien Tel . : <unk> 43 1 71120 0
T-1826	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 / Top 2A A-1031 Wien Tel . : <<unk>> 43 1 71120 0
H-1826	-0.1679820716381073	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 <unk> Top 2A A-1031 Wien Tel . : <unk> 43 1 71120 0
D-1826	-0.1679820716381073	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 <unk> Top 2A A-1031 Wien Tel . : <unk> 43 1 71120 0
P-1826	-0.3238 -0.1670 -0.1427 -0.1519 -0.0963 -0.0798 -0.1229 -0.0503 -0.0978 -0.1952 -0.1226 -0.1468 -0.9590 -0.1356 -0.0611 -0.0659 -0.1626 -0.1419 -0.1262 -0.1330 -0.1591 -0.1968 -0.0996 -0.3971 -0.0399 -0.4125 -0.1507 -0.0646 -0.1032 -0.1493 -0.1282 -0.0892 -0.0812 -0.1539 -0.1716
S-790	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-790	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-790	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
D-790	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
P-790	-3.6239 -0.0666 -0.1266 -0.5487 -0.3868 -0.3329 -0.0337 -0.0872 -0.0954 -0.1310 -0.2627 -0.0793 -0.0589 -0.0814 -0.1511 -0.1490 -0.1272 -0.3028 -0.6433 -0.4978 -1.0642 -1.2093 -1.1278 -0.9295 -0.1204 -0.6269 -0.1456 -0.0848 -0.1769 -0.0590 -0.2169 -1.1795 -0.0117 -0.1358 -0.1689 -0.1537
S-616	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-616	Based on the rare occurrence of haemophilia A in women , experience regarding the use of Factor VIII during pregnancy and breast-feeding is not available .
H-616	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
D-616	-0.4221493899822235	Due to the rare occurrence of haemophilia A in women , no experience exists of the use of factor VIII during pregnancy and lactation .
P-616	-3.6239 -0.0666 -0.1266 -0.5487 -0.3868 -0.3329 -0.0337 -0.0872 -0.0954 -0.1310 -0.2627 -0.0793 -0.0589 -0.0814 -0.1511 -0.1490 -0.1272 -0.3028 -0.6433 -0.4978 -1.0642 -1.2093 -1.1278 -0.9295 -0.1204 -0.6269 -0.1456 -0.0848 -0.1769 -0.0590 -0.2169 -1.1795 -0.0117 -0.1358 -0.1689 -0.1537
S-1886	Nach Ansicht des CHMP wurde nicht ausreichend nachgewiesen , dass die Injektion von Advexin in Li-Fraumeni-Tumore Vorteile für die Patienten bringt .
T-1886	The CHMP was concerned that there was not enough evidence to show that the injection of Advexin into Li-Fraumeni tumours led to benefits for patients .
H-1886	-0.6911099553108215	The CHMP considers that there is insufficient evidence that injection of Advexin into Li-Fraumeni delivers benefits for patients .
D-1886	-0.6911099553108215	The CHMP considers that there is insufficient evidence that injection of Advexin into Li-Fraumeni delivers benefits for patients .
P-1886	-1.7287 -0.0883 -0.0528 -2.0987 -0.7503 -1.0480 -0.9077 -0.4076 -0.1462 -0.0968 -1.4218 -0.7146 -0.2299 -0.1280 -1.2386 -0.1743 -0.1297 -0.3720 -3.3552 -0.3660 -0.2633 -0.0489 -0.2362 -2.9158 -0.0689 -0.2108 -0.9991 -0.2118 -0.1690 -0.1542
S-318	ADROVANCE wird für Patienten mit Niereninsuffizienz mit einer GFR unter 35 ml<unk> min nicht empfohlen ( siehe Abschnitt 4.2 ) .
T-318	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min ( see section 4.2 ) .
H-318	-0.2112220823764801	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
D-318	-0.2112220823764801	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
P-318	-0.0429 -0.0639 -0.1305 -0.1014 -0.0765 -0.2029 -0.1529 -0.1360 -1.0096 -0.5630 -0.1465 -0.2477 -0.0788 -0.1638 -0.8337 -0.1028 -0.5222 -0.1315 -0.1334 -0.1747 -0.1469 -0.1181 -0.1567 -0.1032 -0.0850 -0.1148 -0.1283 -0.1417 -0.1721 -0.1551
S-130	ADROVANCE wird für Patienten mit Niereninsuffizienz mit einer GFR unter 35 ml<unk> min nicht empfohlen ( siehe Abschnitt 4.2 ) .
T-130	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min ( see section 4.2 ) .
H-130	-0.2112220823764801	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
D-130	-0.2112220823764801	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
P-130	-0.0429 -0.0639 -0.1305 -0.1014 -0.0765 -0.2029 -0.1529 -0.1360 -1.0096 -0.5630 -0.1465 -0.2477 -0.0788 -0.1638 -0.8337 -0.1028 -0.5222 -0.1315 -0.1334 -0.1747 -0.1469 -0.1181 -0.1567 -0.1032 -0.0850 -0.1148 -0.1283 -0.1417 -0.1721 -0.1551
S-1948	Nach Rückgang der Schwellung der Schleimhäute in den oberen Atemwegen kann die Behandlung bei Bedarf mit Desloratadin als Monotherapie fortgesetzt werden .
T-1948	After improvement of the congestive condition of the mucosae of the upper airway , treatment may be maintained with desloratadine alone , if necessary .
H-1948	-0.4051012098789215	After decreased mucosal swelling in the upper respiratory tract , treatment with desloratadine as monotherapy may be continued as necessary .
D-1948	-0.4051012098789215	After decreased mucosal swelling in the upper respiratory tract , treatment with desloratadine as monotherapy may be continued as necessary .
P-1948	-1.6252 -0.9154 -0.5257 -1.3984 -0.0897 -0.0808 -0.1175 -0.1301 -0.2877 -0.1506 -0.1523 -0.7362 -0.0307 -0.0505 -0.3878 -0.3275 -0.2254 -0.6879 -0.3566 -0.4511 -0.0540 -0.1076 -0.2131 -0.4292 -0.4161 -0.1976 -0.1374 -0.0527 -1.2137 -0.2009 -0.5655 -1.0209 -0.5150 -0.1753 -0.1525
S-1841	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <unk> 46 8 6326400
T-1841	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <<unk>> 46 8 6326400
H-1841	-0.11529804021120071	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <unk> 46 8 6326400
D-1841	-0.11529804021120071	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <unk> 46 8 6326400
P-1841	-0.1326 -0.0938 -0.0424 -0.1337 -0.1542 -0.1514 -0.1389 -0.0360 -0.1407 -0.0582 -0.1461 -0.0386 -0.1097 -0.1249 -0.1468 -0.1634 -0.0996 -0.1274 -0.1110 -0.1226 -0.1443 -0.1233 -0.1515 -0.0547 -0.1371 -0.1061 -0.1381 -0.0301 -0.0726 -0.1367 -0.2091 -0.1587 -0.0670 -0.0770 -0.1571
S-1120	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-1120	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-1120	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-1120	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-1120	-1.5107 -1.0585 -0.5400 -0.1875 -0.2207 -1.2871 -0.0840 -0.5896 -0.3541 -1.8283 -0.1461 -0.1565 -0.1013 -1.6585 -0.7174 -0.0755 -0.3744 -0.0689 -0.2544 -0.1651 -0.1471 -0.1370 -0.1492 -0.1656 -0.1249 -0.0769 -0.1530 -0.1481 -0.0385 -0.0984 -0.2115 -0.1520
S-594	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-594	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-594	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-594	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-594	-1.5107 -1.0585 -0.5400 -0.1875 -0.2207 -1.2871 -0.0840 -0.5896 -0.3541 -1.8283 -0.1461 -0.1565 -0.1013 -1.6585 -0.7174 -0.0755 -0.3744 -0.0689 -0.2544 -0.1651 -0.1471 -0.1370 -0.1492 -0.1656 -0.1249 -0.0769 -0.1530 -0.1481 -0.0385 -0.0984 -0.2115 -0.1520
S-768	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-768	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-768	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-768	-0.4056501090526581	The rate of administration should vary with the condition of the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-768	-1.5107 -1.0585 -0.5400 -0.1875 -0.2207 -1.2871 -0.0840 -0.5896 -0.3541 -1.8283 -0.1461 -0.1565 -0.1013 -1.6585 -0.7174 -0.0755 -0.3744 -0.0689 -0.2544 -0.1651 -0.1471 -0.1370 -0.1492 -0.1656 -0.1249 -0.0769 -0.1530 -0.1481 -0.0385 -0.0984 -0.2115 -0.1520
S-350	Es liegen jedoch keine Informationen vor , die nahelegen , dass ADROVANCE die Verkehrstüchtigkeit oder die Fähigkeit zum Bedienen von Maschinen beeinträchtigt .
T-350	However , there is no information to indicate that ADROVANCE affects a patient s ability to drive or operate machines .
H-350	-0.4381394684314728	However , there is no information to suggest that ADROVANCE impairs the ability to drive or use machines .
D-350	-0.4381394684314728	However , there is no information to suggest that ADROVANCE impairs the ability to drive or use machines .
P-350	-0.6031 -0.1698 -0.7574 -0.2501 -0.1004 -0.3049 -0.6266 -0.1177 -0.2554 -0.0877 -0.0602 -0.1271 -0.1052 -0.1088 -1.1305 -0.3410 -1.0531 -0.0769 -0.9666 -1.0281 -0.1901 -1.3116 -0.8403 -0.1798 -0.1613
S-162	Es liegen jedoch keine Informationen vor , die nahelegen , dass ADROVANCE die Verkehrstüchtigkeit oder die Fähigkeit zum Bedienen von Maschinen beeinträchtigt .
T-162	However , there is no information to indicate that ADROVANCE affects a patient s ability to drive or operate machines .
H-162	-0.4381394684314728	However , there is no information to suggest that ADROVANCE impairs the ability to drive or use machines .
D-162	-0.4381394684314728	However , there is no information to suggest that ADROVANCE impairs the ability to drive or use machines .
P-162	-0.6031 -0.1698 -0.7574 -0.2501 -0.1004 -0.3049 -0.6266 -0.1177 -0.2554 -0.0877 -0.0602 -0.1271 -0.1052 -0.1088 -1.1305 -0.3410 -1.0531 -0.0769 -0.9666 -1.0281 -0.1901 -1.3116 -0.8403 -0.1798 -0.1613
S-1765	Ihr Arzt wird in regelmäßigen Abständen geeignete Labortests durchführen , um sicherzustellen , dass Sie ausreichende Faktor-VIII-Spiegel haben .
T-1765	Your doctor will perform appropriate laboratory tests to make sure that you have adequate Factor VIII levels .
H-1765	-0.47131484746932983	Your doctor will periodically conduct appropriate laboratory tests to ensure you have adequate factor VIII levels .
D-1765	-0.47131484746932983	Your doctor will periodically conduct appropriate laboratory tests to ensure you have adequate factor VIII levels .
P-1765	-0.2054 -0.1342 -0.1355 -1.1661 -0.1162 -0.0734 -2.0132 -0.2245 -0.1685 -0.0666 -0.2688 -0.1648 -0.4547 -0.8514 -0.1768 -0.1124 -1.2247 -0.5494 -0.4455 -1.7977 -0.1473 -0.1848 -0.1585
S-1113	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-1113	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-1113	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-1113	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-1113	-0.3009 -0.1881 -0.7502 -0.2424 -0.1709 -0.3196 -0.0994 -0.3859 -2.2204 -0.0760 -0.1179 -0.1887 -0.0533 -0.6155 -0.1272 -0.2109 -0.1404 -0.1217 -0.1226 -1.0763 -0.2339 -0.1614 -0.0924 -0.1073 -0.0706 -0.9203 -0.0506 -0.3190 -0.7495 -0.2310 -0.4915 -0.1700 -0.2592 -0.2086 -0.1517
S-761	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-761	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-761	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-761	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-761	-0.3009 -0.1881 -0.7502 -0.2424 -0.1709 -0.3196 -0.0994 -0.3859 -2.2204 -0.0760 -0.1179 -0.1887 -0.0533 -0.6155 -0.1272 -0.2109 -0.1404 -0.1217 -0.1226 -1.0763 -0.2339 -0.1614 -0.0924 -0.1073 -0.0706 -0.9203 -0.0506 -0.3190 -0.7495 -0.2310 -0.4915 -0.1700 -0.2592 -0.2086 -0.1517
S-937	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-937	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-937	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-937	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-937	-0.3009 -0.1881 -0.7502 -0.2424 -0.1709 -0.3196 -0.0994 -0.3859 -2.2204 -0.0760 -0.1179 -0.1887 -0.0533 -0.6155 -0.1272 -0.2109 -0.1404 -0.1217 -0.1226 -1.0763 -0.2339 -0.1614 -0.0924 -0.1073 -0.0706 -0.9203 -0.0506 -0.3190 -0.7495 -0.2310 -0.4915 -0.1700 -0.2592 -0.2086 -0.1517
S-587	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-587	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-587	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-587	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-587	-0.3009 -0.1881 -0.7502 -0.2424 -0.1709 -0.3196 -0.0994 -0.3859 -2.2204 -0.0760 -0.1179 -0.1887 -0.0533 -0.6155 -0.1272 -0.2109 -0.1404 -0.1217 -0.1226 -1.0763 -0.2339 -0.1614 -0.0924 -0.1073 -0.0706 -0.9203 -0.0506 -0.3190 -0.7495 -0.2310 -0.4915 -0.1700 -0.2592 -0.2086 -0.1517
S-1289	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-1289	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-1289	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-1289	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-1289	-0.3009 -0.1881 -0.7502 -0.2424 -0.1709 -0.3196 -0.0994 -0.3859 -2.2204 -0.0760 -0.1179 -0.1887 -0.0533 -0.6155 -0.1272 -0.2109 -0.1404 -0.1217 -0.1226 -1.0763 -0.2339 -0.1614 -0.0924 -0.1073 -0.0706 -0.9203 -0.0506 -0.3190 -0.7495 -0.2310 -0.4915 -0.1700 -0.2592 -0.2086 -0.1517
S-1906	Desloratadin blockiert die Rezeptoren , an denen Histamin , eine körpereigene Substanz , die allergische Symptome verursacht , normalerweise andockt .
T-1906	When the receptors are blocked , histamine cannot have its effect , and this leads to a decrease in the symptoms of allergy .
H-1906	-0.34029003977775574	Desloratadine blocks receptors to which histamine , an endogenous substance that causes allergic symptoms , normally attaches .
D-1906	-0.34029003977775574	Desloratadine blocks receptors to which histamine , an endogenous substance that causes allergic symptoms , normally attaches .
P-1906	-0.3793 -0.0415 -0.1067 -0.2037 -0.4682 -0.2356 -0.7826 -0.0577 -0.0563 -1.7619 -0.1491 -0.1061 -0.0271 -0.1839 -1.1777 -0.3640 -0.2057 -0.0528 -0.1321 -0.9757 -0.1808 -0.1528 -0.0624 -0.0778 -0.1365 -1.4185 -0.2200 -0.0892 -0.2459 -0.1571
S-1631	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1631	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1631	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1631	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1631	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-258	Daher ist bei Patienten mit eingeschränkter Nierenfunktion eine etwas erhöhte Kumulation von Alendronat im Knochen zu erwarten ( siehe Abschnitt 4.2 ) .
T-258	Therefore , somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function ( see section 4.2 ) .
H-258	-0.40058326721191406	Patients with impaired renal function are therefore expected to experience slightly increased accumulation of alendronate in bone ( see section 4.2 ) .
D-258	-0.40058326721191406	Patients with impaired renal function are therefore expected to experience slightly increased accumulation of alendronate in bone ( see section 4.2 ) .
P-258	-2.1173 -0.0949 -0.1433 -0.6069 -0.2059 -0.1433 -0.1473 -0.0488 -2.2147 -0.2558 -1.1252 -0.1409 -0.6613 -1.6965 -0.1859 -0.3946 -0.0827 -0.1394 -0.0777 -0.1182 -0.1706 -0.0587 -0.1522 -0.8391 -0.1425 -0.0934 -0.0785 -0.1155 -0.1325 -0.1348 -0.1485 -0.1519
S-1647	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1647	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1647	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1647	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1647	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-454	Daher ist bei Patienten mit eingeschränkter Nierenfunktion eine etwas erhöhte Kumulation von Alendronat im Knochen zu erwarten ( siehe Abschnitt 4.2 ) .
T-454	Therefore , somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function ( see section 4.2 ) .
H-454	-0.40058326721191406	Patients with impaired renal function are therefore expected to experience slightly increased accumulation of alendronate in bone ( see section 4.2 ) .
D-454	-0.40058326721191406	Patients with impaired renal function are therefore expected to experience slightly increased accumulation of alendronate in bone ( see section 4.2 ) .
P-454	-2.1173 -0.0949 -0.1433 -0.6069 -0.2059 -0.1433 -0.1473 -0.0488 -2.2147 -0.2558 -1.1252 -0.1409 -0.6613 -1.6965 -0.1859 -0.3946 -0.0827 -0.1394 -0.0777 -0.1182 -0.1706 -0.0587 -0.1522 -0.8391 -0.1425 -0.0934 -0.0785 -0.1155 -0.1325 -0.1348 -0.1485 -0.1519
S-1664	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1664	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1664	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1664	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1664	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-1880	Basierend auf der Prüfung der anfänglich eingereichten Unterlagen erstellt der CHMP an Tag 120 eine Liste von Fragen , die dem Unternehmen zugesandt wird .
T-1880	Based on the review of the initial documentation , the CHMP prepares a list of questions at day 120 , which is sent to the company .
H-1880	-0.6545548439025879	Based on examination of initial submissions , the CHMP will draw up a list of questions to be sent to the company on day 120 .
D-1880	-0.6545548439025879	Based on examination of initial submissions , the CHMP will draw up a list of questions to be sent to the company on day 120 .
P-1880	-1.4696 -0.1594 -3.0223 -0.1269 -0.8005 -2.1319 -0.4137 -0.2461 -1.7944 -0.0943 -0.0444 -0.6186 -1.2212 -0.3077 -0.4504 -0.1160 -0.1848 -0.3845 -1.3269 -0.1651 -1.3188 -0.1343 -0.1990 -1.2849 -0.1005 -0.4041 -0.0941 -0.2080 -0.1597
S-63	Knochengewebe ist ein lebendes Gewebe , das ständig erneuert wird , indem altes Knochengewebe abgebaut und durch neues ersetzt wird .
T-63	Bone is a living tissue that is constantly renewed by a process that erodes old bone and replaces it with new bone at the same rate .
H-63	-0.5596919655799866	Bone is a living tissue that is constantly renewed by breaking down old bone and replacing it with new .
D-63	-0.5596919655799866	Bone is a living tissue that is constantly renewed by breaking down old bone and replacing it with new .
P-63	-0.3109 -0.1507 -1.0788 -0.6001 -0.5908 -0.1253 -0.9609 -0.1632 -1.3610 -0.7120 -0.5869 -2.0450 -0.1662 -0.6903 -0.1106 -0.9384 -0.4427 -0.1511 -0.1767 -0.2405 -0.5351 -0.1763
S-1864	Advexin hätte direkt in die Tumore gespritzt werden und so den Krebszellen ermöglichen sollen , das normale p53-Protein erneut zu bilden .
T-1864	Advexin was expected to be injected directly into the tumours , thus allowing the cancer cells to produce normal p53 protein again .
H-1864	-0.3542182445526123	Advexin should have been injected directly into tumours , enabling cancer cells to reproduce the normal p53 protein .
D-1864	-0.3542182445526123	Advexin should have been injected directly into tumours , enabling cancer cells to reproduce the normal p53 protein .
P-1864	-1.2457 -0.1552 -0.1359 -0.0938 -0.2239 -0.0916 -0.5416 -0.0432 -0.2555 -0.1769 -0.9621 -0.1419 -0.6855 -1.3696 -0.1140 -0.4390 -0.0789 -0.1320 -0.7596 -0.5126 -0.4941 -0.0918 -0.1034 -0.3395 -0.0449 -0.1742 -0.1574
S-18	Er wirkt durch Hemmung eines Enzyms , der so genannten Xanthinoxidase , das für die Harnsäureproduktion im Körper erforderlich ist .
T-18	It works by blocking an enzyme called xanthine oxidase , which is needed to make uric acid in the body .
H-18	-0.24159123003482819	It works by inhibiting an enzyme called xanthine oxidase , which is necessary for uric acid production in the body .
D-18	-0.24159123003482819	It works by inhibiting an enzyme called xanthine oxidase , which is necessary for uric acid production in the body .
P-18	-0.2553 -0.3450 -0.1353 -1.1361 -0.1513 -0.0908 -0.2017 -0.1806 -0.0839 -0.2136 -0.5737 -0.1124 -0.0521 -0.1569 -0.0396 -0.1490 -0.0805 -0.7194 -0.3398 -0.1577 -0.7704 -0.2084 -0.3371 -0.0770 -0.0518 -0.1357 -0.1655 -0.1743 -0.0882 -0.1512 -0.1548
S-1763	Dosis ( I.E. ) = Körpergewicht ( kg ) x erwünschter Faktor VIII-Anstieg ( % des Normalwertes ) x 0,5
T-1763	Dose ( IU ) = body weight ( kg ) x desired Factor VIII rise ( % of normal ) x 0.5
H-1763	-0.26678788661956787	dose ( IU ) = body weight ( kg ) x desired factor VIII-increase ( % of normal ) x 0.5
D-1763	-0.26678788661956787	dose ( IU ) = body weight ( kg ) x desired factor VIII-increase ( % of normal ) x 0.5
P-1763	-0.9136 -0.1390 -0.1357 -0.0564 -0.1344 -0.1730 -0.7746 -0.0657 -0.1426 -0.0670 -0.1357 -0.1271 -0.1443 -0.7657 -0.0706 -0.1200 -0.3679 -1.1680 -0.3005 -0.3842 -0.1390 -0.2026 -0.1386 -0.1588 -0.2605 -0.1631 -0.0669 -0.1543
S-1635	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1635	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1635	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1635	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1635	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-32	Adenuric war bei der Senkung des Harnsäurespiegels im Blut wirksamer als Allopurinol und Placebo .
T-32	Adenuric was more effective than allopurinol and placebo in reducing blood uric acid levels .
H-32	-0.27454936504364014	Adenuric was more effective in lowering uric acid levels in the blood than allopurinol and placebo .
D-32	-0.27454936504364014	Adenuric was more effective in lowering uric acid levels in the blood than allopurinol and placebo .
P-32	-0.1539 -0.1422 -0.0968 -0.1200 -0.8595 -0.2539 -0.1975 -1.7977 -0.8598 -0.0735 -0.2597 -0.0821 -0.1178 -0.8355 -0.2680 -0.1899 -0.0785 -0.1165 -0.0973 -0.1003 -0.1658 -0.1233 -0.2077 -0.0532 -0.1280 -0.1372 -0.1375 -0.1535 -0.1552
S-1807	- Die sonstigen Bestandteile sind Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid ,
T-1807	- The other ingredients are mannitol , sodium chloride , histidine , trehalose , calcium chloride ,
H-1807	-0.17062397301197052	- The other ingredients are mannitol , sodium chloride , histidine , trehalose , calcium chloride ,
D-1807	-0.17062397301197052	- The other ingredients are mannitol , sodium chloride , histidine , trehalose , calcium chloride ,
P-1807	-0.5692 -0.4845 -0.5730 -0.0968 -0.1199 -0.1708 -0.1054 -0.0850 -0.1383 -0.1136 -0.0869 -0.1236 -0.0748 -0.0839 -0.0869 -0.1372 -0.1128 -0.1476 -0.1692 -0.1363 -0.1183 -0.2123 -0.3068 -0.1383 -0.2655 -0.1272 -0.1261 -0.1756 -0.0616 -0.0823 -0.0853 -0.1688 -0.1470
S-1718	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1718	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1718	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1718	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1718	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-1955	Bei Patienten ab 60 Jahren ist die Wahrscheinlichkeit für das Auftreten von unerwünschten Ereignissen unter Sympathomimetika wie Pseudoephedrin höher .
T-1955	Patients of 60 years or older are more likely to experience adverse reactions to sympathomimetic medicinal products , such as pseudoephedrine .
H-1955	-0.2864551246166229	Patients over 60 years of age are more likely to experience adverse events with sympathomimetics such as pseudoephedrine .
D-1955	-0.2864551246166229	Patients over 60 years of age are more likely to experience adverse events with sympathomimetics such as pseudoephedrine .
P-1955	-0.3815 -0.0966 -1.7234 -0.2730 -0.6074 -0.3898 -0.1090 -0.2061 -0.3858 -0.1248 -0.1721 -0.4512 -0.0282 -0.0163 -0.1640 -1.6640 -0.2170 -0.0537 -0.0602 -0.0955 -0.2525 -0.1436 -0.1094 -0.1671 -0.1431 -0.0608 -0.1092 -0.2426 -0.1005 -0.1791 -0.1526
S-1834	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <unk> 353 1 2065500
T-1834	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <<unk>> 353 1 2065500
H-1834	-0.12607283890247345	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <unk> 353 1 2065500
D-1834	-0.12607283890247345	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <unk> 353 1 2065500
P-1834	-0.0442 -0.1285 -0.2257 -0.1570 -0.0486 -0.0870 -0.1487 -0.0428 -0.1824 -0.1635 -0.1518 -0.1403 -0.0576 -0.1255 -0.0990 -0.0513 -0.1192 -0.2199 -0.2096 -0.2464 -0.1288 -0.1186 -0.1395 -0.0973 -0.0671 -0.1431 -0.0238 -0.1469 -0.0899 -0.1413 -0.1988 -0.1134 -0.0740 -0.1549
S-1830	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <unk> 34 96 2722800
T-1830	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <<unk>> 34 96 2722800
H-1830	-0.17431563138961792	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <unk> 34 96 2722800
D-1830	-0.17431563138961792	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <unk> 34 96 2722800
P-1830	-0.1472 -0.0889 -0.1486 -0.1323 -0.1522 -0.0874 -0.1281 -0.1398 -0.1616 -1.9467 -0.1902 -0.1393 -0.1550 -0.1303 -0.1754 -0.1605 -0.1056 -0.0801 -0.0931 -0.1163 -0.0620 -0.1518 -0.0967 -0.1233 -0.0859 -0.1401 -0.0316 -0.1118 -0.0833 -0.0708 -0.1298 -0.0854 -0.1181 -0.1575
S-291	Bei Patienten mit einer glomerulären Filtrationsrate ( GFR ) über 35 ml<unk> min ist eine Dosisanpassung nicht erforderlich .
T-291	No dosage adjustment is necessary for patients with a glomerular filtration rate ( GFR ) greater than 35ml/ min .
H-291	-0.23615427315235138	No dose adjustment is necessary in patients with a glomerular filtration rate ( GFR ) greater than 35 ml/ min .
D-291	-0.23615427315235138	No dose adjustment is necessary in patients with a glomerular filtration rate ( GFR ) greater than 35 ml/ min .
P-291	-1.4927 -0.3711 -0.0757 -0.0584 -0.1029 -0.2196 -0.3015 -0.4064 -0.1811 -0.1779 -0.2687 -0.4179 -0.0924 -0.1295 -0.3279 -0.0825 -0.0677 -0.1395 -0.3792 -0.1263 -0.1513 -0.0828 -0.1319 -0.5453 -0.1137 -0.1193 -0.1365 -0.1708 -0.1354 -0.1096 -0.2886 -0.1526
S-103	Bei Patienten mit einer glomerulären Filtrationsrate ( GFR ) über 35 ml<unk> min ist eine Dosisanpassung nicht erforderlich .
T-103	No dosage adjustment is necessary for patients with a glomerular filtration rate ( GFR ) greater than 35ml/ min .
H-103	-0.23615427315235138	No dose adjustment is necessary in patients with a glomerular filtration rate ( GFR ) greater than 35 ml/ min .
D-103	-0.23615427315235138	No dose adjustment is necessary in patients with a glomerular filtration rate ( GFR ) greater than 35 ml/ min .
P-103	-1.4927 -0.3711 -0.0757 -0.0584 -0.1029 -0.2196 -0.3015 -0.4064 -0.1811 -0.1779 -0.2687 -0.4179 -0.0924 -0.1295 -0.3279 -0.0825 -0.0677 -0.1395 -0.3792 -0.1263 -0.1513 -0.0828 -0.1319 -0.5453 -0.1137 -0.1193 -0.1365 -0.1708 -0.1354 -0.1096 -0.2886 -0.1526
S-1968	Außerdem ist bei der Anwendung bei Patienten mit Migräne , die gleichzeitig mit gefäßverengenden Ergotalkaloiden behandelt werden , Vorsicht geboten .
T-1968	Caution should be exercised in patients suffering from migraine who are currently being treated with ergot alkaloid vasoconstrictors .
H-1968	-0.3826935589313507	Caution should also be exercised in migraine patients receiving concomitant vasoconstricting ergotalkaloids .
D-1968	-0.3826935589313507	Caution should also be exercised in migraine patients receiving concomitant vasoconstricting ergotalkaloids .
P-1968	-1.1661 -0.0784 -0.3711 -0.3278 -0.1580 -0.0526 -0.1378 -2.5086 -1.1776 -0.0176 -0.2166 -0.2289 -1.5275 -0.6079 -0.0496 -0.0076 -0.1879 -0.2576 -0.0500 -0.2519 -0.1173 -0.2387 -0.4865 -0.7512 -0.1444 -0.1449 -0.1536 -0.0477 -0.0793 -0.1632 -0.1557
S-1465	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-1465	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-1465	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-1465	-0.33558720350265503	In patients under 6 years of age , the administration of doses between 20 and 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-1465	-0.3009 -0.1881 -0.7502 -0.2424 -0.1709 -0.3196 -0.0994 -0.3859 -2.2204 -0.0760 -0.1179 -0.1887 -0.0533 -0.6155 -0.1272 -0.2109 -0.1404 -0.1217 -0.1226 -1.0763 -0.2339 -0.1614 -0.0924 -0.1073 -0.0706 -0.9203 -0.0506 -0.3190 -0.7495 -0.2310 -0.4915 -0.1700 -0.2592 -0.2086 -0.1517
S-1797	Während der Laufzeit kann die Pulver-Durchstechflasche einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) aufbewahrt werden .
T-1797	During the shelf life the powder vial may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1797	-0.3070775270462036	During runtime , the vial can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1797	-0.3070775270462036	During runtime , the vial can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1797	-1.0991 -0.6240 -0.2118 -0.5658 -0.2251 -0.6514 -0.0620 -0.6966 -0.1501 -0.3911 -0.1155 -1.0022 -0.0905 -0.0786 -0.1415 -0.6273 -0.1239 -0.2987 -0.1719 -0.1698 -0.1404 -0.1623 -0.2194 -0.0380 -0.1583 -0.2253 -0.1340 -0.1756 -0.1550
S-1651	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1651	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1651	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1651	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1651	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-1713	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1713	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1713	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1713	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1713	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-1701	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1701	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1701	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1701	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1701	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-1697	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1697	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1697	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1697	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1697	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-1685	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1685	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1685	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1685	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1685	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-1681	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1681	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1681	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1681	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1681	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-1669	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1669	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1669	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
D-1669	-0.20267179608345032	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S OF ADMINISTRATION
P-1669	-0.0809 -0.0586 -0.0617 -0.0145 -0.1622 -0.0584 -0.1975 -0.0369 -0.0503 -0.0513 -0.0715 -0.0477 -0.0181 -0.0224 -0.0276 -0.2198 -0.1276 -2.4599 -0.0454 -0.0136 -0.0009 -0.0348 -0.5450 -0.3999 -1.2334 -0.0338 -0.0376 -0.0089 -0.0174 -0.0322 -0.0970 -0.2188
S-1108	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-1108	Under certain circumstances ( e. g. presence of a low-titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-1108	-0.32768362760543823	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-1108	-0.32768362760543823	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-1108	-0.7130 -1.2471 -0.2435 -0.1629 -0.3563 -0.0872 -0.0611 -1.1249 -0.1264 -0.2717 -0.6109 -0.1388 -0.0995 -0.0627 -0.5276 -0.1294 -0.7467 -0.1355 -0.7426 -0.1733 -0.1957 -0.4396 -0.1156 -0.4016 -0.1045 -0.6708 -0.2546 -0.2139 -0.0831 -0.1423 -0.0595 -0.2189 -0.1525
S-335	In klinischen Studien erhielten mehrere Patientinnen Östrogen ( intravaginal , transdermal oder oral ) gemeinsam mit Alendronat .
T-335	A number of patients in the clinical trials received oestrogen ( intravaginal , transdermal , or oral ) while taking alendronate .
H-335	-0.27085214853286743	In clinical trials , several patients received estrogen ( intravaginal , transdermal or oral ) in conjunction with alendronate .
D-335	-0.27085214853286743	In clinical trials , several patients received estrogen ( intravaginal , transdermal or oral ) in conjunction with alendronate .
P-335	-0.2330 -0.1202 -0.1908 -0.3786 -0.2190 -0.3970 -0.7788 -0.4720 -0.0870 -0.0830 -0.1536 -0.2176 -0.3752 -0.1079 -0.0675 -0.1374 -0.0455 -0.2627 -0.2550 -0.8082 -0.0536 -0.1324 -1.6815 -0.4529 -0.0397 -0.1407 -0.1404 -0.1010 -0.1446 -0.0721 -0.1644 -0.1539
S-582	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-582	Under certain circumstances ( e. g. presence of a low-titre inhibitor ) , doses larger than those calculated using the formula may be necessary .
H-582	-0.32768362760543823	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-582	-0.32768362760543823	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-582	-0.7130 -1.2471 -0.2435 -0.1629 -0.3563 -0.0872 -0.0611 -1.1249 -0.1264 -0.2717 -0.6109 -0.1388 -0.0995 -0.0627 -0.5276 -0.1294 -0.7467 -0.1355 -0.7426 -0.1733 -0.1957 -0.4396 -0.1156 -0.4016 -0.1045 -0.6708 -0.2546 -0.2139 -0.0831 -0.1423 -0.0595 -0.2189 -0.1525
S-369	Wegen des Risikos einer ösophagealen Irritation sollten keine Maßnahmen zum Erbrechen eingeleitet werden und der Patient sollte sich vollständig aufrecht halten .
T-369	Owing to the risk of oesophageal irritation , vomiting should not be induced and the patient should remain fully upright .
H-369	-0.4747767746448517	Due to the risk of oesophageal irritation , no vomiting measures should be taken and the patient should remain upright .
D-369	-0.4747767746448517	Due to the risk of oesophageal irritation , no vomiting measures should be taken and the patient should remain upright .
P-369	-4.4079 -0.0602 -0.1236 -0.2203 -0.1861 -0.1549 -0.3010 -0.0324 -0.2105 -0.0599 -0.0772 -0.1284 -0.0850 -0.1301 -0.2795 -0.8618 -1.6478 -0.0767 -0.1065 -2.0151 -0.1233 -0.1331 -0.4811 -0.2613 -0.1863 -0.0887 -0.0985 -0.9053 -1.4308 -0.0516 -0.0832 -0.5051 -0.1544
S-620	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-620	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-620	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
D-620	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
P-620	-0.7413 -0.2390 -0.4997 -0.2631 -0.0830 -0.0645 -0.3997 -0.1247 -0.2587 -0.3565 -0.0807 -1.5400 -0.1826 -0.0392 -0.0489 -0.0995 -0.0684 -0.7402 -0.1767 -0.1467 -0.0991 -0.0839 -0.1167 -0.1347 -0.1345 -0.1581 -0.1540
S-181	Wegen des Risikos einer ösophagealen Irritation sollten keine Maßnahmen zum Erbrechen eingeleitet werden und der Patient sollte sich vollständig aufrecht halten .
T-181	Owing to the risk of oesophageal irritation , vomiting should not be induced and the patient should remain fully upright .
H-181	-0.4747767746448517	Due to the risk of oesophageal irritation , no vomiting measures should be taken and the patient should remain upright .
D-181	-0.4747767746448517	Due to the risk of oesophageal irritation , no vomiting measures should be taken and the patient should remain upright .
P-181	-4.4079 -0.0602 -0.1236 -0.2203 -0.1861 -0.1549 -0.3010 -0.0324 -0.2105 -0.0599 -0.0772 -0.1284 -0.0850 -0.1301 -0.2795 -0.8618 -1.6478 -0.0767 -0.1065 -2.0151 -0.1233 -0.1331 -0.4811 -0.2613 -0.1863 -0.0887 -0.0985 -0.9053 -1.4308 -0.0516 -0.0832 -0.5051 -0.1544
S-147	In klinischen Studien erhielten mehrere Patientinnen Östrogen ( intravaginal , transdermal oder oral ) gemeinsam mit Alendronat .
T-147	A number of patients in the clinical trials received oestrogen ( intravaginal , transdermal , or oral ) while taking alendronate .
H-147	-0.27085214853286743	In clinical trials , several patients received estrogen ( intravaginal , transdermal or oral ) in conjunction with alendronate .
D-147	-0.27085214853286743	In clinical trials , several patients received estrogen ( intravaginal , transdermal or oral ) in conjunction with alendronate .
P-147	-0.2330 -0.1202 -0.1908 -0.3786 -0.2190 -0.3970 -0.7788 -0.4720 -0.0870 -0.0830 -0.1536 -0.2176 -0.3752 -0.1079 -0.0675 -0.1374 -0.0455 -0.2627 -0.2550 -0.8082 -0.0536 -0.1324 -1.6815 -0.4529 -0.0397 -0.1407 -0.1404 -0.1010 -0.1446 -0.0721 -0.1644 -0.1539
S-1832	103 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <unk> 33 1 3461 5050
T-1832	97 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <<unk>> 33 1 3461 5050
H-1832	-0.11875829845666885	103 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <unk> 33 1 3461 5050
D-1832	-0.11875829845666885	103 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <unk> 33 1 3461 5050
P-1832	-0.2160 -0.0873 -0.1321 -0.1565 -0.1463 -0.1221 -0.0611 -0.1390 -0.0536 -0.0870 -0.0755 -0.1112 -0.1171 -0.1003 -0.0688 -0.1262 -0.1387 -0.1345 -0.1255 -0.1217 -0.1398 -0.0583 -0.1130 -0.1416 -0.0398 -0.1350 -0.1406 -0.1569 -0.1232 -0.1267 -0.1310 -0.1367 -0.1561
S-1538	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-1538	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-1538	-0.22415176033973694	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-1538	-0.22415176033973694	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-1538	-0.9442 -0.1840 -0.1034 -0.0717 -0.1978 -0.1072 -0.1640 -0.1429 -0.2794 -0.1777 -0.0532 -0.1622 -0.6978 -0.0666 -0.1012 -0.0597 -0.1406 -0.1256 -0.2975 -0.5460 -0.0964 -0.1932 -0.1745 -0.1279 -0.1419 -0.1057 -0.0903 -0.0760 -0.2516 -0.2508 -0.9389 -0.1585 -0.1690
S-1460	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-1460	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-1460	-0.32768362760543823	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-1460	-0.32768362760543823	In certain circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-1460	-0.7130 -1.2471 -0.2435 -0.1629 -0.3563 -0.0872 -0.0611 -1.1249 -0.1264 -0.2717 -0.6109 -0.1388 -0.0995 -0.0627 -0.5276 -0.1294 -0.7467 -0.1355 -0.7426 -0.1733 -0.1957 -0.4396 -0.1156 -0.4016 -0.1045 -0.6708 -0.2546 -0.2139 -0.0831 -0.1423 -0.0595 -0.2189 -0.1525
S-256	Es wurden keine Hinweise auf eine Sättigung der Aufnahmefähigkeit des Knochens nach Langzeitdosierung von kumulativen intravenösen Dosen bis zu
T-256	No evidence of saturation of bone uptake was found after chronic dosing with cumulative intravenous doses up to 35 mg/ kg in animals .
H-256	-0.46854493021965027	No evidence of bone absorption saturation after long-term doses ranging from cumulative intravenous doses to
D-256	-0.46854493021965027	No evidence of bone absorption saturation after long-term doses ranging from cumulative intravenous doses to
P-256	-0.8898 -0.0234 -1.3498 -0.4383 -1.6997 -0.1153 -0.6615 -0.0628 -0.1316 -0.9943 -2.2625 -0.1894 -0.0947 -0.1724 -1.0345 -1.1332 -0.2000 -0.1334 -0.0578 -0.1235 -0.2608 -0.0927 -0.0741 -0.1151 -0.2769 -0.0721 -0.3097 -0.1501
S-1449	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-1449	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-1449	-0.43345463275909424	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
D-1449	-0.43345463275909424	Table 1 : Dosage guidance for bleeding events and operations Grade of bleeding / type of surgery Bleeding
P-1449	-0.0634 -0.1472 -0.1432 -0.3344 -0.1300 -0.0964 -1.2028 -0.5541 -1.5186 -0.1627 -0.2007 -0.1418 -1.4491 -1.1174 -0.1674 -0.1144 -0.2944 -0.1565 -0.1536 -0.4202 -0.1181 -0.1394 -1.6694 -0.1788 -0.1622
S-794	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-794	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-794	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
D-794	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
P-794	-0.7413 -0.2390 -0.4997 -0.2631 -0.0830 -0.0645 -0.3997 -0.1247 -0.2587 -0.3565 -0.0807 -1.5400 -0.1826 -0.0392 -0.0489 -0.0995 -0.0684 -0.7402 -0.1767 -0.1467 -0.0991 -0.0839 -0.1167 -0.1347 -0.1345 -0.1581 -0.1540
S-1188	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-1188	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-1188	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
D-1188	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
P-1188	-0.2856 -0.0359 -0.0719 -0.1002 -0.1381 -0.1392 -0.2329 -0.6783 -2.1081 -1.0060 -1.1122 -0.3954 -0.0141 -0.0919 -0.6468 -0.1523 -0.0500 -0.0938 -0.1007 -1.8960 -0.1253 -1.6002 -0.0403 -0.7880 -0.5023 -0.4122 -1.1224 -0.1769 -0.2050 -0.1554
S-836	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-836	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-836	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
D-836	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
P-836	-0.2856 -0.0359 -0.0719 -0.1002 -0.1381 -0.1392 -0.2329 -0.6783 -2.1081 -1.0060 -1.1122 -0.3954 -0.0141 -0.0919 -0.6468 -0.1523 -0.0500 -0.0938 -0.1007 -1.8960 -0.1253 -1.6002 -0.0403 -0.7880 -0.5023 -0.4122 -1.1224 -0.1769 -0.2050 -0.1554
S-1789	100 Anschwellen von Füßen und Beinen , erhöhte Leberenzyme , Hämatokritabfall und Schmerzen im Oberbauch oder unteren Brustbereich
T-1789	94 itching , increased sweating , unusual taste in the mouth , hot flushes , migraines , memory impairment , chills , diarrhoea , nausea , vomiting , shortness of breath , sore throat , infection of the lymphatic vessels , whitening of skin , eye inflammation , rashes , excessive sweating , foot and leg swelling , increase in enzymes that track liver function , reduced percentage of red blood cells and pain in the upper abdomen or lower chest .
H-1789	-0.443272203207016	100 swelling of feet and legs , increased liver enzymes , haematocrisy , and pain in the upper abdomen or lower chest
D-1789	-0.443272203207016	100 swelling of feet and legs , increased liver enzymes , haematocrisy , and pain in the upper abdomen or lower chest
P-1789	-1.3270 -0.5136 -0.0956 -0.1443 -0.2848 -0.1668 -0.1915 -0.1375 -0.4965 -0.2257 -0.0755 -0.0639 -0.1580 -0.1371 -0.8413 -0.0869 -0.0511 -0.2783 -0.1738 -3.1646 -1.2224 -0.2177 -1.3822 -0.1348 -0.3677 -0.5763 -0.4701 -0.0403 -0.1267 -0.4582 -0.6771 -0.1531 -0.1877
S-1541	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-1541	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-1541	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
D-1541	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
P-1541	-0.2856 -0.0359 -0.0719 -0.1002 -0.1381 -0.1392 -0.2329 -0.6783 -2.1081 -1.0060 -1.1122 -0.3954 -0.0141 -0.0919 -0.6468 -0.1523 -0.0500 -0.0938 -0.1007 -1.8960 -0.1253 -1.6002 -0.0403 -0.7880 -0.5023 -0.4122 -1.1224 -0.1769 -0.2050 -0.1554
S-1364	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-1364	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-1364	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
D-1364	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
P-1364	-0.2856 -0.0359 -0.0719 -0.1002 -0.1381 -0.1392 -0.2329 -0.6783 -2.1081 -1.0060 -1.1122 -0.3954 -0.0141 -0.0919 -0.6468 -0.1523 -0.0500 -0.0938 -0.1007 -1.8960 -0.1253 -1.6002 -0.0403 -0.7880 -0.5023 -0.4122 -1.1224 -0.1769 -0.2050 -0.1554
S-970	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-970	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-970	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
D-970	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
P-970	-0.7413 -0.2390 -0.4997 -0.2631 -0.0830 -0.0645 -0.3997 -0.1247 -0.2587 -0.3565 -0.0807 -1.5400 -0.1826 -0.0392 -0.0489 -0.0995 -0.0684 -0.7402 -0.1767 -0.1467 -0.0991 -0.0839 -0.1167 -0.1347 -0.1345 -0.1581 -0.1540
S-1012	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-1012	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-1012	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
D-1012	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
P-1012	-0.2856 -0.0359 -0.0719 -0.1002 -0.1381 -0.1392 -0.2329 -0.6783 -2.1081 -1.0060 -1.1122 -0.3954 -0.0141 -0.0919 -0.6468 -0.1523 -0.0500 -0.0938 -0.1007 -1.8960 -0.1253 -1.6002 -0.0403 -0.7880 -0.5023 -0.4122 -1.1224 -0.1769 -0.2050 -0.1554
S-1146	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-1146	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-1146	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
D-1146	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
P-1146	-0.7413 -0.2390 -0.4997 -0.2631 -0.0830 -0.0645 -0.3997 -0.1247 -0.2587 -0.3565 -0.0807 -1.5400 -0.1826 -0.0392 -0.0489 -0.0995 -0.0684 -0.7402 -0.1767 -0.1467 -0.0991 -0.0839 -0.1167 -0.1347 -0.1345 -0.1581 -0.1540
S-661	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-661	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel . The plasma levels of factor VIII are
H-661	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
D-661	-0.4825825095176697	Haemophilia A is a gender @-@ based , hereditary blood clotting disorder due to decreased Factor VIII levels .
P-661	-0.2856 -0.0359 -0.0719 -0.1002 -0.1381 -0.1392 -0.2329 -0.6783 -2.1081 -1.0060 -1.1122 -0.3954 -0.0141 -0.0919 -0.6468 -0.1523 -0.0500 -0.0938 -0.1007 -1.8960 -0.1253 -1.6002 -0.0403 -0.7880 -0.5023 -0.4122 -1.1224 -0.1769 -0.2050 -0.1554
S-1498	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-1498	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-1498	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
D-1498	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
P-1498	-0.7413 -0.2390 -0.4997 -0.2631 -0.0830 -0.0645 -0.3997 -0.1247 -0.2587 -0.3565 -0.0807 -1.5400 -0.1826 -0.0392 -0.0489 -0.0995 -0.0684 -0.7402 -0.1767 -0.1467 -0.0991 -0.0839 -0.1167 -0.1347 -0.1345 -0.1581 -0.1540
S-1322	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-1322	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-1322	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
D-1322	-0.2605230212211609	As with any intravenous protein , allergic type hypersensitivity reactions are possible ( see section 4.4 ) .
P-1322	-0.7413 -0.2390 -0.4997 -0.2631 -0.0830 -0.0645 -0.3997 -0.1247 -0.2587 -0.3565 -0.0807 -1.5400 -0.1826 -0.0392 -0.0489 -0.0995 -0.0684 -0.7402 -0.1767 -0.1467 -0.0991 -0.0839 -0.1167 -0.1347 -0.1345 -0.1581 -0.1540
S-1361	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-1361	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-1361	-0.22415176033973694	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-1361	-0.22415176033973694	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-1361	-0.9442 -0.1840 -0.1034 -0.0717 -0.1978 -0.1072 -0.1640 -0.1429 -0.2794 -0.1777 -0.0532 -0.1622 -0.6978 -0.0666 -0.1012 -0.0597 -0.1406 -0.1256 -0.2975 -0.5460 -0.0964 -0.1932 -0.1745 -0.1279 -0.1419 -0.1057 -0.0903 -0.0760 -0.2516 -0.2508 -0.9389 -0.1585 -0.1690
S-688	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-688	Advate is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-688	-0.32309770584106445	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
D-688	-0.32309770584106445	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
P-688	-0.4661 -0.1533 -0.0906 -0.0987 -0.2008 -1.0243 -0.0929 -0.3609 -0.0824 -0.0745 -0.0947 -0.5395 -0.1483 -0.1815 -0.3810 -1.6184 -0.4116 -0.2693 -0.2345 -0.1971 -0.1144 -0.1411 -0.0820 -0.1247 -0.6116 -0.2185 -2.2321 -0.0996 -0.1604 -0.1187 -0.1329 -0.0609 -0.1386 -0.1938 -0.1585
S-1040	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-1040	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-1040	-0.32309770584106445	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
D-1040	-0.32309770584106445	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
P-1040	-0.4661 -0.1533 -0.0906 -0.0987 -0.2008 -1.0243 -0.0929 -0.3609 -0.0824 -0.0745 -0.0947 -0.5395 -0.1483 -0.1815 -0.3810 -1.6184 -0.4116 -0.2693 -0.2345 -0.1971 -0.1144 -0.1411 -0.0820 -0.1247 -0.6116 -0.2185 -2.2321 -0.0996 -0.1604 -0.1187 -0.1329 -0.0609 -0.1386 -0.1938 -0.1585
S-864	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-864	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-864	-0.32309770584106445	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
D-864	-0.32309770584106445	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
P-864	-0.4661 -0.1533 -0.0906 -0.0987 -0.2008 -1.0243 -0.0929 -0.3609 -0.0824 -0.0745 -0.0947 -0.5395 -0.1483 -0.1815 -0.3810 -1.6184 -0.4116 -0.2693 -0.2345 -0.1971 -0.1144 -0.1411 -0.0820 -0.1247 -0.6116 -0.2185 -2.2321 -0.0996 -0.1604 -0.1187 -0.1329 -0.0609 -0.1386 -0.1938 -0.1585
S-27	In der zweiten Studie wurden zwei Dosierungen von Adenuric ( einmal täglich 80 und 120 mg ) ein Jahr lang an 762 Patienten jeweils mit Allopurinol verglichen .
T-27	The second study compared two doses of Adenuric ( 80 and 120 mg once a day ) with allopurinol over one year in 762 patients .
H-27	-0.3982129693031311	In the second trial , two doses of Adenuric ( 80 and 120 mg once daily ) were compared for one year in 762 patients , each with allopurinol .
D-27	-0.3982129693031311	In the second trial , two doses of Adenuric ( 80 and 120 mg once daily ) were compared for one year in 762 patients , each with allopurinol .
P-27	-0.4636 -0.1973 -0.0749 -0.9191 -0.3413 -0.2682 -0.3019 -0.0993 -0.1259 -1.2465 -0.1608 -0.1107 -0.1414 -0.1841 -0.8932 -0.4289 -0.0968 -0.0359 -0.5708 -0.1048 -0.2878 -0.5273 -1.2108 -0.5136 -0.2484 -0.1578 -0.2068 -0.1386 -0.0710 -0.3385 -1.1422 -1.9280 -1.0739 -0.2098 -0.1101 -0.1523 -0.1377 -0.1580 -0.1522
S-1216	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-1216	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-1216	-0.32309770584106445	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
D-1216	-0.32309770584106445	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
P-1216	-0.4661 -0.1533 -0.0906 -0.0987 -0.2008 -1.0243 -0.0929 -0.3609 -0.0824 -0.0745 -0.0947 -0.5395 -0.1483 -0.1815 -0.3810 -1.6184 -0.4116 -0.2693 -0.2345 -0.1971 -0.1144 -0.1411 -0.0820 -0.1247 -0.6116 -0.2185 -2.2321 -0.0996 -0.1604 -0.1187 -0.1329 -0.0609 -0.1386 -0.1938 -0.1585
S-519	Die Dosierung und Häufigkeit der Anwendung richten sich danach , ob Advate zur Behandlung von Blutungen oder zur Vorbeugung von Blutungen bei chirurgischen Eingriffen angewendet wird .
T-519	The dose and frequency depend on whether Advate is used to treat haemorrhage ( bleeding ) or to prevent it during surgery .
H-519	-0.35114455223083496	The dosage and frequency of administration depend on whether Advate is used to treat bleeding or to prevent bleeding during surgery .
D-519	-0.35114455223083496	The dosage and frequency of administration depend on whether Advate is used to treat bleeding or to prevent bleeding during surgery .
P-519	-0.5331 -0.6753 -0.1652 -0.1074 -0.1459 -0.1158 -0.0794 -0.1404 -0.5499 -2.0680 -0.1447 -0.0855 -0.4824 -0.0758 -0.2007 -0.1999 -0.1871 -0.1402 -0.8180 -0.1676 -0.1864 -0.3155 -0.1477 -0.6056 -0.1251 -1.2487 -0.1508 -0.1553 -0.1659
S-1229	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-1229	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-1229	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
D-1229	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
P-1229	-2.1792 -0.2310 -1.4094 -0.1623 -0.1821 -0.0599 -0.1553 -0.0883 -2.7577 -0.1504 -0.2275 -1.3671 -0.2391 -0.7788 -1.1382 -1.1145 -0.4953 -0.3976 -0.0365 -0.0954 -0.7199 -1.4905 -0.0630 -0.1727 -0.1819 -0.1264 -0.1963 -0.1640
S-1053	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-1053	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-1053	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
D-1053	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
P-1053	-2.1792 -0.2310 -1.4094 -0.1623 -0.1821 -0.0599 -0.1553 -0.0883 -2.7577 -0.1504 -0.2275 -1.3671 -0.2391 -0.7788 -1.1382 -1.1145 -0.4953 -0.3976 -0.0365 -0.0954 -0.7199 -1.4905 -0.0630 -0.1727 -0.1819 -0.1264 -0.1963 -0.1640
S-1292	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-1292	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-1292	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
D-1292	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
P-1292	-0.3346 -0.3117 -0.1973 -0.5198 -0.5006 -0.1310 -0.0300 -0.4535 -0.3025 -0.8690 -0.4713 -0.5880 -0.7476 -0.9226 -0.3164 -0.1512 -0.1285 -1.2340 -0.5255 -0.1309 -0.0965 -0.7937 -1.1390 -0.8342 -0.1472 -0.1335 -0.0867 -0.1710 -0.1601
S-701	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-701	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-701	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
D-701	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
P-701	-2.1792 -0.2310 -1.4094 -0.1623 -0.1821 -0.0599 -0.1553 -0.0883 -2.7577 -0.1504 -0.2275 -1.3671 -0.2391 -0.7788 -1.1382 -1.1145 -0.4953 -0.3976 -0.0365 -0.0954 -0.7199 -1.4905 -0.0630 -0.1727 -0.1819 -0.1264 -0.1963 -0.1640
S-590	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-590	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-590	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
D-590	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
P-590	-0.3346 -0.3117 -0.1973 -0.5198 -0.5006 -0.1310 -0.0300 -0.4535 -0.3025 -0.8690 -0.4713 -0.5880 -0.7476 -0.9226 -0.3164 -0.1512 -0.1285 -1.2340 -0.5255 -0.1309 -0.0965 -0.7937 -1.1390 -0.8342 -0.1472 -0.1335 -0.0867 -0.1710 -0.1601
S-1116	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-1116	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-1116	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
D-1116	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
P-1116	-0.3346 -0.3117 -0.1973 -0.5198 -0.5006 -0.1310 -0.0300 -0.4535 -0.3025 -0.8690 -0.4713 -0.5880 -0.7476 -0.9226 -0.3164 -0.1512 -0.1285 -1.2340 -0.5255 -0.1309 -0.0965 -0.7937 -1.1390 -0.8342 -0.1472 -0.1335 -0.0867 -0.1710 -0.1601
S-1582	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-1582	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-1582	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
D-1582	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
P-1582	-2.1792 -0.2310 -1.4094 -0.1623 -0.1821 -0.0599 -0.1553 -0.0883 -2.7577 -0.1504 -0.2275 -1.3671 -0.2391 -0.7788 -1.1382 -1.1145 -0.4953 -0.3976 -0.0365 -0.0954 -0.7199 -1.4905 -0.0630 -0.1727 -0.1819 -0.1264 -0.1963 -0.1640
S-940	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-940	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-940	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
D-940	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
P-940	-0.3346 -0.3117 -0.1973 -0.5198 -0.5006 -0.1310 -0.0300 -0.4535 -0.3025 -0.8690 -0.4713 -0.5880 -0.7476 -0.9226 -0.3164 -0.1512 -0.1285 -1.2340 -0.5255 -0.1309 -0.0965 -0.7937 -1.1390 -0.8342 -0.1472 -0.1335 -0.0867 -0.1710 -0.1601
S-877	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-877	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-877	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
D-877	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
P-877	-2.1792 -0.2310 -1.4094 -0.1623 -0.1821 -0.0599 -0.1553 -0.0883 -2.7577 -0.1504 -0.2275 -1.3671 -0.2391 -0.7788 -1.1382 -1.1145 -0.4953 -0.3976 -0.0365 -0.0954 -0.7199 -1.4905 -0.0630 -0.1727 -0.1819 -0.1264 -0.1963 -0.1640
S-764	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-764	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-764	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
D-764	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
P-764	-0.3346 -0.3117 -0.1973 -0.5198 -0.5006 -0.1310 -0.0300 -0.4535 -0.3025 -0.8690 -0.4713 -0.5880 -0.7476 -0.9226 -0.3164 -0.1512 -0.1285 -1.2340 -0.5255 -0.1309 -0.0965 -0.7937 -1.1390 -0.8342 -0.1472 -0.1335 -0.0867 -0.1710 -0.1601
S-1947	Es wird empfohlen , die Anwendungsdauer auf 10 Tage zu begrenzen , da bei Langzeitanwendung die Aktivität von Pseudoephedrin mit der Zeit abnehmen kann .
T-1947	It is advisable to limit treatment to about 10 days , as during chronic administration the activity of pseudoephedrine may diminish .
H-1947	-0.42543497681617737	It is recommended to limit the duration of administration to 10 days , as long-term use may decrease over time .
D-1947	-0.42543497681617737	It is recommended to limit the duration of administration to 10 days , as long-term use may decrease over time .
P-1947	-0.5888 -0.1687 -0.1389 -0.7717 -0.4322 -0.2986 -0.1523 -0.1149 -0.2286 -0.7294 -0.1409 -0.1606 -0.1303 -0.6968 -1.2448 -0.5996 -0.7018 -0.1245 -0.1780 -0.2063 -0.8396 -0.1074 -1.5581 -0.1141 -0.4718 -0.1622
S-1956	Die Sicherheit und die Wirksamkeit dieser Kombinationstherapie wurden für dieses Patientenkollektiv nicht geprüft und die Daten reichen nicht aus , um entsprechende Empfehlungen zur Dosierung auszusprechen .
T-1956	The safety and efficacy of the combination have not been established in this population , and there are insufficient data to give adequate dose recommendations .
H-1956	-0.30918174982070923	The safety and efficacy of this combination therapy have not been evaluated in this population and data are insufficient to recommend appropriate dosing regimens .
D-1956	-0.30918174982070923	The safety and efficacy of this combination therapy have not been evaluated in this population and data are insufficient to recommend appropriate dosing regimens .
P-1956	-0.3471 -0.0442 -0.1555 -0.0669 -0.0741 -0.0868 -0.1235 -0.1453 -0.0945 -0.4061 -0.8391 -0.1095 -0.1053 -0.3272 -0.1171 -0.6217 -0.1179 -0.4143 -0.8656 -0.5409 -0.7278 -0.7151 -0.2707 -0.1581 -0.3605 -0.1579 -0.1868 -0.7014 -0.5536 -0.0962 -0.2066 -0.1564
S-29	Hauptindikator für die Wirksamkeit war die Anzahl der Patienten , deren Harnsäurespiegel im Blut bei den letzten drei Messungen unter 6 mg<unk> dl lag .
T-29	The main measure of effectiveness was the number of patients whose final three blood uric acid levels were below 6 mg/ dl .
H-29	-0.3480226397514343	The main measure of efficacy was the number of patients whose blood uric acid levels were below 6 mg/ dl in the last three measurements .
D-29	-0.3480226397514343	The main measure of efficacy was the number of patients whose blood uric acid levels were below 6 mg/ dl in the last three measurements .
P-29	-0.2850 -0.8892 -0.5239 -0.1287 -0.2818 -0.0889 -0.0866 -0.2000 -0.2810 -0.2174 -0.1197 -0.2482 -0.4299 -0.6571 -0.8086 -0.0745 -0.1692 -0.7663 -0.5546 -0.5577 -0.1511 -0.1627 -0.1340 -0.1475 -0.0358 -1.0202 -0.1798 -0.6735 -0.1542 -1.1750 -0.0877 -0.2089 -0.1822 -0.1518
S-1468	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-1468	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-1468	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
D-1468	-0.428556352853775	In patients with high inhibitors , Factor VIII may not be effective and other therapeutic measures may need to be considered .
P-1468	-0.3346 -0.3117 -0.1973 -0.5198 -0.5006 -0.1310 -0.0300 -0.4535 -0.3025 -0.8690 -0.4713 -0.5880 -0.7476 -0.9226 -0.3164 -0.1512 -0.1285 -1.2340 -0.5255 -0.1309 -0.0965 -0.7937 -1.1390 -0.8342 -0.1472 -0.1335 -0.0867 -0.1710 -0.1601
S-301	14 werden ( siehe Abschnitt 4.2 ) . Die Patienten sollen darüber informiert werden , dass das Risiko ösophagealer Probleme erhöht sein kann , wenn sie diese Anweisungen nicht einhalten .
T-301	Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems .
H-301	-0.40076059103012085	patients should be advised that failure to follow these instructions may result in an increased risk of oesophageal problems .
D-301	-0.40076059103012085	patients should be advised that failure to follow these instructions may result in an increased risk of oesophageal problems .
P-301	-1.2199 -0.3391 -0.1257 -1.0328 -0.1889 -1.9974 -0.1389 -0.6958 -0.0867 -0.5681 -0.4457 -0.9511 -0.1264 -0.3068 -0.0671 -0.1069 -0.1512 -0.2755 -0.0357 -0.4589 -0.0694 -0.0532 -0.1249 -0.3472 -0.3198 -0.1868
S-1236	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-1236	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-1236	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-1236	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-1236	-1.2230 -0.1621 -0.3713 -0.4431 -1.1993 -0.7720 -0.2892 -0.1336 -0.4931 -0.1507 -0.1740 -0.1879 -0.1065 -0.1203 -0.1236 -0.1839 -0.2093 -1.2231 -0.0927 -0.0519 -0.0716 -0.2714 -1.4136 -1.0896 -0.7167 -0.1845
S-1060	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-1060	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-1060	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-1060	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-1060	-1.2230 -0.1621 -0.3713 -0.4431 -1.1993 -0.7720 -0.2892 -0.1336 -0.4931 -0.1507 -0.1740 -0.1879 -0.1065 -0.1203 -0.1236 -0.1839 -0.2093 -1.2231 -0.0927 -0.0519 -0.0716 -0.2714 -1.4136 -1.0896 -0.7167 -0.1845
S-1839	Suomi<unk> Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh<unk> Tel : <unk> 358 9 8621111
T-1839	Suomi/ Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh/ Tel : <<unk>> 358 9 8621111
H-1839	-0.13410568237304688	Suomi/ Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh/ Tel : <unk> 358 9 8621111
D-1839	-0.13410568237304688	Suomi/ Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh/ Tel : <unk> 358 9 8621111
P-1839	-0.1339 -0.0190 -0.1608 -0.2962 -0.0778 -0.1389 -0.1423 -0.1717 -0.1316 -0.2204 -0.1428 -0.1238 -0.1326 -0.1585 -0.1737 -0.1456 -0.1312 -0.1447 -0.1155 -0.0860 -0.1620 -0.1073 -0.0376 -0.1340 -0.0813 -0.1370 -0.2578 -0.0784 -0.1420 -0.0733 -0.1459 -0.1173 -0.1056 -0.1559 -0.1613 -0.1221 -0.1129 -0.0922 -0.1589
S-510	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-510	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-510	-0.37782174348831177	For more information about your disease or treatment , read the Package Leaflet ( also included in EPAR ) or contact your doctor or pharmacist .
D-510	-0.37782174348831177	For more information about your disease or treatment , read the Package Leaflet ( also included in EPAR ) or contact your doctor or pharmacist .
P-510	-1.4221 -1.5677 -0.0419 -0.9248 -0.1634 -1.2368 -0.2312 -0.4115 -0.3345 -0.6703 -0.3067 -0.2530 -0.1421 -0.1413 -0.0323 -0.1112 -0.2274 -0.4251 -0.7871 -0.2342 -0.4524 -0.0653 -0.1420 -0.3409 -0.5192 -0.1386 -0.1314 -0.1441 -0.0405 -0.1023 -0.1732 -0.1757
S-1	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-1	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-1	-0.37782174348831177	For more information about your disease or treatment , read the Package Leaflet ( also included in EPAR ) or contact your doctor or pharmacist .
D-1	-0.37782174348831177	For more information about your disease or treatment , read the Package Leaflet ( also included in EPAR ) or contact your doctor or pharmacist .
P-1	-1.4221 -1.5677 -0.0419 -0.9248 -0.1634 -1.2368 -0.2312 -0.4115 -0.3345 -0.6703 -0.3067 -0.2530 -0.1421 -0.1413 -0.0323 -0.1112 -0.2274 -0.4251 -0.7871 -0.2342 -0.4524 -0.0653 -0.1420 -0.3409 -0.5192 -0.1386 -0.1314 -0.1441 -0.0405 -0.1023 -0.1732 -0.1757
S-1589	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-1589	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-1589	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-1589	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-1589	-1.2230 -0.1621 -0.3713 -0.4431 -1.1993 -0.7720 -0.2892 -0.1336 -0.4931 -0.1507 -0.1740 -0.1879 -0.1065 -0.1203 -0.1236 -0.1839 -0.2093 -1.2231 -0.0927 -0.0519 -0.0716 -0.2714 -1.4136 -1.0896 -0.7167 -0.1845
S-1412	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-1412	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-1412	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-1412	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-1412	-1.2230 -0.1621 -0.3713 -0.4431 -1.1993 -0.7720 -0.2892 -0.1336 -0.4931 -0.1507 -0.1740 -0.1879 -0.1065 -0.1203 -0.1236 -0.1839 -0.2093 -1.2231 -0.0927 -0.0519 -0.0716 -0.2714 -1.4136 -1.0896 -0.7167 -0.1845
S-1871	Das Unternehmen legte Daten aus einer Studie mit einem Patienten vor , bei dem Li-Fraumeni-Krebs im Bereich des Unterbauchs , in den Knochen und im Gehirn auftrat .
T-1871	The company presented information from a study on one patient with Li-Fraumeni cancer in the lower abdomen , the bones and the brain .
H-1871	-0.5044901371002197	The company presented data from a trial in a patient with Li-Fraumeni cancer in the lower abdomen , bones and brain .
D-1871	-0.5044901371002197	The company presented data from a trial in a patient with Li-Fraumeni cancer in the lower abdomen , bones and brain .
P-1871	-0.4599 -0.3787 -0.9104 -0.1137 -0.1370 -0.1374 -0.3317 -0.6600 -0.5576 -0.1112 -0.9543 -2.3172 -0.2102 -0.2974 -0.0360 -0.3730 -1.6840 -0.6156 -0.1763 -0.8900 -0.1364 -0.0203 -0.7330 -0.1398 -1.2471 -0.5160 -0.0916 -0.2322 -0.1623
S-1405	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-1405	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-1405	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
D-1405	-0.585009753704071	Open the BAXJECT II packaging by removing the protective film without touching the contents ( Fig . A ) .
P-1405	-2.1792 -0.2310 -1.4094 -0.1623 -0.1821 -0.0599 -0.1553 -0.0883 -2.7577 -0.1504 -0.2275 -1.3671 -0.2391 -0.7788 -1.1382 -1.1145 -0.4953 -0.3976 -0.0365 -0.0954 -0.7199 -1.4905 -0.0630 -0.1727 -0.1819 -0.1264 -0.1963 -0.1640
S-884	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-884	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-884	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-884	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-884	-1.2230 -0.1621 -0.3713 -0.4431 -1.1993 -0.7720 -0.2892 -0.1336 -0.4931 -0.1507 -0.1740 -0.1879 -0.1065 -0.1203 -0.1236 -0.1839 -0.2093 -1.2231 -0.0927 -0.0519 -0.0716 -0.2714 -1.4136 -1.0896 -0.7167 -0.1845
S-708	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-708	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-708	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-708	-0.440701961517334	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-708	-1.2230 -0.1621 -0.3713 -0.4431 -1.1993 -0.7720 -0.2892 -0.1336 -0.4931 -0.1507 -0.1740 -0.1879 -0.1065 -0.1203 -0.1236 -0.1839 -0.2093 -1.2231 -0.0927 -0.0519 -0.0716 -0.2714 -1.4136 -1.0896 -0.7167 -0.1845
S-1979	Dihydroergotamin , Ergotamin , Methylergometrin : Risiko für das Auftreten einer Gefäßverengung und einer Hypertonie .
T-1979	Dihydroergotamine , ergotamine , methylergometrine : risk of vasoconstriction and increase in blood pressure .
H-1979	-0.28794845938682556	Dihydroergotamine , ergotamine , methylergometrin : risk of vasoconstriction and hypertension .
D-1979	-0.28794845938682556	Dihydroergotamine , ergotamine , methylergometrin : risk of vasoconstriction and hypertension .
P-1979	-1.0788 -0.0589 -0.1807 -0.0897 -0.1241 -0.1381 -0.3165 -0.1183 -0.1121 -0.1411 -0.1468 -0.2142 -0.5410 -0.1841 -0.1086 -1.3212 -0.1444 -0.1164 -1.0090 -0.5795 -0.0277 -0.9248 -0.0656 -0.1764 -0.1507 -0.1416 -0.0290 -0.0352 -0.2029 -0.1610
S-120	Wenn Patienten während einer Bisphosphonattherapie eine Osteonekrose des Kiefers entwickeln , kann ein kieferchirurgischer Eingriff zu einer Verschlechterung führen .
T-120	For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy , dental surgery may exacerbate the condition .
H-120	-0.3908684551715851	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , orthodontic surgery may result in worsening of the condition .
D-120	-0.3908684551715851	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , orthodontic surgery may result in worsening of the condition .
P-120	-0.8530 -0.4700 -0.1810 -0.7623 -0.0764 -0.1119 -0.1267 -0.0344 -0.0992 -0.1586 -0.1776 -0.0893 -0.1447 -0.5521 -0.0886 -0.0373 -0.0350 -1.2083 -0.2136 -0.1233 -1.7535 -0.4048 -0.1293 -0.1308 -0.0279 -0.3692 -1.8571 -0.1239 -1.4594 -0.0535 -0.1441 -1.1216 -0.2467 -0.3996 -0.1545 -0.1523
S-308	Wenn Patienten während einer Bisphosphonattherapie eine Osteonekrose des Kiefers entwickeln , kann ein kieferchirurgischer Eingriff zu einer Verschlechterung führen .
T-308	For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy , dental surgery may exacerbate the condition .
H-308	-0.3908684551715851	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , orthodontic surgery may result in worsening of the condition .
D-308	-0.3908684551715851	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , orthodontic surgery may result in worsening of the condition .
P-308	-0.8530 -0.4700 -0.1810 -0.7623 -0.0764 -0.1119 -0.1267 -0.0344 -0.0992 -0.1586 -0.1776 -0.0893 -0.1447 -0.5521 -0.0886 -0.0373 -0.0350 -1.2083 -0.2136 -0.1233 -1.7535 -0.4048 -0.1293 -0.1308 -0.0279 -0.3692 -1.8571 -0.1239 -1.4594 -0.0535 -0.1441 -1.1216 -0.2467 -0.3996 -0.1545 -0.1523
S-1076	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-1076	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-1076	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
D-1076	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
P-1076	-0.6749 -0.0595 -0.1069 -0.5716 -0.3166 -1.3266 -0.2228 -0.1818 -0.2030 -0.1471 -1.6887 -0.1374 -0.1477 -0.1691 -1.1178 -0.1015 -0.1323 -0.2030 -0.1334 -0.0731 -0.1196 -0.1362 -0.4772 -0.9212 -0.2147 -0.3255 -0.0089 -1.0418 -1.2231 -0.7847 -0.1561
S-724	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-724	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-724	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
D-724	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
P-724	-0.6749 -0.0595 -0.1069 -0.5716 -0.3166 -1.3266 -0.2228 -0.1818 -0.2030 -0.1471 -1.6887 -0.1374 -0.1477 -0.1691 -1.1178 -0.1015 -0.1323 -0.2030 -0.1334 -0.0731 -0.1196 -0.1362 -0.4772 -0.9212 -0.2147 -0.3255 -0.0089 -1.0418 -1.2231 -0.7847 -0.1561
S-1252	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-1252	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-1252	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
D-1252	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
P-1252	-0.6749 -0.0595 -0.1069 -0.5716 -0.3166 -1.3266 -0.2228 -0.1818 -0.2030 -0.1471 -1.6887 -0.1374 -0.1477 -0.1691 -1.1178 -0.1015 -0.1323 -0.2030 -0.1334 -0.0731 -0.1196 -0.1362 -0.4772 -0.9212 -0.2147 -0.3255 -0.0089 -1.0418 -1.2231 -0.7847 -0.1561
S-1428	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-1428	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-1428	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
D-1428	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
P-1428	-0.6749 -0.0595 -0.1069 -0.5716 -0.3166 -1.3266 -0.2228 -0.1818 -0.2030 -0.1471 -1.6887 -0.1374 -0.1477 -0.1691 -1.1178 -0.1015 -0.1323 -0.2030 -0.1334 -0.0731 -0.1196 -0.1362 -0.4772 -0.9212 -0.2147 -0.3255 -0.0089 -1.0418 -1.2231 -0.7847 -0.1561
S-900	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-900	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-900	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
D-900	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
P-900	-0.6749 -0.0595 -0.1069 -0.5716 -0.3166 -1.3266 -0.2228 -0.1818 -0.2030 -0.1471 -1.6887 -0.1374 -0.1477 -0.1691 -1.1178 -0.1015 -0.1323 -0.2030 -0.1334 -0.0731 -0.1196 -0.1362 -0.4772 -0.9212 -0.2147 -0.3255 -0.0089 -1.0418 -1.2231 -0.7847 -0.1561
S-1845	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-1845	Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <<unk>> www . emea . europa . eu/
H-1845	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
D-1845	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
P-1845	-0.6749 -0.0595 -0.1069 -0.5716 -0.3166 -1.3266 -0.2228 -0.1818 -0.2030 -0.1471 -1.6887 -0.1374 -0.1477 -0.1691 -1.1178 -0.1015 -0.1323 -0.2030 -0.1334 -0.0731 -0.1196 -0.1362 -0.4772 -0.9212 -0.2147 -0.3255 -0.0089 -1.0418 -1.2231 -0.7847 -0.1561
S-1536	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-1536	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-1536	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-1536	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-1536	-0.0704 -0.1010 -0.1228 -0.2116 -0.1193 -0.0599 -0.1454 -0.1346 -0.1921 -0.1038 -0.1073 -0.0451 -0.0803 -1.3875 -0.1751 -0.1296 -0.1730 -0.1506 -0.0798 -0.0602 -0.0395 -0.1093 -0.4373 -0.1307 -0.1043 -0.0961 -0.0926 -0.0718 -0.1258 -0.4869 -0.0670 -0.1122 -0.1450 -0.1763 -0.1591
S-1359	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-1359	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-1359	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-1359	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-1359	-0.0704 -0.1010 -0.1228 -0.2116 -0.1193 -0.0599 -0.1454 -0.1346 -0.1921 -0.1038 -0.1073 -0.0451 -0.0803 -1.3875 -0.1751 -0.1296 -0.1730 -0.1506 -0.0798 -0.0602 -0.0395 -0.1093 -0.4373 -0.1307 -0.1043 -0.0961 -0.0926 -0.0718 -0.1258 -0.4869 -0.0670 -0.1122 -0.1450 -0.1763 -0.1591
S-1183	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-1183	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-1183	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-1183	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-1183	-0.0704 -0.1010 -0.1228 -0.2116 -0.1193 -0.0599 -0.1454 -0.1346 -0.1921 -0.1038 -0.1073 -0.0451 -0.0803 -1.3875 -0.1751 -0.1296 -0.1730 -0.1506 -0.0798 -0.0602 -0.0395 -0.1093 -0.4373 -0.1307 -0.1043 -0.0961 -0.0926 -0.0718 -0.1258 -0.4869 -0.0670 -0.1122 -0.1450 -0.1763 -0.1591
S-1007	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-1007	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-1007	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-1007	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-1007	-0.0704 -0.1010 -0.1228 -0.2116 -0.1193 -0.0599 -0.1454 -0.1346 -0.1921 -0.1038 -0.1073 -0.0451 -0.0803 -1.3875 -0.1751 -0.1296 -0.1730 -0.1506 -0.0798 -0.0602 -0.0395 -0.1093 -0.4373 -0.1307 -0.1043 -0.0961 -0.0926 -0.0718 -0.1258 -0.4869 -0.0670 -0.1122 -0.1450 -0.1763 -0.1591
S-831	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-831	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-831	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-831	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-831	-0.0704 -0.1010 -0.1228 -0.2116 -0.1193 -0.0599 -0.1454 -0.1346 -0.1921 -0.1038 -0.1073 -0.0451 -0.0803 -1.3875 -0.1751 -0.1296 -0.1730 -0.1506 -0.0798 -0.0602 -0.0395 -0.1093 -0.4373 -0.1307 -0.1043 -0.0961 -0.0926 -0.0718 -0.1258 -0.4869 -0.0670 -0.1122 -0.1450 -0.1763 -0.1591
S-656	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-656	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-656	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-656	-0.17152822017669678	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-656	-0.0704 -0.1010 -0.1228 -0.2116 -0.1193 -0.0599 -0.1454 -0.1346 -0.1921 -0.1038 -0.1073 -0.0451 -0.0803 -1.3875 -0.1751 -0.1296 -0.1730 -0.1506 -0.0798 -0.0602 -0.0395 -0.1093 -0.4373 -0.1307 -0.1043 -0.0961 -0.0926 -0.0718 -0.1258 -0.4869 -0.0670 -0.1122 -0.1450 -0.1763 -0.1591
S-1605	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-1605	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-1605	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
D-1605	-0.42334574460983276	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http/ www.emea / .
P-1605	-0.6749 -0.0595 -0.1069 -0.5716 -0.3166 -1.3266 -0.2228 -0.1818 -0.2030 -0.1471 -1.6887 -0.1374 -0.1477 -0.1691 -1.1178 -0.1015 -0.1323 -0.2030 -0.1334 -0.0731 -0.1196 -0.1362 -0.4772 -0.9212 -0.2147 -0.3255 -0.0089 -1.0418 -1.2231 -0.7847 -0.1561
S-333	Daher müssen die Patienten nach der Einnahme von Alendronat mindestens 30 Minuten warten , bevor sie andere Arzneimittel einnehmen ( siehe Abschnitte 4.2 und 5.2 ) .
T-333	Therefore , patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product ( see sections 4.2 and 5.2 ) .
H-333	-0.27166062593460083	Patients should therefore wait at least 30 minutes after taking alendronate before taking other medicines ( see sections 4.2 and 5.2 ) .
D-333	-0.27166062593460083	Patients should therefore wait at least 30 minutes after taking alendronate before taking other medicines ( see sections 4.2 and 5.2 ) .
P-333	-1.1510 -0.1074 -1.4048 -0.3192 -0.3378 -0.2412 -0.1136 -0.1450 -0.1607 -0.2232 -0.2828 -0.1160 -0.1245 -0.1380 -0.1687 -0.2284 -0.1380 -0.5541 -0.1113 -0.9112 -0.1699 -0.1257 -0.0545 -0.1254 -0.1363 -0.1443 -0.0908 -0.1352 -0.1393 -0.1692 -0.1537
S-1013	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-1013	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 27 spontaneously or as a result of accidental or surgical trauma .
H-1013	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
D-1013	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
P-1013	-0.2982 -1.4370 -0.1797 -0.5895 -0.3765 -0.0939 -0.2994 -0.1612 -0.0251 -0.1454 -0.1489 -1.1305 -0.1322 -0.1434 -0.1153 -0.2341 -0.3713 -0.1829 -0.0418 -0.1461 -0.2422 -0.3184 -0.1581 -0.2281 -0.1236 -1.0160 -0.0544 -0.1690 -1.2072 -0.0922 -0.1301 -0.0519 -0.1720 -0.1535
S-359	Selten : vorübergehende Symptome einer Akute-Phase-Reaktion ( Myalgie , Unwohlsein und selten Fieber ) , üblicherweise bei Therapiebeginn .
T-359	( see section 4.4 ) Rare : transient symptoms as in an acute-phase response ( myalgia , malaise and rarely , fever ) , typically in association with initiation of treatment .
H-359	-0.3666187524795532	Rare : transient symptoms of acute phase reaction ( myalgia , discomfort and rare fever ) , usually at the onset of therapy .
D-359	-0.3666187524795532	Rare : transient symptoms of acute phase reaction ( myalgia , discomfort and rare fever ) , usually at the onset of therapy .
P-359	-0.6404 -0.1264 -0.1400 -0.0895 -0.0711 -0.7708 -0.2968 -0.1376 -0.4055 -0.0637 -0.4049 -0.0920 -0.1423 -0.2358 -0.1116 -0.0548 -0.1403 -0.8873 -0.1220 -0.8164 -1.0205 -0.0751 -0.0666 -0.1305 -0.2929 -0.1616 -1.5722 -0.4402 -1.7998 -0.0513 -0.1317 -0.5229 -0.2974 -0.1530
S-527	Octocog alfa wird nicht aus menschlichem Plasma extrahiert , sondern nach einer Methode hergestellt , die als rekombinante DNA-Technologie bezeichnet wird :
T-527	Octocog alfa is not extracted from human plasma but produced by a method known as recombinant DNA technology : it is made by a cell that has received a gene ( DNA ) , which makes it able to produce human coagulation factor VIII .
H-527	-0.2449926733970642	Octocog alfa is not extracted from human plasma , but is produced using a method known as recombinant DNA technology :
D-527	-0.2449926733970642	Octocog alfa is not extracted from human plasma , but is produced using a method known as recombinant DNA technology :
P-527	-0.1147 -0.1107 -0.1298 -0.2558 -0.1249 -0.0624 -0.1923 -0.1686 -0.2108 -0.0837 -0.1633 -0.1848 -0.1238 -0.0612 -0.1219 -0.8582 -0.0967 -1.1140 -0.4591 -0.8768 -0.1294 -0.4602 -0.5047 -0.1412 -0.1349 -0.1215 -0.0730 -0.1336 -0.1160 -0.1072 -0.2428 -0.1618
S-1542	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-1542	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 57 spontaneously or as a result of accidental or surgical trauma .
H-1542	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
D-1542	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
P-1542	-0.2982 -1.4370 -0.1797 -0.5895 -0.3765 -0.0939 -0.2994 -0.1612 -0.0251 -0.1454 -0.1489 -1.1305 -0.1322 -0.1434 -0.1153 -0.2341 -0.3713 -0.1829 -0.0418 -0.1461 -0.2422 -0.3184 -0.1581 -0.2281 -0.1236 -1.0160 -0.0544 -0.1690 -1.2072 -0.0922 -0.1301 -0.0519 -0.1720 -0.1535
S-1365	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-1365	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 47 spontaneously or as a result of accidental or surgical trauma .
H-1365	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
D-1365	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
P-1365	-0.2982 -1.4370 -0.1797 -0.5895 -0.3765 -0.0939 -0.2994 -0.1612 -0.0251 -0.1454 -0.1489 -1.1305 -0.1322 -0.1434 -0.1153 -0.2341 -0.3713 -0.1829 -0.0418 -0.1461 -0.2422 -0.3184 -0.1581 -0.2281 -0.1236 -1.0160 -0.0544 -0.1690 -1.2072 -0.0922 -0.1301 -0.0519 -0.1720 -0.1535
S-1189	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-1189	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 37 spontaneously or as a result of accidental or surgical trauma .
H-1189	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
D-1189	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
P-1189	-0.2982 -1.4370 -0.1797 -0.5895 -0.3765 -0.0939 -0.2994 -0.1612 -0.0251 -0.1454 -0.1489 -1.1305 -0.1322 -0.1434 -0.1153 -0.2341 -0.3713 -0.1829 -0.0418 -0.1461 -0.2422 -0.3184 -0.1581 -0.2281 -0.1236 -1.0160 -0.0544 -0.1690 -1.2072 -0.0922 -0.1301 -0.0519 -0.1720 -0.1535
S-95	Folgende Hinweise sind genau zu befolgen , um das Risiko für ösophageale Reizungen und damit verbundene Nebenwirkungen zu verringern ( siehe Abschnitt 4.4 ) :
T-95	The following instructions should be followed exactly in order to minimize the risk of oesophageal irritation and related adverse reactions ( see section 4.4 ) :
H-95	-0.3093251585960388	The following advice should be followed closely to reduce the risk of oesophageal irritation and associated side effects ( see section 4.4 ) :
D-95	-0.3093251585960388	The following advice should be followed closely to reduce the risk of oesophageal irritation and associated side effects ( see section 4.4 ) :
P-95	-0.6863 -0.0604 -2.7769 -0.5255 -0.1620 -0.1454 -0.2487 -0.7238 -0.4569 -0.2147 -0.1317 -0.2210 -0.3027 -0.0384 -0.1479 -0.0544 -0.0570 -0.1298 -0.0686 -0.1229 -0.1431 -0.5903 -0.6992 -0.1212 -0.1825 -0.0961 -0.0858 -0.1133 -0.1363 -0.1360 -0.1617 -0.1579
S-837	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-837	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 17 spontaneously or as a result of accidental or surgical trauma .
H-837	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
D-837	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
P-837	-0.2982 -1.4370 -0.1797 -0.5895 -0.3765 -0.0939 -0.2994 -0.1612 -0.0251 -0.1454 -0.1489 -1.1305 -0.1322 -0.1434 -0.1153 -0.2341 -0.3713 -0.1829 -0.0418 -0.1461 -0.2422 -0.3184 -0.1581 -0.2281 -0.1236 -1.0160 -0.0544 -0.1690 -1.2072 -0.0922 -0.1301 -0.0519 -0.1720 -0.1535
S-282	Folgende Hinweise sind genau zu befolgen , um das Risiko für ösophageale Reizungen und damit verbundene Nebenwirkungen zu verringern ( siehe Abschnitt 4.4 ) :
T-282	The following instructions should be followed exactly in order to minimize the risk of oesophageal irritation and related adverse reactions ( see section 4.4 ) :
H-282	-0.3093251585960388	The following advice should be followed closely to reduce the risk of oesophageal irritation and associated side effects ( see section 4.4 ) :
D-282	-0.3093251585960388	The following advice should be followed closely to reduce the risk of oesophageal irritation and associated side effects ( see section 4.4 ) :
P-282	-0.6863 -0.0604 -2.7769 -0.5255 -0.1620 -0.1454 -0.2487 -0.7238 -0.4569 -0.2147 -0.1317 -0.2210 -0.3027 -0.0384 -0.1479 -0.0544 -0.0570 -0.1298 -0.0686 -0.1229 -0.1431 -0.5903 -0.6992 -0.1212 -0.1825 -0.0961 -0.0858 -0.1133 -0.1363 -0.1360 -0.1617 -0.1579
S-171	Selten : vorübergehende Symptome einer Akute-Phase-Reaktion ( Myalgie , Unwohlsein und selten Fieber ) , üblicherweise bei Therapiebeginn .
T-171	( see section 4.4 ) Rare : transient symptoms as in an acute-phase response ( myalgia , malaise and rarely , fever ) , typically in association with initiation of treatment .
H-171	-0.3666187524795532	Rare : transient symptoms of acute phase reaction ( myalgia , discomfort and rare fever ) , usually at the onset of therapy .
D-171	-0.3666187524795532	Rare : transient symptoms of acute phase reaction ( myalgia , discomfort and rare fever ) , usually at the onset of therapy .
P-171	-0.6404 -0.1264 -0.1400 -0.0895 -0.0711 -0.7708 -0.2968 -0.1376 -0.4055 -0.0637 -0.4049 -0.0920 -0.1423 -0.2358 -0.1116 -0.0548 -0.1403 -0.8873 -0.1220 -0.8164 -1.0205 -0.0751 -0.0666 -0.1305 -0.2929 -0.1616 -1.5722 -0.4402 -1.7998 -0.0513 -0.1317 -0.5229 -0.2974 -0.1530
S-1986	Das für den Metabolismus von Desloratadin verantwortliche Enzym wurde noch nicht identifiziert , so dass Wechselwirkungen mit anderen Arzneimitteln nicht ganz ausgeschlossen werden können .
T-1986	The enzyme responsible for the metabolism of desloratadine has not been identified yet , and therefore , some interactions with other medicinal products can not be fully excluded .
H-1986	-0.3622685372829437	The enzyme responsible for the metabolism of desloratadine has not yet been identified , so interaction with other medicines cannot be excluded .
D-1986	-0.3622685372829437	The enzyme responsible for the metabolism of desloratadine has not yet been identified , so interaction with other medicines cannot be excluded .
P-1986	-0.4388 -0.2384 -0.0594 -0.1108 -0.3372 -0.1219 -0.5063 -0.5716 -0.0505 -0.0286 -0.1263 -0.6005 -0.0540 -0.1082 -0.3160 -0.7953 -0.2043 -0.1660 -0.1828 -0.1398 -0.1800 -0.5873 -1.4755 -0.1778 -1.0306 -0.1657 -0.1480 -0.2430 -0.5912 -0.1504 -0.2820 -0.6667 -0.0891 -1.5788 -0.1568
S-1843	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
T-1843	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <<unk>> 44 1635 206345
H-1843	-0.11196263134479523	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
D-1843	-0.11196263134479523	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
P-1843	-0.1142 -0.0635 -0.1550 -0.1776 -0.1512 -0.0438 -0.0840 -0.1456 -0.0459 -0.0784 -0.0998 -0.1098 -0.0653 -0.1392 -0.0978 -0.0736 -0.1686 -0.0708 -0.1474 -0.0538 -0.1807 -0.1284 -0.1334 -0.1056 -0.1596 -0.1360 -0.1369 -0.0727 -0.1395 -0.0282 -0.0848 -0.0979 -0.0743 -0.1452 -0.1559 -0.1311 -0.1049 -0.1542
S-1820	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel . : <unk> 44 1635 206345
T-1820	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel . : <<unk>> 44 1635 206345
H-1820	-0.12118184566497803	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
D-1820	-0.12118184566497803	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
P-1820	-0.0697 -0.1301 -0.2118 -0.1520 -0.0407 -0.0845 -0.1498 -0.0445 -0.0713 -0.1005 -0.1045 -0.0651 -0.1391 -0.0929 -0.0726 -0.1649 -0.0674 -0.1266 -0.0495 -0.1814 -0.1151 -0.1347 -0.1125 -0.1552 -0.1371 -0.1651 -0.0389 -0.5397 -0.0232 -0.0799 -0.0953 -0.0725 -0.1463 -0.1569 -0.1309 -0.1042 -0.1572
S-1962	Sympathomimetische Amine können eine Stimulation des Zentralnervensystems mit Krampfanfällen oder einen Herz-Kreislauf-Kollaps mit Hypotonie verursachen .
T-1962	Central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension may be produced by sympathomimetic amines .
H-1962	-0.24655289947986603	Sympathomimetic amines may cause central nervous system stimulation with seizure or cardiovascular collapse with hypotension .
D-1962	-0.24655289947986603	Sympathomimetic amines may cause central nervous system stimulation with seizure or cardiovascular collapse with hypotension .
P-1962	-0.2284 -0.0865 -0.0909 -0.1007 -1.1570 -0.2779 -0.9421 -0.5435 -0.9284 -0.0382 -0.1022 -0.2919 -0.1451 -0.2431 -0.1444 -0.1990 -0.0788 -0.2841 -0.1008 -0.1387 -0.0879 -0.0543 -0.3027 -0.1873 -0.1293 -0.0441 -0.0726 -0.0788 -0.1598 -0.1580
S-34	Im Vergleich dazu war dies bei 22 % ( 60 von 268 ) der Patienten unter Allopurinol und bei keinem der 134 Patienten unter Placebo der Fall .
T-34	This was compared with 22 % of the patients taking allopurinol ( 60 out of 268 ) and none of the 134 patients taking placebo .
H-34	-0.31217584013938904	This compared to 22 % ( 60 out of 268 ) of those receiving allopurinol and none of the 134 receiving placebo .
D-34	-0.31217584013938904	This compared to 22 % ( 60 out of 268 ) of those receiving allopurinol and none of the 134 receiving placebo .
P-34	-0.4519 -1.4713 -1.0418 -0.1194 -0.1148 -0.1478 -0.0837 -1.1835 -0.1250 -0.0670 -0.1094 -0.1373 -0.1536 -1.1454 -0.1552 -0.1096 -0.1350 -0.1572 -0.1020 -0.4122 -0.2295 -0.1369 -1.0689 -0.1225 -0.1507 -0.1026 -0.0434 -0.1244 -0.1342 -0.1356 -0.1651 -0.1529
S-145	Daher müssen die Patienten nach der Einnahme von Alendronat mindestens 30 Minuten warten , bevor sie andere Arzneimittel einnehmen ( siehe Abschnitte 4.2 und 5.2 ) .
T-145	Therefore , patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product ( see sections 4.2 and 5.2 ) .
H-145	-0.27166062593460083	Patients should therefore wait at least 30 minutes after taking alendronate before taking other medicines ( see sections 4.2 and 5.2 ) .
D-145	-0.27166062593460083	Patients should therefore wait at least 30 minutes after taking alendronate before taking other medicines ( see sections 4.2 and 5.2 ) .
P-145	-1.1510 -0.1074 -1.4048 -0.3192 -0.3378 -0.2412 -0.1136 -0.1450 -0.1607 -0.2232 -0.2828 -0.1160 -0.1245 -0.1380 -0.1687 -0.2284 -0.1380 -0.5541 -0.1113 -0.9112 -0.1699 -0.1257 -0.0545 -0.1254 -0.1363 -0.1443 -0.0908 -0.1352 -0.1393 -0.1692 -0.1537
S-345	In Tierstudien wurde unter hohen Vitamin-D-Dosen Hypercalcämie und Reproduktionstoxizität ( siehe Abschnitt 5.3 ) nachgewiesen .
T-345	Studies in animals have shown hypercalcaemia and reproductive toxicity with high doses of vitamin D ( see section 5.3 ) .
H-345	-0.30625611543655396	Animal studies at high doses of vitamin D have shown hypercalcaemia and reproductive toxicity ( see section 5.3 ) .
D-345	-0.30625611543655396	Animal studies at high doses of vitamin D have shown hypercalcaemia and reproductive toxicity ( see section 5.3 ) .
P-345	-1.3875 -0.0702 -0.1240 -1.8103 -0.7869 -0.5121 -0.0932 -0.7100 -0.2839 -0.2837 -0.2453 -0.3835 -0.6111 -0.0845 -0.0749 -0.0141 -0.0189 -0.1252 -0.1311 -0.1801 -0.4907 -0.1326 -0.0961 -0.1452 -0.1333 -0.0937 -0.1069 -0.0926 -0.1269 -0.1328 -0.1660 -0.1530
S-1792	Informieren Sie Ihren Arzt , wenn eine der aufgeführten Nebenwirkungen Sie erheblich beeinträchtigt oder wenn Sie Nebenwirkungen bemerken , die nicht in dieser Packungsbeilage aufgeführt sind .
T-1792	If any of these side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor .
H-1792	-0.38926440477371216	Tell your doctor if any of the listed side effects significantly affect you or if you notice any side effects not listed in this Package Leaflet .
D-1792	-0.38926440477371216	Tell your doctor if any of the listed side effects significantly affect you or if you notice any side effects not listed in this Package Leaflet .
P-1792	-0.6485 -0.0617 -0.1302 -0.1202 -0.0918 -0.1685 -0.1179 -0.2763 -0.3019 -0.9931 -0.1605 -2.2954 -0.8120 -0.1257 -0.6821 -0.1875 -0.0952 -0.5595 -1.2385 -1.1498 -0.1179 -0.3372 -0.2584 -0.1568 -0.1639 -0.3382 -0.1125 -0.2689 -0.0111 -0.0907 -0.2194 -0.1652
S-662	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-662	2 paediatric patients ( age 0 16 years ) and adult patients ( age over 16 years )
H-662	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
D-662	-0.30497637391090393	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgical trauma .
P-662	-0.2982 -1.4370 -0.1797 -0.5895 -0.3765 -0.0939 -0.2994 -0.1612 -0.0251 -0.1454 -0.1489 -1.1305 -0.1322 -0.1434 -0.1153 -0.2341 -0.3713 -0.1829 -0.0418 -0.1461 -0.2422 -0.3184 -0.1581 -0.2281 -0.1236 -1.0160 -0.0544 -0.1690 -1.2072 -0.0922 -0.1301 -0.0519 -0.1720 -0.1535
S-207	Hinsichtlich der Mittelwerte von Serum-Calcium , Phosphat oder Calcium im 24-Stunden-Harn gab es keine Unterschiede zwischen den Behandlungsgruppen .
T-207	There were no differences in mean serum calcium , phosphate , or 24-hour urine calcium between treatment groups .
H-207	-0.45402029156684875	There were no differences between the treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24-hour urine .
D-207	-0.45402029156684875	There were no differences between the treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24-hour urine .
P-207	-1.5983 -0.3304 -0.0546 -0.1137 -0.3003 -1.0178 -0.2517 -1.2090 -1.8461 -0.7246 -0.1297 -1.0176 -0.8197 -1.4031 -0.2850 -0.2052 -0.1095 -0.2827 -0.1093 -0.1146 -0.1347 -0.1405 -0.0263 -0.0823 -0.5618 -0.1123 -0.1121 -0.1132 -0.2064 -1.6391 -0.3778 -0.3152 -0.1377 -0.1143 -0.1958 -0.1524
S-395	Hinsichtlich der Mittelwerte von Serum-Calcium , Phosphat oder Calcium im 24-Stunden-Harn gab es keine Unterschiede zwischen den Behandlungsgruppen .
T-395	There were no differences in mean serum calcium , phosphate , or 24-hour urine calcium between treatment groups .
H-395	-0.45402029156684875	There were no differences between the treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24-hour urine .
D-395	-0.45402029156684875	There were no differences between the treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24-hour urine .
P-395	-1.5983 -0.3304 -0.0546 -0.1137 -0.3003 -1.0178 -0.2517 -1.2090 -1.8461 -0.7246 -0.1297 -1.0176 -0.8197 -1.4031 -0.2850 -0.2052 -0.1095 -0.2827 -0.1093 -0.1146 -0.1347 -0.1405 -0.0263 -0.0823 -0.5618 -0.1123 -0.1121 -0.1132 -0.2064 -1.6391 -0.3778 -0.3152 -0.1377 -0.1143 -0.1958 -0.1524
S-402	Hinsichtlich der Mittelwerte von Serum-Calcium , Phosphat oder Calcium im 24-Stunden- Harn gab es keine Unterschiede zwischen den Behandlungsgruppen .
T-402	There were no differences in mean serum calcium , phosphate , or 24-hour urine calcium between treatment groups .
H-402	-0.44506627321243286	There were no differences between the treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24-hour urine .
D-402	-0.44506627321243286	There were no differences between the treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24-hour urine .
P-402	-1.7069 -0.3290 -0.0545 -0.1114 -0.3012 -1.0043 -0.2505 -1.1722 -1.8203 -0.7340 -0.1300 -1.0305 -0.7847 -1.2679 -0.2906 -0.1796 -0.1095 -0.2724 -0.1113 -0.1121 -0.1347 -0.1396 -0.0258 -0.0827 -0.5244 -0.1144 -0.1116 -0.1121 -0.2063 -1.6157 -0.2505 -0.3121 -0.1515 -0.1153 -0.2002 -0.1527
S-129	Sie sollen keine zwei Tabletten am selben Tag einnehmen , sondern die Einnahme von einer Tablette pro Woche wie ursprünglich geplant am dafür vorgesehenen Wochentag weiterführen .
T-129	They should not take two tablets on the same day but should return to taking one tablet once a week , as originally scheduled on their chosen day .
H-129	-0.43759819865226746	Do not take two tablets on the same day , but continue taking one tablet per week as originally planned on the designated day of the week .
D-129	-0.43759819865226746	Do not take two tablets on the same day , but continue taking one tablet per week as originally planned on the designated day of the week .
P-129	-1.4198 -0.1276 -0.0225 -0.2637 -0.2174 -0.1306 -0.2762 -0.1513 -0.3619 -0.1175 -1.4640 -0.2621 -0.4768 -1.2881 -0.1601 -0.6012 -0.1173 -0.2911 -0.1164 -1.0748 -0.5717 -0.4542 -0.1723 -0.4142 -1.5602 -0.1109 -0.8844 -0.2242 -0.1642 -0.1878 -0.1626 -0.1562
S-157	In Tierstudien wurde unter hohen Vitamin-D-Dosen Hypercalcämie und Reproduktionstoxizität ( siehe Abschnitt 5.3 ) nachgewiesen .
T-157	Studies in animals have shown hypercalcaemia and reproductive toxicity with high doses of vitamin D ( see section 5.3 ) .
H-157	-0.30625611543655396	Animal studies at high doses of vitamin D have shown hypercalcaemia and reproductive toxicity ( see section 5.3 ) .
D-157	-0.30625611543655396	Animal studies at high doses of vitamin D have shown hypercalcaemia and reproductive toxicity ( see section 5.3 ) .
P-157	-1.3875 -0.0702 -0.1240 -1.8103 -0.7869 -0.5121 -0.0932 -0.7100 -0.2839 -0.2837 -0.2453 -0.3835 -0.6111 -0.0845 -0.0749 -0.0141 -0.0189 -0.1252 -0.1311 -0.1801 -0.4907 -0.1326 -0.0961 -0.1452 -0.1333 -0.0937 -0.1069 -0.0926 -0.1269 -0.1328 -0.1660 -0.1530
S-317	Sie sollen keine zwei Tabletten am selben Tag einnehmen , sondern die Einnahme von einer Tablette pro Woche wie ursprünglich geplant am dafür vorgesehenen Wochentag weiterführen .
T-317	They should not take two tablets on the same day but should return to taking one tablet once a week , as originally scheduled on their chosen day .
H-317	-0.43759819865226746	Do not take two tablets on the same day , but continue taking one tablet per week as originally planned on the designated day of the week .
D-317	-0.43759819865226746	Do not take two tablets on the same day , but continue taking one tablet per week as originally planned on the designated day of the week .
P-317	-1.4198 -0.1276 -0.0225 -0.2637 -0.2174 -0.1306 -0.2762 -0.1513 -0.3619 -0.1175 -1.4640 -0.2621 -0.4768 -1.2881 -0.1601 -0.6012 -0.1173 -0.2911 -0.1164 -1.0748 -0.5717 -0.4542 -0.1723 -0.4142 -1.5602 -0.1109 -0.8844 -0.2242 -0.1642 -0.1878 -0.1626 -0.1562
S-1481	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-1481	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-1481	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
D-1481	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
P-1481	-0.8049 -0.5226 -0.1243 -1.8531 -0.1800 -0.0918 -0.1555 -0.8852 -0.1959 -0.1712 -0.0763 -0.1736 -0.1033 -0.0848 -0.0425 -0.1703 -0.1328 -0.1740 -0.1326 -0.5080 -0.0652 -0.1602 -0.1779 -0.2352 -0.1869 -0.1178 -0.8574 -0.1420 -0.1540 -0.0749 -0.0582 -0.0456 -0.5514 -0.1736
S-174	Osteonekrose des Kiefers steht üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) .
T-174	Osteonecrosis of the jaw is generally associated with tooth extraction and / or local infection ( including osteomyelitis ) .
H-174	-0.1742713451385498	jaw osteonecrosis is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
D-174	-0.1742713451385498	jaw osteonecrosis is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
P-174	-0.5063 -0.2527 -0.1530 -0.0704 -0.1255 -0.0737 -0.0546 -0.0827 -0.1571 -0.6886 -0.1706 -0.1643 -0.0969 -0.0351 -0.1608 -0.1647 -0.1257 -0.0798 -0.2259 -0.8260 -0.0645 -0.1729 -0.0614 -0.1219 -0.0914 -0.0988 -0.1724 -0.0608 -0.0651 -0.1301 -0.1702 -0.1529
S-777	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-777	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-777	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
D-777	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
P-777	-0.8049 -0.5226 -0.1243 -1.8531 -0.1800 -0.0918 -0.1555 -0.8852 -0.1959 -0.1712 -0.0763 -0.1736 -0.1033 -0.0848 -0.0425 -0.1703 -0.1328 -0.1740 -0.1326 -0.5080 -0.0652 -0.1602 -0.1779 -0.2352 -0.1869 -0.1178 -0.8574 -0.1420 -0.1540 -0.0749 -0.0582 -0.0456 -0.5514 -0.1736
S-362	Osteonekrose des Kiefers steht üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) .
T-362	Osteonecrosis of the jaw is generally associated with tooth extraction and / or local infection ( including osteomyelitis ) .
H-362	-0.1742713451385498	jaw osteonecrosis is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
D-362	-0.1742713451385498	jaw osteonecrosis is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
P-362	-0.5063 -0.2527 -0.1530 -0.0704 -0.1255 -0.0737 -0.0546 -0.0827 -0.1571 -0.6886 -0.1706 -0.1643 -0.0969 -0.0351 -0.1608 -0.1647 -0.1257 -0.0798 -0.2259 -0.8260 -0.0645 -0.1729 -0.0614 -0.1219 -0.0914 -0.0988 -0.1724 -0.0608 -0.0651 -0.1301 -0.1702 -0.1529
S-603	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-603	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-603	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
D-603	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
P-603	-0.8049 -0.5226 -0.1243 -1.8531 -0.1800 -0.0918 -0.1555 -0.8852 -0.1959 -0.1712 -0.0763 -0.1736 -0.1033 -0.0848 -0.0425 -0.1703 -0.1328 -0.1740 -0.1326 -0.5080 -0.0652 -0.1602 -0.1779 -0.2352 -0.1869 -0.1178 -0.8574 -0.1420 -0.1540 -0.0749 -0.0582 -0.0456 -0.5514 -0.1736
S-39	Adenuric darf nicht bei Patienten angewendet werden , die möglicherweise überempfindlich ( allergisch ) gegen Feboxustat oder einen der sonstigen Bestandteile sind .
T-39	Adenuric should not be used in people who may be hypersensitive ( allergic ) to feboxustat or any of the other ingredients .
H-39	-0.2223074734210968	Adenuric should not be used in patients who may be hypersensitive ( allergic ) to feboxustat or any of the ingredients .
D-39	-0.2223074734210968	Adenuric should not be used in patients who may be hypersensitive ( allergic ) to feboxustat or any of the ingredients .
P-39	-0.1461 -0.1463 -0.0864 -0.1389 -0.4932 -0.1413 -0.1392 -0.2388 -0.1456 -0.2528 -0.1885 -0.2651 -0.1925 -0.0651 -0.1547 -0.2595 -0.1649 -0.0332 -0.2440 -0.1307 -1.0808 -0.2976 -0.1337 -0.1262 -0.1558 -0.1284 -0.1515 -0.4174 -0.1320 -0.5009 -0.1417 -0.2812 -0.1620
S-953	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-953	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-953	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
D-953	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
P-953	-0.8049 -0.5226 -0.1243 -1.8531 -0.1800 -0.0918 -0.1555 -0.8852 -0.1959 -0.1712 -0.0763 -0.1736 -0.1033 -0.0848 -0.0425 -0.1703 -0.1328 -0.1740 -0.1326 -0.5080 -0.0652 -0.1602 -0.1779 -0.2352 -0.1869 -0.1178 -0.8574 -0.1420 -0.1540 -0.0749 -0.0582 -0.0456 -0.5514 -0.1736
S-1129	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-1129	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-1129	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
D-1129	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
P-1129	-0.8049 -0.5226 -0.1243 -1.8531 -0.1800 -0.0918 -0.1555 -0.8852 -0.1959 -0.1712 -0.0763 -0.1736 -0.1033 -0.0848 -0.0425 -0.1703 -0.1328 -0.1740 -0.1326 -0.5080 -0.0652 -0.1602 -0.1779 -0.2352 -0.1869 -0.1178 -0.8574 -0.1420 -0.1540 -0.0749 -0.0582 -0.0456 -0.5514 -0.1736
S-1305	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-1305	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-1305	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
D-1305	-0.2818455398082733	The formation of factor VIII neutralizing antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A
P-1305	-0.8049 -0.5226 -0.1243 -1.8531 -0.1800 -0.0918 -0.1555 -0.8852 -0.1959 -0.1712 -0.0763 -0.1736 -0.1033 -0.0848 -0.0425 -0.1703 -0.1328 -0.1740 -0.1326 -0.5080 -0.0652 -0.1602 -0.1779 -0.2352 -0.1869 -0.1178 -0.8574 -0.1420 -0.1540 -0.0749 -0.0582 -0.0456 -0.5514 -0.1736
S-993	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-993	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-993	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
D-993	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
P-993	-0.2346 -0.0978 -0.0863 -0.0712 -0.2714 -0.1915 -0.5264 -0.0929 -0.1220 -0.2074 -0.2200 -0.2339 -0.8022 -0.1305 -0.1629 -0.1240 -0.0996 -0.1379 -0.1325 -0.5043 -0.1622 -0.0982 -0.0950 -1.3866 -0.2151 -0.6915 -1.3863 -0.1654 -0.0795 -0.1616 -0.7547 -0.1931 -0.1706 -0.0912 -0.4370
S-643	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-643	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-643	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
D-643	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
P-643	-0.2346 -0.0978 -0.0863 -0.0712 -0.2714 -0.1915 -0.5264 -0.0929 -0.1220 -0.2074 -0.2200 -0.2339 -0.8022 -0.1305 -0.1629 -0.1240 -0.0996 -0.1379 -0.1325 -0.5043 -0.1622 -0.0982 -0.0950 -1.3866 -0.2151 -0.6915 -1.3863 -0.1654 -0.0795 -0.1616 -0.7547 -0.1931 -0.1706 -0.0912 -0.4370
S-1169	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-1169	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-1169	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
D-1169	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
P-1169	-0.2346 -0.0978 -0.0863 -0.0712 -0.2714 -0.1915 -0.5264 -0.0929 -0.1220 -0.2074 -0.2200 -0.2339 -0.8022 -0.1305 -0.1629 -0.1240 -0.0996 -0.1379 -0.1325 -0.5043 -0.1622 -0.0982 -0.0950 -1.3866 -0.2151 -0.6915 -1.3863 -0.1654 -0.0795 -0.1616 -0.7547 -0.1931 -0.1706 -0.0912 -0.4370
S-817	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-817	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-817	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
D-817	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
P-817	-0.2346 -0.0978 -0.0863 -0.0712 -0.2714 -0.1915 -0.5264 -0.0929 -0.1220 -0.2074 -0.2200 -0.2339 -0.8022 -0.1305 -0.1629 -0.1240 -0.0996 -0.1379 -0.1325 -0.5043 -0.1622 -0.0982 -0.0950 -1.3866 -0.2151 -0.6915 -1.3863 -0.1654 -0.0795 -0.1616 -0.7547 -0.1931 -0.1706 -0.0912 -0.4370
S-405	Die Anstiege über die Ausgangswerte der BMD an der Lendenwirbelsäule betrugen nach einem Jahr im Mittel 5,1 % ( 95 % CI :
T-405	The mean increases from baseline in lumbar spine BMD at one year were 5.1 % ( 95 % CI :
H-405	-0.4927252531051636	Elevations above baseline lumbar BMD were 5.1 % ( 95 % CI :
D-405	-0.4927252531051636	Elevations above baseline lumbar BMD were 5.1 % ( 95 % CI :
P-405	-4.4383 -0.1525 -0.2817 -0.9581 -0.0501 -0.0211 -0.7732 -0.0716 -0.0323 -0.9451 -0.1509 -0.2708 -0.5979 -0.1388 -0.1277 -0.9995 -0.1014 -0.1048 -0.1049 -0.1533 -0.2017 -0.1641
S-1753	Wichtige Informationen über bestimmte sonstige Bestandteile von ADVATE Dieses Arzneimittel enthält 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1753	Important information about some of the ingredients of ADVATE This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1753	-0.20086973905563354	Important information about certain other ingredients of ADVATE This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
D-1753	-0.20086973905563354	Important information about certain other ingredients of ADVATE This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
P-1753	-0.1745 -0.1062 -0.1131 -0.0649 -0.6604 -0.4520 -1.4641 -0.0630 -0.1578 -0.0795 -0.1495 -0.1008 -0.0867 -0.1174 -0.0446 -0.0576 -0.1797 -0.0736 -0.0901 -0.1707 -0.1147 -0.2281 -0.0926 -0.8624 -0.0684 -0.1423 -0.1640 -0.0570 -0.1572 -0.0671 -0.0223 -0.0509 -0.2395 -0.1569
S-5	Adenuric wird zur Behandlung der chronischen ( langfristigen ) Hyperurikämie ( hohe Harnsäure- bzw. Uratspiegel im Blut ) angewendet .
T-5	Adenuric is used to treat chronic ( long-term ) hyperuricaemia ( high levels of uric acid or urate in the blood ) .
H-5	-0.2731061577796936	Adenuric is used to treat chronic ( long @-@ term ) hyperuricaemia ( high levels of uric acid and urate in the blood ) .
D-5	-0.2731061577796936	Adenuric is used to treat chronic ( long @-@ term ) hyperuricaemia ( high levels of uric acid and urate in the blood ) .
P-5	-0.0901 -0.1534 -0.0898 -0.1408 -0.1867 -0.0986 -0.2992 -0.1384 -0.0753 -0.1722 -1.0928 -1.1032 -0.2546 -0.1292 -0.1138 -0.0555 -0.4944 -0.0190 -0.1307 -0.1530 -0.7942 -0.4460 -0.1589 -0.0598 -0.0865 -0.3549 -0.5423 -0.3578 -0.7370 -0.2828 -0.1756 -0.0772 -0.1626 -0.1743 -0.1581
S-1734	ADVATE wird bei Patienten mit Hämophilie A eingesetzt zur Vorbeugung oder Behandlung von Sponatanblutungen oder Blutungen nach chirurgischen Eingriffen .
T-1734	ADVATE is used in patients with haemophilia A for prevention or treatment of spontaneous or surgery-related bleeding .
H-1734	-0.34892427921295166	ADVATE is used in patients with haemophilia A to prevent or treat spontaneous haemorrhage or bleeding following surgery .
D-1734	-0.34892427921295166	ADVATE is used in patients with haemophilia A to prevent or treat spontaneous haemorrhage or bleeding following surgery .
P-1734	-0.4160 -0.1567 -0.0930 -0.0992 -0.2094 -0.2293 -0.2740 -1.0099 -0.1374 -0.1986 -0.0544 -0.0615 -0.0564 -0.1368 -0.1969 -0.2025 -0.2233 -0.0945 -0.5949 -0.4830 -0.1047 -2.2762 -0.3939 -0.0461 -0.4514 -0.2772 -1.0077 -0.1575 -1.0718 -0.1236 -0.1679 -0.1600
S-136	4 Aufgrund der Stimulation der Knochenmineralisation durch Alendronat können Abnahmen des Serum-Calciums und -Phosphats auftreten .
T-136	Due to the positive effects of alendronate in increasing bone mineral , decreases in serum calcium and phosphate may occur .
H-136	-0.3377286493778229	Due to bone mineralization stimulation by alendronate , decreases in serum calcium and phosphate may occur .
D-136	-0.3377286493778229	Due to bone mineralization stimulation by alendronate , decreases in serum calcium and phosphate may occur .
P-136	-2.3791 -0.0866 -0.1269 -1.5064 -0.2258 -0.1389 -1.0649 -0.0899 -0.3333 -0.5968 -0.1113 -0.1032 -0.1491 -0.0888 -0.2314 -0.7008 -0.2928 -0.2057 -0.1675 -0.1032 -0.1588 -0.1172 -0.1071 -0.1401 -0.1792 -0.0790 -0.0925 -0.4778 -0.1027 -0.1584 -0.1544
S-1372	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1372	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-1372	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
D-1372	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
P-1372	-0.1170 -0.0900 -0.1521 -0.1466 -0.2213 -0.1150 -0.0416 -0.1262 -1.0359 -0.0961 -0.1240 -0.1426 -0.2510 -0.2422 -0.0868 -0.3337 -0.1212 -0.0877 -0.1223 -0.1456 -0.3344 -0.1241 -0.1262 -0.0568 -0.1480 -0.3226 -0.1058 -0.0571 -0.1310 -0.0971 -0.6687 -0.0775 -0.1287 -1.5833 -0.2263
S-1345	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-1345	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-1345	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
D-1345	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
P-1345	-0.2346 -0.0978 -0.0863 -0.0712 -0.2714 -0.1915 -0.5264 -0.0929 -0.1220 -0.2074 -0.2200 -0.2339 -0.8022 -0.1305 -0.1629 -0.1240 -0.0996 -0.1379 -0.1325 -0.5043 -0.1622 -0.0982 -0.0950 -1.3866 -0.2151 -0.6915 -1.3863 -0.1654 -0.0795 -0.1616 -0.7547 -0.1931 -0.1706 -0.0912 -0.4370
S-1774	Wenn Sie eine größere Menge von ADVATE angewendet haben , als Sie sollten Wenden Sie ADVATE immer genauso an , wie es Ihnen Ihr Arzt empfohlen hat .
T-1774	If you use more ADVATE than you should Always take ADVATE exactly as your doctor has told you .
H-1774	-0.4280163645744324	If you have used a greater amount of ADVATE than you should , use ADVATE exactly as your doctor has recommended .
D-1774	-0.4280163645744324	If you have used a greater amount of ADVATE than you should , use ADVATE exactly as your doctor has recommended .
P-1774	-0.4465 -0.1169 -0.2879 -1.3128 -0.9567 -1.0373 -0.5515 -0.2597 -0.0891 -0.1492 -0.1064 -0.0926 -0.1128 -0.2308 -0.0582 -0.3435 -1.8482 -0.0961 -0.1517 -0.1018 -0.1019 -0.3029 -0.1689 -0.2263 -0.0803 -1.2204 -1.5497 -0.1929 -0.2194
S-94	Andere Getränke ( einschließlich Mineralwasser ) , Nahrungsmittel und manche Arzneimittel können möglicherweise die Resorption von Alendronat beeinträchtigen ( siehe Abschnitt 4.5 ) .
T-94	Other beverages ( including mineral water ) , food and some medicinal products are likely to reduce the absorption of alendronate ( see section 4.5 ) .
H-94	-0.3241148591041565	Other beverages ( including mineral water ) , foods and some medicines may affect the absorption of alendronate ( see section 4.5 ) .
D-94	-0.3241148591041565	Other beverages ( including mineral water ) , foods and some medicines may affect the absorption of alendronate ( see section 4.5 ) .
P-94	-0.6413 -0.5322 -0.0585 -0.1171 -0.3561 -0.0566 -0.6701 -0.0803 -0.5888 -0.1409 -0.1470 -1.3192 -0.4348 -0.3000 -0.1853 -0.8580 -0.3219 -2.1007 -0.3244 -0.0901 -0.0586 -0.1274 -0.1417 -0.1067 -0.1322 -0.0730 -0.1447 -0.1080 -0.0770 -0.1177 -0.1464 -0.1357 -0.1726 -0.1548
S-668	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-668	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-668	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
D-668	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
P-668	-0.1170 -0.0900 -0.1521 -0.1466 -0.2213 -0.1150 -0.0416 -0.1262 -1.0359 -0.0961 -0.1240 -0.1426 -0.2510 -0.2422 -0.0868 -0.3337 -0.1212 -0.0877 -0.1223 -0.1456 -0.3344 -0.1241 -0.1262 -0.0568 -0.1480 -0.3226 -0.1058 -0.0571 -0.1310 -0.0971 -0.6687 -0.0775 -0.1287 -1.5833 -0.2263
S-844	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-844	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-844	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
D-844	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
P-844	-0.1170 -0.0900 -0.1521 -0.1466 -0.2213 -0.1150 -0.0416 -0.1262 -1.0359 -0.0961 -0.1240 -0.1426 -0.2510 -0.2422 -0.0868 -0.3337 -0.1212 -0.0877 -0.1223 -0.1456 -0.3344 -0.1241 -0.1262 -0.0568 -0.1480 -0.3226 -0.1058 -0.0571 -0.1310 -0.0971 -0.6687 -0.0775 -0.1287 -1.5833 -0.2263
S-528	Es wird von einer Zelle produziert , in die ein Gen ( DNA ) eingebracht wurde , das sie zur Bildung des menschlichen Gerinnungsfaktors VIII befähigt .
T-528	Es wird von einer Zelle produziert , in die ein Gen ( DNA ) eingebracht wurde , das sie zur Bildung des menschlichen Gerinnungsfaktors VIII befähigt . Advate is similar to another medicine approved in the European Union ( EU ) called Recombinate , but it is prepared differently so that there are no human- or animal-derived proteins in the medicine .
H-528	-0.28342190384864807	It is produced by a cell into which a gene ( DNA ) has been introduced that enables it to form the human clotting factor VIII .
D-528	-0.28342190384864807	It is produced by a cell into which a gene ( DNA ) has been introduced that enables it to form the human clotting factor VIII .
P-528	-0.4103 -0.1836 -0.0601 -0.2091 -0.1586 -0.0649 -0.5630 -0.2079 -0.1728 -0.1673 -0.1860 -0.0799 -0.1266 -0.4186 -0.1015 -1.2606 -0.8776 -0.2033 -0.1054 -0.2893 -0.1408 -0.8568 -0.8137 -0.1149 -0.5288 -0.0287 -0.0982 -0.0688 -0.1642 -0.0793 -0.1691 -0.1598
S-1549	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1549	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-1549	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
D-1549	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
P-1549	-0.1170 -0.0900 -0.1521 -0.1466 -0.2213 -0.1150 -0.0416 -0.1262 -1.0359 -0.0961 -0.1240 -0.1426 -0.2510 -0.2422 -0.0868 -0.3337 -0.1212 -0.0877 -0.1223 -0.1456 -0.3344 -0.1241 -0.1262 -0.0568 -0.1480 -0.3226 -0.1058 -0.0571 -0.1310 -0.0971 -0.6687 -0.0775 -0.1287 -1.5833 -0.2263
S-1196	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1196	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-1196	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
D-1196	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
P-1196	-0.1170 -0.0900 -0.1521 -0.1466 -0.2213 -0.1150 -0.0416 -0.1262 -1.0359 -0.0961 -0.1240 -0.1426 -0.2510 -0.2422 -0.0868 -0.3337 -0.1212 -0.0877 -0.1223 -0.1456 -0.3344 -0.1241 -0.1262 -0.0568 -0.1480 -0.3226 -0.1058 -0.0571 -0.1310 -0.0971 -0.6687 -0.0775 -0.1287 -1.5833 -0.2263
S-281	Andere Getränke ( einschließlich Mineralwasser ) , Nahrungsmittel und manche Arzneimittel können möglicherweise die Resorption von Alendronat beeinträchtigen ( siehe Abschnitt 4.5 ) .
T-281	Other beverages ( including mineral water ) , food and some medicinal products are likely to reduce the absorption of alendronate ( see section 4.5 ) .
H-281	-0.3241148591041565	Other beverages ( including mineral water ) , foods and some medicines may affect the absorption of alendronate ( see section 4.5 ) .
D-281	-0.3241148591041565	Other beverages ( including mineral water ) , foods and some medicines may affect the absorption of alendronate ( see section 4.5 ) .
P-281	-0.6413 -0.5322 -0.0585 -0.1171 -0.3561 -0.0566 -0.6701 -0.0803 -0.5888 -0.1409 -0.1470 -1.3192 -0.4348 -0.3000 -0.1853 -0.8580 -0.3219 -2.1007 -0.3244 -0.0901 -0.0586 -0.1274 -0.1417 -0.1067 -0.1322 -0.0730 -0.1447 -0.1080 -0.0770 -0.1177 -0.1464 -0.1357 -0.1726 -0.1548
S-1020	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1020	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-1020	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
D-1020	-0.22818748652935028	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric means
P-1020	-0.1170 -0.0900 -0.1521 -0.1466 -0.2213 -0.1150 -0.0416 -0.1262 -1.0359 -0.0961 -0.1240 -0.1426 -0.2510 -0.2422 -0.0868 -0.3337 -0.1212 -0.0877 -0.1223 -0.1456 -0.3344 -0.1241 -0.1262 -0.0568 -0.1480 -0.3226 -0.1058 -0.0571 -0.1310 -0.0971 -0.6687 -0.0775 -0.1287 -1.5833 -0.2263
S-1916	Während der Studie trugen die Patienten ihre Symptome alle 12 Stunden in ein Tagebuch ein und bewerteten mit einer Standardskala , wie schwer die Symptome in den letzten 12 Stunden waren .
T-1916	The patients recorded their symptoms in a diary every 12 hours during the study , scoring on a standard symptom scale how severe the symptoms were over the previous 12-hour period .
H-1916	-0.49444618821144104	During the trial , patients entered their symptoms in a diary every 12 hours and used a standard scale to assess how severe their symptoms had been over the previous 12 hours .
D-1916	-0.49444618821144104	During the trial , patients entered their symptoms in a diary every 12 hours and used a standard scale to assess how severe their symptoms had been over the previous 12 hours .
P-1916	-0.5974 -0.1950 -0.9030 -0.2599 -0.2443 -1.8660 -0.3055 -0.0489 -0.5426 -0.1500 -0.7962 -0.1186 -0.2420 -0.1412 -0.0968 -0.3194 -1.4714 -0.1422 -0.2341 -0.0715 -0.1564 -1.6542 -0.1107 -0.1997 -1.6046 -0.0659 -1.5218 -0.1522 -1.3947 -0.1670 -0.9367 -0.1484 -0.1362 -0.1592 -0.1521
S-1522	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-1522	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-1522	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
D-1522	-0.30106422305107117	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients were inhibitors of factor VIII
P-1522	-0.2346 -0.0978 -0.0863 -0.0712 -0.2714 -0.1915 -0.5264 -0.0929 -0.1220 -0.2074 -0.2200 -0.2339 -0.8022 -0.1305 -0.1629 -0.1240 -0.0996 -0.1379 -0.1325 -0.5043 -0.1622 -0.0982 -0.0950 -1.3866 -0.2151 -0.6915 -1.3863 -0.1654 -0.0795 -0.1616 -0.7547 -0.1931 -0.1706 -0.0912 -0.4370
S-422	Die Bioverfügbarkeit nahm entsprechend auf etwa 0,46 % und 0,39 % ab , wenn Alendronat eine oder eine halbe Stunde vor einem standardisierten Frühstück
T-422	Bioavailability was decreased similarly to an estimated 0.46 % and 0.39 % when alendronate was administered one hour or half an hour before a standardised breakfast .
H-422	-0.38600605726242065	Bioavailability decreased accordingly to approximately 0.46 % and 0.39 % when alendronate was given one or half an hour prior to a standardized breakfast
D-422	-0.38600605726242065	Bioavailability decreased accordingly to approximately 0.46 % and 0.39 % when alendronate was given one or half an hour prior to a standardized breakfast
P-422	-2.0951 -0.1175 -0.4566 -0.0779 -0.8152 -0.0925 -0.4372 -0.5479 -0.1209 -0.0795 -0.1216 -0.1413 -0.0858 -0.0826 -0.1099 -0.4724 -0.1704 -0.1105 -0.1322 -0.0825 -0.1169 -1.3861 -0.3046 -0.5439 -0.8130 -0.7720 -0.0784 -0.7710 -0.1291 -0.3078 -0.8502 -0.1756 -0.3364 -0.3305 -0.2452
S-1945	Aerinaze sollte aufgrund des Fehlens von Daten zur Unbedenklichkeit und Wirksamkeit ( siehe Abschnitt 5.1 ) nicht bei Kindern unter 12 Jahren angewendet werden .
T-1945	Aerinaze should not be used in children below the age of 12 years due to a lack of data on safety and efficacy ( see section 5.1 ) .
H-1945	-0.2594175636768341	Due to the lack of safety and efficacy data ( see section 5.1 ) , Aerinaze should not be used in children under 12 years of age .
D-1945	-0.2594175636768341	Due to the lack of safety and efficacy data ( see section 5.1 ) , Aerinaze should not be used in children under 12 years of age .
P-1945	-1.6934 -0.0544 -0.1260 -1.0059 -0.9130 -0.1264 -0.0112 -0.1535 -0.0287 -0.0912 -0.0897 -0.1170 -0.1414 -0.1023 -0.0964 -0.1017 -0.1359 -0.1299 -0.2951 -0.1780 -0.1327 -0.1472 -0.1302 -0.0994 -0.1422 -0.1410 -0.1272 -0.6034 -0.1596 -0.1507 -0.4266 -0.2033 -0.7539 -0.3634 -0.0944 -0.1769 -0.1552
S-209	Die Anstiege über die Ausgangswerte der BMD an der Lendenwirbelsäule betrugen nach einem Jahr im Mittel 5,1 % ( 95 % CI :
T-209	The mean increases from baseline in lumbar spine BMD at one year were 5.1 % ( 95 % CI :
H-209	-0.4927252531051636	Elevations above baseline lumbar BMD were 5.1 % ( 95 % CI :
D-209	-0.4927252531051636	Elevations above baseline lumbar BMD were 5.1 % ( 95 % CI :
P-209	-4.4383 -0.1525 -0.2817 -0.9581 -0.0501 -0.0211 -0.7732 -0.0716 -0.0323 -0.9451 -0.1509 -0.2708 -0.5979 -0.1388 -0.1277 -0.9995 -0.1014 -0.1048 -0.1049 -0.1533 -0.2017 -0.1641
S-1433	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-1433	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-1433	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
D-1433	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
P-1433	-2.2673 -0.0949 -0.0887 -0.8075 -0.0911 -0.1255 -1.7371 -0.3974 -0.1301 -0.1543 -0.1132 -0.1243 -0.1355 -0.1838 -0.0658 -0.0492 -0.1949 -1.1007 -0.2631 -0.1811 -0.3564 -0.0955 -0.1226 -0.9960 -0.2436 -0.0343 -0.0837 -1.0225 -0.1572
S-584	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-584	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma factor VIII activity assay is indispensable .
H-584	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
D-584	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
P-584	-1.6182 -0.1610 -1.5227 -0.1367 -0.3760 -0.5061 -0.8899 -0.2441 -0.1373 -0.7887 -0.0803 -0.1364 -0.2270 -1.7105 -0.1281 -0.3371 -0.3928 -0.5490 -1.1546 -0.1178 -0.1433 -0.9202 -0.0540 -0.1030 -0.2032 -0.8150 -0.1647 -0.1549
S-87	Kapselförmige , weiße bis gebrochen weiße Tabletten , gekennzeichnet mit dem Umriss eines Knochens auf der einen Seite und 710 auf der anderen Seite .
T-87	Capsule-shaped , white to off-white tablets , marked with an outline of a bone image on one side , and <<unk>> 710 <<unk>> on the other .
H-87	-0.3114076256752014	Capsule @-@ shaped , white to broken white tablets marked with the outline of a bone on one side and 710 on the other .
D-87	-0.3114076256752014	Capsule @-@ shaped , white to broken white tablets marked with the outline of a bone on one side and 710 on the other .
P-87	-0.4559 -0.1122 -0.7995 -1.7156 -0.2107 -0.8223 -0.0632 -0.1489 -0.8508 -0.0972 -0.1210 -0.1058 -1.1896 -0.1816 -0.2261 -0.3104 -0.0927 -0.1368 -0.2029 -0.0788 -0.1218 -0.1744 -0.1014 -0.1568 -0.1384 -0.1587 -0.1181 -0.1500 -0.1363 -0.3161 -0.1595
S-737	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-737	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-737	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
D-737	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
P-737	-1.9399 -1.5708 -0.3185 -0.6383 -0.1574 -0.0862 -0.0755 -0.1403 -0.6115 -0.1390 -0.5218 -0.3099 -0.1425 -0.1713 -0.0316 -0.1320 -1.7870 -1.6434 -0.1069 -0.1539 -0.4089 -0.5856 -0.3515 -0.2977 -0.1457 -0.1583 -0.5272 -0.1502 -1.2331 -0.2583 -1.0916 -0.2510 -0.1581
S-1257	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-1257	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-1257	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
D-1257	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
P-1257	-2.2673 -0.0949 -0.0887 -0.8075 -0.0911 -0.1255 -1.7371 -0.3974 -0.1301 -0.1543 -0.1132 -0.1243 -0.1355 -0.1838 -0.0658 -0.0492 -0.1949 -1.1007 -0.2631 -0.1811 -0.3564 -0.0955 -0.1226 -0.9960 -0.2436 -0.0343 -0.0837 -1.0225 -0.1572
S-1081	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-1081	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-1081	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
D-1081	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
P-1081	-2.2673 -0.0949 -0.0887 -0.8075 -0.0911 -0.1255 -1.7371 -0.3974 -0.1301 -0.1543 -0.1132 -0.1243 -0.1355 -0.1838 -0.0658 -0.0492 -0.1949 -1.1007 -0.2631 -0.1811 -0.3564 -0.0955 -0.1226 -0.9960 -0.2436 -0.0343 -0.0837 -1.0225 -0.1572
S-905	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-905	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-905	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
D-905	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
P-905	-2.2673 -0.0949 -0.0887 -0.8075 -0.0911 -0.1255 -1.7371 -0.3974 -0.1301 -0.1543 -0.1132 -0.1243 -0.1355 -0.1838 -0.0658 -0.0492 -0.1949 -1.1007 -0.2631 -0.1811 -0.3564 -0.0955 -0.1226 -0.9960 -0.2436 -0.0343 -0.0837 -1.0225 -0.1572
S-729	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-729	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-729	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
D-729	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
P-729	-2.2673 -0.0949 -0.0887 -0.8075 -0.0911 -0.1255 -1.7371 -0.3974 -0.1301 -0.1543 -0.1132 -0.1243 -0.1355 -0.1838 -0.0658 -0.0492 -0.1949 -1.1007 -0.2631 -0.1811 -0.3564 -0.0955 -0.1226 -0.9960 -0.2436 -0.0343 -0.0837 -1.0225 -0.1572
S-562	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-562	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-562	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
D-562	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
P-562	-1.9399 -1.5708 -0.3185 -0.6383 -0.1574 -0.0862 -0.0755 -0.1403 -0.6115 -0.1390 -0.5218 -0.3099 -0.1425 -0.1713 -0.0316 -0.1320 -1.7870 -1.6434 -0.1069 -0.1539 -0.4089 -0.5856 -0.3515 -0.2977 -0.1457 -0.1583 -0.5272 -0.1502 -1.2331 -0.2583 -1.0916 -0.2510 -0.1581
S-554	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-554	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-554	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
D-554	-0.39370593428611755	Prepared without the addition of an ( exogenous ) human or animal protein during cell culture , purification and final formulation .
P-554	-2.2673 -0.0949 -0.0887 -0.8075 -0.0911 -0.1255 -1.7371 -0.3974 -0.1301 -0.1543 -0.1132 -0.1243 -0.1355 -0.1838 -0.0658 -0.0492 -0.1949 -1.1007 -0.2631 -0.1811 -0.3564 -0.0955 -0.1226 -0.9960 -0.2436 -0.0343 -0.0837 -1.0225 -0.1572
S-758	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-758	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 13 factor VIII activity assay is indispensable .
H-758	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
D-758	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
P-758	-1.6182 -0.1610 -1.5227 -0.1367 -0.3760 -0.5061 -0.8899 -0.2441 -0.1373 -0.7887 -0.0803 -0.1364 -0.2270 -1.7105 -0.1281 -0.3371 -0.3928 -0.5490 -1.1546 -0.1178 -0.1433 -0.9202 -0.0540 -0.1030 -0.2032 -0.8150 -0.1647 -0.1549
S-913	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-913	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-913	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
D-913	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
P-913	-1.9399 -1.5708 -0.3185 -0.6383 -0.1574 -0.0862 -0.0755 -0.1403 -0.6115 -0.1390 -0.5218 -0.3099 -0.1425 -0.1713 -0.0316 -0.1320 -1.7870 -1.6434 -0.1069 -0.1539 -0.4089 -0.5856 -0.3515 -0.2977 -0.1457 -0.1583 -0.5272 -0.1502 -1.2331 -0.2583 -1.0916 -0.2510 -0.1581
S-934	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-934	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 23 factor VIII activity assay is indispensable .
H-934	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
D-934	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
P-934	-1.6182 -0.1610 -1.5227 -0.1367 -0.3760 -0.5061 -0.8899 -0.2441 -0.1373 -0.7887 -0.0803 -0.1364 -0.2270 -1.7105 -0.1281 -0.3371 -0.3928 -0.5490 -1.1546 -0.1178 -0.1433 -0.9202 -0.0540 -0.1030 -0.2032 -0.8150 -0.1647 -0.1549
S-1089	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-1089	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-1089	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
D-1089	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
P-1089	-1.9399 -1.5708 -0.3185 -0.6383 -0.1574 -0.0862 -0.0755 -0.1403 -0.6115 -0.1390 -0.5218 -0.3099 -0.1425 -0.1713 -0.0316 -0.1320 -1.7870 -1.6434 -0.1069 -0.1539 -0.4089 -0.5856 -0.3515 -0.2977 -0.1457 -0.1583 -0.5272 -0.1502 -1.2331 -0.2583 -1.0916 -0.2510 -0.1581
S-1110	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-1110	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 33 factor VIII activity assay is indispensable .
H-1110	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
D-1110	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
P-1110	-1.6182 -0.1610 -1.5227 -0.1367 -0.3760 -0.5061 -0.8899 -0.2441 -0.1373 -0.7887 -0.0803 -0.1364 -0.2270 -1.7105 -0.1281 -0.3371 -0.3928 -0.5490 -1.1546 -0.1178 -0.1433 -0.9202 -0.0540 -0.1030 -0.2032 -0.8150 -0.1647 -0.1549
S-1265	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-1265	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-1265	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
D-1265	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
P-1265	-1.9399 -1.5708 -0.3185 -0.6383 -0.1574 -0.0862 -0.0755 -0.1403 -0.6115 -0.1390 -0.5218 -0.3099 -0.1425 -0.1713 -0.0316 -0.1320 -1.7870 -1.6434 -0.1069 -0.1539 -0.4089 -0.5856 -0.3515 -0.2977 -0.1457 -0.1583 -0.5272 -0.1502 -1.2331 -0.2583 -1.0916 -0.2510 -0.1581
S-1286	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-1286	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 43 factor VIII activity assay is indispensable .
H-1286	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
D-1286	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
P-1286	-1.6182 -0.1610 -1.5227 -0.1367 -0.3760 -0.5061 -0.8899 -0.2441 -0.1373 -0.7887 -0.0803 -0.1364 -0.2270 -1.7105 -0.1281 -0.3371 -0.3928 -0.5490 -1.1546 -0.1178 -0.1433 -0.9202 -0.0540 -0.1030 -0.2032 -0.8150 -0.1647 -0.1549
S-1441	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-1441	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-1441	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
D-1441	-0.49378514289855957	on demand The Factor VIII dose is given in international units ( IU ) in accordance with the WHO standard for Factor VIII-products .
P-1441	-1.9399 -1.5708 -0.3185 -0.6383 -0.1574 -0.0862 -0.0755 -0.1403 -0.6115 -0.1390 -0.5218 -0.3099 -0.1425 -0.1713 -0.0316 -0.1320 -1.7870 -1.6434 -0.1069 -0.1539 -0.4089 -0.5856 -0.3515 -0.2977 -0.1457 -0.1583 -0.5272 -0.1502 -1.2331 -0.2583 -1.0916 -0.2510 -0.1581
S-1462	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-1462	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 53 factor VIII activity assay is indispensable .
H-1462	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
D-1462	-0.4918802082538605	Especially in major surgery , close monitoring of substitution therapy by determination of factor VIII activity in plasma is essential .
P-1462	-1.6182 -0.1610 -1.5227 -0.1367 -0.3760 -0.5061 -0.8899 -0.2441 -0.1373 -0.7887 -0.0803 -0.1364 -0.2270 -1.7105 -0.1281 -0.3371 -0.3928 -0.5490 -1.1546 -0.1178 -0.1433 -0.9202 -0.0540 -0.1030 -0.2032 -0.8150 -0.1647 -0.1549
S-1976	Reversible und irreversible MAO-Hemmer können das Risiko für das Auftreten einer Gefäßverengung und einer Hypertonie erhöhen .
T-1976	Reversible and irreversible MAO inhibitor<<unk>> s ) may cause : risk of vasoconstriction and increased blood pressure .
H-1976	-0.21676146984100342	Reversible and irreversible MAOI may increase the risk of vasoconstriction and hypertension .
D-1976	-0.21676146984100342	Reversible and irreversible MAOI may increase the risk of vasoconstriction and hypertension .
P-1976	-0.1986 -0.0766 -0.1026 -0.1642 -0.1439 -0.1874 -0.0581 -0.0901 -0.0956 -0.1194 -0.1202 -0.5852 -0.0841 -0.2176 -0.1574 -0.2739 -0.9780 -0.0446 -1.2275 -0.0510 -0.1444 -0.1665 -0.1448 -0.0335 -0.0407 -0.1854 -0.1612
S-1749	Bei Einnahme mit anderen Arzneimitteln Bitte informieren Sie Ihren Arzt , wenn Sie andere Arzneimittel einnehmen bzw. vor kurzem eingenommen haben , auch wenn es sich um nicht-verschreibungspflichtige Arzneimittel handelt .
T-1749	Taking other medicines Please tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
H-1749	-0.42998120188713074	When taking other medicines Please tell your doctor if you are taking other medicines or have recently taken them , even if they are non @-@ prescription medicines .
D-1749	-0.42998120188713074	When taking other medicines Please tell your doctor if you are taking other medicines or have recently taken them , even if they are non @-@ prescription medicines .
P-1749	-1.7361 -0.1855 -0.3664 -0.1551 -0.1715 -1.7456 -0.1332 -0.1485 -0.0969 -0.0748 -0.1060 -0.1591 -0.3205 -0.5226 -0.1763 -0.1800 -0.4409 -0.6306 -0.5652 -0.5711 -0.1370 -0.1581 -0.2618 -0.3701 -0.4870 -0.0882 -1.5248 -0.8759 -0.3318 -0.9207 -0.1765 -0.1938 -0.1781
S-284	13 Die Patienten sollen sich nach Einnahme von ADROVANCE mindestens 30 Minuten nicht hinlegen . ADROVANCE soll nicht vor dem Schlafengehen oder vor dem ersten Aufstehen des Tages eingenommen werden .
T-284	Patients should not lie down until after their first food of the day which should be at least 30 minutes after taking the tablet .
H-284	-0.3253523111343384	Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bed or before getting up for the first time .
D-284	-0.3253523111343384	Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bed or before getting up for the first time .
P-284	-1.8134 -0.1075 -0.1032 -0.1372 -0.0413 -0.1113 -0.2153 -0.2276 -0.1251 -0.1278 -0.1822 -0.1121 -0.0901 -0.0713 -0.0652 -0.1267 -0.1141 -0.0865 -0.1609 -0.0764 -0.0641 -0.1238 -0.1139 -0.1021 -0.1621 -0.1454 -0.1549 -0.1251 -0.4981 -1.2062 -0.2053 -1.5163 -1.1172 -0.4421 -1.4210 -0.1679 -0.0798 -0.1809 -0.9281 -0.1642
S-254	Die mittlere Halbwertszeit von Vitamin D3 im Serum beträgt ca. 24 Stunden nach einer oralen Dosis von ADROVANCE ( 70 mg<unk> 2.800 I.E . ) .
T-254	The mean half-life of vitamin D3 in the serum following an oral dose of ADROVANCE ( 70 mg/ 2800 IU ) is approximately 24 hours .
H-254	-0.17486952245235443	The mean half-life of vitamin D3 in serum is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
D-254	-0.17486952245235443	The mean half-life of vitamin D3 in serum is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
P-254	-0.2364 -0.1185 -0.1737 -0.1875 -0.0937 -0.1332 -0.3974 -0.0696 -0.1646 -0.1459 -0.1670 -0.7068 -0.1152 -0.1561 -0.0987 -0.1615 -0.1031 -0.4112 -0.7530 -0.0437 -0.0708 -0.1255 -0.0778 -0.0667 -0.1362 -0.1132 -0.0945 -0.1422 -0.1906 -0.1801 -0.1528 -0.0791 -0.2901 -0.0905 -0.0928 -0.0347 -0.1425 -0.1510 -0.1521
S-663	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-663	7 increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-663	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
D-663	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
P-663	-1.2790 -2.2582 -0.3316 -0.5803 -1.1390 -0.1587 -0.8433 -0.0406 -0.0787 -0.3514 -0.1960 -0.1228 -0.2660 -0.8558 -0.0605 -0.1841 -0.4911 -0.9618 -0.1439 -0.8441 -0.1834 -0.0539 -0.9558 -0.0323 -0.1367 -0.1526 -0.4490 -0.2167 -0.2256 -0.4103 -0.0650 -0.1592 -0.0566 -0.0973 -0.1377 -2.2206 -0.1538 -1.4777 -0.2109 -0.8426 -0.0515 -0.1634 -0.1558
S-1005	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-1005	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-1005	-0.29619303345680237	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
D-1005	-0.29619303345680237	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
P-1005	-0.3030 -0.5484 -0.5073 -0.2186 -0.6326 -0.1820 -1.1463 -0.6346 -0.1209 -0.1868 -0.6576 -0.1746 -0.2722 -0.0932 -0.1327 -0.1782 -0.0820 -0.0890 -0.1541 -0.3715 -0.1785 -0.0922 -0.1783 -0.5250 -0.1215 -0.1320 -0.2205 -0.4101 -0.1338 -0.2435 -0.9134 -0.1814 -0.1436 -0.1649 -0.1822 -0.1563
S-1181	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-1181	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-1181	-0.29619303345680237	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
D-1181	-0.29619303345680237	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
P-1181	-0.3030 -0.5484 -0.5073 -0.2186 -0.6326 -0.1820 -1.1463 -0.6346 -0.1209 -0.1868 -0.6576 -0.1746 -0.2722 -0.0932 -0.1327 -0.1782 -0.0820 -0.0890 -0.1541 -0.3715 -0.1785 -0.0922 -0.1783 -0.5250 -0.1215 -0.1320 -0.2205 -0.4101 -0.1338 -0.2435 -0.9134 -0.1814 -0.1436 -0.1649 -0.1822 -0.1563
S-1357	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-1357	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-1357	-0.29619303345680237	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
D-1357	-0.29619303345680237	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
P-1357	-0.3030 -0.5484 -0.5073 -0.2186 -0.6326 -0.1820 -1.1463 -0.6346 -0.1209 -0.1868 -0.6576 -0.1746 -0.2722 -0.0932 -0.1327 -0.1782 -0.0820 -0.0890 -0.1541 -0.3715 -0.1785 -0.0922 -0.1783 -0.5250 -0.1215 -0.1320 -0.2205 -0.4101 -0.1338 -0.2435 -0.9134 -0.1814 -0.1436 -0.1649 -0.1822 -0.1563
S-1534	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-1534	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-1534	-0.29619303345680237	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
D-1534	-0.29619303345680237	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
P-1534	-0.3030 -0.5484 -0.5073 -0.2186 -0.6326 -0.1820 -1.1463 -0.6346 -0.1209 -0.1868 -0.6576 -0.1746 -0.2722 -0.0932 -0.1327 -0.1782 -0.0820 -0.0890 -0.1541 -0.3715 -0.1785 -0.0922 -0.1783 -0.5250 -0.1215 -0.1320 -0.2205 -0.4101 -0.1338 -0.2435 -0.9134 -0.1814 -0.1436 -0.1649 -0.1822 -0.1563
S-1867	Bei Li-Fraumeni-Krebs , bei dem das p53-Gen defekt ist , arbeitet das p53-Protein nicht richtig , und die Krebszellen können weiter wachsen und sich teilen .
T-1867	In Li-Fraumeni cancer , where the p53 gene is defective , the p53 protein does not work properly and the cancer cells can continue to grow and divide .
H-1867	-0.443290650844574	In Li-Fraumeni cancer , where the p53 gene is defective , the p53 protein does not function properly and the cancer cells can continue to grow and divide .
D-1867	-0.443290650844574	In Li-Fraumeni cancer , where the p53 gene is defective , the p53 protein does not function properly and the cancer cells can continue to grow and divide .
P-1867	-0.2480 -2.8416 -0.3047 -0.1929 -0.0541 -0.1983 -1.5440 -0.4008 -0.9138 -0.9952 -0.1397 -0.0666 -0.1276 -0.1789 -0.2253 -0.2691 -0.1333 -0.2980 -0.1324 -0.0843 -0.1098 -1.0611 -0.1270 -0.7541 -0.5466 -0.5102 -1.1339 -0.1146 -0.0512 -0.7133 -1.0322 -0.1759 -0.2391 -0.1388 -0.0345 -0.1540 -0.1569
S-829	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-829	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-829	-0.29619303345680237	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
D-829	-0.29619303345680237	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
P-829	-0.3030 -0.5484 -0.5073 -0.2186 -0.6326 -0.1820 -1.1463 -0.6346 -0.1209 -0.1868 -0.6576 -0.1746 -0.2722 -0.0932 -0.1327 -0.1782 -0.0820 -0.0890 -0.1541 -0.3715 -0.1785 -0.0922 -0.1783 -0.5250 -0.1215 -0.1320 -0.2205 -0.4101 -0.1338 -0.2435 -0.9134 -0.1814 -0.1436 -0.1649 -0.1822 -0.1563
S-514	Advate wird zur Behandlung und Vorbeugung von Blutungen bei Patienten mit Hämophilie A ( eine durch den Mangel an Faktor VIII bedingte , angeborene Blutgerinnungsstörung ) verwendet .
T-514	Advate is used for the treatment and prevention of bleeding in patients with haemophilia A ( an inherited bleeding disorder caused by lack of factor VIII ) .
H-514	-0.3082481622695923	Advate is used to treat and prevent bleeding in patients with haemophilia A ( a congenital blood clotting disorder caused by deficiency of factor VIII ) .
D-514	-0.3082481622695923	Advate is used to treat and prevent bleeding in patients with haemophilia A ( a congenital blood clotting disorder caused by deficiency of factor VIII ) .
P-514	-0.5430 -0.0991 -0.1608 -0.0622 -0.1926 -0.1319 -0.1314 -0.1464 -0.8497 -0.1623 -0.1405 -0.4183 -0.1300 -0.1550 -0.0605 -0.0698 -0.0761 -0.1555 -0.1613 -0.4267 -0.3375 -0.0783 -0.2110 -0.9968 -0.2955 -0.0502 -0.0948 -0.1216 -1.1613 -0.1524 -2.5994 -0.1456 -0.1107 -0.4014 -0.5717 -0.1382 -0.0876 -0.1514 -0.1921 -0.1592
S-450	Die mittlere Halbwertszeit von Vitamin D3 im Serum beträgt ca. 24 Stunden nach einer oralen Dosis von ADROVANCE ( 70 mg<unk> 2.800 I.E . ) .
T-450	The mean half-life of vitamin D3 in the serum following an oral dose of ADROVANCE ( 70 mg/ 2800 IU ) is approximately 24 hours .
H-450	-0.17486952245235443	The mean half-life of vitamin D3 in serum is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
D-450	-0.17486952245235443	The mean half-life of vitamin D3 in serum is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
P-450	-0.2364 -0.1185 -0.1737 -0.1875 -0.0937 -0.1332 -0.3974 -0.0696 -0.1646 -0.1459 -0.1670 -0.7068 -0.1152 -0.1561 -0.0987 -0.1615 -0.1031 -0.4112 -0.7530 -0.0437 -0.0708 -0.1255 -0.0778 -0.0667 -0.1362 -0.1132 -0.0945 -0.1422 -0.1906 -0.1801 -0.1528 -0.0791 -0.2901 -0.0905 -0.0928 -0.0347 -0.1425 -0.1510 -0.1521
S-1791	Seltene Nebenwirkungen Seit der Einführung des Arzneimittels auf dem Markt wurde vereinzelt über schwere und potentiell lebensbedrohliche Reaktionen ( Anaphylaxie ) und andere allergische Reaktionen berichtet ( siehe oben ) .
T-1791	Rare side effects Since the medicine has been on the market , there have been rare reports of severe and potentially life-threatening reactions ( anaphylaxis ) and other allergic reactions ( see above ) .
H-1791	-0.3869421184062958	Rare side effects Severe and potentially life @-@ threatening reactions ( anaphylaxis ) and other allergic reactions ( see above ) have been isolated since the product was marketed .
D-1791	-0.3869421184062958	Rare side effects Severe and potentially life @-@ threatening reactions ( anaphylaxis ) and other allergic reactions ( see above ) have been isolated since the product was marketed .
P-1791	-1.0584 -0.1369 -1.2738 -0.1695 -0.1870 -0.1101 -0.1736 -0.0281 -0.1482 -1.5770 -0.1043 -0.5522 -0.0591 -0.1590 -0.2544 -0.1121 -0.0878 -0.1130 -0.2683 -0.1398 -0.1562 -0.1671 -0.0639 -0.1010 -0.0665 -0.0285 -1.0352 -0.1673 -0.2253 -0.1316 -0.2327 -0.2170 -2.0891 -0.2949 -0.4511 -1.0080 -1.1799 -1.0727 -0.0634 -0.2433 -0.1571
S-1958	Die Sicherheit und die Wirksamkeit von Aerinaze wurden bei Patienten mit Nieren- oder Leberfunktionsstörung nicht geprüft und die Daten reichen nicht aus , um entsprechende Empfehlungen zur Dosierung auszusprechen .
T-1958	The safety and efficacy of Aerinaze has not been established in patients with impaired renal or hepatic function , and there are insufficient data to give adequate dose recommendations .
H-1958	-0.2577596604824066	The safety and efficacy of Aerinaze have not been evaluated in patients with renal or hepatic impairment , and data are insufficient to recommend appropriate dosing regimens .
D-1958	-0.2577596604824066	The safety and efficacy of Aerinaze have not been evaluated in patients with renal or hepatic impairment , and data are insufficient to recommend appropriate dosing regimens .
P-1958	-0.4619 -0.0315 -0.1430 -0.1176 -0.0780 -0.0979 -0.1205 -0.1264 -0.1324 -0.1425 -0.1408 -0.0937 -0.7847 -0.1096 -0.1001 -0.3554 -0.1232 -0.1445 -0.7073 -0.1488 -0.1035 -0.1391 -0.2282 -0.3128 -0.0266 -0.0941 -0.0549 -0.0599 -0.0322 -0.1008 -0.8808 -0.1367 -0.6025 -0.7965 -0.6500 -0.2791 -0.1485 -0.4137 -0.2093 -0.2252 -0.7771 -0.6917 -0.1144 -0.2040 -0.1579
S-1190	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-1190	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-1190	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
D-1190	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
P-1190	-1.2790 -2.2582 -0.3316 -0.5803 -1.1390 -0.1587 -0.8433 -0.0406 -0.0787 -0.3514 -0.1960 -0.1228 -0.2660 -0.8558 -0.0605 -0.1841 -0.4911 -0.9618 -0.1439 -0.8441 -0.1834 -0.0539 -0.9558 -0.0323 -0.1367 -0.1526 -0.4490 -0.2167 -0.2256 -0.4103 -0.0650 -0.1592 -0.0566 -0.0973 -0.1377 -2.2206 -0.1538 -1.4777 -0.2109 -0.8426 -0.0515 -0.1634 -0.1558
S-1366	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-1366	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-1366	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
D-1366	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
P-1366	-1.2790 -2.2582 -0.3316 -0.5803 -1.1390 -0.1587 -0.8433 -0.0406 -0.0787 -0.3514 -0.1960 -0.1228 -0.2660 -0.8558 -0.0605 -0.1841 -0.4911 -0.9618 -0.1439 -0.8441 -0.1834 -0.0539 -0.9558 -0.0323 -0.1367 -0.1526 -0.4490 -0.2167 -0.2256 -0.4103 -0.0650 -0.1592 -0.0566 -0.0973 -0.1377 -2.2206 -0.1538 -1.4777 -0.2109 -0.8426 -0.0515 -0.1634 -0.1558
S-1543	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-1543	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-1543	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
D-1543	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
P-1543	-1.2790 -2.2582 -0.3316 -0.5803 -1.1390 -0.1587 -0.8433 -0.0406 -0.0787 -0.3514 -0.1960 -0.1228 -0.2660 -0.8558 -0.0605 -0.1841 -0.4911 -0.9618 -0.1439 -0.8441 -0.1834 -0.0539 -0.9558 -0.0323 -0.1367 -0.1526 -0.4490 -0.2167 -0.2256 -0.4103 -0.0650 -0.1592 -0.0566 -0.0973 -0.1377 -2.2206 -0.1538 -1.4777 -0.2109 -0.8426 -0.0515 -0.1634 -0.1558
S-838	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-838	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-838	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
D-838	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
P-838	-1.2790 -2.2582 -0.3316 -0.5803 -1.1390 -0.1587 -0.8433 -0.0406 -0.0787 -0.3514 -0.1960 -0.1228 -0.2660 -0.8558 -0.0605 -0.1841 -0.4911 -0.9618 -0.1439 -0.8441 -0.1834 -0.0539 -0.9558 -0.0323 -0.1367 -0.1526 -0.4490 -0.2167 -0.2256 -0.4103 -0.0650 -0.1592 -0.0566 -0.0973 -0.1377 -2.2206 -0.1538 -1.4777 -0.2109 -0.8426 -0.0515 -0.1634 -0.1558
S-1999	In klinischen Prüfungen mit 414 Erwachsenen wurden als häufigste unerwünschte Ereignisse Schlaflosigkeit ( 8,9 % ) , Mundtrockenheit ( 7,2 % ) und Kopfschmerzen ( 3,1 % ) beobachtet .
T-1999	In clinical trials involving 414 adults the most frequent of adverse events reported were insomnia ( 8.9 % ) , dry mouth ( 7.2 % ) and headache ( 3.1 % ) .
H-1999	-0.19963739812374115	In clinical trials of 414 adults , the most common adverse events reported were insomnia ( 8.9 % ) , dry mouth ( 7.2 % ) and headache ( 3.1 % ) .
D-1999	-0.19963739812374115	In clinical trials of 414 adults , the most common adverse events reported were insomnia ( 8.9 % ) , dry mouth ( 7.2 % ) and headache ( 3.1 % ) .
P-1999	-0.3433 -0.1457 -0.0823 -0.9850 -0.1326 -0.0977 -0.4363 -0.1867 -0.4160 -0.1701 -0.3303 -0.0582 -0.0192 -0.0941 -1.1281 -0.2483 -0.2319 -0.0969 -0.0321 -0.1395 -0.0935 -0.1182 -0.1305 -0.1315 -0.1396 -0.1101 -0.0778 -0.1449 -0.0772 -0.1476 -0.1201 -0.1300 -0.5513 -0.0789 -0.0412 -0.2063 -0.1451 -0.0599 -0.1387 -0.1243 -0.1285 -0.1597 -0.1551
S-1014	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-1014	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-1014	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
D-1014	-0.46035048365592957	The factor VIII-plasma levels are increased by substitution therapy , whereby a transient correction of factor VIII-deficiency and bleeding tendency occurs .
P-1014	-1.2790 -2.2582 -0.3316 -0.5803 -1.1390 -0.1587 -0.8433 -0.0406 -0.0787 -0.3514 -0.1960 -0.1228 -0.2660 -0.8558 -0.0605 -0.1841 -0.4911 -0.9618 -0.1439 -0.8441 -0.1834 -0.0539 -0.9558 -0.0323 -0.1367 -0.1526 -0.4490 -0.2167 -0.2256 -0.4103 -0.0650 -0.1592 -0.0566 -0.0973 -0.1377 -2.2206 -0.1538 -1.4777 -0.2109 -0.8426 -0.0515 -0.1634 -0.1558
S-1637	ADVATE 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1637	ADVATE 500 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1637	-0.28034475445747375	ADVATE 500 IU powder and solvent for solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
D-1637	-0.28034475445747375	ADVATE 500 IU powder and solvent for solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
P-1637	-0.0954 -0.1483 -0.0899 -0.0876 -0.0856 -0.1166 -0.1107 -0.8977 -0.1668 -0.1903 -0.1936 -0.4077 -2.6115 -0.1561 -0.1429 -0.0571 -0.3493 -0.1149 -0.1264 -0.2225 -0.1338 -0.0637 -0.1511 -0.1873 -0.1588 -0.0982 -0.0978 -0.1380 -1.4001 -0.8278 -0.0472 -0.0688 -0.0549 -0.1518 -0.0846 -0.1357 -0.2025
S-1671	ADVATE 1500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1671	ADVATE 1500 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1671	-0.2743350863456726	ADVATE 1500 IU powder and solvent for solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
D-1671	-0.2743350863456726	ADVATE 1500 IU powder and solvent for solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
P-1671	-0.0596 -0.1509 -0.0883 -0.0871 -0.1200 -0.1200 -0.1158 -0.9494 -0.1667 -0.1935 -0.1877 -0.3805 -2.4032 -0.1532 -0.1407 -0.0588 -0.3051 -0.1155 -0.1261 -0.2235 -0.1355 -0.0655 -0.1493 -0.1896 -0.1570 -0.0982 -0.0978 -0.1393 -1.4156 -0.8084 -0.0463 -0.0704 -0.0559 -0.1537 -0.0865 -0.1350 -0.2006
S-1653	ADVATE 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1653	ADVATE 1000 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1653	-0.2622596025466919	ADVATE 1000 IU powder and solvent for solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
D-1653	-0.2622596025466919	ADVATE 1000 IU powder and solvent for solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
P-1653	-0.0914 -0.1502 -0.0856 -0.0847 -0.0805 -0.1175 -0.0999 -0.5963 -0.1691 -0.1889 -0.1927 -0.3744 -2.3372 -0.1622 -0.1443 -0.0595 -0.3362 -0.1156 -0.1261 -0.2224 -0.1341 -0.0641 -0.1505 -0.1854 -0.1576 -0.0985 -0.0985 -0.1392 -1.3952 -0.8009 -0.0463 -0.0702 -0.0544 -0.1508 -0.0859 -0.1354 -0.2019
S-316	Die Patienten sollen angewiesen werden , dass sie beim Versäumnis der Einnahme einer Dosis ADROVANCE die Tablette am nächsten Morgen einnehmen sollen , nachdem sie ihr Versäumnis bemerkt haben .
T-316	Patients should be instructed that if they miss a dose of ADROVANCE they should take one tablet on the morning after they remember .
H-316	-0.33565235137939453	Patients should be advised that if they fail to take a dose of ADROVANCE , they should take the tablet the next morning after noticing their failure .
D-316	-0.33565235137939453	Patients should be advised that if they fail to take a dose of ADROVANCE , they should take the tablet the next morning after noticing their failure .
P-316	-0.1250 -0.1043 -0.2401 -0.1237 -0.5636 -0.3559 -0.4095 -0.1261 -1.1836 -0.1364 -0.0645 -0.1602 -0.0503 -0.1298 -0.1187 -0.0562 -0.1259 -0.1015 -0.0989 -1.3280 -0.3973 -0.1045 -0.0226 -0.7282 -0.2864 -0.1485 -0.1331 -0.7274 -0.3200 -0.3718 -0.9686 -0.1302 -0.4120 -1.0288 -0.5449 -0.1570
S-1621	ADVATE 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1621	ADVATE 250 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1621	-0.2832328975200653	ADVATE 250 IU of powder and solvent for solution for injection Octocog alfa ( human recombinant clotting factor VIII )
D-1621	-0.2832328975200653	ADVATE 250 IU of powder and solvent for solution for injection Octocog alfa ( human recombinant clotting factor VIII )
P-1621	-0.0676 -0.1472 -0.0894 -0.0873 -0.0896 -0.1183 -0.0987 -1.6552 -0.1093 -0.1617 -0.1839 -0.2065 -0.3921 -2.1824 -0.1542 -0.1412 -0.0559 -0.4047 -0.1162 -0.1253 -0.2218 -0.1335 -0.0636 -0.1494 -0.1711 -0.1584 -0.0972 -0.0979 -0.1371 -1.9477 -0.0515 -0.0508 -0.0419 -0.1512 -0.0820 -0.1365 -0.2010
S-1862	Bei dem Virus in Advexin handelt es sich um ein Adenovirus , das so verändert wurde , dass es keine Kopien von sich selbst herstellen und somit keine Infektionen beim Menschen auslösen kann .
T-1862	The virus in Advexin is an adenovirus that has been engineered so that it cannot make copies of itself and therefore does not cause infections in humans .
H-1862	-0.47401538491249084	The virus in Advexin is an adenovirus that has been modified to make no copies of itself and therefore cannot cause infection in humans .
D-1862	-0.47401538491249084	The virus in Advexin is an adenovirus that has been modified to make no copies of itself and therefore cannot cause infection in humans .
P-1862	-0.3335 -0.9502 -0.2054 -0.7419 -0.1538 -0.1383 -0.1497 -0.3802 -0.0786 -0.1411 -0.1245 -1.6673 -0.2924 -0.1011 -0.5498 -0.0851 -0.9921 -2.2573 -0.1679 -0.1748 -0.1597 -0.2661 -0.6279 -1.8694 -0.1489 -0.7247 -0.5612 -0.1261 -0.1783 -0.1514 -0.1957
S-1901	Die Dauer der Behandlung sollte so kurz wie möglich sein und beendet werden , sobald die Symptome , vor allem die Schwellung der Nasenschleimhaut ( verstopfte Nase ) , abgeklungen sind .
T-1901	Treatment should continue for as short a time as possible and should stop when symptoms , chiefly the congestion ( blocked nose ) , have disappeared .
H-1901	-0.4130612909793854	The duration of treatment should be as short as possible and should be stopped as soon as the symptoms , especially swelling of the nasal mucosa ( clogged nose ) , have subsided .
D-1901	-0.4130612909793854	The duration of treatment should be as short as possible and should be stopped as soon as the symptoms , especially swelling of the nasal mucosa ( clogged nose ) , have subsided .
P-1901	-1.6535 -0.0944 -0.1184 -0.1200 -0.2882 -0.0933 -0.1661 -0.2461 -0.4702 -0.1785 -0.1782 -0.3276 -0.5420 -0.1935 -1.5354 -1.0337 -0.0742 -0.1534 -1.0304 -0.0584 -0.5751 -0.6832 -0.8814 -0.0842 -0.2169 -0.1510 -0.1567 -0.0235 -0.1699 -1.2977 -0.0067 -0.3346 -0.1376 -2.0937 -0.1130 -0.1641 -0.1384 -0.4520 -0.5485 -0.5580 -0.0590 -0.2060 -0.1550
S-1687	ADVATE 2000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1687	ADVATE 2000 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1687	-0.2705634534358978	ADVATE 2000 IU powder and solvent for solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
D-1687	-0.2705634534358978	ADVATE 2000 IU powder and solvent for solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
P-1687	-0.0959 -0.1529 -0.0871 -0.0898 -0.0951 -0.1278 -0.0957 -0.5861 -0.1688 -0.1879 -0.1886 -0.3761 -2.5872 -0.1413 -0.1438 -0.0598 -0.3575 -0.1152 -0.1252 -0.2247 -0.1337 -0.0644 -0.1504 -0.1761 -0.1558 -0.0973 -0.0978 -0.1383 -1.4188 -0.8237 -0.0458 -0.0692 -0.0551 -0.1523 -0.0878 -0.1370 -0.2012
S-128	Die Patienten sollen angewiesen werden , dass sie beim Versäumnis der Einnahme einer Dosis ADROVANCE die Tablette am nächsten Morgen einnehmen sollen , nachdem sie ihr Versäumnis bemerkt haben .
T-128	Patients should be instructed that if they miss a dose of ADROVANCE they should take one tablet on the morning after they remember .
H-128	-0.33565235137939453	Patients should be advised that if they fail to take a dose of ADROVANCE , they should take the tablet the next morning after noticing their failure .
D-128	-0.33565235137939453	Patients should be advised that if they fail to take a dose of ADROVANCE , they should take the tablet the next morning after noticing their failure .
P-128	-0.1250 -0.1043 -0.2401 -0.1237 -0.5636 -0.3559 -0.4095 -0.1261 -1.1836 -0.1364 -0.0645 -0.1602 -0.0503 -0.1298 -0.1187 -0.0562 -0.1259 -0.1015 -0.0989 -1.3280 -0.3973 -0.1045 -0.0226 -0.7282 -0.2864 -0.1485 -0.1331 -0.7274 -0.3200 -0.3718 -0.9686 -0.1302 -0.4120 -1.0288 -0.5449 -0.1570
S-1746	Diese Symptome können frühe Anzeichen eines anaphylaktischen Schocks darstellen , der zusätzlich folgende Symptome einschließen kann : extremer Schwindel , Bewusstseinsverlust und extreme Atembeschwerden .
T-1746	92 symptom of an anaphylactic shock , manifestations of which may additionally include extreme dizziness , loss of consciousness , and extreme difficulty in breathing .
H-1746	-0.36151406168937683	These symptoms may include early signs of anaphylactic shock , which may include extreme dizziness , loss of consciousness , and extreme difficulty breathing .
D-1746	-0.36151406168937683	These symptoms may include early signs of anaphylactic shock , which may include extreme dizziness , loss of consciousness , and extreme difficulty breathing .
P-1746	-0.2618 -0.1000 -1.0592 -1.4548 -0.3379 -0.2012 -0.1239 -0.1889 -0.1116 -0.1068 -0.1239 -0.0855 -0.0266 -0.6280 -0.6963 -0.4982 -0.8162 -0.8924 -0.1637 -0.0449 -0.0405 -0.1362 -0.3458 -0.1234 -0.0389 -0.0713 -0.4981 -0.1711 -1.2545 -0.9236 -0.0804 -0.1660 -0.1585
S-1915	Die Hauptwirksamkeitsmaße waren die Veränderungen des Schweregrades der Heuschnupfensymptome , die von den Patienten vor Beginn der Behandlung und während der 15-tägigen Behandlung berichtet wurden .
T-1915	The main measures of effectiveness were the change in the severity of hayfever symptoms reported by the patients between before treatment started , and over the entire 15 days of treatment .
H-1915	-0.29579317569732666	The main efficacy measures were changes in the severity of hayfever symptoms reported by patients prior to commencement of treatment and during 15 days of treatment .
D-1915	-0.29579317569732666	The main efficacy measures were changes in the severity of hayfever symptoms reported by patients prior to commencement of treatment and during 15 days of treatment .
P-1915	-0.9581 -0.7807 -0.3341 -0.0833 -0.0957 -0.1922 -0.2059 -0.1269 -0.1249 -0.9453 -0.0659 -0.1105 -0.1214 -0.1759 -0.8467 -0.0773 -0.1802 -0.0927 -0.1158 -0.2054 -0.2253 -0.4246 -0.1307 -1.1332 -0.2155 -0.1557 -0.3043 -0.1447 -0.0793 -0.5991 -0.3121 -0.1603 -0.3178 -0.1582 -0.1533
S-100	Die Äquivalenz der Einnahme von 2.800 I.E. Vitamin D3 einmal pro Woche in ADROVANCE und von 400 I.E. Vitamin D einmal pro Tag wurde nicht untersucht .
T-100	The equivalence of intake of 2800 IU of vitamin D3 weekly in ADROVANCE to daily dosing of vitamin D 400 IU has not been studied .
H-100	-0.24236014485359192	The equivalent of taking 2,800 IU of vitamin D3 once a week in ADROVANCE and 400 IU of vitamin D once a day has not been investigated .
D-100	-0.24236014485359192	The equivalent of taking 2,800 IU of vitamin D3 once a week in ADROVANCE and 400 IU of vitamin D once a day has not been investigated .
P-100	-0.3889 -1.0389 -0.1753 -0.4994 -0.2754 -0.0984 -0.0939 -0.0814 -0.2623 -0.3156 -0.1068 -0.1636 -0.1494 -0.1589 -1.0528 -0.0798 -0.1501 -0.0564 -0.0788 -0.1292 -0.1052 -0.0736 -0.1859 -0.1610 -0.1700 -0.1030 -0.2011 -0.1136 -0.0768 -0.1155 -0.0709 -0.1450 -0.1029 -0.9200 -0.1073 -0.1125 -0.9903 -0.1852 -0.1571
S-646	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-646	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-646	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
D-646	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
P-646	-1.9254 -0.1469 -0.8558 -0.1732 -0.7988 -0.1788 -0.1978 -0.2112 -0.1280 -0.1943 -0.4741 -0.2595 -0.1306 -0.0634 -0.2325 -0.8626 -0.2143 -0.2332 -2.6348 -0.0865 -0.3994 -0.2021 -0.1040 -0.4306 -0.8849 -0.1497 -0.0639 -0.0843 -0.1420 -0.1919 -0.0427 -0.1043 -0.0429 -0.1073 -1.1661 -0.1301 -0.0341 -0.6341 -0.0335 -0.2749 -0.0145 -0.1578 -0.1540
S-820	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-820	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-820	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
D-820	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
P-820	-1.9254 -0.1469 -0.8558 -0.1732 -0.7988 -0.1788 -0.1978 -0.2112 -0.1280 -0.1943 -0.4741 -0.2595 -0.1306 -0.0634 -0.2325 -0.8626 -0.2143 -0.2332 -2.6348 -0.0865 -0.3994 -0.2021 -0.1040 -0.4306 -0.8849 -0.1497 -0.0639 -0.0843 -0.1420 -0.1919 -0.0427 -0.1043 -0.0429 -0.1073 -1.1661 -0.1301 -0.0341 -0.6341 -0.0335 -0.2749 -0.0145 -0.1578 -0.1540
S-1703	ADVATE 3000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1703	ADVATE 3000 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1703	-0.26148709654808044	ADVATE 3000 IU powder and solvent for solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
D-1703	-0.26148709654808044	ADVATE 3000 IU powder and solvent for solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
P-1703	-0.0936 -0.1525 -0.0889 -0.0860 -0.0527 -0.1170 -0.1129 -0.6433 -0.1673 -0.1958 -0.1948 -0.3927 -2.2080 -0.1585 -0.1436 -0.0577 -0.3478 -0.1156 -0.1252 -0.2240 -0.1344 -0.0650 -0.1502 -0.1889 -0.1603 -0.0984 -0.0980 -0.1381 -1.4169 -0.7982 -0.0460 -0.0701 -0.0561 -0.1516 -0.0870 -0.1357 -0.2024
S-1172	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-1172	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-1172	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
D-1172	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
P-1172	-1.9254 -0.1469 -0.8558 -0.1732 -0.7988 -0.1788 -0.1978 -0.2112 -0.1280 -0.1943 -0.4741 -0.2595 -0.1306 -0.0634 -0.2325 -0.8626 -0.2143 -0.2332 -2.6348 -0.0865 -0.3994 -0.2021 -0.1040 -0.4306 -0.8849 -0.1497 -0.0639 -0.0843 -0.1420 -0.1919 -0.0427 -0.1043 -0.0429 -0.1073 -1.1661 -0.1301 -0.0341 -0.6341 -0.0335 -0.2749 -0.0145 -0.1578 -0.1540
S-1348	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-1348	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-1348	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
D-1348	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
P-1348	-1.9254 -0.1469 -0.8558 -0.1732 -0.7988 -0.1788 -0.1978 -0.2112 -0.1280 -0.1943 -0.4741 -0.2595 -0.1306 -0.0634 -0.2325 -0.8626 -0.2143 -0.2332 -2.6348 -0.0865 -0.3994 -0.2021 -0.1040 -0.4306 -0.8849 -0.1497 -0.0639 -0.0843 -0.1420 -0.1919 -0.0427 -0.1043 -0.0429 -0.1073 -1.1661 -0.1301 -0.0341 -0.6341 -0.0335 -0.2749 -0.0145 -0.1578 -0.1540
S-996	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-996	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-996	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
D-996	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
P-996	-1.9254 -0.1469 -0.8558 -0.1732 -0.7988 -0.1788 -0.1978 -0.2112 -0.1280 -0.1943 -0.4741 -0.2595 -0.1306 -0.0634 -0.2325 -0.8626 -0.2143 -0.2332 -2.6348 -0.0865 -0.3994 -0.2021 -0.1040 -0.4306 -0.8849 -0.1497 -0.0639 -0.0843 -0.1420 -0.1919 -0.0427 -0.1043 -0.0429 -0.1073 -1.1661 -0.1301 -0.0341 -0.6341 -0.0335 -0.2749 -0.0145 -0.1578 -0.1540
S-1525	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-1525	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-1525	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
D-1525	-0.3616501986980438	Patients &quot; immune response to traces of contaminating proteins was analysed by examining antibody titers against these proteins , laboratory parameters , and reported adverse reactions .
P-1525	-1.9254 -0.1469 -0.8558 -0.1732 -0.7988 -0.1788 -0.1978 -0.2112 -0.1280 -0.1943 -0.4741 -0.2595 -0.1306 -0.0634 -0.2325 -0.8626 -0.2143 -0.2332 -2.6348 -0.0865 -0.3994 -0.2021 -0.1040 -0.4306 -0.8849 -0.1497 -0.0639 -0.0843 -0.1420 -0.1919 -0.0427 -0.1043 -0.0429 -0.1073 -1.1661 -0.1301 -0.0341 -0.6341 -0.0335 -0.2749 -0.0145 -0.1578 -0.1540
S-1720	ADVATE 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1720	ADVATE 250 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1720	-0.2798584997653961	ADVATE 250 IU powder and solvent for the preparation of a solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
D-1720	-0.2798584997653961	ADVATE 250 IU powder and solvent for the preparation of a solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
P-1720	-0.0636 -0.1464 -0.0864 -0.0859 -0.0873 -0.1200 -0.0979 -0.8570 -0.1684 -0.2078 -0.2047 -0.3919 -1.3810 -1.3004 -0.1281 -0.9031 -0.0225 -0.1254 -0.0909 -0.0481 -0.2792 -0.1192 -0.1276 -0.2285 -0.1371 -0.0677 -0.1455 -0.2269 -0.1502 -0.0993 -0.0978 -0.1372 -1.5265 -0.9089 -0.0446 -0.0683 -0.0590 -0.1488 -0.0817 -0.1343 -0.1693
S-1360	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-1360	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-1360	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
D-1360	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
P-1360	-0.7143 -1.2679 -0.1381 -0.1316 -0.2921 -0.1499 -0.0605 -0.1517 -2.1100 -0.2629 -0.4690 -0.2470 -0.0769 -0.0754 -0.4260 -0.4598 -0.1353 -0.2793 -0.9603 -0.2235 -0.1355 -0.5617 -0.2596 -0.1028 -0.1038 -0.0549 -0.4757 -0.2541 -0.1332 -0.4105 -0.1370 -0.2287 -0.2414 -0.4308 -0.0693 -0.0597 -0.1835 -0.1563
S-1896	Aerinaze ist ein Arzneimittel , das die arzneilich wirksamen Bestandteile Desloratadin ( 2,5 mg ) und Pseudoephedrin ( 120 mg ) enthält .
T-1896	Aerinaze is a medicine containing the active substances desloratadine ( 2.5 mg ) and pseudoephedrine ( 120 mg ) .
H-1896	-0.20013779401779175	Aerinaze is a medicine containing the active ingredients desloratadine ( 2.5 mg ) and pseudoephedrine ( 120 mg ) .
D-1896	-0.20013779401779175	Aerinaze is a medicine containing the active ingredients desloratadine ( 2.5 mg ) and pseudoephedrine ( 120 mg ) .
P-1896	-0.1501 -0.1344 -0.1479 -0.1260 -0.0983 -0.1541 -0.1345 -0.8897 -1.1804 -0.2168 -0.0195 -0.1412 -0.4786 -0.0620 -0.1177 -0.1897 -0.4317 -0.1290 -0.3174 -0.0440 -0.1328 -0.1481 -0.0792 -0.1742 -0.1513 -0.0678 -0.1245 -0.1366 -0.1114 -0.1442 -0.0855 -0.0419 -0.1261 -0.1591 -0.1590
S-1537	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-1537	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-1537	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
D-1537	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
P-1537	-0.7143 -1.2679 -0.1381 -0.1316 -0.2921 -0.1499 -0.0605 -0.1517 -2.1100 -0.2629 -0.4690 -0.2470 -0.0769 -0.0754 -0.4260 -0.4598 -0.1353 -0.2793 -0.9603 -0.2235 -0.1355 -0.5617 -0.2596 -0.1028 -0.1038 -0.0549 -0.4757 -0.2541 -0.1332 -0.4105 -0.1370 -0.2287 -0.2414 -0.4308 -0.0693 -0.0597 -0.1835 -0.1563
S-343	Tierstudien mit Alendronat lassen keinen Hinweis auf direkt schädigende Wirkungen im Hinblick auf die Schwangerschaft , die embryonale<unk> fetale oder postnatale Entwicklung erkennen .
T-343	Animal studies with alendronate do not indicate direct harmful effects with respect to pregnancy , embryonal/ foetal development , or postnatal development .
H-343	-0.40478217601776123	Animal studies of alendronate show no evidence of direct adverse effects on pregnancy , embryonic or postnatal development .
D-343	-0.40478217601776123	Animal studies of alendronate show no evidence of direct adverse effects on pregnancy , embryonic or postnatal development .
P-343	-1.1298 -0.0909 -0.1337 -0.3278 -0.1100 -0.1084 -0.1177 -0.1470 -1.1361 -0.0670 -0.1093 -0.2171 -1.8288 -0.6391 -0.0979 -0.1892 -0.8619 -0.0923 -0.1455 -0.8323 -0.0754 -0.1380 -0.3045 -1.6324 -0.5552 -0.4130 -0.1300 -0.1767 -0.1846 -0.1518
S-1184	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-1184	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-1184	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
D-1184	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
P-1184	-0.7143 -1.2679 -0.1381 -0.1316 -0.2921 -0.1499 -0.0605 -0.1517 -2.1100 -0.2629 -0.4690 -0.2470 -0.0769 -0.0754 -0.4260 -0.4598 -0.1353 -0.2793 -0.9603 -0.2235 -0.1355 -0.5617 -0.2596 -0.1028 -0.1038 -0.0549 -0.4757 -0.2541 -0.1332 -0.4105 -0.1370 -0.2287 -0.2414 -0.4308 -0.0693 -0.0597 -0.1835 -0.1563
S-1008	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-1008	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-1008	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
D-1008	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
P-1008	-0.7143 -1.2679 -0.1381 -0.1316 -0.2921 -0.1499 -0.0605 -0.1517 -2.1100 -0.2629 -0.4690 -0.2470 -0.0769 -0.0754 -0.4260 -0.4598 -0.1353 -0.2793 -0.9603 -0.2235 -0.1355 -0.5617 -0.2596 -0.1028 -0.1038 -0.0549 -0.4757 -0.2541 -0.1332 -0.4105 -0.1370 -0.2287 -0.2414 -0.4308 -0.0693 -0.0597 -0.1835 -0.1563
S-832	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-832	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-832	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
D-832	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
P-832	-0.7143 -1.2679 -0.1381 -0.1316 -0.2921 -0.1499 -0.0605 -0.1517 -2.1100 -0.2629 -0.4690 -0.2470 -0.0769 -0.0754 -0.4260 -0.4598 -0.1353 -0.2793 -0.9603 -0.2235 -0.1355 -0.5617 -0.2596 -0.1028 -0.1038 -0.0549 -0.4757 -0.2541 -0.1332 -0.4105 -0.1370 -0.2287 -0.2414 -0.4308 -0.0693 -0.0597 -0.1835 -0.1563
S-657	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-657	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-657	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
D-657	-0.33237096667289734	When octocog alfa is given to a haemophilia A patient , it binds to the endogenous von Willebrand factor in the bloodstream .
P-657	-0.7143 -1.2679 -0.1381 -0.1316 -0.2921 -0.1499 -0.0605 -0.1517 -2.1100 -0.2629 -0.4690 -0.2470 -0.0769 -0.0754 -0.4260 -0.4598 -0.1353 -0.2793 -0.9603 -0.2235 -0.1355 -0.5617 -0.2596 -0.1028 -0.1038 -0.0549 -0.4757 -0.2541 -0.1332 -0.4105 -0.1370 -0.2287 -0.2414 -0.4308 -0.0693 -0.0597 -0.1835 -0.1563
S-155	Tierstudien mit Alendronat lassen keinen Hinweis auf direkt schädigende Wirkungen im Hinblick auf die Schwangerschaft , die embryonale<unk> fetale oder postnatale Entwicklung erkennen .
T-155	Animal studies with alendronate do not indicate direct harmful effects with respect to pregnancy , embryonal/ foetal development , or postnatal development .
H-155	-0.40478217601776123	Animal studies of alendronate show no evidence of direct adverse effects on pregnancy , embryonic or postnatal development .
D-155	-0.40478217601776123	Animal studies of alendronate show no evidence of direct adverse effects on pregnancy , embryonic or postnatal development .
P-155	-1.1298 -0.0909 -0.1337 -0.3278 -0.1100 -0.1084 -0.1177 -0.1470 -1.1361 -0.0670 -0.1093 -0.2171 -1.8288 -0.6391 -0.0979 -0.1892 -0.8619 -0.0923 -0.1455 -0.8323 -0.0754 -0.1380 -0.3045 -1.6324 -0.5552 -0.4130 -0.1300 -0.1767 -0.1846 -0.1518
S-1892	Das Unternehmen setzte den CHMP nicht davon in Kenntnis , ob die Rücknahme Konsequenzen für Patienten hat , die derzeit an klinischen Studien oder Compassionate-Use -Programmen mit Advexin teilnehmen .
T-1892	The company did not inform the CHMP whether there were any consequences of the withdrawal for patients in clinical trials or compassionate use programmes with Advexin .
H-1892	-0.5594437122344971	The company did not notify the CHMP whether the withdrawal has consequences for patients currently participating in clinical trials or Compassion Use Programmes with Advexin .
D-1892	-0.5594437122344971	The company did not notify the CHMP whether the withdrawal has consequences for patients currently participating in clinical trials or Compassion Use Programmes with Advexin .
P-1892	-0.3184 -0.5082 -0.8467 -0.1344 -2.0142 -0.0944 -1.3814 -0.0934 -0.0483 -0.7157 -0.4639 -0.3894 -1.0986 -0.7819 -0.1711 -0.4291 -0.5572 -0.9751 -0.1000 -0.1263 -0.1471 -0.1053 -0.1482 -1.1880 -1.1807 -0.2291 -2.5973 -0.0996 -0.9550 -0.5131 -0.1517 -0.1301 -0.1699 -0.1581
S-1455	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-1455	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-1455	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
D-1455	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
P-1455	-1.9964 -0.1931 -0.3016 -0.1396 -1.6275 -0.1645 -0.1169 -0.1673 -0.6814 -0.1836 -0.1865 -0.1206 -0.3590 -0.2572 -0.4660 -0.2081 -0.1024 -1.0082 -0.0938 -0.1347 -0.1942 -0.4158 -0.1770 -0.1477 -0.1159 -0.1335 -1.0532 -0.8174 -0.6410 -0.1341 -0.2648 -0.0515 -0.4016 -0.0224 -0.0359 -0.0874 -1.3834 -1.6635 -0.3388 -0.1588
S-1279	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-1279	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-1279	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
D-1279	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
P-1279	-1.9964 -0.1931 -0.3016 -0.1396 -1.6275 -0.1645 -0.1169 -0.1673 -0.6814 -0.1836 -0.1865 -0.1206 -0.3590 -0.2572 -0.4660 -0.2081 -0.1024 -1.0082 -0.0938 -0.1347 -0.1942 -0.4158 -0.1770 -0.1477 -0.1159 -0.1335 -1.0532 -0.8174 -0.6410 -0.1341 -0.2648 -0.0515 -0.4016 -0.0224 -0.0359 -0.0874 -1.3834 -1.6635 -0.3388 -0.1588
S-1740	Besondere Vorsicht bei der Anwendung von ADVATE ist erforderlich Sie sollten Ihren Arzt informieren , wenn Sie kürzlich mit Faktor VIII-Produkten behandelt wurden , besonders wenn Sie Inhibitoren entwickelt haben .
T-1740	Take special care with ADVATE You should tell your doctor if you have been previously treated with Factor VIII products , especially if you developed inhibitors , since there might be a higher risk that it happens again .
H-1740	-0.35507869720458984	Special care should be taken when using ADVATE You should tell your doctor if you have recently been treated with Factor VIII products , especially if you have developed inhibitors .
D-1740	-0.35507869720458984	Special care should be taken when using ADVATE You should tell your doctor if you have recently been treated with Factor VIII products , especially if you have developed inhibitors .
P-1740	-0.6255 -1.6131 -1.3953 -0.1607 -0.7163 -0.2897 -0.3713 -0.0823 -0.1550 -0.0895 -0.0952 -1.1878 -0.1377 -0.4004 -0.1304 -0.1448 -0.0918 -0.1114 -0.3511 -1.0504 -0.0810 -0.1381 -0.1618 -0.3093 -0.3920 -0.4755 -1.0867 -0.1408 -0.1582 -0.2089 -0.1069 -0.0892 -0.2815 -0.5446 -0.1912 -0.0642 -0.0743 -0.1493 -0.1874 -0.1630
S-1900	Bei Erwachsenen und Jugendlichen ab 12 Jahren ist die empfohlene Dosis von Aerinaze zweimal täglich eine Tablette , die ganz mit einem Glas Wasser mit oder ohne Nahrung eingenommen werden soll .
T-1900	In adults and adolescents over 12 years of age , the recommended dose of Aerinaze is one tablet twice a day , taken whole with a full glass of water , with or without food .
H-1900	-0.38920193910598755	In adults and adolescents aged 12 years and over , the recommended dose of Aerinaze 2 times daily is a tablet to be taken whole with a glass of water with or without food .
D-1900	-0.38920193910598755	In adults and adolescents aged 12 years and over , the recommended dose of Aerinaze 2 times daily is a tablet to be taken whole with a glass of water with or without food .
P-1900	-0.4011 -0.6720 -0.1483 -0.1538 -0.0572 -0.0361 -1.6163 -0.0888 -1.0217 -0.1682 -0.3899 -0.1718 -0.1725 -0.2375 -0.0691 -0.1192 -0.1483 -0.1306 -0.1487 -0.1446 -0.1079 -1.5099 -0.2987 -0.5011 -0.1619 -1.3515 -0.1829 -0.1094 -0.9638 -0.1732 -0.2794 -3.3222 -0.2008 -0.1439 -0.0416 -0.1221 -0.1069 -0.4758 -0.1371 -0.0901 -0.0539 -0.1477 -0.1581
S-1842	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <unk> 371 67 784 784
T-1842	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <<unk>> 371 67 784 784
H-1842	-0.11336015164852142	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <unk> 371 67 784 784
D-1842	-0.11336015164852142	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <unk> 371 67 784 784
P-1842	-0.0761 -0.0787 -0.0737 -0.0799 -0.1491 -0.1224 -0.1045 -0.1089 -0.0652 -0.0805 -0.1845 -0.1335 -0.1207 -0.1214 -0.1227 -0.1409 -0.1004 -0.1369 -0.0766 -0.1511 -0.0468 -0.1273 -0.1038 -0.0889 -0.0656 -0.1470 -0.1385 -0.1298 -0.1324 -0.1933 -0.1216 -0.0540 -0.2665 -0.1423 -0.0349 -0.1489 -0.0735 -0.0638 -0.1255 -0.0679 -0.1374 -0.0728 -0.1646
S-79	Bei Patienten mit etwaiger Überempfindlichkeit ( Allergie ) gegen Alendronat , Vitamin D3 oder einen der sonstigen Bestandteile darf ADROVANCE nicht angewendet werden .
T-79	ADROVANCE should not be used in people who may be hypersensitive ( allergic ) to alendronate , vitamin D3 or any of the other ingredients .
H-79	-0.2517963945865631	In patients with possible hypersensitivity ( allergy ) to alendronate , vitamin D3 or any of the ingredients , ADROVANCE should not be used .
D-79	-0.2517963945865631	In patients with possible hypersensitivity ( allergy ) to alendronate , vitamin D3 or any of the ingredients , ADROVANCE should not be used .
P-79	-1.7504 -0.2107 -0.3424 -1.2357 -0.0793 -0.0628 -0.0475 -0.2266 -0.1912 -0.1373 -0.2056 -0.1607 -0.1449 -0.1082 -0.1109 -0.1988 -0.0864 -0.1447 -0.1299 -0.0819 -0.1528 -0.1374 -0.4293 -0.2784 -0.1429 -0.1928 -0.3591 -0.4266 -0.1900 -0.0534 -0.1265 -0.1012 -0.0850 -0.6390 -0.1432 -0.1322 -0.1932 -0.2203 -0.1610
S-577	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-577	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-577	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
D-577	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
P-577	-1.9964 -0.1931 -0.3016 -0.1396 -1.6275 -0.1645 -0.1169 -0.1673 -0.6814 -0.1836 -0.1865 -0.1206 -0.3590 -0.2572 -0.4660 -0.2081 -0.1024 -1.0082 -0.0938 -0.1347 -0.1942 -0.4158 -0.1770 -0.1477 -0.1159 -0.1335 -1.0532 -0.8174 -0.6410 -0.1341 -0.2648 -0.0515 -0.4016 -0.0224 -0.0359 -0.0874 -1.3834 -1.6635 -0.3388 -0.1588
S-1103	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-1103	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-1103	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
D-1103	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
P-1103	-1.9964 -0.1931 -0.3016 -0.1396 -1.6275 -0.1645 -0.1169 -0.1673 -0.6814 -0.1836 -0.1865 -0.1206 -0.3590 -0.2572 -0.4660 -0.2081 -0.1024 -1.0082 -0.0938 -0.1347 -0.1942 -0.4158 -0.1770 -0.1477 -0.1159 -0.1335 -1.0532 -0.8174 -0.6410 -0.1341 -0.2648 -0.0515 -0.4016 -0.0224 -0.0359 -0.0874 -1.3834 -1.6635 -0.3388 -0.1588
S-927	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-927	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-927	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
D-927	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
P-927	-1.9964 -0.1931 -0.3016 -0.1396 -1.6275 -0.1645 -0.1169 -0.1673 -0.6814 -0.1836 -0.1865 -0.1206 -0.3590 -0.2572 -0.4660 -0.2081 -0.1024 -1.0082 -0.0938 -0.1347 -0.1942 -0.4158 -0.1770 -0.1477 -0.1159 -0.1335 -1.0532 -0.8174 -0.6410 -0.1341 -0.2648 -0.0515 -0.4016 -0.0224 -0.0359 -0.0874 -1.3834 -1.6635 -0.3388 -0.1588
S-751	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-751	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-751	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
D-751	-0.4186636507511139	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for 3 -4 days or longer until pain and acute impairment are resolved .
P-751	-1.9964 -0.1931 -0.3016 -0.1396 -1.6275 -0.1645 -0.1169 -0.1673 -0.6814 -0.1836 -0.1865 -0.1206 -0.3590 -0.2572 -0.4660 -0.2081 -0.1024 -1.0082 -0.0938 -0.1347 -0.1942 -0.4158 -0.1770 -0.1477 -0.1159 -0.1335 -1.0532 -0.8174 -0.6410 -0.1341 -0.2648 -0.0515 -0.4016 -0.0224 -0.0359 -0.0874 -1.3834 -1.6635 -0.3388 -0.1588
S-1970	Bei Anwendung von leicht flüchtigen halogenierten Anästhetika während der Therapie mit indirekten Sympathomimetika kann es perioperativ zu einer akuten Hypertonie kommen .
T-1970	3 Perioperative acute hypertension can occur if volatile halogenated anaesthetics are used during treatment with indirect sympathomimetic agents .
H-1970	-0.324053019285202	Use of volatile halogenated anaesthetics during therapy with indirect sympathomimetics may result in perioperative acute hypertension .
D-1970	-0.324053019285202	Use of volatile halogenated anaesthetics during therapy with indirect sympathomimetics may result in perioperative acute hypertension .
P-1970	-2.3383 -0.1278 -1.1917 -0.1009 -0.0291 -0.1485 -0.1077 -0.0865 -0.1686 -0.1569 -0.2964 -0.0612 -0.2653 -2.1428 -0.1598 -0.1279 -0.1407 -0.0368 -0.0458 -0.0954 -0.0806 -0.2780 -0.5294 -0.1328 -0.3177 -0.5158 -0.2385 -0.0649 -0.0189 -0.0315 -0.1767 -0.1568
S-1874	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu
T-1874	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu
H-1874	-0.2238381952047348	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 Email : mail/ emea
D-1874	-0.2238381952047348	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 Email : mail/ emea
P-1874	-0.2191 -0.0930 -0.0691 -0.1119 -0.1258 -0.0722 -0.0988 -0.0676 -0.0949 -0.1396 -0.1422 -0.0911 -0.0492 -0.1111 -0.1211 -0.0647 -0.0750 -0.0897 -0.0929 -0.1658 -0.4461 -0.1574 -0.4840 -0.2720 -0.0332 -1.9634 -0.5929
S-66	Osteoporose tritt vor allem bei postmenopausalen Frauen ( nach der 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-66	Osteoporose tritt vor allem bei postmenopausalen Frauen ( nach der 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel. 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-66	-0.21906732022762299	osteoporosis primarily occurs in post-menopausal women ( after 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-66	-0.21906732022762299	osteoporosis primarily occurs in post-menopausal women ( after 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-66	-0.5036 -0.0820 -0.0878 -0.1106 -0.0762 -0.0911 -1.9616 -0.3150 -0.0571 -0.1474 -0.1722 -0.3103 -0.0965 -0.0944 -0.0547 -0.1151 -0.0981 -0.1558 -0.5257 -1.1941 -0.1040 -0.0844 -0.0625 -0.1610 -0.0640 -0.1353 -0.1131 -0.1814 -0.1163 -0.1166 -0.1180 -0.1374 -0.0918 -0.1239 -0.0865 -0.2090 -0.1752 -0.1084 -0.1386 -0.1389 -0.4142 -0.1414 -0.1489
S-21	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu
T-21	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu
H-21	-0.2260744422674179	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 Email : mail/ emea
D-21	-0.2260744422674179	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 Email : mail/ emea
P-21	-0.2236 -0.0944 -0.0724 -0.1141 -0.1260 -0.0725 -0.0978 -0.0675 -0.1022 -0.1415 -0.1452 -0.0979 -0.0538 -0.1131 -0.1204 -0.0677 -0.0966 -0.0459 -0.0679 -0.1470 -0.6260 -0.1542 -0.4261 -0.2612 -0.0334 -1.9191 -0.6167
S-530	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu
T-530	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu
H-530	-0.23333892226219177	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 Email : mail/ emea
D-530	-0.23333892226219177	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 Email : mail/ emea
P-530	-0.2255 -0.0928 -0.0740 -0.1124 -0.1257 -0.0742 -0.0976 -0.0752 -0.1000 -0.1421 -0.1446 -0.0972 -0.0551 -0.1131 -0.1210 -0.0697 -0.0916 -0.0611 -0.1244 -0.1524 -0.6406 -0.1572 -0.4622 -0.2701 -0.0346 -1.9753 -0.6104
S-1731	ADVATE enthält als arzneilich wirksamen Bestandteil Octocog alfa , Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie .
T-1731	ADVATE contains the active substance octocog alfa , human coagulation factor VIII produced by recombinant DNA technology .
H-1731	-0.3928138315677643	As a active substance , ADVATE contains human coagulation factor VIII , Octocog alfa , produced by recombinant DNA technology .
D-1731	-0.3928138315677643	As a active substance , ADVATE contains human coagulation factor VIII , Octocog alfa , produced by recombinant DNA technology .
P-1731	-1.3751 -0.4648 -1.7154 -1.3286 -0.2629 -0.0964 -0.1561 -0.0961 -0.1075 -0.0764 -1.1902 -1.3068 -0.0727 -0.2901 -0.0261 -0.1642 -0.0819 -0.4386 -0.8266 -0.1167 -0.1242 -0.2352 -0.1211 -0.0556 -0.3086 -1.1139 -0.7541 -0.1138 -0.0849 -0.0695 -0.1230 -0.0522 -0.0692 -0.1721 -0.1581
S-99	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell unter Berücksichtung der Vitamin-D-Aufnahme durch Vitaminpräparate und Nahrungsergänzungsmittel erwogen werden .
T-99	Additional supplementation with vitamin D should be considered on an individual basis taking into account any vitamin D intake from vitamins and dietary supplements .
H-99	-0.4020192325115204	Additional vitamin D supplementation should be considered individually , taking into account vitamin D uptake by vitamin supplements and supplements .
D-99	-0.4020192325115204	Additional vitamin D supplementation should be considered individually , taking into account vitamin D uptake by vitamin supplements and supplements .
P-99	-1.9865 -0.9011 -0.0617 -0.1325 -0.0471 -0.1116 -0.1132 -0.1534 -0.1445 -0.1702 -0.7129 -0.1550 -0.7840 -0.3147 -1.0553 -0.2798 -0.3787 -0.0584 -0.1359 -0.9724 -0.0368 -1.5109 -0.1370 -0.2043 -0.4496 -0.1168 -0.1968 -0.7551 -0.0765 -0.1555 -0.1542
S-1936	Blister ( PCTFE<unk> PVC<unk> Alu ) 20 Tabletten 2.5 mg Desloratadin<unk> 120 mg Pseudoephedrinsulphat 1<unk> 1
T-1936	1/ 1
H-1936	-0.2640123665332794	Blister ( PCTFE/ PVC/ alu ) 20 tablets 2.5 mg desloratadine / 120 mg pseudoephedrine sulphate 1/ 1
D-1936	-0.2640123665332794	Blister ( PCTFE/ PVC/ alu ) 20 tablets 2.5 mg desloratadine / 120 mg pseudoephedrine sulphate 1/ 1
P-1936	-0.6938 -0.0827 -0.1507 -0.1394 -0.1194 -0.1285 -0.1731 -0.2202 -0.1286 -0.1141 -0.1392 -0.2384 -1.0626 -0.1380 -0.1257 -0.1338 -0.1588 -0.0989 -0.6091 -0.0438 -0.6277 -0.0584 -0.1264 -0.0836 -1.2742 -0.5754 -0.1553 -0.0446 -0.1010 -0.2233 -0.1354 -0.0623 -0.1232 -0.1253 -0.1655 -0.1168 -0.3180 -0.1011 -0.8452 -0.1006 -0.8721 -0.1546
S-156	Alendronat , das an trächtige Ratten gegeben wurde , verursachte Dystokie , die mit einer Hypocalcämie in Zusammenhang stand ( siehe Abschnitt 5.3 ) .
T-156	Alendronate given during pregnancy in rats caused dystocia related to hypocalcaemia ( see section 5.3 ) .
H-156	-0.23300306499004364	Alendronate given to pregnant rats caused dystocia associated with hypocalcaemia ( see section 5.3 ) .
D-156	-0.23300306499004364	Alendronate given to pregnant rats caused dystocia associated with hypocalcaemia ( see section 5.3 ) .
P-156	-0.2894 -0.1193 -0.1121 -0.0806 -1.2642 -0.1956 -0.0868 -0.0804 -0.8710 -0.1523 -0.0725 -0.8814 -0.5939 -0.1453 -0.0465 -0.1198 -0.0280 -0.0270 -0.1291 -0.1425 -0.0952 -0.0837 -0.0921 -0.1255 -0.1309 -0.1656 -0.1605
S-344	Alendronat , das an trächtige Ratten gegeben wurde , verursachte Dystokie , die mit einer Hypocalcämie in Zusammenhang stand ( siehe Abschnitt 5.3 ) .
T-344	Alendronate given during pregnancy in rats caused dystocia related to hypocalcaemia ( see section 5.3 ) .
H-344	-0.23300306499004364	Alendronate given to pregnant rats caused dystocia associated with hypocalcaemia ( see section 5.3 ) .
D-344	-0.23300306499004364	Alendronate given to pregnant rats caused dystocia associated with hypocalcaemia ( see section 5.3 ) .
P-344	-0.2894 -0.1193 -0.1121 -0.0806 -1.2642 -0.1956 -0.0868 -0.0804 -0.8710 -0.1523 -0.0725 -0.8814 -0.5939 -0.1453 -0.0465 -0.1198 -0.0280 -0.0270 -0.1291 -0.1425 -0.0952 -0.0837 -0.0921 -0.1255 -0.1309 -0.1656 -0.1605
S-887	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-887	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-887	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-887	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-887	-1.4471 -0.0849 -0.6260 -0.1548 -0.0961 -0.0992 -0.3319 -1.4592 -0.3360 -0.0482 -0.0926 -0.7915 -0.5865 -0.3805 -1.1862 -0.3440 -0.0655 -0.1044 -0.0900 -0.3614 -0.1592 -0.1454 -1.1139 -0.2280 -0.1762 -0.6912 -0.3095 -0.5252 -0.1787 -0.2022 -0.1053 -0.1201 -0.1028 -0.1909 -0.1714
S-1063	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-1063	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-1063	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-1063	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-1063	-1.4471 -0.0849 -0.6260 -0.1548 -0.0961 -0.0992 -0.3319 -1.4592 -0.3360 -0.0482 -0.0926 -0.7915 -0.5865 -0.3805 -1.1862 -0.3440 -0.0655 -0.1044 -0.0900 -0.3614 -0.1592 -0.1454 -1.1139 -0.2280 -0.1762 -0.6912 -0.3095 -0.5252 -0.1787 -0.2022 -0.1053 -0.1201 -0.1028 -0.1909 -0.1714
S-1239	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-1239	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-1239	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-1239	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-1239	-1.4471 -0.0849 -0.6260 -0.1548 -0.0961 -0.0992 -0.3319 -1.4592 -0.3360 -0.0482 -0.0926 -0.7915 -0.5865 -0.3805 -1.1862 -0.3440 -0.0655 -0.1044 -0.0900 -0.3614 -0.1592 -0.1454 -1.1139 -0.2280 -0.1762 -0.6912 -0.3095 -0.5252 -0.1787 -0.2022 -0.1053 -0.1201 -0.1028 -0.1909 -0.1714
S-1415	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-1415	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-1415	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-1415	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-1415	-1.4471 -0.0849 -0.6260 -0.1548 -0.0961 -0.0992 -0.3319 -1.4592 -0.3360 -0.0482 -0.0926 -0.7915 -0.5865 -0.3805 -1.1862 -0.3440 -0.0655 -0.1044 -0.0900 -0.3614 -0.1592 -0.1454 -1.1139 -0.2280 -0.1762 -0.6912 -0.3095 -0.5252 -0.1787 -0.2022 -0.1053 -0.1201 -0.1028 -0.1909 -0.1714
S-711	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-711	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-711	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-711	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-711	-1.4471 -0.0849 -0.6260 -0.1548 -0.0961 -0.0992 -0.3319 -1.4592 -0.3360 -0.0482 -0.0926 -0.7915 -0.5865 -0.3805 -1.1862 -0.3440 -0.0655 -0.1044 -0.0900 -0.3614 -0.1592 -0.1454 -1.1139 -0.2280 -0.1762 -0.6912 -0.3095 -0.5252 -0.1787 -0.2022 -0.1053 -0.1201 -0.1028 -0.1909 -0.1714
S-275	Therapie der postmenopausalen Osteoporose bei Patienten mit Risiko für einen Vitamin-D-Mangel , die keine zusätzliche Vitamin-D-Supplementierung erhalten .
T-275	Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin D supplementation and are at risk of vitamin D insufficiency .
H-275	-0.25613993406295776	Treatment of post-menopausal osteoporosis in patients at risk for vitamin D deficiency who are not receiving additional vitamin D supplementation .
D-275	-0.25613993406295776	Treatment of post-menopausal osteoporosis in patients at risk for vitamin D deficiency who are not receiving additional vitamin D supplementation .
P-275	-2.1707 -0.0679 -0.1099 -0.1234 -0.0735 -0.5906 -0.0645 -0.0905 -0.0297 -0.1181 -0.1846 -0.0908 -0.1009 -0.1290 -0.0895 -0.0798 -0.1255 -0.5404 -0.1287 -0.1469 -1.0428 -0.3115 -0.0470 -0.1117 -0.0327 -0.0573 -0.1359 -0.0936 -1.3219 -0.6792 -0.0123 -0.3370 -0.2724 -0.0493 -0.1239 -0.0378 -0.0269 -0.1025 -0.2394 -0.1555
S-452	Es wurden keine Hinweise auf eine Sättigung der Aufnahmefähigkeit des Knochens nach Langzeitdosierung von kumulativen intravenösen Dosen bis zu 35 mg<unk> kg bei Tieren gefunden .
T-452	No evidence of saturation of bone uptake was found after chronic dosing with cumulative intravenous doses up to 35 mg/ kg in animals .
H-452	-0.38304194808006287	No evidence was found of bone saturation after long-term doses of cumulative intravenous doses of up to 35 mg/ kg in animals .
D-452	-0.38304194808006287	No evidence was found of bone saturation after long-term doses of cumulative intravenous doses of up to 35 mg/ kg in animals .
P-452	-0.4980 -0.0221 -1.1831 -0.2506 -0.8464 -0.4262 -2.1640 -0.0748 -0.1505 -0.6981 -1.9813 -0.2160 -0.1142 -0.2981 -0.7667 -0.1640 -0.1194 -0.0642 -0.1169 -0.2049 -0.0908 -0.0880 -0.1131 -0.2766 -0.0721 -1.3121 -0.5270 -0.1235 -0.1403 -0.1355 -0.1546 -0.1228 -0.0715 -0.1570 -0.1003 -0.1728 -0.1551
S-82	Am 4. Januar2007 erteilte die Europäische Kommission dem Unternehmen Merck Sharp <unk> Dohme Ltd. eine Genehmigung für das Inverkehrbringen von ADROVANCE in der gesamten Europäischen Union .
T-82	The European Commission granted a marketing authorisation valid throughout the European Union for ADROVANCE to Merck Sharp <<unk>> Dohme Ltd. on 4 January 2007.
H-82	-0.30715212225914	On 4 January 2007 , the European Commission authorised Merck Sharp <unk> Dohme Ltd to market ADROVANCE throughout the European Union .
D-82	-0.30715212225914	On 4 January 2007 , the European Commission authorised Merck Sharp <unk> Dohme Ltd to market ADROVANCE throughout the European Union .
P-82	-0.4668 -0.8226 -0.5046 -0.1207 -0.5811 -0.1642 -0.1752 -0.1322 -1.2480 -0.1655 -0.3988 -0.1161 -0.0845 -0.1481 -0.2993 -0.1490 -0.1908 -0.2579 -0.9383 -0.9156 -0.1060 -0.0646 -0.1284 -0.1132 -0.0930 -0.2597 -0.1543 -0.2112 -0.1860 -0.1668 -0.1592
S-524	Patienten mit Hämophilie A leiden an einem Faktor VIII-Mangel , was Blutgerinnungsprobleme wie Blutungen in den Gelenken , Muskeln oder inneren Organen verursacht .
T-524	Patients with haemophilia A lack factor VIII , and this causes blood coagulation problems , such as bleeding in the joints , muscles or internal organs .
H-524	-0.3718058466911316	Patients with haemophilia A suffer from factor VIII deficiency , which causes blood clotting problems such as bleeding in joints , muscles or internal organs .
D-524	-0.3718058466911316	Patients with haemophilia A suffer from factor VIII deficiency , which causes blood clotting problems such as bleeding in joints , muscles or internal organs .
P-524	-1.7802 -0.1001 -0.1284 -0.1742 -0.0525 -0.0601 -0.0467 -0.1427 -0.8886 -0.1690 -1.7462 -0.6990 -0.7938 -0.9334 -0.0664 -0.0458 -0.0951 -0.3996 -0.4780 -0.2497 -0.7081 -0.3883 -0.1082 -0.1652 -0.1995 -0.4863 -0.1454 -0.3607 -0.0949 -0.1866 -1.0319 -0.0259 -0.1461 -0.1344 -0.9503 -0.1127 -0.1313 -0.1172 -0.1746 -0.1550
S-534	In der Hauptstudie wurde die Wirksamkeit von Advate bei der Vorbeugung von Blutungen in 86 % von 510 neuen Blutungsepisoden mit ausgezeichnet bzw. mit gut bewertet .
T-534	In the main study , the effectiveness of Advate in the prevention of bleeding was rated as excellent or good in 86 % of the 510 new bleeding episodes .
H-534	-0.48029839992523193	In the main study , the efficacy of Advate in preventing bleeding in 86 % of 510 new bleeding episodes was excellent or well evaluated .
D-534	-0.48029839992523193	In the main study , the efficacy of Advate in preventing bleeding in 86 % of 510 new bleeding episodes was excellent or well evaluated .
P-534	-1.1134 -0.2255 -0.2330 -0.9305 -0.2301 -2.3425 -0.7960 -0.0468 -0.0798 -0.1232 -0.2755 -0.0963 -0.1753 -0.0958 -0.8625 -0.2015 -1.2063 -0.0628 -0.1123 -0.1390 -0.3320 -0.1469 -0.3366 -0.5825 -0.1894 -0.0145 -0.2488 -2.9021 -0.4820 -0.5164 -0.7926 -0.1038 -0.1779 -0.1565
S-1592	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-1592	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-1592	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-1592	-0.3744468688964844	Make sure ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-1592	-1.4471 -0.0849 -0.6260 -0.1548 -0.0961 -0.0992 -0.3319 -1.4592 -0.3360 -0.0482 -0.0926 -0.7915 -0.5865 -0.3805 -1.1862 -0.3440 -0.0655 -0.1044 -0.0900 -0.3614 -0.1592 -0.1454 -1.1139 -0.2280 -0.1762 -0.6912 -0.3095 -0.5252 -0.1787 -0.2022 -0.1053 -0.1201 -0.1028 -0.1909 -0.1714
S-244	Die Bioverfügbarkeit von 2.800 I.E. Vitamin D3 in ADROVANCE ist der von allein eingenommenem 2.800 I.E. Vitamin D3 vergleichbar .
T-244	The bioavailability of the 2800 IU vitamin D3 in ADROVANCE is similar to 2800 IU vitamin D3 administered alone .
H-244	-0.234659343957901	The bioavailability of 2,800 IU of vitamin D3 in ADROVANCE is comparable to that of 2,800 IU of vitamin D3 alone .
D-244	-0.234659343957901	The bioavailability of 2,800 IU of vitamin D3 in ADROVANCE is comparable to that of 2,800 IU of vitamin D3 alone .
P-244	-0.2766 -0.0974 -0.1113 -0.1348 -0.4156 -0.1056 -0.0986 -0.1222 -0.3207 -0.1750 -0.1329 -0.1560 -0.1537 -0.1539 -0.0521 -0.0687 -0.1315 -0.0937 -0.0690 -0.1666 -0.8125 -0.1196 -0.2259 -1.1990 -0.2442 -0.3503 -0.1045 -0.1268 -0.1409 -0.2325 -0.2945 -0.1094 -0.1525 -0.1451 -1.0670 -0.1615 -0.1601
S-451	Charakteristika bei Patienten Präklinische Studien haben gezeigt , dass der Anteil von Alendronat , der nicht im Knochen abgelagert wird , schnell über den Urin ausgeschieden wird .
T-451	Characteristics in patients Preclinical studies show that alendronate that is not deposited in bone is rapidly excreted in the urine .
H-451	-0.3458425998687744	Characteristics in patients Preclinical studies have shown that the proportion of alendronate not deposited in the bone is rapidly excreted via urine .
D-451	-0.3458425998687744	Characteristics in patients Preclinical studies have shown that the proportion of alendronate not deposited in the bone is rapidly excreted via urine .
P-451	-1.4708 -0.0730 -0.0704 -0.4427 -0.1273 -0.2920 -0.8135 -0.3742 -0.2700 -0.2075 -0.1817 -0.6844 -0.2483 -0.2310 -0.1585 -0.6048 -0.8263 -0.1236 -0.1082 -0.1058 -0.1267 -0.0598 -0.5260 -0.2920 -0.0870 -0.1596 -1.0757 -0.1236 -0.1868 -0.8624 -0.2363 -0.0226 -0.0544 -0.9841 -0.5290 -0.0764 -0.1687 -0.1570
S-255	Charakteristika bei Patienten Präklinische Studien haben gezeigt , dass der Anteil von Alendronat , der nicht im Knochen abgelagert wird , schnell über den Urin ausgeschieden wird .
T-255	Characteristics in patients Preclinical studies show that alendronate that is not deposited in bone is rapidly excreted in the urine .
H-255	-0.3458425998687744	Characteristics in patients Preclinical studies have shown that the proportion of alendronate not deposited in the bone is rapidly excreted via urine .
D-255	-0.3458425998687744	Characteristics in patients Preclinical studies have shown that the proportion of alendronate not deposited in the bone is rapidly excreted via urine .
P-255	-1.4708 -0.0730 -0.0704 -0.4427 -0.1273 -0.2920 -0.8135 -0.3742 -0.2700 -0.2075 -0.1817 -0.6844 -0.2483 -0.2310 -0.1585 -0.6048 -0.8263 -0.1236 -0.1082 -0.1058 -0.1267 -0.0598 -0.5260 -0.2920 -0.0870 -0.1596 -1.0757 -0.1236 -0.1868 -0.8624 -0.2363 -0.0226 -0.0544 -0.9841 -0.5290 -0.0764 -0.1687 -0.1570
S-440	Die Bioverfügbarkeit von 5.600 I.E. Vitamin D3 in ADROVANCE ist der von allein eingenommenem 5.600 I.E. Vitamin D3 vergleichbar .
T-440	The bioavailability of the 5600 IU vitamin D3 in ADROVANCE is similar to 5600 IU vitamin D3 administered alone .
H-440	-0.24552878737449646	The bioavailability of 5,600 IU of vitamin D3 in ADROVANCE is comparable to that of 5,600 IU of vitamin D3 alone .
D-440	-0.24552878737449646	The bioavailability of 5,600 IU of vitamin D3 in ADROVANCE is comparable to that of 5,600 IU of vitamin D3 alone .
P-440	-0.2726 -0.1009 -0.1137 -0.1372 -0.3866 -0.0902 -0.0991 -0.1085 -0.3151 -0.1681 -0.1333 -0.1578 -0.1557 -0.1534 -0.0499 -0.0681 -0.1303 -0.0945 -0.0688 -0.1681 -0.8336 -0.1199 -0.2272 -1.3789 -0.2630 -0.5470 -0.0815 -0.1318 -0.1320 -0.2371 -0.2621 -0.1077 -0.1520 -0.1434 -1.1739 -0.1619 -0.1594
S-423	20 eingenommen wurde . In Osteoporosestudien war Alendronat wirksam , wenn es mindestens 30 Minuten vor dem ersten Essen oder Trinken des Tages eingenommen wurde .
T-423	In osteoporosis studies , alendronate was effective when administered at least 30 minutes before the first food or beverage of the day .
H-423	-0.2732032835483551	20 . In osteoporosis studies , alendronate was effective when taken at least 30 minutes before the first meal or drink of the day .
D-423	-0.2732032835483551	20 . In osteoporosis studies , alendronate was effective when taken at least 30 minutes before the first meal or drink of the day .
P-423	-0.7129 -0.4070 -0.2373 -0.1397 -0.0729 -0.1011 -0.1528 -0.1289 -0.0904 -0.2194 -0.4108 -0.1221 -0.1151 -0.1100 -0.0627 -0.2707 -0.0819 -0.8288 -0.6097 -0.1424 -0.1205 -0.1294 -0.1630 -0.8867 -0.8138 -0.0730 -0.9845 -0.1360 -0.2079 -0.1292 -0.1682 -0.1070 -0.1957 -0.1574
S-1759	Vorbeugung von Blutungen Die übliche Dosierung mit Octocog alfa beträgt 20-40 I.E.pro kg Köprergewicht , verabreicht alle 2-3 Tage .
T-1759	Prevention of bleeding The usual dose of octocog alfa is 20 to 40 IU per kg body weight , administered every 2 to 3 days.
H-1759	-0.35381582379341125	prevention of bleeding The usual dose of Octocog alfa is 20 -40 IU per kg body weight , given every 2 -3 days .
D-1759	-0.35381582379341125	prevention of bleeding The usual dose of Octocog alfa is 20 -40 IU per kg body weight , given every 2 -3 days .
P-1759	-2.6139 -0.1277 -0.1192 -0.4599 -0.1288 -0.2403 -0.0936 -0.4208 -0.3410 -0.4303 -0.1093 -0.1253 -0.2290 -0.1154 -0.0656 -0.1318 -0.3141 -0.7967 -0.1279 -0.1499 -0.1938 -0.1146 -0.0815 -1.4436 -0.0380 -0.3367 -1.2383 -0.2568 -0.2424 -0.3962 -0.1070 -0.1081 -0.1751 -0.1571
S-1584	65 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1584	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-1584	-0.4250927269458771	Do not use the BAXJECT II Unit if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
D-1584	-0.4250927269458771	Do not use the BAXJECT II Unit if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
P-1584	-0.0609 -0.1294 -0.0428 -0.3534 -0.1530 -0.1575 -0.1961 -0.1065 -0.1121 -0.2074 -3.1112 -0.1076 -0.1794 -0.3301 -0.1428 -0.0437 -0.0719 -0.9538 -0.1623 -0.8458 -0.0667 -0.1504 -0.2802 -0.3267 -0.1236 -1.4678 -0.2318 -0.1754 -0.5170 -1.5748 -1.5463 -0.4687 -0.3861 -0.1517 -0.9019 -0.1866 -0.0857 -0.1066 -0.6267 -0.1613
S-722	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-722	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-722	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
D-722	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
P-722	-1.0833 -0.7981 -0.4916 -0.2421 -0.8467 -0.1307 -1.8626 -0.5519 -0.6487 -0.1505 -2.0549 -0.0876 -0.5880 -0.1302 -0.1053 -0.8742 -2.5914 -0.1912 -0.1697 -0.1550 -0.8734 -0.2511 -0.1407 -0.1191 -0.0618 -0.1166 -0.1347 -0.1588 -0.1184 -0.1163 -0.1366 -0.1546 -0.1539
S-898	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-898	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-898	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
D-898	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
P-898	-1.0833 -0.7981 -0.4916 -0.2421 -0.8467 -0.1307 -1.8626 -0.5519 -0.6487 -0.1505 -2.0549 -0.0876 -0.5880 -0.1302 -0.1053 -0.8742 -2.5914 -0.1912 -0.1697 -0.1550 -0.8734 -0.2511 -0.1407 -0.1191 -0.0618 -0.1166 -0.1347 -0.1588 -0.1184 -0.1163 -0.1366 -0.1546 -0.1539
S-1847	Benutzen Sie zum Auflösen ausschließlich das sterilisierte Wasser für Injektionszwecke und das Rekonstitutions-Gerät , das jeder Packung ADVATE beigepackt ist .
T-1847	Use only the sterilised water for injections and the reconstitution device for preparation of the solution that are provided with each package of ADVATE .
H-1847	-0.49881231784820557	To dissolve , use only sterilised water for injections and the Reconstitution Unit included with each pack of ADVATE .
D-1847	-0.49881231784820557	To dissolve , use only sterilised water for injections and the Reconstitution Unit included with each pack of ADVATE .
P-1847	-2.5556 -0.2081 -0.1288 -0.2599 -0.3014 -0.8058 -0.3422 -0.1406 -0.2398 -0.1070 -0.1052 -0.1645 -0.1666 -0.2470 -0.1970 -2.2373 -0.2810 -0.9157 -0.1110 -2.0414 -0.8453 -0.5546 -1.0635 -0.1186 -0.1406 -0.1492 -0.0930 -0.0853 -0.1915 -0.1670
S-1250	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-1250	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-1250	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
D-1250	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
P-1250	-1.0833 -0.7981 -0.4916 -0.2421 -0.8467 -0.1307 -1.8626 -0.5519 -0.6487 -0.1505 -2.0549 -0.0876 -0.5880 -0.1302 -0.1053 -0.8742 -2.5914 -0.1912 -0.1697 -0.1550 -0.8734 -0.2511 -0.1407 -0.1191 -0.0618 -0.1166 -0.1347 -0.1588 -0.1184 -0.1163 -0.1366 -0.1546 -0.1539
S-1407	54 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1407	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-1407	-0.42012932896614075	Do not use the BAXJECT II Unit if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
D-1407	-0.42012932896614075	Do not use the BAXJECT II Unit if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
P-1407	-0.0918 -0.1260 -0.0417 -0.3731 -0.1459 -0.1575 -0.1985 -0.1082 -0.1136 -0.2205 -2.9503 -0.1090 -0.1755 -0.3285 -0.1427 -0.0435 -0.0704 -0.9543 -0.1613 -0.7996 -0.0666 -0.1506 -0.2755 -0.3364 -0.1243 -1.4591 -0.2285 -0.1723 -0.4950 -1.5254 -1.5296 -0.4729 -0.3954 -0.1524 -0.8936 -0.1897 -0.0851 -0.1070 -0.6707 -0.1634
S-1231	43 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1231	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-1231	-0.42504122853279114	Do not use the BAXJECT II Unit if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
D-1231	-0.42504122853279114	Do not use the BAXJECT II Unit if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
P-1231	-0.0818 -0.1268 -0.0438 -0.3695 -0.1512 -0.1567 -0.1981 -0.1074 -0.1141 -0.2336 -3.2144 -0.1088 -0.1730 -0.3306 -0.1396 -0.0430 -0.0722 -0.9375 -0.1628 -0.8344 -0.0652 -0.1503 -0.2800 -0.3273 -0.1231 -1.4689 -0.2286 -0.1680 -0.4864 -1.5068 -1.4967 -0.4524 -0.3890 -0.1522 -0.8915 -0.1897 -0.0868 -0.1058 -0.6698 -0.1638
S-1055	32 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1055	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-1055	-0.4286385476589203	Do not use the BAXJECT II unit set if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
D-1055	-0.4286385476589203	Do not use the BAXJECT II unit set if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
P-1055	-0.0615 -0.1296 -0.0439 -0.3512 -0.1528 -0.1577 -0.1986 -0.1094 -0.1125 -0.2366 -1.8112 -1.2448 -0.3039 -0.2539 -0.1426 -0.0443 -0.0680 -1.0671 -0.1663 -0.8038 -0.0669 -0.1482 -0.2548 -0.3215 -0.1216 -1.6236 -0.2309 -0.1672 -0.5383 -1.5116 -1.6077 -0.4650 -0.3859 -0.1513 -0.9437 -0.1909 -0.0851 -0.1080 -0.6048 -0.1589
S-879	21 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-879	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-879	-0.4308752119541168	Do not use the BAXJECT II unit set if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
D-879	-0.4308752119541168	Do not use the BAXJECT II unit set if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
P-879	-0.0764 -0.1298 -0.0443 -0.3501 -0.1507 -0.1569 -0.1958 -0.1096 -0.1143 -0.2323 -1.7274 -1.4368 -0.3144 -0.2416 -0.1342 -0.0439 -0.0705 -1.0702 -0.1648 -0.8098 -0.0667 -0.1487 -0.2459 -0.3101 -0.1241 -1.6154 -0.2328 -0.1793 -0.5552 -1.6091 -1.5017 -0.4572 -0.3758 -0.1510 -0.9637 -0.1865 -0.0840 -0.1091 -0.5855 -0.1598
S-703	10 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-703	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-703	-0.4264856278896332	Do not use the BAXJECT II unit set if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
D-703	-0.4264856278896332	Do not use the BAXJECT II unit set if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering .
P-703	-0.0920 -0.1297 -0.0449 -0.3505 -0.1506 -0.1571 -0.1972 -0.1092 -0.1140 -0.2353 -1.6156 -1.3018 -0.3121 -0.2527 -0.1390 -0.0440 -0.0674 -1.0758 -0.1660 -0.7865 -0.0674 -0.1481 -0.2509 -0.3117 -0.1233 -1.6268 -0.2291 -0.1726 -0.5461 -1.5422 -1.5767 -0.4644 -0.3772 -0.1511 -0.9883 -0.1890 -0.0859 -0.1091 -0.6005 -0.1576
S-1943	Die Tablette kann mit einem Glas Wasser eingenommen werden , ist jedoch im Ganzen zu schlucken ( d. h. ohne sie zu zerbeißen , zu zerbrechen oder zu kauen ) .
T-1943	The tablet may be taken with a full glass of water but must be swallowed entirely ( without crushing , breaking or chewing it ) .
H-1943	-0.38678136467933655	The tablet may be taken with a glass of water but should be swallowed whole ( i. e. without biting , breaking or chewing ) .
D-1943	-0.38678136467933655	The tablet may be taken with a glass of water but should be swallowed whole ( i. e. without biting , breaking or chewing ) .
P-1943	-0.6939 -0.1185 -0.1232 -0.9682 -0.1529 -0.2654 -0.1916 -0.1499 -0.0541 -0.1251 -0.0967 -1.0010 -1.7194 -0.1593 -0.3650 -0.2313 -0.0575 -0.4732 -0.1615 -0.4823 -0.4384 -0.1164 -0.1189 -0.1061 -2.5130 -0.1532 -0.5212 -0.4599 -0.0956 -0.0644 -0.2576 -0.1718 -0.1572
S-925	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-925	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-925	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-925	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-925	-1.6802 -0.1546 -0.2181 -0.1568 -2.1625 -0.1621 -0.1128 -0.1627 -0.5735 -0.2011 -0.1911 -0.1223 -0.3373 -0.2675 -0.4720 -0.2168 -0.1039 -0.9081 -0.0926 -0.1343 -0.2311 -0.1803 -0.1086 -0.3630 -0.1503 -0.8146 -0.1510 -0.9090 -0.1015 -0.6476 -0.5001 -0.7410 -0.1115 -0.1681 -0.1926 -0.1318 -1.0945 -0.0798 -0.2630 -0.1577
S-1074	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-1074	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-1074	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
D-1074	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
P-1074	-1.0833 -0.7981 -0.4916 -0.2421 -0.8467 -0.1307 -1.8626 -0.5519 -0.6487 -0.1505 -2.0549 -0.0876 -0.5880 -0.1302 -0.1053 -0.8742 -2.5914 -0.1912 -0.1697 -0.1550 -0.8734 -0.2511 -0.1407 -0.1191 -0.0618 -0.1166 -0.1347 -0.1588 -0.1184 -0.1163 -0.1366 -0.1546 -0.1539
S-46	EU<unk> 1<unk> 08<unk> 447<unk> 002 ADENURIC 80 mg Filmtablette Zum Einnehmen Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-46	Adenuric Adenuric Adenuric Adenuric
H-46	-0.3153526186943054	08/ 447/ 002 ADENURIC 80mg Filmtablet Blister ( Aclar/ PVC/ aluminium )
D-46	-0.3153526186943054	08/ 447/ 002 ADENURIC 80mg Filmtablet Blister ( Aclar/ PVC/ aluminium )
P-46	-1.1218 -0.1242 -0.1664 -0.1895 -0.1174 -0.0985 -0.1375 -0.0712 -0.1421 -0.1497 -0.1141 -0.6987 -0.0399 -2.3201 -0.0401 -0.3870 -1.3537 -0.0820 -0.1858 -0.1043 -0.2191 -0.2200 -0.0910 -0.1172 -0.2655 -0.1251 -0.1150 -0.3584 -0.0502 -0.3676 -0.2029
S-1426	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-1426	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-1426	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
D-1426	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
P-1426	-1.0833 -0.7981 -0.4916 -0.2421 -0.8467 -0.1307 -1.8626 -0.5519 -0.6487 -0.1505 -2.0549 -0.0876 -0.5880 -0.1302 -0.1053 -0.8742 -2.5914 -0.1912 -0.1697 -0.1550 -0.8734 -0.2511 -0.1407 -0.1191 -0.0618 -0.1166 -0.1347 -0.1588 -0.1184 -0.1163 -0.1366 -0.1546 -0.1539
S-749	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-749	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-749	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-749	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-749	-1.6802 -0.1546 -0.2181 -0.1568 -2.1625 -0.1621 -0.1128 -0.1627 -0.5735 -0.2011 -0.1911 -0.1223 -0.3373 -0.2675 -0.4720 -0.2168 -0.1039 -0.9081 -0.0926 -0.1343 -0.2311 -0.1803 -0.1086 -0.3630 -0.1503 -0.8146 -0.1510 -0.9090 -0.1015 -0.6476 -0.5001 -0.7410 -0.1115 -0.1681 -0.1926 -0.1318 -1.0945 -0.0798 -0.2630 -0.1577
S-1028	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-1028	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-1028	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-1028	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-1028	-2.2193 -0.8200 -0.1172 -0.0822 -0.1161 -0.0542 -0.1311 -0.0834 -0.1009 -0.0934 -0.3572 -0.9726 -0.1264 -0.4183 -0.0707 -0.0352 -0.3922 -0.1236 -0.1301 -0.1289 -0.0750 -0.0913 -0.0895 -0.2621 -0.1404 -0.1457 -0.0721 -0.2042 -0.0398 -0.1872 -0.0870 -0.1135 -0.0258 -0.0767 -0.0577 -0.1459 -0.2081 -0.1475 -0.0937 -0.1325 -0.6379 -0.1625
S-64	Osteoporose ist eine Krankheit , bei der die Knochen allmählich dünn und brüchig werden ; es kommt zu einer erhöhten Anfälligkeit für Frakturen ( Brüche ) .
T-64	Osteoporose ist eine Krankheit , bei der die Knochen allmählich dünn und brüchig werden ; es kommt zu einer erhöhten Anfälligkeit für Frakturen ( Brüche ) . It happens when not enough new bone grows to replace the bone that is naturally broken down .
H-64	-0.35822099447250366	Osteoporosis is a condition in which the bones gradually become thin and fragile , resulting in increased susceptibility to fractures ( fractures ) .
D-64	-0.35822099447250366	Osteoporosis is a condition in which the bones gradually become thin and fragile , resulting in increased susceptibility to fractures ( fractures ) .
P-64	-0.3554 -0.0776 -0.1060 -0.1233 -0.0823 -0.0703 -0.1386 -0.1604 -0.9676 -0.6254 -0.1385 -1.2553 -0.2643 -0.3764 -0.3581 -0.0917 -0.1394 -0.5204 -0.0809 -0.9625 -1.7493 -0.1240 -0.6102 -1.0969 -0.1189 -0.0553 -0.1462 -0.0591 -0.1635 -0.4655 -0.1019 -0.4379 -0.7166 -0.0643 -0.1340 -0.1612 -0.1551
S-1453	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-1453	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-1453	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-1453	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-1453	-1.6802 -0.1546 -0.2181 -0.1568 -2.1625 -0.1621 -0.1128 -0.1627 -0.5735 -0.2011 -0.1911 -0.1223 -0.3373 -0.2675 -0.4720 -0.2168 -0.1039 -0.9081 -0.0926 -0.1343 -0.2311 -0.1803 -0.1086 -0.3630 -0.1503 -0.8146 -0.1510 -0.9090 -0.1015 -0.6476 -0.5001 -0.7410 -0.1115 -0.1681 -0.1926 -0.1318 -1.0945 -0.0798 -0.2630 -0.1577
S-1277	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-1277	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-1277	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-1277	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-1277	-1.6802 -0.1546 -0.2181 -0.1568 -2.1625 -0.1621 -0.1128 -0.1627 -0.5735 -0.2011 -0.1911 -0.1223 -0.3373 -0.2675 -0.4720 -0.2168 -0.1039 -0.9081 -0.0926 -0.1343 -0.2311 -0.1803 -0.1086 -0.3630 -0.1503 -0.8146 -0.1510 -0.9090 -0.1015 -0.6476 -0.5001 -0.7410 -0.1115 -0.1681 -0.1926 -0.1318 -1.0945 -0.0798 -0.2630 -0.1577
S-1101	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-1101	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-1101	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-1101	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-1101	-1.6802 -0.1546 -0.2181 -0.1568 -2.1625 -0.1621 -0.1128 -0.1627 -0.5735 -0.2011 -0.1911 -0.1223 -0.3373 -0.2675 -0.4720 -0.2168 -0.1039 -0.9081 -0.0926 -0.1343 -0.2311 -0.1803 -0.1086 -0.3630 -0.1503 -0.8146 -0.1510 -0.9090 -0.1015 -0.6476 -0.5001 -0.7410 -0.1115 -0.1681 -0.1926 -0.1318 -1.0945 -0.0798 -0.2630 -0.1577
S-575	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-575	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-575	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-575	-0.3881854712963104	injection every 12 -24 hours ( 8 -24 hours in patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-575	-1.6802 -0.1546 -0.2181 -0.1568 -2.1625 -0.1621 -0.1128 -0.1627 -0.5735 -0.2011 -0.1911 -0.1223 -0.3373 -0.2675 -0.4720 -0.2168 -0.1039 -0.9081 -0.0926 -0.1343 -0.2311 -0.1803 -0.1086 -0.3630 -0.1503 -0.8146 -0.1510 -0.9090 -0.1015 -0.6476 -0.5001 -0.7410 -0.1115 -0.1681 -0.1926 -0.1318 -1.0945 -0.0798 -0.2630 -0.1577
S-1603	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-1603	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-1603	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
D-1603	-0.49363383650779724	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of injection ( see sections 4.4 and 4.8 ) .
P-1603	-1.0833 -0.7981 -0.4916 -0.2421 -0.8467 -0.1307 -1.8626 -0.5519 -0.6487 -0.1505 -2.0549 -0.0876 -0.5880 -0.1302 -0.1053 -0.8742 -2.5914 -0.1912 -0.1697 -0.1550 -0.8734 -0.2511 -0.1407 -0.1191 -0.0618 -0.1166 -0.1347 -0.1588 -0.1184 -0.1163 -0.1366 -0.1546 -0.1539
S-226	Die Bioverfügbarkeit nahm entsprechend auf etwa 0,46 % und 0,39 % ab , wenn Alendronat eine oder eine halbe Stunde vor einem standardisierten Frühstück eingenommen wurde .
T-226	Bioavailability was decreased similarly to an estimated 0.46 % and 0.39 % when alendronate was administered one hour or half an hour before a standardised breakfast .
H-226	-0.3658931851387024	The bioavailability decreased accordingly to approximately 0.46 % and 0.39 % when alendronate was taken one or half an hour prior to a standardized breakfast .
D-226	-0.3658931851387024	The bioavailability decreased accordingly to approximately 0.46 % and 0.39 % when alendronate was taken one or half an hour prior to a standardized breakfast .
P-226	-2.7819 -0.1106 -0.1408 -0.2304 -0.0771 -0.6312 -0.0988 -0.3026 -0.6720 -0.1246 -0.0806 -0.1310 -0.1454 -0.0886 -0.0824 -0.1182 -0.4605 -0.4058 -0.1116 -0.1288 -0.0933 -0.1594 -0.7943 -0.1833 -0.6808 -0.6765 -0.6392 -0.0780 -1.2580 -0.1265 -0.2101 -0.6749 -0.2532 -0.3320 -0.1356 -0.1676 -0.1522
S-1557	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-1557	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-1557	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-1557	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-1557	-2.2193 -0.8200 -0.1172 -0.0822 -0.1161 -0.0542 -0.1311 -0.0834 -0.1009 -0.0934 -0.3572 -0.9726 -0.1264 -0.4183 -0.0707 -0.0352 -0.3922 -0.1236 -0.1301 -0.1289 -0.0750 -0.0913 -0.0895 -0.2621 -0.1404 -0.1457 -0.0721 -0.2042 -0.0398 -0.1872 -0.0870 -0.1135 -0.0258 -0.0767 -0.0577 -0.1459 -0.2081 -0.1475 -0.0937 -0.1325 -0.6379 -0.1625
S-1380	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-1380	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-1380	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-1380	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-1380	-2.2193 -0.8200 -0.1172 -0.0822 -0.1161 -0.0542 -0.1311 -0.0834 -0.1009 -0.0934 -0.3572 -0.9726 -0.1264 -0.4183 -0.0707 -0.0352 -0.3922 -0.1236 -0.1301 -0.1289 -0.0750 -0.0913 -0.0895 -0.2621 -0.1404 -0.1457 -0.0721 -0.2042 -0.0398 -0.1872 -0.0870 -0.1135 -0.0258 -0.0767 -0.0577 -0.1459 -0.2081 -0.1475 -0.0937 -0.1325 -0.6379 -0.1625
S-1204	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-1204	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-1204	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-1204	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-1204	-2.2193 -0.8200 -0.1172 -0.0822 -0.1161 -0.0542 -0.1311 -0.0834 -0.1009 -0.0934 -0.3572 -0.9726 -0.1264 -0.4183 -0.0707 -0.0352 -0.3922 -0.1236 -0.1301 -0.1289 -0.0750 -0.0913 -0.0895 -0.2621 -0.1404 -0.1457 -0.0721 -0.2042 -0.0398 -0.1872 -0.0870 -0.1135 -0.0258 -0.0767 -0.0577 -0.1459 -0.2081 -0.1475 -0.0937 -0.1325 -0.6379 -0.1625
S-852	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-852	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-852	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-852	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-852	-2.2193 -0.8200 -0.1172 -0.0822 -0.1161 -0.0542 -0.1311 -0.0834 -0.1009 -0.0934 -0.3572 -0.9726 -0.1264 -0.4183 -0.0707 -0.0352 -0.3922 -0.1236 -0.1301 -0.1289 -0.0750 -0.0913 -0.0895 -0.2621 -0.1404 -0.1457 -0.0721 -0.2042 -0.0398 -0.1872 -0.0870 -0.1135 -0.0258 -0.0767 -0.0577 -0.1459 -0.2081 -0.1475 -0.0937 -0.1325 -0.6379 -0.1625
S-676	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-676	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-676	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-676	-0.23259709775447845	powder Mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-676	-2.2193 -0.8200 -0.1172 -0.0822 -0.1161 -0.0542 -0.1311 -0.0834 -0.1009 -0.0934 -0.3572 -0.9726 -0.1264 -0.4183 -0.0707 -0.0352 -0.3922 -0.1236 -0.1301 -0.1289 -0.0750 -0.0913 -0.0895 -0.2621 -0.1404 -0.1457 -0.0721 -0.2042 -0.0398 -0.1872 -0.0870 -0.1135 -0.0258 -0.0767 -0.0577 -0.1459 -0.2081 -0.1475 -0.0937 -0.1325 -0.6379 -0.1625
S-246	Vitamin D3 wird rasch verteilt , hauptsächlich in die Leber , wo es zu 25-Hydroxyvitamin D3 , der Hauptspeicherform , metabolisiert wird .
T-246	Vitamin D3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D3 , the major storage form .
H-246	-0.38509657979011536	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised into 25-hydroxyvitamin D3 , the main store .
D-246	-0.38509657979011536	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised into 25-hydroxyvitamin D3 , the main store .
P-246	-1.1780 -0.0727 -0.1605 -0.1375 -0.1792 -0.5178 -1.5611 -0.1645 -0.2636 -1.2745 -0.7386 -0.1533 -0.0970 -0.4097 -0.1719 -0.2028 -0.1730 -0.1526 -0.0660 -0.0938 -0.8774 -0.7121 -0.1048 -0.0429 -0.1028 -0.1121 -0.0888 -0.0792 -0.1579 -0.1378 -0.1773 -0.4316 -0.2763 -1.7255 -0.9108 -0.1580
S-442	Vitamin D3 wird rasch verteilt , hauptsächlich in die Leber , wo es zu 25-Hydroxyvitamin D3 , der Hauptspeicherform , metabolisiert wird .
T-442	Vitamin D3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D3 , the major storage form .
H-442	-0.38509657979011536	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised into 25-hydroxyvitamin D3 , the main store .
D-442	-0.38509657979011536	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised into 25-hydroxyvitamin D3 , the main store .
P-442	-1.1780 -0.0727 -0.1605 -0.1375 -0.1792 -0.5178 -1.5611 -0.1645 -0.2636 -1.2745 -0.7386 -0.1533 -0.0970 -0.4097 -0.1719 -0.2028 -0.1730 -0.1526 -0.0660 -0.0938 -0.8774 -0.7121 -0.1048 -0.0429 -0.1028 -0.1121 -0.0888 -0.0792 -0.1579 -0.1378 -0.1773 -0.4316 -0.2763 -1.7255 -0.9108 -0.1580
S-234	Die Plasmakonzentrationen nach Aufnahme oraler therapeutischer Dosen von Alendronat sind zu niedrig für einen analytischen Nachweis ( <unk> 5 ng<unk> ml ) .
T-234	Concentrations of alendronate in plasma following therapeutic oral doses are too low for analytical detection ( <<unk>> 5 ng/ ml ) .
H-234	-0.2548711597919464	Plasma concentrations after oral therapeutic doses of alendronate are too low for analytical detection ( <unk> 5 ng/ ml ) .
D-234	-0.2548711597919464	Plasma concentrations after oral therapeutic doses of alendronate are too low for analytical detection ( <unk> 5 ng/ ml ) .
P-234	-1.1920 -0.0632 -0.0628 -0.0520 -0.0362 -0.0509 -0.5505 -0.1712 -0.0364 -0.0995 -0.1044 -0.0985 -0.1221 -0.1592 -0.1173 -0.1223 -0.0785 -1.0016 -0.3469 -0.4334 -0.4015 -0.6867 -1.0222 -0.4934 -0.0974 -0.1514 -0.0876 -0.1767 -0.1013 -0.1355 -0.1121 -0.0531 -0.1267 -0.2241 -0.1524
S-1854	Advexin ist eine Injektionssuspension , die Contusugene Ladenovec , ein genetisch verändertes Virus enthält , welches das p53-Gen trägt .
T-1854	Advexin is a suspension for injection that contains contusugene ladenovec , a genetically modified virus which carries the p53 gene .
H-1854	-0.3413546085357666	Advexin is a suspension injection containing Contusugene Ladovec , a genetically modified virus carrying the p53 gene .
D-1854	-0.3413546085357666	Advexin is a suspension injection containing Contusugene Ladovec , a genetically modified virus carrying the p53 gene .
P-1854	-0.6201 -0.1580 -0.1364 -0.1541 -0.4897 -0.0292 -1.2480 -0.0700 -0.3389 -0.8415 -0.1607 -0.1040 -0.9701 -1.0166 -0.3038 -0.0983 -0.1340 -0.1427 -0.1288 -0.4227 -0.2762 -0.5486 -0.0784 -0.1597 -0.9663 -0.4203 -0.1261 -0.0318 -0.0681 -0.1745 -0.1643
S-430	Die Plasmakonzentrationen nach Aufnahme oraler therapeutischer Dosen von Alendronat sind zu niedrig für einen analytischen Nachweis ( <unk> 5 ng<unk> ml ) .
T-430	Concentrations of alendronate in plasma following therapeutic oral doses are too low for analytical detection ( <<unk>> 5 ng/ ml ) .
H-430	-0.2548711597919464	Plasma concentrations after oral therapeutic doses of alendronate are too low for analytical detection ( <unk> 5 ng/ ml ) .
D-430	-0.2548711597919464	Plasma concentrations after oral therapeutic doses of alendronate are too low for analytical detection ( <unk> 5 ng/ ml ) .
P-430	-1.1920 -0.0632 -0.0628 -0.0520 -0.0362 -0.0509 -0.5505 -0.1712 -0.0364 -0.0995 -0.1044 -0.0985 -0.1221 -0.1592 -0.1173 -0.1223 -0.0785 -1.0016 -0.3469 -0.4334 -0.4015 -0.6867 -1.0222 -0.4934 -0.0974 -0.1514 -0.0876 -0.1767 -0.1013 -0.1355 -0.1121 -0.0531 -0.1267 -0.2241 -0.1524
S-1569	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-1569	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-1569	-0.3233283758163452	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
D-1569	-0.3233283758163452	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
P-1569	-0.4674 -0.1521 -0.0906 -0.0987 -0.2007 -1.0299 -0.0923 -0.3585 -0.0824 -0.0746 -0.0940 -0.5415 -0.1461 -0.1814 -0.3829 -1.6183 -0.4119 -0.2673 -0.2351 -0.1959 -0.1152 -0.1412 -0.0826 -0.1247 -0.6110 -0.2185 -2.2363 -0.1003 -0.1594 -0.1186 -0.1339 -0.0613 -0.1396 -0.1938 -0.1586
S-49	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) , oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-49	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-49	-0.3936324119567871	For more information about your disease or treatment , read the Package Leaflet ( also included in EPAR ) or contact your doctor or pharmacist .
D-49	-0.3936324119567871	For more information about your disease or treatment , read the Package Leaflet ( also included in EPAR ) or contact your doctor or pharmacist .
P-49	-1.3634 -1.5048 -0.0416 -0.9231 -0.1637 -1.2407 -0.2309 -0.4102 -0.3220 -0.7046 -0.3154 -0.2228 -0.1466 -0.1454 -0.0336 -0.1117 -0.2241 -0.4051 -0.7698 -0.2342 -0.4124 -0.0651 -0.1448 -1.0141 -0.5437 -0.1382 -0.1285 -0.1448 -0.0399 -0.1024 -0.1705 -0.1784
S-1894	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) , oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-1894	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-1894	-0.3936324119567871	For more information about your disease or treatment , read the Package Leaflet ( also included in EPAR ) or contact your doctor or pharmacist .
D-1894	-0.3936324119567871	For more information about your disease or treatment , read the Package Leaflet ( also included in EPAR ) or contact your doctor or pharmacist .
P-1894	-1.3634 -1.5048 -0.0416 -0.9231 -0.1637 -1.2407 -0.2309 -0.4102 -0.3220 -0.7046 -0.3154 -0.2228 -0.1466 -0.1454 -0.0336 -0.1117 -0.2241 -0.4051 -0.7698 -0.2342 -0.4124 -0.0651 -0.1448 -1.0141 -0.5437 -0.1382 -0.1285 -0.1448 -0.0399 -0.1024 -0.1705 -0.1784
S-192	Die Konversion zum aktiven calciummobilisierenden Hormon 1,25-Dihydroxyvitamin D3 ( Calcitriol ) in der Niere ist streng reguliert .
T-192	Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D3 ( calcitriol ) in the kidney is tightly regulated .
H-192	-0.27086538076400757	Conversion to the active calcium mobilising hormone 1,25 -dihydroxyvitamin D3 ( calcitriol ) in the kidney is strictly regulated .
D-192	-0.27086538076400757	Conversion to the active calcium mobilising hormone 1,25 -dihydroxyvitamin D3 ( calcitriol ) in the kidney is strictly regulated .
P-192	-1.9653 -0.1856 -0.3555 -0.2457 -0.0419 -0.0775 -0.1388 -0.1042 -0.8217 -0.3093 -0.1048 -0.0627 -0.2525 -0.5127 -1.1628 -0.1613 -0.0652 -0.1646 -0.1005 -0.1025 -0.0831 -0.1524 -0.1360 -0.1332 -0.2140 -0.0534 -0.1089 -0.1221 -0.1230 -0.2538 -0.1501 -0.2152 -0.1701 -0.1662 -0.4062 -0.1464 -0.8331 -0.1049 -0.1735 -0.1538
S-380	Die Konversion zum aktiven calciummobilisierenden Hormon 1,25-Dihydroxyvitamin D3 ( Calcitriol ) in der Niere ist streng reguliert .
T-380	Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D3 ( calcitriol ) in the kidney is tightly regulated .
H-380	-0.27086538076400757	Conversion to the active calcium mobilising hormone 1,25 -dihydroxyvitamin D3 ( calcitriol ) in the kidney is strictly regulated .
D-380	-0.27086538076400757	Conversion to the active calcium mobilising hormone 1,25 -dihydroxyvitamin D3 ( calcitriol ) in the kidney is strictly regulated .
P-380	-1.9653 -0.1856 -0.3555 -0.2457 -0.0419 -0.0775 -0.1388 -0.1042 -0.8217 -0.3093 -0.1048 -0.0627 -0.2525 -0.5127 -1.1628 -0.1613 -0.0652 -0.1646 -0.1005 -0.1025 -0.0831 -0.1524 -0.1360 -0.1332 -0.2140 -0.0534 -0.1089 -0.1221 -0.1230 -0.2538 -0.1501 -0.2152 -0.1701 -0.1662 -0.4062 -0.1464 -0.8331 -0.1049 -0.1735 -0.1538
S-1859	Normalerweise sind jedoch die Brust , das Gehirn , die Knochen oder die Weichteile ( Gewebe , das andere Strukturen im Körper verbindet , umgibt und stützt ) davon betroffen .
T-1859	Li-Fraumeni cancer can occur in many areas of the body but usually affects the breast , brain , bone or soft tissue ( tissue that connects , surrounds and supports other structures in the body ) .
H-1859	-0.39437976479530334	However , this usually affects the breast , brain , bones or soft tissues ( tissue that surrounds and supports other structures in the body ) .
D-1859	-0.39437976479530334	However , this usually affects the breast , brain , bones or soft tissues ( tissue that surrounds and supports other structures in the body ) .
P-1859	-0.9327 -0.1510 -1.7751 -0.7211 -0.3585 -0.1691 -0.9667 -0.1419 -0.1406 -0.1434 -0.3597 -0.8761 -0.1110 -0.6590 -0.0435 -0.1432 -0.2349 -0.2684 -0.9172 -1.0310 -0.0783 -0.2094 -0.2664 -0.2056 -0.4136 -0.1491 -0.1560 -0.0953 -0.1877 -0.1649 -0.1552
S-1392	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-1392	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-1392	-0.3233283758163452	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
D-1392	-0.3233283758163452	ADVATE is administered intravenously for injections after dissolving the lyophilised product with the accompanying sterilised water .
P-1392	-0.4674 -0.1521 -0.0906 -0.0987 -0.2007 -1.0299 -0.0923 -0.3585 -0.0824 -0.0746 -0.0940 -0.5415 -0.1461 -0.1814 -0.3829 -1.6183 -0.4119 -0.2673 -0.2351 -0.1959 -0.1152 -0.1412 -0.0826 -0.1247 -0.6110 -0.2185 -2.2363 -0.1003 -0.1594 -0.1186 -0.1339 -0.0613 -0.1396 -0.1938 -0.1586
S-1756	Ihr Arzt wird Ihre Dosis ADVATE ( in internationalen Einheiten oder I.E. ) berechnen , abhängig von Ihrem körperlichen Befinden und Ihrem Körpergewicht , und ob es zur Vorbeugung oder zur Behandlung von Blutungen eingesetzt wird .
T-1756	Your doctor will calculate your dose of ADVATE ( in international units or IU ) depending on your condition and body weight , and on whether it is used for prevention or treatment of bleeding .
H-1756	-0.2816639840602875	Your doctor will calculate your dose of ADVATE ( in international units or IU ) depending on your physical condition and body weight , and whether it is used to prevent or treat bleeding .
D-1756	-0.2816639840602875	Your doctor will calculate your dose of ADVATE ( in international units or IU ) depending on your physical condition and body weight , and whether it is used to prevent or treat bleeding .
P-1756	-0.1714 -0.1483 -0.1202 -0.8778 -0.0936 -0.1553 -0.1379 -0.5357 -0.0736 -0.1490 -0.1024 -0.0863 -0.1398 -0.3118 -0.0879 -0.2615 -0.1469 -0.2961 -0.0438 -0.2762 -1.7357 -0.1487 -0.1485 -0.1585 -0.5055 -0.1600 -0.7493 -0.0597 -0.8660 -0.1363 -0.1473 -0.1643 -0.2791 -0.5799 -0.1645 -0.1927 -0.1635 -0.0794 -0.6834 -0.1361 -0.1918 -0.1643
S-372	ADROVANCE ist eine Kombinationstablette mit den beiden arzneilich wirksamen Bestandteilen Natriumalendronat 3 H2O und Colecalciferol ( Vitamin D3 ) .
T-372	ADROVANCE is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-372	-0.20128373801708221	ADROVANCE is a combination tablet with the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
D-372	-0.20128373801708221	ADROVANCE is a combination tablet with the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
P-372	-0.0645 -0.0580 -0.1246 -0.1050 -0.0885 -0.1453 -0.1288 -0.1061 -0.5010 -0.1328 -0.6408 -0.8553 -0.3943 -0.1828 -0.3253 -0.0776 -0.1671 -0.4629 -0.2763 -0.1227 -0.3247 -0.1975 -0.1385 -0.1334 -0.1629 -0.1142 -0.1622 -0.2020 -0.1090 -0.1365 -0.1143 -0.1402 -0.1364 -0.0906 -0.1383 -0.1331 -0.1328 -0.1607 -0.1631
S-184	ADROVANCE ist eine Kombinationstablette mit den beiden arzneilich wirksamen Bestandteilen Natriumalendronat 3 H2O und Colecalciferol ( Vitamin D3 ) .
T-184	ADROVANCE is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-184	-0.20128373801708221	ADROVANCE is a combination tablet with the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
D-184	-0.20128373801708221	ADROVANCE is a combination tablet with the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
P-184	-0.0645 -0.0580 -0.1246 -0.1050 -0.0885 -0.1453 -0.1288 -0.1061 -0.5010 -0.1328 -0.6408 -0.8553 -0.3943 -0.1828 -0.3253 -0.0776 -0.1671 -0.4629 -0.2763 -0.1227 -0.3247 -0.1975 -0.1385 -0.1334 -0.1629 -0.1142 -0.1622 -0.2020 -0.1090 -0.1365 -0.1143 -0.1402 -0.1364 -0.0906 -0.1383 -0.1331 -0.1328 -0.1607 -0.1631
S-76	Das Unternehmen legte außerdem Daten vor , die darlegen , dass die in ADROVANCE enthaltene Alendronat-Dosis genau der Dosis entspricht , die für die Verhinderung eines Knochenverlusts benötigt wird .
T-76	The company also presented evidence that the dose of alendronate included in ADROVANCE was the same as the dose needed to prevent bone loss .
H-76	-0.44736215472221375	The company also presented data showing that the alendronate dose contained in ADROVANCE is exactly the dose needed to prevent bone loss .
D-76	-0.44736215472221375	The company also presented data showing that the alendronate dose contained in ADROVANCE is exactly the dose needed to prevent bone loss .
P-76	-0.6115 -0.4413 -0.5835 -1.4838 -0.2586 -1.5250 -0.1833 -0.4656 -0.3230 -0.1107 -0.1739 -1.0159 -0.4156 -0.3595 -1.5798 -0.1344 -0.0564 -0.0654 -0.1295 -0.0961 -0.0788 -0.4489 -0.7976 -0.5391 -0.3144 -1.1897 -0.1573 -0.1579 -0.0389 -0.2278 -0.1880 -0.1645
S-238	Nach intravenöser Gabe einer einzelnen Dosis von 10 mg betrug die renale Clearance von Alendronat 71 ml<unk> min und die systemische Clearance überschritt nicht 200 ml<unk> min .
T-238	Following a single 10 mg intravenous dose , the renal clearance of alendronate was 71 ml/ min , and systemic clearance did not exceed 200 ml/ min .
H-238	-0.1827731877565384	After the intravenous administration of a single dose of 10 mg , the renal clearance of alendronate was 71 ml/ min and the systemic clearance did not exceed 200 ml/ min .
D-238	-0.1827731877565384	After the intravenous administration of a single dose of 10 mg , the renal clearance of alendronate was 71 ml/ min and the systemic clearance did not exceed 200 ml/ min .
P-238	-0.7296 -0.7082 -0.6902 -0.0822 -0.0695 -0.1270 -0.1814 -0.1387 -0.1303 -0.3312 -0.5759 -0.1281 -0.2259 -0.0391 -0.2271 -0.2663 -0.0897 -0.1019 -0.0220 -0.1150 -0.1533 -0.1338 -0.1031 -0.1225 -0.0667 -0.1334 -0.0838 -0.1013 -0.1615 -0.1234 -0.1199 -0.3115 -0.5051 -0.0582 -0.0820 -0.0954 -0.0362 -0.0949 -0.3068 -0.1181 -0.0222 -0.0934 -0.1555 -0.0827 -0.1603 -0.1143 -0.1167 -0.1702 -0.1504
S-337	Obwohl spezifische Interaktionsstudien nicht durchgeführt wurden , wurde Alendronat in klinischen Studien gemeinsam mit einer Vielzahl von gewöhnlich verschriebenen Arzneimitteln eingenommen , ohne dass klinisch relevante Wechselwirkungen auftraten .
T-337	Although specific interaction studies were not performed , in clinical studies alendronate was used concomitantly with a wide range of commonly prescribed medicinal products without evidence of interactions of clinical relevance .
H-337	-0.43143704533576965	Although no specific interaction studies have been conducted , alendronate has been used in clinical trials alongside a variety of commonly prescribed medicines without clinically relevant interactions .
D-337	-0.43143704533576965	Although no specific interaction studies have been conducted , alendronate has been used in clinical trials alongside a variety of commonly prescribed medicines without clinically relevant interactions .
P-337	-0.2425 -0.9105 -0.3263 -0.1584 -0.2151 -0.2759 -1.1031 -0.1308 -0.5137 -0.1375 -0.5603 -0.1051 -0.0890 -0.0726 -0.3656 -0.1177 -2.0882 -0.4134 -0.1360 -0.1450 -1.2764 -0.1029 -1.7503 -0.1272 -0.7564 -0.2210 -0.0600 -0.3865 -0.3607 -0.6512 -0.5427 -0.0784 -0.6016 -0.1679 -0.3292 -0.2883 -0.1561
S-914	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-914	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-914	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
D-914	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
P-914	-0.3798 -0.3620 -0.1687 -2.1065 -0.1981 -0.1671 -0.2284 -0.1029 -0.0969 -0.1614 -1.5413 -0.4095 -0.2317 -0.1830 -0.1479 -0.1486 -0.0431 -0.1316 -0.2647 -0.1290 -0.1045 -0.0806 -0.0861 -0.2570 -0.1207 -0.2196 -0.3783 -0.4330 -0.0552 -0.1421 -0.0420 -0.1330 -0.2722 -0.7627 -0.2553 -0.1828 -0.3729 -0.1615 -0.0877 -0.1392 -0.1571 -0.0868 -0.0974 -0.1403 -0.1729 -0.1548
S-675	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-675	Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-675	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-675	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-675	-0.8664 -1.0617 -0.1740 -1.4164 -0.1604 -0.1428 -1.1334 -0.9316 -0.1928 -0.3329 -0.1129 -0.0754 -0.1680 -1.2519 -0.8190 -0.1846 -0.1095 -0.1547 -0.1745 -0.9220 -0.0427 -0.0722 -0.1813 -0.0972 -0.1236 -0.2872 -0.2020 -1.4275 -0.0730 -1.0556 -1.4488 -0.1684 -0.2554 -0.1629
S-149	Obwohl spezifische Interaktionsstudien nicht durchgeführt wurden , wurde Alendronat in klinischen Studien gemeinsam mit einer Vielzahl von gewöhnlich verschriebenen Arzneimitteln eingenommen , ohne dass klinisch relevante Wechselwirkungen auftraten .
T-149	Although specific interaction studies were not performed , in clinical studies alendronate was used concomitantly with a wide range of commonly prescribed medicinal products without evidence of interactions of clinical relevance .
H-149	-0.43143704533576965	Although no specific interaction studies have been conducted , alendronate has been used in clinical trials alongside a variety of commonly prescribed medicines without clinically relevant interactions .
D-149	-0.43143704533576965	Although no specific interaction studies have been conducted , alendronate has been used in clinical trials alongside a variety of commonly prescribed medicines without clinically relevant interactions .
P-149	-0.2425 -0.9105 -0.3263 -0.1584 -0.2151 -0.2759 -1.1031 -0.1308 -0.5137 -0.1375 -0.5603 -0.1051 -0.0890 -0.0726 -0.3656 -0.1177 -2.0882 -0.4134 -0.1360 -0.1450 -1.2764 -0.1029 -1.7503 -0.1272 -0.7564 -0.2210 -0.0600 -0.3865 -0.3607 -0.6512 -0.5427 -0.0784 -0.6016 -0.1679 -0.3292 -0.2883 -0.1561
S-1485	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-1485	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-1485	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
D-1485	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
P-1485	-0.1664 -0.2186 -0.1790 -0.1326 -0.1974 -0.0525 -0.0596 -0.1546 -1.4208 -0.0842 -0.0725 -0.2012 -0.6518 -1.4714 -0.1243 -0.0725 -0.1499 -0.1451 -0.1526 -0.0915 -0.5356 -0.5740 -0.2610 -1.4549 -0.1427 -0.8564 -0.0706 -0.5279 -0.1611 -0.0766 -0.1101 -0.6189 -0.2771 -0.0340 -0.3866 -2.0340 -0.1432 -0.1472 -0.1656 -0.4267 -0.0451 -0.1613 -0.1544
S-563	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-563	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-563	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
D-563	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
P-563	-0.3798 -0.3620 -0.1687 -2.1065 -0.1981 -0.1671 -0.2284 -0.1029 -0.0969 -0.1614 -1.5413 -0.4095 -0.2317 -0.1830 -0.1479 -0.1486 -0.0431 -0.1316 -0.2647 -0.1290 -0.1045 -0.0806 -0.0861 -0.2570 -0.1207 -0.2196 -0.3783 -0.4330 -0.0552 -0.1421 -0.0420 -0.1330 -0.2722 -0.7627 -0.2553 -0.1828 -0.3729 -0.1615 -0.0877 -0.1392 -0.1571 -0.0868 -0.0974 -0.1403 -0.1729 -0.1548
S-738	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-738	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-738	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
D-738	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
P-738	-0.3798 -0.3620 -0.1687 -2.1065 -0.1981 -0.1671 -0.2284 -0.1029 -0.0969 -0.1614 -1.5413 -0.4095 -0.2317 -0.1830 -0.1479 -0.1486 -0.0431 -0.1316 -0.2647 -0.1290 -0.1045 -0.0806 -0.0861 -0.2570 -0.1207 -0.2196 -0.3783 -0.4330 -0.0552 -0.1421 -0.0420 -0.1330 -0.2722 -0.7627 -0.2553 -0.1828 -0.3729 -0.1615 -0.0877 -0.1392 -0.1571 -0.0868 -0.0974 -0.1403 -0.1729 -0.1548
S-851	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-851	18 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-851	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-851	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-851	-0.8664 -1.0617 -0.1740 -1.4164 -0.1604 -0.1428 -1.1334 -0.9316 -0.1928 -0.3329 -0.1129 -0.0754 -0.1680 -1.2519 -0.8190 -0.1846 -0.1095 -0.1547 -0.1745 -0.9220 -0.0427 -0.0722 -0.1813 -0.0972 -0.1236 -0.2872 -0.2020 -1.4275 -0.0730 -1.0556 -1.4488 -0.1684 -0.2554 -0.1629
S-781	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-781	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-781	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
D-781	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
P-781	-0.1664 -0.2186 -0.1790 -0.1326 -0.1974 -0.0525 -0.0596 -0.1546 -1.4208 -0.0842 -0.0725 -0.2012 -0.6518 -1.4714 -0.1243 -0.0725 -0.1499 -0.1451 -0.1526 -0.0915 -0.5356 -0.5740 -0.2610 -1.4549 -0.1427 -0.8564 -0.0706 -0.5279 -0.1611 -0.0766 -0.1101 -0.6189 -0.2771 -0.0340 -0.3866 -2.0340 -0.1432 -0.1472 -0.1656 -0.4267 -0.0451 -0.1613 -0.1544
S-439	Die mittlere maximale Konzentration im Serum ( Cmax ) von Vitamin D3 betrug 12,2 ng<unk> ml und die Medianzeit bis zum Erreichen der maximalen Serumkonzentration ( Tmax ) 10,6 Stunden .
T-439	The mean maximal serum concentration ( Cmax ) of vitamin D3 was 12.2 ng/ ml and the median time to maximal serum concentration ( Tmax ) was 10.6 hours .
H-439	-0.21807850897312164	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 12.2 ng/ ml and the median time to reach peak serum concentration ( Tmax ) was 10.6 hours .
D-439	-0.21807850897312164	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 12.2 ng/ ml and the median time to reach peak serum concentration ( Tmax ) was 10.6 hours .
P-439	-0.2040 -0.1061 -0.2551 -1.1321 -0.1170 -0.2297 -0.1346 -0.1402 -0.0455 -0.1224 -0.1647 -0.1060 -0.0759 -0.1644 -0.1390 -0.1307 -0.1743 -0.1814 -0.0781 -0.1438 -0.1023 -0.0680 -0.6592 -0.1580 -0.1016 -0.1136 -0.5342 -0.4174 -0.3996 -0.9834 -0.4671 -0.1480 -0.1791 -0.1187 -0.1446 -0.0374 -0.1224 -0.1275 -0.0964 -0.1482 -0.1002 -0.1517 -0.1536
S-1027	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-1027	28 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-1027	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-1027	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-1027	-0.8664 -1.0617 -0.1740 -1.4164 -0.1604 -0.1428 -1.1334 -0.9316 -0.1928 -0.3329 -0.1129 -0.0754 -0.1680 -1.2519 -0.8190 -0.1846 -0.1095 -0.1547 -0.1745 -0.9220 -0.0427 -0.0722 -0.1813 -0.0972 -0.1236 -0.2872 -0.2020 -1.4275 -0.0730 -1.0556 -1.4488 -0.1684 -0.2554 -0.1629
S-1309	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-1309	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-1309	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
D-1309	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
P-1309	-0.1664 -0.2186 -0.1790 -0.1326 -0.1974 -0.0525 -0.0596 -0.1546 -1.4208 -0.0842 -0.0725 -0.2012 -0.6518 -1.4714 -0.1243 -0.0725 -0.1499 -0.1451 -0.1526 -0.0915 -0.5356 -0.5740 -0.2610 -1.4549 -0.1427 -0.8564 -0.0706 -0.5279 -0.1611 -0.0766 -0.1101 -0.6189 -0.2771 -0.0340 -0.3866 -2.0340 -0.1432 -0.1472 -0.1656 -0.4267 -0.0451 -0.1613 -0.1544
S-1516	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-1516	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-1516	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
D-1516	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
P-1516	-2.1679 -0.0969 -0.2968 -0.3520 -0.6132 -0.3444 -1.1346 -0.2924 -1.7462 -0.0648 -0.0831 -0.4968 -1.1155 -0.7396 -0.8264 -0.1437 -0.0404 -0.1307 -1.6504 -1.2830 -0.1622 -1.5524 -0.1980 -0.2503 -1.1699 -0.1367 -0.6311 -1.1028 -0.2088 -0.1558 -0.1662
S-218	In der Zwei-Jahres-Verlängerung dieser Studien hielten die Anstiege der BMD von Wirbelsäule und Trochanter weiterhin an ; auch die BMD des Femurhalses und des gesamten Körpers wurde aufrechterhalten .
T-218	In the two-year extension of these studies BMD at the spine and trochanter continued to increase and BMD at the femoral neck and total body were maintained .
H-218	-0.5411844849586487	Throughout the two year extension of these studies , spinal and trochanter BMD continued to rise and femoral and body BMD was maintained .
D-218	-0.5411844849586487	Throughout the two year extension of these studies , spinal and trochanter BMD continued to rise and femoral and body BMD was maintained .
P-218	-2.1216 -0.1065 -0.0871 -1.0438 -1.0176 -1.5143 -0.7386 -0.1735 -0.1046 -0.9034 -0.1480 -0.7266 -0.5384 -0.1495 -0.0367 -0.2855 -0.4403 -0.1814 -0.1829 -1.4939 -0.1661 -0.7538 -1.3682 -0.4975 -0.1209 -0.8488 -0.6661 -0.3969 -0.1281 -0.2826 -0.3015 -0.1667 -0.1678
S-987	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-987	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-987	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
D-987	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
P-987	-2.1679 -0.0969 -0.2968 -0.3520 -0.6132 -0.3444 -1.1346 -0.2924 -1.7462 -0.0648 -0.0831 -0.4968 -1.1155 -0.7396 -0.8264 -0.1437 -0.0404 -0.1307 -1.6504 -1.2830 -0.1622 -1.5524 -0.1980 -0.2503 -1.1699 -0.1367 -0.6311 -1.1028 -0.2088 -0.1558 -0.1662
S-1163	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-1163	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-1163	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
D-1163	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
P-1163	-2.1679 -0.0969 -0.2968 -0.3520 -0.6132 -0.3444 -1.1346 -0.2924 -1.7462 -0.0648 -0.0831 -0.4968 -1.1155 -0.7396 -0.8264 -0.1437 -0.0404 -0.1307 -1.6504 -1.2830 -0.1622 -1.5524 -0.1980 -0.2503 -1.1699 -0.1367 -0.6311 -1.1028 -0.2088 -0.1558 -0.1662
S-1339	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-1339	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-1339	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
D-1339	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
P-1339	-2.1679 -0.0969 -0.2968 -0.3520 -0.6132 -0.3444 -1.1346 -0.2924 -1.7462 -0.0648 -0.0831 -0.4968 -1.1155 -0.7396 -0.8264 -0.1437 -0.0404 -0.1307 -1.6504 -1.2830 -0.1622 -1.5524 -0.1980 -0.2503 -1.1699 -0.1367 -0.6311 -1.1028 -0.2088 -0.1558 -0.1662
S-1133	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-1133	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-1133	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
D-1133	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
P-1133	-0.1664 -0.2186 -0.1790 -0.1326 -0.1974 -0.0525 -0.0596 -0.1546 -1.4208 -0.0842 -0.0725 -0.2012 -0.6518 -1.4714 -0.1243 -0.0725 -0.1499 -0.1451 -0.1526 -0.0915 -0.5356 -0.5740 -0.2610 -1.4549 -0.1427 -0.8564 -0.0706 -0.5279 -0.1611 -0.0766 -0.1101 -0.6189 -0.2771 -0.0340 -0.3866 -2.0340 -0.1432 -0.1472 -0.1656 -0.4267 -0.0451 -0.1613 -0.1544
S-957	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-957	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-957	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
D-957	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
P-957	-0.1664 -0.2186 -0.1790 -0.1326 -0.1974 -0.0525 -0.0596 -0.1546 -1.4208 -0.0842 -0.0725 -0.2012 -0.6518 -1.4714 -0.1243 -0.0725 -0.1499 -0.1451 -0.1526 -0.0915 -0.5356 -0.5740 -0.2610 -1.4549 -0.1427 -0.8564 -0.0706 -0.5279 -0.1611 -0.0766 -0.1101 -0.6189 -0.2771 -0.0340 -0.3866 -2.0340 -0.1432 -0.1472 -0.1656 -0.4267 -0.0451 -0.1613 -0.1544
S-414	In der Zwei-Jahres-Verlängerung dieser Studien hielten die Anstiege der BMD von Wirbelsäule und Trochanter weiterhin an ; auch die BMD des Femurhalses und des gesamten Körpers wurde aufrechterhalten .
T-414	In the two-year extension of these studies BMD at the spine and trochanter continued to increase and BMD at the femoral neck and total body were maintained .
H-414	-0.5411844849586487	Throughout the two year extension of these studies , spinal and trochanter BMD continued to rise and femoral and body BMD was maintained .
D-414	-0.5411844849586487	Throughout the two year extension of these studies , spinal and trochanter BMD continued to rise and femoral and body BMD was maintained .
P-414	-2.1216 -0.1065 -0.0871 -1.0438 -1.0176 -1.5143 -0.7386 -0.1735 -0.1046 -0.9034 -0.1480 -0.7266 -0.5384 -0.1495 -0.0367 -0.2855 -0.4403 -0.1814 -0.1829 -1.4939 -0.1661 -0.7538 -1.3682 -0.4975 -0.1209 -0.8488 -0.6661 -0.3969 -0.1281 -0.2826 -0.3015 -0.1667 -0.1678
S-607	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-607	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-607	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
D-607	-0.35263746976852417	The risk of developing inhibitors correlates with the level of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and depending on genetic and other factors .
P-607	-0.1664 -0.2186 -0.1790 -0.1326 -0.1974 -0.0525 -0.0596 -0.1546 -1.4208 -0.0842 -0.0725 -0.2012 -0.6518 -1.4714 -0.1243 -0.0725 -0.1499 -0.1451 -0.1526 -0.0915 -0.5356 -0.5740 -0.2610 -1.4549 -0.1427 -0.8564 -0.0706 -0.5279 -0.1611 -0.0766 -0.1101 -0.6189 -0.2771 -0.0340 -0.3866 -2.0340 -0.1432 -0.1472 -0.1656 -0.4267 -0.0451 -0.1613 -0.1544
S-1442	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-1442	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-1442	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
D-1442	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
P-1442	-0.3798 -0.3620 -0.1687 -2.1065 -0.1981 -0.1671 -0.2284 -0.1029 -0.0969 -0.1614 -1.5413 -0.4095 -0.2317 -0.1830 -0.1479 -0.1486 -0.0431 -0.1316 -0.2647 -0.1290 -0.1045 -0.0806 -0.0861 -0.2570 -0.1207 -0.2196 -0.3783 -0.4330 -0.0552 -0.1421 -0.0420 -0.1330 -0.2722 -0.7627 -0.2553 -0.1828 -0.3729 -0.1615 -0.0877 -0.1392 -0.1571 -0.0868 -0.0974 -0.1403 -0.1729 -0.1548
S-1090	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-1090	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-1090	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
D-1090	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
P-1090	-0.3798 -0.3620 -0.1687 -2.1065 -0.1981 -0.1671 -0.2284 -0.1029 -0.0969 -0.1614 -1.5413 -0.4095 -0.2317 -0.1830 -0.1479 -0.1486 -0.0431 -0.1316 -0.2647 -0.1290 -0.1045 -0.0806 -0.0861 -0.2570 -0.1207 -0.2196 -0.3783 -0.4330 -0.0552 -0.1421 -0.0420 -0.1330 -0.2722 -0.7627 -0.2553 -0.1828 -0.3729 -0.1615 -0.0877 -0.1392 -0.1571 -0.0868 -0.0974 -0.1403 -0.1729 -0.1548
S-637	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-637	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-637	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
D-637	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
P-637	-2.1679 -0.0969 -0.2968 -0.3520 -0.6132 -0.3444 -1.1346 -0.2924 -1.7462 -0.0648 -0.0831 -0.4968 -1.1155 -0.7396 -0.8264 -0.1437 -0.0404 -0.1307 -1.6504 -1.2830 -0.1622 -1.5524 -0.1980 -0.2503 -1.1699 -0.1367 -0.6311 -1.1028 -0.2088 -0.1558 -0.1662
S-849	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-849	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-849	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-849	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-849	-1.4301 -0.4708 -0.1561 -0.3184 -0.0559 -0.1491 -0.0831 -1.5988 -1.3607 -0.1564 -0.2349 -0.7808 -0.2159 -0.0946 -0.5104 -0.3196 -0.1508 -0.1094 -0.1374 -0.7256 -0.2028 -0.3532 -0.6046 -0.5480 -1.0585 -1.0640 -0.1432 -0.3559 -0.1320 -0.4779 -0.2602 -0.2259 -0.0528 -0.0914 -0.0423 -0.1088 -0.0992 -1.1899 -0.0658 -0.1872 -0.0747 -0.1282 -0.1726 -0.1558
S-1025	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-1025	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-1025	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-1025	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-1025	-1.4301 -0.4708 -0.1561 -0.3184 -0.0559 -0.1491 -0.0831 -1.5988 -1.3607 -0.1564 -0.2349 -0.7808 -0.2159 -0.0946 -0.5104 -0.3196 -0.1508 -0.1094 -0.1374 -0.7256 -0.2028 -0.3532 -0.6046 -0.5480 -1.0585 -1.0640 -0.1432 -0.3559 -0.1320 -0.4779 -0.2602 -0.2259 -0.0528 -0.0914 -0.0423 -0.1088 -0.0992 -1.1899 -0.0658 -0.1872 -0.0747 -0.1282 -0.1726 -0.1558
S-387	Bone mineral density ) an Wirbelsäule oder Hüfte , die 2,5 Standardabweichungen unter dem Mittelwert für eine normale , junge Bevölkerung liegt , oder ungeachtet der Knochendichte als vorliegende pathologische Fraktur .
T-387	Osteoporosis is defined as bone mineral density ( BMD ) of the spine or hip 2.5 standard deviations ( SD ) below the mean value of a normal young population or as a previous fragility fracture , irrespective of BMD .
H-387	-0.35747140645980835	bone mineral density ) in the spine or hip that is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as a pathological fracture .
D-387	-0.35747140645980835	bone mineral density ) in the spine or hip that is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as a pathological fracture .
P-387	-0.0716 -0.0650 -0.0856 -0.0898 -0.1400 -0.1516 -0.7910 -0.3845 -0.3914 -0.1683 -0.2147 -0.1542 -2.4439 -0.2683 -0.1945 -0.2260 -0.1005 -0.2063 -0.4854 -0.6008 -0.0789 -0.1921 -0.4952 -0.0460 -1.2895 -0.1769 -0.0838 -0.5092 -0.1448 -1.2345 -0.1238 -0.0229 -0.0999 -0.1186 -0.2320 -1.0988 -0.7656 -0.1422 -0.0935 -0.0689 -0.6079 -0.1557
S-80	Es darf nicht angewendet werden bei Erkrankungen der Speiseröhre , bei Patienten mit Hypocalcämie ( geringem Kalziumspiegel ) oder bei Patienten , die nicht mindestens 30 Minuten lang aufrecht stehen oder sitzen können .
T-80	It should not be used where there are abnormalities of the oesophagus ( gullet ) , in patients who have hypocalcaemia ( low calcium levels ) , or in patients who cannot stand or sit upright for at least 30 minutes .
H-80	-0.33066803216934204	Do not use in oesophageal disorders , in patients with hypocalcaemia ( low calcium ) , or in patients who cannot stand or sit upright for at least 30 minutes .
D-80	-0.33066803216934204	Do not use in oesophageal disorders , in patients with hypocalcaemia ( low calcium ) , or in patients who cannot stand or sit upright for at least 30 minutes .
P-80	-0.3854 -0.1222 -0.0448 -0.2505 -1.0309 -0.0055 -0.6076 -0.0377 -0.0768 -0.1150 -0.3703 -0.0653 -0.1337 -1.5154 -0.7312 -0.1433 -0.0494 -0.1170 -0.0846 -0.0487 -0.1374 -0.1729 -0.3397 -0.2456 -0.1163 -0.0940 -1.4144 -0.9503 -0.2069 -0.3190 -0.5348 -0.2935 -1.0869 -0.4407 -0.4739 -0.1534 -1.0684 -0.0738 -0.1016 -0.1344 -0.1071 -0.1164 -0.1468 -0.1367 -0.2357 -0.1745
S-673	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-673	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-673	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-673	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-673	-1.4301 -0.4708 -0.1561 -0.3184 -0.0559 -0.1491 -0.0831 -1.5988 -1.3607 -0.1564 -0.2349 -0.7808 -0.2159 -0.0946 -0.5104 -0.3196 -0.1508 -0.1094 -0.1374 -0.7256 -0.2028 -0.3532 -0.6046 -0.5480 -1.0585 -1.0640 -0.1432 -0.3559 -0.1320 -0.4779 -0.2602 -0.2259 -0.0528 -0.0914 -0.0423 -0.1088 -0.0992 -1.1899 -0.0658 -0.1872 -0.0747 -0.1282 -0.1726 -0.1558
S-1705	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1705	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1705	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1705	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1705	-2.8794 -0.0502 -0.1730 -0.2786 -0.1130 -0.0832 -0.1381 -0.1119 -0.0869 -0.1118 -0.0780 -0.0815 -0.0833 -0.1379 -0.1098 -0.3937 -0.1420 -0.1355 -0.1034 -0.5263 -0.1215 -0.1351 -0.1237 -0.1002 -0.1294 -0.1313 -0.0663 -0.0982 -0.0840 -0.1354 -0.1729 -0.1150 -0.1422 -0.1086 -0.1370 -0.0975 -0.0711 -0.1390 -0.1025 -0.1599 -0.1407 -0.6379 -0.0676 -0.0690 -0.1291 -0.1773 -0.2721 -0.0767 -0.1580 -0.1633
S-1673	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1673	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1673	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1673	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1673	-2.8794 -0.0502 -0.1730 -0.2786 -0.1130 -0.0832 -0.1381 -0.1119 -0.0869 -0.1118 -0.0780 -0.0815 -0.0833 -0.1379 -0.1098 -0.3937 -0.1420 -0.1355 -0.1034 -0.5263 -0.1215 -0.1351 -0.1237 -0.1002 -0.1294 -0.1313 -0.0663 -0.0982 -0.0840 -0.1354 -0.1729 -0.1150 -0.1422 -0.1086 -0.1370 -0.0975 -0.0711 -0.1390 -0.1025 -0.1599 -0.1407 -0.6379 -0.0676 -0.0690 -0.1291 -0.1773 -0.2721 -0.0767 -0.1580 -0.1633
S-1201	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-1201	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-1201	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-1201	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-1201	-1.4301 -0.4708 -0.1561 -0.3184 -0.0559 -0.1491 -0.0831 -1.5988 -1.3607 -0.1564 -0.2349 -0.7808 -0.2159 -0.0946 -0.5104 -0.3196 -0.1508 -0.1094 -0.1374 -0.7256 -0.2028 -0.3532 -0.6046 -0.5480 -1.0585 -1.0640 -0.1432 -0.3559 -0.1320 -0.4779 -0.2602 -0.2259 -0.0528 -0.0914 -0.0423 -0.1088 -0.0992 -1.1899 -0.0658 -0.1872 -0.0747 -0.1282 -0.1726 -0.1558
S-1377	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-1377	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-1377	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-1377	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-1377	-1.4301 -0.4708 -0.1561 -0.3184 -0.0559 -0.1491 -0.0831 -1.5988 -1.3607 -0.1564 -0.2349 -0.7808 -0.2159 -0.0946 -0.5104 -0.3196 -0.1508 -0.1094 -0.1374 -0.7256 -0.2028 -0.3532 -0.6046 -0.5480 -1.0585 -1.0640 -0.1432 -0.3559 -0.1320 -0.4779 -0.2602 -0.2259 -0.0528 -0.0914 -0.0423 -0.1088 -0.0992 -1.1899 -0.0658 -0.1872 -0.0747 -0.1282 -0.1726 -0.1558
S-1554	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-1554	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-1554	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-1554	-0.3830391466617584	The recovery and measured half-life in infants ( below 6 years ) was approximately 20 % lower than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-1554	-1.4301 -0.4708 -0.1561 -0.3184 -0.0559 -0.1491 -0.0831 -1.5988 -1.3607 -0.1564 -0.2349 -0.7808 -0.2159 -0.0946 -0.5104 -0.3196 -0.1508 -0.1094 -0.1374 -0.7256 -0.2028 -0.3532 -0.6046 -0.5480 -1.0585 -1.0640 -0.1432 -0.3559 -0.1320 -0.4779 -0.2602 -0.2259 -0.0528 -0.0914 -0.0423 -0.1088 -0.0992 -1.1899 -0.0658 -0.1872 -0.0747 -0.1282 -0.1726 -0.1558
S-199	Bone mineral density ) an Wirbelsäule oder Hüfte , die 2,5 Standardabweichungen unter dem Mittelwert für eine normale , junge Bevölkerung liegt , oder ungeachtet der Knochendichte als vorliegende pathologische Fraktur .
T-199	Osteoporosis is defined as bone mineral density ( BMD ) of the spine or hip 2.5 standard deviations ( SD ) below the mean value of a normal young population or as a previous fragility fracture , irrespective of BMD .
H-199	-0.35747140645980835	bone mineral density ) in the spine or hip that is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as a pathological fracture .
D-199	-0.35747140645980835	bone mineral density ) in the spine or hip that is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as a pathological fracture .
P-199	-0.0716 -0.0650 -0.0856 -0.0898 -0.1400 -0.1516 -0.7910 -0.3845 -0.3914 -0.1683 -0.2147 -0.1542 -2.4439 -0.2683 -0.1945 -0.2260 -0.1005 -0.2063 -0.4854 -0.6008 -0.0789 -0.1921 -0.4952 -0.0460 -1.2895 -0.1769 -0.0838 -0.5092 -0.1448 -1.2345 -0.1238 -0.0229 -0.0999 -0.1186 -0.2320 -1.0988 -0.7656 -0.1422 -0.0935 -0.0689 -0.6079 -0.1557
S-1266	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-1266	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-1266	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
D-1266	-0.26734688878059387	Factor VIII activity in plasma is given either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the international standard for factor VIII in plasma ) .
P-1266	-0.3798 -0.3620 -0.1687 -2.1065 -0.1981 -0.1671 -0.2284 -0.1029 -0.0969 -0.1614 -1.5413 -0.4095 -0.2317 -0.1830 -0.1479 -0.1486 -0.0431 -0.1316 -0.2647 -0.1290 -0.1045 -0.0806 -0.0861 -0.2570 -0.1207 -0.2196 -0.3783 -0.4330 -0.0552 -0.1421 -0.0420 -0.1330 -0.2722 -0.7627 -0.2553 -0.1828 -0.3729 -0.1615 -0.0877 -0.1392 -0.1571 -0.0868 -0.0974 -0.1403 -0.1729 -0.1548
S-1689	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1689	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1689	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1689	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1689	-2.8794 -0.0502 -0.1730 -0.2786 -0.1130 -0.0832 -0.1381 -0.1119 -0.0869 -0.1118 -0.0780 -0.0815 -0.0833 -0.1379 -0.1098 -0.3937 -0.1420 -0.1355 -0.1034 -0.5263 -0.1215 -0.1351 -0.1237 -0.1002 -0.1294 -0.1313 -0.0663 -0.0982 -0.0840 -0.1354 -0.1729 -0.1150 -0.1422 -0.1086 -0.1370 -0.0975 -0.0711 -0.1390 -0.1025 -0.1599 -0.1407 -0.6379 -0.0676 -0.0690 -0.1291 -0.1773 -0.2721 -0.0767 -0.1580 -0.1633
S-165	<unk> Häufig ( 1<unk> 100 , <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 , <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 , <unk> 1<unk> 1.000 ) , sehr selten ( <unk> 1<unk> 10.000 ) <unk>
T-165	<<unk>> Common ( 1/ 100 , <<unk>> 1/ 10 ) , uncommon ( 1/ 1000 , <<unk>> 1/ 100 ) , rare ( 1/ 10,000 , <<unk>> 1/ 1000 ) , very rare ( <<unk>> 1/ 10,000 ) <<unk>>
H-165	-0.18884500861167908	Common ( 1<unk> 100 , <unk> 1<unk> 10 ) , occasional ( 1<unk> 1,000 , <unk> 1<unk> 100 ) , rare ( 1<unk> 10,000 , <unk> 1<unk> 1,000 ) , very rare ( <unk> 1<unk> 10,000 ) <unk>
D-165	-0.18884500861167908	Common ( 1<unk> 100 , <unk> 1<unk> 10 ) , occasional ( 1<unk> 1,000 , <unk> 1<unk> 100 ) , rare ( 1<unk> 10,000 , <unk> 1<unk> 1,000 ) , very rare ( <unk> 1<unk> 10,000 ) <unk>
P-165	-0.6843 -0.1173 -0.1476 -0.1443 -0.5172 -0.3422 -0.1414 -0.0739 -0.1162 -0.0746 -0.2094 -0.1363 -0.1280 -1.3602 -0.1240 -0.1506 -0.1879 -0.0885 -0.3075 -0.1390 -0.0266 -0.1159 -0.1407 -0.1675 -0.1332 -0.1341 -0.0534 -0.1530 -0.1137 -0.0803 -0.1793 -0.1384 -0.0272 -0.3390 -0.2130 -0.2421 -0.1324 -0.1402 -0.2711 -0.0441 -0.1453 -0.0424 -0.1482 -0.1144 -0.2142 -0.1249 -0.0760 -0.1633
S-353	<unk> Häufig ( 1<unk> 100 , <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 , <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 , <unk> 1<unk> 1.000 ) , sehr selten ( <unk> 1<unk> 10.000 ) <unk>
T-353	<<unk>> Common ( 1/ 100 , <<unk>> 1/ 10 ) , uncommon ( 1/ 1000 , <<unk>> 1/ 100 ) , rare ( 1/ 10,000 , <<unk>> 1/ 1000 ) , very rare ( <<unk>> 1/ 10,000 ) <<unk>>
H-353	-0.18884500861167908	Common ( 1<unk> 100 , <unk> 1<unk> 10 ) , occasional ( 1<unk> 1,000 , <unk> 1<unk> 100 ) , rare ( 1<unk> 10,000 , <unk> 1<unk> 1,000 ) , very rare ( <unk> 1<unk> 10,000 ) <unk>
D-353	-0.18884500861167908	Common ( 1<unk> 100 , <unk> 1<unk> 10 ) , occasional ( 1<unk> 1,000 , <unk> 1<unk> 100 ) , rare ( 1<unk> 10,000 , <unk> 1<unk> 1,000 ) , very rare ( <unk> 1<unk> 10,000 ) <unk>
P-353	-0.6843 -0.1173 -0.1476 -0.1443 -0.5172 -0.3422 -0.1414 -0.0739 -0.1162 -0.0746 -0.2094 -0.1363 -0.1280 -1.3602 -0.1240 -0.1506 -0.1879 -0.0885 -0.3075 -0.1390 -0.0266 -0.1159 -0.1407 -0.1675 -0.1332 -0.1341 -0.0534 -0.1530 -0.1137 -0.0803 -0.1793 -0.1384 -0.0272 -0.3390 -0.2130 -0.2421 -0.1324 -0.1402 -0.2711 -0.0441 -0.1453 -0.0424 -0.1482 -0.1144 -0.2142 -0.1249 -0.0760 -0.1633
S-1379	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-1379	48 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-1379	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-1379	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-1379	-0.8664 -1.0617 -0.1740 -1.4164 -0.1604 -0.1428 -1.1334 -0.9316 -0.1928 -0.3329 -0.1129 -0.0754 -0.1680 -1.2519 -0.8190 -0.1846 -0.1095 -0.1547 -0.1745 -0.9220 -0.0427 -0.0722 -0.1813 -0.0972 -0.1236 -0.2872 -0.2020 -1.4275 -0.0730 -1.0556 -1.4488 -0.1684 -0.2554 -0.1629
S-1556	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-1556	58 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-1556	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-1556	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-1556	-0.8664 -1.0617 -0.1740 -1.4164 -0.1604 -0.1428 -1.1334 -0.9316 -0.1928 -0.3329 -0.1129 -0.0754 -0.1680 -1.2519 -0.8190 -0.1846 -0.1095 -0.1547 -0.1745 -0.9220 -0.0427 -0.0722 -0.1813 -0.0972 -0.1236 -0.2872 -0.2020 -1.4275 -0.0730 -1.0556 -1.4488 -0.1684 -0.2554 -0.1629
S-1967	Diese beinhalten : Dekongestiva Anorektika oder Psychostimulanzien vom Amphetamintyp 3 Antihypertensiva trizyklische Antidepressiva und andere Antihistaminika .
T-1967	These include : decongestants anorexogenics or amphetamine-type psychostimulants antihypertensive agents tricyclic antidepressants and other antihistamines .
H-1967	-0.3035507798194885	These include : decongestants anorectics or type 3 amphetamine psychostimulants , tricyclic antidepressants and other antihistamines .
D-1967	-0.3035507798194885	These include : decongestants anorectics or type 3 amphetamine psychostimulants , tricyclic antidepressants and other antihistamines .
P-1967	-0.4567 -0.1700 -0.7172 -0.3564 -0.1162 -0.4480 -0.2885 -0.5764 -0.1325 -0.1936 -0.3335 -0.1756 -1.6385 -0.1138 -0.3315 -0.1412 -0.0945 -0.3403 -0.7385 -0.0455 -0.0938 -0.2293 -1.3343 -0.2159 -0.0459 -0.1547 -0.1354 -0.0367 -0.1791 -0.2053 -0.4925 -0.1714 -0.0743 -0.0605 -0.1657 -0.1457 -0.2305 -0.1558
S-1203	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-1203	38 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-1203	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-1203	-0.4700714349746704	Nonclinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-1203	-0.8664 -1.0617 -0.1740 -1.4164 -0.1604 -0.1428 -1.1334 -0.9316 -0.1928 -0.3329 -0.1129 -0.0754 -0.1680 -1.2519 -0.8190 -0.1846 -0.1095 -0.1547 -0.1745 -0.9220 -0.0427 -0.0722 -0.1813 -0.0972 -0.1236 -0.2872 -0.2020 -1.4275 -0.0730 -1.0556 -1.4488 -0.1684 -0.2554 -0.1629
S-1655	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1655	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1655	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1655	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1655	-2.8794 -0.0502 -0.1730 -0.2786 -0.1130 -0.0832 -0.1381 -0.1119 -0.0869 -0.1118 -0.0780 -0.0815 -0.0833 -0.1379 -0.1098 -0.3937 -0.1420 -0.1355 -0.1034 -0.5263 -0.1215 -0.1351 -0.1237 -0.1002 -0.1294 -0.1313 -0.0663 -0.0982 -0.0840 -0.1354 -0.1729 -0.1150 -0.1422 -0.1086 -0.1370 -0.0975 -0.0711 -0.1390 -0.1025 -0.1599 -0.1407 -0.6379 -0.0676 -0.0690 -0.1291 -0.1773 -0.2721 -0.0767 -0.1580 -0.1633
S-1925	Es darf nicht angewendet werden bei Patienten , die einen Monoaminooxidasehemmer ( wie z. B. einige Arzneimittel gegen Depressionen ) einnehmen oder die Einnahme eines solchen Arzneimittels in den letzten zwei Wochen beendet haben .
T-1925	It should not be used in people who are taking a monoamine oxidase inhibitor ( such as some medicines used to treat depression ) or who have stopped taking one of these medicines within the last two weeks .
H-1925	-0.3690773844718933	Do not use in patients taking a monoamine oxidase inhibitor ( such as some antidepressant medicines ) or who have stopped taking such medicines within the last two weeks .
D-1925	-0.3690773844718933	Do not use in patients taking a monoamine oxidase inhibitor ( such as some antidepressant medicines ) or who have stopped taking such medicines within the last two weeks .
P-1925	-0.6894 -0.1164 -0.1196 -0.2386 -0.4630 -0.5551 -2.0573 -0.0547 -0.1417 -0.0676 -0.4247 -0.0688 -0.0993 -0.1197 -0.0681 -0.0650 -0.2132 -0.2655 -0.9248 -0.1563 -0.2054 -0.5315 -0.0937 -0.1505 -0.2831 -0.8749 -0.3043 -0.1354 -0.2776 -0.1899 -0.2296 -0.4165 -0.1923 -0.2864 -1.1876 -0.6185 -1.5815 -0.1764 -0.4987 -0.2225 -0.1170 -0.2248 -0.1636
S-1623	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1623	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1623	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1623	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1623	-2.8794 -0.0502 -0.1730 -0.2786 -0.1130 -0.0832 -0.1381 -0.1119 -0.0869 -0.1118 -0.0780 -0.0815 -0.0833 -0.1379 -0.1098 -0.3937 -0.1420 -0.1355 -0.1034 -0.5263 -0.1215 -0.1351 -0.1237 -0.1002 -0.1294 -0.1313 -0.0663 -0.0982 -0.0840 -0.1354 -0.1729 -0.1150 -0.1422 -0.1086 -0.1370 -0.0975 -0.0711 -0.1390 -0.1025 -0.1599 -0.1407 -0.6379 -0.0676 -0.0690 -0.1291 -0.1773 -0.2721 -0.0767 -0.1580 -0.1633
S-1639	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1639	Exipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1639	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1639	-0.20160366594791412	Other ingredients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1639	-2.8794 -0.0502 -0.1730 -0.2786 -0.1130 -0.0832 -0.1381 -0.1119 -0.0869 -0.1118 -0.0780 -0.0815 -0.0833 -0.1379 -0.1098 -0.3937 -0.1420 -0.1355 -0.1034 -0.5263 -0.1215 -0.1351 -0.1237 -0.1002 -0.1294 -0.1313 -0.0663 -0.0982 -0.0840 -0.1354 -0.1729 -0.1150 -0.1422 -0.1086 -0.1370 -0.0975 -0.0711 -0.1390 -0.1025 -0.1599 -0.1407 -0.6379 -0.0676 -0.0690 -0.1291 -0.1773 -0.2721 -0.0767 -0.1580 -0.1633
S-811	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-811	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-811	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
D-811	-0.6242902874946594	Clotting was maintained throughout and both plasma factor VIII levels and clearance rates returned to adequate levels on day 15 postoperatively .
P-811	-2.1679 -0.0969 -0.2968 -0.3520 -0.6132 -0.3444 -1.1346 -0.2924 -1.7462 -0.0648 -0.0831 -0.4968 -1.1155 -0.7396 -0.8264 -0.1437 -0.0404 -0.1307 -1.6504 -1.2830 -0.1622 -1.5524 -0.1980 -0.2503 -1.1699 -0.1367 -0.6311 -1.1028 -0.2088 -0.1558 -0.1662
S-221	In dieser Studie reduzierte die tägliche Gabe von Alendronat das Auftreten von mindestens einer neuen Wirbelfraktur um 47 % ( Alendronat 7,9 % gegenüber Plazebo 15,0 % ) .
T-221	In this study alendronate daily reduced the incidence of 1 new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
H-221	-0.21499291062355042	In this study , daily alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
D-221	-0.21499291062355042	In this study , daily alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
P-221	-0.2344 -0.1309 -0.5356 -0.6237 -0.1203 -0.8657 -0.1414 -0.1333 -0.1066 -0.6459 -0.2181 -0.9525 -0.0446 -0.1005 -0.0899 -0.1254 -0.1480 -0.1160 -0.1529 -0.1724 -0.1730 -0.0960 -0.0803 -0.2159 -0.0561 -0.0618 -0.1614 -0.0493 -0.1399 -0.1449 -0.2491 -0.1208 -0.1405 -0.0665 -0.4191 -0.1156 -0.1082 -0.9386 -0.1125 -0.1663 -0.1784 -0.1248 -0.0883 -0.0992 -0.1100 -0.1280 -0.1653 -0.1517
S-1978	Von den folgenden Begleittherapien wird abgeraten : Bromocriptin Cabergolin Lisurid , Pergolid : Risiko für das Auftreten einer Gefäßverengung und einer Hypertonie .
T-1978	The following combinations are not recommended : bromocriptine cabergoline lisuride , pergolide : risk of vasoconstriction and increase in blood pressure .
H-1978	-0.33290359377861023	The following concomitant therapies are not recommended : bromocriptine cabergoline lisuride , pergolide : risk of vasoconstriction and hypertension .
D-1978	-0.33290359377861023	The following concomitant therapies are not recommended : bromocriptine cabergoline lisuride , pergolide : risk of vasoconstriction and hypertension .
P-1978	-0.8638 -0.1016 -0.6591 -0.0042 -0.0100 -0.1266 -0.4583 -0.1441 -0.1384 -1.2372 -0.8991 -0.1351 -0.2085 -0.1208 -0.0975 -0.1172 -1.1687 -0.1217 -0.6514 -0.0746 -0.9961 -1.2202 -0.3696 -0.2733 -0.1532 -0.1975 -0.1924 -0.1411 -0.1999 -0.1500 -0.0559 -0.6950 -0.5980 -0.0339 -0.7711 -0.0829 -0.1332 -0.1341 -0.1378 -0.0284 -0.0422 -0.2149 -0.1561
S-243	Die mittlere maximale Konzentration im Serum ( Cmax ) von Vitamin D3 betrug 5,9 ng<unk> ml und die Medianzeit bis zum Erreichen der maximalen Serumkonzentration ( Tmax ) 12 Stunden .
T-243	The mean maximal serum concentration ( Cmax ) of vitamin D3 was 5.9 ng/ ml , and the median time to maximal serum concentration ( Tmax ) was 12 hours .
H-243	-0.21844664216041565	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 5.9 ng/ ml and the median time to reach peak serum concentration ( Tmax ) was 12 hours .
D-243	-0.21844664216041565	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 5.9 ng/ ml and the median time to reach peak serum concentration ( Tmax ) was 12 hours .
P-243	-0.1872 -0.1229 -0.2607 -1.0897 -0.1163 -0.2234 -0.1358 -0.1356 -0.0461 -0.1229 -0.1659 -0.1008 -0.0748 -0.1666 -0.1402 -0.1320 -0.0845 -0.1382 -0.0827 -0.1519 -0.1064 -0.0683 -0.6179 -0.1569 -0.0940 -0.1138 -0.6208 -0.4198 -0.3467 -1.0415 -0.4814 -0.1499 -0.1992 -0.1197 -0.1456 -0.0384 -0.1235 -0.1176 -0.1143 -0.1109 -0.1565 -0.1535
S-417	In dieser Studie reduzierte die tägliche Gabe von Alendronat das Auftreten von mindestens einer neuen Wirbelfraktur um 47 % ( Alendronat 7,9 % gegenüber Plazebo 15,0 % ) .
T-417	In this study alendronate daily reduced the incidence of 1 new 18 vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
H-417	-0.21499291062355042	In this study , daily alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
D-417	-0.21499291062355042	In this study , daily alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
P-417	-0.2344 -0.1309 -0.5356 -0.6237 -0.1203 -0.8657 -0.1414 -0.1333 -0.1066 -0.6459 -0.2181 -0.9525 -0.0446 -0.1005 -0.0899 -0.1254 -0.1480 -0.1160 -0.1529 -0.1724 -0.1730 -0.0960 -0.0803 -0.2159 -0.0561 -0.0618 -0.1614 -0.0493 -0.1399 -0.1449 -0.2491 -0.1208 -0.1405 -0.0665 -0.4191 -0.1156 -0.1082 -0.9386 -0.1125 -0.1663 -0.1784 -0.1248 -0.0883 -0.0992 -0.1100 -0.1280 -0.1653 -0.1517
S-377	18 Colecalciferol ( Vitamin D3 ) Vitamin D3 wird in der Haut durch UV-Licht über die Umwandlung von 7-Dehydrocholesterol zu Vitamin D3 produziert .
T-377	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by conversion of 7-dehydrocholesterol to vitamin D3 by ultraviolet light .
H-377	-0.26969730854034424	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light via the conversion of 7-dehydrocholesterol to vitamin D3 .
D-377	-0.26969730854034424	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light via the conversion of 7-dehydrocholesterol to vitamin D3 .
P-377	-0.7472 -0.1309 -0.1861 -0.1301 -0.1311 -0.1683 -0.1498 -0.1466 -0.0885 -0.1496 -0.1314 -0.1290 -0.2656 -0.0533 -0.1541 -0.1394 -0.1797 -0.1208 -0.3715 -0.1822 -0.0958 -0.3248 -0.6357 -0.1502 -0.3068 -1.3657 -0.4586 -0.2584 -0.2225 -0.1468 -1.4426 -0.0591 -0.1011 -0.0655 -0.2271 -0.1167 -0.1659 -1.0562 -0.1951 -0.0641 -0.1541 -0.1337 -0.1996 -0.1656
S-1271	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-1271	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-1271	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
D-1271	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
P-1271	-0.6530 -0.9386 -0.2457 -0.7048 -0.0693 -0.3789 -0.0847 -0.1269 -0.5780 -0.8038 -0.5118 -0.2098 -1.0178 -0.3452 -0.4715 -0.4444 -0.1331 -1.5427 -0.1679 -0.1666 -2.0263 -0.7726 -0.2837 -0.0432 -0.0651 -0.4661 -0.2083 -1.2549 -0.1539 -0.1527 -1.1433 -0.6222 -0.1233 -0.1682 -0.3466 -0.1348 -0.0880 -0.0851 -0.0363 -0.1602 -1.3282 -0.3766 -0.9292 -0.1293 -0.5788 -0.2609 -0.1524
S-919	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-919	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-919	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
D-919	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
P-919	-0.6530 -0.9386 -0.2457 -0.7048 -0.0693 -0.3789 -0.0847 -0.1269 -0.5780 -0.8038 -0.5118 -0.2098 -1.0178 -0.3452 -0.4715 -0.4444 -0.1331 -1.5427 -0.1679 -0.1666 -2.0263 -0.7726 -0.2837 -0.0432 -0.0651 -0.4661 -0.2083 -1.2549 -0.1539 -0.1527 -1.1433 -0.6222 -0.1233 -0.1682 -0.3466 -0.1348 -0.0880 -0.0851 -0.0363 -0.1602 -1.3282 -0.3766 -0.9292 -0.1293 -0.5788 -0.2609 -0.1524
S-1447	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-1447	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-1447	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
D-1447	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
P-1447	-0.6530 -0.9386 -0.2457 -0.7048 -0.0693 -0.3789 -0.0847 -0.1269 -0.5780 -0.8038 -0.5118 -0.2098 -1.0178 -0.3452 -0.4715 -0.4444 -0.1331 -1.5427 -0.1679 -0.1666 -2.0263 -0.7726 -0.2837 -0.0432 -0.0651 -0.4661 -0.2083 -1.2549 -0.1539 -0.1527 -1.1433 -0.6222 -0.1233 -0.1682 -0.3466 -0.1348 -0.0880 -0.0851 -0.0363 -0.1602 -1.3282 -0.3766 -0.9292 -0.1293 -0.5788 -0.2609 -0.1524
S-1981	Sympathomimetika können die antihypertensive Wirkung von -Methyldopa , Mecamylamin , Reserpin , Veratrum-Alkaloiden und Guanethidin mindern .
T-1981	Sympathomimetic medicines reduce the antihypertensive effect of -methyldopa , mecamylamine , reserpine , veratrum alkaloids , and guanethidine .
H-1981	-0.330157995223999	Sympathomimetics may reduce the antihypertensive effects of -methyldopa , mecamylamine , reserpine , veratrum alkaloids , and guanethidine .
D-1981	-0.330157995223999	Sympathomimetics may reduce the antihypertensive effects of -methyldopa , mecamylamine , reserpine , veratrum alkaloids , and guanethidine .
P-1981	-1.0059 -0.0579 -0.0632 -0.0696 -0.6167 -1.3170 -0.2387 -0.2911 -0.0176 -0.1530 -0.1334 -2.2571 -0.1301 -0.0575 -0.0544 -0.2984 -0.4073 -0.3430 -0.1314 -0.1366 -0.1948 -0.0941 -0.1168 -0.2898 -0.0705 -0.1366 -0.3835 -0.5249 -0.2053 -0.1393 -1.3842 -0.0349 -1.3598 -0.1007 -0.1058 -0.0607 -0.0482 -0.9654 -0.1227 -0.1624 -0.1113 -0.0944 -0.1294 -0.2113 -0.2042 -0.1568
S-1095	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-1095	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-1095	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
D-1095	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
P-1095	-0.6530 -0.9386 -0.2457 -0.7048 -0.0693 -0.3789 -0.0847 -0.1269 -0.5780 -0.8038 -0.5118 -0.2098 -1.0178 -0.3452 -0.4715 -0.4444 -0.1331 -1.5427 -0.1679 -0.1666 -2.0263 -0.7726 -0.2837 -0.0432 -0.0651 -0.4661 -0.2083 -1.2549 -0.1539 -0.1527 -1.1433 -0.6222 -0.1233 -0.1682 -0.3466 -0.1348 -0.0880 -0.0851 -0.0363 -0.1602 -1.3282 -0.3766 -0.9292 -0.1293 -0.5788 -0.2609 -0.1524
S-569	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-569	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-569	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
D-569	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
P-569	-0.6530 -0.9386 -0.2457 -0.7048 -0.0693 -0.3789 -0.0847 -0.1269 -0.5780 -0.8038 -0.5118 -0.2098 -1.0178 -0.3452 -0.4715 -0.4444 -0.1331 -1.5427 -0.1679 -0.1666 -2.0263 -0.7726 -0.2837 -0.0432 -0.0651 -0.4661 -0.2083 -1.2549 -0.1539 -0.1527 -1.1433 -0.6222 -0.1233 -0.1682 -0.3466 -0.1348 -0.0880 -0.0851 -0.0363 -0.1602 -1.3282 -0.3766 -0.9292 -0.1293 -0.5788 -0.2609 -0.1524
S-743	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-743	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-743	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
D-743	-0.4613754451274872	In subsequent haemorrhagic events , factor VIII-activity should not decrease below the indicated plasma levels ( in % of the norm or in IU/ dl ) over the corresponding period .
P-743	-0.6530 -0.9386 -0.2457 -0.7048 -0.0693 -0.3789 -0.0847 -0.1269 -0.5780 -0.8038 -0.5118 -0.2098 -1.0178 -0.3452 -0.4715 -0.4444 -0.1331 -1.5427 -0.1679 -0.1666 -2.0263 -0.7726 -0.2837 -0.0432 -0.0651 -0.4661 -0.2083 -1.2549 -0.1539 -0.1527 -1.1433 -0.6222 -0.1233 -0.1682 -0.3466 -0.1348 -0.0880 -0.0851 -0.0363 -0.1602 -1.3282 -0.3766 -0.9292 -0.1293 -0.5788 -0.2609 -0.1524
S-219	FIT bestand aus zwei plazebokontrollierten Studien , bei denen Alendronat täglich ( 5 mg täglich über 2 Jahre und anschließend 10 mg täglich weiterhin entweder über 1 oder 2 Jahre ) eingenommen wurde :
T-219	FIT consisted of two placebo-controlled studies using alendronate daily ( 5 mg daily for two years and 10 mg daily for either one or two additional years ) :
H-219	-0.2794952392578125	FIT consisted of two placebo-controlled studies in which alendronate was given daily ( 5 mg daily for 2 years and subsequently 10 mg daily for either 1 or 2 years ) :
D-219	-0.2794952392578125	FIT consisted of two placebo-controlled studies in which alendronate was given daily ( 5 mg daily for 2 years and subsequently 10 mg daily for either 1 or 2 years ) :
P-219	-0.1038 -0.1104 -0.1702 -0.1885 -0.1315 -0.2146 -0.0399 -0.1075 -0.0650 -0.2102 -0.0736 -0.8935 -1.9449 -0.1629 -0.1082 -0.1068 -0.1074 -0.0818 -0.1958 -1.5347 -0.1032 -0.1570 -0.3871 -0.0417 -0.2401 -0.1254 -0.1580 -0.0922 -0.8964 -1.1612 -0.1965 -0.0426 -0.2183 -0.2546 -0.0478 -0.1026 -0.2363 -0.1133 -0.0913 -0.1563 -0.2121 -0.1534
S-1017	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-1017	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-1017	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
D-1017	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
P-1017	-0.6181 -0.2085 -0.0734 -0.0589 -0.6597 -0.2939 -0.0442 -0.1150 -0.8515 -2.5978 -0.2290 -2.5056 -0.2999 -0.3345 -1.1187 -0.3388 -0.0703 -0.1587 -0.0832 -0.0873 -0.1595 -0.1134 -0.1139 -0.2036 -0.1857 -0.0616 -0.2382 -0.2328 -1.2428 -0.1233 -0.6323 -0.0876 -0.6520 -0.3764 -0.7462 -0.1618 -0.0932 -0.1219 -0.1505 -0.1839 -0.1532
S-1997	Die Patienten sollten jedoch darüber aufgeklärt werden , dass es in sehr seltenen Fällen zu einer Benommenheit kommen kann , die zu einer Beeinträchtigung der Verkehrstüchtigkeit oder der Fähigkeit zum Bedienen von Maschinen führen kann .
T-1997	However , patients should be informed that very rarely some people experience drowsiness , which may affect their ability to drive or use machines .
H-1997	-0.47010618448257446	However , patients should be advised that , in very rare cases , drowsiness may occur which may result in impairment of ability to drive or use machines .
D-1997	-0.47010618448257446	However , patients should be advised that , in very rare cases , drowsiness may occur which may result in impairment of ability to drive or use machines .
P-1997	-1.0093 -0.1900 -0.1912 -0.1746 -0.1155 -1.1843 -0.1667 -2.7579 -0.2108 -0.3535 -0.0594 -0.0947 -0.1295 -1.0236 -0.0208 -0.1280 -0.0284 -0.6296 -0.6385 -1.2709 -0.4198 -1.6414 -0.1300 -0.3858 -0.0339 -0.0441 -0.1134 -0.1703 -0.6369 -0.1719 -0.8599 -0.2210 -0.7190 -0.6812 -0.1593 -0.1583
S-666	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-666	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-666	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
D-666	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
P-666	-0.6181 -0.2085 -0.0734 -0.0589 -0.6597 -0.2939 -0.0442 -0.1150 -0.8515 -2.5978 -0.2290 -2.5056 -0.2999 -0.3345 -1.1187 -0.3388 -0.0703 -0.1587 -0.0832 -0.0873 -0.1595 -0.1134 -0.1139 -0.2036 -0.1857 -0.0616 -0.2382 -0.2328 -1.2428 -0.1233 -0.6323 -0.0876 -0.6520 -0.3764 -0.7462 -0.1618 -0.0932 -0.1219 -0.1505 -0.1839 -0.1532
S-841	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-841	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-841	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
D-841	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
P-841	-0.6181 -0.2085 -0.0734 -0.0589 -0.6597 -0.2939 -0.0442 -0.1150 -0.8515 -2.5978 -0.2290 -2.5056 -0.2999 -0.3345 -1.1187 -0.3388 -0.0703 -0.1587 -0.0832 -0.0873 -0.1595 -0.1134 -0.1139 -0.2036 -0.1857 -0.0616 -0.2382 -0.2328 -1.2428 -0.1233 -0.6323 -0.0876 -0.6520 -0.3764 -0.7462 -0.1618 -0.0932 -0.1219 -0.1505 -0.1839 -0.1532
S-1193	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-1193	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-1193	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
D-1193	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
P-1193	-0.6181 -0.2085 -0.0734 -0.0589 -0.6597 -0.2939 -0.0442 -0.1150 -0.8515 -2.5978 -0.2290 -2.5056 -0.2999 -0.3345 -1.1187 -0.3388 -0.0703 -0.1587 -0.0832 -0.0873 -0.1595 -0.1134 -0.1139 -0.2036 -0.1857 -0.0616 -0.2382 -0.2328 -1.2428 -0.1233 -0.6323 -0.0876 -0.6520 -0.3764 -0.7462 -0.1618 -0.0932 -0.1219 -0.1505 -0.1839 -0.1532
S-1369	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-1369	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-1369	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
D-1369	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
P-1369	-0.6181 -0.2085 -0.0734 -0.0589 -0.6597 -0.2939 -0.0442 -0.1150 -0.8515 -2.5978 -0.2290 -2.5056 -0.2999 -0.3345 -1.1187 -0.3388 -0.0703 -0.1587 -0.0832 -0.0873 -0.1595 -0.1134 -0.1139 -0.2036 -0.1857 -0.0616 -0.2382 -0.2328 -1.2428 -0.1233 -0.6323 -0.0876 -0.6520 -0.3764 -0.7462 -0.1618 -0.0932 -0.1219 -0.1505 -0.1839 -0.1532
S-1546	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-1546	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-1546	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
D-1546	-0.4092895984649658	The pharmacokinetic parameters are from a cross-over trial of ADVATE in 100 previously treated patients equal to or equal to 10 years and are listed in Table 3 below .
P-1546	-0.6181 -0.2085 -0.0734 -0.0589 -0.6597 -0.2939 -0.0442 -0.1150 -0.8515 -2.5978 -0.2290 -2.5056 -0.2999 -0.3345 -1.1187 -0.3388 -0.0703 -0.1587 -0.0832 -0.0873 -0.1595 -0.1134 -0.1139 -0.2036 -0.1857 -0.0616 -0.2382 -0.2328 -1.2428 -0.1233 -0.6323 -0.0876 -0.6520 -0.3764 -0.7462 -0.1618 -0.0932 -0.1219 -0.1505 -0.1839 -0.1532
S-189	Colecalciferol ( Vitamin D3 ) Vitamin D3 wird in der Haut durch UV-Licht über die Umwandlung von 7-Dehydrocholesterol zu Vitamin D3 produziert .
T-189	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by conversion of 7-dehydrocholesterol to vitamin D3 by ultraviolet light .
H-189	-0.25335732102394104	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light via the conversion of 7 -dehydrocholesterol to vitamin D3 .
D-189	-0.25335732102394104	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light via the conversion of 7 -dehydrocholesterol to vitamin D3 .
P-189	-0.4849 -0.1238 -0.1862 -0.1255 -0.1330 -0.1682 -0.1541 -0.1480 -0.0891 -0.1491 -0.1320 -0.1290 -0.2751 -0.0535 -0.1547 -0.1386 -0.1783 -0.1149 -0.3527 -0.1781 -0.0968 -0.3216 -0.6290 -0.1564 -0.2798 -1.2885 -0.4658 -0.2559 -0.2174 -0.1442 -0.8189 -0.3142 -0.1423 -0.0646 -0.2351 -0.1129 -0.1718 -1.0452 -0.2149 -0.0666 -0.1564 -0.1272 -0.1896 -0.1639
S-610	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-610	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-610	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
D-610	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
P-610	-0.1884 -0.2730 -0.8985 -0.1732 -1.0094 -0.0451 -0.0775 -0.0530 -0.1588 -0.0786 -0.1087 -0.1844 -2.6082 -0.3697 -0.1316 -0.2274 -0.0903 -0.2153 -0.4167 -0.1891 -0.1146 -0.0555 -0.2161 -0.4724 -2.3903 -0.1284 -0.1186 -0.0519 -0.0570 -0.1334 -0.3125 -0.2025 -0.0769 -0.1206 -0.1469 -0.1795 -0.1582
S-1136	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-1136	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-1136	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
D-1136	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
P-1136	-0.1884 -0.2730 -0.8985 -0.1732 -1.0094 -0.0451 -0.0775 -0.0530 -0.1588 -0.0786 -0.1087 -0.1844 -2.6082 -0.3697 -0.1316 -0.2274 -0.0903 -0.2153 -0.4167 -0.1891 -0.1146 -0.0555 -0.2161 -0.4724 -2.3903 -0.1284 -0.1186 -0.0519 -0.0570 -0.1334 -0.3125 -0.2025 -0.0769 -0.1206 -0.1469 -0.1795 -0.1582
S-784	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-784	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-784	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
D-784	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
P-784	-0.1884 -0.2730 -0.8985 -0.1732 -1.0094 -0.0451 -0.0775 -0.0530 -0.1588 -0.0786 -0.1087 -0.1844 -2.6082 -0.3697 -0.1316 -0.2274 -0.0903 -0.2153 -0.4167 -0.1891 -0.1146 -0.0555 -0.2161 -0.4724 -2.3903 -0.1284 -0.1186 -0.0519 -0.0570 -0.1334 -0.3125 -0.2025 -0.0769 -0.1206 -0.1469 -0.1795 -0.1582
S-960	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-960	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-960	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
D-960	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
P-960	-0.1884 -0.2730 -0.8985 -0.1732 -1.0094 -0.0451 -0.0775 -0.0530 -0.1588 -0.0786 -0.1087 -0.1844 -2.6082 -0.3697 -0.1316 -0.2274 -0.0903 -0.2153 -0.4167 -0.1891 -0.1146 -0.0555 -0.2161 -0.4724 -2.3903 -0.1284 -0.1186 -0.0519 -0.0570 -0.1334 -0.3125 -0.2025 -0.0769 -0.1206 -0.1469 -0.1795 -0.1582
S-415	FIT bestand aus zwei plazebokontrollierten Studien , bei denen Alendronat täglich ( 5 mg täglich über 2 Jahre und anschließend 10 mg täglich weiterhin entweder über 1 oder 2 Jahre ) eingenommen wurde :
T-415	FIT consisted of two placebo-controlled studies using alendronate daily ( 5 mg daily for two years and 10 mg daily for either one or two additional years ) :
H-415	-0.2794952392578125	FIT consisted of two placebo-controlled studies in which alendronate was given daily ( 5 mg daily for 2 years and subsequently 10 mg daily for either 1 or 2 years ) :
D-415	-0.2794952392578125	FIT consisted of two placebo-controlled studies in which alendronate was given daily ( 5 mg daily for 2 years and subsequently 10 mg daily for either 1 or 2 years ) :
P-415	-0.1038 -0.1104 -0.1702 -0.1885 -0.1315 -0.2146 -0.0399 -0.1075 -0.0650 -0.2102 -0.0736 -0.8935 -1.9449 -0.1629 -0.1082 -0.1068 -0.1074 -0.0818 -0.1958 -1.5347 -0.1032 -0.1570 -0.3871 -0.0417 -0.2401 -0.1254 -0.1580 -0.0922 -0.8964 -1.1612 -0.1965 -0.0426 -0.2183 -0.2546 -0.0478 -0.1026 -0.2363 -0.1133 -0.0913 -0.1563 -0.2121 -0.1534
S-1312	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-1312	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-1312	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
D-1312	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
P-1312	-0.1884 -0.2730 -0.8985 -0.1732 -1.0094 -0.0451 -0.0775 -0.0530 -0.1588 -0.0786 -0.1087 -0.1844 -2.6082 -0.3697 -0.1316 -0.2274 -0.0903 -0.2153 -0.4167 -0.1891 -0.1146 -0.0555 -0.2161 -0.4724 -2.3903 -0.1284 -0.1186 -0.0519 -0.0570 -0.1334 -0.3125 -0.2025 -0.0769 -0.1206 -0.1469 -0.1795 -0.1582
S-1488	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-1488	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-1488	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
D-1488	-0.3360038697719574	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for development of inhibitors . See section 4.8 .
P-1488	-0.1884 -0.2730 -0.8985 -0.1732 -1.0094 -0.0451 -0.0775 -0.0530 -0.1588 -0.0786 -0.1087 -0.1844 -2.6082 -0.3697 -0.1316 -0.2274 -0.0903 -0.2153 -0.4167 -0.1891 -0.1146 -0.0555 -0.2161 -0.4724 -2.3903 -0.1284 -0.1186 -0.0519 -0.0570 -0.1334 -0.3125 -0.2025 -0.0769 -0.1206 -0.1469 -0.1795 -0.1582
S-1191	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-1191	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-1191	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-1191	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-1191	-0.1548 -0.2162 -0.0524 -0.0444 -0.6732 -0.7834 -0.5240 -0.0705 -0.1567 -0.0821 -0.0903 -0.4004 -0.5111 -0.1478 -0.0726 -0.2188 -0.3069 -0.1388 -0.1028 -0.4689 -0.4220 -0.3894 -0.1225 -0.0619 -0.0819 -0.1652 -0.1441 -0.0674 -0.0410 -2.1236 -0.4556 -0.9469 -0.1965 -0.9547 -0.1482 -0.1355 -0.1818 -0.1532
S-839	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-839	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-839	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-839	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-839	-0.1548 -0.2162 -0.0524 -0.0444 -0.6732 -0.7834 -0.5240 -0.0705 -0.1567 -0.0821 -0.0903 -0.4004 -0.5111 -0.1478 -0.0726 -0.2188 -0.3069 -0.1388 -0.1028 -0.4689 -0.4220 -0.3894 -0.1225 -0.0619 -0.0819 -0.1652 -0.1441 -0.0674 -0.0410 -2.1236 -0.4556 -0.9469 -0.1965 -0.9547 -0.1482 -0.1355 -0.1818 -0.1532
S-1367	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-1367	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-1367	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-1367	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-1367	-0.1548 -0.2162 -0.0524 -0.0444 -0.6732 -0.7834 -0.5240 -0.0705 -0.1567 -0.0821 -0.0903 -0.4004 -0.5111 -0.1478 -0.0726 -0.2188 -0.3069 -0.1388 -0.1028 -0.4689 -0.4220 -0.3894 -0.1225 -0.0619 -0.0819 -0.1652 -0.1441 -0.0674 -0.0410 -2.1236 -0.4556 -0.9469 -0.1965 -0.9547 -0.1482 -0.1355 -0.1818 -0.1532
S-1544	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-1544	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-1544	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-1544	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-1544	-0.1548 -0.2162 -0.0524 -0.0444 -0.6732 -0.7834 -0.5240 -0.0705 -0.1567 -0.0821 -0.0903 -0.4004 -0.5111 -0.1478 -0.0726 -0.2188 -0.3069 -0.1388 -0.1028 -0.4689 -0.4220 -0.3894 -0.1225 -0.0619 -0.0819 -0.1652 -0.1441 -0.0674 -0.0410 -2.1236 -0.4556 -0.9469 -0.1965 -0.9547 -0.1482 -0.1355 -0.1818 -0.1532
S-1015	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-1015	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-1015	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-1015	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-1015	-0.1548 -0.2162 -0.0524 -0.0444 -0.6732 -0.7834 -0.5240 -0.0705 -0.1567 -0.0821 -0.0903 -0.4004 -0.5111 -0.1478 -0.0726 -0.2188 -0.3069 -0.1388 -0.1028 -0.4689 -0.4220 -0.3894 -0.1225 -0.0619 -0.0819 -0.1652 -0.1441 -0.0674 -0.0410 -2.1236 -0.4556 -0.9469 -0.1965 -0.9547 -0.1482 -0.1355 -0.1818 -0.1532
S-1086	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-1086	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-1086	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
D-1086	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
P-1086	-0.1521 -0.1613 -0.0992 -0.1098 -0.5683 -0.0936 -2.4760 -0.1062 -0.1112 -0.1341 -1.0408 -0.1297 -0.4391 -0.7400 -0.2036 -0.1228 -0.3149 -0.1246 -0.2755 -0.2634 -0.2286 -0.5131 -0.8281 -0.1979 -0.3158 -0.1996 -0.1209 -0.5267 -0.1474 -0.1234 -0.3424 -0.1328 -0.7225 -2.4727 -0.0433 -0.1647 -0.1605
S-664	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-664	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-664	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-664	-0.3159875273704529	All pharmacokinetics studies of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-664	-0.1548 -0.2162 -0.0524 -0.0444 -0.6732 -0.7834 -0.5240 -0.0705 -0.1567 -0.0821 -0.0903 -0.4004 -0.5111 -0.1478 -0.0726 -0.2188 -0.3069 -0.1388 -0.1028 -0.4689 -0.4220 -0.3894 -0.1225 -0.0619 -0.0819 -0.1652 -0.1441 -0.0674 -0.0410 -2.1236 -0.4556 -0.9469 -0.1965 -0.9547 -0.1482 -0.1355 -0.1818 -0.1532
S-1438	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-1438	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-1438	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
D-1438	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
P-1438	-0.1521 -0.1613 -0.0992 -0.1098 -0.5683 -0.0936 -2.4760 -0.1062 -0.1112 -0.1341 -1.0408 -0.1297 -0.4391 -0.7400 -0.2036 -0.1228 -0.3149 -0.1246 -0.2755 -0.2634 -0.2286 -0.5131 -0.8281 -0.1979 -0.3158 -0.1996 -0.1209 -0.5267 -0.1474 -0.1234 -0.3424 -0.1328 -0.7225 -2.4727 -0.0433 -0.1647 -0.1605
S-1262	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-1262	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-1262	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
D-1262	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
P-1262	-0.1521 -0.1613 -0.0992 -0.1098 -0.5683 -0.0936 -2.4760 -0.1062 -0.1112 -0.1341 -1.0408 -0.1297 -0.4391 -0.7400 -0.2036 -0.1228 -0.3149 -0.1246 -0.2755 -0.2634 -0.2286 -0.5131 -0.8281 -0.1979 -0.3158 -0.1996 -0.1209 -0.5267 -0.1474 -0.1234 -0.3424 -0.1328 -0.7225 -2.4727 -0.0433 -0.1647 -0.1605
S-910	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-910	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-910	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
D-910	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
P-910	-0.1521 -0.1613 -0.0992 -0.1098 -0.5683 -0.0936 -2.4760 -0.1062 -0.1112 -0.1341 -1.0408 -0.1297 -0.4391 -0.7400 -0.2036 -0.1228 -0.3149 -0.1246 -0.2755 -0.2634 -0.2286 -0.5131 -0.8281 -0.1979 -0.3158 -0.1996 -0.1209 -0.5267 -0.1474 -0.1234 -0.3424 -0.1328 -0.7225 -2.4727 -0.0433 -0.1647 -0.1605
S-1149	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 7 gemeldet .
T-1149	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 7 gemeldet . 7
H-1149	-0.3593439757823944	No adverse reactions were reported in newborns , 16 in 13<unk> 32 infants , 7 in 4<unk> 56 children , 8 in 4<unk> 31 adolescents and 25 in 14<unk> 94 adults .
D-1149	-0.3593439757823944	No adverse reactions were reported in newborns , 16 in 13<unk> 32 infants , 7 in 4<unk> 56 children , 8 in 4<unk> 31 adolescents and 25 in 14<unk> 94 adults .
P-1149	-1.8666 -0.7301 -0.0330 -0.9747 -0.0204 -0.2489 -1.3302 -0.2042 -0.4660 -0.3859 -0.0636 -0.1994 -0.2385 -0.8352 -0.9153 -2.1021 -0.1161 -0.9811 -0.1360 -0.1358 -0.1573 -0.1283 -0.1248 -0.0110 -0.1100 -0.4564 -0.1351 -0.1140 -0.1281 -0.1596 -0.0130 -0.0794 -0.1279 -0.0453 -0.0426 -0.6303 -0.1101 -0.1326 -0.2225 -0.0359 -0.1063 -0.3766 -0.2268 -0.1542
S-175	Eine Krebsdiagnose , Chemotherapie , Strahlentherapie , Kortikosteroide und unzureichende Mundhygiene gelten ebenfalls als Risikofaktoren ( siehe Abschnitt 4.4 ) . Gelenkschwellungen .
T-175	Diagnosis of cancer , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also deemed as risk factors ( see section 4.4 ) ; joint swelling .
H-175	-0.18178561329841614	Cancer diagnosis , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also considered risk factors ( see section 4.4 ) .
D-175	-0.18178561329841614	Cancer diagnosis , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also considered risk factors ( see section 4.4 ) .
P-175	-0.4780 -0.1705 -0.1420 -0.1022 -0.0459 -0.0725 -0.1407 -0.3378 -0.0637 -0.1392 -0.2172 -0.1436 -0.0796 -0.1054 -0.1713 -0.0644 -0.6743 -0.3438 -0.0868 -0.0779 -0.0730 -0.2997 -0.6282 -0.1943 -0.1422 -0.0618 -0.1858 -0.0940 -0.1026 -0.1264 -0.1314 -0.1360 -0.1854 -0.1631
S-559	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-559	ADVATE does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-559	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
D-559	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
P-559	-0.1521 -0.1613 -0.0992 -0.1098 -0.5683 -0.0936 -2.4760 -0.1062 -0.1112 -0.1341 -1.0408 -0.1297 -0.4391 -0.7400 -0.2036 -0.1228 -0.3149 -0.1246 -0.2755 -0.2634 -0.2286 -0.5131 -0.8281 -0.1979 -0.3158 -0.1996 -0.1209 -0.5267 -0.1474 -0.1234 -0.3424 -0.1328 -0.7225 -2.4727 -0.0433 -0.1647 -0.1605
S-363	Eine Krebsdiagnose , Chemotherapie , Strahlentherapie , Kortikosteroide und unzureichende Mundhygiene gelten ebenfalls als Risikofaktoren ( siehe Abschnitt 4.4 ) . Gelenkschwellungen .
T-363	Diagnosis of cancer , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also deemed as risk factors ( see section 4.4 ) ; joint swelling .
H-363	-0.18178561329841614	Cancer diagnosis , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also considered risk factors ( see section 4.4 ) .
D-363	-0.18178561329841614	Cancer diagnosis , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also considered risk factors ( see section 4.4 ) .
P-363	-0.4780 -0.1705 -0.1420 -0.1022 -0.0459 -0.0725 -0.1407 -0.3378 -0.0637 -0.1392 -0.2172 -0.1436 -0.0796 -0.1054 -0.1713 -0.0644 -0.6743 -0.3438 -0.0868 -0.0779 -0.0730 -0.2997 -0.6282 -0.1943 -0.1422 -0.0618 -0.1858 -0.0940 -0.1026 -0.1264 -0.1314 -0.1360 -0.1854 -0.1631
S-973	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 5 gemeldet .
T-973	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 5 gemeldet . 5
H-973	-0.3574191927909851	No adverse reactions were reported in newborns , 16 in 13<unk> 32 infants , 7 in 4<unk> 56 children , 8 in 4<unk> 31 adolescents and 25 in 14<unk> 94 adults .
D-973	-0.3574191927909851	No adverse reactions were reported in newborns , 16 in 13<unk> 32 infants , 7 in 4<unk> 56 children , 8 in 4<unk> 31 adolescents and 25 in 14<unk> 94 adults .
P-973	-1.8092 -0.7294 -0.0330 -0.9805 -0.0202 -0.2585 -1.2850 -0.2046 -0.4696 -0.3841 -0.0630 -0.2030 -0.2225 -0.8258 -0.9277 -2.1170 -0.1145 -0.9976 -0.1373 -0.1340 -0.1728 -0.1269 -0.1288 -0.0109 -0.1096 -0.4460 -0.1349 -0.1167 -0.1272 -0.1694 -0.0134 -0.0788 -0.1242 -0.0460 -0.0423 -0.5904 -0.1200 -0.1317 -0.2178 -0.0367 -0.1122 -0.3599 -0.2401 -0.1534
S-540	Die häufigsten Nebenwirkungen von Advate ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Schwindel , Kopfschmerzen , Pyrexie ( Fieber ) und die Bildung von Antikörpern gegenüber Faktor VIII.
T-540	The most common side effects with Advate ( seen in between 1 to 10 patients in 100 ) are dizziness , headache , pyrexia ( fever ) and the presence of antibodies against factor VIII .
H-540	-0.2927318811416626	The most common adverse reactions of Advate ( observed in 1 to 10 out of 100 patients ) are dizziness , headache , pyrexia ( fever ) , and antibody formation to factor VIII
D-540	-0.2927318811416626	The most common adverse reactions of Advate ( observed in 1 to 10 out of 100 patients ) are dizziness , headache , pyrexia ( fever ) , and antibody formation to factor VIII
P-540	-0.2303 -0.1604 -0.3679 -0.7567 -0.0226 -0.2640 -0.0292 -0.8636 -0.2713 -0.0861 -0.1724 -0.3808 -0.1354 -0.1944 -0.1480 -0.1320 -1.4429 -0.1248 -0.1805 -0.1434 -0.1353 -0.3275 -0.1130 -0.0487 -0.0593 -0.1347 -0.1209 -0.0444 -0.1322 -0.1410 -0.0487 -0.1564 -0.1028 -0.0408 -0.5992 -0.1013 -0.0842 -0.1400 -1.1274 -0.1313 -0.5559 -0.1523 -0.7087 -0.9918 -0.2792 -0.1898 -0.0853 -1.1923
S-1816	Luxembourg<unk> Luxemburg Baxter Belgium SPRL Bd. de la Plaine<unk> Pleinlaan 5 B-1050 Bruxelles<unk> Brüssel Tél<unk> Tel : <unk> 32 2 650 1711
T-1816	Luxembourg/ Luxemburg Baxter Belgium SPRL Bd . de la Plaine/ Pleinlaan 5 B-1050 Bruxelles/ Brüssel Tél/ Tel : <<unk>> 32 2 650 1711
H-1816	-0.16172556579113007	Luxembourg/ Luxemburg Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Bruxelles/ Brüssel Tél/ Tel : <unk> 32 2 650 1711
D-1816	-0.16172556579113007	Luxembourg/ Luxemburg Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Bruxelles/ Brüssel Tél/ Tel : <unk> 32 2 650 1711
P-1816	-0.2004 -0.0339 -0.1720 -0.1164 -0.1725 -0.1266 -0.1578 -0.1678 -0.1028 -0.0634 -0.1636 -0.1174 -0.1788 -0.1701 -0.1421 -0.2387 -0.1946 -0.0242 -0.0827 -0.3133 -0.1037 -0.1369 -0.1508 -0.1438 -0.1463 -0.1014 -0.1738 -0.1328 -0.1667 -0.1325 -0.0949 -0.1310 -0.1398 -1.3878 -0.1264 -0.0879 -0.1354 -0.1789 -0.0558 -0.1420 -0.0453 -0.1091 -0.1254 -0.1394 -0.1104 -0.1050 -0.1590
S-1618	Wie in der CHMP-Richtlinie zum Risiko-Managment-Plan für Human-Arzneimittel festgelegt , sollen diese Aktualisierungen gleichzeitig mit dem nächsten Periodic Safety Update Report ( PSUR ) eingereicht werden .
T-1618	As per the CHMP Guideline on Risk Management Systems for medicinal products for human use , the updated RMP should be submitted at the same time as the next Periodic Safety Update Report ( PSUR ) .
H-1618	-0.41941162943840027	As defined in the CHMP Risk Management Plan for Medicinal Products for Human Use , these updates should be presented concomitantly with the next Periodic Safety Update Report ( PSUR ) .
D-1618	-0.41941162943840027	As defined in the CHMP Risk Management Plan for Medicinal Products for Human Use , these updates should be presented concomitantly with the next Periodic Safety Update Report ( PSUR ) .
P-1618	-0.6572 -2.1735 -0.3122 -0.2932 -0.1482 -0.5838 -1.5010 -0.1050 -0.2549 -0.3168 -0.1425 -2.3447 -0.3229 -0.3091 -0.1339 -0.1968 -0.3389 -0.0848 -0.3284 -0.5951 -0.2692 -1.0848 -0.1536 -2.2267 -0.5682 -0.3181 -0.0077 -0.2506 -0.1556 -0.1605 -0.3659 -0.2669 -0.1329 -0.0551 -0.0411 -0.1018 -0.2390 -0.1431 -0.1224 -0.1153 -0.0774 -0.1254 -0.1771 -0.1528
S-1501	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 11 gemeldet .
T-1501	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 11 gemeldet . 11
H-1501	-0.35619229078292847	No adverse reactions were reported in newborns , 16 in 13<unk> 32 infants , 7 in 4<unk> 56 children , 8 in 4<unk> 31 adolescents and 25 in 14<unk> 94 adults .
D-1501	-0.35619229078292847	No adverse reactions were reported in newborns , 16 in 13<unk> 32 infants , 7 in 4<unk> 56 children , 8 in 4<unk> 31 adolescents and 25 in 14<unk> 94 adults .
P-1501	-1.8124 -0.7364 -0.0325 -1.0116 -0.0204 -0.2498 -1.3257 -0.2031 -0.4611 -0.3792 -0.0629 -0.2028 -0.2403 -0.7511 -0.9314 -2.1908 -0.1143 -0.9591 -0.1346 -0.1351 -0.1931 -0.1265 -0.1286 -0.0097 -0.1080 -0.4544 -0.1344 -0.1154 -0.1275 -0.1639 -0.0114 -0.0776 -0.1250 -0.0459 -0.0423 -0.5948 -0.1136 -0.1341 -0.2284 -0.0357 -0.1023 -0.3023 -0.1914 -0.1515
S-1325	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 9 gemeldet .
T-1325	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 9 gemeldet . 9
H-1325	-0.35540109872817993	No adverse reactions were reported in newborns , 16 in 13<unk> 32 infants , 7 in 4<unk> 56 children , 8 in 4<unk> 31 adolescents and 25 in 14<unk> 94 adults .
D-1325	-0.35540109872817993	No adverse reactions were reported in newborns , 16 in 13<unk> 32 infants , 7 in 4<unk> 56 children , 8 in 4<unk> 31 adolescents and 25 in 14<unk> 94 adults .
P-1325	-1.7790 -0.7163 -0.0327 -0.9743 -0.0202 -0.2492 -1.3262 -0.2013 -0.4652 -0.3774 -0.0636 -0.1990 -0.2337 -0.7926 -0.8984 -2.0900 -0.1129 -0.9971 -0.1365 -0.1349 -0.1738 -0.1269 -0.1287 -0.0107 -0.1087 -0.4495 -0.1342 -0.1178 -0.1276 -0.1599 -0.0138 -0.0793 -0.1269 -0.0463 -0.0419 -0.6536 -0.1104 -0.1341 -0.2226 -0.0365 -0.1011 -0.3632 -0.2166 -0.1530
S-543	Advate darf nicht bei Patienten angewendet werden , die möglicherweise überempfindlich ( allergisch ) gegen den menschlichen Gerinnungsfaktor VIII , Maus- oder Hamsterprotein oder einen der sonstigen Bestandteile sind .
T-543	Advate should not be used in people who may be hypersensitive ( allergic ) to human coagulation factor VIII , to mouse or hamster protein , or to any of the other ingredients .
H-543	-0.25447866320610046	Advate should not be used in patients who may be hypersensitive ( allergic ) to human clotting factor VIII , mouse or hamster protein or any of the ingredients .
D-543	-0.25447866320610046	Advate should not be used in patients who may be hypersensitive ( allergic ) to human clotting factor VIII , mouse or hamster protein or any of the ingredients .
P-543	-1.9226 -0.0847 -0.6490 -0.1523 -0.1407 -0.2432 -0.1484 -0.2406 -0.1933 -0.2342 -0.1862 -0.0707 -0.1219 -0.3387 -0.2004 -0.0352 -0.2236 -0.1355 -0.1665 -0.7247 -0.0367 -0.1032 -0.0684 -0.1590 -0.0804 -0.1436 -0.1121 -0.0340 -0.2432 -0.1741 -0.0844 -0.0480 -0.7316 -0.5470 -0.1402 -0.2650 -0.2961 -0.2761 -0.1692
S-59	Um eine Reizung der Speiseröhre zu vermeiden , darf die Patientin sich bis nach der ersten Nahrungsaufnahme des Tages , die frühestens 30 Minuten nach Einnahme der Tablette erfolgen soll , nicht hinlegen .
T-59	To avoid irritation of the oesophagus ( gullet ) , the patient should not lie down until after their first food of the day , which should be at least 30 minutes after taking the tablet .
H-59	-0.3523576557636261	In order to avoid irritation of the oesophagus , the patient should not lie down until after the first food intake of the day , which should not be earlier than 30 minutes after taking the tablet .
D-59	-0.3523576557636261	In order to avoid irritation of the oesophagus , the patient should not lie down until after the first food intake of the day , which should not be earlier than 30 minutes after taking the tablet .
P-59	-1.5426 -0.0776 -0.1538 -0.9777 -1.1902 -0.1304 -0.3059 -0.1520 -1.0321 -0.0139 -0.0592 -0.0422 -0.1063 -0.2134 -0.3494 -0.1735 -0.7097 -0.1301 -0.0404 -0.1103 -0.1825 -0.1907 -0.2567 -0.0739 -0.6901 -0.1653 -0.1820 -0.1388 -0.1687 -0.1140 -0.3146 -0.7699 -0.6616 -1.3256 -0.4586 -1.1564 -0.0977 -0.1235 -0.1758 -0.2818 -0.3914 -0.1489 -0.1244 -0.1894 -0.1634 -0.1524
S-797	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 3 gemeldet .
T-797	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 3 gemeldet . 3
H-797	-0.37053030729293823	No adverse reactions were reported in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults .
D-797	-0.37053030729293823	No adverse reactions were reported in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults .
P-797	-1.7955 -0.7235 -0.0329 -0.9749 -0.0203 -0.2558 -1.3119 -0.2011 -0.4618 -0.3764 -0.0632 -0.2013 -0.2318 -1.4634 -0.0717 -0.1315 -0.9368 -1.5907 -0.1288 -0.9166 -0.1498 -0.1355 -0.1282 -0.3137 -0.1034 -0.1739 -0.0927 -0.5462 -0.1339 -0.1245 -0.1466 -0.1198 -0.1501 -0.0783 -0.0878 -0.0444 -0.0418 -0.9226 -0.1152 -0.1519 -0.2206 -0.1112 -0.0962 -0.3439 -0.4369 -0.1854
S-623	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 1 gemeldet .
T-623	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 1 gemeldet . 1
H-623	-0.376335084438324	No adverse reactions were observed in newborns , 16 were reported in 13<unk> 32 infants , 7 in 4<unk> 56 children , 8 in 4<unk> 31 adolescents and 25 in 14<unk> 94 adults .
D-623	-0.376335084438324	No adverse reactions were observed in newborns , 16 were reported in 13<unk> 32 infants , 7 in 4<unk> 56 children , 8 in 4<unk> 31 adolescents and 25 in 14<unk> 94 adults .
P-623	-1.7846 -0.7195 -0.0333 -0.9723 -0.0200 -0.2640 -1.8372 -0.1728 -0.4125 -0.3781 -0.0653 -0.2091 -0.2234 -0.9822 -0.0863 -0.1308 -0.9215 -2.1038 -0.1170 -0.9083 -0.1422 -0.1337 -0.1538 -0.2964 -0.1270 -0.0128 -0.1141 -0.4291 -0.1345 -0.1196 -0.1342 -0.1642 -0.0143 -0.0770 -0.1216 -0.0446 -0.0419 -0.6158 -0.1175 -0.1406 -0.1948 -0.0393 -0.1072 -0.8210 -0.4962 -0.1761
S-1973	Aerinaze ist mindestens 48 Stunden vor der Durchführung dermatologischer Tests abzusetzen , da Antihistaminika ansonsten positive Reaktionen auf Indikatoren für Hautreaktionen verhindern bzw. in ihrem Ausmaß reduzieren können .
T-1973	The administration of Aerinaze should be discontinued at least 48 hours before skin tests since antihistamines maybe prevent or reduce other wise positive reaction to dermal reactivity index .
H-1973	-0.3941487967967987	Aerinaze should be discontinued at least 48 hours prior to performing dermatological tests as antihistamines may otherwise prevent or reduce the extent of positive reactions to indicators of skin reaction .
D-1973	-0.3941487967967987	Aerinaze should be discontinued at least 48 hours prior to performing dermatological tests as antihistamines may otherwise prevent or reduce the extent of positive reactions to indicators of skin reaction .
P-1973	-0.4219 -0.1438 -0.1428 -0.1156 -0.0897 -0.4871 -0.1285 -0.1672 -0.0160 -0.1454 -0.1404 -0.0839 -0.0985 -0.6061 -0.1213 -2.6364 -0.1756 -0.1412 -0.2948 -0.4537 -1.4984 -0.5093 -0.0565 -0.1530 -0.1690 -0.2756 -0.8334 -0.5529 -0.3004 -0.2260 -1.1260 -0.8765 -0.2752 -1.2799 -0.2763 -0.0377 -0.2253 -1.4140 -0.0456 -0.1406 -0.1691 -0.1445 -0.2000 -0.1877 -0.1542
S-1888	Darüber hinaus hatte das Unternehmen nicht ausreichend nachgewiesen , dass Advexin auf zuverlässige Weise hergestellt werden kann und dass es weder für die Umwelt noch für Menschen , die in engem Kontakt mit dem Patienten kommen , schädlich ist .
T-1888	In addition , the company had not supplied enough evidence to demonstrate that Advexin could be made in a reliable manner , or that it would not be harmful to the environment or to people in close contact with the patient .
H-1888	-0.4382787346839905	Moreover , the company had not sufficiently demonstrated that Advexin can be produced in a reliable manner and that it is neither harmful to the environment nor to people who come into close contact with the patient .
D-1888	-0.4382787346839905	Moreover , the company had not sufficiently demonstrated that Advexin can be produced in a reliable manner and that it is neither harmful to the environment nor to people who come into close contact with the patient .
P-1888	-1.5490 -0.1510 -0.4871 -0.4800 -0.8830 -0.1919 -1.7826 -0.0594 -0.1576 -0.8312 -0.1429 -0.3742 -0.1785 -0.1322 -1.0102 -0.1235 -1.0564 -1.4150 -0.1433 -0.3700 -0.2340 -0.3399 -0.3124 -0.1701 -0.2789 -1.2424 -0.2458 -0.1083 -0.4209 -0.1396 -0.1098 -0.2087 -0.1686 -1.4925 -0.8199 -0.2194 -0.1492 -0.1898 -0.0926 -0.1738 -0.2726 -0.0634 -0.1557 -0.1570
S-734	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-734	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-734	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
D-734	-0.40288275480270386	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen syndrome .
P-734	-0.1521 -0.1613 -0.0992 -0.1098 -0.5683 -0.0936 -2.4760 -0.1062 -0.1112 -0.1341 -1.0408 -0.1297 -0.4391 -0.7400 -0.2036 -0.1228 -0.3149 -0.1246 -0.2755 -0.2634 -0.2286 -0.5131 -0.8281 -0.1979 -0.3158 -0.1996 -0.1209 -0.5267 -0.1474 -0.1234 -0.3424 -0.1328 -0.7225 -2.4727 -0.0433 -0.1647 -0.1605
S-1908	Pseudoephedrin regt die Nervenenden dazu an , den chemischen Botenstoff Noradrenalin freizusetzen , der eine Konstriktion ( Verengung ) der Blutgefäße verursacht .
T-1908	In Aerinaze , the two active substances are used together , since an antihistamine alone may not provide adequate relief for patients with nasal congestion .
H-1908	-0.29835045337677	Pseudoephedrine stimulates nerve endings to release the chemical messenger substance noradrenaline , which causes constriction ( narrowing ) of blood vessels .
D-1908	-0.29835045337677	Pseudoephedrine stimulates nerve endings to release the chemical messenger substance noradrenaline , which causes constriction ( narrowing ) of blood vessels .
P-1908	-0.4081 -0.0880 -0.1296 -0.0529 -0.1624 -0.1557 -0.0905 -0.4172 -0.0798 -0.7954 -0.1026 -0.1705 -0.1659 -0.4814 -0.3251 -0.1308 -0.2560 -0.2474 -0.1226 -0.6759 -0.3512 -1.0461 -0.1059 -0.1407 -0.3253 -0.7353 -0.2975 -0.0858 -2.2860 -0.0584 -0.0862 -0.3379 -0.1278 -0.0609 -0.1768 -0.1492 -0.2350 -0.1685 -0.0732 -0.1697 -0.1573
S-70	Da Alendronat und Vitamin D3 bereits getrennt voneinander in Arzneimitteln verwendet werden , die in der Europäischen Union zugelassen sind , legte das Unternehmen Daten vor , die aus früheren Studien und der veröffentlichten Literatur stammen .
T-70	Because alendronate and vitamin D3 are already used separately in authorised medicines in the European Union , the company presented data obtained in earlier studies and from the published literature .
H-70	-0.3401477634906769	Since alendronate and vitamin D3 are already used separately in medicinal products authorised in the European Union , the company presented data from previous studies and published literature .
D-70	-0.3401477634906769	Since alendronate and vitamin D3 are already used separately in medicinal products authorised in the European Union , the company presented data from previous studies and published literature .
P-70	-1.4426 -0.1777 -0.1155 -0.1076 -0.0710 -0.1459 -0.1312 -0.0975 -0.1567 -0.1372 -0.1766 -0.8928 -0.4550 -0.3148 -0.0958 -0.1578 -0.5203 -1.1776 -0.0734 -0.6396 -0.2299 -0.4830 -0.1543 -0.2421 -0.1734 -0.1342 -0.2310 -0.3081 -1.2717 -0.1517 -1.2091 -0.4842 -0.3845 -0.1386 -0.0998 -0.0570 -0.1023 -0.1695 -0.1546
S-453	Obwohl keine klinischen Daten darüber vorliegen , ist dennoch damit zu rechnen , dass die renale Elimination von Alendronat wie in den Tierversuchen auch bei Patienten mit eingeschränkter Nierenfunktion reduziert sein wird .
T-453	Although no clinical information is available , it is likely that , as in animals , elimination of alendronate via the kidney will be reduced in patients with impaired renal function .
H-453	-0.4125385582447052	Although no clinical data are available , renal elimination of alendronate is expected to be reduced in patients with impaired renal function , as in animal studies .
D-453	-0.4125385582447052	Although no clinical data are available , renal elimination of alendronate is expected to be reduced in patients with impaired renal function , as in animal studies .
P-453	-0.4733 -0.7434 -0.1560 -0.1502 -0.8378 -0.1597 -0.5487 -0.5211 -0.1059 -0.0997 -0.0859 -0.1265 -0.1279 -0.1197 -0.1572 -0.0741 -1.5531 -1.3527 -0.1789 -0.2971 -0.4132 -0.8438 -0.6109 -0.1404 -0.5880 -0.2196 -0.1526 -0.1559 -0.0724 -0.7422 -0.3351 -1.3571 -0.2015 -0.8327 -0.1583 -0.1588
S-736	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-736	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-736	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
D-736	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
P-736	-0.4260 -0.0568 -0.0927 -1.5177 -0.3029 -0.1258 -0.1015 -0.1400 -0.0412 -0.1181 -0.1234 -1.5661 -0.0703 -0.1718 -0.7860 -0.1426 -0.1969 -0.3468 -0.1279 -0.1273 -1.3247 -1.5637 -0.2593 -0.0712 -0.0443 -0.1034 -0.1650 -0.5702 -1.3288 -0.1471 -0.2015 -0.1246 -1.2980 -0.1062 -0.6958 -0.9575 -0.8490 -0.4515 -0.1359 -0.1549 -0.1021 -0.1780 -0.1537
S-1461	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-1461	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-1461	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
D-1461	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
P-1461	-0.6647 -0.9627 -0.0419 -0.1429 -0.3176 -0.5896 -0.4107 -2.1145 -0.0486 -0.1033 -0.5414 -1.8231 -0.0779 -0.3457 -0.6505 -0.8536 -1.1200 -0.8997 -1.3745 -0.0392 -0.8351 -0.1094 -0.3771 -0.1100 -0.1304 -0.5519 -0.1299 -0.0923 -0.1296 -0.2454 -0.1013 -0.1798 -0.1552
S-1285	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-1285	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-1285	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
D-1285	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
P-1285	-0.6647 -0.9627 -0.0419 -0.1429 -0.3176 -0.5896 -0.4107 -2.1145 -0.0486 -0.1033 -0.5414 -1.8231 -0.0779 -0.3457 -0.6505 -0.8536 -1.1200 -0.8997 -1.3745 -0.0392 -0.8351 -0.1094 -0.3771 -0.1100 -0.1304 -0.5519 -0.1299 -0.0923 -0.1296 -0.2454 -0.1013 -0.1798 -0.1552
S-1109	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-1109	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-1109	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
D-1109	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
P-1109	-0.6647 -0.9627 -0.0419 -0.1429 -0.3176 -0.5896 -0.4107 -2.1145 -0.0486 -0.1033 -0.5414 -1.8231 -0.0779 -0.3457 -0.6505 -0.8536 -1.1200 -0.8997 -1.3745 -0.0392 -0.8351 -0.1094 -0.3771 -0.1100 -0.1304 -0.5519 -0.1299 -0.0923 -0.1296 -0.2454 -0.1013 -0.1798 -0.1552
S-933	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-933	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-933	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
D-933	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
P-933	-0.6647 -0.9627 -0.0419 -0.1429 -0.3176 -0.5896 -0.4107 -2.1145 -0.0486 -0.1033 -0.5414 -1.8231 -0.0779 -0.3457 -0.6505 -0.8536 -1.1200 -0.8997 -1.3745 -0.0392 -0.8351 -0.1094 -0.3771 -0.1100 -0.1304 -0.5519 -0.1299 -0.0923 -0.1296 -0.2454 -0.1013 -0.1798 -0.1552
S-561	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-561	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-561	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
D-561	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
P-561	-0.4260 -0.0568 -0.0927 -1.5177 -0.3029 -0.1258 -0.1015 -0.1400 -0.0412 -0.1181 -0.1234 -1.5661 -0.0703 -0.1718 -0.7860 -0.1426 -0.1969 -0.3468 -0.1279 -0.1273 -1.3247 -1.5637 -0.2593 -0.0712 -0.0443 -0.1034 -0.1650 -0.5702 -1.3288 -0.1471 -0.2015 -0.1246 -1.2980 -0.1062 -0.6958 -0.9575 -0.8490 -0.4515 -0.1359 -0.1549 -0.1021 -0.1780 -0.1537
S-757	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-757	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-757	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
D-757	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
P-757	-0.6647 -0.9627 -0.0419 -0.1429 -0.3176 -0.5896 -0.4107 -2.1145 -0.0486 -0.1033 -0.5414 -1.8231 -0.0779 -0.3457 -0.6505 -0.8536 -1.1200 -0.8997 -1.3745 -0.0392 -0.8351 -0.1094 -0.3771 -0.1100 -0.1304 -0.5519 -0.1299 -0.0923 -0.1296 -0.2454 -0.1013 -0.1798 -0.1552
S-912	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-912	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-912	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
D-912	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
P-912	-0.4260 -0.0568 -0.0927 -1.5177 -0.3029 -0.1258 -0.1015 -0.1400 -0.0412 -0.1181 -0.1234 -1.5661 -0.0703 -0.1718 -0.7860 -0.1426 -0.1969 -0.3468 -0.1279 -0.1273 -1.3247 -1.5637 -0.2593 -0.0712 -0.0443 -0.1034 -0.1650 -0.5702 -1.3288 -0.1471 -0.2015 -0.1246 -1.2980 -0.1062 -0.6958 -0.9575 -0.8490 -0.4515 -0.1359 -0.1549 -0.1021 -0.1780 -0.1537
S-1088	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-1088	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-1088	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
D-1088	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
P-1088	-0.4260 -0.0568 -0.0927 -1.5177 -0.3029 -0.1258 -0.1015 -0.1400 -0.0412 -0.1181 -0.1234 -1.5661 -0.0703 -0.1718 -0.7860 -0.1426 -0.1969 -0.3468 -0.1279 -0.1273 -1.3247 -1.5637 -0.2593 -0.0712 -0.0443 -0.1034 -0.1650 -0.5702 -1.3288 -0.1471 -0.2015 -0.1246 -1.2980 -0.1062 -0.6958 -0.9575 -0.8490 -0.4515 -0.1359 -0.1549 -0.1021 -0.1780 -0.1537
S-1264	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-1264	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-1264	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
D-1264	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
P-1264	-0.4260 -0.0568 -0.0927 -1.5177 -0.3029 -0.1258 -0.1015 -0.1400 -0.0412 -0.1181 -0.1234 -1.5661 -0.0703 -0.1718 -0.7860 -0.1426 -0.1969 -0.3468 -0.1279 -0.1273 -1.3247 -1.5637 -0.2593 -0.0712 -0.0443 -0.1034 -0.1650 -0.5702 -1.3288 -0.1471 -0.2015 -0.1246 -1.2980 -0.1062 -0.6958 -0.9575 -0.8490 -0.4515 -0.1359 -0.1549 -0.1021 -0.1780 -0.1537
S-1440	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-1440	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-1440	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
D-1440	-0.4085608720779419	Dosage The dosage and duration of substitution therapy depend on the severity of Factor VIII deficiency , the location and extent of bleeding and the clinical condition of the patient .
P-1440	-0.4260 -0.0568 -0.0927 -1.5177 -0.3029 -0.1258 -0.1015 -0.1400 -0.0412 -0.1181 -0.1234 -1.5661 -0.0703 -0.1718 -0.7860 -0.1426 -0.1969 -0.3468 -0.1279 -0.1273 -1.3247 -1.5637 -0.2593 -0.0712 -0.0443 -0.1034 -0.1650 -0.5702 -1.3288 -0.1471 -0.2015 -0.1246 -1.2980 -0.1062 -0.6958 -0.9575 -0.8490 -0.4515 -0.1359 -0.1549 -0.1021 -0.1780 -0.1537
S-36	Die häufigsten Nebenwirkungen von Adenuric ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Kopfschmerzen , Durchfall , Übelkeit ( Nausea ) , Hautausschlag und abnormale Leberwerte .
T-36	The most common side effects with Adenuric ( seen in between 1 and 10 patients in 100 ) are headache , diarrhoea , nausea ( feeling sick ) , rash and abnormal liver test results .
H-36	-0.23508930206298828	The most common adverse reactions of Adenuric ( observed in 1 to 10 out of 100 patients ) are headache , diarrhoea , nausea , rash and abnormal liver enzymes .
D-36	-0.23508930206298828	The most common adverse reactions of Adenuric ( observed in 1 to 10 out of 100 patients ) are headache , diarrhoea , nausea , rash and abnormal liver enzymes .
P-36	-0.2288 -0.1434 -0.3213 -0.5892 -0.0432 -0.2502 -0.0276 -0.8490 -0.2030 -0.1627 -0.0979 -0.1269 -0.1768 -0.3880 -0.1324 -0.1832 -0.1430 -0.1370 -1.2499 -0.1257 -0.1715 -0.1629 -0.1344 -0.3516 -0.1324 -0.0377 -0.1386 -0.1455 -0.1049 -0.0301 -0.1009 -0.0316 -0.1386 -0.0094 -0.0266 -0.1391 -0.2907 -0.0521 -0.5830 -0.1118 -0.0600 -0.7012 -1.2503 -0.1047 -0.1471 -0.1587 -0.1546
S-1910	In Aerinaze werden zwei arzneilich wirksame Bestandteile kombiniert , weil ein Antihistaminikum allein bei Patienten mit Verstopfung der Nase häufig keine ausreichende Linderung der Symptome bewirkt .
T-1910	In Aerinaze werden zwei arzneilich wirksame Bestandteile kombiniert , weil ein Antihistaminikum allein bei Patienten mit Verstopfung der Nase häufig keine ausreichende Linderung der Symptome bewirkt . This means that patients only need to take the tablet twice a day .
H-1910	-0.4370397627353668	Aerinaze combines two active ingredients because antihistamines alone often do not provide adequate relief in patients with nasal constipation .
D-1910	-0.4370397627353668	Aerinaze combines two active ingredients because antihistamines alone often do not provide adequate relief in patients with nasal constipation .
P-1910	-0.6944 -0.1341 -0.1487 -0.1261 -0.0855 -0.0986 -0.0646 -0.1173 -0.1452 -0.1023 -0.1998 -0.8805 -1.7830 -0.0407 -0.8097 -0.0788 -0.2724 -1.7109 -0.6167 -0.2021 -1.2556 -0.5444 -0.3676 -1.3780 -0.8358 -0.2192 -0.9399 -0.0346 -0.1798 -0.4933 -0.2207 -0.0513 -0.1421 -0.1584 -0.1642
S-97	2 Die Patienten sollen sich nach Einnahme von ADROVANCE mindestens 30 Minuten nicht hinlegen . ADROVANCE soll nicht vor dem Schlafengehen oder vor dem ersten Aufstehen des Tages eingenommen werden .
T-97	2 Die Patienten sollen sich nach Einnahme von ADROVANCE mindestens 30 Minuten nicht hinlegen . ADROVANCE soll nicht vor dem Schlafengehen oder vor dem ersten Aufstehen des Tages eingenommen werden . 2 ADROVANCE should not be taken at bedtime or before arising for the day .
H-97	-0.33333009481430054	2 Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bed or before getting up for the first time .
D-97	-0.33333009481430054	2 Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bed or before getting up for the first time .
P-97	-0.8927 -1.3959 -0.0988 -0.0969 -0.1412 -0.0410 -0.1137 -0.2034 -0.2179 -0.1184 -0.1297 -0.1759 -0.1151 -0.0927 -0.0687 -0.0649 -0.1284 -0.1150 -0.0860 -0.1635 -0.0737 -0.0634 -0.1240 -0.1146 -0.1023 -0.1630 -0.1447 -0.1562 -0.1200 -0.5174 -1.2628 -0.2024 -1.5304 -1.2188 -0.4555 -1.4487 -0.1669 -0.0786 -0.1797 -0.9218 -0.1618
S-173	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet .
T-173	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet . The majority of the reports refer to cancer patients , but such cases have also been reported in patients treated for osteoporosis .
H-173	-0.3666352331638336	jaw osteonecrosis has been reported in bisphosphonate patients ; most reports have been from cancer patients , but osteoporosis patients have also been reported .
D-173	-0.3666352331638336	jaw osteonecrosis has been reported in bisphosphonate patients ; most reports have been from cancer patients , but osteoporosis patients have also been reported .
P-173	-0.5412 -0.2587 -0.1460 -0.0643 -0.1227 -0.0629 -0.0628 -0.0901 -0.7191 -0.1227 -0.1094 -0.1518 -0.4094 -0.0316 -0.0588 -0.4898 -0.9349 -0.4728 -1.1081 -0.1059 -0.3741 -0.8880 -0.2933 -2.4066 -0.0581 -0.7693 -0.5916 -0.4710 -0.7344 -0.0637 -0.1104 -0.1395 -0.1058 -0.0649 -0.1985 -0.2853 -0.3309 -0.2058 -0.4812 -0.2416 -0.1552
S-361	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet .
T-361	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet . The majority of the reports refer to cancer patients , but such cases have also been reported in patients treated for osteoporosis .
H-361	-0.3666352331638336	jaw osteonecrosis has been reported in bisphosphonate patients ; most reports have been from cancer patients , but osteoporosis patients have also been reported .
D-361	-0.3666352331638336	jaw osteonecrosis has been reported in bisphosphonate patients ; most reports have been from cancer patients , but osteoporosis patients have also been reported .
P-361	-0.5412 -0.2587 -0.1460 -0.0643 -0.1227 -0.0629 -0.0628 -0.0901 -0.7191 -0.1227 -0.1094 -0.1518 -0.4094 -0.0316 -0.0588 -0.4898 -0.9349 -0.4728 -1.1081 -0.1059 -0.3741 -0.8880 -0.2933 -2.4066 -0.0581 -0.7693 -0.5916 -0.4710 -0.7344 -0.0637 -0.1104 -0.1395 -0.1058 -0.0649 -0.1985 -0.2853 -0.3309 -0.2058 -0.4812 -0.2416 -0.1552
S-583	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-583	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-583	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
D-583	-0.4930131137371063	During the course of treatment , appropriate plasma level measurement is recommended to control the dose to be administered and the frequency of injections .
P-583	-0.6647 -0.9627 -0.0419 -0.1429 -0.3176 -0.5896 -0.4107 -2.1145 -0.0486 -0.1033 -0.5414 -1.8231 -0.0779 -0.3457 -0.6505 -0.8536 -1.1200 -0.8997 -1.3745 -0.0392 -0.8351 -0.1094 -0.3771 -0.1100 -0.1304 -0.5519 -0.1299 -0.0923 -0.1296 -0.2454 -0.1013 -0.1798 -0.1552
S-302	Während in groß angelegten klinischen Studien mit Alendronat kein erhöhtes Risiko festgestellt wurde , wurden selten ( nach Markteinführung ) Magen- und Duodenalulzera , darunter manche schwerwiegend und mit Komplikationen , berichtet ( siehe Abschnitt 4.8 ) .
T-302	13 While no increased risk was observed in extensive clinical trials with alendronate , there have been rare ( post-marketing ) reports of gastric and duodenal ulcers , some of which were severe and with complications ( see section 4.8 ) .
H-302	-0.35265684127807617	While large @-@ scale clinical trials of alendronate have not shown an increased risk , gastric and duodenal ulcers , some severe and with complications , have rarely been reported ( see section 4.8 ) .
D-302	-0.35265684127807617	While large @-@ scale clinical trials of alendronate have not shown an increased risk , gastric and duodenal ulcers , some severe and with complications , have rarely been reported ( see section 4.8 ) .
P-302	-1.0416 -0.7334 -1.8544 -0.0599 -0.0776 -0.2316 -0.2762 -0.1343 -0.1331 -0.1292 -0.1120 -0.7800 -0.4298 -1.2788 -0.6167 -0.0974 -0.1311 -0.3587 -1.4851 -0.0353 -0.1065 -0.2522 -0.4186 -0.1961 -0.0324 -0.0745 -0.0484 -0.2971 -0.1758 -0.3320 -0.5897 -0.5130 -0.2066 -0.4750 -0.0932 -0.1610 -0.1822 -0.4694 -0.9069 -0.3622 -0.1544 -0.2022 -0.2256 -0.0817 -0.1172 -0.1255 -0.1349 -0.1958 -0.1536
S-1567	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-1567	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-1567	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
D-1567	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
P-1567	-0.0817 -1.7687 -1.7530 -0.0240 -0.5173 -0.1102 -0.1347 -0.1784 -0.3185 -0.0983 -1.0763 -0.2374 -0.1438 -0.1450 -0.0365 -0.1001 -0.3670 -0.2257 -0.0911 -0.8139 -0.1637 -0.3374 -0.1653 -0.0676 -1.1715 -0.2134 -0.4033 -0.2994 -0.4611 -0.0836 -0.0807 -0.0815 -0.6419 -0.5406 -0.0557 -0.1222 -0.3239 -0.1419 -0.7858 -0.1657 -1.0247 -0.1454 -0.1397 -0.1645 -0.1789 -0.1014 -0.1239 -0.1119 -0.1308 -0.1513 -0.1561
S-862	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-862	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-862	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
D-862	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
P-862	-0.0817 -1.7687 -1.7530 -0.0240 -0.5173 -0.1102 -0.1347 -0.1784 -0.3185 -0.0983 -1.0763 -0.2374 -0.1438 -0.1450 -0.0365 -0.1001 -0.3670 -0.2257 -0.0911 -0.8139 -0.1637 -0.3374 -0.1653 -0.0676 -1.1715 -0.2134 -0.4033 -0.2994 -0.4611 -0.0836 -0.0807 -0.0815 -0.6419 -0.5406 -0.0557 -0.1222 -0.3239 -0.1419 -0.7858 -0.1657 -1.0247 -0.1454 -0.1397 -0.1645 -0.1789 -0.1014 -0.1239 -0.1119 -0.1308 -0.1513 -0.1561
S-1038	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-1038	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-1038	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
D-1038	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
P-1038	-0.0817 -1.7687 -1.7530 -0.0240 -0.5173 -0.1102 -0.1347 -0.1784 -0.3185 -0.0983 -1.0763 -0.2374 -0.1438 -0.1450 -0.0365 -0.1001 -0.3670 -0.2257 -0.0911 -0.8139 -0.1637 -0.3374 -0.1653 -0.0676 -1.1715 -0.2134 -0.4033 -0.2994 -0.4611 -0.0836 -0.0807 -0.0815 -0.6419 -0.5406 -0.0557 -0.1222 -0.3239 -0.1419 -0.7858 -0.1657 -1.0247 -0.1454 -0.1397 -0.1645 -0.1789 -0.1014 -0.1239 -0.1119 -0.1308 -0.1513 -0.1561
S-1214	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-1214	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-1214	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
D-1214	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
P-1214	-0.0817 -1.7687 -1.7530 -0.0240 -0.5173 -0.1102 -0.1347 -0.1784 -0.3185 -0.0983 -1.0763 -0.2374 -0.1438 -0.1450 -0.0365 -0.1001 -0.3670 -0.2257 -0.0911 -0.8139 -0.1637 -0.3374 -0.1653 -0.0676 -1.1715 -0.2134 -0.4033 -0.2994 -0.4611 -0.0836 -0.0807 -0.0815 -0.6419 -0.5406 -0.0557 -0.1222 -0.3239 -0.1419 -0.7858 -0.1657 -1.0247 -0.1454 -0.1397 -0.1645 -0.1789 -0.1014 -0.1239 -0.1119 -0.1308 -0.1513 -0.1561
S-686	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-686	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-686	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
D-686	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
P-686	-0.0817 -1.7687 -1.7530 -0.0240 -0.5173 -0.1102 -0.1347 -0.1784 -0.3185 -0.0983 -1.0763 -0.2374 -0.1438 -0.1450 -0.0365 -0.1001 -0.3670 -0.2257 -0.0911 -0.8139 -0.1637 -0.3374 -0.1653 -0.0676 -1.1715 -0.2134 -0.4033 -0.2994 -0.4611 -0.0836 -0.0807 -0.0815 -0.6419 -0.5406 -0.0557 -0.1222 -0.3239 -0.1419 -0.7858 -0.1657 -1.0247 -0.1454 -0.1397 -0.1645 -0.1789 -0.1014 -0.1239 -0.1119 -0.1308 -0.1513 -0.1561
S-1390	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-1390	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-1390	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
D-1390	-0.3324744999408722	Each individual carton consists of a vial with powder , a vial with 5 ml of solvent ( both type I glass with chlorobutyl stopper ) and a reconstitution device ( BAXJECT II ) .
P-1390	-0.0817 -1.7687 -1.7530 -0.0240 -0.5173 -0.1102 -0.1347 -0.1784 -0.3185 -0.0983 -1.0763 -0.2374 -0.1438 -0.1450 -0.0365 -0.1001 -0.3670 -0.2257 -0.0911 -0.8139 -0.1637 -0.3374 -0.1653 -0.0676 -1.1715 -0.2134 -0.4033 -0.2994 -0.4611 -0.0836 -0.0807 -0.0815 -0.6419 -0.5406 -0.0557 -0.1222 -0.3239 -0.1419 -0.7858 -0.1657 -1.0247 -0.1454 -0.1397 -0.1645 -0.1789 -0.1014 -0.1239 -0.1119 -0.1308 -0.1513 -0.1561
S-232	9 Verteilung Studien an Ratten haben ergeben , dass Alendronat sich nach intravenöser Gabe von 1 mg<unk> kg vorübergehend in Weichteilgeweben verteilt , sich aber dann rasch in den Knochen umverteilt oder mit dem Urin ausgeschieden wird .
T-232	Distribution Studies in rats show that alendronate transiently distributes to soft tissues following 1 mg/ kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine .
H-232	-0.41003426909446716	Distribution Studies in rats have shown that alendronate temporarily distributes into soft tissue after the intravenous administration of 1 mg/ kg , but is then rapidly redistributed to the bone or excreted in the urine .
D-232	-0.41003426909446716	Distribution Studies in rats have shown that alendronate temporarily distributes into soft tissue after the intravenous administration of 1 mg/ kg , but is then rapidly redistributed to the bone or excreted in the urine .
P-232	-0.3527 -0.0890 -0.2658 -0.2231 -0.0532 -0.4105 -0.4605 -0.1687 -0.3527 -0.1109 -0.1043 -0.0994 -1.2503 -3.8764 -0.0839 -0.9418 -0.1718 -0.3629 -0.4159 -1.4309 -0.2404 -0.0925 -0.0694 -0.1207 -0.1215 -0.1313 -0.2045 -0.1513 -0.1329 -0.1003 -0.0594 -0.6264 -0.2882 -0.6524 -1.3037 -0.4382 -0.2038 -0.2812 -0.1276 -0.9939 -0.9158 -0.0697 -0.2185 -0.1694 -0.0265 -0.0408 -1.4055 -0.4283 -0.1020 -0.0711 -0.1553 -0.1548
S-1975	Im Rahmen von klinischen Prüfungen mit Desloratadin , bei denen Erythromycin oder Ketoconazol zusätzlich verabreicht wurden , wurden jedoch keine klinisch relevanten Wechselwirkungen oder Veränderungen der Plasmakonzentration von Desloratadin beobachtet .
T-1975	However , no clinically relevant interactions or changes in desloratadine plasma concentrations were observed in clinical trials with desloratadine in which erythromycin or ketoconazole were co-administered .
H-1975	-0.3257468640804291	However , no clinically relevant interactions or changes in plasma concentrations of desloratadine were observed in clinical trials with additional erythromycin or ketoconazole .
D-1975	-0.3257468640804291	However , no clinically relevant interactions or changes in plasma concentrations of desloratadine were observed in clinical trials with additional erythromycin or ketoconazole .
P-1975	-0.7078 -0.1332 -0.3077 -0.0436 -0.0739 -0.7173 -0.2386 -0.3135 -0.1890 -0.2217 -0.1444 -0.6958 -0.0552 -0.0651 -1.9293 -0.0211 -0.0382 -0.2685 -0.4819 -0.0570 -0.1139 -0.3246 -0.4485 -0.3024 -0.3734 -0.3959 -0.5170 -0.0613 -1.5532 -1.1908 -0.6121 -0.1359 -0.0623 -0.2038 -0.1331 -0.1270 -0.1720 -0.0287 -0.1152 -0.0908 -0.0712 -0.0276 -0.3980 -0.1710
S-114	Während in groß angelegten klinischen Studien mit Alendronat kein erhöhtes Risiko festgestellt wurde , wurden selten ( nach Markteinführung ) Magen- und Duodenalulzera , darunter manche schwerwiegend und mit Komplikationen , berichtet ( siehe Abschnitt 4.8 ) .
T-114	3 While no increased risk was observed in extensive clinical trials with alendronate , there have been rare ( post-marketing ) reports of gastric and duodenal ulcers , some of which were severe and with complications ( see section 4.8 ) .
H-114	-0.35265684127807617	While large @-@ scale clinical trials of alendronate have not shown an increased risk , gastric and duodenal ulcers , some severe and with complications , have rarely been reported ( see section 4.8 ) .
D-114	-0.35265684127807617	While large @-@ scale clinical trials of alendronate have not shown an increased risk , gastric and duodenal ulcers , some severe and with complications , have rarely been reported ( see section 4.8 ) .
P-114	-1.0416 -0.7334 -1.8544 -0.0599 -0.0776 -0.2316 -0.2762 -0.1343 -0.1331 -0.1292 -0.1120 -0.7800 -0.4298 -1.2788 -0.6167 -0.0974 -0.1311 -0.3587 -1.4851 -0.0353 -0.1065 -0.2522 -0.4186 -0.1961 -0.0324 -0.0745 -0.0484 -0.2971 -0.1758 -0.3320 -0.5897 -0.5130 -0.2066 -0.4750 -0.0932 -0.1610 -0.1822 -0.4694 -0.9069 -0.3622 -0.1544 -0.2022 -0.2256 -0.0817 -0.1172 -0.1255 -0.1349 -0.1958 -0.1536
S-1897	Es ist als blau-weiße Tabletten mit veränderter Wirkstofffreisetzung erhältlich . Veränderte Wirkstofffreisetzung bedeutet , dass die Tabletten so zusammengesetzt sind , dass einer der wirksamen Bestandteile sofort und der andere langsam über einige Stunden hinweg freigesetzt wird .
T-1897	It is available as blue and white modified-release tablets . Modified-release means that the tablets have been made to allow one of the active substances to be released immediately and the other one released over a few hours .
H-1897	-0.4572666883468628	It is available as blue and white altered agent release tablets . Altered agent release means that the tablets are designed to release one of the active ingredients immediately and the other slowly over a few hours .
D-1897	-0.4572666883468628	It is available as blue and white altered agent release tablets . Altered agent release means that the tablets are designed to release one of the active ingredients immediately and the other slowly over a few hours .
P-1897	-0.9945 -0.1771 -0.3177 -0.5367 -0.4039 -0.5176 -0.0725 -1.2227 -0.0481 -2.2731 -0.7701 -0.2037 -0.1609 -0.3298 -1.5555 -0.0725 -0.1394 -0.2528 -0.2308 -0.5236 -0.3934 -0.0959 -0.1241 -0.1959 -1.6496 -0.3673 -0.6988 -0.2332 -0.8576 -0.2228 -0.3675 -0.1123 -0.0722 -0.2109 -0.4239 -0.1337 -0.1116 -0.9389 -0.2718 -0.9270 -0.1003 -0.1836 -0.1670
S-428	Verteilung Studien an Ratten haben ergeben , dass Alendronat sich nach intravenöser Gabe von 1 mg<unk> kg vorübergehend in Weichteilgeweben verteilt , sich aber dann rasch in den Knochen umverteilt oder mit dem Urin ausgeschieden wird .
T-428	Distribution Studies in rats show that alendronate transiently distributes to soft tissues following 1 mg/ kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine .
H-428	-0.4173959493637085	Distribution Studies in rats have shown that alendronate temporarily disseminates into soft tissue after the intravenous administration of 1 mg/ kg , but is then rapidly redistributed to the bone or excreted in the urine .
D-428	-0.4173959493637085	Distribution Studies in rats have shown that alendronate temporarily disseminates into soft tissue after the intravenous administration of 1 mg/ kg , but is then rapidly redistributed to the bone or excreted in the urine .
P-428	-0.2064 -0.0995 -0.8686 -0.2321 -0.0496 -0.3751 -0.4594 -0.1653 -0.3319 -0.1114 -0.1029 -0.1021 -1.3337 -1.2167 -3.4376 -0.1186 -0.4104 -0.1689 -0.3241 -0.4218 -1.4856 -0.2518 -0.0894 -0.0675 -0.1192 -0.1147 -0.1317 -0.2054 -0.1484 -0.1347 -0.1010 -0.0582 -0.6400 -0.2953 -0.6677 -1.1812 -0.4253 -0.1998 -0.2698 -0.1248 -1.0510 -0.9002 -0.0687 -0.2139 -0.1517 -0.0253 -0.0401 -1.5127 -0.4297 -0.1008 -0.0739 -0.1527 -0.1537
S-12	Adenuric senkt den Harnsäurespiegel im Blut üblicherweise innerhalb von zwei Wochen . Wenn der Harnsäurespiegel nach zwei bis vier Wochen immer noch über 6 mg pro Deziliter liegt , kann die Dosis auf einmal täglich 120 mg erhöht werden .
T-12	Adenuric usually reduces blood uric acid levels within two weeks , but the dose can be increased to 120 mg once a day if blood uric acid levels remain above 6 mg per decilitre after two to four weeks .
H-12	-0.3668537735939026	Adenuric lowers uric acid levels in the blood usually within two weeks . If uric acid levels remain above 6 mg per deciliter after two to four weeks , the dose may be increased to 120 mg once daily .
D-12	-0.3668537735939026	Adenuric lowers uric acid levels in the blood usually within two weeks . If uric acid levels remain above 6 mg per deciliter after two to four weeks , the dose may be increased to 120 mg once daily .
P-12	-0.1550 -0.1437 -0.0730 -0.1335 -2.2848 -0.0661 -1.0181 -0.0791 -0.1833 -1.2364 -0.1999 -0.1931 -0.1039 -1.2720 -0.3645 -0.2730 -0.1245 -0.1780 -0.1984 -0.8780 -0.0886 -0.2525 -1.2494 -0.5761 -0.3873 -0.2287 -0.0407 -0.0962 -0.0817 -0.1337 -0.3684 -0.2600 -0.2982 -0.1412 -0.0760 -0.0965 -0.1784 -0.3029 -0.0810 -0.5841 -0.2393 -0.0300 -0.7574 -0.0746 -0.0463 -0.9141 -0.9177 -0.1567 -0.1597
S-1950	Da Aerinaze Pseudoephedrin enthält , ist das Arzneimittel ebenfalls kontraindiziert bei Patienten , die mit einem Monoaminoxidase ( MAO<unk> -Hemmer behandelt werden bzw. innerhalb der 2 Wochen nach Beendigung einer solchen Therapie .
T-1950	As Aerinaze contains pseudoephedrine , it is also contraindicated in patients who are receiving monoamine oxidase ( MAO ) inhibitor therapy or during the 2 weeks following the stopping of such treatment .
H-1950	-0.3028685748577118	Because Aerinaze contains pseudoephedrine , it is also contraindicated in patients receiving monoamine oxidase ( MAO/ inhibitors ) and within 2 weeks of discontinuation of such therapy .
D-1950	-0.3028685748577118	Because Aerinaze contains pseudoephedrine , it is also contraindicated in patients receiving monoamine oxidase ( MAO/ inhibitors ) and within 2 weeks of discontinuation of such therapy .
P-1950	-1.9327 -0.1152 -0.1312 -0.1443 -0.1383 -0.0984 -0.0718 -0.1156 -0.0965 -0.1462 -0.0475 -0.1146 -0.1532 -0.0932 -0.2274 -0.7568 -0.1903 -0.1884 -0.1389 -0.0458 -0.3936 -0.4553 -0.1534 -0.3501 -0.1551 -0.0209 -0.0294 -0.1431 -0.0734 -0.2028 -0.0949 -0.0962 -0.3603 -0.2108 -0.0313 -0.0546 -0.4300 -0.6408 -1.2217 -0.3877 -0.4786 -0.1643 -0.3290 -2.3312 -0.1188 -0.1078 -0.3298 -0.2129 -0.6005 -0.1642 -0.1578
S-93	ADROVANCE ist nur mit Wasser ( nicht mit Mineralwasser ) mindestens 30 Minuten vor dem ersten Essen , Getränk oder Einnehmen von Arzneimitteln ( einschließlich Antazida , Calcium- und Vitaminergänzungsmitteln ) für den Tag einzunehmen .
T-93	ADROVANCE must be taken with water only ( not mineral water ) at least 30 minutes before the first food , beverage , or medicinal product ( including antacids , calcium supplements and vitamins ) of the day .
H-93	-0.3310427665710449	ADROVANCE should be taken only with water ( not mineral water ) at least 30 minutes before your first meal , drink or take medicines ( including antacids , calcium and vitamin supplements ) for the day .
D-93	-0.3310427665710449	ADROVANCE should be taken only with water ( not mineral water ) at least 30 minutes before your first meal , drink or take medicines ( including antacids , calcium and vitamin supplements ) for the day .
P-93	-0.1634 -0.0556 -0.1313 -0.1060 -0.0777 -0.9630 -0.3052 -0.5748 -1.2081 -0.1815 -0.1682 -0.1913 -0.4289 -0.4682 -0.0719 -0.0735 -0.1276 -0.4046 -0.1104 -0.1380 -0.1452 -0.5727 -1.1965 -0.0619 -0.7051 -0.1489 -0.4811 -0.3182 -1.3797 -1.3652 -0.4352 -0.2995 -0.0593 -0.0727 -0.0299 -0.2185 -0.1438 -0.2292 -0.1063 -0.1399 -0.2291 -0.0690 -0.1983 -0.0224 -0.1001 -0.1294 -1.2925 -0.2262 -0.2142 -0.1804 -0.1636
S-280	ADROVANCE ist nur mit Wasser ( nicht mit Mineralwasser ) mindestens 30 Minuten vor dem ersten Essen , Getränk oder Einnehmen von Arzneimitteln ( einschließlich Antazida , Calcium- und Vitaminergänzungsmitteln ) für den Tag einzunehmen .
T-280	ADROVANCE must be taken with water only ( not mineral water ) at least 30 minutes before the first food , beverage , or medicinal product ( including antacids , calcium supplements and vitamins ) of the day .
H-280	-0.3310427665710449	ADROVANCE should be taken only with water ( not mineral water ) at least 30 minutes before your first meal , drink or take medicines ( including antacids , calcium and vitamin supplements ) for the day .
D-280	-0.3310427665710449	ADROVANCE should be taken only with water ( not mineral water ) at least 30 minutes before your first meal , drink or take medicines ( including antacids , calcium and vitamin supplements ) for the day .
P-280	-0.1634 -0.0556 -0.1313 -0.1060 -0.0777 -0.9630 -0.3052 -0.5748 -1.2081 -0.1815 -0.1682 -0.1913 -0.4289 -0.4682 -0.0719 -0.0735 -0.1276 -0.4046 -0.1104 -0.1380 -0.1452 -0.5727 -1.1965 -0.0619 -0.7051 -0.1489 -0.4811 -0.3182 -1.3797 -1.3652 -0.4352 -0.2995 -0.0593 -0.0727 -0.0299 -0.2185 -0.1438 -0.2292 -0.1063 -0.1399 -0.2291 -0.0690 -0.1983 -0.0224 -0.1001 -0.1294 -1.2925 -0.2262 -0.2142 -0.1804 -0.1636
S-332	Alendronat Nahrungsmittel und Getränke ( einschließlich Mineralwasser ) , Calcium-Ergänzungsmittel , Antazida und einige orale Arzneimittel können die Resorption von Alendronat beeinträchtigen , wenn sie zur gleichen Zeit eingenommen werden .
T-332	Alendronate If taken at the same time , it is likely that food and beverages ( including mineral water ) , calcium supplements , antacids , and some oral medicinal products will interfere with absorption of alendronate .
H-332	-0.3387734889984131	Alendronate Foods and drinks ( including mineral water ) , calcium supplements , antacids and some oral medicines can affect the absorption of alendronate if taken at the same time .
D-332	-0.3387734889984131	Alendronate Foods and drinks ( including mineral water ) , calcium supplements , antacids and some oral medicines can affect the absorption of alendronate if taken at the same time .
P-332	-0.8993 -0.1269 -0.1443 -0.1002 -1.7853 -0.4070 -0.1471 -1.1300 -0.1875 -0.0511 -0.7497 -0.0792 -0.5349 -0.1430 -0.1421 -0.2546 -0.1237 -0.1234 -0.0377 -0.1022 -0.1414 -0.1169 -0.0547 -0.2317 -0.4536 -0.4313 -0.0778 -0.1831 -0.1997 -1.2260 -1.5849 -0.2879 -0.0699 -0.0563 -0.1286 -0.2315 -0.1107 -0.1526 -0.0742 -0.9298 -0.2409 -0.5412 -0.1352 -0.3819 -0.2264 -0.2240 -0.1608
S-397	Vitamin D3 ( der Menge von Vitamin D3 in der höheren Dosis von ADROVANCE ) einmal wöchentlich entspricht , wurde in einer 24-wöchigen Verlängerungsstudie mit 619 postmenopausalen Frauen mit Osteoporose gezeigt .
T-397	Patients in the Vitamin D3 2800 group received ADROVANCE ( 70 mg/ 2800 IU ) ( n<<unk>> 299 ) and patients in the Vitamin D3 5600 group received ADROVANCE ( 70 mg/ 2800 IU ) plus an additional 2800 IU vitamin D3 ( n<<unk>> 309 ) once a week ; additional vitamin D supplements were allowed .
H-397	-0.29001912474632263	vitamin D3 ( equivalent to the amount of vitamin D3 in the higher dose of ADROVANCE ) given weekly was shown in a 24 week extension study in 619 post-menopausal women with osteoporosis .
D-397	-0.29001912474632263	vitamin D3 ( equivalent to the amount of vitamin D3 in the higher dose of ADROVANCE ) given weekly was shown in a 24 week extension study in 619 post-menopausal women with osteoporosis .
P-397	-0.5580 -0.0675 -0.1613 -0.1378 -0.1493 -0.9005 -0.1355 -0.3832 -0.6520 -0.1289 -0.2344 -0.0827 -0.1695 -0.1411 -1.0178 -0.3109 -0.3192 -0.2365 -0.1356 -0.0562 -0.0741 -0.1226 -0.1043 -0.0921 -0.1475 -0.2713 -0.4764 -1.0896 -0.8330 -0.2144 -0.1341 -0.4718 -1.4559 -0.2609 -0.7146 -0.7748 -0.1747 -0.1048 -0.1003 -0.5028 -0.0949 -0.0988 -0.0601 -0.1214 -0.0871 -0.1474 -0.1455 -0.0880 -0.1079 -0.1128 -0.0864 -0.0786 -0.1796 -0.1546
S-144	Alendronat Nahrungsmittel und Getränke ( einschließlich Mineralwasser ) , Calcium-Ergänzungsmittel , Antazida und einige orale Arzneimittel können die Resorption von Alendronat beeinträchtigen , wenn sie zur gleichen Zeit eingenommen werden .
T-144	Alendronate If taken at the same time , it is likely that food and beverages ( including mineral water ) , calcium supplements , antacids , and some oral medicinal products will interfere with absorption of alendronate .
H-144	-0.3387734889984131	Alendronate Foods and drinks ( including mineral water ) , calcium supplements , antacids and some oral medicines can affect the absorption of alendronate if taken at the same time .
D-144	-0.3387734889984131	Alendronate Foods and drinks ( including mineral water ) , calcium supplements , antacids and some oral medicines can affect the absorption of alendronate if taken at the same time .
P-144	-0.8993 -0.1269 -0.1443 -0.1002 -1.7853 -0.4070 -0.1471 -1.1300 -0.1875 -0.0511 -0.7497 -0.0792 -0.5349 -0.1430 -0.1421 -0.2546 -0.1237 -0.1234 -0.0377 -0.1022 -0.1414 -0.1169 -0.0547 -0.2317 -0.4536 -0.4313 -0.0778 -0.1831 -0.1997 -1.2260 -1.5849 -0.2879 -0.0699 -0.0563 -0.1286 -0.2315 -0.1107 -0.1526 -0.0742 -0.9298 -0.2409 -0.5412 -0.1352 -0.3819 -0.2264 -0.2240 -0.1608
S-111	3 Das Risiko schwerer ösophagealer Nebenwirkungen scheint bei Patienten erhöht zu sein , die das Arzneimittel nicht korrekt einnehmen und<unk> oder es nach dem Auftreten von Symptomen , die auf eine ösophageale Irritation hinweisen , weiter einnehmen .
T-111	The risk of severe oesophageal adverse reactions appears to be greater in patients who fail to take alendronate properly and/ or who continue to take alendronate after developing symptoms suggestive of oesophageal irritation .
H-111	-0.4904960095882416	The risk of severe oesophageal adverse events appears to be increased in patients who are not taking the medicine<unk> or who continue to take it after symptoms indicating oesophageal irritation have occurred .
D-111	-0.4904960095882416	The risk of severe oesophageal adverse events appears to be increased in patients who are not taking the medicine<unk> or who continue to take it after symptoms indicating oesophageal irritation have occurred .
P-111	-0.7593 -0.1772 -0.1446 -0.9772 -0.5155 -0.0463 -0.2933 -0.0745 -0.0732 -0.1288 -1.0387 -0.0451 -1.0684 -0.9065 -0.3125 -0.1436 -0.2890 -0.2022 -0.3993 -0.2985 -0.8920 -0.4302 -0.3500 -0.3563 -0.5129 -0.5180 -1.4914 -0.2412 -1.1850 -1.0914 -0.2460 -0.1794 -1.0756 -0.2892 -0.4993 -2.8134 -0.1013 -0.2890 -0.1207 -0.3816 -0.0724 -0.0831 -0.1122 -0.0637 -0.1232 -1.7789 -0.5319 -0.1576 -0.1539
S-58	Die Patientin muss die Tablette mit einem vollen Glas Wasser ( kein Mineralwasser ) mindestens 30 Minuten vor dem Essen , Trinken oder Einnehmen anderer Arzneimittel ( einschließlich Antazida , Calcium- und Vitaminergänzungsmittel ) einnehmen .
T-58	The patient must take the tablet with a full glass of water ( not mineral water ) , at least 30 minutes before any food , drink , or other medicines ( including antacids , calcium supplements and vitamins ) .
H-58	-0.2431284785270691	The patient must take the tablet with a full glass of water ( not mineral water ) at least 30 minutes before eating , drinking or taking other medicines ( including antacids , calcium and vitamin supplements ) .
D-58	-0.2431284785270691	The patient must take the tablet with a full glass of water ( not mineral water ) at least 30 minutes before eating , drinking or taking other medicines ( including antacids , calcium and vitamin supplements ) .
P-58	-0.8792 -0.6044 -1.3156 -0.0238 -0.2445 -0.1402 -0.1372 -0.2777 -0.1436 -0.0665 -0.0387 -0.1401 -0.1385 -0.1667 -0.9917 -0.3695 -0.0750 -0.0730 -0.1276 -0.2114 -0.1100 -0.1448 -0.2007 -0.2997 -0.5505 -0.1426 -0.3556 -0.3868 -0.0862 -0.1891 -0.1141 -0.6029 -0.5005 -0.0738 -0.0882 -0.0409 -0.2521 -0.1458 -0.2036 -0.1227 -0.1336 -0.1964 -0.0568 -0.1557 -0.0161 -0.0917 -0.1388 -0.1920 -0.1565
S-1852	Am 17 . Dezember 2008 teilte Gendux Molecular Limited dem Ausschuss für Humanarzneimittel ( CHMP ) offiziell mit , dass das Unternehmen seinen Antrag auf Genehmigung für das Inverkehrbringen von Advexin zur Behandlung von Li-Fraumeni-Krebs zurücknimmt .
T-1852	On 17 December 2008 , Gendux Molecular Limited officially notified the Committee for Medicinal Products for Human Use ( CHMP ) that it wishes to withdraw its application for a marketing authorisation for Advexin for the treatment of Li-Fraumeni cancer .
H-1852	-0.28233158588409424	On 17 December 2008 , Gendux Molecular Limited officially notified the Committee for Medicinal Products for Human Use ( CHMP ) that it was withdrawing its marketing authorisation application for Advexin for the treatment of Li-Fraumeni cancer .
D-1852	-0.28233158588409424	On 17 December 2008 , Gendux Molecular Limited officially notified the Committee for Medicinal Products for Human Use ( CHMP ) that it was withdrawing its marketing authorisation application for Advexin for the treatment of Li-Fraumeni cancer .
P-1852	-0.4324 -0.5895 -0.1471 -0.1544 -0.2855 -0.1473 -0.1571 -0.1132 -0.1100 -0.0659 -0.0736 -0.0431 -1.0822 -1.1936 -0.0841 -0.1716 -0.1353 -0.2132 -0.3239 -0.1268 -0.1892 -0.1406 -0.1328 -0.2115 -0.0875 -0.1432 -0.0740 -0.0719 -0.1199 -0.3799 -0.4845 -0.5432 -0.2027 -0.0838 -0.1286 -0.9032 -0.1183 -0.0438 -0.1735 -0.1496 -0.2780 -0.1610 -0.1254 -0.5239 -0.1913 -0.0917 -0.1220 -1.6419 -0.2227 -0.3477 -0.0440 -0.2712 -1.1494 -0.1734 -0.1528
S-448	Ausscheidung Bei Gabe von radioaktiv markiertem Vitamin D3 an gesunde Probanden betrug die mittlere Ausscheidung der Radioaktivität im Urin nach 48 Stunden 2,4 % , in den Fäzes nach 4 Tagen 4,9 <unk> .
T-448	Elimination When radioactive vitamin D3 was administered to healthy subjects , the mean urinary excretion of radioactivity after 48 hours was 2.4 % , and the mean faecal excretion of radioactivity after 4 days was 4.9 % .
H-448	-0.4533795416355133	When radioactively labelled vitamin D3 was administered to healthy subjects , the mean level of radioactivity in the urine was 2.4 % after 48 hours , and 4.9 % in the faeces after 4 days .
D-448	-0.4533795416355133	When radioactively labelled vitamin D3 was administered to healthy subjects , the mean level of radioactivity in the urine was 2.4 % after 48 hours , and 4.9 % in the faeces after 4 days .
P-448	-2.6185 -0.6338 -0.6693 -0.6098 -0.6919 -0.2227 -0.0660 -0.1506 -0.1424 -0.1321 -0.9642 -0.1081 -0.1570 -0.0654 -0.0344 -0.1483 -0.7934 -0.0387 -1.6429 -0.1251 -1.8373 -0.1153 -0.8653 -0.8369 -0.0839 -0.0670 -1.1069 -0.1320 -0.1411 -0.1211 -1.4909 -0.0908 -0.1137 -0.4596 -0.6905 -0.1041 -0.1210 -0.8420 -0.1463 -0.5592 -0.2787 -0.0092 -0.1640 -0.4814 -0.4565 -0.1107 -0.1635 -0.1586
S-299	Das Risiko schwerer ösophagealer Nebenwirkungen scheint bei Patienten erhöht zu sein , die das Arzneimittel nicht korrekt einnehmen und<unk> oder es nach dem Auftreten von Symptomen , die auf eine ösophageale Irritation hinweisen , weiter einnehmen .
T-299	The risk of severe oesophageal adverse reactions appears to be greater in patients who fail to take alendronate properly and/ or who continue to take alendronate after developing symptoms suggestive of oesophageal irritation .
H-299	-0.47751331329345703	The risk of severe oesophageal adverse events appears to be increased in patients who are not taking the medicine correctly and / or who continue to take it after symptoms indicating oesophageal irritation have occurred .
D-299	-0.47751331329345703	The risk of severe oesophageal adverse events appears to be increased in patients who are not taking the medicine correctly and / or who continue to take it after symptoms indicating oesophageal irritation have occurred .
P-299	-0.5576 -0.1793 -0.1510 -0.9349 -0.6244 -0.0453 -0.2810 -0.0747 -0.0740 -0.1306 -1.1661 -0.0431 -1.0272 -0.8787 -0.2938 -0.1395 -0.2875 -0.2254 -0.3879 -0.2829 -0.9852 -0.4325 -0.3933 -0.3383 -1.5912 -0.2964 -0.2281 -1.1132 -0.3760 -0.1492 -1.4465 -1.0980 -0.2677 -0.1787 -0.3862 -0.3008 -0.4224 -2.6395 -0.1078 -0.3092 -0.1092 -0.3527 -0.0723 -0.0855 -0.1141 -0.0700 -0.1208 -1.8128 -0.4628 -0.1545 -0.1534
S-252	Ausscheidung Bei Gabe von radioaktiv markiertem Vitamin D3 an gesunde Probanden betrug die mittlere Ausscheidung der Radioaktivität im Urin nach 48 Stunden 2,4 % , in den Fäzes nach 4 Tagen 4,9 <unk> .
T-252	Elimination When radioactive vitamin D3 was administered to healthy subjects , the mean urinary excretion of radioactivity after 48 hours was 2.4 % , and the mean faecal excretion of radioactivity after 4 days was 4.9 % .
H-252	-0.4533795416355133	When radioactively labelled vitamin D3 was administered to healthy subjects , the mean level of radioactivity in the urine was 2.4 % after 48 hours , and 4.9 % in the faeces after 4 days .
D-252	-0.4533795416355133	When radioactively labelled vitamin D3 was administered to healthy subjects , the mean level of radioactivity in the urine was 2.4 % after 48 hours , and 4.9 % in the faeces after 4 days .
P-252	-2.6185 -0.6338 -0.6693 -0.6098 -0.6919 -0.2227 -0.0660 -0.1506 -0.1424 -0.1321 -0.9642 -0.1081 -0.1570 -0.0654 -0.0344 -0.1483 -0.7934 -0.0387 -1.6429 -0.1251 -1.8373 -0.1153 -0.8653 -0.8369 -0.0839 -0.0670 -1.1069 -0.1320 -0.1411 -0.1211 -1.4909 -0.0908 -0.1137 -0.4596 -0.6905 -0.1041 -0.1210 -0.8420 -0.1463 -0.5592 -0.2787 -0.0092 -0.1640 -0.4814 -0.4565 -0.1107 -0.1635 -0.1586
S-1989	Die Unbedenklichkeit der Anwendung von Aerinaze während der Schwangerschaft ist nicht gesichert , Erfahrungen aus einer großen Anzahl von betroffenen Schwangerschaften ergaben jedoch keine Erhöhung der Frequenz von Missbildungen im Vergleich zur Häufigkeit bei der Normalbevölkerung .
T-1989	The safe use of Aerinaze during pregnancy has not been established ; however experience from a large number of exposed pregnancies in humans does not reveal any increase in the frequency of malformations as compared to the incidence in the general population .
H-1989	-0.38316431641578674	The safety of the use of Aerinaze during pregnancy has not been established , but experience from a large number of affected pregnancies has not shown an increase in the frequency of malformations compared to the incidence in the normal population .
D-1989	-0.38316431641578674	The safety of the use of Aerinaze during pregnancy has not been established , but experience from a large number of affected pregnancies has not shown an increase in the frequency of malformations compared to the incidence in the normal population .
P-1989	-1.1153 -0.0151 -0.1466 -1.8191 -0.0962 -0.1183 -0.1405 -0.1252 -0.1374 -0.1553 -0.0879 -0.2068 -0.0766 -1.0226 -0.1304 -0.1294 -0.1100 -0.3407 -0.4924 -0.2214 -1.3193 -0.1346 -0.5120 -0.1047 -0.1343 -0.8463 -0.3025 -0.0942 -0.0891 -0.5397 -0.6367 -0.9240 -0.4548 -0.6701 -0.1221 -0.2314 -0.5202 -0.0818 -0.1372 -0.3334 -0.0774 -0.1237 -0.4869 -0.6202 -0.4163 -2.2127 -0.0748 -0.2555 -0.1781 -0.6293 -0.0496 -0.1534 -0.1546
S-373	Alendronat Natriumalendronat 3 H2O ist ein Bisphosphonat , das die durch Osteoklasten vermittelte Knochenresorption hemmt , ohne eine direkte Wirkung auf die Knochenbildung auszuüben .
T-373	Alendronate Alendronate sodium is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation .
H-373	-0.24665242433547974	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
D-373	-0.24665242433547974	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
P-373	-1.2553 -0.1269 -0.1538 -0.0999 -0.1730 -0.1025 -0.1307 -0.1436 -0.1776 -0.0851 -0.2898 -0.1715 -0.1335 -0.1300 -0.1640 -0.1236 -0.1187 -0.0356 -0.0315 -0.0883 -0.5252 -0.5494 -0.1008 -0.1688 -1.7168 -0.2576 -0.1628 -0.0622 -0.4931 -0.0946 -0.1577 -0.1179 -0.0559 -0.1276 -0.0596 -0.1375 -0.3955 -0.8169 -0.1318 -0.5152 -0.0904 -0.5165 -0.1266 -0.0751 -0.0827 -0.1561 -0.1634
S-185	Alendronat Natriumalendronat 3 H2O ist ein Bisphosphonat , das die durch Osteoklasten vermittelte Knochenresorption hemmt , ohne eine direkte Wirkung auf die Knochenbildung auszuüben .
T-185	Alendronate Alendronate sodium is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation .
H-185	-0.24665242433547974	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
D-185	-0.24665242433547974	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
P-185	-1.2553 -0.1269 -0.1538 -0.0999 -0.1730 -0.1025 -0.1307 -0.1436 -0.1776 -0.0851 -0.2898 -0.1715 -0.1335 -0.1300 -0.1640 -0.1236 -0.1187 -0.0356 -0.0315 -0.0883 -0.5252 -0.5494 -0.1008 -0.1688 -1.7168 -0.2576 -0.1628 -0.0622 -0.4931 -0.0946 -0.1577 -0.1179 -0.0559 -0.1276 -0.0596 -0.1375 -0.3955 -0.8169 -0.1318 -0.5152 -0.0904 -0.5165 -0.1266 -0.0751 -0.0827 -0.1561 -0.1634
S-1690	1 Durchstechflasche mit ADVATE 2000 I.E. Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Mediziprodukt
T-1690	1 vial with 2000 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1690	-0.18005095422267914	1 vial of ADVATE 2000 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II product
D-1690	-0.18005095422267914	1 vial of ADVATE 2000 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II product
P-1690	-0.1363 -0.0538 -0.0984 -0.5795 -0.1433 -0.1592 -0.0887 -0.0920 -0.0938 -0.0988 -0.1838 -0.2022 -0.1067 -0.1187 -0.2200 -0.1149 -0.0787 -0.1467 -0.1434 -0.0217 -0.0901 -0.1607 -0.3255 -0.0917 -0.3155 -0.1447 -0.1078 -0.1017 -0.1217 -0.1608 -0.2138 -0.1475 -0.1380 -0.3525 -0.1548 -0.1813 -0.0994 -0.1156 -0.2428 -1.0567 -0.1787
S-1706	1 Durchstechflasche mit ADVATE 3000 I.E.Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt .
T-1706	1 vial with 3000 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1706	-0.18874716758728027	1 vial of ADVATE 3000 IUOctocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
D-1706	-0.18874716758728027	1 vial of ADVATE 3000 IUOctocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
P-1706	-0.1407 -0.0505 -0.1057 -0.5329 -0.1111 -0.1577 -0.0889 -0.0925 -0.0386 -0.0969 -0.3336 -0.0320 -0.1153 -0.1337 -0.2286 -0.1049 -0.0835 -0.1492 -0.1416 -0.0226 -0.1044 -0.1668 -0.3109 -0.0925 -0.4493 -0.1487 -0.1134 -0.0959 -0.1185 -0.1687 -0.2395 -0.1457 -0.1328 -0.3584 -0.1567 -0.1793 -0.1028 -0.1183 -0.2813 -0.5051 -0.6376 -0.5690 -0.1604
S-257	10 35 mg<unk> kg bei Tieren gefunden . Obwohl keine klinischen Daten darüber vorliegen , ist dennoch damit zu rechnen , dass die renale Elimination von Alendronat wie in den Tierversuchen auch bei Patienten mit eingeschränkter Nierenfunktion reduziert sein wird .
T-257	Although no clinical information is available , it is likely that , as in animals , elimination of alendronate via the kidney will be reduced in patients with impaired renal function .
H-257	-0.43017739057540894	10 35 mg/ kg in animals . Although no clinical data are available , renal elimination of alendronate is expected to be reduced in patients with impaired renal function , as in animal studies .
D-257	-0.43017739057540894	10 35 mg/ kg in animals . Although no clinical data are available , renal elimination of alendronate is expected to be reduced in patients with impaired renal function , as in animal studies .
P-257	-1.4298 -0.4141 -0.1115 -0.1300 -0.1112 -0.0747 -1.2525 -0.1065 -1.2836 -0.5507 -0.8968 -0.1416 -0.0909 -1.0664 -0.1470 -0.7006 -0.6560 -0.1050 -0.0839 -0.0861 -0.1263 -0.1269 -0.1323 -0.1427 -0.0675 -0.9579 -1.1163 -0.1848 -0.2896 -0.2703 -1.0309 -0.6348 -0.1391 -0.4204 -0.2064 -0.1391 -0.1594 -0.0940 -0.7652 -0.2463 -1.2879 -0.2829 -0.7555 -0.1846 -0.1579
S-1640	1 Durchstechflasche mit ADVATE 500 I.E Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt .
T-1640	1 vial with 500 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1640	-0.19044655561447144	1 vial of ADVATE 500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
D-1640	-0.19044655561447144	1 vial of ADVATE 500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
P-1640	-0.1345 -0.0607 -0.1077 -0.4915 -0.1401 -0.1544 -0.0890 -0.0923 -0.0832 -0.0970 -0.4099 -0.1909 -0.1055 -0.1175 -0.2191 -0.1031 -0.0791 -0.1471 -0.1412 -0.0229 -0.1028 -0.1694 -0.3059 -0.0897 -0.3793 -0.1481 -0.1162 -0.0964 -0.1184 -0.1678 -0.2304 -0.1458 -0.1324 -0.3557 -0.1589 -0.1809 -0.1029 -0.1160 -0.2294 -0.5306 -0.6430 -0.5230 -0.1594
S-212	Die mittleren BMD-Zunahmen betrugen 2,3 % bzw. 2,9 % am Femurhals und 2,9 % bzw. 3,1 % an der gesamten Hüfte in der Gruppe mit 70 mg einmal wöchentlich bzw. in der mit 10 mg täglich . Die zwei
T-212	The mean BMD increases were 2.3 % and 2.9 % at the femoral neck and 2.9 % and 3.1 % at the total hip in the 70 mg once weekly and 10 mg daily groups , respectively .
H-212	-0.37376928329467773	Mean BMD increases were 2.3 % and 2.9 % for the femoral neck and 2.9 % and 3.1 % for the entire hip , respectively , in the 70 mg weekly and 10 mg daily groups .
D-212	-0.37376928329467773	Mean BMD increases were 2.3 % and 2.9 % for the femoral neck and 2.9 % and 3.1 % for the entire hip , respectively , in the 70 mg weekly and 10 mg daily groups .
P-212	-1.4587 -0.1514 -0.8025 -0.1798 -0.2610 -0.1428 -0.1228 -0.1395 -0.1103 -0.1712 -0.1230 -0.1175 -0.1007 -1.6675 -0.1786 -0.0896 -0.1987 -0.0862 -0.8305 -0.1478 -0.1078 -0.0881 -0.1321 -0.0560 -0.1423 -0.1032 -0.1896 -0.3071 -1.2071 -0.1841 -1.2675 -0.1492 -0.1954 -0.1802 -0.1517 -0.3265 -0.0292 -0.4214 -0.2991 -0.1594 -0.0578 -0.3328 -3.1202 -0.3729 -0.1587
S-1782	Wenn plötzliche , schwere ( anaphylaktische ) Nebenwirkungen auftreten , muss die Injektion sofort abgebrochen werden.Sie müssen sofort Kontakt mit Ihrem Arzt aufnehmen , wenn Sieeins der folgenden Frühsymptome für allergische ( überempfindliche ) Reaktionen haben :
T-1782	Wenn plötzliche , schwere ( anaphylaktische ) Nebenwirkungen auftreten , muss die Injektion sofort abgebrochen werden.Sie müssen sofort Kontakt mit Ihrem Arzt aufnehmen , wenn Sieeins der folgenden Frühsymptome für allergische ( überempfindliche ) Reaktionen haben : You must contact your doctor immediately if you have any of the following early symptoms of allergic ( hypersensitivity ) reactions :
H-1782	-0.266475111246109	If sudden , severe ( anaphylactic ) side effects occur , the injection must be discontinued immediately . Contact your doctor immediately if you have any of the following early symptoms of allergic ( hypersensitive ) reactions :
D-1782	-0.266475111246109	If sudden , severe ( anaphylactic ) side effects occur , the injection must be discontinued immediately . Contact your doctor immediately if you have any of the following early symptoms of allergic ( hypersensitive ) reactions :
P-1782	-0.5236 -0.4528 -0.2158 -0.2223 -0.1684 -0.1885 -0.1068 -0.1148 -0.1284 -0.0733 -0.1563 -0.8478 -0.1334 -0.4956 -0.1738 -1.3545 -0.0880 -0.1397 -0.9304 -0.1392 -0.5063 -0.0488 -0.1102 -0.1689 -1.0301 -0.1239 -0.0961 -0.0794 -0.0593 -0.0902 -0.3457 -0.4861 -0.1291 -0.1634 -0.0649 -0.3055 -0.1960 -0.1741 -0.1833 -0.0360 -0.1935 -0.0708 -0.4507 -0.1353 -0.5053 -0.0800 -0.1492 -0.1555
S-445	21 Vitamin D3 wird in der Leber rasch zu 25-Hydroxyvitamin D3 hydroxyliert und dann in der Niere zu 1,25-Dihydroxyvitamin D3 , der biologisch aktiven Form , metabolisiert .
T-445	Biotransformation Vitamin D3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D3 , and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D3 , which represents the biologically active form .
H-445	-0.2452952116727829	21 vitamin D3 is rapidly hydroxylated in the liver to 25-hydroxyvitamin D3 and then metabolised in the kidney to 1,25-dihydroxyvitamin D3 , the biologically active form .
D-445	-0.2452952116727829	21 vitamin D3 is rapidly hydroxylated in the liver to 25-hydroxyvitamin D3 and then metabolised in the kidney to 1,25-dihydroxyvitamin D3 , the biologically active form .
P-445	-0.6613 -0.3742 -0.0895 -0.1543 -0.1452 -0.1946 -0.1348 -0.0790 -0.1588 -0.1827 -0.0305 -0.5971 -0.1663 -0.0858 -0.3964 -1.6998 -0.0851 -0.0602 -0.1417 -0.1101 -0.1091 -0.0701 -0.1538 -0.1428 -1.0834 -0.6646 -0.1706 -0.0397 -0.0860 -0.3742 -0.1556 -0.2324 -0.2702 -0.2358 -0.8274 -0.3736 -0.0956 -0.1339 -0.0661 -0.0988 -0.1243 -0.0669 -0.0713 -0.1530 -0.1334 -0.1924 -0.6299 -0.1179 -0.1326 -0.0808 -0.0405 -0.1650 -0.2461 -0.1612
S-396	Die Wirkung der niedrigeren Dosis von ADROVANCE ( 70 mg Alendronat<unk> 2.800 I.E. Vitamin D3 ) mit zusätzlicher Gabe von 2.800 I.E. Vitamin D3 , was insgesamt 5.600 I.E.
T-396	The effect of the lower dose of ADROVANCE ( alendronate 70 mg/ vitamin D3 2800 IU ) plus an additional 2800 IU Vitamin D3 for a total of 5600 IU ( the amount of vitamin D3 in the higher dose of ADROVANCE ) once weekly was demonstrated in a 24-week , extension study that enrolled 619 osteoporotic post-menopausal women .
H-396	-0.32385990023612976	The effect of the lower dose of ADROVANCE ( 70 mg alendronate<unk> 2,800 IU of vitamin D3 ) with an additional dose of 2,800 IU of vitamin D3 , totaling 5,600 IU
D-396	-0.32385990023612976	The effect of the lower dose of ADROVANCE ( 70 mg alendronate<unk> 2,800 IU of vitamin D3 ) with an additional dose of 2,800 IU of vitamin D3 , totaling 5,600 IU
P-396	-0.1896 -1.7755 -0.1265 -0.5247 -0.2971 -0.0613 -0.1208 -0.0406 -0.0628 -0.1396 -0.1001 -0.0979 -0.1387 -0.3356 -0.0271 -0.2804 -0.0894 -0.1576 -0.3359 -2.0034 -1.0253 -0.2143 -0.0768 -0.0854 -0.1673 -0.6033 -0.1409 -0.1246 -0.1495 -0.1496 -0.1403 -0.3564 -0.6379 -0.3764 -1.1964 -0.1290 -0.1794 -0.0859 -0.1254 -0.1845 -0.1470 -0.1500 -0.1034 -0.1477 -0.1447 -0.3593 -2.0459 -0.1983 -0.1704 -0.0755 -0.1386 -0.1009 -0.3293
S-1507	11 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-1507	11 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-1507	-0.21415989100933075	11 newborns ( aged 0 -1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 -12 years ) , adolescents ( aged 12 -16 years ) , adults ( over 16 years )
D-1507	-0.21415989100933075	11 newborns ( aged 0 -1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 -12 years ) , adolescents ( aged 12 -16 years ) , adults ( over 16 years )
P-1507	-0.3136 -0.2443 -0.5549 -0.0702 -0.1514 -1.0381 -0.2778 -0.5489 -0.1408 -0.3537 -0.1323 -0.1394 -0.9163 -0.1996 -0.1584 -0.0636 -0.1544 -0.1735 -0.6930 -0.1461 -0.0846 -0.1252 -0.1388 -0.1777 -0.1571 -0.1073 -0.1364 -0.2234 -0.1210 -0.0821 -0.1237 -0.1364 -0.3586 -0.0561 -0.0373 -0.1571 -0.1231 -0.1239 -0.1736 -0.1257 -0.0908 -0.1245 -0.1443 -0.2183 -0.1491 -0.2301 -0.1334 -0.0837 -0.1420 -0.1523
S-1154	7 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-1154	7 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-1154	-0.21700821816921234	7 newborns ( aged 0 -1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 -12 years ) , adolescents ( aged 12 -16 years ) , adults ( over 16 years )
D-1154	-0.21700821816921234	7 newborns ( aged 0 -1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 -12 years ) , adolescents ( aged 12 -16 years ) , adults ( over 16 years )
P-1154	-0.2142 -0.2446 -0.6235 -0.0711 -0.1501 -1.2150 -0.2748 -0.5724 -0.1405 -0.3168 -0.1324 -0.1391 -0.8946 -0.1970 -0.1576 -0.0692 -0.1544 -0.1716 -0.7096 -0.1478 -0.0850 -0.1258 -0.1396 -0.1830 -0.1569 -0.1093 -0.1363 -0.2292 -0.1204 -0.0821 -0.1230 -0.1361 -0.3590 -0.0544 -0.0387 -0.1579 -0.1250 -0.1234 -0.1745 -0.1258 -0.0906 -0.1244 -0.1440 -0.2186 -0.1495 -0.2286 -0.1331 -0.0845 -0.1403 -0.1551
S-740	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-740	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-740	-0.2887675166130066	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
D-740	-0.2887675166130066	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
P-740	-0.6629 -0.6010 -0.1079 -0.0935 -0.1766 -0.3648 -1.2715 -0.3634 -0.1448 -0.0919 -0.0378 -0.2161 -0.1117 -0.1527 -0.6037 -0.1304 -0.1756 -0.1258 -0.5381 -0.2903 -0.2378 -0.0791 -0.0855 -0.4478 -0.1695 -0.1394 -0.0817 -0.0620 -0.1051 -1.4352 -0.0519 -0.4728 -0.3068 -1.4024 -0.3587 -0.1480 -0.1396 -0.6221 -0.0692 -0.0770 -0.1252 -0.1132 -0.1691 -0.2675 -0.0755 -0.0271 -0.1746 -0.1562
S-1330	9 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-1330	9 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-1330	-0.21893885731697083	9 newborns ( aged 0 -1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 -12 years ) , adolescents ( aged 12 -16 years ) , adults ( over 16 years )
D-1330	-0.21893885731697083	9 newborns ( aged 0 -1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 -12 years ) , adolescents ( aged 12 -16 years ) , adults ( over 16 years )
P-1330	-0.3750 -0.2501 -0.6035 -0.0732 -0.1513 -1.2219 -0.2674 -0.5744 -0.1413 -0.3357 -0.1326 -0.1396 -0.8592 -0.1971 -0.1578 -0.0667 -0.1544 -0.1722 -0.6945 -0.1475 -0.0849 -0.1254 -0.1394 -0.1803 -0.1572 -0.1111 -0.1352 -0.2244 -0.1201 -0.0812 -0.1235 -0.1367 -0.3540 -0.0555 -0.0372 -0.1569 -0.1246 -0.1226 -0.1732 -0.1259 -0.0912 -0.1240 -0.1438 -0.2142 -0.1502 -0.2268 -0.1331 -0.0842 -0.1405 -0.1541
S-1092	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-1092	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-1092	-0.2887675166130066	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
D-1092	-0.2887675166130066	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
P-1092	-0.6629 -0.6010 -0.1079 -0.0935 -0.1766 -0.3648 -1.2715 -0.3634 -0.1448 -0.0919 -0.0378 -0.2161 -0.1117 -0.1527 -0.6037 -0.1304 -0.1756 -0.1258 -0.5381 -0.2903 -0.2378 -0.0791 -0.0855 -0.4478 -0.1695 -0.1394 -0.0817 -0.0620 -0.1051 -1.4352 -0.0519 -0.4728 -0.3068 -1.4024 -0.3587 -0.1480 -0.1396 -0.6221 -0.0692 -0.0770 -0.1252 -0.1132 -0.1691 -0.2675 -0.0755 -0.0271 -0.1746 -0.1562
S-978	5 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-978	5 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-978	-0.21868246793746948	5 newborns ( aged 0 -1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 -12 years ) , adolescents ( aged 12 -16 years ) , adults ( over 16 years )
D-978	-0.21868246793746948	5 newborns ( aged 0 -1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 -12 years ) , adolescents ( aged 12 -16 years ) , adults ( over 16 years )
P-978	-0.3849 -0.2093 -0.6171 -0.0692 -0.1490 -1.2031 -0.2959 -0.5669 -0.1414 -0.3112 -0.1331 -0.1387 -0.8769 -0.2019 -0.1574 -0.0649 -0.1534 -0.1692 -0.6871 -0.1476 -0.0850 -0.1256 -0.1383 -0.1867 -0.1571 -0.1087 -0.1381 -0.2243 -0.1203 -0.0814 -0.1236 -0.1355 -0.3690 -0.0539 -0.0383 -0.1570 -0.1253 -0.1235 -0.1719 -0.1251 -0.0909 -0.1238 -0.1430 -0.2140 -0.1494 -0.2338 -0.1338 -0.0843 -0.1409 -0.1536
S-802	3 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-802	3 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-802	-0.2145000547170639	3 newborns ( aged 0 -1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 -12 years ) , adolescents ( aged 12 -16 years ) , adults ( over 16 years )
D-802	-0.2145000547170639	3 newborns ( aged 0 -1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 -12 years ) , adolescents ( aged 12 -16 years ) , adults ( over 16 years )
P-802	-0.1896 -0.1968 -0.5697 -0.0685 -0.1505 -1.3128 -0.2828 -0.5339 -0.1418 -0.3042 -0.1328 -0.1389 -0.8672 -0.2012 -0.1587 -0.0600 -0.1544 -0.1707 -0.6671 -0.1466 -0.0850 -0.1266 -0.1390 -0.1898 -0.1572 -0.1089 -0.1374 -0.2281 -0.1207 -0.0826 -0.1228 -0.1361 -0.3734 -0.0537 -0.0392 -0.1577 -0.1254 -0.1239 -0.1702 -0.1254 -0.0914 -0.1243 -0.1432 -0.2189 -0.1500 -0.2304 -0.1327 -0.0851 -0.1408 -0.1568
S-1865	Das p53-Protein , das aus dem nicht defekten im menschlichen Körper vorhandenen p53-Gen gebildet wird , trägt normalerweise zur Wiederherstellung beschädigter DNA und zum Abtöten der Zellen bei , wenn die DNA nicht wiederhergestellt werden kann .
T-1865	The p53 protein , which is produced from the non-defective p53 gene present in the human body , normally contributes to the repair of damaged DNA and causes cell death when the DNA cannot be repaired .
H-1865	-0.5689126253128052	The p53 protein , which consists of the non @-@ defective p53 gene present in the human body , normally contributes to the recovery of damaged DNA and to the killing of cells when DNA cannot be recovered .
D-1865	-0.5689126253128052	The p53 protein , which consists of the non @-@ defective p53 gene present in the human body , normally contributes to the recovery of damaged DNA and to the killing of cells when DNA cannot be recovered .
P-1865	-0.7393 -0.1622 -0.0674 -0.1088 -0.4208 -1.4130 -3.0969 -0.0984 -0.1408 -0.2546 -3.3439 -1.1771 -0.3803 -0.0886 -0.1939 -0.0496 -0.2919 -1.1531 -0.1366 -0.1637 -0.1748 -0.1582 -0.1350 -1.2674 -0.6261 -0.0649 -0.1993 -0.5320 -1.6975 -0.1281 -0.5077 -0.0400 -0.1699 -1.5426 -0.7908 -0.6697 -0.1337 -0.1084 -0.8148 -0.7867 -0.1079 -0.1307 -1.0225 -0.1557 -0.1555
S-1674	1 Durchstechflasche mit ADVATE 1500 I.E. Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt
T-1674	1 vial with 1500 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1674	-0.18571165204048157	1 vial of ADVATE 1500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
D-1674	-0.18571165204048157	1 vial of ADVATE 1500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
P-1674	-0.1315 -0.0502 -0.1012 -0.5988 -0.0998 -0.1538 -0.0902 -0.0893 -0.1390 -0.0930 -0.1795 -0.3367 -0.1076 -0.1176 -0.2210 -0.1081 -0.0797 -0.1462 -0.1401 -0.0200 -0.0937 -0.1572 -0.3097 -0.0915 -0.3182 -0.1494 -0.1149 -0.0971 -0.1175 -0.1607 -0.2221 -0.1471 -0.1352 -0.3414 -0.1565 -0.1799 -0.0986 -0.1166 -0.2242 -0.6220 -0.7640 -0.1790
S-1656	1 Durchstechflasche mit ADVATE 1000 I.E Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt
T-1656	1 vial with 1000 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1656	-0.18968583643436432	1 vial of ADVATE 1000 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
D-1656	-0.18968583643436432	1 vial of ADVATE 1000 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
P-1656	-0.1313 -0.0746 -0.1034 -0.5638 -0.1281 -0.1549 -0.0890 -0.0892 -0.0705 -0.0953 -0.4579 -0.2067 -0.1057 -0.1187 -0.2243 -0.1030 -0.0779 -0.1464 -0.1425 -0.0223 -0.1009 -0.1551 -0.3145 -0.0923 -0.3259 -0.1475 -0.1068 -0.0957 -0.1174 -0.1628 -0.2287 -0.1469 -0.1357 -0.3426 -0.1572 -0.1788 -0.1006 -0.1159 -0.2105 -0.6715 -0.7754 -0.1785
S-916	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-916	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-916	-0.2887675166130066	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
D-916	-0.2887675166130066	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
P-916	-0.6629 -0.6010 -0.1079 -0.0935 -0.1766 -0.3648 -1.2715 -0.3634 -0.1448 -0.0919 -0.0378 -0.2161 -0.1117 -0.1527 -0.6037 -0.1304 -0.1756 -0.1258 -0.5381 -0.2903 -0.2378 -0.0791 -0.0855 -0.4478 -0.1695 -0.1394 -0.0817 -0.0620 -0.1051 -1.4352 -0.0519 -0.4728 -0.3068 -1.4024 -0.3587 -0.1480 -0.1396 -0.6221 -0.0692 -0.0770 -0.1252 -0.1132 -0.1691 -0.2675 -0.0755 -0.0271 -0.1746 -0.1562
S-1624	1 Durchstechflasche mit ADVATE 250 I.E. Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt
T-1624	1 vial with 250 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1624	-0.18539248406887054	1 vial of ADVATE 250 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
D-1624	-0.18539248406887054	1 vial of ADVATE 250 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
P-1624	-0.1353 -0.0629 -0.1028 -0.5870 -0.1104 -0.1531 -0.0896 -0.0902 -0.0949 -0.0974 -0.1724 -0.3834 -0.1086 -0.1187 -0.2185 -0.1082 -0.0782 -0.1464 -0.1402 -0.0217 -0.0987 -0.1564 -0.2729 -0.0915 -0.3207 -0.1467 -0.1208 -0.0973 -0.1168 -0.1640 -0.2218 -0.1471 -0.1350 -0.3329 -0.1565 -0.1802 -0.0987 -0.1168 -0.2415 -0.6104 -0.7626 -0.1774
S-1691	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1691	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1691	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
D-1691	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
P-1691	-0.2967 -0.0444 -0.0588 -0.0764 -0.0541 -0.0390 -0.0396 -0.0178 -0.1081 -0.0379 -0.1895 -0.2717 -0.0596 -0.0255 -0.0711 -0.1366 -0.0588 -0.0725 -0.0375 -0.0207 -0.1525 -0.0795 -0.3237 -0.0101 -0.1597 -0.0691 -0.0341 -0.2250 -0.0602 -0.0064 -0.1680 -2.5959 -0.0162 -0.0738 -0.1103 -0.1054 -0.1178 -2.6891 -0.0028 -0.1231 -0.0185 -0.0190 -0.7166
S-1658	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1658	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1658	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
D-1658	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
P-1658	-0.2967 -0.0444 -0.0588 -0.0764 -0.0541 -0.0390 -0.0396 -0.0178 -0.1081 -0.0379 -0.1895 -0.2717 -0.0596 -0.0255 -0.0711 -0.1366 -0.0588 -0.0725 -0.0375 -0.0207 -0.1525 -0.0795 -0.3237 -0.0101 -0.1597 -0.0691 -0.0341 -0.2250 -0.0602 -0.0064 -0.1680 -2.5959 -0.0162 -0.0738 -0.1103 -0.1054 -0.1178 -2.6891 -0.0028 -0.1231 -0.0185 -0.0190 -0.7166
S-355	Hautausschlag , Pruritus , Erythem . Selten : Ausschlag mit Photosensitivität . Sehr selten : schwere Hautreaktionen einschließlich Stevens-Johnson- Syndrom und toxische epidermale Nekrolyse .
T-355	Uncommon : rash , pruritus , erythema Rare : rash with photosensitivity Very rare : severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
H-355	-0.22098587453365326	rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevens Johnson syndrome and toxic epidermal necrolysis .
D-355	-0.22098587453365326	rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevens Johnson syndrome and toxic epidermal necrolysis .
P-355	-0.1968 -0.0712 -0.1351 -0.1940 -0.0228 -0.0464 -0.1301 -0.1364 -0.1143 -0.1771 -0.1065 -0.1550 -0.3540 -0.1146 -0.1427 -0.2807 -0.0444 -0.1865 -0.3238 -0.0632 -0.0953 -0.2429 -0.0541 -0.1547 -0.0905 -0.0887 -0.1435 -0.1521 -0.0966 -0.5414 -0.0647 -0.0526 -2.1725 -0.2604 -0.9354 -0.0414 -0.1405 -0.1523 -0.0886 -0.1452 -0.1850 -0.1700 -0.7156 -0.2510 -0.1203 -0.1086 -0.1910 -0.1570
S-167	Hautausschlag , Pruritus , Erythem . Selten : Ausschlag mit Photosensitivität . Sehr selten : schwere Hautreaktionen einschließlich Stevens-Johnson- Syndrom und toxische epidermale Nekrolyse .
T-167	Uncommon : rash , pruritus , erythema Rare : rash with photosensitivity Very rare : severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
H-167	-0.22098587453365326	rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevens Johnson syndrome and toxic epidermal necrolysis .
D-167	-0.22098587453365326	rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevens Johnson syndrome and toxic epidermal necrolysis .
P-167	-0.1968 -0.0712 -0.1351 -0.1940 -0.0228 -0.0464 -0.1301 -0.1364 -0.1143 -0.1771 -0.1065 -0.1550 -0.3540 -0.1146 -0.1427 -0.2807 -0.0444 -0.1865 -0.3238 -0.0632 -0.0953 -0.2429 -0.0541 -0.1547 -0.0905 -0.0887 -0.1435 -0.1521 -0.0966 -0.5414 -0.0647 -0.0526 -2.1725 -0.2604 -0.9354 -0.0414 -0.1405 -0.1523 -0.0886 -0.1452 -0.1850 -0.1700 -0.7156 -0.2510 -0.1203 -0.1086 -0.1910 -0.1570
S-1707	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1707	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1707	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
D-1707	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
P-1707	-0.2967 -0.0444 -0.0588 -0.0764 -0.0541 -0.0390 -0.0396 -0.0178 -0.1081 -0.0379 -0.1895 -0.2717 -0.0596 -0.0255 -0.0711 -0.1366 -0.0588 -0.0725 -0.0375 -0.0207 -0.1525 -0.0795 -0.3237 -0.0101 -0.1597 -0.0691 -0.0341 -0.2250 -0.0602 -0.0064 -0.1680 -2.5959 -0.0162 -0.0738 -0.1103 -0.1054 -0.1178 -2.6891 -0.0028 -0.1231 -0.0185 -0.0190 -0.7166
S-1268	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-1268	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-1268	-0.2887675166130066	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
D-1268	-0.2887675166130066	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
P-1268	-0.6629 -0.6010 -0.1079 -0.0935 -0.1766 -0.3648 -1.2715 -0.3634 -0.1448 -0.0919 -0.0378 -0.2161 -0.1117 -0.1527 -0.6037 -0.1304 -0.1756 -0.1258 -0.5381 -0.2903 -0.2378 -0.0791 -0.0855 -0.4478 -0.1695 -0.1394 -0.0817 -0.0620 -0.1051 -1.4352 -0.0519 -0.4728 -0.3068 -1.4024 -0.3587 -0.1480 -0.1396 -0.6221 -0.0692 -0.0770 -0.1252 -0.1132 -0.1691 -0.2675 -0.0755 -0.0271 -0.1746 -0.1562
S-1675	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1675	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1675	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
D-1675	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
P-1675	-0.2967 -0.0444 -0.0588 -0.0764 -0.0541 -0.0390 -0.0396 -0.0178 -0.1081 -0.0379 -0.1895 -0.2717 -0.0596 -0.0255 -0.0711 -0.1366 -0.0588 -0.0725 -0.0375 -0.0207 -0.1525 -0.0795 -0.3237 -0.0101 -0.1597 -0.0691 -0.0341 -0.2250 -0.0602 -0.0064 -0.1680 -2.5959 -0.0162 -0.0738 -0.1103 -0.1054 -0.1178 -2.6891 -0.0028 -0.1231 -0.0185 -0.0190 -0.7166
S-1444	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-1444	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-1444	-0.2887675166130066	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
D-1444	-0.2887675166130066	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
P-1444	-0.6629 -0.6010 -0.1079 -0.0935 -0.1766 -0.3648 -1.2715 -0.3634 -0.1448 -0.0919 -0.0378 -0.2161 -0.1117 -0.1527 -0.6037 -0.1304 -0.1756 -0.1258 -0.5381 -0.2903 -0.2378 -0.0791 -0.0855 -0.4478 -0.1695 -0.1394 -0.0817 -0.0620 -0.1051 -1.4352 -0.0519 -0.4728 -0.3068 -1.4024 -0.3587 -0.1480 -0.1396 -0.6221 -0.0692 -0.0770 -0.1252 -0.1132 -0.1691 -0.2675 -0.0755 -0.0271 -0.1746 -0.1562
S-1641	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1641	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1641	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
D-1641	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
P-1641	-0.2967 -0.0444 -0.0588 -0.0764 -0.0541 -0.0390 -0.0396 -0.0178 -0.1081 -0.0379 -0.1895 -0.2717 -0.0596 -0.0255 -0.0711 -0.1366 -0.0588 -0.0725 -0.0375 -0.0207 -0.1525 -0.0795 -0.3237 -0.0101 -0.1597 -0.0691 -0.0341 -0.2250 -0.0602 -0.0064 -0.1680 -2.5959 -0.0162 -0.0738 -0.1103 -0.1054 -0.1178 -2.6891 -0.0028 -0.1231 -0.0185 -0.0190 -0.7166
S-1625	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1625	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1625	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
D-1625	-0.22310370206832886	SPECIAL WARNING THAT THE MEDICINAL PRODUCT IS OUT OF THE REACH AND SIGHT OF CHILDREN
P-1625	-0.2967 -0.0444 -0.0588 -0.0764 -0.0541 -0.0390 -0.0396 -0.0178 -0.1081 -0.0379 -0.1895 -0.2717 -0.0596 -0.0255 -0.0711 -0.1366 -0.0588 -0.0725 -0.0375 -0.0207 -0.1525 -0.0795 -0.3237 -0.0101 -0.1597 -0.0691 -0.0341 -0.2250 -0.0602 -0.0064 -0.1680 -2.5959 -0.0162 -0.0738 -0.1103 -0.1054 -0.1178 -2.6891 -0.0028 -0.1231 -0.0185 -0.0190 -0.7166
S-1615	BEDINGUNGEN ODER EINSCHRÄNKUNGEN BEZÜGLICH DER SICHEREN UND WIRKSAMEN ANWENDUNG DES ARZNEIMITTELS
T-1615	CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
H-1615	-0.161408469080925	CONDITIONS OR RESTRICTIONS REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
D-1615	-0.161408469080925	CONDITIONS OR RESTRICTIONS REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
P-1615	-0.2943 -0.1169 -0.0144 -0.0446 -0.0459 -0.1707 -0.1699 -0.0547 -0.1395 -0.0565 -0.0250 -0.0143 -0.0330 -0.0401 -0.1272 -0.7071 -0.4121 -0.8477 -0.2503 -0.2381 -0.3752 -0.0411 -0.0540 -0.2277 -0.6474 -0.0359 -0.0310 -0.1839 -0.0800 -0.0987 -0.0674 -0.0688 -0.0440 -0.6371 -0.0843 -0.0866 -0.0511 -0.0397 -0.0467 -0.0961 -0.0738 -0.0130 -0.0444 -0.0228 -0.2038 -0.2677
S-1464	58 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-1464	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-1464	-0.3556522727012634	58 prophylaxis Long-term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
D-1464	-0.3556522727012634	58 prophylaxis Long-term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
P-1464	-3.9537 -0.2677 -0.0871 -0.1571 -0.1146 -0.0593 -1.5639 -0.1218 -0.0834 -0.1912 -0.0896 -0.1561 -0.1091 -0.0959 -0.1227 -0.7376 -0.1233 -0.1215 -0.5554 -0.3272 -0.0951 -0.0671 -0.0909 -0.2215 -0.1374 -0.5554 -0.1551 -0.6876 -0.1695 -0.0592 -1.0134 -0.1102 -0.2412 -0.0851 -0.0995 -0.1509 -0.1266 -0.1036 -0.1639 -0.0929 -0.0916 -0.0734 -1.0077 -0.0540 -1.6451 -1.0662 -0.1048 -0.0919 -0.1213 -0.2640 -0.1541
S-1112	36 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-1112	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-1112	-0.31041213870048523	36 prophylaxis Long-term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
D-1112	-0.31041213870048523	36 prophylaxis Long-term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
P-1112	-1.6880 -0.2150 -0.0901 -0.1558 -0.1156 -0.0460 -1.7329 -0.1241 -0.0840 -0.2009 -0.0890 -0.1579 -0.1124 -0.0925 -0.1225 -0.7275 -0.1247 -0.1211 -0.5159 -0.3284 -0.0933 -0.0692 -0.0899 -0.2226 -0.1318 -0.4928 -0.1531 -0.6984 -0.1745 -0.0601 -0.9822 -0.1109 -0.2322 -0.0837 -0.0989 -0.1545 -0.1273 -0.0987 -0.1656 -0.0951 -0.0921 -0.0739 -0.9877 -0.0543 -1.5617 -1.1005 -0.1045 -0.0904 -0.1296 -0.3038 -0.1535
S-586	3 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-586	3 Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-586	-0.30649009346961975	3 prophylaxis Long-term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
D-586	-0.30649009346961975	3 prophylaxis Long-term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
P-586	-1.2923 -0.3121 -0.0936 -0.1556 -0.1146 -0.0521 -1.6907 -0.1337 -0.0850 -0.2088 -0.0903 -0.1575 -0.1103 -0.0972 -0.1245 -0.7349 -0.1203 -0.1225 -0.5466 -0.3380 -0.0940 -0.0680 -0.0911 -0.2298 -0.1335 -0.5560 -0.1539 -0.7020 -0.1667 -0.0607 -0.9766 -0.1078 -0.2498 -0.0871 -0.1007 -0.1602 -0.1284 -0.1077 -0.1647 -0.0972 -0.0942 -0.0743 -0.9961 -0.0547 -1.6953 -0.9897 -0.1019 -0.0912 -0.1187 -0.2436 -0.1548
S-1288	47 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-1288	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-1288	-0.2890974283218384	47 prophylaxis Long-term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
D-1288	-0.2890974283218384	47 prophylaxis Long-term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
P-1288	-0.4951 -0.2631 -0.0863 -0.1556 -0.1169 -0.0497 -1.7582 -0.1205 -0.0867 -0.1982 -0.0900 -0.1568 -0.1108 -0.0927 -0.1234 -0.7232 -0.1229 -0.1204 -0.5331 -0.3265 -0.0939 -0.0681 -0.0894 -0.2223 -0.1358 -0.5467 -0.1538 -0.6843 -0.1721 -0.0603 -1.0202 -0.1101 -0.2405 -0.0855 -0.1009 -0.1521 -0.1284 -0.1000 -0.1648 -0.0964 -0.0929 -0.0753 -0.9903 -0.0552 -1.5706 -1.0479 -0.1045 -0.0913 -0.1265 -0.2794 -0.1547
S-760	14 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-760	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-760	-0.33313992619514465	Long @-@ term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
D-760	-0.33313992619514465	Long @-@ term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
P-760	-2.3303 -1.0596 -0.1443 -0.2387 -0.0889 -0.1553 -0.1110 -0.0667 -0.1309 -0.6734 -0.1251 -0.1215 -0.6402 -0.3441 -0.0978 -0.0793 -0.0935 -0.2296 -0.1180 -0.5472 -0.2050 -0.4069 -0.1618 -0.0599 -1.0632 -0.1087 -0.2276 -0.0853 -0.1023 -0.1518 -0.1303 -0.1084 -0.1639 -0.0957 -0.0921 -0.0777 -1.0543 -0.0556 -1.5964 -0.9625 -0.1047 -0.0958 -0.1064 -0.2181 -0.1610
S-936	25 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-936	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-936	-0.3430153429508209	Long @-@ term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
D-936	-0.3430153429508209	Long @-@ term prophylaxis of bleeding in severe haemophilia A patients should be given doses between 20 and 40 IU of factor VIII per kg bodyweight 2 to 3 days apart .
P-936	-2.7212 -1.0646 -0.1450 -0.2451 -0.0889 -0.1565 -0.1089 -0.0697 -0.1301 -0.6560 -0.1238 -0.1219 -0.6131 -0.3447 -0.0976 -0.0794 -0.0930 -0.2304 -0.1186 -0.5642 -0.1930 -0.4270 -0.1615 -0.0586 -1.0635 -0.1109 -0.2288 -0.0854 -0.1045 -0.1503 -0.1302 -0.1088 -0.1645 -0.0961 -0.0915 -0.0796 -1.0547 -0.0560 -1.6299 -0.9748 -0.1046 -0.0974 -0.1076 -0.2264 -0.1574
S-71	Das Unternehmen führte außerdem eine Studie mit 35 Männern und 682 postmenopausalen Frauen mit Osteoporose durch , um die Wirksamkeit von ADROVANCE in Bezug auf die Steigerung des Vitamin-D-Spiegels nachzuweisen .
T-71	The company also carried out a study in 35 men and 682 post-menopausal women with osteoporosis to show ADROVANCE s effectiveness in increasing vitamin D levels .
H-71	-0.30920034646987915	The company also conducted a trial in 35 men and 682 post-menopausal women with osteoporosis to demonstrate ADROVANCE &apos;s efficacy in increasing D levels .
D-71	-0.30920034646987915	The company also conducted a trial in 35 men and 682 post-menopausal women with osteoporosis to demonstrate ADROVANCE &apos;s efficacy in increasing D levels .
P-71	-0.6491 -0.4802 -0.2467 -0.2665 -0.1366 -1.0477 -0.9232 -0.0946 -0.2595 -0.1311 -0.1543 -0.0748 -0.1349 -0.2501 -0.0955 -0.0904 -0.0482 -0.1137 -0.0698 -0.1486 -0.1361 -0.0994 -0.1056 -0.1265 -0.0854 -0.0965 -0.3078 -1.3434 -0.3819 -0.0664 -0.1247 -0.1106 -0.0814 -0.8882 -0.6916 -0.0471 -0.0831 -0.1800 -0.5683 -1.3325 -0.5857 -0.2742 -0.1635
S-826	18 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-826	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-826	-0.3395591676235199	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
D-826	-0.3395591676235199	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
P-826	-0.8360 -0.3425 -0.1753 -0.2867 -0.0826 -0.0714 -0.1184 -0.1356 -0.1540 -0.6129 -0.1465 -0.0788 -0.0952 -0.3713 -0.2327 -1.3343 -0.4119 -1.6865 -0.0599 -0.1162 -0.0693 -0.6977 -0.1121 -0.0496 -0.0464 -0.1709 -0.0581 -0.8734 -0.1866 -0.1241 -0.1110 -0.1318 -0.0802 -0.1775 -0.1792 -0.1140 -0.0856 -0.1280 -0.4132 -0.7732 -1.4943 -1.1967 -0.1709 -1.0453 -0.0594 -0.2389 -0.1368 -0.2081 -0.1573
S-1920	Wenn nur die Schwellung der Nasenschleimhaut betrachtet wurde , zeigten die Patienten unter Aerinaze eine Linderung der Symptome um 37,4 % gegenüber 26,7 % bei den Patienten , die Desloratadin allein einnahmen .
T-1920	When looking at nasal congestion , patients taking Aerinaze had a reduction in symptoms of 37.4 % , compared with 26.7 % in those taking desloratadine alone .
H-1920	-0.4351348578929901	When only nasal swelling was considered , Aerinaze patients exhibited symptoms relief of 37.4 % compared to 26.7 % for those taking desloratadine alone .
D-1920	-0.4351348578929901	When only nasal swelling was considered , Aerinaze patients exhibited symptoms relief of 37.4 % compared to 26.7 % for those taking desloratadine alone .
P-1920	-1.0000 -1.0956 -0.2248 -0.0174 -0.2635 -0.0536 -0.1256 -0.1807 -1.1141 -0.1541 -0.9639 -0.1412 -0.1347 -0.1299 -0.1036 -0.5218 -2.6785 -0.0839 -2.1006 -1.2571 -0.1475 -0.1447 -0.1085 -0.1427 -0.1296 -1.1793 -0.5915 -0.0602 -0.1326 -0.1096 -0.3805 -0.4222 -0.1716 -0.1763 -0.0508 -0.1095 -0.1722 -0.8347 -0.1188 -0.1523 -0.1610
S-1531	62 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-1531	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-1531	-0.3341422379016876	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
D-1531	-0.3341422379016876	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
P-1531	-0.5798 -0.3737 -0.1771 -0.2935 -0.0830 -0.0716 -0.1184 -0.1331 -0.1541 -0.5978 -0.1461 -0.0793 -0.0954 -0.3795 -0.2281 -1.3229 -0.4100 -1.6789 -0.0612 -0.1173 -0.0691 -0.6759 -0.1123 -0.0501 -0.0469 -0.1729 -0.0581 -0.8796 -0.1884 -0.1242 -0.1098 -0.1330 -0.0792 -0.1773 -0.1794 -0.1152 -0.0852 -0.1275 -0.4231 -0.7510 -1.4888 -1.2338 -0.1705 -1.0103 -0.0593 -0.2551 -0.1371 -0.2006 -0.1583
S-408	Die mittleren BMD-Zunahmen betrugen 2,3 % bzw. 2,9 % am Femurhals und 2,9 % bzw. 3,1 % an der gesamten Hüfte in der Gruppe mit 70 mg einmal wöchentlich bzw. in der mit 10 mg täglich .
T-408	The mean BMD increases were 2.3 % and 2.9 % at the femoral neck and 2.9 % and 3.1 % at the total hip in the 70 mg once weekly and 10 mg daily groups , respectively .
H-408	-0.3756779432296753	Mean BMD increases were 2.3 % and 2.9 % respectively for the femoral neck and 2.9 % and 3.1 % for the entire hip in the 70 mg weekly and 10 mg daily groups .
D-408	-0.3756779432296753	Mean BMD increases were 2.3 % and 2.9 % respectively for the femoral neck and 2.9 % and 3.1 % for the entire hip in the 70 mg weekly and 10 mg daily groups .
P-408	-1.1938 -0.1510 -0.7997 -0.1719 -0.2602 -0.1356 -0.1154 -0.1388 -0.1093 -0.1654 -0.1242 -0.1184 -0.1036 -2.0549 -0.8454 -0.1598 -0.0710 -0.2303 -0.0939 -0.5435 -0.1559 -0.1092 -0.0857 -0.1330 -0.0537 -0.1428 -0.1016 -0.1677 -0.3592 -1.2447 -0.1742 -0.3044 -0.1571 -0.3222 -0.0291 -0.7270 -0.2903 -0.1432 -0.0551 -0.2990 -2.6638 -0.6975 -0.1517
S-1741	Dann besteht nämlich ein erhöhtes Risiko , dass dies abermals auftritt . Inhibitoren sind neutralisierende Antikörper gegen Faktor VIII , die die Wirksamkeit von ADVATE , Blutungen zu verhindern oder zu kontrollieren , vermindern .
T-1741	Inhibitors are blocking antibodies against factor VIII that reduce the efficacy of ADVATE to prevent or control bleeding .
H-1741	-0.498216450214386	This increases the risk of recurrence . Inhibitors are neutralising antibodies to factor VIII that reduce ADVATE &apos;s efficacy in preventing or controlling bleeding .
D-1741	-0.498216450214386	This increases the risk of recurrence . Inhibitors are neutralising antibodies to factor VIII that reduce ADVATE &apos;s efficacy in preventing or controlling bleeding .
P-1741	-3.0262 -1.5286 -0.1981 -0.3307 -0.2432 -0.1448 -0.0725 -0.0525 -0.0878 -2.1320 -0.9265 -0.0339 -0.0487 -0.1457 -0.1143 -0.2500 -0.8480 -0.8651 -0.0713 -0.7532 -0.6084 -0.1731 -0.0846 -1.1506 -1.2762 -0.9496 -0.1419 -0.0814 -0.0913 -0.4891 -1.4218 -0.0394 -0.0939 -0.2225 -0.0433 -0.2515 -0.1881 -0.6924 -0.1995 -0.1736 -0.1815
S-652	7 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-652	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-652	-0.34191814064979553	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
D-652	-0.34191814064979553	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
P-652	-0.7970 -0.3363 -0.1792 -0.2885 -0.0838 -0.0711 -0.1175 -0.1325 -0.1531 -0.6535 -0.1470 -0.0781 -0.0960 -0.3333 -0.2142 -1.3268 -0.4065 -1.7350 -0.0607 -0.1184 -0.0697 -0.7582 -0.1157 -0.0483 -0.0474 -0.1727 -0.0585 -0.9080 -0.1864 -0.1233 -0.1110 -0.1326 -0.0808 -0.1791 -0.1794 -0.1142 -0.0852 -0.1283 -0.4238 -0.7471 -1.5200 -1.2327 -0.1681 -1.0314 -0.0588 -0.2500 -0.1363 -0.2014 -0.1569
S-1002	29 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-1002	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-1002	-0.3397033214569092	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
D-1002	-0.3397033214569092	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
P-1002	-0.6924 -0.3383 -0.1774 -0.2865 -0.0832 -0.0715 -0.1180 -0.1333 -0.1543 -0.6093 -0.1460 -0.0790 -0.0940 -0.3588 -0.2250 -1.3196 -0.3988 -1.7801 -0.0608 -0.1189 -0.0689 -0.7075 -0.1182 -0.0479 -0.0468 -0.1693 -0.0576 -0.8797 -0.1871 -0.1239 -0.1110 -0.1331 -0.0813 -0.1784 -0.1779 -0.1140 -0.0853 -0.1282 -0.4096 -0.7882 -1.5296 -1.2741 -0.1692 -1.0111 -0.0589 -0.2473 -0.1364 -0.2020 -0.1580
S-1178	40 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-1178	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-1178	-0.3353962302207947	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
D-1178	-0.3353962302207947	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
P-1178	-0.6487 -0.3648 -0.1791 -0.2942 -0.0836 -0.0721 -0.1161 -0.1295 -0.1561 -0.6489 -0.1469 -0.0785 -0.0955 -0.3421 -0.2230 -1.3493 -0.4191 -1.7150 -0.0618 -0.1184 -0.0680 -0.6706 -0.1131 -0.0484 -0.0469 -0.1684 -0.0590 -0.9085 -0.1877 -0.1235 -0.1107 -0.1329 -0.0793 -0.1803 -0.1792 -0.1145 -0.0857 -0.1274 -0.4343 -0.7250 -1.4780 -1.1376 -0.1704 -1.0297 -0.0588 -0.2552 -0.1363 -0.2031 -0.1592
S-1354	51 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-1354	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-1354	-0.33542677760124207	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
D-1354	-0.33542677760124207	As with other intravenous products , ADVATE has been reported to exhibit allergic type hypersensitivity reactions including anaphylactic / anaphylactoid reaction ( frequency unknown ) .
P-1354	-0.6251 -0.3644 -0.1752 -0.2925 -0.0830 -0.0712 -0.1168 -0.1311 -0.1520 -0.5906 -0.1448 -0.0777 -0.0946 -0.3608 -0.2211 -1.3031 -0.4103 -1.7158 -0.0617 -0.1119 -0.0682 -0.6956 -0.1114 -0.0499 -0.0472 -0.1720 -0.0584 -0.8541 -0.1876 -0.1234 -0.1091 -0.1313 -0.0811 -0.1780 -0.1796 -0.1136 -0.0853 -0.1265 -0.4074 -0.7949 -1.5267 -1.1884 -0.1727 -1.0658 -0.0592 -0.2465 -0.1370 -0.2031 -0.1582
S-54	ADROVANCE wird zur Behandlung von Osteoporose ( einer Erkrankung , bei der die Knochen brüchig werden ) bei Frauen nach der Menopause eingesetzt , bei denen ein Risiko für einen geringen Vitamin-D-Spiegel besteht .
T-54	ADROVANCE is used to treat osteoporosis ( a disease that makes bones fragile ) in post-menopausal women at risk of low vitamin D levels .
H-54	-0.3339911997318268	ADROVANCE is used to treat osteoporosis ( a condition in which bones become fragile ) in post-menopausal women who are at risk for low D levels .
D-54	-0.3339911997318268	ADROVANCE is used to treat osteoporosis ( a condition in which bones become fragile ) in post-menopausal women who are at risk for low D levels .
P-54	-0.0571 -0.0607 -0.1266 -0.1063 -0.0998 -0.1855 -0.1124 -0.2361 -0.1257 -0.1191 -0.0904 -0.1053 -0.1317 -0.0906 -0.0788 -0.1580 -0.3216 -1.6221 -1.4366 -0.1384 -0.5852 -0.3492 -0.4176 -0.0977 -0.1279 -0.1314 -0.1375 -0.4066 -0.1059 -0.1181 -0.0710 -0.1210 -0.0890 -0.7309 -0.3451 -0.0429 -0.1794 -1.0298 -0.6646 -1.6848 -0.7771 -0.5741 -0.1720
S-133	Andere Erkrankungen , die den Mineralstoffwechsel beeinträchtigen ( wie Vitamin-D-Mangel und Hypoparathyreoidismus ) , sollten vor Beginn der Therapie mit ADROVANCE ebenfalls adäquat behandelt werden .
T-133	Other disorders affecting mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be effectively treated before starting ADROVANCE .
H-133	-0.2851638197898865	Other disorders that affect mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be adequately treated before starting therapy with ADROVANCE .
D-133	-0.2851638197898865	Other disorders that affect mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be adequately treated before starting therapy with ADROVANCE .
P-133	-0.5999 -0.9450 -0.0777 -1.2613 -0.9527 -0.6988 -0.1188 -0.1131 -0.0678 -0.0682 -0.2579 -0.3774 -0.1517 -0.1105 -0.0449 -0.1124 -0.0647 -0.0395 -0.1452 -0.1585 -0.1671 -0.0688 -0.1197 -0.1657 -0.0996 -0.1276 -0.1597 -0.0858 -0.0779 -0.1110 -0.1213 -0.2260 -0.1631 -0.1563 -0.2012 -0.0769 -0.5773 -1.2576 -1.1178 -1.2810 -0.1810 -0.0631 -0.0646 -0.1278 -0.1091 -0.0937 -0.1650 -0.1558
S-260	Alendronat Nicht-klinische Daten auf Grundlage konventioneller Studien zur Sicherheitspharmakologie , zur chronischen Toxizität , zur Genotoxizität und zum kanzerogenen Potenzial lassen keine besonderen Gefahren für den Menschen erkennen .
T-260	Alendronate Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology , repeated dose toxicity , genotoxicity and carcinogenic potential .
H-260	-0.46791696548461914	Alendronate Non-clinical data based on conventional safety , chronic toxicity , genotoxicity and carcinogenic potential studies show no particular human risk .
D-260	-0.46791696548461914	Alendronate Non-clinical data based on conventional safety , chronic toxicity , genotoxicity and carcinogenic potential studies show no particular human risk .
P-260	-0.8394 -0.1122 -0.0947 -0.0980 -1.5768 -0.3260 -0.0363 -0.1224 -1.1666 -0.1357 -0.1502 -0.8542 -0.4940 -0.1517 -0.0554 -0.1202 -0.1628 -0.1439 -0.0161 -0.0611 -0.1808 -0.0680 -0.1071 -0.7081 -0.9156 -0.0908 -0.1835 -0.0547 -0.0977 -0.1821 -0.1569 -2.5336 -0.0616 -1.3323 -1.0421 -2.4388 -0.7408 -0.1687
S-456	Alendronat Nicht-klinische Daten auf Grundlage konventioneller Studien zur Sicherheitspharmakologie , zur chronischen Toxizität , zur Genotoxizität und zum kanzerogenen Potenzial lassen keine besonderen Gefahren für den Menschen erkennen .
T-456	Alendronate Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology , repeated dose toxicity , genotoxicity and carcinogenic potential .
H-456	-0.46791696548461914	Alendronate Non-clinical data based on conventional safety , chronic toxicity , genotoxicity and carcinogenic potential studies show no particular human risk .
D-456	-0.46791696548461914	Alendronate Non-clinical data based on conventional safety , chronic toxicity , genotoxicity and carcinogenic potential studies show no particular human risk .
P-456	-0.8394 -0.1122 -0.0947 -0.0980 -1.5768 -0.3260 -0.0363 -0.1224 -1.1666 -0.1357 -0.1502 -0.8542 -0.4940 -0.1517 -0.0554 -0.1202 -0.1628 -0.1439 -0.0161 -0.0611 -0.1808 -0.0680 -0.1071 -0.7081 -0.9156 -0.0908 -0.1835 -0.0547 -0.0977 -0.1821 -0.1569 -2.5336 -0.0616 -1.3323 -1.0421 -2.4388 -0.7408 -0.1687
S-468	INHABER DER HERSTELLUNGSERLAUBNIS , DER ( DIE ) FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST ( SIND )
T-468	MANUFACTURING AUTHORISATION HOLDER<<unk>> S ) RESPONSIBLE FOR BATCH RELEASE
H-468	-0.37340542674064636	MANUFACTURING AUTHORISATION OF UNUSED MEDICINAL PRODUCTS , THE MANUFACTURING AUTHORISATION HOLDER ( IS )
D-468	-0.37340542674064636	MANUFACTURING AUTHORISATION OF UNUSED MEDICINAL PRODUCTS , THE MANUFACTURING AUTHORISATION HOLDER ( IS )
P-468	-1.1333 -0.0122 -0.1152 -0.0096 -0.0090 -0.0170 -0.0270 -0.0670 -0.6102 -0.0151 -0.0650 -0.0183 -0.0128 -0.0560 -3.8281 -0.3873 -0.9197 -0.0091 -0.0800 -0.0062 -0.0149 -0.0099 -0.0237 -0.0744 -0.0209 -0.0234 -0.0290 -0.0293 -0.0825 -1.8459 -2.2716 -0.4583 -0.0128 -0.1241 -0.0019 -0.0013 -0.0463 -0.0252 -0.0998 -0.6099 -0.0065 -0.0600 -0.0110 -0.0098 -0.0835 -2.7467 -0.0705 -0.1757 -0.6216 -1.4876 -0.1868 -0.7540
S-401	19 Vitamin-D-Mangel war 0,3 % in der 2.800-I.E.-Vitamin-D3-Gruppe vs . 0 % in der 5.600-I.E.-Vitamin- D3-Gruppe .
T-401	The percentage of patients with vitamin D deficiency was 0.3 % in the Vitamin D3 2800 group vs. zero in the Vitamin D3 5600 group .
H-401	-0.24934972822666168	D deficiency was 0.3 % in the 2,800 IU vitamin D 3 group vs. 0 % in the 5,600 IU vitamin D 3 group .
D-401	-0.24934972822666168	D deficiency was 0.3 % in the 2,800 IU vitamin D 3 group vs. 0 % in the 5,600 IU vitamin D 3 group .
P-401	-0.5902 -0.0580 -0.0593 -0.1272 -0.1062 -0.0933 -0.1419 -0.1266 -0.1484 -0.1700 -1.1317 -0.1110 -0.1742 -0.1777 -1.7743 -0.0819 -0.4992 -0.2602 -0.3655 -0.4145 -0.0910 -0.1005 -0.1244 -0.1614 -0.2305 -0.0413 -0.1642 -0.0908 -0.2219 -0.1443 -0.1312 -0.0788 -0.1854 -0.1942 -0.1561
S-321	Andere Erkrankungen , die den Mineralstoffwechsel beeinträchtigen ( wie Vitamin-D-Mangel und Hypoparathyreoidismus ) , sollten vor Beginn der Therapie mit ADROVANCE ebenfalls adäquat behandelt werden .
T-321	Other disorders affecting mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be effectively treated before starting ADROVANCE .
H-321	-0.2851638197898865	Other disorders that affect mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be adequately treated before starting therapy with ADROVANCE .
D-321	-0.2851638197898865	Other disorders that affect mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be adequately treated before starting therapy with ADROVANCE .
P-321	-0.5999 -0.9450 -0.0777 -1.2613 -0.9527 -0.6988 -0.1188 -0.1131 -0.0678 -0.0682 -0.2579 -0.3774 -0.1517 -0.1105 -0.0449 -0.1124 -0.0647 -0.0395 -0.1452 -0.1585 -0.1671 -0.0688 -0.1197 -0.1657 -0.0996 -0.1276 -0.1597 -0.0858 -0.0779 -0.1110 -0.1213 -0.2260 -0.1631 -0.1563 -0.2012 -0.0769 -0.5773 -1.2576 -1.1178 -1.2810 -0.1810 -0.0631 -0.0646 -0.1278 -0.1091 -0.0937 -0.1650 -0.1558
S-1358	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-1358	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-1358	-0.22903087735176086	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
D-1358	-0.22903087735176086	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
P-1358	-0.0437 -0.1557 -0.0931 -0.1080 -0.0949 -0.1065 -0.1019 -0.0893 -0.1476 -1.3243 -0.0480 -0.0561 -0.0521 -0.1490 -0.0825 -0.1440 -0.9688 -0.1208 -0.1179 -0.2589 -0.1209 -0.0696 -0.1296 -0.1629 -0.2126 -0.2259 -0.1362 -0.2348 -0.0335 -0.1747 -0.0818 -0.1494 -1.3876 -0.1310 -0.1847 -0.0330 -0.1979 -1.2914 -0.1468 -0.2779 -0.1076 -0.0671 -0.1469 -0.1750 -0.1644
S-1535	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-1535	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-1535	-0.22903087735176086	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
D-1535	-0.22903087735176086	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
P-1535	-0.0437 -0.1557 -0.0931 -0.1080 -0.0949 -0.1065 -0.1019 -0.0893 -0.1476 -1.3243 -0.0480 -0.0561 -0.0521 -0.1490 -0.0825 -0.1440 -0.9688 -0.1208 -0.1179 -0.2589 -0.1209 -0.0696 -0.1296 -0.1629 -0.2126 -0.2259 -0.1362 -0.2348 -0.0335 -0.1747 -0.0818 -0.1494 -1.3876 -0.1310 -0.1847 -0.0330 -0.1979 -1.2914 -0.1468 -0.2779 -0.1076 -0.0671 -0.1469 -0.1750 -0.1644
S-1006	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-1006	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-1006	-0.22903087735176086	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
D-1006	-0.22903087735176086	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
P-1006	-0.0437 -0.1557 -0.0931 -0.1080 -0.0949 -0.1065 -0.1019 -0.0893 -0.1476 -1.3243 -0.0480 -0.0561 -0.0521 -0.1490 -0.0825 -0.1440 -0.9688 -0.1208 -0.1179 -0.2589 -0.1209 -0.0696 -0.1296 -0.1629 -0.2126 -0.2259 -0.1362 -0.2348 -0.0335 -0.1747 -0.0818 -0.1494 -1.3876 -0.1310 -0.1847 -0.0330 -0.1979 -1.2914 -0.1468 -0.2779 -0.1076 -0.0671 -0.1469 -0.1750 -0.1644
S-1182	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-1182	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-1182	-0.22903087735176086	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
D-1182	-0.22903087735176086	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
P-1182	-0.0437 -0.1557 -0.0931 -0.1080 -0.0949 -0.1065 -0.1019 -0.0893 -0.1476 -1.3243 -0.0480 -0.0561 -0.0521 -0.1490 -0.0825 -0.1440 -0.9688 -0.1208 -0.1179 -0.2589 -0.1209 -0.0696 -0.1296 -0.1629 -0.2126 -0.2259 -0.1362 -0.2348 -0.0335 -0.1747 -0.0818 -0.1494 -1.3876 -0.1310 -0.1847 -0.0330 -0.1979 -1.2914 -0.1468 -0.2779 -0.1076 -0.0671 -0.1469 -0.1750 -0.1644
S-1831	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710-089 Sintra Tel : <unk> 351 21 925 25 00
T-1831	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710-089 Sintra Tel : <<unk>> 351 21 925 25 00
H-1831	-0.12347488105297089	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710 -089 Sintra Tel : <unk> 351 21 925 25 00
D-1831	-0.12347488105297089	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710 -089 Sintra Tel : <unk> 351 21 925 25 00
P-1831	-0.0639 -0.1333 -0.1635 -0.1517 -0.1697 -0.0834 -0.1103 -0.1931 -0.0605 -0.0706 -0.0191 -0.1459 -0.0491 -0.1477 -0.0813 -0.0917 -0.0888 -0.0738 -0.0947 -0.1604 -0.1109 -0.0605 -0.0997 -0.1232 -0.0985 -0.0825 -0.0936 -0.1435 -0.1862 -0.1307 -0.0682 -0.0290 -0.1370 -0.1015 -0.0975 -0.0549 -0.5575 -0.6082 -0.0838 -0.1041 -0.0706 -0.0919 -0.0778 -0.1421 -0.0386 -0.1390 -0.1018 -0.0932 -0.1233 -0.1262 -0.1449 -0.1127 -0.1583
S-830	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-830	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-830	-0.22903087735176086	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
D-830	-0.22903087735176086	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
P-830	-0.0437 -0.1557 -0.0931 -0.1080 -0.0949 -0.1065 -0.1019 -0.0893 -0.1476 -1.3243 -0.0480 -0.0561 -0.0521 -0.1490 -0.0825 -0.1440 -0.9688 -0.1208 -0.1179 -0.2589 -0.1209 -0.0696 -0.1296 -0.1629 -0.2126 -0.2259 -0.1362 -0.2348 -0.0335 -0.1747 -0.0818 -0.1494 -1.3876 -0.1310 -0.1847 -0.0330 -0.1979 -1.2914 -0.1468 -0.2779 -0.1076 -0.0671 -0.1469 -0.1750 -0.1644
S-1815	België<unk> Belgique<unk> Belgien Baxter Belgium SPRL Bd. de la Plaine<unk> Pleinlaan 5 B-1050 Brussel<unk> Bruxelles<unk> Brüssel Tél<unk> Tel : <unk> 32 2 650 1711
T-1815	België/ Belgique/ Belgien Baxter Belgium SPRL Bd . de la Plaine/ Pleinlaan 5 B-1050 Brussel/ Bruxelles/ Brüssel Tél/ Tel : <<unk>> 32 2 650 1711
H-1815	-0.2450912445783615	België/ Belgique/ Belgien Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Brussel/ Bruxelles/ Brussel/ Tel : <unk> 32 2 650 1711
D-1815	-0.2450912445783615	België/ Belgique/ Belgien Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Brussel/ Bruxelles/ Brussel/ Tel : <unk> 32 2 650 1711
P-1815	-0.0204 -0.0199 -0.0775 -0.0333 -0.1083 -0.1207 -0.1024 -0.0650 -0.1315 -0.1667 -0.1606 -0.1302 -0.0654 -0.1642 -0.1200 -0.1786 -0.1812 -0.1329 -0.2477 -0.2176 -0.0224 -0.0704 -0.3745 -0.0825 -0.1354 -0.1536 -0.1454 -0.1497 -0.1135 -0.1748 -0.1382 -0.1645 -0.2338 -0.1341 -0.2377 -0.1354 -0.0862 -0.1815 -0.1598 -3.7051 -1.6722 -0.3939 -0.4870 -0.1523 -0.0459 -0.1010 -0.1226 -0.1149 -0.1024 -0.1046 -0.1603
S-651	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-651	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-651	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
D-651	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
P-651	-0.5069 -0.1405 -0.2133 -1.0540 -0.3523 -0.5204 -0.0264 -0.4889 -0.0843 -0.1165 -0.1091 -0.1183 -0.0774 -0.1382 -0.1722 -0.0102 -0.0435 -0.1440 -0.1385 -0.2014 -0.0584 -0.7958 -0.1602 -1.2171 -0.1419 -0.0711 -0.1226 -0.1803 -0.4024 -0.0848 -0.1439 -0.1417 -0.1174 -0.1172 -0.0833 -2.4181 -0.9973 -0.7802 -0.1818 -0.5468 -0.0246 -0.0664 -0.7149 -0.0870 -1.3934 -0.2239 -1.1170 -0.1679 -0.1520
S-1177	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-1177	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-1177	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
D-1177	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
P-1177	-0.5069 -0.1405 -0.2133 -1.0540 -0.3523 -0.5204 -0.0264 -0.4889 -0.0843 -0.1165 -0.1091 -0.1183 -0.0774 -0.1382 -0.1722 -0.0102 -0.0435 -0.1440 -0.1385 -0.2014 -0.0584 -0.7958 -0.1602 -1.2171 -0.1419 -0.0711 -0.1226 -0.1803 -0.4024 -0.0848 -0.1439 -0.1417 -0.1174 -0.1172 -0.0833 -2.4181 -0.9973 -0.7802 -0.1818 -0.5468 -0.0246 -0.0664 -0.7149 -0.0870 -1.3934 -0.2239 -1.1170 -0.1679 -0.1520
S-825	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-825	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-825	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
D-825	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
P-825	-0.5069 -0.1405 -0.2133 -1.0540 -0.3523 -0.5204 -0.0264 -0.4889 -0.0843 -0.1165 -0.1091 -0.1183 -0.0774 -0.1382 -0.1722 -0.0102 -0.0435 -0.1440 -0.1385 -0.2014 -0.0584 -0.7958 -0.1602 -1.2171 -0.1419 -0.0711 -0.1226 -0.1803 -0.4024 -0.0848 -0.1439 -0.1417 -0.1174 -0.1172 -0.0833 -2.4181 -0.9973 -0.7802 -0.1818 -0.5468 -0.0246 -0.0664 -0.7149 -0.0870 -1.3934 -0.2239 -1.1170 -0.1679 -0.1520
S-1001	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-1001	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-1001	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
D-1001	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
P-1001	-0.5069 -0.1405 -0.2133 -1.0540 -0.3523 -0.5204 -0.0264 -0.4889 -0.0843 -0.1165 -0.1091 -0.1183 -0.0774 -0.1382 -0.1722 -0.0102 -0.0435 -0.1440 -0.1385 -0.2014 -0.0584 -0.7958 -0.1602 -1.2171 -0.1419 -0.0711 -0.1226 -0.1803 -0.4024 -0.0848 -0.1439 -0.1417 -0.1174 -0.1172 -0.0833 -2.4181 -0.9973 -0.7802 -0.1818 -0.5468 -0.0246 -0.0664 -0.7149 -0.0870 -1.3934 -0.2239 -1.1170 -0.1679 -0.1520
S-424	Der Alendronatbestandteil der ADROVANCE Kombinationstablette ( 70 mg<unk> 5.600 I.E. ) und einer Tablette mit 70 mg Alendronat sind bioäquivalent .
T-424	The alendronate component in the ADROVANCE ( 70mg/ 5600 IU ) combination tablet is bioequivalent to the alendronate 70 mg tablet .
H-424	-0.22920460999011993	The alendronate component of the ADROVANCE combination tablet ( 70 mg/ 5,600 IU ) and a tablet of 70 mg alendronate are bioequivalent .
D-424	-0.22920460999011993	The alendronate component of the ADROVANCE combination tablet ( 70 mg/ 5,600 IU ) and a tablet of 70 mg alendronate are bioequivalent .
P-424	-0.2764 -0.1375 -0.1101 -0.1920 -0.2853 -1.8609 -0.1132 -0.1765 -0.4257 -0.1319 -0.0643 -0.1188 -0.1028 -0.0936 -0.1677 -0.6133 -0.1233 -0.1386 -0.1731 -0.1472 -0.1671 -0.0720 -0.3947 -0.1020 -0.1182 -0.1059 -0.1304 -0.1529 -0.3897 -0.8068 -0.0990 -0.2264 -0.1549 -0.0315 -0.2189 -0.1240 -0.1402 -0.0705 -0.4120 -0.0841 -0.0724 -0.1765 -0.1536
S-1530	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-1530	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-1530	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
D-1530	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
P-1530	-0.5069 -0.1405 -0.2133 -1.0540 -0.3523 -0.5204 -0.0264 -0.4889 -0.0843 -0.1165 -0.1091 -0.1183 -0.0774 -0.1382 -0.1722 -0.0102 -0.0435 -0.1440 -0.1385 -0.2014 -0.0584 -0.7958 -0.1602 -1.2171 -0.1419 -0.0711 -0.1226 -0.1803 -0.4024 -0.0848 -0.1439 -0.1417 -0.1174 -0.1172 -0.0833 -2.4181 -0.9973 -0.7802 -0.1818 -0.5468 -0.0246 -0.0664 -0.7149 -0.0870 -1.3934 -0.2239 -1.1170 -0.1679 -0.1520
S-228	Der Alendronatbestandteil der ADROVANCE Kombinationstablette ( 70 mg<unk> 2.800 I.E. ) und der Tablette mit 70 mg Alendronat sind bioäquivalent .
T-228	The alendronate component in the ADROVANCE ( 70 mg/ 2800 IU ) combination tablet is bioequivalent to the alendronate 70 mg tablet .
H-228	-0.23437049984931946	The alendronate compound of the ADROVANCE combination tablet ( 70 mg/ 2,800 IU ) and the 70 mg alendronate tablet are bioequivalent .
D-228	-0.23437049984931946	The alendronate compound of the ADROVANCE combination tablet ( 70 mg/ 2,800 IU ) and the 70 mg alendronate tablet are bioequivalent .
P-228	-0.2511 -0.1331 -0.1141 -0.1839 -0.3486 -1.3609 -0.3751 -0.5315 -0.1401 -0.0652 -0.1187 -0.1036 -0.0876 -0.1900 -0.7546 -0.1282 -0.1381 -0.1604 -0.1554 -0.1639 -0.0662 -0.3027 -0.0981 -0.1199 -0.1147 -0.1287 -0.1421 -0.6075 -0.3026 -0.0326 -0.1564 -0.1224 -0.1425 -0.0579 -0.3612 -0.1247 -0.7155 -0.0913 -0.0837 -0.1810 -0.1531
S-309	Es stehen keine Daten zur Verfügung , die Hinweise geben , ob das Absetzen einer Bisphosphonattherapie bei Patienten , die einen kieferchirurgischen Eingriff benötigen , das Risiko einer Osteonekrose des Kiefers vermindert .
T-309	For patients requiring dental procedures , there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw .
H-309	-0.35281476378440857	No data are available to indicate whether discontinuation of bisphosphonate therapy in patients requiring maxillofacial surgery reduces the risk of osteonecrosis of the jaw .
D-309	-0.35281476378440857	No data are available to indicate whether discontinuation of bisphosphonate therapy in patients requiring maxillofacial surgery reduces the risk of osteonecrosis of the jaw .
P-309	-1.4037 -0.1824 -0.6534 -0.1620 -0.7207 -2.0164 -0.1356 -0.3955 -0.1391 -0.1012 -0.1243 -0.0942 -0.0349 -0.0300 -0.8676 -0.1959 -0.6167 -0.3640 -1.1651 -1.0413 -0.1442 -0.3965 -0.1568 -0.0419 -0.0344 -1.1152 -0.1108 -0.1854 -0.1266 -0.1257 -0.6353 -0.0990 -0.1228 -0.1053 -0.0267 -0.0820 -0.1782 -0.1404 -0.0901 -0.1346 -0.1603 -0.1621
S-121	Es stehen keine Daten zur Verfügung , die Hinweise geben , ob das Absetzen einer Bisphosphonattherapie bei Patienten , die einen kieferchirurgischen Eingriff benötigen , das Risiko einer Osteonekrose des Kiefers vermindert .
T-121	For patients requiring dental procedures , there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw .
H-121	-0.35281476378440857	No data are available to indicate whether discontinuation of bisphosphonate therapy in patients requiring maxillofacial surgery reduces the risk of osteonecrosis of the jaw .
D-121	-0.35281476378440857	No data are available to indicate whether discontinuation of bisphosphonate therapy in patients requiring maxillofacial surgery reduces the risk of osteonecrosis of the jaw .
P-121	-1.4037 -0.1824 -0.6534 -0.1620 -0.7207 -2.0164 -0.1356 -0.3955 -0.1391 -0.1012 -0.1243 -0.0942 -0.0349 -0.0300 -0.8676 -0.1959 -0.6167 -0.3640 -1.1651 -1.0413 -0.1442 -0.3965 -0.1568 -0.0419 -0.0344 -1.1152 -0.1108 -0.1854 -0.1266 -0.1257 -0.6353 -0.0990 -0.1228 -0.1053 -0.0267 -0.0820 -0.1782 -0.1404 -0.0901 -0.1346 -0.1603 -0.1621
S-457	Studien an Ratten zeigten , dass die Gabe von Alendronat an trächtige Ratten mit dem Auftreten von Dystokie bei den Muttertieren einherging , die auf eine Hypocalcämie zurückzuführen war .
T-457	Studies in rats have shown that treatment with alendronate during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia .
H-457	-0.3826017677783966	Studies in rats showed that administration of alendronate to pregnant rats was associated with the occurrence of mother dystocia due to hypocalcaemia .
D-457	-0.3826017677783966	Studies in rats showed that administration of alendronate to pregnant rats was associated with the occurrence of mother dystocia due to hypocalcaemia .
P-457	-0.7081 -0.4546 -0.0479 -1.3490 -0.2385 -0.8201 -0.1270 -0.1794 -0.1104 -0.1361 -0.1362 -0.1853 -0.0780 -0.1080 -0.2218 -0.2058 -0.1517 -1.3450 -0.5159 -0.0444 -0.1104 -0.0958 -0.1313 -2.8881 -0.1593 -0.0637 -0.7324 -1.5960 -0.1266 -0.0469 -0.1245 -0.0508 -0.0288 -0.1220 -0.1695 -0.1642
S-261	Studien an Ratten zeigten , dass die Gabe von Alendronat an trächtige Ratten mit dem Auftreten von Dystokie bei den Muttertieren einherging , die auf eine Hypocalcämie zurückzuführen war .
T-261	Studies in rats have shown that treatment with alendronate during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia .
H-261	-0.3826017677783966	Studies in rats showed that administration of alendronate to pregnant rats was associated with the occurrence of mother dystocia due to hypocalcaemia .
D-261	-0.3826017677783966	Studies in rats showed that administration of alendronate to pregnant rats was associated with the occurrence of mother dystocia due to hypocalcaemia .
P-261	-0.7081 -0.4546 -0.0479 -1.3490 -0.2385 -0.8201 -0.1270 -0.1794 -0.1104 -0.1361 -0.1362 -0.1853 -0.0780 -0.1080 -0.2218 -0.2058 -0.1517 -1.3450 -0.5159 -0.0444 -0.1104 -0.0958 -0.1313 -2.8881 -0.1593 -0.0637 -0.7324 -1.5960 -0.1266 -0.0469 -0.1245 -0.0508 -0.0288 -0.1220 -0.1695 -0.1642
S-467	INHABER DER HERSTELLUNGSERLAUBNIS , DER ( DIE ) FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST ( SIND
T-467	MANUFACTURING AUTHORISATION HOLDER<<unk>> S ) RESPONSIBLE FOR BATCH RELEASE
H-467	-0.36612099409103394	MANUFACTURING AUTHORISATION OF UNUSED MEDICINAL PRODUCTS , THE MANUFACTURING AUTHORISATION HOLDER ( IS
D-467	-0.36612099409103394	MANUFACTURING AUTHORISATION OF UNUSED MEDICINAL PRODUCTS , THE MANUFACTURING AUTHORISATION HOLDER ( IS
P-467	-1.1044 -0.0138 -0.1159 -0.0091 -0.0103 -0.0170 -0.0267 -0.0631 -0.5822 -0.0148 -0.0620 -0.0173 -0.0116 -0.0555 -3.7012 -0.4071 -0.7383 -0.0093 -0.0841 -0.0058 -0.0149 -0.0108 -0.0243 -0.0766 -0.0225 -0.0247 -0.0276 -0.0296 -0.0836 -1.3517 -2.3810 -0.4378 -0.0102 -0.1291 -0.0019 -0.0013 -0.0444 -0.0233 -0.0888 -0.5135 -0.0053 -0.0558 -0.0102 -0.0089 -0.0835 -2.9709 -0.0863 -0.1350 -0.7302 -1.7805 -0.4587
S-1401	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-1401	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-1401	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
D-1401	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
P-1401	-0.9770 -2.6906 -0.0731 -0.0711 -0.1255 -0.2507 -1.1583 -0.2325 -0.0159 -0.1254 -0.4097 -0.1781 -0.1665 -0.0852 -0.0765 -0.2328 -0.1521 -0.3102 -0.2429 -0.9951 -0.1863 -1.0620 -0.0289 -0.0665 -0.1365 -0.1565 -0.8597 -0.3176 -1.0886 -1.8547 -0.2972 -0.1945 -0.0826 -0.1207 -0.2404 -0.1734 -0.1694 -0.2865 -0.4434 -0.2006 -0.1767 -0.1968 -0.1744 -0.1574
S-1353	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-1353	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-1353	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
D-1353	-0.35439860820770264	In four patients , isolated occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes following multiple repeated product exposures were reported in the study .
P-1353	-0.5069 -0.1405 -0.2133 -1.0540 -0.3523 -0.5204 -0.0264 -0.4889 -0.0843 -0.1165 -0.1091 -0.1183 -0.0774 -0.1382 -0.1722 -0.0102 -0.0435 -0.1440 -0.1385 -0.2014 -0.0584 -0.7958 -0.1602 -1.2171 -0.1419 -0.0711 -0.1226 -0.1803 -0.4024 -0.0848 -0.1439 -0.1417 -0.1174 -0.1172 -0.0833 -2.4181 -0.9973 -0.7802 -0.1818 -0.5468 -0.0246 -0.0664 -0.7149 -0.0870 -1.3934 -0.2239 -1.1170 -0.1679 -0.1520
S-399	Der Anteil an Patientinnen mit Vitamin-D-Insuffizienz betrug während der 24-wöchigen Verlängerungsstudie 5,4 % in der 2.800-I.E.- Vitamin-D3-Gruppe vs .
T-399	The percentage of patients with vitamin D insufficiency was 5.4 % in the Vitamin D3 2800 group vs.
H-399	-0.4746491611003876	The proportion of vitamin D deficient patients during the 24 week extension trial was 5.4 % in the 2,800 IU vitamin D 3 group vs.
D-399	-0.4746491611003876	The proportion of vitamin D deficient patients during the 24 week extension trial was 5.4 % in the 2,800 IU vitamin D 3 group vs.
P-399	-0.6510 -0.8463 -0.1506 -1.6498 -0.0474 -0.1182 -0.3303 -0.5164 -0.3008 -1.3175 -0.2026 -0.4127 -0.8028 -0.4170 -1.0780 -0.1172 -0.0763 -0.1452 -0.1333 -0.2168 -0.1538 -0.6285 -0.1175 -0.2714 -0.1997 -0.9503 -0.0701 -0.6164 -0.3407 -1.5580 -0.3947 -0.3574
S-873	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-873	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-873	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
D-873	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
P-873	-0.9770 -2.6906 -0.0731 -0.0711 -0.1255 -0.2507 -1.1583 -0.2325 -0.0159 -0.1254 -0.4097 -0.1781 -0.1665 -0.0852 -0.0765 -0.2328 -0.1521 -0.3102 -0.2429 -0.9951 -0.1863 -1.0620 -0.0289 -0.0665 -0.1365 -0.1565 -0.8597 -0.3176 -1.0886 -1.8547 -0.2972 -0.1945 -0.0826 -0.1207 -0.2404 -0.1734 -0.1694 -0.2865 -0.4434 -0.2006 -0.1767 -0.1968 -0.1744 -0.1574
S-1291	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-1291	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-1291	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
D-1291	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
P-1291	-0.7900 -0.9141 -0.5282 -0.6450 -0.7231 -0.2624 -1.5910 -0.2165 -0.0560 -0.0610 -0.9723 -0.3095 -0.2214 -0.3665 -0.8844 -0.1584 -0.2948 -0.7341 -0.0858 -0.3300 -0.1857 -0.3198 -0.4702 -0.3134 -0.4870 -0.0706 -0.1381 -0.3236 -0.1219 -1.1326 -0.1198 -1.4115 -0.1692 -1.9868 -0.0790 -0.3378 -0.1187 -0.0581 -0.0824 -0.1788 -1.3195 -0.1582
S-1578	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-1578	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-1578	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
D-1578	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
P-1578	-0.9770 -2.6906 -0.0731 -0.0711 -0.1255 -0.2507 -1.1583 -0.2325 -0.0159 -0.1254 -0.4097 -0.1781 -0.1665 -0.0852 -0.0765 -0.2328 -0.1521 -0.3102 -0.2429 -0.9951 -0.1863 -1.0620 -0.0289 -0.0665 -0.1365 -0.1565 -0.8597 -0.3176 -1.0886 -1.8547 -0.2972 -0.1945 -0.0826 -0.1207 -0.2404 -0.1734 -0.1694 -0.2865 -0.4434 -0.2006 -0.1767 -0.1968 -0.1744 -0.1574
S-1225	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-1225	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-1225	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
D-1225	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
P-1225	-0.9770 -2.6906 -0.0731 -0.0711 -0.1255 -0.2507 -1.1583 -0.2325 -0.0159 -0.1254 -0.4097 -0.1781 -0.1665 -0.0852 -0.0765 -0.2328 -0.1521 -0.3102 -0.2429 -0.9951 -0.1863 -1.0620 -0.0289 -0.0665 -0.1365 -0.1565 -0.8597 -0.3176 -1.0886 -1.8547 -0.2972 -0.1945 -0.0826 -0.1207 -0.2404 -0.1734 -0.1694 -0.2865 -0.4434 -0.2006 -0.1767 -0.1968 -0.1744 -0.1574
S-1467	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-1467	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-1467	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
D-1467	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
P-1467	-0.7900 -0.9141 -0.5282 -0.6450 -0.7231 -0.2624 -1.5910 -0.2165 -0.0560 -0.0610 -0.9723 -0.3095 -0.2214 -0.3665 -0.8844 -0.1584 -0.2948 -0.7341 -0.0858 -0.3300 -0.1857 -0.3198 -0.4702 -0.3134 -0.4870 -0.0706 -0.1381 -0.3236 -0.1219 -1.1326 -0.1198 -1.4115 -0.1692 -1.9868 -0.0790 -0.3378 -0.1187 -0.0581 -0.0824 -0.1788 -1.3195 -0.1582
S-1049	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-1049	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-1049	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
D-1049	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
P-1049	-0.9770 -2.6906 -0.0731 -0.0711 -0.1255 -0.2507 -1.1583 -0.2325 -0.0159 -0.1254 -0.4097 -0.1781 -0.1665 -0.0852 -0.0765 -0.2328 -0.1521 -0.3102 -0.2429 -0.9951 -0.1863 -1.0620 -0.0289 -0.0665 -0.1365 -0.1565 -0.8597 -0.3176 -1.0886 -1.8547 -0.2972 -0.1945 -0.0826 -0.1207 -0.2404 -0.1734 -0.1694 -0.2865 -0.4434 -0.2006 -0.1767 -0.1968 -0.1744 -0.1574
S-13	Während der ersten Behandlungsmonate können immer noch Gichtanfälle auftreten ; deshalb wird empfohlen , dass die Patienten mindestens während der ersten sechs Monate unter Behandlung mit Adenuric noch weitere Arzneimittel zur Verhütung von Gichtanfällen einnehmen .
T-13	Attacks of gout can still occur during the first few months of treatment , so it is recommended that patients take other medicines to prevent attacks of gout for at least the first six months of treatment with Adenuric .
H-13	-0.3981182873249054	Attacks of gout can still occur during the first few months of treatment , and it is therefore recommended that patients take other medicines to prevent gout during at least the first six months of treatment with Adenuric .
D-13	-0.3981182873249054	Attacks of gout can still occur during the first few months of treatment , and it is therefore recommended that patients take other medicines to prevent gout during at least the first six months of treatment with Adenuric .
P-13	-1.1535 -0.0856 -0.2466 -0.0895 -0.1167 -1.1814 -0.1636 -0.1646 -0.2117 -0.1851 -0.1404 -1.5573 -0.1153 -0.1336 -0.1892 -1.0558 -0.6706 -0.9735 -0.1843 -0.2478 -0.1616 -0.1619 -0.5416 -0.6121 -1.2651 -0.4887 -0.2545 -0.2318 -0.1519 -0.6629 -0.0881 -2.2789 -0.3811 -0.1075 -0.1809 -0.1095 -0.1591 -0.1438 -0.6756 -0.2512 -0.1423 -0.0912 -0.1627 -0.1027 -0.1261 -0.1571 -0.1556
S-697	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-697	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-697	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
D-697	-0.3918322026729584	When refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to be reheated to room temperature ( between 15 and 25<unk> C ) .
P-697	-0.9770 -2.6906 -0.0731 -0.0711 -0.1255 -0.2507 -1.1583 -0.2325 -0.0159 -0.1254 -0.4097 -0.1781 -0.1665 -0.0852 -0.0765 -0.2328 -0.1521 -0.3102 -0.2429 -0.9951 -0.1863 -1.0620 -0.0289 -0.0665 -0.1365 -0.1565 -0.8597 -0.3176 -1.0886 -1.8547 -0.2972 -0.1945 -0.0826 -0.1207 -0.2404 -0.1734 -0.1694 -0.2865 -0.4434 -0.2006 -0.1767 -0.1968 -0.1744 -0.1574
S-1990	Da sich Reproduktionsstudien an Tieren nicht immer auf den Menschen übertragen lassen und auf Grund der vasokonstriktorischen Eigenschaften von Pseudoephedrin sollte Aerinaze in der Schwangerschaft nicht angewendet werden .
T-1990	4 Because animal reproduction studies are not always predictive of human response , and due to the vasoconstrictive properties of pseudoephedrine , Aerinaze should not be used during pregnancy .
H-1990	-0.5078775882720947	Aerinaze should not be used in pregnancy as reproduction studies in animals cannot always be extended to humans and due to the vasoconstrictory characteristics of pseudoephedrine .
D-1990	-0.5078775882720947	Aerinaze should not be used in pregnancy as reproduction studies in animals cannot always be extended to humans and due to the vasoconstrictory characteristics of pseudoephedrine .
P-1990	-3.2505 -0.1136 -0.1500 -0.1381 -0.0749 -0.2251 -0.1527 -0.1752 -0.3680 -0.6863 -0.0588 -1.4634 -1.6099 -0.1484 -0.1203 -0.3677 -0.0416 -0.9790 -0.1334 -0.1073 -3.0811 -0.1414 -0.2810 -0.4408 -0.5428 -0.1270 -0.3116 -0.0752 -0.1433 -0.1241 -0.5229 -0.0647 -2.1503 -1.1073 -1.4666 -0.1297 -0.1237 -0.1346 -0.1790 -0.1688 -0.0589 -0.1544 -0.1517 -0.1042 -1.0524 -0.1605
S-1115	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-1115	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-1115	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
D-1115	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
P-1115	-0.7900 -0.9141 -0.5282 -0.6450 -0.7231 -0.2624 -1.5910 -0.2165 -0.0560 -0.0610 -0.9723 -0.3095 -0.2214 -0.3665 -0.8844 -0.1584 -0.2948 -0.7341 -0.0858 -0.3300 -0.1857 -0.3198 -0.4702 -0.3134 -0.4870 -0.0706 -0.1381 -0.3236 -0.1219 -1.1326 -0.1198 -1.4115 -0.1692 -1.9868 -0.0790 -0.3378 -0.1187 -0.0581 -0.0824 -0.1788 -1.3195 -0.1582
S-939	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-939	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-939	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
D-939	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
P-939	-0.7900 -0.9141 -0.5282 -0.6450 -0.7231 -0.2624 -1.5910 -0.2165 -0.0560 -0.0610 -0.9723 -0.3095 -0.2214 -0.3665 -0.8844 -0.1584 -0.2948 -0.7341 -0.0858 -0.3300 -0.1857 -0.3198 -0.4702 -0.3134 -0.4870 -0.0706 -0.1381 -0.3236 -0.1219 -1.1326 -0.1198 -1.4115 -0.1692 -1.9868 -0.0790 -0.3378 -0.1187 -0.0581 -0.0824 -0.1788 -1.3195 -0.1582
S-763	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-763	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-763	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
D-763	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
P-763	-0.7900 -0.9141 -0.5282 -0.6450 -0.7231 -0.2624 -1.5910 -0.2165 -0.0560 -0.0610 -0.9723 -0.3095 -0.2214 -0.3665 -0.8844 -0.1584 -0.2948 -0.7341 -0.0858 -0.3300 -0.1857 -0.3198 -0.4702 -0.3134 -0.4870 -0.0706 -0.1381 -0.3236 -0.1219 -1.1326 -0.1198 -1.4115 -0.1692 -1.9868 -0.0790 -0.3378 -0.1187 -0.0581 -0.0824 -0.1788 -1.3195 -0.1582
S-589	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-589	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-589	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
D-589	-0.4696981906890869	If the expected Factor VIII plasma activity is not achieved , or if bleeding is not controlled at an appropriate dose , a test should be performed to detect an inhibitor .
P-589	-0.7900 -0.9141 -0.5282 -0.6450 -0.7231 -0.2624 -1.5910 -0.2165 -0.0560 -0.0610 -0.9723 -0.3095 -0.2214 -0.3665 -0.8844 -0.1584 -0.2948 -0.7341 -0.0858 -0.3300 -0.1857 -0.3198 -0.4702 -0.3134 -0.4870 -0.0706 -0.1381 -0.3236 -0.1219 -1.1326 -0.1198 -1.4115 -0.1692 -1.9868 -0.0790 -0.3378 -0.1187 -0.0581 -0.0824 -0.1788 -1.3195 -0.1582
S-842	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-842	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-842	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-842	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-842	-0.2005 -0.1397 -0.1124 -0.0621 -0.1278 -0.6422 -0.1546 -0.0761 -0.0809 -0.9611 -0.1221 -0.0606 -0.3505 -0.1891 -0.0435 -0.1185 -0.3558 -0.1891 -0.9571 -0.4384 -0.0373 -0.3372 -0.0911 -0.0698 -0.0717 -0.2369 -0.1207 -0.3918 -0.1907 -0.0853 -0.3383 -0.1373 -0.1099 -0.1286 -0.2021 -0.1140 -1.3892 -0.0907 -0.1096 -0.1898 -0.1984 -0.1072 -0.0760 -0.0891 -0.1464 -0.1710
S-1194	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-1194	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-1194	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-1194	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-1194	-0.2005 -0.1397 -0.1124 -0.0621 -0.1278 -0.6422 -0.1546 -0.0761 -0.0809 -0.9611 -0.1221 -0.0606 -0.3505 -0.1891 -0.0435 -0.1185 -0.3558 -0.1891 -0.9571 -0.4384 -0.0373 -0.3372 -0.0911 -0.0698 -0.0717 -0.2369 -0.1207 -0.3918 -0.1907 -0.0853 -0.3383 -0.1373 -0.1099 -0.1286 -0.2021 -0.1140 -1.3892 -0.0907 -0.1096 -0.1898 -0.1984 -0.1072 -0.0760 -0.0891 -0.1464 -0.1710
S-84	Jede Tablette enthält 70 mg Alendronsäure als Natriumalendronat 3 H2O und 70 Mikrogramm ( 2.800 I.E. ) Colecalciferol ( Vitamin D3 ) .
T-84	Each tablet contains 70 mg alendronic acid as alendronate sodium trihydrate , and 70 micrograms ( 2800 IU ) colecalciferol ( vitamin D3 ) .
H-84	-0.1707819402217865	Each tablet contains 70 mg alendronic acid as sodium alendronate 3 H2O and 70 micrograms ( 2,800 IU ) colecalciferol ( vitamin D3 ) .
D-84	-0.1707819402217865	Each tablet contains 70 mg alendronic acid as sodium alendronate 3 H2O and 70 micrograms ( 2,800 IU ) colecalciferol ( vitamin D3 ) .
P-84	-0.0459 -0.1660 -0.1042 -0.0703 -0.2211 -0.0448 -0.3783 -0.1034 -0.1686 -0.1673 -0.0865 -0.3689 -0.1306 -0.0851 -0.1521 -0.2945 -0.2216 -0.1213 -0.1575 -0.1952 -0.1333 -0.1324 -0.2031 -0.1074 -0.1077 -0.0751 -0.1478 -0.4076 -0.1122 -0.0992 -0.1426 -0.1347 -0.9815 -0.1383 -0.1721 -0.0985 -0.1298 -0.1354 -0.1449 -0.1564 -0.0870 -0.1386 -0.1341 -0.1310 -0.1646 -0.1574
S-1018	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-1018	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-1018	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-1018	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-1018	-0.2005 -0.1397 -0.1124 -0.0621 -0.1278 -0.6422 -0.1546 -0.0761 -0.0809 -0.9611 -0.1221 -0.0606 -0.3505 -0.1891 -0.0435 -0.1185 -0.3558 -0.1891 -0.9571 -0.4384 -0.0373 -0.3372 -0.0911 -0.0698 -0.0717 -0.2369 -0.1207 -0.3918 -0.1907 -0.0853 -0.3383 -0.1373 -0.1099 -0.1286 -0.2021 -0.1140 -1.3892 -0.0907 -0.1096 -0.1898 -0.1984 -0.1072 -0.0760 -0.0891 -0.1464 -0.1710
S-434	Nach intravenöser Gabe einer einzelnen Dosis von 10 mg betrug die renale Clearance von Alendronat 71 ml<unk> min und die systemische Clearance überschritt nicht 200 ml<unk> min .
T-434	Following a single 10 mg intravenous dose , the renal clearance of alendronate was 71 ml/ min , and systemic clearance did not exceed 200 ml/ min .
H-434	-0.1828344315290451	After the intravenous administration of a single dose of 10 mg , the renal clearance of alendronate was 71 ml/ min and the systemic clearance did not exceed 200 ml/ min .
D-434	-0.1828344315290451	After the intravenous administration of a single dose of 10 mg , the renal clearance of alendronate was 71 ml/ min and the systemic clearance did not exceed 200 ml/ min .
P-434	-0.7297 -0.7087 -0.6856 -0.0821 -0.0694 -0.1270 -0.1807 -0.1387 -0.1293 -0.3340 -0.5759 -0.1280 -0.2259 -0.0388 -0.2271 -0.2668 -0.0903 -0.1012 -0.0220 -0.1160 -0.1533 -0.1338 -0.1030 -0.1236 -0.0672 -0.1332 -0.0844 -0.1012 -0.1615 -0.1236 -0.1208 -0.3103 -0.5064 -0.0586 -0.0826 -0.0954 -0.0365 -0.0948 -0.3067 -0.1181 -0.0221 -0.0942 -0.1555 -0.0833 -0.1590 -0.1144 -0.1174 -0.1702 -0.1503
S-1370	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-1370	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-1370	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-1370	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-1370	-0.2005 -0.1397 -0.1124 -0.0621 -0.1278 -0.6422 -0.1546 -0.0761 -0.0809 -0.9611 -0.1221 -0.0606 -0.3505 -0.1891 -0.0435 -0.1185 -0.3558 -0.1891 -0.9571 -0.4384 -0.0373 -0.3372 -0.0911 -0.0698 -0.0717 -0.2369 -0.1207 -0.3918 -0.1907 -0.0853 -0.3383 -0.1373 -0.1099 -0.1286 -0.2021 -0.1140 -1.3892 -0.0907 -0.1096 -0.1898 -0.1984 -0.1072 -0.0760 -0.0891 -0.1464 -0.1710
S-1547	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-1547	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-1547	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-1547	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-1547	-0.2005 -0.1397 -0.1124 -0.0621 -0.1278 -0.6422 -0.1546 -0.0761 -0.0809 -0.9611 -0.1221 -0.0606 -0.3505 -0.1891 -0.0435 -0.1185 -0.3558 -0.1891 -0.9571 -0.4384 -0.0373 -0.3372 -0.0911 -0.0698 -0.0717 -0.2369 -0.1207 -0.3918 -0.1907 -0.0853 -0.3383 -0.1373 -0.1099 -0.1286 -0.2021 -0.1140 -1.3892 -0.0907 -0.1096 -0.1898 -0.1984 -0.1072 -0.0760 -0.0891 -0.1464 -0.1710
S-241	Alendronat wird bei Ratten nicht über das saure oder basische Transportsystem der Nieren ausgeschieden und daher wird nicht angenommen , dass es beim Menschen die Ausscheidung anderer Arzneimittel durch diese Transportsysteme beeinflusst .
T-241	Alendronate is not excreted through the acidic or basic transport systems of the kidney in rats , and thus it is not anticipated to interfere with the excretion of other medicinal products by those systems in humans .
H-241	-0.37322965264320374	In rats , alendronate is not excreted via the acidic or alkaline transport system of the kidneys and is therefore not thought to affect the excretion of other medicines by these transport systems in humans .
D-241	-0.37322965264320374	In rats , alendronate is not excreted via the acidic or alkaline transport system of the kidneys and is therefore not thought to affect the excretion of other medicines by these transport systems in humans .
P-241	-1.0697 -0.0509 -0.3155 -0.1137 -0.1142 -0.1089 -0.0646 -0.2042 -0.1456 -0.4666 -0.0353 -0.0735 -0.5994 -0.2171 -0.6492 -0.0668 -0.2822 -0.6139 -0.0919 -0.0856 -1.4379 -0.2702 -0.5689 -0.1683 -0.3368 -0.2919 -0.0402 -0.8650 -1.3024 -0.4191 -0.1272 -0.5171 -0.1446 -0.8930 -0.6101 -0.2028 -0.0087 -0.1125 -0.1588 -0.1467 -0.2749 -0.6705 -2.3506 -0.1820 -0.2981 -0.2234 -0.2563 -0.1053 -0.1551 -0.1540
S-437	Alendronat wird bei Ratten nicht über das saure oder basische Transportsystem der Nieren ausgeschieden und daher wird nicht angenommen , dass es beim Menschen die Ausscheidung anderer Arzneimittel durch diese Transportsysteme beeinflusst .
T-437	Alendronate is not excreted through the acidic or basic transport systems of the kidney in rats , and thus it is not anticipated to interfere with the excretion of other medicinal products by those systems in humans .
H-437	-0.37322965264320374	In rats , alendronate is not excreted via the acidic or alkaline transport system of the kidneys and is therefore not thought to affect the excretion of other medicines by these transport systems in humans .
D-437	-0.37322965264320374	In rats , alendronate is not excreted via the acidic or alkaline transport system of the kidneys and is therefore not thought to affect the excretion of other medicines by these transport systems in humans .
P-437	-1.0697 -0.0509 -0.3155 -0.1137 -0.1142 -0.1089 -0.0646 -0.2042 -0.1456 -0.4666 -0.0353 -0.0735 -0.5994 -0.2171 -0.6492 -0.0668 -0.2822 -0.6139 -0.0919 -0.0856 -1.4379 -0.2702 -0.5689 -0.1683 -0.3368 -0.2919 -0.0402 -0.8650 -1.3024 -0.4191 -0.1272 -0.5171 -0.1446 -0.8930 -0.6101 -0.2028 -0.0087 -0.1125 -0.1588 -0.1467 -0.2749 -0.6705 -2.3506 -0.1820 -0.2981 -0.2234 -0.2563 -0.1053 -0.1551 -0.1540
S-667	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-667	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-667	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-667	-0.2307058423757553	Table 3 Summary of ADVATE pharmacokinetic parameters in 100 severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-667	-0.2005 -0.1397 -0.1124 -0.0621 -0.1278 -0.6422 -0.1546 -0.0761 -0.0809 -0.9611 -0.1221 -0.0606 -0.3505 -0.1891 -0.0435 -0.1185 -0.3558 -0.1891 -0.9571 -0.4384 -0.0373 -0.3372 -0.0911 -0.0698 -0.0717 -0.2369 -0.1207 -0.3918 -0.1907 -0.0853 -0.3383 -0.1373 -0.1099 -0.1286 -0.2021 -0.1140 -1.3892 -0.0907 -0.1096 -0.1898 -0.1984 -0.1072 -0.0760 -0.0891 -0.1464 -0.1710
S-271	Jede Tablette enthält 70 mg Alendronsäure als Natriumalendronat 3 H2O und 140 Mikrogramm ( 5.600 I.E. ) Colecalciferol ( Vitamin D3 ) .
T-271	Each tablet contains 70 mg alendronic acid as alendronate sodium trihydrate and 140 micrograms ( 5600 IU ) colecalciferol ( vitamin D3 ) .
H-271	-0.17139464616775513	Each tablet contains 70 mg alendronic acid as sodium alendronate 3 H2O and 140 micrograms ( 5,600 IU ) colecalciferol ( vitamin D3 ) .
D-271	-0.17139464616775513	Each tablet contains 70 mg alendronic acid as sodium alendronate 3 H2O and 140 micrograms ( 5,600 IU ) colecalciferol ( vitamin D3 ) .
P-271	-0.0470 -0.1623 -0.1037 -0.0705 -0.2408 -0.0436 -0.3710 -0.1047 -0.1713 -0.1641 -0.0845 -0.3784 -0.1343 -0.0832 -0.1506 -0.3059 -0.2260 -0.1190 -0.1556 -0.1912 -0.1331 -0.1277 -0.1947 -0.2549 -0.1292 -0.0733 -0.1458 -0.3373 -0.0984 -0.1036 -0.1264 -0.1360 -0.9384 -0.1368 -0.1698 -0.0963 -0.1299 -0.1338 -0.1427 -0.1587 -0.0880 -0.1377 -0.1336 -0.1314 -0.1628 -0.1563
S-1612	BEDINGUNGEN ODER EINSCHRÄNKUNGEN FÜR DIE ABGABE UND DEN GEBRAUCH , DIE DEM INHABER DER GENEHMIGUNG FÜR DAS INVERKEHRBRINGEN AUFERLEGT WERDEN
T-1612	CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
H-1612	-0.36113861203193665	CONDITIONS OR RESTRICTIONS OR WASTE MATERIALS OF SUPPLY AND USE THERAPY MATERIALS OR WASTE MATERIALS
D-1612	-0.36113861203193665	CONDITIONS OR RESTRICTIONS OR WASTE MATERIALS OF SUPPLY AND USE THERAPY MATERIALS OR WASTE MATERIALS
P-1612	-0.2753 -0.1299 -0.0139 -0.0463 -0.0503 -0.1484 -0.1941 -0.0652 -0.1201 -0.0904 -0.0248 -0.0117 -0.0423 -0.0320 -0.1046 -0.2515 -0.5116 -1.9651 -0.0546 -0.0133 -0.0409 -0.1346 -0.0636 -0.0643 -0.0702 -0.0337 -0.0827 -0.5339 -1.6545 -0.9452 -0.8769 -0.0119 -0.1670 -1.0161 -0.2312 -0.1707 -0.3478 -1.4468 -0.2819 -0.0589 -3.7314 -1.0516 -0.1317 -0.0630 -0.0764 -0.2229 -0.7380 -0.3695 -0.3612 -0.0321 -0.0056 -0.0443 -0.1457 -0.0432 -0.0480 -0.0506 -0.0450 -0.1268 -1.6422
S-1607	68 A. HERSTELLER DES WIRKSTOFFS BIOLOGISCHEN URSPRUNGS UND INHABER DER HERSTELLUNGSERLAUBNIS , DER FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST
T-1607	62 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
H-1607	-0.37941062450408936	MANUFACTURER OF THE EFFECTIVE BIOLOGICAL ORIGIN AND MANUFACTURER OF THE AUTHORISATION OF UNUSED MEDICINAL PRODUCTS
D-1607	-0.37941062450408936	MANUFACTURER OF THE EFFECTIVE BIOLOGICAL ORIGIN AND MANUFACTURER OF THE AUTHORISATION OF UNUSED MEDICINAL PRODUCTS
P-1607	-1.9828 -0.0392 -0.1089 -0.0144 -0.0048 -0.0615 -0.0293 -0.1926 -0.0272 -0.2583 -0.0787 -3.2984 -0.0131 -0.4118 -1.2888 -0.2509 -0.0368 -0.6179 -0.2051 -0.0526 -0.1299 -0.1260 -0.6966 -0.2401 -1.2158 -0.0685 -0.8773 -0.2937 -0.6180 -0.0157 -0.1569 -0.0058 -0.0097 -0.0342 -0.0289 -0.9191 -0.2249 -0.2999 -0.4626 -0.2603 -0.1019 -0.1080 -0.0265 -0.0036 -0.0438 -3.3034 -0.0997 -1.5482 -0.0160 -0.0625 -0.0050 -0.0193 -0.0104 -0.0320 -0.0684 -0.0346 -0.0444 -0.0291 -0.0295 -0.0817 -1.8188
S-1500	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-1500	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-1500	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-1500	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-1500	-0.5667 -0.8840 -0.1437 -0.1008 -2.7342 -0.1458 -0.3986 -0.9550 -0.4364 -0.1930 -0.1955 -0.1543 -0.3171 -0.1768 -0.0789 -0.1157 -0.0467 -0.0577 -0.1389 -0.1360 -0.1805 -0.2357 -0.1317 -0.2580 -0.3979 -0.2851 -0.4864 -0.2328 -0.1205 -0.0393 -0.1462 -0.0397 -0.2681 -1.0563 -1.2785 -0.0817 -1.4123 -1.0595 -0.1227 -0.0470 -0.1380 -1.0024 -0.0834 -0.0262 -0.1452 -0.1362 -0.1527 -0.1496 -0.1340 -0.1386 -0.1288 -0.0571 -0.2316 -0.0961 -0.0364 -0.0725 -0.1408 -0.2420 -0.7646 -0.5103 -0.1272 -0.1543 -0.1537
S-176	Laborwerte In klinischen Studien wurden asymptomatische , leichte und vorübergehende Abnahmen des Serum- Calciums und -Phosphats bei ca. 18 % beziehungsweise 10 % der Patienten beobachtet , die Alendronat 10 mg<unk> Tag einnahmen , gegenüber ca. 12 % und 3 % derjenigen , die Plazebo einnahmen .
T-176	Laboratory test findings In clinical studies , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % , respectively , of patients taking alendronate 10 mg/ day versus approximately 12 % and 3 % of those taking placebo .
H-176	-0.2581103444099426	In clinical trials , asymptomatic , mild , and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of those taking alendronate 10 mg/ day , respectively , compared to approximately 12 % and 3 % of those taking placebo .
D-176	-0.2581103444099426	In clinical trials , asymptomatic , mild , and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of those taking alendronate 10 mg/ day , respectively , compared to approximately 12 % and 3 % of those taking placebo .
P-176	-1.3266 -0.0645 -0.2523 -0.4193 -0.0788 -0.1065 -0.1046 -0.1104 -0.1410 -0.5706 -0.6168 -0.1601 -0.0731 -0.0860 -0.9334 -0.2891 -0.0938 -0.4266 -0.1465 -0.0864 -0.1922 -0.1081 -0.0979 -0.1543 -0.1367 -0.0655 -0.0966 -0.2371 -0.3061 -0.1441 -0.2692 -0.0974 -0.1364 -0.1372 -0.1442 -0.1203 -0.7420 -0.7059 -0.3615 -0.1351 -0.1157 -0.1178 -0.1292 -0.1941 -0.1784 -0.1331 -0.0884 -0.2715 -0.2468 -1.5405 -0.1519 -0.4358 -0.9920 -0.0782 -0.1212 -0.1129 -0.1292 -0.1477 -0.1121 -0.2361 -0.0690 -0.5447 -0.0446 -0.1271 -0.1804 -0.1352 -0.2892 -0.1545
S-972	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-972	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-972	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-972	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-972	-0.5667 -0.8840 -0.1437 -0.1008 -2.7342 -0.1458 -0.3986 -0.9550 -0.4364 -0.1930 -0.1955 -0.1543 -0.3171 -0.1768 -0.0789 -0.1157 -0.0467 -0.0577 -0.1389 -0.1360 -0.1805 -0.2357 -0.1317 -0.2580 -0.3979 -0.2851 -0.4864 -0.2328 -0.1205 -0.0393 -0.1462 -0.0397 -0.2681 -1.0563 -1.2785 -0.0817 -1.4123 -1.0595 -0.1227 -0.0470 -0.1380 -1.0024 -0.0834 -0.0262 -0.1452 -0.1362 -0.1527 -0.1496 -0.1340 -0.1386 -0.1288 -0.0571 -0.2316 -0.0961 -0.0364 -0.0725 -0.1408 -0.2420 -0.7646 -0.5103 -0.1272 -0.1543 -0.1537
S-1148	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-1148	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-1148	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-1148	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-1148	-0.5667 -0.8840 -0.1437 -0.1008 -2.7342 -0.1458 -0.3986 -0.9550 -0.4364 -0.1930 -0.1955 -0.1543 -0.3171 -0.1768 -0.0789 -0.1157 -0.0467 -0.0577 -0.1389 -0.1360 -0.1805 -0.2357 -0.1317 -0.2580 -0.3979 -0.2851 -0.4864 -0.2328 -0.1205 -0.0393 -0.1462 -0.0397 -0.2681 -1.0563 -1.2785 -0.0817 -1.4123 -1.0595 -0.1227 -0.0470 -0.1380 -1.0024 -0.0834 -0.0262 -0.1452 -0.1362 -0.1527 -0.1496 -0.1340 -0.1386 -0.1288 -0.0571 -0.2316 -0.0961 -0.0364 -0.0725 -0.1408 -0.2420 -0.7646 -0.5103 -0.1272 -0.1543 -0.1537
S-622	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-622	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-622	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-622	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-622	-0.5667 -0.8840 -0.1437 -0.1008 -2.7342 -0.1458 -0.3986 -0.9550 -0.4364 -0.1930 -0.1955 -0.1543 -0.3171 -0.1768 -0.0789 -0.1157 -0.0467 -0.0577 -0.1389 -0.1360 -0.1805 -0.2357 -0.1317 -0.2580 -0.3979 -0.2851 -0.4864 -0.2328 -0.1205 -0.0393 -0.1462 -0.0397 -0.2681 -1.0563 -1.2785 -0.0817 -1.4123 -1.0595 -0.1227 -0.0470 -0.1380 -1.0024 -0.0834 -0.0262 -0.1452 -0.1362 -0.1527 -0.1496 -0.1340 -0.1386 -0.1288 -0.0571 -0.2316 -0.0961 -0.0364 -0.0725 -0.1408 -0.2420 -0.7646 -0.5103 -0.1272 -0.1543 -0.1537
S-1324	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-1324	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-1324	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-1324	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-1324	-0.5667 -0.8840 -0.1437 -0.1008 -2.7342 -0.1458 -0.3986 -0.9550 -0.4364 -0.1930 -0.1955 -0.1543 -0.3171 -0.1768 -0.0789 -0.1157 -0.0467 -0.0577 -0.1389 -0.1360 -0.1805 -0.2357 -0.1317 -0.2580 -0.3979 -0.2851 -0.4864 -0.2328 -0.1205 -0.0393 -0.1462 -0.0397 -0.2681 -1.0563 -1.2785 -0.0817 -1.4123 -1.0595 -0.1227 -0.0470 -0.1380 -1.0024 -0.0834 -0.0262 -0.1452 -0.1362 -0.1527 -0.1496 -0.1340 -0.1386 -0.1288 -0.0571 -0.2316 -0.0961 -0.0364 -0.0725 -0.1408 -0.2420 -0.7646 -0.5103 -0.1272 -0.1543 -0.1537
S-109	Ösophageale Reaktionen , wie Ösophagitis , ösophageale Ulzera und ösophageale Erosionen , selten gefolgt von ösophagealen Strikturen , wurden bei Patienten unter der Einnahme von Alendronat berichtet ( teilweise waren diese schwerwiegend und erforderten eine Krankenhauseinweisung ) .
T-109	Oesophageal reactions ( sometimes severe and requiring hospitalisation ) , such as oesophagitis , oesophageal ulcers and oesophageal erosions , rarely followed by oesophageal stricture , have been reported in patients receiving alendronate .
H-109	-0.31154686212539673	Oesophageal reactions such as oesophagitis , oesophageal ulcers and oesophageal erosion , rarely followed by oesophageal stricture , were reported in patients taking alendronate ( some of these were severe and required hospitalization ) .
D-109	-0.31154686212539673	Oesophageal reactions such as oesophagitis , oesophageal ulcers and oesophageal erosion , rarely followed by oesophageal stricture , were reported in patients taking alendronate ( some of these were severe and required hospitalization ) .
P-109	-0.3173 -0.0865 -1.9761 -0.0723 -0.0902 -0.1461 -0.2658 -0.0796 -0.9994 -0.1533 -0.7573 -0.0751 -0.0798 -0.0729 -0.1071 -0.0704 -0.1350 -0.5965 -0.0451 -1.2529 -0.0760 -0.1110 -0.1449 -0.1014 -0.2585 -0.1852 -0.6466 -0.3080 -0.0639 -0.3633 -0.0672 -0.1002 -0.1435 -0.0715 -1.0971 -0.1825 -0.5869 -0.0929 -0.1382 -0.1732 -0.1113 -0.7100 -0.0644 -0.0988 -0.1392 -0.5338 -0.3519 -0.1997 -0.4463 -0.1760 -0.1641 -0.4408 -0.1730 -0.1537 -0.0957 -0.1670 -0.1305 -0.1537 -1.3002 -0.3872 -0.9231 -0.1494 -0.3361 -0.1700 -0.5918 -0.6972 -0.3808 -0.1467 -0.1259 -0.1589 -0.1520
S-297	Ösophageale Reaktionen , wie Ösophagitis , ösophageale Ulzera und ösophageale Erosionen , selten gefolgt von ösophagealen Strikturen , wurden bei Patienten unter der Einnahme von Alendronat berichtet ( teilweise waren diese schwerwiegend und erforderten eine Krankenhauseinweisung ) .
T-297	Oesophageal reactions ( sometimes severe and requiring hospitalisation ) , such as oesophagitis , oesophageal ulcers and oesophageal erosions , rarely followed by oesophageal stricture , have been reported in patients receiving alendronate .
H-297	-0.31154686212539673	Oesophageal reactions such as oesophagitis , oesophageal ulcers and oesophageal erosion , rarely followed by oesophageal stricture , were reported in patients taking alendronate ( some of these were severe and required hospitalization ) .
D-297	-0.31154686212539673	Oesophageal reactions such as oesophagitis , oesophageal ulcers and oesophageal erosion , rarely followed by oesophageal stricture , were reported in patients taking alendronate ( some of these were severe and required hospitalization ) .
P-297	-0.3173 -0.0865 -1.9761 -0.0723 -0.0902 -0.1461 -0.2658 -0.0796 -0.9994 -0.1533 -0.7573 -0.0751 -0.0798 -0.0729 -0.1071 -0.0704 -0.1350 -0.5965 -0.0451 -1.2529 -0.0760 -0.1110 -0.1449 -0.1014 -0.2585 -0.1852 -0.6466 -0.3080 -0.0639 -0.3633 -0.0672 -0.1002 -0.1435 -0.0715 -1.0971 -0.1825 -0.5869 -0.0929 -0.1382 -0.1732 -0.1113 -0.7100 -0.0644 -0.0988 -0.1392 -0.5338 -0.3519 -0.1997 -0.4463 -0.1760 -0.1641 -0.4408 -0.1730 -0.1537 -0.0957 -0.1670 -0.1305 -0.1537 -1.3002 -0.3872 -0.9231 -0.1494 -0.3361 -0.1700 -0.5918 -0.6972 -0.3808 -0.1467 -0.1259 -0.1589 -0.1520
S-364	Laborwerte In klinischen Studien wurden asymptomatische , leichte und vorübergehende Abnahmen des Serum- Calciums und -Phosphats bei ca. 18 % beziehungsweise 10 % der Patienten beobachtet , die Alendronat 10 mg<unk> Tag einnahmen , gegenüber ca. 12 % und 3 % derjenigen , die Plazebo einnahmen .
T-364	Laboratory test findings In clinical studies , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % , respectively , of patients taking alendronate 10 mg/ day versus approximately 12 % and 3 % of those taking placebo .
H-364	-0.2581103444099426	In clinical trials , asymptomatic , mild , and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of those taking alendronate 10 mg/ day , respectively , compared to approximately 12 % and 3 % of those taking placebo .
D-364	-0.2581103444099426	In clinical trials , asymptomatic , mild , and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of those taking alendronate 10 mg/ day , respectively , compared to approximately 12 % and 3 % of those taking placebo .
P-364	-1.3266 -0.0645 -0.2523 -0.4193 -0.0788 -0.1065 -0.1046 -0.1104 -0.1410 -0.5706 -0.6168 -0.1601 -0.0731 -0.0860 -0.9334 -0.2891 -0.0938 -0.4266 -0.1465 -0.0864 -0.1922 -0.1081 -0.0979 -0.1543 -0.1367 -0.0655 -0.0966 -0.2371 -0.3061 -0.1441 -0.2692 -0.0974 -0.1364 -0.1372 -0.1442 -0.1203 -0.7420 -0.7059 -0.3615 -0.1351 -0.1157 -0.1178 -0.1292 -0.1941 -0.1784 -0.1331 -0.0884 -0.2715 -0.2468 -1.5405 -0.1519 -0.4358 -0.9920 -0.0782 -0.1212 -0.1129 -0.1292 -0.1477 -0.1121 -0.2361 -0.0690 -0.5447 -0.0446 -0.1271 -0.1804 -0.1352 -0.2892 -0.1545
S-796	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-796	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-796	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-796	-0.3282124400138855	The ADRs seen in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-796	-0.5667 -0.8840 -0.1437 -0.1008 -2.7342 -0.1458 -0.3986 -0.9550 -0.4364 -0.1930 -0.1955 -0.1543 -0.3171 -0.1768 -0.0789 -0.1157 -0.0467 -0.0577 -0.1389 -0.1360 -0.1805 -0.2357 -0.1317 -0.2580 -0.3979 -0.2851 -0.4864 -0.2328 -0.1205 -0.0393 -0.1462 -0.0397 -0.2681 -1.0563 -1.2785 -0.0817 -1.4123 -1.0595 -0.1227 -0.0470 -0.1380 -1.0024 -0.0834 -0.0262 -0.1452 -0.1362 -0.1527 -0.1496 -0.1340 -0.1386 -0.1288 -0.0571 -0.2316 -0.0961 -0.0364 -0.0725 -0.1408 -0.2420 -0.7646 -0.5103 -0.1272 -0.1543 -0.1537
S-1024	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1024	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-1024	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
D-1024	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
P-1024	-0.0460 -0.1466 -0.4228 -0.1698 -0.1579 -1.1539 -0.1649 -0.1211 -0.0463 -0.1344 -0.1925 -0.1114 -0.0964 -0.1457 -0.1462 -0.2831 -0.1285 -0.4043 -0.1560 -0.1195 -0.1417 -0.1979 -0.8319 -0.0816 -0.2799 -0.2593 -0.1696 -0.2578 -0.7803 -0.0928 -0.5796 -0.1312 -0.1126 -0.0609 -0.1525 -0.1885 -0.4659 -0.1015 -0.0358 -0.1301 -0.4365 -0.1415 -0.1160 -0.1457 -0.2291 -0.1217 -0.0844 -0.3361 -0.1236 -0.0812 -0.1110 -0.1397 -0.2961 -0.1264 -0.1151 -0.0384 -0.1463 -0.2956 -0.1005 -0.0602 -0.1294 -0.0805 -1.2386
S-1200	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1200	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-1200	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
D-1200	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
P-1200	-0.0460 -0.1466 -0.4228 -0.1698 -0.1579 -1.1539 -0.1649 -0.1211 -0.0463 -0.1344 -0.1925 -0.1114 -0.0964 -0.1457 -0.1462 -0.2831 -0.1285 -0.4043 -0.1560 -0.1195 -0.1417 -0.1979 -0.8319 -0.0816 -0.2799 -0.2593 -0.1696 -0.2578 -0.7803 -0.0928 -0.5796 -0.1312 -0.1126 -0.0609 -0.1525 -0.1885 -0.4659 -0.1015 -0.0358 -0.1301 -0.4365 -0.1415 -0.1160 -0.1457 -0.2291 -0.1217 -0.0844 -0.3361 -0.1236 -0.0812 -0.1110 -0.1397 -0.2961 -0.1264 -0.1151 -0.0384 -0.1463 -0.2956 -0.1005 -0.0602 -0.1294 -0.0805 -1.2386
S-1376	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1376	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-1376	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
D-1376	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
P-1376	-0.0460 -0.1466 -0.4228 -0.1698 -0.1579 -1.1539 -0.1649 -0.1211 -0.0463 -0.1344 -0.1925 -0.1114 -0.0964 -0.1457 -0.1462 -0.2831 -0.1285 -0.4043 -0.1560 -0.1195 -0.1417 -0.1979 -0.8319 -0.0816 -0.2799 -0.2593 -0.1696 -0.2578 -0.7803 -0.0928 -0.5796 -0.1312 -0.1126 -0.0609 -0.1525 -0.1885 -0.4659 -0.1015 -0.0358 -0.1301 -0.4365 -0.1415 -0.1160 -0.1457 -0.2291 -0.1217 -0.0844 -0.3361 -0.1236 -0.0812 -0.1110 -0.1397 -0.2961 -0.1264 -0.1151 -0.0384 -0.1463 -0.2956 -0.1005 -0.0602 -0.1294 -0.0805 -1.2386
S-848	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-848	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-848	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
D-848	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
P-848	-0.0460 -0.1466 -0.4228 -0.1698 -0.1579 -1.1539 -0.1649 -0.1211 -0.0463 -0.1344 -0.1925 -0.1114 -0.0964 -0.1457 -0.1462 -0.2831 -0.1285 -0.4043 -0.1560 -0.1195 -0.1417 -0.1979 -0.8319 -0.0816 -0.2799 -0.2593 -0.1696 -0.2578 -0.7803 -0.0928 -0.5796 -0.1312 -0.1126 -0.0609 -0.1525 -0.1885 -0.4659 -0.1015 -0.0358 -0.1301 -0.4365 -0.1415 -0.1160 -0.1457 -0.2291 -0.1217 -0.0844 -0.3361 -0.1236 -0.0812 -0.1110 -0.1397 -0.2961 -0.1264 -0.1151 -0.0384 -0.1463 -0.2956 -0.1005 -0.0602 -0.1294 -0.0805 -1.2386
S-672	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-672	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-672	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
D-672	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
P-672	-0.0460 -0.1466 -0.4228 -0.1698 -0.1579 -1.1539 -0.1649 -0.1211 -0.0463 -0.1344 -0.1925 -0.1114 -0.0964 -0.1457 -0.1462 -0.2831 -0.1285 -0.4043 -0.1560 -0.1195 -0.1417 -0.1979 -0.8319 -0.0816 -0.2799 -0.2593 -0.1696 -0.2578 -0.7803 -0.0928 -0.5796 -0.1312 -0.1126 -0.0609 -0.1525 -0.1885 -0.4659 -0.1015 -0.0358 -0.1301 -0.4365 -0.1415 -0.1160 -0.1457 -0.2291 -0.1217 -0.0844 -0.3361 -0.1236 -0.0812 -0.1110 -0.1397 -0.2961 -0.1264 -0.1151 -0.0384 -0.1463 -0.2956 -0.1005 -0.0602 -0.1294 -0.0805 -1.2386
S-1553	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1553	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-1553	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
D-1553	-0.22368907928466797	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) *
P-1553	-0.0460 -0.1466 -0.4228 -0.1698 -0.1579 -1.1539 -0.1649 -0.1211 -0.0463 -0.1344 -0.1925 -0.1114 -0.0964 -0.1457 -0.1462 -0.2831 -0.1285 -0.4043 -0.1560 -0.1195 -0.1417 -0.1979 -0.8319 -0.0816 -0.2799 -0.2593 -0.1696 -0.2578 -0.7803 -0.0928 -0.5796 -0.1312 -0.1126 -0.0609 -0.1525 -0.1885 -0.4659 -0.1015 -0.0358 -0.1301 -0.4365 -0.1415 -0.1160 -0.1457 -0.2291 -0.1217 -0.0844 -0.3361 -0.1236 -0.0812 -0.1110 -0.1397 -0.2961 -0.1264 -0.1151 -0.0384 -0.1463 -0.2956 -0.1005 -0.0602 -0.1294 -0.0805 -1.2386
S-381	Die Hauptwirkung von 1,25-Dihydroxyvitamin D3 ist die Erhöhung der intestinalen Resorption von Calcium und Phosphat sowie die Regulierung von Serum-Calcium , der renalen Ausscheidung von Calcium und von Phosphat , der Knochenbildung und Knochenresorption .
T-381	The principal action of 1,25-dihydroxyvitamin D3 is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium , renal calcium and phosphate excretion , bone formation and bone resorption .
H-381	-0.22602491080760956	The main effect of 1,25 -dihydroxyvitamin D3 is to increase intestinal absorption of calcium and phosphate and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
D-381	-0.22602491080760956	The main effect of 1,25 -dihydroxyvitamin D3 is to increase intestinal absorption of calcium and phosphate and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
P-381	-0.1814 -0.3029 -0.2473 -0.1296 -0.5946 -0.4257 -1.1444 -0.1818 -0.0726 -0.1523 -0.0962 -0.1017 -0.0891 -0.1616 -0.1437 -0.1752 -0.1772 -0.0906 -0.7364 -0.0642 -0.0549 -0.3081 -0.0623 -0.1356 -0.1598 -0.1051 -0.1164 -0.1436 -0.1424 -0.0330 -0.0964 -1.4759 -0.3662 -0.4938 -0.0982 -0.1877 -0.1051 -0.2005 -0.1004 -0.1108 -0.1589 -0.2448 -0.1040 -0.5826 -0.0230 -0.1092 -0.1312 -0.1647 -0.1163 -0.1245 -0.1416 -0.1385 -0.0343 -0.0968 -0.1493 -0.1629 -0.1159 -0.1934 -0.9500 -0.4168 -0.1761 -0.0479 -0.1590 -0.1591
S-410	Die Wirkungen von Alendronat auf Knochenmasse und Frakturinzidenz bei postmenopausalen Frauen wurden in zwei Phase-III-Studien von identischem Design ( n<unk> 944 ) sowie in der Fraktur-Interventions- Studie ( FIT : n<unk> 6.459 ) untersucht .
T-410	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were examined in two initial efficacy studies of identical design ( n<<unk>> 994 ) as well as in the Fracture Intervention Trial ( FIT : n<<unk>> 6,459 ) .
H-410	-0.2973591089248657	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were investigated in two identical design Phase II ( n/ 944 ) and Fracture Intervention ( FIT : n/ 6,459 ) studies .
D-410	-0.2973591089248657	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were investigated in two identical design Phase II ( n/ 944 ) and Fracture Intervention ( FIT : n/ 6,459 ) studies .
P-410	-0.4380 -0.8902 -0.1296 -0.1803 -0.1116 -0.1236 -0.0902 -0.0982 -0.0331 -0.1102 -0.1397 -0.6671 -0.0384 -0.0954 -0.0802 -0.1512 -0.1200 -0.2974 -0.0720 -0.0939 -0.0410 -0.1181 -0.0855 -0.3829 -0.6754 -0.1338 -0.2238 -1.2220 -0.1752 -0.7305 -0.6374 -2.1164 -1.2580 -0.1528 -0.8183 -0.1484 -0.1074 -0.1295 -0.1982 -0.2349 -0.0414 -0.1106 -0.0361 -0.2231 -0.1299 -0.0957 -0.1490 -0.1744 -0.1579 -0.3477 -0.1245 -0.0865 -0.1234 -0.9605 -0.1874 -0.1540
S-325	Jedoch wurden selten Fälle symptomatischer Hypocalcämie berichtet , manche auch 15 schwer , die oft bei Patienten mit entsprechenden prädisponierenden Faktoren auftraten ( z. B. Hypoparathyreoidismus , Vitamin-D-Mangel und Calcium-Malabsorption ) ( siehe Abschnitt 4.8 ) .
T-325	However , there have been rare reports of symptomatic hypocalcaemia , which have occasionally been severe and often occurred in patients with predisposing conditions ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
H-325	-0.2716805636882782	However , rare cases of symptomatic hypocalcaemia , some severe even 15 , were reported , often in patients with appropriate predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
D-325	-0.2716805636882782	However , rare cases of symptomatic hypocalcaemia , some severe even 15 , were reported , often in patients with appropriate predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
P-325	-0.3054 -0.1490 -0.7377 -0.1031 -0.1370 -0.0729 -0.0795 -0.0946 -0.0160 -0.1288 -0.0816 -0.0660 -0.1261 -0.2339 -0.3372 -0.1277 -2.7064 -0.2650 -0.3803 -1.4730 -0.1743 -1.8150 -0.8419 -0.4007 -0.1940 -0.2509 -1.0351 -0.4644 -0.4251 -0.1121 -0.1359 -0.1744 -0.1336 -0.0857 -0.0659 -0.2821 -0.0911 -0.1139 -0.1600 -0.0924 -0.1266 -0.1985 -0.0934 -0.0800 -0.1117 -0.1409 -0.2755 -0.0380 -0.1177 -0.0536 -0.0336 -0.1252 -0.5510 -0.1526 -0.1414 -0.1307 -0.1000 -0.0807 -0.0682 -0.1403 -0.1632 -0.0904 -0.0861 -0.1158 -0.1217 -0.1401 -0.1740 -0.1534
S-193	Die Hauptwirkung von 1,25-Dihydroxyvitamin D3 ist die Erhöhung der intestinalen Resorption von Calcium und Phosphat sowie die Regulierung von Serum-Calcium , der renalen Ausscheidung von Calcium und von Phosphat , der Knochenbildung und Knochenresorption .
T-193	The principal action of 1,25-dihydroxyvitamin D3 is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium , renal calcium and phosphate excretion , bone formation and bone resorption .
H-193	-0.22602491080760956	The main effect of 1,25 -dihydroxyvitamin D3 is to increase intestinal absorption of calcium and phosphate and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
D-193	-0.22602491080760956	The main effect of 1,25 -dihydroxyvitamin D3 is to increase intestinal absorption of calcium and phosphate and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
P-193	-0.1814 -0.3029 -0.2473 -0.1296 -0.5946 -0.4257 -1.1444 -0.1818 -0.0726 -0.1523 -0.0962 -0.1017 -0.0891 -0.1616 -0.1437 -0.1752 -0.1772 -0.0906 -0.7364 -0.0642 -0.0549 -0.3081 -0.0623 -0.1356 -0.1598 -0.1051 -0.1164 -0.1436 -0.1424 -0.0330 -0.0964 -1.4759 -0.3662 -0.4938 -0.0982 -0.1877 -0.1051 -0.2005 -0.1004 -0.1108 -0.1589 -0.2448 -0.1040 -0.5826 -0.0230 -0.1092 -0.1312 -0.1647 -0.1163 -0.1245 -0.1416 -0.1385 -0.0343 -0.0968 -0.1493 -0.1629 -0.1159 -0.1934 -0.9500 -0.4168 -0.1761 -0.0479 -0.1590 -0.1591
S-1606	HERSTELLER DES WIRKSTOFFS BIOLOGISCHEN URSPRUNGS UND INHABER DER HERSTELLUNGSERLAUBNIS , DER FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST
T-1606	MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
H-1606	-0.36192068457603455	MANUFACTURER OF THE EFFECTIVE BIOLOGICAL ORIGINAL PRODUCT AND MANUFACTURER OF UNUSED MEDICINAL PRODUCTS
D-1606	-0.36192068457603455	MANUFACTURER OF THE EFFECTIVE BIOLOGICAL ORIGINAL PRODUCT AND MANUFACTURER OF UNUSED MEDICINAL PRODUCTS
P-1606	-0.5148 -0.0302 -0.1072 -0.0107 -0.0042 -0.0620 -0.0245 -0.1637 -0.0396 -0.2801 -0.1226 -3.5852 -0.0138 -0.3633 -1.3342 -0.3514 -0.0370 -0.4057 -0.2039 -0.0508 -0.1355 -0.1295 -0.6532 -0.2503 -1.1822 -0.0627 -2.2498 -0.0671 -0.8633 -0.0111 -0.0391 -0.0232 -0.5101 -0.0698 -0.5259 -0.0147 -0.1786 -0.0049 -0.0054 -0.0428 -0.0234 -1.2523 -0.3162 -0.3084 -1.5811 -0.0094 -0.0412 -0.0076 -0.0226 -0.0200 -0.0289 -0.0816 -0.0526 -0.0509 -0.0233 -0.0283 -0.1753 -2.2445
S-8	Adenuric wird bei Patienten angewendet , die bereits Anzeichen von Kristallablagerungen aufweisen , einschließlich Arthritis ( Schmerzen und Entzündung in den Gelenken ) oder Gichtknoten ( Steine d. h. größere Uratkristallablagerungen , die zu Gelenk- und Knochenschädigungen führen können ) .
T-8	Adenuric is used in patients who already have signs of a build-up of crystals , including arthritis ( pain and inflammation in the joints ) or tophi ( stones , larger deposits of urate crystals that can cause joint and bone damage ) .
H-8	-0.3884713649749756	Adenuric is used in patients who already show signs of crystal deposits , including arthritis ( pain and inflammation in the joints ) or rheumatoid nodules ( stones i. e. larger urine crystal deposits that can cause joint and bone damage ) .
D-8	-0.3884713649749756	Adenuric is used in patients who already show signs of crystal deposits , including arthritis ( pain and inflammation in the joints ) or rheumatoid nodules ( stones i. e. larger urine crystal deposits that can cause joint and bone damage ) .
P-8	-0.0912 -0.1325 -0.0828 -0.1405 -0.2061 -0.4515 -0.2110 -0.2018 -0.3070 -0.7295 -1.1110 -0.1906 -0.1255 -0.5714 -0.1446 -1.5996 -0.1555 -0.4244 -0.0833 -0.1418 -0.0808 -0.0958 -0.1462 -0.3798 -0.1331 -0.1340 -0.0777 -0.1180 -0.2668 -0.2507 -0.0394 -0.0293 -0.1275 -0.3014 -1.0943 -0.2447 -0.4761 -0.5753 -0.1589 -1.1269 -1.1595 -0.1355 -0.1483 -0.7895 -1.0034 -0.8237 -0.1106 -0.1175 -0.7351 -0.9621 -0.4616 -0.4252 -0.0991 -0.3098 -0.1553 -0.6501 -0.9346 -1.5771 -0.5890 -0.1977 -0.1020 -0.3466 -0.1436 -0.1585 -0.1568
S-214	Die Wirkungen von Alendronat auf Knochenmasse und Frakturinzidenz bei postmenopausalen Frauen wurden in zwei Phase-III-Studien von identischem Design ( n<unk> 944 ) sowie in der Fraktur-Interventions- Studie ( FIT : n<unk> 6.459 ) untersucht .
T-214	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were examined in two initial efficacy studies of identical design ( n<<unk>> 994 ) as well as in the Fracture Intervention Trial ( FIT : n<<unk>> 6,459 ) .
H-214	-0.2973591089248657	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were investigated in two identical design Phase II ( n/ 944 ) and Fracture Intervention ( FIT : n/ 6,459 ) studies .
D-214	-0.2973591089248657	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were investigated in two identical design Phase II ( n/ 944 ) and Fracture Intervention ( FIT : n/ 6,459 ) studies .
P-214	-0.4380 -0.8902 -0.1296 -0.1803 -0.1116 -0.1236 -0.0902 -0.0982 -0.0331 -0.1102 -0.1397 -0.6671 -0.0384 -0.0954 -0.0802 -0.1512 -0.1200 -0.2974 -0.0720 -0.0939 -0.0410 -0.1181 -0.0855 -0.3829 -0.6754 -0.1338 -0.2238 -1.2220 -0.1752 -0.7305 -0.6374 -2.1164 -1.2580 -0.1528 -0.8183 -0.1484 -0.1074 -0.1295 -0.1982 -0.2349 -0.0414 -0.1106 -0.0361 -0.2231 -0.1299 -0.0957 -0.1490 -0.1744 -0.1579 -0.3477 -0.1245 -0.0865 -0.1234 -0.9605 -0.1874 -0.1540
S-1964	Bei der Behandlung von folgenden Patientengruppen wird zur Vorsicht geraten : Patienten unter Digitalis Patienten mit Herzrhythmusstörungen Patienten mit Hypertonie Patienten mit einem Myokardinfarkt in der Anamnese , Diabetes mellitus , Blasenhalsobstruktion oder Bronchospasmus in der Anamnese .
T-1964	Caution should be exercised in the following patient groups : Patients receiving digitalis Patients with cardiac arrhythmias Patients with hypertension Patients with a history of myocardial infarction , diabetes mellitus , bladder neck obstruction , or positive anamnesis of bronchospasm .
H-1964	-0.3485422432422638	Caution should be exercised when treating the following populations : Digitalis patients with irregular heart rhythm Patients with hypertension Patients with a history of myocardial infarction , diabetes mellitus , bladder obstruction or a history of bronchospasm .
D-1964	-0.3485422432422638	Caution should be exercised when treating the following populations : Digitalis patients with irregular heart rhythm Patients with hypertension Patients with a history of myocardial infarction , diabetes mellitus , bladder obstruction or a history of bronchospasm .
P-1964	-0.2150 -0.0611 -0.5489 -0.1913 -0.0852 -0.1383 -0.3569 -0.5973 -0.7326 -0.0562 -1.7918 -0.0579 -0.2125 -1.7188 -0.1532 -0.2002 -0.1172 -1.9655 -0.0142 -0.4545 -0.0288 -0.9362 -1.4017 -0.0918 -0.1304 -0.0219 -0.0159 -0.3353 -0.0916 -0.1244 -0.1249 -0.5181 -0.1138 -0.0922 -0.0657 -0.0174 -0.0709 -0.0680 -0.0323 -0.0429 -0.1276 -0.0605 -0.0458 -0.1275 -0.0452 -0.1376 -0.1065 -0.2172 -0.3834 -0.0195 -0.8520 -1.8551 -0.4237 -0.1168 -0.8871 -0.1311 -0.1245 -0.0068 -0.1335 -1.3017 -0.1655
S-404	Studien mit Alendronat Die therapeutische Gleichwertigkeit von Alendronat einmal wöchentlich 70 mg ( n<unk> 519 ) und Alendronat 10 mg täglich ( n<unk> 370 ) wurde in einer Ein-Jahres-Multicenter-Studie an postmenopausalen Frauen mit Osteoporose nachgewiesen .
T-404	Alendronate studies The therapeutic equivalence of alendronate once weekly 70 mg ( n<<unk>> 519 ) and alendronate 10 mg daily ( n<<unk>> 370 ) was demonstrated in a one-year multicentre study of post-menopausal women with osteoporosis .
H-404	-0.29003798961639404	trials of alendronate The therapeutic equivalence of alendronate once weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year multicentre trial in post-menopausal women with osteoporosis .
D-404	-0.29003798961639404	trials of alendronate The therapeutic equivalence of alendronate once weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year multicentre trial in post-menopausal women with osteoporosis .
P-404	-1.1501 -0.2493 -0.1608 -0.1195 -0.1144 -0.0863 -0.9658 -0.1851 -0.1302 -0.3062 -0.0635 -0.2340 -0.1540 -0.3553 -0.1159 -0.1185 -0.0674 -2.8395 -0.1991 -1.1604 -0.0364 -0.1587 -0.1512 -0.0966 -0.1906 -0.1237 -0.1213 -0.1733 -0.3624 -0.1138 -0.1146 -0.0460 -0.1837 -0.0354 -0.2483 -0.1426 -0.1416 -0.1697 -0.0265 -0.1162 -0.8436 -0.8384 -0.1316 -0.1469 -0.6963 -0.3872 -0.0770 -0.1668 -0.1223 -1.8227 -0.2274 -0.7053 -0.2092 -0.0969 -0.3690 -0.0735 -0.1031 -0.0482 -0.1182 -0.0904 -0.1485 -0.1410 -0.0930 -0.1096 -0.1312 -0.0847 -0.0813 -0.2709 -0.1508
S-137	Jedoch wurden selten Fälle symptomatischer Hypocalcämie berichtet , manche auch schwer , die oft bei Patienten mit entsprechenden prädisponierenden Faktoren auftraten ( z. B. Hypoparathyreoidismus , Vitamin-D-Mangel und Calcium-Malabsorption ) ( siehe Abschnitt 4.8 ) .
T-137	However , there have been rare reports of symptomatic hypocalcaemia , which have occasionally been severe and often occurred in patients with predisposing conditions ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
H-137	-0.2493286430835724	However , rare cases of symptomatic hypocalcaemia , some severe , were reported , often in patients with appropriate predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
D-137	-0.2493286430835724	However , rare cases of symptomatic hypocalcaemia , some severe , were reported , often in patients with appropriate predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
P-137	-0.2742 -0.1469 -1.1731 -0.1846 -0.1701 -0.0726 -0.0795 -0.0968 -0.0232 -0.1279 -0.0790 -0.0610 -0.1271 -0.2161 -0.3379 -0.0430 -0.3746 -1.3881 -0.1971 -2.1077 -0.9422 -0.5669 -0.1890 -0.2466 -1.0190 -0.4888 -0.4707 -0.1130 -0.1433 -0.1806 -0.1337 -0.0859 -0.0644 -0.2575 -0.0862 -0.1201 -0.1602 -0.0881 -0.1230 -0.1716 -0.0955 -0.0703 -0.1089 -0.1399 -0.2447 -0.0387 -0.1152 -0.0575 -0.0335 -0.1162 -0.6501 -0.1435 -0.1415 -0.1275 -0.1018 -0.0822 -0.0666 -0.1406 -0.1647 -0.0893 -0.0896 -0.1167 -0.1206 -0.1419 -0.1735 -0.1542
S-208	Studien mit Alendronat Die therapeutische Gleichwertigkeit von Alendronat einmal wöchentlich 70 mg ( n<unk> 519 ) und Alendronat 10 mg täglich ( n<unk> 370 ) wurde in einer Ein-Jahres-Multicenter-Studie an postmenopausalen Frauen mit Osteoporose nachgewiesen .
T-208	Alendronate studies The therapeutic equivalence of alendronate once weekly 70 mg ( n<<unk>> 519 ) and alendronate 10 mg daily ( n<<unk>> 370 ) was demonstrated in a one-year multicentre study of post-menopausal women with osteoporosis .
H-208	-0.29003798961639404	trials of alendronate The therapeutic equivalence of alendronate once weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year multicentre trial in post-menopausal women with osteoporosis .
D-208	-0.29003798961639404	trials of alendronate The therapeutic equivalence of alendronate once weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year multicentre trial in post-menopausal women with osteoporosis .
P-208	-1.1501 -0.2493 -0.1608 -0.1195 -0.1144 -0.0863 -0.9658 -0.1851 -0.1302 -0.3062 -0.0635 -0.2340 -0.1540 -0.3553 -0.1159 -0.1185 -0.0674 -2.8395 -0.1991 -1.1604 -0.0364 -0.1587 -0.1512 -0.0966 -0.1906 -0.1237 -0.1213 -0.1733 -0.3624 -0.1138 -0.1146 -0.0460 -0.1837 -0.0354 -0.2483 -0.1426 -0.1416 -0.1697 -0.0265 -0.1162 -0.8436 -0.8384 -0.1316 -0.1469 -0.6963 -0.3872 -0.0770 -0.1668 -0.1223 -1.8227 -0.2274 -0.7053 -0.2092 -0.0969 -0.3690 -0.0735 -0.1031 -0.0482 -0.1182 -0.0904 -0.1485 -0.1410 -0.0930 -0.1096 -0.1312 -0.0847 -0.0813 -0.2709 -0.1508
S-40	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass Adenuric bei der Senkung des Harnsäurespiegels im Blut wirksamer war als Allopurinol , dafür aber auch ein höheres Risiko von Nebenwirkungen im Zusammenhang mit dem Herzen und den Blutgefäßen bergen könnte .
T-40	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that Adenuric was more effective than allopurinol at lowering blood uric acid levels , but that it could carry a greater risk of side effects affecting the heart and blood vessels .
H-40	-0.3769546151161194	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that while Adenuric was more effective at lowering uric acid levels in the blood than allopurinol , it could also increase the risk of heart and vascular adverse reactions .
D-40	-0.3769546151161194	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that while Adenuric was more effective at lowering uric acid levels in the blood than allopurinol , it could also increase the risk of heart and vascular adverse reactions .
P-40	-0.2137 -0.1327 -0.1551 -0.2623 -0.1006 -0.1040 -0.1379 -0.1395 -0.2180 -0.0792 -0.1218 -0.0676 -0.0673 -0.1197 -0.7076 -0.1418 -1.3306 -0.3758 -0.1546 -0.0784 -0.1164 -0.3901 -0.2246 -0.2059 -2.1196 -0.8579 -0.0939 -0.1746 -0.0790 -0.1343 -1.1357 -0.2344 -0.1722 -0.0686 -0.1188 -0.2097 -0.0941 -0.1688 -0.1340 -0.2971 -0.1352 -1.6716 -0.1207 -2.8498 -0.2375 -0.1766 -0.1243 -0.6529 -0.1855 -1.1435 -0.0963 -0.0266 -1.4079 -0.0950 -0.8498 -0.0178 -0.1822 -0.1522
S-411	In den Phase-III-Studien betrugen die mittleren Anstiege der BMD mit Alendronat 10 mg<unk> Tag im Verhältnis zu Plazebo nach 3 Jahren 8,8 % an der Wirbelsäule , 5,9 % am Femurhals und 7,8 % am Trochanter .
T-411	In the initial efficacy studies , the mean BMD increases with alendronate 10 mg/ day relative to placebo at three years were 8.8 % , 5.9 % and 7.8 % at the spine , femoral neck and trochanter , respectively .
H-411	-0.31485411524772644	In the Phase III-1 trials , mean increases in BMD with alendronate were 10 mg/ day versus placebo at 3 years , 8.8 % in the spine , 5.9 % in the femoral neck , and 7.8 % in the trochanter .
D-411	-0.31485411524772644	In the Phase III-1 trials , mean increases in BMD with alendronate were 10 mg/ day versus placebo at 3 years , 8.8 % in the spine , 5.9 % in the femoral neck , and 7.8 % in the trochanter .
P-411	-0.2557 -1.4569 -0.5090 -0.2858 -0.1590 -0.9644 -0.4707 -1.6869 -0.5855 -0.1967 -0.2331 -0.3453 -0.3499 -0.0971 -0.1443 -0.4375 -0.1217 -0.1070 -0.1321 -0.0724 -0.3616 -0.2734 -0.1622 -0.1527 -0.1677 -0.3070 -0.6890 -0.0376 -0.1308 -0.1727 -0.1318 -1.0057 -0.2729 -0.1019 -2.1148 -0.1711 -0.1263 -0.1159 -0.8234 -0.2099 -0.1269 -0.2849 -0.1331 -0.0729 -0.1142 -0.0913 -0.1510 -0.1506 -0.0828 -0.2303 -0.1367 -0.4285 -0.1275 -0.0730 -0.1278 -0.0943 -0.1986 -0.1532 -0.1059 -0.2311 -0.2129 -0.2164 -0.1522
S-1616	Pharmakovigilanz-System Der Zulassungsinhaber muss sicherstellen , dass ein Pharmakovigilanz-System , wie im Abschnitt 1.1 des Kapitels 1.8.1 der Arzneimittelzulassung beschrieben , eingerichtet wurde und dass dieses System während des gesamten Zeitraumes , in dem sich das Produkt auf dem Markt befindet , in Kraft bleibt .
T-1616	Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance , as described in version 1.1 presented in Module 1.8.1 . of the Marketing Authorisation , is in place and functioning before and whilst the product is on the market .
H-1616	-0.4530372619628906	Pharmacovigilance The holder of the authorisation must ensure that a pharmacovigilance system as described in section 1.1 of section 1.8.1 of the authorisation for medicinal products has been put in place and that this system remains in place for the entire period during which the product is on the market .
D-1616	-0.4530372619628906	Pharmacovigilance The holder of the authorisation must ensure that a pharmacovigilance system as described in section 1.1 of section 1.8.1 of the authorisation for medicinal products has been put in place and that this system remains in place for the entire period during which the product is on the market .
P-1616	-1.7664 -0.1306 -0.1013 -0.1602 -0.0841 -0.2155 -0.2940 -1.5144 -1.6737 -1.0739 -0.2663 -0.2137 -0.0384 -0.8419 -0.1281 -0.1561 -0.1650 -0.5298 -0.1455 -0.1158 -0.2476 -0.3392 -0.5096 -1.1627 -0.4124 -0.1377 -0.2246 -0.0895 -0.2318 -1.9275 -0.1315 -0.0916 -0.1413 -0.1836 -0.2487 -0.2953 -0.0659 -2.2233 -0.2852 -0.2541 -0.1273 -0.5261 -0.1319 -1.6920 -0.0781 -0.1991 -0.2225 -0.2586 -0.6842 -0.2780 -0.5899 -0.1346 -0.5422 -0.8361 -0.2079 -0.8913 -1.1025 -1.0351 -0.1778 -0.1777 -0.1357 -0.2569 -0.3861 -0.1582 -0.3524 -0.2002 -0.1534
S-51	ADROVANCE ist eine weiße Tablette in Kapselform , die zwei arzneilich wirksame Bestandteile enthält : Natriumalendronat 3 H2O ( 70 mg ) und Colecalciferol ( Vitamin D3 , 70 Mikrogramm entsprechend 2800 internationalen Einheiten I.E . ) .
T-51	ADROVANCE is a white capsule-shaped tablet containing two active substances : alendronate sodium trihydrate ( 70 mg ) and colecalciferol ( vitamin D3 , 70 micrograms equivalent to 2,800 international units ) .
H-51	-0.2004367858171463	ADROVANCE is a white capsule tablet containing two active ingredients : sodium alendronate 3 H2O ( 70 mg ) and colecalciferol ( vitamin D3 , 70 micrograms equivalent to 2800 international units IU ) .
D-51	-0.2004367858171463	ADROVANCE is a white capsule tablet containing two active ingredients : sodium alendronate 3 H2O ( 70 mg ) and colecalciferol ( vitamin D3 , 70 micrograms equivalent to 2800 international units IU ) .
P-51	-0.1314 -0.0597 -0.1259 -0.1001 -0.0808 -0.1450 -0.1381 -0.2874 -1.1314 -0.0874 -0.1968 -0.2700 -0.1241 -0.9418 -0.1972 -0.0412 -0.5805 -0.2242 -0.1454 -0.1140 -0.1696 -0.2324 -0.2288 -0.1410 -0.2709 -0.1648 -0.1431 -0.1296 -0.1543 -0.2520 -0.0380 -0.1328 -0.1780 -0.0952 -0.1612 -0.1795 -0.1088 -0.1245 -0.1160 -0.1486 -0.1412 -0.0775 -0.1397 -0.1492 -0.2173 -0.1152 -0.1067 -0.0889 -0.4049 -0.1293 -0.1341 -0.0986 -0.1311 -0.5736 -0.5222 -0.0444 -0.1448 -0.1534 -0.1622
S-1924	Aerinaze darf bei Patienten , die möglicherweise überempfindlich ( allergisch ) gegen Desloratadin , Pseudoephedrin oder einen der anderen Bestandteile , gegen adrenerge Wirkstoffe oder Loratadin ( ein anderes Arzneimittel zur Behandlung von Allergien ) sind , nicht angewendet werden .
T-1924	Aerinaze should not be used in people who may be hypersensitive ( allergic ) to desloratadine , pseudoephedrine or any of the other ingredients , to adrenergic agents or to loratadine ( another medicine used to treat allergies ) .
H-1924	-0.261583536863327	Aerinaze should not be used in patients who may be hypersensitive ( allergic ) to desloratadine , pseudoephedrine or any of the other ingredients , adrenergic agents or loratadine ( another medicinal product used to treat allergies ) .
D-1924	-0.261583536863327	Aerinaze should not be used in patients who may be hypersensitive ( allergic ) to desloratadine , pseudoephedrine or any of the other ingredients , adrenergic agents or loratadine ( another medicinal product used to treat allergies ) .
P-1924	-0.9088 -0.1322 -0.1473 -0.1440 -0.0866 -0.5386 -0.1446 -0.1328 -0.2348 -0.1519 -0.3340 -0.1620 -0.2531 -0.2008 -0.0665 -0.1273 -0.2552 -0.1909 -0.0261 -0.2505 -0.1345 -0.4331 -0.0607 -0.1221 -0.2484 -0.4887 -0.1437 -0.0955 -0.1507 -0.1485 -0.0519 -0.1326 -0.1501 -0.1382 -0.2271 -0.5238 -0.1401 -0.2330 -0.4286 -0.1144 -0.1464 -0.9334 -0.1027 -0.1229 -0.0937 -0.0246 -0.7097 -0.2002 -0.1219 -0.1164 -1.6168 -0.2213 -0.0810 -2.0671 -0.0856 -0.0724 -0.2095 -0.2141 -0.0421 -0.1925 -0.2224 -0.1424 -0.1889 -0.1599
S-142	Patienten mit der seltenen hereditären Fructose-Intoleranz , Galactose-Intoleranz , Lactase-Mangel , Glucose-Galactose-Malabsorption oder Sucrase-Isomaltase-Insuffizienz sollten dieses Arzneimittel nicht einnehmen .
T-142	Patients with rare hereditary problems of fructose intolerance , galactose intolerance , the Lapp lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product .
H-142	-0.199575737118721	Patients with rare hereditary fructose intolerance , galactose intolerance , lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine .
D-142	-0.199575737118721	Patients with rare hereditary fructose intolerance , galactose intolerance , lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine .
P-142	-0.3866 -0.0950 -0.1440 -0.5798 -0.0579 -0.0690 -0.0202 -0.0738 -0.0830 -0.0379 -0.0309 -0.0589 -0.2072 -0.1389 -0.2952 -0.1064 -0.0454 -0.0712 -0.0493 -0.1425 -0.1427 -0.1475 -0.0710 -0.0660 -0.0536 -0.0452 -0.1013 -0.1434 -0.0378 -0.3743 -0.5850 -0.2706 -0.1038 -0.0959 -0.0325 -0.0462 -0.0738 -0.0645 -0.7450 -1.0501 -0.3179 -0.7352 -0.2176 -0.0616 -0.0609 -0.0630 -0.1065 -1.2808 -0.0633 -0.0533 -0.0919 -0.1378 -0.1755 -0.2232 -0.1204 -0.5655 -0.2024 -0.1551
S-330	Patienten mit der seltenen hereditären Fructose-Intoleranz , Galactose-Intoleranz , Lactase-Mangel , Glucose-Galactose-Malabsorption oder Sucrase-Isomaltase-Insuffizienz sollten dieses Arzneimittel nicht einnehmen .
T-330	Patients with rare hereditary problems of fructose intolerance , galactose intolerance , the Lapp lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product .
H-330	-0.199575737118721	Patients with rare hereditary fructose intolerance , galactose intolerance , lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine .
D-330	-0.199575737118721	Patients with rare hereditary fructose intolerance , galactose intolerance , lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine .
P-330	-0.3866 -0.0950 -0.1440 -0.5798 -0.0579 -0.0690 -0.0202 -0.0738 -0.0830 -0.0379 -0.0309 -0.0589 -0.2072 -0.1389 -0.2952 -0.1064 -0.0454 -0.0712 -0.0493 -0.1425 -0.1427 -0.1475 -0.0710 -0.0660 -0.0536 -0.0452 -0.1013 -0.1434 -0.0378 -0.3743 -0.5850 -0.2706 -0.1038 -0.0959 -0.0325 -0.0462 -0.0738 -0.0645 -0.7450 -1.0501 -0.3179 -0.7352 -0.2176 -0.0616 -0.0609 -0.0630 -0.1065 -1.2808 -0.0633 -0.0533 -0.0919 -0.1378 -0.1755 -0.2232 -0.1204 -0.5655 -0.2024 -0.1551
S-215	In den Phase-III-Studien betrugen die mittleren Anstiege der BMD mit Alendronat 10 mg<unk> Tag im Verhältnis zu Plazebo nach 3 Jahren 8,8 % an der Wirbelsäule , 5,9 % am Femurhals und 7,8 % am Trochanter .
T-215	In the initial efficacy studies , the mean BMD increases with alendronate 10 mg/ day relative to placebo at three years were 8.8 % , 5.9 % and 7.8 % at the spine , femoral neck and trochanter , respectively .
H-215	-0.31485411524772644	In the Phase III-1 trials , mean increases in BMD with alendronate were 10 mg/ day versus placebo at 3 years , 8.8 % in the spine , 5.9 % in the femoral neck , and 7.8 % in the trochanter .
D-215	-0.31485411524772644	In the Phase III-1 trials , mean increases in BMD with alendronate were 10 mg/ day versus placebo at 3 years , 8.8 % in the spine , 5.9 % in the femoral neck , and 7.8 % in the trochanter .
P-215	-0.2557 -1.4569 -0.5090 -0.2858 -0.1590 -0.9644 -0.4707 -1.6869 -0.5855 -0.1967 -0.2331 -0.3453 -0.3499 -0.0971 -0.1443 -0.4375 -0.1217 -0.1070 -0.1321 -0.0724 -0.3616 -0.2734 -0.1622 -0.1527 -0.1677 -0.3070 -0.6890 -0.0376 -0.1308 -0.1727 -0.1318 -1.0057 -0.2729 -0.1019 -2.1148 -0.1711 -0.1263 -0.1159 -0.8234 -0.2099 -0.1269 -0.2849 -0.1331 -0.0729 -0.1142 -0.0913 -0.1510 -0.1506 -0.0828 -0.2303 -0.1367 -0.4285 -0.1275 -0.0730 -0.1278 -0.0943 -0.1986 -0.1532 -0.1059 -0.2311 -0.2129 -0.2164 -0.1522
S-810	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-810	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-810	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
D-810	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
P-810	-0.1496 -0.1208 -0.5306 -0.6027 -0.3377 -0.3275 -0.3633 -0.4629 -0.1130 -2.3046 -0.1832 -0.4613 -0.1407 -1.4694 -0.3380 -0.1853 -0.1391 -0.1027 -0.0699 -0.1349 -0.2872 -0.1274 -0.1193 -0.5463 -0.2918 -0.8761 -0.1389 -0.1872 -0.9372 -1.1106 -0.0346 -0.0999 -0.1194 -0.4489 -1.7412 -0.0671 -0.3797 -0.4675 -0.2617 -0.1362 -1.3398 -1.1002 -0.4583 -0.4751 -0.4847 -0.3100 -0.2010 -0.1487 -0.2308 -0.7555 -0.1474 -0.1990 -0.1559 -0.1344 -0.2928 -0.1648 -0.0745 -0.1715 -0.2119 -0.1552
S-986	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-986	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-986	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
D-986	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
P-986	-0.1496 -0.1208 -0.5306 -0.6027 -0.3377 -0.3275 -0.3633 -0.4629 -0.1130 -2.3046 -0.1832 -0.4613 -0.1407 -1.4694 -0.3380 -0.1853 -0.1391 -0.1027 -0.0699 -0.1349 -0.2872 -0.1274 -0.1193 -0.5463 -0.2918 -0.8761 -0.1389 -0.1872 -0.9372 -1.1106 -0.0346 -0.0999 -0.1194 -0.4489 -1.7412 -0.0671 -0.3797 -0.4675 -0.2617 -0.1362 -1.3398 -1.1002 -0.4583 -0.4751 -0.4847 -0.3100 -0.2010 -0.1487 -0.2308 -0.7555 -0.1474 -0.1990 -0.1559 -0.1344 -0.2928 -0.1648 -0.0745 -0.1715 -0.2119 -0.1552
S-1338	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-1338	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-1338	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
D-1338	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
P-1338	-0.1496 -0.1208 -0.5306 -0.6027 -0.3377 -0.3275 -0.3633 -0.4629 -0.1130 -2.3046 -0.1832 -0.4613 -0.1407 -1.4694 -0.3380 -0.1853 -0.1391 -0.1027 -0.0699 -0.1349 -0.2872 -0.1274 -0.1193 -0.5463 -0.2918 -0.8761 -0.1389 -0.1872 -0.9372 -1.1106 -0.0346 -0.0999 -0.1194 -0.4489 -1.7412 -0.0671 -0.3797 -0.4675 -0.2617 -0.1362 -1.3398 -1.1002 -0.4583 -0.4751 -0.4847 -0.3100 -0.2010 -0.1487 -0.2308 -0.7555 -0.1474 -0.1990 -0.1559 -0.1344 -0.2928 -0.1648 -0.0745 -0.1715 -0.2119 -0.1552
S-636	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-636	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-636	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
D-636	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
P-636	-0.1496 -0.1208 -0.5306 -0.6027 -0.3377 -0.3275 -0.3633 -0.4629 -0.1130 -2.3046 -0.1832 -0.4613 -0.1407 -1.4694 -0.3380 -0.1853 -0.1391 -0.1027 -0.0699 -0.1349 -0.2872 -0.1274 -0.1193 -0.5463 -0.2918 -0.8761 -0.1389 -0.1872 -0.9372 -1.1106 -0.0346 -0.0999 -0.1194 -0.4489 -1.7412 -0.0671 -0.3797 -0.4675 -0.2617 -0.1362 -1.3398 -1.1002 -0.4583 -0.4751 -0.4847 -0.3100 -0.2010 -0.1487 -0.2308 -0.7555 -0.1474 -0.1990 -0.1559 -0.1344 -0.2928 -0.1648 -0.0745 -0.1715 -0.2119 -0.1552
S-385	In schweren Fällen kann ein Mangel zu sekundärem Hyperparathyreoidismus , Hypophosphatämie , Schwäche der proximalen Muskulatur und Osteomalazie und so zu einem weiter erhöhten Risiko für Stürze und Knochenbrüche bei osteoporotischen Personen führen .
T-385	In severe cases , deficiency results in secondary hyperparathyroidism , hypophosphataemia , proximal muscle weakness and osteomalacia , further increasing the risk of falls and fractures in osteoporotic individuals .
H-385	-0.2791273295879364	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphatemia , proximal muscle weakness and osteomalacia , and thus to a further increased risk of falls and fractures in osteoporotic subjects .
D-385	-0.2791273295879364	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphatemia , proximal muscle weakness and osteomalacia , and thus to a further increased risk of falls and fractures in osteoporotic subjects .
P-385	-0.1946 -0.1600 -0.0474 -0.4941 -0.3164 -0.0517 -0.1564 -0.5557 -0.7621 -0.1380 -0.0806 -0.0315 -0.1667 -0.0824 -0.1227 -0.1633 -0.0934 -0.0764 -0.0981 -0.1355 -0.1887 -0.0403 -0.3881 -0.1446 -0.1561 -0.5007 -0.1189 -0.1385 -0.1568 -0.0774 -0.1171 -0.3237 -0.0125 -0.8746 -0.1001 -0.0940 -0.0822 -0.1392 -0.4201 -0.0735 -0.4922 -1.3061 -0.9205 -1.7005 -0.4757 -1.2073 -0.1312 -0.1562 -0.3520 -0.1234 -0.1412 -0.7216 -0.0565 -0.1596 -0.0883 -0.0926 -0.1087 -0.1252 -0.2763 -0.2889 -0.1546 -0.1531
S-197	In schweren Fällen kann ein Mangel zu sekundärem Hyperparathyreoidismus , Hypophosphatämie , Schwäche der proximalen Muskulatur und Osteomalazie und so zu einem weiter erhöhten Risiko für Stürze und Knochenbrüche bei osteoporotischen Personen führen .
T-197	In severe cases , deficiency results in secondary hyperparathyroidism , hypophosphataemia , proximal muscle weakness and osteomalacia , further increasing the risk of falls and fractures in osteoporotic individuals .
H-197	-0.2791273295879364	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphatemia , proximal muscle weakness and osteomalacia , and thus to a further increased risk of falls and fractures in osteoporotic subjects .
D-197	-0.2791273295879364	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphatemia , proximal muscle weakness and osteomalacia , and thus to a further increased risk of falls and fractures in osteoporotic subjects .
P-197	-0.1946 -0.1600 -0.0474 -0.4941 -0.3164 -0.0517 -0.1564 -0.5557 -0.7621 -0.1380 -0.0806 -0.0315 -0.1667 -0.0824 -0.1227 -0.1633 -0.0934 -0.0764 -0.0981 -0.1355 -0.1887 -0.0403 -0.3881 -0.1446 -0.1561 -0.5007 -0.1189 -0.1385 -0.1568 -0.0774 -0.1171 -0.3237 -0.0125 -0.8746 -0.1001 -0.0940 -0.0822 -0.1392 -0.4201 -0.0735 -0.4922 -1.3061 -0.9205 -1.7005 -0.4757 -1.2073 -0.1312 -0.1562 -0.3520 -0.1234 -0.1412 -0.7216 -0.0565 -0.1596 -0.0883 -0.0926 -0.1087 -0.1252 -0.2763 -0.2889 -0.1546 -0.1531
S-1162	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-1162	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-1162	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
D-1162	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
P-1162	-0.1496 -0.1208 -0.5306 -0.6027 -0.3377 -0.3275 -0.3633 -0.4629 -0.1130 -2.3046 -0.1832 -0.4613 -0.1407 -1.4694 -0.3380 -0.1853 -0.1391 -0.1027 -0.0699 -0.1349 -0.2872 -0.1274 -0.1193 -0.5463 -0.2918 -0.8761 -0.1389 -0.1872 -0.9372 -1.1106 -0.0346 -0.0999 -0.1194 -0.4489 -1.7412 -0.0671 -0.3797 -0.4675 -0.2617 -0.1362 -1.3398 -1.1002 -0.4583 -0.4751 -0.4847 -0.3100 -0.2010 -0.1487 -0.2308 -0.7555 -0.1474 -0.1990 -0.1559 -0.1344 -0.2928 -0.1648 -0.0745 -0.1715 -0.2119 -0.1552
S-389	Die Patienten erhielten ADROVANCE in der niedrigeren Stärke ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 350 ) oder FOSAMAX ( Alendronat ) 70 mg einmal wöchentlich ( n<unk> 332 ) ; weitere Vitamin-D-Ergänzungsmittel waren untersagt .
T-389	Patients received the lower strength ( 70 mg/ 2800 IU ) of ADROVANCE ( n<<unk>> 350 ) or FOSAMAX ( alendronate ) 70 mg ( n<<unk>> 332 ) once a week ; additional vitamin
H-389	-0.29588189721107483	Patients were receiving lower strength ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 350 ) or FOSAMAX ( alendronate ) 70 mg once weekly ( n/ 332 ) , with no other vitamin D supplements .
D-389	-0.29588189721107483	Patients were receiving lower strength ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 350 ) or FOSAMAX ( alendronate ) 70 mg once weekly ( n/ 332 ) , with no other vitamin D supplements .
P-389	-1.0523 -0.0989 -1.3248 -0.2048 -0.6908 -1.2529 -0.5938 -0.0522 -0.1319 -0.1106 -0.0709 -0.1250 -0.1523 -0.1164 -0.1560 -0.0558 -0.2790 -0.1005 -0.1116 -0.1059 -0.1403 -0.1617 -0.1675 -0.0825 -0.2227 -0.1225 -0.2043 -0.2081 -0.1097 -0.1103 -0.1472 -0.0951 -0.1412 -0.1815 -0.1001 -0.1417 -0.0582 -0.1305 -0.8135 -0.0242 -0.5868 -0.2034 -0.1358 -0.1391 -0.1175 -0.1077 -0.1150 -0.1212 -1.1781 -1.6864 -0.6106 -0.5360 -0.3205 -0.0803 -0.2292 -0.0887 -0.3039 -0.5934 -0.1537
S-1515	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-1515	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-1515	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
D-1515	-0.4021064341068268	a ) The percentage of patients was calculated using the sum of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperatively ( 10 - 14 postoperatively ) in a continuous ADVATE infusion patient .
P-1515	-0.1496 -0.1208 -0.5306 -0.6027 -0.3377 -0.3275 -0.3633 -0.4629 -0.1130 -2.3046 -0.1832 -0.4613 -0.1407 -1.4694 -0.3380 -0.1853 -0.1391 -0.1027 -0.0699 -0.1349 -0.2872 -0.1274 -0.1193 -0.5463 -0.2918 -0.8761 -0.1389 -0.1872 -0.9372 -1.1106 -0.0346 -0.0999 -0.1194 -0.4489 -1.7412 -0.0671 -0.3797 -0.4675 -0.2617 -0.1362 -1.3398 -1.1002 -0.4583 -0.4751 -0.4847 -0.3100 -0.2010 -0.1487 -0.2308 -0.7555 -0.1474 -0.1990 -0.1559 -0.1344 -0.2928 -0.1648 -0.0745 -0.1715 -0.2119 -0.1552
S-642	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-642	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-642	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-642	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-642	-1.6646 -0.0599 -0.1235 -1.0830 -0.2788 -0.2238 -1.2484 -0.4617 -0.1082 -0.0427 -0.0767 -0.1911 -0.7072 -1.6237 -0.0789 -0.1607 -0.3066 -0.1306 -0.2944 -0.0973 -0.1110 -0.0250 -0.0501 -0.1086 -0.1916 -2.2713 -0.1178 -0.2028 -0.0797 -0.5729 -0.0894 -1.1998 -0.7940 -0.2200 -0.1924 -0.3161 -0.2264 -0.2826 -0.2247 -0.0549 -0.0777 -0.1290 -0.1406 -0.1915 -0.1678 -0.1078 -0.1078 -0.1426 -0.1339 -0.6755 -0.3068 -0.0685 -0.1413 -0.5078 -0.3012 -0.9715 -0.4447 -0.3252 -0.1232 -0.1254 -0.1370 -0.0890 -0.1493 -0.1700 -0.1521
S-816	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-816	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-816	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-816	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-816	-1.6646 -0.0599 -0.1235 -1.0830 -0.2788 -0.2238 -1.2484 -0.4617 -0.1082 -0.0427 -0.0767 -0.1911 -0.7072 -1.6237 -0.0789 -0.1607 -0.3066 -0.1306 -0.2944 -0.0973 -0.1110 -0.0250 -0.0501 -0.1086 -0.1916 -2.2713 -0.1178 -0.2028 -0.0797 -0.5729 -0.0894 -1.1998 -0.7940 -0.2200 -0.1924 -0.3161 -0.2264 -0.2826 -0.2247 -0.0549 -0.0777 -0.1290 -0.1406 -0.1915 -0.1678 -0.1078 -0.1078 -0.1426 -0.1339 -0.6755 -0.3068 -0.0685 -0.1413 -0.5078 -0.3012 -0.9715 -0.4447 -0.3252 -0.1232 -0.1254 -0.1370 -0.0890 -0.1493 -0.1700 -0.1521
S-992	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-992	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-992	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-992	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-992	-1.6646 -0.0599 -0.1235 -1.0830 -0.2788 -0.2238 -1.2484 -0.4617 -0.1082 -0.0427 -0.0767 -0.1911 -0.7072 -1.6237 -0.0789 -0.1607 -0.3066 -0.1306 -0.2944 -0.0973 -0.1110 -0.0250 -0.0501 -0.1086 -0.1916 -2.2713 -0.1178 -0.2028 -0.0797 -0.5729 -0.0894 -1.1998 -0.7940 -0.2200 -0.1924 -0.3161 -0.2264 -0.2826 -0.2247 -0.0549 -0.0777 -0.1290 -0.1406 -0.1915 -0.1678 -0.1078 -0.1078 -0.1426 -0.1339 -0.6755 -0.3068 -0.0685 -0.1413 -0.5078 -0.3012 -0.9715 -0.4447 -0.3252 -0.1232 -0.1254 -0.1370 -0.0890 -0.1493 -0.1700 -0.1521
S-1168	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-1168	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-1168	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-1168	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-1168	-1.6646 -0.0599 -0.1235 -1.0830 -0.2788 -0.2238 -1.2484 -0.4617 -0.1082 -0.0427 -0.0767 -0.1911 -0.7072 -1.6237 -0.0789 -0.1607 -0.3066 -0.1306 -0.2944 -0.0973 -0.1110 -0.0250 -0.0501 -0.1086 -0.1916 -2.2713 -0.1178 -0.2028 -0.0797 -0.5729 -0.0894 -1.1998 -0.7940 -0.2200 -0.1924 -0.3161 -0.2264 -0.2826 -0.2247 -0.0549 -0.0777 -0.1290 -0.1406 -0.1915 -0.1678 -0.1078 -0.1078 -0.1426 -0.1339 -0.6755 -0.3068 -0.0685 -0.1413 -0.5078 -0.3012 -0.9715 -0.4447 -0.3252 -0.1232 -0.1254 -0.1370 -0.0890 -0.1493 -0.1700 -0.1521
S-1344	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-1344	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-1344	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-1344	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-1344	-1.6646 -0.0599 -0.1235 -1.0830 -0.2788 -0.2238 -1.2484 -0.4617 -0.1082 -0.0427 -0.0767 -0.1911 -0.7072 -1.6237 -0.0789 -0.1607 -0.3066 -0.1306 -0.2944 -0.0973 -0.1110 -0.0250 -0.0501 -0.1086 -0.1916 -2.2713 -0.1178 -0.2028 -0.0797 -0.5729 -0.0894 -1.1998 -0.7940 -0.2200 -0.1924 -0.3161 -0.2264 -0.2826 -0.2247 -0.0549 -0.0777 -0.1290 -0.1406 -0.1915 -0.1678 -0.1078 -0.1078 -0.1426 -0.1339 -0.6755 -0.3068 -0.0685 -0.1413 -0.5078 -0.3012 -0.9715 -0.4447 -0.3252 -0.1232 -0.1254 -0.1370 -0.0890 -0.1493 -0.1700 -0.1521
S-1521	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-1521	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-1521	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-1521	-0.3412344753742218	In addition , no FVIII inhibitor was detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-1521	-1.6646 -0.0599 -0.1235 -1.0830 -0.2788 -0.2238 -1.2484 -0.4617 -0.1082 -0.0427 -0.0767 -0.1911 -0.7072 -1.6237 -0.0789 -0.1607 -0.3066 -0.1306 -0.2944 -0.0973 -0.1110 -0.0250 -0.0501 -0.1086 -0.1916 -2.2713 -0.1178 -0.2028 -0.0797 -0.5729 -0.0894 -1.1998 -0.7940 -0.2200 -0.1924 -0.3161 -0.2264 -0.2826 -0.2247 -0.0549 -0.0777 -0.1290 -0.1406 -0.1915 -0.1678 -0.1078 -0.1078 -0.1426 -0.1339 -0.6755 -0.3068 -0.0685 -0.1413 -0.5078 -0.3012 -0.9715 -0.4447 -0.3252 -0.1232 -0.1254 -0.1370 -0.0890 -0.1493 -0.1700 -0.1521
S-1961	Die Patienten müssen darüber informiert werden , dass die Behandlung bei Auftreten einer Hypertonie oder einer Tachykardie oder von Palpitationen , Herzrhythmusstörungen , Übelkeit oder etwaigen sonstigen neurologischen Symptomen ( wie Kopfschmerzen oder einer Verstärkung der Kopfschmerzen ) abgesetzt werden muss .
T-1961	Patients should be informed that the treatment should be discontinued in case of hypertension , tachycardia , palpitations or cardiac arrhythmias , nausea or any other neurological sign ( such as headache or increased headache ) .
H-1961	-0.3307388126850128	Patients should be advised that treatment should be discontinued if hypertension or tachycardia or palpitations , irregular heart rhythm , nausea or any other neurological symptoms ( such as headache or headache aggravation ) occur .
D-1961	-0.3307388126850128	Patients should be advised that treatment should be discontinued if hypertension or tachycardia or palpitations , irregular heart rhythm , nausea or any other neurological symptoms ( such as headache or headache aggravation ) occur .
P-1961	-0.2053 -0.0982 -1.0373 -0.1342 -0.5606 -0.2409 -1.7671 -0.7240 -0.1290 -0.2584 -0.0150 -1.1440 -0.1582 -0.0284 -0.2875 -0.0464 -0.1000 -0.1396 -0.1298 -0.0558 -1.0641 -0.0567 -0.1105 -0.4429 -0.1259 -1.3032 -0.0369 -0.2854 -0.0330 -1.0035 -0.1496 -0.0608 -0.0240 -0.3477 -0.3208 -0.3129 -0.0661 -0.1497 -0.1464 -0.2115 -0.2368 -0.1636 -0.0890 -0.0404 -0.3384 -0.2011 -1.4075 -0.0215 -0.1103 -1.1582 -0.0387 -0.0703 -0.1308 -0.6666 -0.1795 -0.1577
S-1857	Li-Fraumeni-Krebs ist eine Art von Krebs , der bei Patienten mit Li- Fraumeni-Syndrom auftritt , bei dem das so genannte p53-Gen aufgrund einer Mutation defekt ist . Bei Menschen , die diese Mutation aufweisen , besteht eine höhere Wahrscheinlichkeit , an Krebs zu erkranken .
T-1857	Li-Fraumeni cancer is a type of cancer that occurs in patients with Li-Fraumeni syndrome , a condition where a gene called p53 is defective because of a mutation .
H-1857	-0.5155564546585083	Li-Fraumeni is a type of cancer that occurs in patients with Li-Fraumeni syndrome who have a mutation in a gene called p53 that makes them more likely to develop cancer .
D-1857	-0.5155564546585083	Li-Fraumeni is a type of cancer that occurs in patients with Li-Fraumeni syndrome who have a mutation in a gene called p53 that makes them more likely to develop cancer .
P-1857	-2.0968 -0.5470 -0.3275 -0.0566 -0.2962 -0.5542 -0.1582 -0.2149 -0.1228 -0.0721 -0.7235 -1.1652 -0.0640 -0.1290 -0.3643 -0.1414 -2.4561 -0.4599 -0.2724 -0.0540 -0.2869 -0.7065 -0.0428 -0.7023 -0.5177 -0.2914 -0.6873 -0.2771 -1.2333 -2.0096 -0.3026 -0.5078 -0.1738 -0.0573 -1.9493 -0.7831 -0.1669 -0.2206 -0.1371 -0.1467 -0.3406 -0.2769 -0.2367 -0.3541
S-201	Die Patienten erhielten ADROVANCE in der niedrigeren Stärke ( 70 mg <unk> 2.800 I.E. ) ( n<unk> 350 ) oder FOSAMAX ( Alendronat ) 70 mg einmal wöchentlich ( n<unk> 332 ) ; weitere Vitamin-D-Ergänzungsmittel waren untersagt .
T-201	Patients received the lower strength ( 70 mg/ 2800 IU ) of ADROVANCE ( n<<unk>> 350 ) or FOSAMAX ( alendronate ) 70 mg ( n<<unk>> 332 ) once a week ; additional vitamin D supplements
H-201	-0.3011428117752075	Patients were receiving lower strength ADROVANCE ( 70 mg / 2,800 IU ) ( n/ 350 ) or FOSAMAX ( alendronate ) 70 mg once weekly ( n/ 332 ) , with no other vitamin D supplements .
D-201	-0.3011428117752075	Patients were receiving lower strength ADROVANCE ( 70 mg / 2,800 IU ) ( n/ 350 ) or FOSAMAX ( alendronate ) 70 mg once weekly ( n/ 332 ) , with no other vitamin D supplements .
P-201	-1.0683 -0.0997 -1.3484 -0.1974 -0.7071 -1.3314 -0.4327 -0.0548 -0.1299 -0.1113 -0.0755 -0.1232 -0.2181 -0.0407 -0.4735 -0.1990 -0.0921 -0.1072 -0.0851 -0.1483 -0.1690 -0.1692 -0.0636 -0.2104 -0.1200 -0.2206 -0.2062 -0.1048 -0.1121 -0.1494 -0.0994 -0.1464 -0.1896 -0.0991 -0.1452 -0.0623 -0.1393 -0.5455 -0.0279 -0.7544 -0.2080 -0.1367 -0.1385 -0.1040 -0.1080 -0.1139 -0.1209 -1.1811 -1.6764 -0.5586 -0.5003 -0.3197 -0.0755 -0.2504 -0.0908 -0.3102 -0.6407 -0.1544
S-1898	Aerinaze wird zur Behandlung der Symptome der saisonalen allergischen Rhinitis ( Heuschnupfen , durch eine Allergie gegen Pollen hervorgerufene Entzündung der Nasenwege ) bei Patienten mit Nasenschleimhautschwellung ( verstopfter Nase ) angewendet .
T-1898	Aerinaze is used to treat the symptoms of seasonal allergic rhinitis ( hayfever , inflammation of the nasal passages caused by an allergy to pollen ) in patients who have nasal congestion ( a blocked nose ) .
H-1898	-0.29162538051605225	Aerinaze is used to treat symptoms of seasonal allergic rhinitis ( hayfever , nasal inflammation caused by allergy to pollen ) in patients with nasal swelling ( nasal congestion ) .
D-1898	-0.29162538051605225	Aerinaze is used to treat symptoms of seasonal allergic rhinitis ( hayfever , nasal inflammation caused by allergy to pollen ) in patients with nasal swelling ( nasal congestion ) .
P-1898	-0.1094 -0.1413 -0.1510 -0.1614 -0.0801 -0.1718 -0.1005 -0.1817 -0.1241 -0.3289 -0.1219 -0.2274 -0.1108 -0.0814 -0.0814 -0.1030 -0.0729 -0.1005 -0.0697 -0.1358 -0.0810 -1.1138 -0.1537 -0.1235 -0.1369 -0.7351 -0.0239 -0.2154 -2.3163 -0.0524 -0.1153 -1.4119 -0.1446 -0.9622 -0.1211 -0.1915 -0.1380 -0.1146 -0.0906 -0.1291 -0.1409 -0.7049 -0.1446 -0.0489 -0.0231 -0.1794 -0.5978 -0.1192 -0.1312 -1.3170 -0.0482 -0.1585 -0.7975 -0.8569 -0.1562 -0.1361 -0.1682 -0.1596
S-306	Eine zahnärztliche Untersuchung mit geeigneten Präventionsmaßnahmen sollte einer Behandlung mit Bisphosphonaten vorangehen , wenn die Patienten entsprechende Risikofaktoren aufweisen ( z. B. Krebs , Chemotherapie , Strahlentherapie , Kortikosteroide , schlechte Mundhygiene , Parodontitis ) .
T-306	A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontal disease ) .
H-306	-0.2568850517272949	A dental examination with appropriate preventive measures should be preceded by treatment with bisphosphonates if patients exhibit corresponding risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontitis ) .
D-306	-0.2568850517272949	A dental examination with appropriate preventive measures should be preceded by treatment with bisphosphonates if patients exhibit corresponding risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontitis ) .
P-306	-1.2300 -0.4953 -1.4207 -0.5862 -0.3523 -0.3595 -0.2345 -0.2001 -0.2515 -0.1415 -0.8733 -0.1402 -0.1789 -0.1435 -0.4944 -0.1595 -0.1133 -0.0364 -0.0571 -0.1259 -0.0673 -0.5459 -1.3177 -0.4044 -0.0423 -1.3309 -0.0960 -0.0921 -0.0394 -0.1636 -0.3118 -0.0863 -0.0567 -0.0894 -0.1398 -0.1019 -0.0435 -0.0636 -0.1403 -0.3975 -0.0710 -0.1401 -0.2025 -0.1206 -0.0786 -0.1071 -0.1410 -0.0576 -0.1389 -0.1519 -0.0778 -0.0687 -0.0699 -0.1606 -0.0964 -0.0841 -0.2531 -0.0615 -0.1340 -0.1782 -0.1519
S-1985	4 leistungsmindernde Wirkung von Alkohol jedoch nicht verstärkt . Bei den Ergebnissen des psychomotorischen Tests konnten keine signifikanten Unterschiede zwischen den mit Desloratadin und den mit Placebo behandelten Patienten festgestellt werden , unabhängig davon , ob Desloratadin alleine oder mit Alkohol eingenommen wurde .
T-1985	No significant differences were found in the psychomotor test results between desloratadine and placebo groups , whether administered alone or with alcohol .
H-1985	-0.5218884348869324	no significant differences could be detected between those receiving desloratadine and those receiving placebo , regardless of whether desloratadine was taken alone or with alcohol .
D-1985	-0.5218884348869324	no significant differences could be detected between those receiving desloratadine and those receiving placebo , regardless of whether desloratadine was taken alone or with alcohol .
P-1985	-2.5103 -0.2020 -0.2575 -1.5481 -0.1513 -1.7380 -0.0794 -0.9692 -0.8487 -0.5257 -0.4231 -0.0672 -0.1029 -0.3075 -1.2947 -0.1652 -0.0526 -0.0206 -0.0532 -0.1201 -0.1500 -0.1530 -0.3647 -1.4381 -0.1421 -0.0644 -0.4140 -0.0825 -0.1105 -0.1631 -1.8798 -0.2703 -1.8233 -0.1595 -0.1518 -0.4151 -0.1660 -0.4753 -0.4929
S-1980	Andere Wirkstoffe mit gefäßverengender Wirkung , die oral oder nasal als abschwellende Rhinologika angewendet werden ( Phenylpropanolamin , Phenylephrin , Ephedrin , Oxymetazolin , Naphazolin etc . ) :
T-1980	Other vasoconstrictors used as nasal decongestant , by oral or nasal route ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazoline ) : risk of vasoconstriction .
H-1980	-0.3090236783027649	Other vasoconstricting agents used orally or nasally as decongestant rhinologics ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazolin , etc . ) :
D-1980	-0.3090236783027649	Other vasoconstricting agents used orally or nasally as decongestant rhinologics ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazolin , etc . ) :
P-1980	-1.4285 -0.3319 -0.0228 -0.1682 -0.1113 -0.2067 -0.4886 -0.0721 -0.8134 -0.5383 -0.1294 -0.2497 -0.0947 -0.1151 -0.2006 -0.1602 -0.2691 -0.0982 -0.0758 -0.7081 -0.1627 -0.0944 -0.6804 -1.0701 -0.1443 -0.4200 -0.3328 -0.0965 -0.1597 -0.0614 -0.0595 -0.1367 -0.5897 -0.1895 -0.0603 -0.1108 -0.0588 -0.1799 -0.1389 -0.0996 -0.1364 -0.0895 -0.1152 -0.1387 -1.3606 -0.1091 -0.0816 -0.0508 -0.7676 -0.1437 -0.1908 -0.6134 -0.1093 -0.1305 -1.8860 -0.2156 -0.4684 -0.3498 -0.2491 -0.1401 -0.5245 -0.1604
S-118	Eine zahnärztliche Untersuchung mit geeigneten Präventionsmaßnahmen sollte einer Behandlung mit Bisphosphonaten vorangehen , wenn die Patienten entsprechende Risikofaktoren aufweisen ( z. B. Krebs , Chemotherapie , Strahlentherapie , Kortikosteroide , schlechte Mundhygiene , Parodontitis ) .
T-118	A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontal disease ) .
H-118	-0.2568850517272949	A dental examination with appropriate preventive measures should be preceded by treatment with bisphosphonates if patients exhibit corresponding risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontitis ) .
D-118	-0.2568850517272949	A dental examination with appropriate preventive measures should be preceded by treatment with bisphosphonates if patients exhibit corresponding risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontitis ) .
P-118	-1.2300 -0.4953 -1.4207 -0.5862 -0.3523 -0.3595 -0.2345 -0.2001 -0.2515 -0.1415 -0.8733 -0.1402 -0.1789 -0.1435 -0.4944 -0.1595 -0.1133 -0.0364 -0.0571 -0.1259 -0.0673 -0.5459 -1.3177 -0.4044 -0.0423 -1.3309 -0.0960 -0.0921 -0.0394 -0.1636 -0.3118 -0.0863 -0.0567 -0.0894 -0.1398 -0.1019 -0.0435 -0.0636 -0.1403 -0.3975 -0.0710 -0.1401 -0.2025 -0.1206 -0.0786 -0.1071 -0.1410 -0.0576 -0.1389 -0.1519 -0.0778 -0.0687 -0.0699 -0.1606 -0.0964 -0.0841 -0.2531 -0.0615 -0.1340 -0.1782 -0.1519
S-303	Osteonekrose des Kiefers , üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) , wurde bei Krebspatienten berichtet , deren Therapieregime vorwiegend intravenös verabreichte Bisphosphonate enthält .
T-303	Osteonecrosis of the jaw , generally associated with tooth extraction and/ or local infection ( including osteomyelitis ) has been reported in patients with cancer who are receiving treatment regimens including primarily intravenously administered bisphosphonates .
H-303	-0.22864417731761932	jaw osteonecrosis , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) , has been reported in cancer patients whose regimens primarily include intravenous bisphosphonates .
D-303	-0.22864417731761932	jaw osteonecrosis , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) , has been reported in cancer patients whose regimens primarily include intravenous bisphosphonates .
P-303	-0.5473 -0.2544 -0.1487 -0.0683 -0.1227 -0.0663 -0.0693 -0.0936 -0.1510 -0.3565 -0.2459 -0.1749 -0.1255 -0.0386 -0.1578 -0.1755 -0.1324 -0.0874 -0.2413 -0.4078 -0.0912 -0.1839 -0.0594 -0.1261 -0.0815 -0.1057 -0.1750 -0.0607 -0.0618 -0.1270 -0.3447 -0.3695 -0.1529 -0.1181 -0.1363 -0.1037 -0.3276 -0.1564 -0.2938 -0.4479 -1.9076 -1.1074 -0.4152 -0.0614 -0.0654 -0.6605 -0.1261 -0.0389 -0.0921 -0.0784 -0.0480 -0.1751 -0.1534
S-366	Alendronat Infolge einer oralen Überdosis können Hypocalcämie , Hypophosphatämie und Nebenwirkungen im oberen Gastrointestinaltrakt wie Magenverstimmung , Sodbrennen , Ösophagitis , Gastritis oder Ulzera auftreten .
T-366	Alendronate Hypocalcaemia , hypophosphataemia and upper gastrointestinal adverse reactions , such as upset stomach , heartburn , oesophagitis , gastritis , or ulcer , may result from oral overdose .
H-366	-0.26853257417678833	Oral overdose may result in hypocalcaemia , hypophosphatemia and upper gastrointestinal adverse reactions such as upset stomach , heartburn , oesophagitis , gastritis or ulcers .
D-366	-0.26853257417678833	Oral overdose may result in hypocalcaemia , hypophosphatemia and upper gastrointestinal adverse reactions such as upset stomach , heartburn , oesophagitis , gastritis or ulcers .
P-366	-0.8047 -0.0368 -0.1550 -0.0651 -0.3194 -0.6671 -0.1376 -0.0157 -0.1115 -0.0240 -0.0214 -0.1264 -0.1361 -0.2223 -0.0394 -0.6322 -0.1718 -0.1716 -0.3905 -0.1226 -1.0208 -0.2397 -0.0996 -0.1162 -0.5206 -0.0832 -0.0686 -2.1875 -0.0311 -0.5869 -0.0251 -0.4105 -0.1562 -0.5946 -0.1728 -0.1452 -0.0322 -0.0730 -0.1387 -0.4744 -0.0578 -0.0567 -0.0841 -0.1094 -0.0819 -0.1375 -0.2813 -0.0666 -0.0667 -0.7632 -0.1670 -0.8245 -0.1810 -0.1834 -0.1598
S-178	Alendronat Infolge einer oralen Überdosis können Hypocalcämie , Hypophosphatämie und Nebenwirkungen im oberen Gastrointestinaltrakt wie Magenverstimmung , Sodbrennen , Ösophagitis , Gastritis oder Ulzera auftreten .
T-178	Alendronate Hypocalcaemia , hypophosphataemia and upper gastrointestinal adverse reactions , such as upset stomach , heartburn , oesophagitis , gastritis , or ulcer , may result from oral overdose .
H-178	-0.26853257417678833	Oral overdose may result in hypocalcaemia , hypophosphatemia and upper gastrointestinal adverse reactions such as upset stomach , heartburn , oesophagitis , gastritis or ulcers .
D-178	-0.26853257417678833	Oral overdose may result in hypocalcaemia , hypophosphatemia and upper gastrointestinal adverse reactions such as upset stomach , heartburn , oesophagitis , gastritis or ulcers .
P-178	-0.8047 -0.0368 -0.1550 -0.0651 -0.3194 -0.6671 -0.1376 -0.0157 -0.1115 -0.0240 -0.0214 -0.1264 -0.1361 -0.2223 -0.0394 -0.6322 -0.1718 -0.1716 -0.3905 -0.1226 -1.0208 -0.2397 -0.0996 -0.1162 -0.5206 -0.0832 -0.0686 -2.1875 -0.0311 -0.5869 -0.0251 -0.4105 -0.1562 -0.5946 -0.1728 -0.1452 -0.0322 -0.0730 -0.1387 -0.4744 -0.0578 -0.0567 -0.0841 -0.1094 -0.0819 -0.1375 -0.2813 -0.0666 -0.0667 -0.7632 -0.1670 -0.8245 -0.1810 -0.1834 -0.1598
S-1458	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-1458	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-1458	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-1458	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-1458	-2.0889 -0.1429 -0.1790 -2.1889 -0.1677 -0.2489 -0.1204 -0.1747 -0.2895 -0.0594 -0.1970 -0.1343 -0.4022 -0.2670 -0.5604 -0.2616 -0.1215 -1.5137 -0.0914 -0.1366 -0.5114 -1.7393 -0.1246 -0.2071 -0.0885 -1.3794 -0.7162 -0.4231 -0.4251 -0.1049 -0.1864 -0.0952 -0.1888 -0.2543 -0.3213 -0.0226 -0.4200 -0.5526 -1.4974 -0.5509 -0.2230 -1.0192 -0.0699 -0.0882 -0.1343 -0.1365 -0.1525 -0.0522 -0.0881 -0.0254 -0.1420 -0.4073 -0.1567
S-115	Osteonekrose des Kiefers , üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) , wurde bei Krebspatienten berichtet , deren Therapieregime vorwiegend intravenös verabreichte Bisphosphonate enthält .
T-115	Osteonecrosis of the jaw , generally associated with tooth extraction and/ or local infection ( including osteomyelitis ) has been reported in patients with cancer who are receiving treatment regimens including primarily intravenously administered bisphosphonates .
H-115	-0.22864417731761932	jaw osteonecrosis , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) , has been reported in cancer patients whose regimens primarily include intravenous bisphosphonates .
D-115	-0.22864417731761932	jaw osteonecrosis , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) , has been reported in cancer patients whose regimens primarily include intravenous bisphosphonates .
P-115	-0.5473 -0.2544 -0.1487 -0.0683 -0.1227 -0.0663 -0.0693 -0.0936 -0.1510 -0.3565 -0.2459 -0.1749 -0.1255 -0.0386 -0.1578 -0.1755 -0.1324 -0.0874 -0.2413 -0.4078 -0.0912 -0.1839 -0.0594 -0.1261 -0.0815 -0.1057 -0.1750 -0.0607 -0.0618 -0.1270 -0.3447 -0.3695 -0.1529 -0.1181 -0.1363 -0.1037 -0.3276 -0.1564 -0.2938 -0.4479 -1.9076 -1.1074 -0.4152 -0.0614 -0.0654 -0.6605 -0.1261 -0.0389 -0.0921 -0.0784 -0.0480 -0.1751 -0.1534
S-1487	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-1487	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-1487	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
D-1487	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
P-1487	-0.4045 -0.3229 -0.1507 -0.2933 -0.1341 -0.1104 -0.2617 -0.1576 -0.1442 -0.1877 -0.7606 -0.1042 -0.1178 -0.9787 -0.0852 -0.1379 -1.4828 -0.5145 -0.1204 -0.3484 -0.0676 -0.0762 -0.6419 -0.5774 -0.2930 -0.4084 -0.0299 -0.0973 -0.0883 -0.1149 -0.1349 -1.5139 -0.5626 -1.0445 -0.1569 -0.1420 -0.0533 -0.0670 -0.1334 -1.3863 -0.2722 -0.4233 -2.4061 -0.2560 -0.1836 -0.3865 -0.0949 -0.0736 -0.0633 -0.1589 -0.6068 -0.3551 -1.1187 -0.1969 -0.1529 -0.2168 -0.1791 -0.1527
S-1790	In Verbindung mit Operationen Katheterinfektionen , geringere Anzahl der roten Blutkörperchen , Anschwellen von Gliedmaßen und Gelenken , verlängerte Blutung nach der Entfernung einer Drainage , verminderter Faktor-VIII-Spiegel und postoperative Hämatome .
T-1790	Related to surgery catheter-related infection , decreased red cell blood count , swelling of limbs and joints , prolonged bleeding after drain removal , decreased Factor VIII level and post-operative bruise .
H-1790	-0.35773953795433044	In conjunction with surgery , catheter infections , decreased red blood cell count , swelling of limbs and joints , prolonged bleeding after drainage removal , decreased factor VIII levels and post-operative haematoma .
D-1790	-0.35773953795433044	In conjunction with surgery , catheter infections , decreased red blood cell count , swelling of limbs and joints , prolonged bleeding after drainage removal , decreased factor VIII levels and post-operative haematoma .
P-1790	-2.4988 -0.2933 -0.0700 -0.1402 -0.4526 -0.6763 -0.1521 -0.0355 -0.1342 -1.1395 -0.0647 -0.1253 -1.6717 -0.0461 -0.1228 -0.1529 -0.0337 -0.0742 -0.1395 -0.1701 -0.0720 -0.1257 -0.1546 -0.0550 -0.1361 -0.1366 -0.0502 -0.0237 -0.1390 -0.1275 -0.1764 -0.0713 -0.3579 -0.0691 -0.9277 -0.9991 -0.2650 -0.1265 -0.3828 -0.1417 -0.1035 -0.0589 -0.1414 -0.4922 -0.9276 -1.0985 -0.8976 -0.8357 -0.1281 -0.8563 -0.3907 -0.2585 -0.0868 -0.0479 -0.8761 -0.3045 -0.1558
S-783	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-783	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-783	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
D-783	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
P-783	-0.4045 -0.3229 -0.1507 -0.2933 -0.1341 -0.1104 -0.2617 -0.1576 -0.1442 -0.1877 -0.7606 -0.1042 -0.1178 -0.9787 -0.0852 -0.1379 -1.4828 -0.5145 -0.1204 -0.3484 -0.0676 -0.0762 -0.6419 -0.5774 -0.2930 -0.4084 -0.0299 -0.0973 -0.0883 -0.1149 -0.1349 -1.5139 -0.5626 -1.0445 -0.1569 -0.1420 -0.0533 -0.0670 -0.1334 -1.3863 -0.2722 -0.4233 -2.4061 -0.2560 -0.1836 -0.3865 -0.0949 -0.0736 -0.0633 -0.1589 -0.6068 -0.3551 -1.1187 -0.1969 -0.1529 -0.2168 -0.1791 -0.1527
S-959	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-959	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-959	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
D-959	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
P-959	-0.4045 -0.3229 -0.1507 -0.2933 -0.1341 -0.1104 -0.2617 -0.1576 -0.1442 -0.1877 -0.7606 -0.1042 -0.1178 -0.9787 -0.0852 -0.1379 -1.4828 -0.5145 -0.1204 -0.3484 -0.0676 -0.0762 -0.6419 -0.5774 -0.2930 -0.4084 -0.0299 -0.0973 -0.0883 -0.1149 -0.1349 -1.5139 -0.5626 -1.0445 -0.1569 -0.1420 -0.0533 -0.0670 -0.1334 -1.3863 -0.2722 -0.4233 -2.4061 -0.2560 -0.1836 -0.3865 -0.0949 -0.0736 -0.0633 -0.1589 -0.6068 -0.3551 -1.1187 -0.1969 -0.1529 -0.2168 -0.1791 -0.1527
S-1135	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-1135	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-1135	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
D-1135	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
P-1135	-0.4045 -0.3229 -0.1507 -0.2933 -0.1341 -0.1104 -0.2617 -0.1576 -0.1442 -0.1877 -0.7606 -0.1042 -0.1178 -0.9787 -0.0852 -0.1379 -1.4828 -0.5145 -0.1204 -0.3484 -0.0676 -0.0762 -0.6419 -0.5774 -0.2930 -0.4084 -0.0299 -0.0973 -0.0883 -0.1149 -0.1349 -1.5139 -0.5626 -1.0445 -0.1569 -0.1420 -0.0533 -0.0670 -0.1334 -1.3863 -0.2722 -0.4233 -2.4061 -0.2560 -0.1836 -0.3865 -0.0949 -0.0736 -0.0633 -0.1589 -0.6068 -0.3551 -1.1187 -0.1969 -0.1529 -0.2168 -0.1791 -0.1527
S-1282	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-1282	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-1282	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-1282	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-1282	-2.0889 -0.1429 -0.1790 -2.1889 -0.1677 -0.2489 -0.1204 -0.1747 -0.2895 -0.0594 -0.1970 -0.1343 -0.4022 -0.2670 -0.5604 -0.2616 -0.1215 -1.5137 -0.0914 -0.1366 -0.5114 -1.7393 -0.1246 -0.2071 -0.0885 -1.3794 -0.7162 -0.4231 -0.4251 -0.1049 -0.1864 -0.0952 -0.1888 -0.2543 -0.3213 -0.0226 -0.4200 -0.5526 -1.4974 -0.5509 -0.2230 -1.0192 -0.0699 -0.0882 -0.1343 -0.1365 -0.1525 -0.0522 -0.0881 -0.0254 -0.1420 -0.4073 -0.1567
S-609	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-609	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-609	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
D-609	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
P-609	-0.4045 -0.3229 -0.1507 -0.2933 -0.1341 -0.1104 -0.2617 -0.1576 -0.1442 -0.1877 -0.7606 -0.1042 -0.1178 -0.9787 -0.0852 -0.1379 -1.4828 -0.5145 -0.1204 -0.3484 -0.0676 -0.0762 -0.6419 -0.5774 -0.2930 -0.4084 -0.0299 -0.0973 -0.0883 -0.1149 -0.1349 -1.5139 -0.5626 -1.0445 -0.1569 -0.1420 -0.0533 -0.0670 -0.1334 -1.3863 -0.2722 -0.4233 -2.4061 -0.2560 -0.1836 -0.3865 -0.0949 -0.0736 -0.0633 -0.1589 -0.6068 -0.3551 -1.1187 -0.1969 -0.1529 -0.2168 -0.1791 -0.1527
S-1311	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-1311	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-1311	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
D-1311	-0.3742155432701111	In previously treated patients ( PTPs ) with more than 100 exposure days and a history of inhibitor development , recurrence of ( lowtitre ) inhibitors was observed after conversion from one recombinant factor VIII product to another .
P-1311	-0.4045 -0.3229 -0.1507 -0.2933 -0.1341 -0.1104 -0.2617 -0.1576 -0.1442 -0.1877 -0.7606 -0.1042 -0.1178 -0.9787 -0.0852 -0.1379 -1.4828 -0.5145 -0.1204 -0.3484 -0.0676 -0.0762 -0.6419 -0.5774 -0.2930 -0.4084 -0.0299 -0.0973 -0.0883 -0.1149 -0.1349 -1.5139 -0.5626 -1.0445 -0.1569 -0.1420 -0.0533 -0.0670 -0.1334 -1.3863 -0.2722 -0.4233 -2.4061 -0.2560 -0.1836 -0.3865 -0.0949 -0.0736 -0.0633 -0.1589 -0.6068 -0.3551 -1.1187 -0.1969 -0.1529 -0.2168 -0.1791 -0.1527
S-580	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-580	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-580	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-580	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-580	-2.0889 -0.1429 -0.1790 -2.1889 -0.1677 -0.2489 -0.1204 -0.1747 -0.2895 -0.0594 -0.1970 -0.1343 -0.4022 -0.2670 -0.5604 -0.2616 -0.1215 -1.5137 -0.0914 -0.1366 -0.5114 -1.7393 -0.1246 -0.2071 -0.0885 -1.3794 -0.7162 -0.4231 -0.4251 -0.1049 -0.1864 -0.0952 -0.1888 -0.2543 -0.3213 -0.0226 -0.4200 -0.5526 -1.4974 -0.5509 -0.2230 -1.0192 -0.0699 -0.0882 -0.1343 -0.1365 -0.1525 -0.0522 -0.0881 -0.0254 -0.1420 -0.4073 -0.1567
S-754	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-754	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-754	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-754	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-754	-2.0889 -0.1429 -0.1790 -2.1889 -0.1677 -0.2489 -0.1204 -0.1747 -0.2895 -0.0594 -0.1970 -0.1343 -0.4022 -0.2670 -0.5604 -0.2616 -0.1215 -1.5137 -0.0914 -0.1366 -0.5114 -1.7393 -0.1246 -0.2071 -0.0885 -1.3794 -0.7162 -0.4231 -0.4251 -0.1049 -0.1864 -0.0952 -0.1888 -0.2543 -0.3213 -0.0226 -0.4200 -0.5526 -1.4974 -0.5509 -0.2230 -1.0192 -0.0699 -0.0882 -0.1343 -0.1365 -0.1525 -0.0522 -0.0881 -0.0254 -0.1420 -0.4073 -0.1567
S-930	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-930	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-930	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-930	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-930	-2.0889 -0.1429 -0.1790 -2.1889 -0.1677 -0.2489 -0.1204 -0.1747 -0.2895 -0.0594 -0.1970 -0.1343 -0.4022 -0.2670 -0.5604 -0.2616 -0.1215 -1.5137 -0.0914 -0.1366 -0.5114 -1.7393 -0.1246 -0.2071 -0.0885 -1.3794 -0.7162 -0.4231 -0.4251 -0.1049 -0.1864 -0.0952 -0.1888 -0.2543 -0.3213 -0.0226 -0.4200 -0.5526 -1.4974 -0.5509 -0.2230 -1.0192 -0.0699 -0.0882 -0.1343 -0.1365 -0.1525 -0.0522 -0.0881 -0.0254 -0.1420 -0.4073 -0.1567
S-1106	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-1106	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-1106	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-1106	-0.41227269172668457	injection every 8-24 hours ( 6-24 hours in patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-1106	-2.0889 -0.1429 -0.1790 -2.1889 -0.1677 -0.2489 -0.1204 -0.1747 -0.2895 -0.0594 -0.1970 -0.1343 -0.4022 -0.2670 -0.5604 -0.2616 -0.1215 -1.5137 -0.0914 -0.1366 -0.5114 -1.7393 -0.1246 -0.2071 -0.0885 -1.3794 -0.7162 -0.4231 -0.4251 -0.1049 -0.1864 -0.0952 -0.1888 -0.2543 -0.3213 -0.0226 -0.4200 -0.5526 -1.4974 -0.5509 -0.2230 -1.0192 -0.0699 -0.0882 -0.1343 -0.1365 -0.1525 -0.0522 -0.0881 -0.0254 -0.1420 -0.4073 -0.1567
S-413	In der mit Alendronat behandelten Gruppe wurde im Vergleich zur Plazebo-Gruppe eine Reduktion um 48 % ( Alendronat 3,2 % gegenüber Plazebo 6,2 % ) bei dem Anteil von Patientinnen , die eine oder mehrere Wirbelfrakturen erlitten , erreicht .
T-413	There was a 48 % reduction ( alendronate 3.2 % vs placebo 6.2 % ) in the proportion of patients treated with alendronate experiencing one or more vertebral fractures relative to those treated with placebo .
H-413	-0.31257542967796326	In the alendronate treated group , a 48 % reduction ( alendronate 3.2 % vs. placebo 6.2 % ) was achieved in the proportion of patients who sustained one or more vertebral fractures compared to the placebo group .
D-413	-0.31257542967796326	In the alendronate treated group , a 48 % reduction ( alendronate 3.2 % vs. placebo 6.2 % ) was achieved in the proportion of patients who sustained one or more vertebral fractures compared to the placebo group .
P-413	-0.8639 -0.2530 -0.1868 -0.1598 -0.1545 -0.0972 -0.8245 -0.3277 -0.6352 -0.3597 -0.1946 -0.1278 -0.7738 -0.3691 -0.2661 -0.1125 -0.1434 -0.0602 -0.0982 -0.1470 -0.0926 -0.9308 -0.1155 -0.1514 -0.2879 -0.1185 -0.1092 -0.1534 -0.1066 -0.1283 -0.3731 -0.1466 -0.8405 -0.2175 -0.1762 -0.1254 -0.4425 -0.7045 -1.2201 -0.1719 -0.1849 -0.2804 -0.1024 -0.1738 -0.0866 -0.2571 -0.2572 -0.0675 -0.5494 -0.6660 -0.3744 -0.0391 -0.1297 -1.3061 -0.1435 -0.4247 -0.1679 -0.1512
S-821	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-821	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-821	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
D-821	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
P-821	-1.9887 -0.3465 -0.1138 -0.1408 -0.0521 -0.9429 -1.6021 -0.1464 -0.7144 -0.1030 -0.3571 -0.1820 -0.8993 -0.5137 -0.0938 -0.1663 -0.1365 -1.9908 -0.6197 -0.1605 -0.0795 -0.0717 -0.1029 -0.1489 -2.1324 -0.4570 -0.0721 -0.4362 -0.7675 -0.1268 -0.1245 -0.0265 -0.1229 -0.1314 -0.2963 -0.3528 -0.2900 -0.2154 -0.1198 -0.2333 -0.7527 -0.1305 -0.1681 -0.3793 -0.0389 -0.1426 -0.1336 -0.0664 -1.0808 -0.8192 -0.0515 -0.1656 -0.1570
S-225	Resorption Bezogen auf eine intravenöse Referenzdosis betrug die mittlere orale Bioverfügbarkeit von Alendronat bei Frauen 0,64 % für Dosen zwischen 5 und 70 mg nach nächtlichem Fasten und zwei Stunden vor Aufnahme eines standardisierten Frühstücks .
T-225	Absorption Relative to an intravenous reference dose , the oral mean bioavailability of alendronate in women was 0.64 % for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardised breakfast .
H-225	-0.3829192519187927	Regarding intravenous reference dose , mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after nocturnal fasting and two hours prior to standardized breakfast .
D-225	-0.3829192519187927	Regarding intravenous reference dose , mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after nocturnal fasting and two hours prior to standardized breakfast .
P-225	-2.5986 -0.2296 -0.4200 -0.8260 -0.0697 -0.0734 -0.1165 -0.1858 -0.5653 -0.1574 -0.7303 -0.0907 -0.0937 -0.0802 -0.1344 -0.1514 -0.1157 -0.1511 -0.0840 -0.6586 -0.1454 -0.2631 -0.1135 -0.0762 -0.1494 -0.9358 -0.2387 -0.0487 -0.5956 -0.1422 -0.2183 -0.2131 -0.0463 -1.0561 -1.0312 -0.0805 -0.0213 -0.1655 -0.0262 -0.3113 -0.1470 -0.8615 -0.0956 -0.5645 -0.1314 -2.1913 -0.2978 -0.2602 -0.2792 -1.1355 -0.1539
S-217	In der mit Alendronat behandelten Gruppe wurde im Vergleich zur Plazebo-Gruppe eine Reduktion um 48 % ( Alendronat 3,2 % gegenüber Plazebo 6,2 % ) bei dem Anteil von Patientinnen , die eine oder mehrere Wirbelfrakturen erlitten , erreicht .
T-217	There was a 48 % reduction ( alendronate 3.2 % vs placebo 6.2 % ) in the proportion of patients treated with alendronate experiencing one or more vertebral fractures relative to those treated with placebo .
H-217	-0.31257542967796326	In the alendronate treated group , a 48 % reduction ( alendronate 3.2 % vs. placebo 6.2 % ) was achieved in the proportion of patients who sustained one or more vertebral fractures compared to the placebo group .
D-217	-0.31257542967796326	In the alendronate treated group , a 48 % reduction ( alendronate 3.2 % vs. placebo 6.2 % ) was achieved in the proportion of patients who sustained one or more vertebral fractures compared to the placebo group .
P-217	-0.8639 -0.2530 -0.1868 -0.1598 -0.1545 -0.0972 -0.8245 -0.3277 -0.6352 -0.3597 -0.1946 -0.1278 -0.7738 -0.3691 -0.2661 -0.1125 -0.1434 -0.0602 -0.0982 -0.1470 -0.0926 -0.9308 -0.1155 -0.1514 -0.2879 -0.1185 -0.1092 -0.1534 -0.1066 -0.1283 -0.3731 -0.1466 -0.8405 -0.2175 -0.1762 -0.1254 -0.4425 -0.7045 -1.2201 -0.1719 -0.1849 -0.2804 -0.1024 -0.1738 -0.0866 -0.2571 -0.2572 -0.0675 -0.5494 -0.6660 -0.3744 -0.0391 -0.1297 -1.3061 -0.1435 -0.4247 -0.1679 -0.1512
S-647	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-647	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-647	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
D-647	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
P-647	-1.9887 -0.3465 -0.1138 -0.1408 -0.0521 -0.9429 -1.6021 -0.1464 -0.7144 -0.1030 -0.3571 -0.1820 -0.8993 -0.5137 -0.0938 -0.1663 -0.1365 -1.9908 -0.6197 -0.1605 -0.0795 -0.0717 -0.1029 -0.1489 -2.1324 -0.4570 -0.0721 -0.4362 -0.7675 -0.1268 -0.1245 -0.0265 -0.1229 -0.1314 -0.2963 -0.3528 -0.2900 -0.2154 -0.1198 -0.2333 -0.7527 -0.1305 -0.1681 -0.3793 -0.0389 -0.1426 -0.1336 -0.0664 -1.0808 -0.8192 -0.0515 -0.1656 -0.1570
S-1349	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-1349	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-1349	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
D-1349	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
P-1349	-1.9887 -0.3465 -0.1138 -0.1408 -0.0521 -0.9429 -1.6021 -0.1464 -0.7144 -0.1030 -0.3571 -0.1820 -0.8993 -0.5137 -0.0938 -0.1663 -0.1365 -1.9908 -0.6197 -0.1605 -0.0795 -0.0717 -0.1029 -0.1489 -2.1324 -0.4570 -0.0721 -0.4362 -0.7675 -0.1268 -0.1245 -0.0265 -0.1229 -0.1314 -0.2963 -0.3528 -0.2900 -0.2154 -0.1198 -0.2333 -0.7527 -0.1305 -0.1681 -0.3793 -0.0389 -0.1426 -0.1336 -0.0664 -1.0808 -0.8192 -0.0515 -0.1656 -0.1570
S-997	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-997	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-997	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
D-997	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
P-997	-1.9887 -0.3465 -0.1138 -0.1408 -0.0521 -0.9429 -1.6021 -0.1464 -0.7144 -0.1030 -0.3571 -0.1820 -0.8993 -0.5137 -0.0938 -0.1663 -0.1365 -1.9908 -0.6197 -0.1605 -0.0795 -0.0717 -0.1029 -0.1489 -2.1324 -0.4570 -0.0721 -0.4362 -0.7675 -0.1268 -0.1245 -0.0265 -0.1229 -0.1314 -0.2963 -0.3528 -0.2900 -0.2154 -0.1198 -0.2333 -0.7527 -0.1305 -0.1681 -0.3793 -0.0389 -0.1426 -0.1336 -0.0664 -1.0808 -0.8192 -0.0515 -0.1656 -0.1570
S-421	Resorption Bezogen auf eine intravenöse Referenzdosis betrug die mittlere orale Bioverfügbarkeit von Alendronat bei Frauen 0,64 % für Dosen zwischen 5 und 70 mg nach nächtlichem Fasten und zwei Stunden vor Aufnahme eines standardisierten Frühstücks .
T-421	Absorption Relative to an intravenous reference dose , the oral mean bioavailability of alendronate in women was 0.64 % for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardised breakfast .
H-421	-0.3829192519187927	Regarding intravenous reference dose , mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after nocturnal fasting and two hours prior to standardized breakfast .
D-421	-0.3829192519187927	Regarding intravenous reference dose , mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after nocturnal fasting and two hours prior to standardized breakfast .
P-421	-2.5986 -0.2296 -0.4200 -0.8260 -0.0697 -0.0734 -0.1165 -0.1858 -0.5653 -0.1574 -0.7303 -0.0907 -0.0937 -0.0802 -0.1344 -0.1514 -0.1157 -0.1511 -0.0840 -0.6586 -0.1454 -0.2631 -0.1135 -0.0762 -0.1494 -0.9358 -0.2387 -0.0487 -0.5956 -0.1422 -0.2183 -0.2131 -0.0463 -1.0561 -1.0312 -0.0805 -0.0213 -0.1655 -0.0262 -0.3113 -0.1470 -0.8615 -0.0956 -0.5645 -0.1314 -2.1913 -0.2978 -0.2602 -0.2792 -1.1355 -0.1539
S-1526	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-1526	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-1526	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
D-1526	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
P-1526	-1.9887 -0.3465 -0.1138 -0.1408 -0.0521 -0.9429 -1.6021 -0.1464 -0.7144 -0.1030 -0.3571 -0.1820 -0.8993 -0.5137 -0.0938 -0.1663 -0.1365 -1.9908 -0.6197 -0.1605 -0.0795 -0.0717 -0.1029 -0.1489 -2.1324 -0.4570 -0.0721 -0.4362 -0.7675 -0.1268 -0.1245 -0.0265 -0.1229 -0.1314 -0.2963 -0.3528 -0.2900 -0.2154 -0.1198 -0.2333 -0.7527 -0.1305 -0.1681 -0.3793 -0.0389 -0.1426 -0.1336 -0.0664 -1.0808 -0.8192 -0.0515 -0.1656 -0.1570
S-41	Der Ausschuss gelangte zu dem Schluss , dass die Vorteile von Adenuric bei der Behandlung der chronischen Hyperurikämie , wenn bereits Uratablagerungen auftraten , gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Adenuric zu erteilen .
T-41	Der Ausschuss gelangte zu dem Schluss , dass die Vorteile von Adenuric bei der Behandlung der chronischen Hyperurikämie , wenn bereits Uratablagerungen auftraten , gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Adenuric zu erteilen . The Committee recommended that Adenuric be given marketing authorisation .
H-41	-0.41809266805648804	The Committee concluded that the benefits of Adenuric in the treatment of chronic hyperuricaemia outweigh the risks when urine deposits have already occurred and recommended that marketing authorisation be granted for Adenuric .
D-41	-0.41809266805648804	The Committee concluded that the benefits of Adenuric in the treatment of chronic hyperuricaemia outweigh the risks when urine deposits have already occurred and recommended that marketing authorisation be granted for Adenuric .
P-41	-0.3855 -0.5120 -0.5654 -0.1502 -0.5451 -0.8136 -0.2377 -0.1232 -0.2047 -0.1311 -0.1237 -0.5225 -0.6605 -0.3717 -0.1205 -0.0684 -0.0745 -0.1260 -0.6168 -0.0300 -0.1287 -1.6468 -0.3930 -0.2395 -0.2562 -0.7816 -0.6381 -0.6494 -0.5617 -0.1777 -0.7927 -1.3039 -0.4286 -0.4304 -0.1273 -0.9412 -1.0368 -0.0346 -0.0955 -0.6621 -1.0571 -0.3379 -0.1002 -0.2110 -0.1259 -0.1269 -0.2472 -0.1532
S-1173	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-1173	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-1173	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
D-1173	-0.40877512097358704	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed a statistically significant uptrend in titers in linear regression analysis . 4 of these patients exhibited sustained peaks or transient peaks .
P-1173	-1.9887 -0.3465 -0.1138 -0.1408 -0.0521 -0.9429 -1.6021 -0.1464 -0.7144 -0.1030 -0.3571 -0.1820 -0.8993 -0.5137 -0.0938 -0.1663 -0.1365 -1.9908 -0.6197 -0.1605 -0.0795 -0.0717 -0.1029 -0.1489 -2.1324 -0.4570 -0.0721 -0.4362 -0.7675 -0.1268 -0.1245 -0.0265 -0.1229 -0.1314 -0.2963 -0.3528 -0.2900 -0.2154 -0.1198 -0.2333 -0.7527 -0.1305 -0.1681 -0.3793 -0.0389 -0.1426 -0.1336 -0.0664 -1.0808 -0.8192 -0.0515 -0.1656 -0.1570
S-1527	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-1527	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-1527	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
D-1527	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
P-1527	-1.0476 -0.1362 -1.4953 -0.0865 -0.2565 -0.2201 -0.1090 -0.0931 -0.0740 -0.0935 -0.1476 -1.5757 -0.2628 -0.1840 -1.8981 -0.0464 -0.0251 -0.5007 -0.1975 -0.9756 -0.1211 -0.6101 -0.5971 -0.1675 -1.3937 -0.3454 -0.5830 -1.5038 -0.3855 -0.1709 -0.0866 -2.0772 -1.3199 -0.1140 -0.0419 -0.0614 -0.1357 -0.0577 -0.0327 -0.0442 -1.1792 -0.7434 -0.1629 -0.1618
S-823	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-823	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-823	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
D-823	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
P-823	-1.6086 -0.3095 -0.1037 -0.1427 -0.0627 -0.0545 -1.1994 -0.1423 -0.3005 -0.0545 -0.5089 -0.0210 -0.2583 -0.0532 -0.1053 -0.1445 -0.1686 -2.0045 -0.1056 -0.5117 -0.1521 -0.0745 -0.0688 -0.1037 -0.1508 -2.6585 -0.2228 -0.1497 -0.2843 -0.4525 -0.4158 -0.1349 -0.1287 -0.0281 -0.1412 -0.1335 -0.3195 -0.3851 -0.1677 -1.0213 -0.5570 -0.2551 -0.7136 -0.1024 -0.6918 -0.0228 -0.2009 -0.5010 -0.0699 -1.0440 -0.3338 -0.7014 -0.1614
S-649	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-649	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-649	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
D-649	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
P-649	-1.6086 -0.3095 -0.1037 -0.1427 -0.0627 -0.0545 -1.1994 -0.1423 -0.3005 -0.0545 -0.5089 -0.0210 -0.2583 -0.0532 -0.1053 -0.1445 -0.1686 -2.0045 -0.1056 -0.5117 -0.1521 -0.0745 -0.0688 -0.1037 -0.1508 -2.6585 -0.2228 -0.1497 -0.2843 -0.4525 -0.4158 -0.1349 -0.1287 -0.0281 -0.1412 -0.1335 -0.3195 -0.3851 -0.1677 -1.0213 -0.5570 -0.2551 -0.7136 -0.1024 -0.6918 -0.0228 -0.2009 -0.5010 -0.0699 -1.0440 -0.3338 -0.7014 -0.1614
S-998	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-998	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-998	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
D-998	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
P-998	-1.0476 -0.1362 -1.4953 -0.0865 -0.2565 -0.2201 -0.1090 -0.0931 -0.0740 -0.0935 -0.1476 -1.5757 -0.2628 -0.1840 -1.8981 -0.0464 -0.0251 -0.5007 -0.1975 -0.9756 -0.1211 -0.6101 -0.5971 -0.1675 -1.3937 -0.3454 -0.5830 -1.5038 -0.3855 -0.1709 -0.0866 -2.0772 -1.3199 -0.1140 -0.0419 -0.0614 -0.1357 -0.0577 -0.0327 -0.0442 -1.1792 -0.7434 -0.1629 -0.1618
S-1350	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-1350	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-1350	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
D-1350	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
P-1350	-1.0476 -0.1362 -1.4953 -0.0865 -0.2565 -0.2201 -0.1090 -0.0931 -0.0740 -0.0935 -0.1476 -1.5757 -0.2628 -0.1840 -1.8981 -0.0464 -0.0251 -0.5007 -0.1975 -0.9756 -0.1211 -0.6101 -0.5971 -0.1675 -1.3937 -0.3454 -0.5830 -1.5038 -0.3855 -0.1709 -0.0866 -2.0772 -1.3199 -0.1140 -0.0419 -0.0614 -0.1357 -0.0577 -0.0327 -0.0442 -1.1792 -0.7434 -0.1629 -0.1618
S-1174	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-1174	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-1174	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
D-1174	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
P-1174	-1.0476 -0.1362 -1.4953 -0.0865 -0.2565 -0.2201 -0.1090 -0.0931 -0.0740 -0.0935 -0.1476 -1.5757 -0.2628 -0.1840 -1.8981 -0.0464 -0.0251 -0.5007 -0.1975 -0.9756 -0.1211 -0.6101 -0.5971 -0.1675 -1.3937 -0.3454 -0.5830 -1.5038 -0.3855 -0.1709 -0.0866 -2.0772 -1.3199 -0.1140 -0.0419 -0.0614 -0.1357 -0.0577 -0.0327 -0.0442 -1.1792 -0.7434 -0.1629 -0.1618
S-822	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-822	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-822	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
D-822	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
P-822	-1.0476 -0.1362 -1.4953 -0.0865 -0.2565 -0.2201 -0.1090 -0.0931 -0.0740 -0.0935 -0.1476 -1.5757 -0.2628 -0.1840 -1.8981 -0.0464 -0.0251 -0.5007 -0.1975 -0.9756 -0.1211 -0.6101 -0.5971 -0.1675 -1.3937 -0.3454 -0.5830 -1.5038 -0.3855 -0.1709 -0.0866 -2.0772 -1.3199 -0.1140 -0.0419 -0.0614 -0.1357 -0.0577 -0.0327 -0.0442 -1.1792 -0.7434 -0.1629 -0.1618
S-999	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-999	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-999	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
D-999	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
P-999	-1.6086 -0.3095 -0.1037 -0.1427 -0.0627 -0.0545 -1.1994 -0.1423 -0.3005 -0.0545 -0.5089 -0.0210 -0.2583 -0.0532 -0.1053 -0.1445 -0.1686 -2.0045 -0.1056 -0.5117 -0.1521 -0.0745 -0.0688 -0.1037 -0.1508 -2.6585 -0.2228 -0.1497 -0.2843 -0.4525 -0.4158 -0.1349 -0.1287 -0.0281 -0.1412 -0.1335 -0.3195 -0.3851 -0.1677 -1.0213 -0.5570 -0.2551 -0.7136 -0.1024 -0.6918 -0.0228 -0.2009 -0.5010 -0.0699 -1.0440 -0.3338 -0.7014 -0.1614
S-648	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-648	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-648	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
D-648	-0.4891372323036194	One patient exhibited both a statistically significant upward trend and a sustained peak in anti-CHO cell protein , but otherwise no signs or symptoms suggesting an allergic reaction or hypersensitivity were observed .
P-648	-1.0476 -0.1362 -1.4953 -0.0865 -0.2565 -0.2201 -0.1090 -0.0931 -0.0740 -0.0935 -0.1476 -1.5757 -0.2628 -0.1840 -1.8981 -0.0464 -0.0251 -0.5007 -0.1975 -0.9756 -0.1211 -0.6101 -0.5971 -0.1675 -1.3937 -0.3454 -0.5830 -1.5038 -0.3855 -0.1709 -0.0866 -2.0772 -1.3199 -0.1140 -0.0419 -0.0614 -0.1357 -0.0577 -0.0327 -0.0442 -1.1792 -0.7434 -0.1629 -0.1618
S-1175	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-1175	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-1175	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
D-1175	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
P-1175	-1.6086 -0.3095 -0.1037 -0.1427 -0.0627 -0.0545 -1.1994 -0.1423 -0.3005 -0.0545 -0.5089 -0.0210 -0.2583 -0.0532 -0.1053 -0.1445 -0.1686 -2.0045 -0.1056 -0.5117 -0.1521 -0.0745 -0.0688 -0.1037 -0.1508 -2.6585 -0.2228 -0.1497 -0.2843 -0.4525 -0.4158 -0.1349 -0.1287 -0.0281 -0.1412 -0.1335 -0.3195 -0.3851 -0.1677 -1.0213 -0.5570 -0.2551 -0.7136 -0.1024 -0.6918 -0.0228 -0.2009 -0.5010 -0.0699 -1.0440 -0.3338 -0.7014 -0.1614
S-1528	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-1528	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-1528	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
D-1528	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
P-1528	-1.6086 -0.3095 -0.1037 -0.1427 -0.0627 -0.0545 -1.1994 -0.1423 -0.3005 -0.0545 -0.5089 -0.0210 -0.2583 -0.0532 -0.1053 -0.1445 -0.1686 -2.0045 -0.1056 -0.5117 -0.1521 -0.0745 -0.0688 -0.1037 -0.1508 -2.6585 -0.2228 -0.1497 -0.2843 -0.4525 -0.4158 -0.1349 -0.1287 -0.0281 -0.1412 -0.1335 -0.3195 -0.3851 -0.1677 -1.0213 -0.5570 -0.2551 -0.7136 -0.1024 -0.6918 -0.0228 -0.2009 -0.5010 -0.0699 -1.0440 -0.3338 -0.7014 -0.1614
S-1351	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-1351	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-1351	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
D-1351	-0.38506510853767395	Of the 182 treated subjects tested for antibodies to murine IgG , 10 exhibited a statistically significant uptick in titers in linear regression analysis . 2 of the patients exhibited sustained peak or transitory peak .
P-1351	-1.6086 -0.3095 -0.1037 -0.1427 -0.0627 -0.0545 -1.1994 -0.1423 -0.3005 -0.0545 -0.5089 -0.0210 -0.2583 -0.0532 -0.1053 -0.1445 -0.1686 -2.0045 -0.1056 -0.5117 -0.1521 -0.0745 -0.0688 -0.1037 -0.1508 -2.6585 -0.2228 -0.1497 -0.2843 -0.4525 -0.4158 -0.1349 -0.1287 -0.0281 -0.1412 -0.1335 -0.3195 -0.3851 -0.1677 -1.0213 -0.5570 -0.2551 -0.7136 -0.1024 -0.6918 -0.0228 -0.2009 -0.5010 -0.0699 -1.0440 -0.3338 -0.7014 -0.1614
S-237	Ausscheidung Nach intravenöser Gabe einer einzelnen Dosis von 14C-Alendronat wurden etwa 50 % der radioaktiv markierten Substanz innerhalb von 72 Stunden mit dem Urin ausgeschieden und wenig oder keine Radioaktivität wurde in den Fäzes wiedergefunden .
T-237	Elimination Following a single intravenous dose of <<unk>> 14C<<unk>> alendronate , approximately 50 % of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
H-237	-0.33021172881126404	After the intravenous administration of a single dose of 14C-alendronate , approximately 50 % of the radioactively labelled substance was excreted within 72 hours and little or no radioactivity was detected in the faeces .
D-237	-0.33021172881126404	After the intravenous administration of a single dose of 14C-alendronate , approximately 50 % of the radioactively labelled substance was excreted within 72 hours and little or no radioactivity was detected in the faeces .
P-237	-2.1185 -1.1241 -0.6086 -0.0763 -0.0537 -0.1107 -0.0422 -0.1362 -0.1665 -0.3110 -0.0521 -0.1258 -0.1969 -1.0506 -0.1274 -0.0822 -0.1005 -0.1285 -0.0681 -0.3715 -0.1590 -0.1658 -0.1256 -0.1290 -0.2099 -0.5496 -0.8217 -0.3484 -1.0689 -0.0822 -0.3711 -0.3451 -0.0152 -0.0593 -1.3369 -0.0717 -0.1398 -0.5575 -0.1638 -0.2390 -0.1187 -0.1506 -0.0717 -0.1111 -1.7189 -0.0876 -0.1588 -0.1639 -0.4361 -0.0140 -0.1394 -0.1636 -0.1561
S-1919	Bei Betrachtung aller Heuschnupfensymptome außer der Verstopfung der Nase berichteten die Patienten , die Aerinaze einnahmen , über eine Abnahme der Symptome um 46,0 % , verglichen mit 35,9 % bei den Patienten , die Pseudoephedrin allein einnahmen .
T-1919	When looking at all hayfever symptoms except for nasal congestion , patients taking Aerinaze reported a reduction in symptoms of 46.0 % , compared with 35.9 % in those taking pseudoephedrine alone .
H-1919	-0.3048914074897766	When all hayfever symptoms except nose constipation were considered , those taking Aerinaze reported a 46.0 % decrease in symptoms compared to 35.9 % for those taking pseudoephedrine alone .
D-1919	-0.3048914074897766	When all hayfever symptoms except nose constipation were considered , those taking Aerinaze reported a 46.0 % decrease in symptoms compared to 35.9 % for those taking pseudoephedrine alone .
P-1919	-1.4432 -0.9040 -0.8446 -0.8975 -0.1202 -0.1484 -0.0788 -0.8795 -0.9098 -0.4078 -0.2144 -0.0764 -0.1348 -0.0854 -0.6500 -0.1304 -1.1811 -0.1936 -0.1363 -0.1169 -0.1413 -0.1465 -0.0922 -0.0951 -0.1478 -0.4598 -0.1282 -0.1206 -0.1256 -0.3798 -0.2224 -0.2911 -0.1708 -0.6667 -0.6438 -0.1588 -0.0589 -0.1123 -0.0976 -0.2374 -0.1184 -0.1313 -0.2451 -0.1740 -0.1441 -0.0874 -0.1181 -0.2220 -0.1406 -0.1107 -0.1543 -0.1584
S-177	Dennoch traten Abnahmen des Serum-Calciums bis <unk> 8,0 mg<unk> dl ( 2,0 mmol<unk> l ) und des Serum- Phosphats bis 2,0 mg<unk> dl ( 0,65 mmol<unk> l ) in beiden Behandlungsgruppen mit ähnlicher Häufigkeit auf .
T-177	However , the incidences of decreases in serum calcium to <<unk>> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) were similar in both treatment groups .
H-177	-0.2336931824684143	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) occurred with a similar frequency in both treatment arms .
D-177	-0.2336931824684143	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) occurred with a similar frequency in both treatment arms .
P-177	-0.8825 -0.1356 -0.5627 -0.1576 -0.4836 -0.1379 -0.1027 -0.1964 -0.1249 -0.0937 -0.1516 -0.8208 -0.1679 -0.1012 -0.1232 -0.1689 -0.1437 -0.1067 -0.1461 -0.0376 -0.0832 -0.0962 -0.1059 -0.0709 -0.1231 -0.1571 -0.6213 -0.0967 -0.3550 -0.0542 -0.0782 -0.1252 -0.0509 -0.1112 -0.1461 -0.1377 -0.0333 -0.1403 -0.0578 -0.1281 -0.1241 -0.0880 -0.1118 -0.0912 -0.1166 -0.8159 -0.6582 -0.6542 -0.1988 -1.0945 -0.0932 -0.1362 -0.1288 -0.5028 -0.5740 -0.1641 -0.1505
S-365	Dennoch traten Abnahmen des Serum-Calciums bis <unk> 8,0 mg<unk> dl ( 2,0 mmol<unk> l ) und des Serum- Phosphats bis 2,0 mg<unk> dl ( 0,65 mmol<unk> l ) in beiden Behandlungsgruppen mit ähnlicher Häufigkeit auf .
T-365	However , the incidences of decreases in serum calcium to <<unk>> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) were similar in both treatment groups .
H-365	-0.2336931824684143	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) occurred with a similar frequency in both treatment arms .
D-365	-0.2336931824684143	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) occurred with a similar frequency in both treatment arms .
P-365	-0.8825 -0.1356 -0.5627 -0.1576 -0.4836 -0.1379 -0.1027 -0.1964 -0.1249 -0.0937 -0.1516 -0.8208 -0.1679 -0.1012 -0.1232 -0.1689 -0.1437 -0.1067 -0.1461 -0.0376 -0.0832 -0.0962 -0.1059 -0.0709 -0.1231 -0.1571 -0.6213 -0.0967 -0.3550 -0.0542 -0.0782 -0.1252 -0.0509 -0.1112 -0.1461 -0.1377 -0.0333 -0.1403 -0.0578 -0.1281 -0.1241 -0.0880 -0.1118 -0.0912 -0.1166 -0.8159 -0.6582 -0.6542 -0.1988 -1.0945 -0.0932 -0.1362 -0.1288 -0.5028 -0.5740 -0.1641 -0.1505
S-433	Ausscheidung Nach intravenöser Gabe einer einzelnen Dosis von 14C-Alendronat wurden etwa 50 % der radioaktiv markierten Substanz innerhalb von 72 Stunden mit dem Urin ausgeschieden und wenig oder keine Radioaktivität wurde in den Fäzes wiedergefunden .
T-433	Elimination Following a single intravenous dose of <<unk>> 14C<<unk>> alendronate , approximately 50 % of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
H-433	-0.33021172881126404	After the intravenous administration of a single dose of 14C-alendronate , approximately 50 % of the radioactively labelled substance was excreted within 72 hours and little or no radioactivity was detected in the faeces .
D-433	-0.33021172881126404	After the intravenous administration of a single dose of 14C-alendronate , approximately 50 % of the radioactively labelled substance was excreted within 72 hours and little or no radioactivity was detected in the faeces .
P-433	-2.1185 -1.1241 -0.6086 -0.0763 -0.0537 -0.1107 -0.0422 -0.1362 -0.1665 -0.3110 -0.0521 -0.1258 -0.1969 -1.0506 -0.1274 -0.0822 -0.1005 -0.1285 -0.0681 -0.3715 -0.1590 -0.1658 -0.1256 -0.1290 -0.2099 -0.5496 -0.8217 -0.3484 -1.0689 -0.0822 -0.3711 -0.3451 -0.0152 -0.0593 -1.3369 -0.0717 -0.1398 -0.5575 -0.1638 -0.2390 -0.1187 -0.1506 -0.0717 -0.1111 -1.7189 -0.0876 -0.1588 -0.1639 -0.4361 -0.0140 -0.1394 -0.1636 -0.1561
S-1987	Desloratadin hemmt in-vivo CYP3A4 nicht , und in-vitro-Studien haben gezeigt , dass das Arzneimittel CYP2D6 nicht hemmt und weder ein Substrat noch ein Inhibitor des P-Glykoproteins ist .
T-1987	Desloratadine does not inhibit CYP3A4 in vivo , and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein .
H-1987	-0.256735235452652	Desloratadine does not inhibit CYP3A4 in vivo , and in vitro studies have shown that the medicine does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein .
D-1987	-0.256735235452652	Desloratadine does not inhibit CYP3A4 in vivo , and in vitro studies have shown that the medicine does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein .
P-1987	-0.8474 -0.0346 -0.1146 -0.2199 -0.4133 -1.1490 -0.1330 -0.2798 -0.1912 -0.0395 -0.6435 -0.1228 -0.1200 -0.1401 -0.0512 -0.3159 -0.0454 -0.0334 -1.1453 -0.1522 -0.2177 -0.0761 -0.0487 -0.2561 -0.3142 -0.2630 -0.2370 -0.6761 -0.7246 -0.6134 -0.1329 -0.3754 -0.2219 -0.0462 -0.1312 -0.1321 -0.1221 -0.1157 -0.1471 -0.1369 -0.3953 -0.1830 -0.3856 -0.1260 -0.0932 -0.0886 -0.1719 -0.1180 -0.2575 -0.1480 -0.1000 -0.0551 -0.1787 -0.1348 -0.8585 -0.5926 -0.2302 -0.1367 -0.1211 -0.0425 -0.2491 -0.1702 -0.1570
S-231	Bei gesunden Probanden führte die Gabe von oralem Prednison ( 20 mg dreimal täglich über fünf Tage ) zu keiner klinisch bedeutsamen Veränderung der oralen Bioverfügbarkeit von Alendronat ( Anstieg im Mittel im Bereich von 20 % bis 44 % ) .
T-231	In healthy subjects , oral prednisone ( 20 mg three times daily for five days ) did not produce a clinically meaningful change in oral bioavailability of alendronate ( a mean increase ranging from 20 % to 44 % ) .
H-231	-0.27311933040618896	In healthy subjects , oral prednisone ( 20 mg 3 times daily for five days ) did not result in a clinically important change in oral bioavailability of alendronate ( mean increase in the 20 % to 44 % range ) .
D-231	-0.27311933040618896	In healthy subjects , oral prednisone ( 20 mg 3 times daily for five days ) did not result in a clinically important change in oral bioavailability of alendronate ( mean increase in the 20 % to 44 % range ) .
P-231	-0.2578 -0.0875 -0.0271 -0.5269 -0.2915 -0.1316 -0.1038 -0.1697 -0.1222 -0.5400 -0.2822 -0.0356 -0.2291 -0.1674 -0.3639 -0.2580 -0.3743 -0.1123 -0.1391 -0.1862 -0.1263 -1.4888 -0.1102 -0.5764 -0.0484 -0.0751 -0.4025 -0.1700 -0.1325 -0.2832 -0.3488 -0.0570 -0.1506 -0.1601 -0.1103 -0.1338 -0.0590 -0.1465 -1.2084 -0.2471 -0.8450 -0.1648 -1.1940 -0.1736 -0.2478 -0.1024 -0.1189 -0.1669 -0.1419 -0.1790 -0.1535
S-1849	Hinweise zur Herstellung der Lösung Nicht nach dem auf Durchstechflaschen und Umkarton angegebenen Haltbarkeitsdatum verwenden . Den BAXJECT II nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist , wie in dem Symbol
T-1849	Instructions for reconstitution Do not use after the expiry date stated on the labels and carton . Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1849	-0.4501860737800598	Instructions on the manufacture of the solution Do not use after the sell @-@ by date on vials and carton . Do not use BAXJECT II if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering , such as
D-1849	-0.4501860737800598	Instructions on the manufacture of the solution Do not use after the sell @-@ by date on vials and carton . Do not use BAXJECT II if its sterile barrier has been breached , its packaging has been damaged or if there are signs of tampering , such as
P-1849	-0.7700 -0.0915 -1.4992 -1.4432 -0.7648 -0.0664 -0.1201 -0.8929 -0.1699 -0.1236 -0.1567 -0.0271 -0.2120 -0.2613 -1.0674 -0.8473 -0.1296 -0.1865 -1.5730 -0.3817 -0.0643 -0.1462 -0.1425 -0.4229 -0.2377 -0.0222 -0.1380 -0.0357 -0.4735 -0.1680 -0.1935 -0.0932 -0.1213 -0.1322 -0.7873 -0.1909 -0.2560 -0.0404 -0.0464 -0.7673 -0.1625 -0.7408 -0.0642 -0.1461 -0.2163 -0.2370 -0.1037 -1.4307 -0.2741 -0.2850 -0.2986 -0.9413 -1.8307 -0.6939 -0.4687 -0.1417 -1.0708 -0.1715 -0.0598 -0.1033 -1.1796 -2.0185 -0.1426 -0.7665
S-427	Bei gesunden Probanden führte die Gabe von oralem Prednison ( 20 mg dreimal täglich über fünf Tage ) zu keiner klinisch bedeutsamen Veränderung der oralen Bioverfügbarkeit von Alendronat ( Anstieg im Mittel im Bereich von 20 % bis 44 % ) .
T-427	In healthy subjects , oral prednisone ( 20 mg three times daily for five days ) did not produce a clinically meaningful change in oral bioavailability of alendronate ( a mean increase ranging from 20 % to 44 % ) .
H-427	-0.27311933040618896	In healthy subjects , oral prednisone ( 20 mg 3 times daily for five days ) did not result in a clinically important change in oral bioavailability of alendronate ( mean increase in the 20 % to 44 % range ) .
D-427	-0.27311933040618896	In healthy subjects , oral prednisone ( 20 mg 3 times daily for five days ) did not result in a clinically important change in oral bioavailability of alendronate ( mean increase in the 20 % to 44 % range ) .
P-427	-0.2578 -0.0875 -0.0271 -0.5269 -0.2915 -0.1316 -0.1038 -0.1697 -0.1222 -0.5400 -0.2822 -0.0356 -0.2291 -0.1674 -0.3639 -0.2580 -0.3743 -0.1123 -0.1391 -0.1862 -0.1263 -1.4888 -0.1102 -0.5764 -0.0484 -0.0751 -0.4025 -0.1700 -0.1325 -0.2832 -0.3488 -0.0570 -0.1506 -0.1601 -0.1103 -0.1338 -0.0590 -0.1465 -1.2084 -0.2471 -0.8450 -0.1648 -1.1940 -0.1736 -0.2478 -0.1024 -0.1189 -0.1669 -0.1419 -0.1790 -0.1535
S-778	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-778	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-778	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
D-778	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
P-778	-0.4260 -0.1676 -0.0510 -0.0728 -0.1615 -0.1729 -3.1809 -0.4238 -0.0795 -0.3022 -0.2758 -0.9205 -2.6464 -0.3384 -0.1492 -0.0928 -0.8574 -0.1465 -0.2198 -0.3043 -0.0481 -0.0537 -0.1465 -1.9678 -0.0939 -0.1822 -0.1114 -0.0913 -0.0966 -0.2281 -0.1402 -0.4978 -1.3399 -0.1307 -0.0845 -0.1060 -1.0082 -0.1123 -0.0549 -0.1202 -0.6762 -0.8619 -0.0417 -0.0866 -0.1267 -0.0863 -0.1012 -0.1748 -0.1374 -0.1613 -0.1678
S-1130	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-1130	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-1130	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
D-1130	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
P-1130	-0.4260 -0.1676 -0.0510 -0.0728 -0.1615 -0.1729 -3.1809 -0.4238 -0.0795 -0.3022 -0.2758 -0.9205 -2.6464 -0.3384 -0.1492 -0.0928 -0.8574 -0.1465 -0.2198 -0.3043 -0.0481 -0.0537 -0.1465 -1.9678 -0.0939 -0.1822 -0.1114 -0.0913 -0.0966 -0.2281 -0.1402 -0.4978 -1.3399 -0.1307 -0.0845 -0.1060 -1.0082 -0.1123 -0.0549 -0.1202 -0.6762 -0.8619 -0.0417 -0.0866 -0.1267 -0.0863 -0.1012 -0.1748 -0.1374 -0.1613 -0.1678
S-604	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-604	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-604	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
D-604	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
P-604	-0.4260 -0.1676 -0.0510 -0.0728 -0.1615 -0.1729 -3.1809 -0.4238 -0.0795 -0.3022 -0.2758 -0.9205 -2.6464 -0.3384 -0.1492 -0.0928 -0.8574 -0.1465 -0.2198 -0.3043 -0.0481 -0.0537 -0.1465 -1.9678 -0.0939 -0.1822 -0.1114 -0.0913 -0.0966 -0.2281 -0.1402 -0.4978 -1.3399 -0.1307 -0.0845 -0.1060 -1.0082 -0.1123 -0.0549 -0.1202 -0.6762 -0.8619 -0.0417 -0.0866 -0.1267 -0.0863 -0.1012 -0.1748 -0.1374 -0.1613 -0.1678
S-531	Reproduction is authorised provided the source is acknowledged . Wie wurde Advate untersucht ? Advate ist einem anderen in der Europäischen Union zugelassenen Arzneimittel namens Recombinate , ähnlich , wird jedoch anders hergestellt , sodass das Arzneimittel keine Proteine humanen bzw. tierischen Ursprungs enthält .
T-531	Reproduction is authorised provided the source is acknowledged . of bleeding episodes and rated Advate s effectiveness in stopping bleeding on a scale from none to excellent in 107 patients , all of whom received Advate .
H-531	-0.41404831409454346	Reproduction is authorised provided the source is acknowledged . How has Advate been investigated ? Advate is similar to another medicinal product authorised in the European Union called Recombinate , but manufactured in a different way so that the medicinal product does not contain proteins of human or animal origin .
D-531	-0.41404831409454346	Reproduction is authorised provided the source is acknowledged . How has Advate been investigated ? Advate is similar to another medicinal product authorised in the European Union called Recombinate , but manufactured in a different way so that the medicinal product does not contain proteins of human or animal origin .
P-531	-0.1609 -0.3853 -0.1482 -0.3610 -0.1934 -0.2633 -0.1595 -0.0645 -0.1441 -1.5851 -0.9505 -0.3808 -0.4485 -0.5725 -0.0875 -0.1028 -1.4801 -0.6274 -1.1485 -0.0930 -0.1544 -0.1701 -0.1735 -0.0934 -1.8678 -0.0615 -0.1032 -0.7901 -0.1941 -0.2897 -0.1524 -0.2043 -0.1698 -0.3196 -0.1583 -0.0687 -0.1069 -0.0984 -1.1689 -0.1203 -1.4374 -0.1354 -1.2312 -0.2204 -0.4157 -0.6599 -1.2526 -0.4744 -0.9904 -0.6854 -0.0286 -0.0545 -1.2657 -0.1230 -0.1208 -0.6307 -0.0506 -0.1386 -0.1392 -0.4663 -0.0659 -0.0580 -0.1058 -0.1810 -0.1595
S-954	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-954	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-954	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
D-954	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
P-954	-0.4260 -0.1676 -0.0510 -0.0728 -0.1615 -0.1729 -3.1809 -0.4238 -0.0795 -0.3022 -0.2758 -0.9205 -2.6464 -0.3384 -0.1492 -0.0928 -0.8574 -0.1465 -0.2198 -0.3043 -0.0481 -0.0537 -0.1465 -1.9678 -0.0939 -0.1822 -0.1114 -0.0913 -0.0966 -0.2281 -0.1402 -0.4978 -1.3399 -0.1307 -0.0845 -0.1060 -1.0082 -0.1123 -0.0549 -0.1202 -0.6762 -0.8619 -0.0417 -0.0866 -0.1267 -0.0863 -0.1012 -0.1748 -0.1374 -0.1613 -0.1678
S-182	Colecalciferol Bei Langzeittherapie allgemein gesunder Erwachsener wurde für Dosierungen von weniger als 10.000 I.E.<unk> Tag keine Vitamin-D-Toxizität dokumentiert . In einer klinischen Studie bei gesunden Erwachsenen war eine tägliche Dosis von 4.000 I.E.
T-182	Colecalciferol Vitamin D toxicity has not been documented during chronic therapy in generally healthy adults at a dose less than 10,000 IU/ day .
H-182	-0.37433189153671265	Colecalciferol No vitamin D toxicity has been documented for doses of less than 10,000 IU / day In a clinical trial in healthy adults , a daily dose of 4,000 IU
D-182	-0.37433189153671265	Colecalciferol No vitamin D toxicity has been documented for doses of less than 10,000 IU / day In a clinical trial in healthy adults , a daily dose of 4,000 IU
P-182	-0.5293 -0.1211 -0.1561 -0.1375 -0.1464 -0.1571 -1.2391 -0.1064 -0.0475 -0.1128 -0.0726 -0.0901 -0.1075 -1.2714 -0.1333 -0.8149 -0.7775 -0.5582 -0.2563 -1.2721 -0.4021 -0.1057 -0.1440 -0.1169 -1.4001 -0.3604 -0.2180 -1.9602 -0.3990 -0.2182 -0.1586 -0.1695 -0.0920 -0.2301 -0.4319 -0.1582 -0.0446 -0.0405 -0.1191 -0.2554 -0.1809 -0.0686 -0.7152
S-1306	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-1306	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-1306	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
D-1306	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
P-1306	-0.4260 -0.1676 -0.0510 -0.0728 -0.1615 -0.1729 -3.1809 -0.4238 -0.0795 -0.3022 -0.2758 -0.9205 -2.6464 -0.3384 -0.1492 -0.0928 -0.8574 -0.1465 -0.2198 -0.3043 -0.0481 -0.0537 -0.1465 -1.9678 -0.0939 -0.1822 -0.1114 -0.0913 -0.0966 -0.2281 -0.1402 -0.4978 -1.3399 -0.1307 -0.0845 -0.1060 -1.0082 -0.1123 -0.0549 -0.1202 -0.6762 -0.8619 -0.0417 -0.0866 -0.1267 -0.0863 -0.1012 -0.1748 -0.1374 -0.1613 -0.1678
S-1482	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-1482	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-1482	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
D-1482	-0.39657819271087646	These inhibitors are procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( B.E. ) per ml of plasma by a modified Bethesda assay .
P-1482	-0.4260 -0.1676 -0.0510 -0.0728 -0.1615 -0.1729 -3.1809 -0.4238 -0.0795 -0.3022 -0.2758 -0.9205 -2.6464 -0.3384 -0.1492 -0.0928 -0.8574 -0.1465 -0.2198 -0.3043 -0.0481 -0.0537 -0.1465 -1.9678 -0.0939 -0.1822 -0.1114 -0.0913 -0.0966 -0.2281 -0.1402 -0.4978 -1.3399 -0.1307 -0.0845 -0.1060 -1.0082 -0.1123 -0.0549 -0.1202 -0.6762 -0.8619 -0.0417 -0.0866 -0.1267 -0.0863 -0.1012 -0.1748 -0.1374 -0.1613 -0.1678
S-48	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-48	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-48	-0.3524101674556732	This document is a summary of the European Public Assessment Report ( EPAR ) explaining how the Committee for Medicinal Products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
D-48	-0.3524101674556732	This document is a summary of the European Public Assessment Report ( EPAR ) explaining how the Committee for Medicinal Products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
P-48	-0.2135 -0.5437 -1.2612 -0.2309 -0.1457 -0.0799 -0.1454 -0.1720 -0.2811 -0.3438 -1.0830 -0.0869 -0.0532 -0.3329 -0.1973 -0.0853 -0.0402 -0.1277 -2.3540 -0.1066 -0.1696 -0.1070 -0.1509 -0.2405 -0.1436 -0.1396 -0.1486 -0.1290 -0.2334 -0.1065 -0.1553 -0.0945 -0.0666 -0.1229 -0.6224 -0.5435 -0.0866 -1.0020 -1.1800 -0.9523 -0.1352 -0.8568 -0.0911 -0.1491 -1.1715 -0.0771 -0.7273 -0.2715 -0.1425 -0.1288 -0.2758 -0.4027 -0.1670 -0.1546
S-1893	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-1893	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-1893	-0.3524101674556732	This document is a summary of the European Public Assessment Report ( EPAR ) explaining how the Committee for Medicinal Products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
D-1893	-0.3524101674556732	This document is a summary of the European Public Assessment Report ( EPAR ) explaining how the Committee for Medicinal Products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
P-1893	-0.2135 -0.5437 -1.2612 -0.2309 -0.1457 -0.0799 -0.1454 -0.1720 -0.2811 -0.3438 -1.0830 -0.0869 -0.0532 -0.3329 -0.1973 -0.0853 -0.0402 -0.1277 -2.3540 -0.1066 -0.1696 -0.1070 -0.1509 -0.2405 -0.1436 -0.1396 -0.1486 -0.1290 -0.2334 -0.1065 -0.1553 -0.0945 -0.0666 -0.1229 -0.6224 -0.5435 -0.0866 -1.0020 -1.1800 -0.9523 -0.1352 -0.8568 -0.0911 -0.1491 -1.1715 -0.0771 -0.7273 -0.2715 -0.1425 -0.1288 -0.2758 -0.4027 -0.1670 -0.1546
S-0	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-0	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-0	-0.3524101674556732	This document is a summary of the European Public Assessment Report ( EPAR ) explaining how the Committee for Medicinal Products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
D-0	-0.3524101674556732	This document is a summary of the European Public Assessment Report ( EPAR ) explaining how the Committee for Medicinal Products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
P-0	-0.2135 -0.5437 -1.2612 -0.2309 -0.1457 -0.0799 -0.1454 -0.1720 -0.2811 -0.3438 -1.0830 -0.0869 -0.0532 -0.3329 -0.1973 -0.0853 -0.0402 -0.1277 -2.3540 -0.1066 -0.1696 -0.1070 -0.1509 -0.2405 -0.1436 -0.1396 -0.1486 -0.1290 -0.2334 -0.1065 -0.1553 -0.0945 -0.0666 -0.1229 -0.6224 -0.5435 -0.0866 -1.0020 -1.1800 -0.9523 -0.1352 -0.8568 -0.0911 -0.1491 -1.1715 -0.0771 -0.7273 -0.2715 -0.1425 -0.1288 -0.2758 -0.4027 -0.1670 -0.1546
S-509	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-509	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-509	-0.3524101674556732	This document is a summary of the European Public Assessment Report ( EPAR ) explaining how the Committee for Medicinal Products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
D-509	-0.3524101674556732	This document is a summary of the European Public Assessment Report ( EPAR ) explaining how the Committee for Medicinal Products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
P-509	-0.2135 -0.5437 -1.2612 -0.2309 -0.1457 -0.0799 -0.1454 -0.1720 -0.2811 -0.3438 -1.0830 -0.0869 -0.0532 -0.3329 -0.1973 -0.0853 -0.0402 -0.1277 -2.3540 -0.1066 -0.1696 -0.1070 -0.1509 -0.2405 -0.1436 -0.1396 -0.1486 -0.1290 -0.2334 -0.1065 -0.1553 -0.0945 -0.0666 -0.1229 -0.6224 -0.5435 -0.0866 -1.0020 -1.1800 -0.9523 -0.1352 -0.8568 -0.0911 -0.1491 -1.1715 -0.0771 -0.7273 -0.2715 -0.1425 -0.1288 -0.2758 -0.4027 -0.1670 -0.1546
S-370	Colecalciferol Bei Langzeittherapie allgemein gesunder Erwachsener wurde für Dosierungen von weniger als 10.000 I.E.<unk> Tag keine Vitamin-D-Toxizität dokumentiert . In einer klinischen Studie bei gesunden Erwachsenen war eine tägliche Dosis von 4.000 I.E.
T-370	Colecalciferol Vitamin D toxicity has not been documented during chronic therapy in generally healthy adults at a dose less than 10,000 IU/ day .
H-370	-0.37433189153671265	Colecalciferol No vitamin D toxicity has been documented for doses of less than 10,000 IU / day In a clinical trial in healthy adults , a daily dose of 4,000 IU
D-370	-0.37433189153671265	Colecalciferol No vitamin D toxicity has been documented for doses of less than 10,000 IU / day In a clinical trial in healthy adults , a daily dose of 4,000 IU
P-370	-0.5293 -0.1211 -0.1561 -0.1375 -0.1464 -0.1571 -1.2391 -0.1064 -0.0475 -0.1128 -0.0726 -0.0901 -0.1075 -1.2714 -0.1333 -0.8149 -0.7775 -0.5582 -0.2563 -1.2721 -0.4021 -0.1057 -0.1440 -0.1169 -1.4001 -0.3604 -0.2180 -1.9602 -0.3990 -0.2182 -0.1586 -0.1695 -0.0920 -0.2301 -0.4319 -0.1582 -0.0446 -0.0405 -0.1191 -0.2554 -0.1809 -0.0686 -0.7152
S-75	Nach einer 15-wöchigen Behandlung war der Anteil der Patienten mit niedrigem Vitamin-D-Spiegel bei den Patienten , die mit ADROVANCE behandelt worden waren , geringer ( 11 % ) als bei denjenigen , die ausschließlich Alendronat einnahmen ( 32 % ) .
T-75	After 15 weeks of treatment , the proportion of patients with low vitamin D levels was lower among the patients treated with ADROVANCE ( 11 % ) than those taking alendronate only ( 32 % ) .
H-75	-0.45895352959632874	Following 15 weeks of treatment , patients receiving ADROVANCE with low D levels had a lower proportion ( 11 % ) than those receiving alendronate alone ( 32 % ) .
D-75	-0.45895352959632874	Following 15 weeks of treatment , patients receiving ADROVANCE with low D levels had a lower proportion ( 11 % ) than those receiving alendronate alone ( 32 % ) .
P-75	-1.1587 -0.3137 -0.1589 -0.2254 -0.3945 -0.1834 -2.2900 -0.7215 -0.2506 -0.0674 -0.1271 -0.1078 -0.0707 -0.8965 -0.9691 -1.0654 -1.0997 -1.1804 -0.1942 -1.0305 -1.2790 -0.2752 -0.1041 -0.1385 -0.1324 -0.4002 -0.0646 -0.6115 -0.4737 -0.1111 -0.1505 -0.1234 -0.6572 -0.1367 -0.1347 -0.1192 -0.1290 -0.1874 -0.1654
S-1619	wenn neue Informationen vorliegen , die Einfluss auf die gültigen Sicherheitshinweise , den Pharmakovigilanz-Plan oder die Maßnahmen zur Risiko-Minimierung haben könnten innerhalb von 60 Tagen nach einem wichtigen Ereignis ( hinsichtlich der Pharmakovigilanz oder hinsichtlich einer Maßnahme zur Risiko-Minimierung )
T-1619	In addition , an updated RMP should be submitted When new information is received that may impact on the current Safety Specification , Pharmacovigilance Plan or risk minimisation activities Within 60 days of an important ( pharmacovigilance or risk minimisation ) milestone being reached At the request of the EMEA
H-1619	-0.5619538426399231	if there is new information that could affect the valid safety warnings , the pharmacovigilance plan or risk minimisation measures , within 60 days of an important event ( in pharmacovigilance or risk minimisation measures )
D-1619	-0.5619538426399231	if there is new information that could affect the valid safety warnings , the pharmacovigilance plan or risk minimisation measures , within 60 days of an important event ( in pharmacovigilance or risk minimisation measures )
P-1619	-1.6855 -2.0799 -0.2263 -0.3685 -0.0668 -0.7211 -1.1735 -1.4066 -0.8912 -2.0754 -0.0838 -0.2061 -1.0802 -0.1515 -1.0542 -0.3495 -0.1167 -0.1180 -0.2043 -0.2046 -0.1703 -0.4943 -0.5500 -1.1035 -0.2555 -0.1006 -0.2233 -1.0217 -0.2203 -0.0860 -0.0990 -0.7561 -1.0683 -0.0499 -0.3201 -0.1546 -0.8445 -1.6324 -0.1455 -0.1587 -0.2095 -0.1706 -0.1974 -1.3457 -0.4598 -0.0491 -0.1050 -1.4721 -0.1810 -0.1888
S-466	EU<unk> 1<unk> 06<unk> 364<unk> 006 2 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 007 4 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 008 12 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 009 40 Tabletten
T-466	EU/ 1/ 06/ 364/ 006 2 tablets EU/ 1/ 06/ 364/ 007 4 tablets EU/ 1/ 06/ 364/ 008 12 tablets EU/ 1/ 06/ 364/ 009 40 tablets
H-466	-0.32264938950538635	06/ 364/ 006 2 tablets EU/ 06/ 364/ 007 4 tablets EU/ 06/ 364/ 008 12 tablets EU/
D-466	-0.32264938950538635	06/ 364/ 006 2 tablets EU/ 06/ 364/ 007 4 tablets EU/ 06/ 364/ 008 12 tablets EU/
P-466	-1.9563 -0.1888 -0.3322 -0.1882 -0.1098 -0.0906 -0.5003 -0.1156 -0.1247 -0.0857 -0.3122 -0.0965 -0.9458 -0.1524 -0.1058 -0.1423 -0.1052 -0.0773 -0.2665 -0.1199 -0.1021 -0.0887 -0.1645 -0.1027 -0.7901 -0.1220 -0.0992 -0.1353 -0.0950 -0.0776 -0.1965 -0.0993 -0.0940 -0.0927 -0.1975 -0.0950 -3.3698
S-1884	Aufgrund der geprüften Daten und Antworten des Unternehmens auf die Liste von Fragen des CHMP bestanden seitens des CHMP zum Zeitpunkt der Rücknahme gewisse Bedenken . Der Ausschuss war der vorläufigen Ansicht , dass Advexin zur Behandlung von Li-Fraumeni-Krebs nicht hätte zugelassen werden können .
T-1884	Based on the review of the data and the company s response to the CHMP list of questions , at the time of the withdrawal , the CHMP had some concerns and was of the provisional opinion that Advexin could not have been approved for the treatment of Li-Fraumeni cancer .
H-1884	-0.5714176297187805	s audited data and responses to the CHMP list of questions , there were some concerns on the part of CHMP at the time of the withdrawal and the Committee &apos;s preliminary view was that Advexin could not have been approved for the treatment of Li-Fraumeni .
D-1884	-0.5714176297187805	s audited data and responses to the CHMP list of questions , there were some concerns on the part of CHMP at the time of the withdrawal and the Committee &apos;s preliminary view was that Advexin could not have been approved for the treatment of Li-Fraumeni .
P-1884	-2.0283 -1.8722 -0.1076 -0.4675 -0.1557 -1.4300 -0.1458 -1.0229 -0.7111 -0.0429 -1.0222 -0.1366 -0.4572 -0.4845 -1.6999 -0.2983 -0.7428 -0.3734 -1.4411 -0.3948 -0.6850 -0.1214 -0.6644 -0.0524 -0.3004 -0.1866 -0.2602 -0.1504 -1.3835 -0.2813 -1.0209 -0.2755 -0.4023 -2.7577 -0.2396 -0.6179 -0.2389 -0.1189 -0.3555 -0.1655 -0.1293 -0.6787 -0.0924 -0.4177 -0.0837 -0.5008 -0.2579 -0.3222 -0.1085 -0.1209 -2.3660 -0.2051 -0.4815 -0.0447 -0.2740 -1.0187 -0.1555
S-249	Biotransformation Vitamin D3 wird in der Leber rasch zu 25-Hydroxyvitamin D3 hydroxyliert und dann in der Niere zu 1,25-Dihydroxyvitamin D3 , der biologisch aktiven Form , metabolisiert .
T-249	Biotransformation Vitamin D3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D3 , and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D3 , which represents the biologically active form .
H-249	-0.24648791551589966	biotransformation Vitamin D3 is rapidly hydroxylated in the liver to 25-hydroxyvitamin D3 and then metabolised in the kidney to 1.25-dihydroxyvitamin D3 , the biologically active form .
D-249	-0.24648791551589966	biotransformation Vitamin D3 is rapidly hydroxylated in the liver to 25-hydroxyvitamin D3 and then metabolised in the kidney to 1.25-dihydroxyvitamin D3 , the biologically active form .
P-249	-1.1356 -0.0806 -0.0305 -0.1095 -0.0339 -0.4749 -0.0689 -0.1537 -0.1359 -0.2058 -0.1183 -0.0750 -0.1651 -0.1778 -0.0298 -0.6280 -0.1624 -0.0845 -0.3401 -1.5870 -0.0857 -0.0650 -0.1040 -0.1145 -0.1116 -0.0731 -0.1535 -0.1376 -0.9400 -0.6671 -0.1704 -0.0442 -0.0853 -0.3108 -0.1569 -0.2594 -0.2431 -0.2284 -0.8198 -0.7980 -0.1103 -0.1269 -0.0633 -0.1012 -0.1269 -0.0681 -0.0791 -0.1524 -0.1329 -0.2046 -0.6317 -0.0964 -0.1276 -0.0866 -0.0400 -0.2038 -0.4184 -0.1602
S-1767	Patienten , die Faktor-VIII-Inhibitoren entwickeln Wenn die erwarteten FaktorVIII-Spiegel in Ihrem Plasma mit ADVATE nicht erreicht werden oder die Blutung nicht beherrscht werden kann , könnte dies an der Entwicklung von Faktor VIII-
T-1767	93 Patients developing Factor VIII inhibitors If your plasma Factor VIII fails to reach expected levels with ADVATE , or if bleeding is not adequately controlled , it could be due to the development of Factor VIII inhibitors .
H-1767	-0.6385253071784973	Patients who develop factor VIII inhibitors If the expected levels of factor VIII in your plasma are not achieved with ADVATE , or if bleeding cannot be controlled , factor VIII may
D-1767	-0.6385253071784973	Patients who develop factor VIII inhibitors If the expected levels of factor VIII in your plasma are not achieved with ADVATE , or if bleeding cannot be controlled , factor VIII may
P-1767	-0.7655 -0.0988 -1.1917 -0.2722 -0.3633 -0.5768 -1.3493 -1.2166 -0.0923 -0.0660 -0.0621 -0.1318 -0.4273 -1.6806 -0.8339 -1.5416 -0.6968 -0.0328 -0.4118 -2.0029 -0.3766 -0.2677 -0.1083 -0.0378 -0.1199 -1.1220 -0.1338 -0.7648 -0.9519 -0.0703 -0.1524 -0.0838 -0.0867 -1.3660 -0.1821 -0.9049 -1.3727 -0.1075 -0.6849 -0.1218 -0.1701 -0.2256 -2.2964 -0.6009 -1.6487 -0.7415 -1.4974
S-398	Die Patientinnen der 2.800-I.E.-Vitamin-D3-Gruppe erhielten ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 299 ) und die Patientinnen der 5.600-I.E.-Vitamin-D3-Gruppe erhielten ADROVANCE ( 70 mg<unk> 2.800 I.E. ) sowie zusätzlich 2.800 I.E. Vitamin D3 ( n<unk> 309 ) einmal wöchentlich ; weitere Vitamin-D- Ergänzungsmittel waren erlaubt . Nach 24-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher in der 5.600-I.E.-Vitamin-D3-Gruppe ( 69 nmol<unk> l <unk> 27,6 ng<unk> ml <unk> ) als in der 2.800-I.E.-Vitamin-D3-Gruppe ( 64 nmol<unk> l <unk> 25,5 ng<unk> ml <unk> ) .
T-398	After 24-weeks of treatment , the mean serum 25- hydroxyvitamin D levels were significantly higher in the Vitamin D3 5600 group ( 69 nmol/ l <<unk>> 27.6 ng/ ml <<unk>> ) than in the Vitamin D3 2800 group ( 64 nmol/ l <<unk>> 25.5 ng/ ml <<unk>> ) .
H-398	-0.25241225957870483	Patients in the 2,800 IU vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 299 ) and those in the 5,600 IU vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) and an additional 2,800 IU vitamin D3 ( n/ 309 ) once weekly ; additional vitamin D supplements were permitted ; after 24 weeks of treatment , mean serum levels of 25 hydroxyvitamin D were significantly higher in the 5,600 IU vitamin D3 group ( 69 nmol/ 27.6 ng/ ml <unk> ) than in the 2,800 IU vitamin D3 group ( 64 nmol/ 25.5 ng/ ml <unk> ) .
D-398	-0.25241225957870483	Patients in the 2,800 IU vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 299 ) and those in the 5,600 IU vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) and an additional 2,800 IU vitamin D3 ( n/ 309 ) once weekly ; additional vitamin D supplements were permitted ; after 24 weeks of treatment , mean serum levels of 25 hydroxyvitamin D were significantly higher in the 5,600 IU vitamin D3 group ( 69 nmol/ 27.6 ng/ ml <unk> ) than in the 2,800 IU vitamin D3 group ( 64 nmol/ 25.5 ng/ ml <unk> ) .
P-398	-1.4021 -0.0956 -0.1400 -0.1622 -0.3907 -0.0990 -0.2116 -0.3079 -1.5455 -0.0965 -0.4267 -0.1236 -0.6913 -0.3935 -0.0615 -0.0631 -0.1277 -0.1177 -0.0910 -0.1461 -0.1310 -0.1450 -0.2066 -0.0394 -0.1965 -0.0919 -0.1175 -0.1136 -0.1354 -0.1702 -0.1988 -0.0554 -0.1093 -0.0555 -0.1266 -1.1547 -0.8039 -0.1676 -0.1476 -0.2683 -0.0610 -0.1591 -0.0858 -0.2246 -0.1531 -0.1937 -0.1316 -0.3742 -0.2853 -0.0555 -0.0574 -0.1329 -0.1293 -0.0847 -0.1451 -0.1074 -0.1056 -0.1969 -0.1095 -0.1049 -0.0922 -0.1304 -0.1992 -0.1190 -1.3230 -0.6535 -0.1546 -0.1544 -0.0942 -0.1283 -0.1242 -0.9146 -0.1214 -0.1540 -0.1543 -0.1558 -0.1709 -0.1141 -0.1067 -0.1048 -0.1248 -0.2291 -0.7895 -0.7333 -0.7706 -0.1922 -0.0801 -0.1203 -0.0522 -0.1785 -0.1428 -0.8600 -0.0775 -0.5424 -0.8963 -0.1788 -0.1070 -0.1524 -0.1934 -0.2049 -0.2177 -1.2174 -0.1159 -0.0729 -0.1200 -0.3032 -1.6248 -0.1595 -0.1474 -0.0997 -0.1038 -0.0950 -0.1536 -0.1173 -0.1625 -0.1275 -0.1507 -0.2473 -0.0612 -0.2016 -0.0684 -0.3369 -0.1539 -0.2654 -0.1120 -0.3063 -0.1389 -0.1110 -0.0992 -0.8494 -0.1267 -0.4336 -0.1495 -0.0829 -0.1555 -0.1037 -0.0594 -1.1194 -0.1207 -0.1606 -0.1590 -0.1494 -0.2911 -0.0568 -0.2583 -0.3429 -0.3318 -0.1594 -0.5582 -0.1168 -0.2994 -0.1590 -0.0592 -0.1137 -0.7460 -0.1840 -0.0582 -0.1346 -0.1038 -0.2322 -0.1409 -0.0631 -0.4554 -0.1219 -0.1814 -0.1503
S-1953	- Harnverhalt , - Herz-Kreislauf-Erkrankungen wie ischämische Herzerkrankung , Tachyarrhythmie und schwere Hypertonie , - Hyperthyreose , - einem hämorrhagischen Schlaganfall in der Anamnese oder Risikofaktoren , die das Risiko für das Auftreten eines hämorrhagischen Schlaganfalls erhöhen können . Dies ist auf die alphamimetische Aktivität bei kombinierter Anwendung von Pseudoephedrin mit anderen Vasokonstriktoren wie Bromocripitin , Pergolid , Lisurid , Cabergolin , Ergotamin , Dihydroergotamin oder anderen Dekongestiva , die peroral oder nasal als abschwellendes Rhinologikum angewendet werden ( Phenylpropanolamin , Phenylephrin , Ephedrin , Oxymetazolin , Naphazolin etc. ) zurückzuführen .
T-1953	This is due to the alpha-mimetic activity of pseudoephedrine in combination with other vasoconstrictors such as bromocripitine , pergolide , lisuride , cabergoline , ergotamine , dihydroergotamine or any other decongestant medicinal product used as a nasal decongestant , either by oral route or by nasal route ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazoline ) .
H-1953	-0.3086668848991394	- Urinary retention , - Cardiovascular disorders such as ischaemic heart disease , tachyarrhythmia and severe hypertension , - hyperthyroidism , - a history of haemorrhagic stroke or risk factors that may increase the risk of haemorrhagic stroke due to alphamimetic activity associated with combined use of pseudoephedrine with other vasoconstrictors such as bromocripitin , pergolide , lisuride , cabergolin , ergotamine , dihydroergotamine or other decongestants used perorally or nasally as a decongestant ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazolin , etc . ) .
D-1953	-0.3086668848991394	- Urinary retention , - Cardiovascular disorders such as ischaemic heart disease , tachyarrhythmia and severe hypertension , - hyperthyroidism , - a history of haemorrhagic stroke or risk factors that may increase the risk of haemorrhagic stroke due to alphamimetic activity associated with combined use of pseudoephedrine with other vasoconstrictors such as bromocripitin , pergolide , lisuride , cabergolin , ergotamine , dihydroergotamine or other decongestants used perorally or nasally as a decongestant ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazolin , etc . ) .
P-1953	-2.8487 -0.3834 -0.4006 -0.0430 -0.1473 -0.1576 -0.9629 -0.1440 -0.1661 -0.1006 -0.0929 -1.5496 -0.0766 -0.2415 -0.1477 -0.1152 -0.0329 -0.1599 -0.0620 -0.4075 -0.1045 -0.1355 -0.0930 -0.1486 -0.1466 -0.0295 -0.1486 -0.3634 -0.1713 -0.0736 -0.0176 -0.0232 -0.1471 -0.5719 -0.0726 -0.1234 -0.1681 -0.0972 -0.4173 -0.0272 -0.0687 -0.1489 -0.2947 -0.7010 -0.9107 -0.1123 -0.3397 -0.6533 -0.0640 -0.2079 -0.1131 -0.1574 -0.7357 -0.1092 -0.0494 -0.4395 -0.3165 -0.0858 -0.2633 -0.1978 -0.5098 -2.3586 -1.1431 -0.0679 -0.2449 -0.0986 -0.1074 -1.3117 -0.1271 -0.1302 -0.0677 -0.2010 -0.1211 -0.1284 -0.3950 -1.9941 -0.1507 -1.2437 -0.2821 -0.1272 -0.1600 -0.1384 -0.1782 -0.0400 -0.1309 -0.1730 -0.1235 -0.3641 -0.1369 -0.0704 -0.0980 -0.1145 -0.5577 -0.1835 -0.1887 -0.1906 -0.1518 -0.0769 -0.1300 -0.0570 -0.2043 -0.3075 -0.1441 -0.2464 -0.1654 -0.1198 -0.1537 -0.1414 -1.7021 -0.3263 -0.4087 -0.1449 -0.0806 -0.0694 -1.6628 -0.1426 -0.1432 -0.2075 -0.1083 -0.1162 -0.1432 -0.1117 -0.0607 -0.1293 -0.0882 -0.1247 -0.6362 -0.1787 -0.0997 -0.0639 -0.5029 -0.2509 -0.6014 -0.1333 -0.9064 -0.0523 -0.1645 -0.0731 -0.0825 -0.2411 -0.1459 -0.7896 -0.1908 -0.3190 -2.5281 -0.2181 -1.1926 -0.8201 -0.2558 -0.0436 -0.1309 -0.0478 -0.0422 -0.1397 -0.7930 -0.1787 -0.0889 -0.0975 -0.1265 -0.2140 -0.1436 -0.1024 -0.1596 -0.2045 -0.1363 -0.1408 -0.6375 -0.0786 -0.0806 -0.0429 -0.8041 -0.1420 -0.1507 -0.6521 -0.1003 -0.1283 -0.3727 -0.1341 -0.4138 -0.2143 -0.2118 -0.1370 -0.4852 -0.1555
S-394	In dieser Studie stiegen nach 15 Wochen die mittleren Serumwerte von 25-Hydroxyvitamin D bei Patienten mit Vitamin-D-Insuffizienz bei Studienbeginn ( 25-Hydroxyvitamin D 22,5 bis 37,5 nmol<unk> l <unk> 9 - <unk> 15 ng<unk> ml <unk> ) von 30 nmol<unk> l ( 12,1 ng<unk> ml ) auf 40 nmol<unk> l ( 15,9 ng<unk> ml ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 75 ) und sanken von 30 nmol<unk> l ( 12,0 ng<unk> ml ) bei Studienbeginn auf 26 nmol<unk> l ( 10,4 ng<unk> ml ) in der Gruppe unter Alendronat allein ( n<unk> 70 ) .
T-394	In this study , mean 25- hydroxyvitamin D levels in patients with vitamin D insufficiency at baseline ( 25- hydroxyvitamin D , 22.5 to 37.5 nmol/ l <<unk>> 9 to <<unk>> 15 ng/ ml <<unk>> ) increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) at week 15 in the ADROVANCE ( 70 mg/ 2800 IU ) group ( n<<unk>> 75 ) and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at baseline to 26 nmol/ l ( 10.4 ng/ ml ) at week 15 in the alendronate-only group ( n<<unk>> 70 ) .
H-394	-0.27163052558898926	In this trial , after 15 weeks , mean serum levels of 25-hydroxyvitamin D in vitamin D deficient patients increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 75 ) group and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 nmol/ l ( 10.4 ng/ ml ) in the alendronate alone ( n/ 70 ) group .
D-394	-0.27163052558898926	In this trial , after 15 weeks , mean serum levels of 25-hydroxyvitamin D in vitamin D deficient patients increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 75 ) group and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 nmol/ l ( 10.4 ng/ ml ) in the alendronate alone ( n/ 70 ) group .
P-394	-0.4018 -0.1229 -0.8191 -0.2438 -2.1635 -0.1429 -0.1033 -0.3453 -0.1269 -0.6271 -0.1205 -0.9371 -0.5096 -0.8568 -0.1336 -0.0998 -0.1222 -0.1268 -0.1312 -0.0751 -0.1073 -0.2585 -1.1325 -0.0600 -0.1226 -0.6707 -0.3532 -0.6287 -1.4712 -0.3340 -0.2335 -0.1675 -0.3821 -0.1743 -0.1858 -0.1365 -0.2125 -0.1502 -0.1332 -0.1671 -0.0972 -0.0959 -0.1231 -0.7015 -0.0763 -0.1759 -0.4452 -0.1476 -0.1567 -0.1371 -0.0634 -0.1146 -0.1194 -0.1348 -0.1211 -0.0718 -0.1198 -0.1786 -0.1820 -0.0226 -0.0639 -0.1227 -0.1041 -0.0846 -0.1617 -0.1309 -0.0840 -0.1712 -0.1198 -0.1824 -0.0997 -0.1428 -0.1189 -0.1548 -0.1687 -0.1412 -1.0319 -0.0814 -0.1193 -1.1035 -0.8268 -0.4705 -0.0570 -0.1837 -0.1472 -0.1590 -0.2527 -0.1194 -0.1296 -0.1446 -0.1400 -0.1066 -0.1104 -0.1329 -0.1095 -0.0807 -0.1323 -0.2727 -1.2965 -1.1076 -0.3633 -0.2708 -0.8593 -0.1517 -0.1767 -0.1440 -0.4866 -0.1312 -0.1465 -0.1373 -0.0800 -0.1350 -0.1001 -0.1303 -0.1001 -0.0680 -0.1274 -0.1393 -0.1548 -0.3673 -0.0845 -0.1368 -0.1189 -0.1853 -1.0267 -0.1118 -0.1047 -0.0746 -0.1234 -0.3052 -0.2169 -0.1542
S-206	In dieser Studie stiegen nach 15 Wochen die mittleren Serumwerte von 25-Hydroxyvitamin D bei Patienten mit Vitamin-D-Insuffizienz bei Studienbeginn ( 25-Hydroxyvitamin D 22,5 bis 37,5 nmol<unk> l <unk> 9 - <unk> 15 ng<unk> ml <unk> ) von 30 nmol<unk> l ( 12,1 ng<unk> ml ) auf 40 nmol<unk> l ( 15,9 ng<unk> ml ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 75 ) und sanken von 30 nmol<unk> l ( 12,0 ng<unk> ml ) bei Studienbeginn auf 26 nmol<unk> l ( 10,4 ng<unk> ml ) in der Gruppe unter Alendronat allein ( n<unk> 70 ) .
T-206	In this study , mean 25-hydroxyvitamin D levels in patients with vitamin D insufficiency at baseline ( 25- hydroxyvitamin D , 22.5 to 37.5 nmol/ l <<unk>> 9 to <<unk>> 15 ng/ ml <<unk>> ) increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) at week 15 in the ADROVANCE ( 70 mg/ 2800 IU ) group ( n<<unk>> 75 ) and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at baseline to 26 nmol/ l ( 10.4 ng/ ml ) at week 15 in the alendronate-only group ( n<<unk>> 70 ) .
H-206	-0.27163052558898926	In this trial , after 15 weeks , mean serum levels of 25-hydroxyvitamin D in vitamin D deficient patients increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 75 ) group and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 nmol/ l ( 10.4 ng/ ml ) in the alendronate alone ( n/ 70 ) group .
D-206	-0.27163052558898926	In this trial , after 15 weeks , mean serum levels of 25-hydroxyvitamin D in vitamin D deficient patients increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 75 ) group and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 nmol/ l ( 10.4 ng/ ml ) in the alendronate alone ( n/ 70 ) group .
P-206	-0.4018 -0.1229 -0.8191 -0.2438 -2.1635 -0.1429 -0.1033 -0.3453 -0.1269 -0.6271 -0.1205 -0.9371 -0.5096 -0.8568 -0.1336 -0.0998 -0.1222 -0.1268 -0.1312 -0.0751 -0.1073 -0.2585 -1.1325 -0.0600 -0.1226 -0.6707 -0.3532 -0.6287 -1.4712 -0.3340 -0.2335 -0.1675 -0.3821 -0.1743 -0.1858 -0.1365 -0.2125 -0.1502 -0.1332 -0.1671 -0.0972 -0.0959 -0.1231 -0.7015 -0.0763 -0.1759 -0.4452 -0.1476 -0.1567 -0.1371 -0.0634 -0.1146 -0.1194 -0.1348 -0.1211 -0.0718 -0.1198 -0.1786 -0.1820 -0.0226 -0.0639 -0.1227 -0.1041 -0.0846 -0.1617 -0.1309 -0.0840 -0.1712 -0.1198 -0.1824 -0.0997 -0.1428 -0.1189 -0.1548 -0.1687 -0.1412 -1.0319 -0.0814 -0.1193 -1.1035 -0.8268 -0.4705 -0.0570 -0.1837 -0.1472 -0.1590 -0.2527 -0.1194 -0.1296 -0.1446 -0.1400 -0.1066 -0.1104 -0.1329 -0.1095 -0.0807 -0.1323 -0.2727 -1.2965 -1.1076 -0.3633 -0.2708 -0.8593 -0.1517 -0.1767 -0.1440 -0.4866 -0.1312 -0.1465 -0.1373 -0.0800 -0.1350 -0.1001 -0.1303 -0.1001 -0.0680 -0.1274 -0.1393 -0.1548 -0.3673 -0.0845 -0.1368 -0.1189 -0.1853 -1.0267 -0.1118 -0.1047 -0.0746 -0.1234 -0.3052 -0.2169 -0.1542
S-354	Uveitis , Skleritis , Episkleritis . Häufig : Bauchschmerzen , Dyspepsie , Verstopfung , Durchfall , Flatulenz , ösophageales Ulkus* , Dysphagie* , aufgetriebenes Abdomen , saures Aufstoßen . Gelegentlich : Übelkeit , Erbrechen , Gastritis , Ösophagitis* , ösophageale Erosionen* , Meläna . Selten : Ösophagusstriktur* , oropharyngeale Ulzerationen* , Perforationen , Ulzera und Blutungen im oberen Gastrointestinaltrakt ( siehe Abschnitt 4.4<unk> . * Siehe Abschnitte 4.2 und 4.4 .
T-354	Rare : uveitis , scleritis , episcleritis Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcer* , dysphagia* , abdominal distension , acid regurgitation Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosions* , melena Rare : oesophageal stricture* , oropharyngeal ulceration* , upper gastrointestinal PUBs ( perforation , ulcers , bleeding<<unk>> <<unk>> see section 4.4 ) . <<unk>> See sections 4.2 and 4.4
H-354	-0.23227500915527344	Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcus* , dysphagia* , distended abdomen , acid regurgitation . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosion* , melena . Rare : oesophagus stricture * , oropharyngeal ulceration* , perforations , ulcers and upper gastrointestinal bleeding ( see section 4.4<unk> . * See sections 4.2 and 4.4 .
D-354	-0.23227500915527344	Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcus* , dysphagia* , distended abdomen , acid regurgitation . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosion* , melena . Rare : oesophagus stricture * , oropharyngeal ulceration* , perforations , ulcers and upper gastrointestinal bleeding ( see section 4.4<unk> . * See sections 4.2 and 4.4 .
P-354	-1.0176 -0.1006 -0.1788 -0.1955 -0.0201 -0.0783 -0.0503 -0.1353 -0.0628 -0.1128 -0.0749 -0.0416 -0.1338 -0.1068 -0.0342 -0.0692 -0.1329 -0.1362 -0.1155 -0.0291 -0.0740 -0.0678 -0.1336 -0.1805 -0.0551 -0.1387 -0.1315 -0.6669 -0.1008 -0.3366 -0.0570 -0.0532 -0.1397 -0.0822 -3.1415 -0.1356 -0.1303 -0.0560 -0.0272 -0.1217 -1.7425 -0.2541 -0.1808 -0.1310 -1.8872 -0.1278 -0.1025 -0.1043 -0.0629 -0.1860 -0.1350 -0.3983 -1.3247 -0.3177 -0.0712 -0.1558 -0.1829 -0.2195 -0.0540 -0.1580 -0.0553 -0.0265 -0.1351 -0.0713 -0.0463 -0.1059 -0.1325 -0.1349 -0.0557 -0.0639 -0.1316 -0.3887 -0.1582 -0.0624 -0.0692 -0.1081 -0.5463 -0.2029 -0.1304 -0.3452 -0.0930 -0.5960 -0.0527 -0.0549 -0.1389 -0.1017 -0.1252 -0.6851 -0.1277 -0.0738 -1.7789 -0.2001 -0.3049 -0.1088 -0.1514 -0.2070 -0.0818 -0.2545 -0.0546 -0.3241 -0.4315 -0.3675 -0.1573 -0.1345 -0.1132 -0.0870 -0.1008 -0.1407 -0.0559 -0.1162 -0.0610 -0.1683 -0.9963 -0.0768 -0.1341 -0.0422 -0.1689 -0.3851 -0.1365 -0.1374 -0.3320 -0.1272 -0.8815 -0.3504 -0.1486 -0.1534 -0.2527 -0.0537 -0.0369 -0.6804 -0.0969 -0.1357 -0.1225 -0.0686 -0.1558 -0.2456 -0.0690 -0.1658 -0.0511 -0.2197 -0.0369 -0.1403 -0.1414 -0.1470 -0.1152 -0.1415 -0.1894 -0.1679
S-166	Uveitis , Skleritis , Episkleritis . Häufig : Bauchschmerzen , Dyspepsie , Verstopfung , Durchfall , Flatulenz , ösophageales Ulkus* , Dysphagie* , aufgetriebenes Abdomen , saures Aufstoßen . Gelegentlich : Übelkeit , Erbrechen , Gastritis , Ösophagitis* , ösophageale Erosionen* , Meläna . Selten : Ösophagusstriktur* , oropharyngeale Ulzerationen* , Perforationen , Ulzera und Blutungen im oberen Gastrointestinaltrakt ( siehe Abschnitt 4.4<unk> . * Siehe Abschnitte 4.2 und 4.4 .
T-166	Rare : uveitis , scleritis , episcleritis Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcer* , dysphagia* , abdominal distension , acid regurgitation Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosions* , melena Rare : oesophageal stricture* , oropharyngeal ulceration* , upper gastrointestinal PUBs ( perforation , ulcers , bleeding<<unk>> <<unk>> see section 4.4 ) . <<unk>> See sections 4.2 and 4.4
H-166	-0.23227500915527344	Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcus* , dysphagia* , distended abdomen , acid regurgitation . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosion* , melena . Rare : oesophagus stricture * , oropharyngeal ulceration* , perforations , ulcers and upper gastrointestinal bleeding ( see section 4.4<unk> . * See sections 4.2 and 4.4 .
D-166	-0.23227500915527344	Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcus* , dysphagia* , distended abdomen , acid regurgitation . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosion* , melena . Rare : oesophagus stricture * , oropharyngeal ulceration* , perforations , ulcers and upper gastrointestinal bleeding ( see section 4.4<unk> . * See sections 4.2 and 4.4 .
P-166	-1.0176 -0.1006 -0.1788 -0.1955 -0.0201 -0.0783 -0.0503 -0.1353 -0.0628 -0.1128 -0.0749 -0.0416 -0.1338 -0.1068 -0.0342 -0.0692 -0.1329 -0.1362 -0.1155 -0.0291 -0.0740 -0.0678 -0.1336 -0.1805 -0.0551 -0.1387 -0.1315 -0.6669 -0.1008 -0.3366 -0.0570 -0.0532 -0.1397 -0.0822 -3.1415 -0.1356 -0.1303 -0.0560 -0.0272 -0.1217 -1.7425 -0.2541 -0.1808 -0.1310 -1.8872 -0.1278 -0.1025 -0.1043 -0.0629 -0.1860 -0.1350 -0.3983 -1.3247 -0.3177 -0.0712 -0.1558 -0.1829 -0.2195 -0.0540 -0.1580 -0.0553 -0.0265 -0.1351 -0.0713 -0.0463 -0.1059 -0.1325 -0.1349 -0.0557 -0.0639 -0.1316 -0.3887 -0.1582 -0.0624 -0.0692 -0.1081 -0.5463 -0.2029 -0.1304 -0.3452 -0.0930 -0.5960 -0.0527 -0.0549 -0.1389 -0.1017 -0.1252 -0.6851 -0.1277 -0.0738 -1.7789 -0.2001 -0.3049 -0.1088 -0.1514 -0.2070 -0.0818 -0.2545 -0.0546 -0.3241 -0.4315 -0.3675 -0.1573 -0.1345 -0.1132 -0.0870 -0.1008 -0.1407 -0.0559 -0.1162 -0.0610 -0.1683 -0.9963 -0.0768 -0.1341 -0.0422 -0.1689 -0.3851 -0.1365 -0.1374 -0.3320 -0.1272 -0.8815 -0.3504 -0.1486 -0.1534 -0.2527 -0.0537 -0.0369 -0.6804 -0.0969 -0.1357 -0.1225 -0.0686 -0.1558 -0.2456 -0.0690 -0.1658 -0.0511 -0.2197 -0.0369 -0.1403 -0.1414 -0.1470 -0.1152 -0.1415 -0.1894 -0.1679
S-69	Es hemmt die Aktivität der Osteoklasten , das sind Zellen , die am Abbau des Knochengewebes beteiligt sind . Indem es die Aktivität dieser Zellen blockiert , verlangsamt Alendronat den Knochenverlust . Vitamin D3 ist ein Nährstoff , der in manchen Lebensmitteln enthalten ist , aber auch bei Bestrahlung mit natürlichem Sonnenlicht in der Haut hergestellt wird . Vitamin D3 wird , genauso wie andere Formen des Vitamins D , für die Calciumaufnahme und die normale Knochenbildung benötigt . Da Patientinnen mit Osteoporose möglicherweise nicht genügend Vitamin D3 durch Sonnenbestrahlung bilden , ist das Vitamin in ADROVANCE enthalten .
T-69	Since patients with osteoporosis may not get enough vitamin D3 through exposure to sunlight , it is included in ADROVANCE .
H-69	-0.3495410680770874	Alendronate inhibits the activity of osteoclasts , cells involved in the breakdown of bone tissue . By blocking the activity of these cells , alendronate slows bone loss . Vitamin D3 is a nutrient found in some foods but also produced in the skin when exposed to natural sunlight . Vitamin D3 , like other forms of vitamin D , is needed for calcium uptake and normal bone formation . As patients with osteoporosis may not produce enough vitamin D3 from sunlight , ADROVANCE contains it .
D-69	-0.3495410680770874	Alendronate inhibits the activity of osteoclasts , cells involved in the breakdown of bone tissue . By blocking the activity of these cells , alendronate slows bone loss . Vitamin D3 is a nutrient found in some foods but also produced in the skin when exposed to natural sunlight . Vitamin D3 , like other forms of vitamin D , is needed for calcium uptake and normal bone formation . As patients with osteoporosis may not produce enough vitamin D3 from sunlight , ADROVANCE contains it .
P-69	-1.6232 -0.1215 -0.1557 -0.0958 -1.7308 -0.0837 -0.1543 -1.8772 -0.4963 -0.1295 -0.1838 -0.0850 -0.1632 -0.0216 -0.1335 -0.2139 -0.4561 -0.3591 -0.1308 -2.4550 -0.2398 -0.1241 -0.0659 -0.3124 -0.3045 -0.5090 -0.1496 -0.6168 -0.3527 -0.1289 -0.1206 -0.1092 -0.1639 -0.1330 -0.0743 -0.1529 -0.0861 -0.2345 -0.1123 -0.2034 -0.2763 -0.1823 -0.4345 -0.0755 -0.1628 -0.1423 -0.1696 -0.1329 -0.1055 -0.0888 -0.8720 -0.1556 -0.2311 -0.1990 -0.9163 -0.8362 -0.3630 -0.4894 -0.2277 -0.1489 -0.9020 -0.1944 -0.1280 -0.3639 -0.1352 -0.1379 -0.1684 -0.8435 -0.0659 -0.1703 -0.1402 -1.1342 -1.0012 -0.1141 -0.1493 -0.1282 -0.0779 -0.0448 -0.1188 -0.1451 -0.2113 -1.7681 -0.2189 -0.1046 -0.0877 -0.1100 -0.6592 -0.0200 -0.1351 -0.3489 -0.1837 -0.2381 -0.2699 -1.0684 -0.7932 -0.1446 -0.1501 -0.0683 -0.1009 -0.1237 -0.0949 -0.0635 -0.1592 -0.1288 -1.1704 -0.7537 -0.1840 -0.0777 -0.1596 -0.1374 -0.6831 -1.6677 -0.3187 -0.1294 -1.0594 -0.0534 -0.1176 -0.0875 -0.0754 -0.0775 -1.2725 -0.1939 -0.2864
S-1912	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu <unk> EMEA 2007 Reproduction and<unk> or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Aerinaze Tabletten bestehen aus zwei Schichten , von denen eine Desloratadin und die andere Pseudoephedrin enthält . Desloratadin wird sofort nach der Einnahme aus seiner Schicht freigesetzt , während Pseudoephedrin langsam über 12 Stunden hinweg freigesetzt wird . Daher muss die Tablette nur zweimal täglich eingenommen werden .
T-1912	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu <<unk>> EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Desloratadine has been available in the European Union ( EU ) since 2001 , and pseudoephedrine is widely used in medicines that have been available over-the-counter for many years .
H-1912	-0.35825976729393005	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 Email : mail/ emea.europa.eu http/ / www.emea.europa.eu / Reproduction and/ or distribution of this document is authorised for non @-@ commercial purposes only provided the EMEA is recognised Aerinaze tablets consist of two layers , one containing desloratadine and the other pseudoephedrine . Desloratadine is released from its layer immediately after administration , while pseudoephedrine is released slowly over 12 hours . Therefore , the tablet should only be taken 2 times daily .
D-1912	-0.35825976729393005	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 Email : mail/ emea.europa.eu http/ / www.emea.europa.eu / Reproduction and/ or distribution of this document is authorised for non @-@ commercial purposes only provided the EMEA is recognised Aerinaze tablets consist of two layers , one containing desloratadine and the other pseudoephedrine . Desloratadine is released from its layer immediately after administration , while pseudoephedrine is released slowly over 12 hours . Therefore , the tablet should only be taken 2 times daily .
P-1912	-1.6616 -0.0842 -0.0449 -0.1114 -0.1262 -0.0778 -0.0932 -0.0527 -0.0954 -0.1061 -0.1426 -0.0765 -0.0467 -0.1104 -0.1205 -0.0820 -0.0971 -0.0436 -0.1472 -0.1865 -1.2011 -0.1460 -0.2123 -0.2187 -0.0462 -1.3164 -0.0950 -0.1726 -0.0984 -0.6389 -0.2504 -0.2088 -0.4872 -2.1244 -0.0188 -1.2722 -0.1450 -0.1551 -0.0874 -0.6370 -1.3994 -0.3515 -0.1138 -0.1474 -0.1732 -0.2728 -0.1261 -0.1369 -0.1013 -0.1666 -0.6948 -0.1659 -0.1315 -0.3987 -1.6819 -0.1449 -0.7844 -0.1370 -0.2586 -0.1615 -0.1473 -0.0707 -0.1124 -0.1516 -1.8846 -0.1163 -0.1429 -0.1628 -0.1265 -0.0905 -0.1432 -0.1145 -0.2046 -0.1219 -0.1281 -0.1702 -0.6508 -0.1412 -0.4119 -0.1472 -0.6747 -0.4852 -0.0769 -0.1216 -0.2379 -0.5778 -0.1527 -0.1670 -0.0913 -0.6783 -0.2038 -0.1660 -0.0459 -0.1336 -0.0606 -0.5363 -0.3630 -0.1419 -0.0598 -0.1240 -0.1939 -1.6869 -0.1746 -0.3736 -0.2518 -0.1659 -0.8609 -0.0452 -0.5020 -1.4112 -0.8055 -0.9454 -0.1013 -0.1823 -0.1759 -0.0554 -0.0976 -0.0865 -0.1318 -0.1620 -1.4212 -0.1520 -0.6309 -0.2310 -0.1249 -1.3416 -0.9073 -0.0830 -0.3617 -0.3016 -0.1469 -0.1468 -2.1125 -0.6028 -0.1390 -0.2244 -1.1203 -0.4205 -0.3026 -0.2478 -0.1621
S-532	Aus diesem Grund wurde Advate in einer Hauptstudie an 111 Patienten , die an Hämophilie A leiden , mit Recombinate verglichen , um zu zeigen , dass beide Arzneimittel äquivalent sind . In der Studie wurde bei 107 Patienten , die alle Advate erhielten , zudem die Anzahl der Blutungsepisoden untersucht und die Wirksamkeit von Advate bei der Blutstillung auf einer Skala von unwirksam bis ausgezeichnet bewertet . In drei zusätzlichen Studien an Patienten mit schwerer bis mittelschwerer Hämophilie A , darunter eine Studie mit 53 Kindern unter sechs Jahren , wurde die Anwendung des Arzneimittels zur Vorbeugung von Blutungen sowie bei chirurgischen Eingriffen untersucht .
T-532	Three additional studies looked at the use of the medicine in the prevention of bleeding and in surgery in patients with severe or moderately severe haemophilia A , including one study in 53 children under the age of six years .
H-532	-0.42850178480148315	For this reason , a major study of 111 patients with haemophilia A compared Advate to Recombinate to show that both medicines are equivalent . In addition , the number of bleeding episodes and the efficacy of Advate in haemostasis were evaluated on a scale of ineffective to excellent in 107 patients receiving all Advate . Three additional studies in patients with severe to moderate haemophilia A , including a trial of 53 children under six years of age , investigated the use of the medicine for preventing bleeding and for surgery .
D-532	-0.42850178480148315	For this reason , a major study of 111 patients with haemophilia A compared Advate to Recombinate to show that both medicines are equivalent . In addition , the number of bleeding episodes and the efficacy of Advate in haemostasis were evaluated on a scale of ineffective to excellent in 107 patients receiving all Advate . Three additional studies in patients with severe to moderate haemophilia A , including a trial of 53 children under six years of age , investigated the use of the medicine for preventing bleeding and for surgery .
P-532	-2.4406 -0.2289 -0.1314 -0.1384 -0.5118 -1.1268 -1.1091 -0.6216 -0.0704 -1.5497 -0.4711 -0.1938 -0.0643 -0.0515 -0.0617 -0.1519 -0.2290 -0.3341 -0.1084 -0.6407 -0.0913 -0.0736 -0.0901 -0.0966 -0.4508 -0.7931 -0.4898 -0.2288 -0.7581 -0.4146 -0.2796 -0.0819 -0.3863 -2.0050 -0.0503 -0.1305 -0.6564 -0.2475 -0.1188 -0.9921 -0.1802 -0.0040 -1.2072 -1.7776 -0.3846 -0.0571 -0.0995 -0.1283 -0.3138 -0.0965 -0.1604 -0.6790 -0.0403 -0.0598 -0.3048 -1.5563 -0.3047 -0.1202 -0.1476 -0.1339 -0.0631 -0.7978 -0.2034 -0.2229 -0.1328 -0.1394 -0.1449 -0.2718 -0.1121 -0.6847 -0.6974 -0.2669 -1.1363 -0.3434 -0.1648 -0.5065 -0.1204 -1.0796 -0.4133 -0.7821 -0.1332 -0.0590 -0.1841 -0.2373 -0.1402 -0.0995 -0.0547 -0.0991 -0.1179 -0.2430 -0.0429 -0.2619 -0.7901 -0.5462 -0.0776 -0.2216 -0.3322 -0.8005 -0.6725 -1.0892 -0.0969 -0.1259 -0.9666 -0.5759 -0.1135 -0.1202 -0.4238 -1.2675 -0.8600 -1.6329 -0.8903 -0.1786 -0.2638 -1.2537 -0.1079 -0.1741 -0.1708
S-388	Studien mit ADROVANCE Die Wirkung der niedrigeren Dosis von ADROVANCE ( 70 mg Alendronat<unk> 2.800 I.E. Vitamin D3 ) auf den Vitamin-D-Status wurde in einer 15-wöchigen , multinationalen Studie an 682 postmenopausalen Frauen mit Osteoporose gezeigt ( mittlerer Serum-Ausgangswert von 25-Hydroxyvitamin D : 56 nmol<unk> l <unk> 22,3 ng<unk> ml <unk> ; Bereich : 22,5-225 nmol<unk> l <unk> 9-90 ng<unk> ml <unk> ) .
T-388	ADROVANCE studies The effect of the lower dose of ADROVANCE ( alendronate 70 mg/ vitamin D3 2800 IU ) on vitamin D status was demonstrated in a 15-week , multinational study that enrolled 682 osteoporotic post- menopausal women ( serum 25-hydroxyvitamin D at baseline : mean , 56 nmol/ l <<unk>> 22.3 ng/ ml <<unk>> ; range , 22.5-225 nmol/ l <<unk>> 9-90 ng/ ml <<unk>> ) .
H-388	-0.251417875289917	trials of ADROVANCE The effect of the lower dose of ADROVANCE ( 70 mg alendronate<unk> 2,800 IU of vitamin D3 ) on vitamin D status was demonstrated in a 15 @-@ week , multinational trial in 682 post-menopausal women with osteoporosis ( mean serum baseline of 25 -hydroxyvitamin D : 56 nmol/ <unk> 22.3 ng/ ml ; range : 22.5 -225 nmol/ l <unk> 9 -90 ng/ ml <unk> ) .
D-388	-0.251417875289917	trials of ADROVANCE The effect of the lower dose of ADROVANCE ( 70 mg alendronate<unk> 2,800 IU of vitamin D3 ) on vitamin D status was demonstrated in a 15 @-@ week , multinational trial in 682 post-menopausal women with osteoporosis ( mean serum baseline of 25 -hydroxyvitamin D : 56 nmol/ <unk> 22.3 ng/ ml ; range : 22.5 -225 nmol/ l <unk> 9 -90 ng/ ml <unk> ) .
P-388	-1.1537 -0.3655 -0.0731 -0.0621 -0.1287 -0.1091 -0.0883 -0.1868 -0.9454 -0.1361 -0.4103 -0.2607 -0.0744 -0.1204 -0.0362 -0.0551 -0.1278 -0.1076 -0.1058 -0.1436 -0.4911 -0.0274 -0.2817 -0.0899 -0.1410 -0.4794 -1.2547 -1.0912 -0.1150 -0.0827 -0.0987 -0.1584 -0.5894 -0.1373 -0.0814 -0.1505 -0.1446 -0.1289 -0.1075 -0.3750 -0.0499 -0.1674 -0.0336 -0.2324 -0.3766 -0.1227 -0.1297 -0.1764 -1.0411 -0.0762 -0.5318 -0.1057 -0.0692 -0.2173 -0.7030 -0.7961 -0.2074 -0.0671 -0.0728 -0.3439 -0.0810 -0.1074 -0.0375 -0.1168 -0.0916 -0.1536 -0.1223 -0.0836 -0.1119 -0.1180 -0.0853 -0.1054 -0.1495 -0.1287 -0.9578 -0.1240 -0.0585 -0.0324 -0.1504 -0.3438 -1.2171 -0.0809 -0.1371 -0.1250 -0.1005 -0.0676 -0.1054 -0.2854 -0.1570 -0.1162 -0.2450 -0.2315 -2.1687 -0.0597 -0.1462 -0.0947 -0.2379 -0.1185 -0.0692 -0.6783 -0.1658 -0.5334 -0.1055 -0.2663 -0.0811 -0.1107 -0.1211 -0.1181 -0.2104 -0.1601 -0.2766 -0.3075 -1.0793 -0.1583 -0.0878 -0.1010 -0.1769 -0.1069 -0.0614 -0.2305 -0.1306 -0.3475 -0.1491
S-296	Aufgrund der möglichen Verschlechterung der zugrunde liegenden Erkrankung sollte Alendronat bei Patienten mit aktiven gastrointestinalen Erkrankungen , wie Dysphagie , Erkrankungen des Ösophagus , Gastritis , Duodenitis , Ulzera , oder mit kürzlich aufgetretenen ( innerhalb des letzten Jahres ) , schweren gastrointestinalen Erkrankungen , wie z. B. peptisches Ulkus , aktive gastrointestinale Blutungen oder chirurgische Eingriffe im oberen Gastrointestinaltrakt außer Pyloroplastik , nur unter besonderer Vorsicht gegeben werden ( siehe Abschnitt 4.3 ) .
T-296	Because there is a potential for worsening of the underlying disease , caution should be used when alendronate is given to patients with active upper gastrointestinal problems , such as dysphagia , oesophageal disease , gastritis , duodenitis , ulcers , or with a recent history ( within the previous year ) of major gastrointestinal disease such as peptic ulcer , or active gastrointestinal bleeding , or surgery of the upper gastrointestinal tract other than pyloroplasty ( see section 4.3 ) .
H-296	-0.29420825839042664	Due to the possible worsening of the underlying condition , alendronate should be given with caution in patients with active gastro-intestinal disorders , such as dysphagia , oesophagus disorders , gastritis , duodenitis , ulcers , or with recent ( within the last year ) , severe gastro-intestinal disorders , such as peptic ulcer , active gastro-intestinal bleeding or upper gastro-intestinal surgery other than pyloroplasty ( see section 4.3 ) .
D-296	-0.29420825839042664	Due to the possible worsening of the underlying condition , alendronate should be given with caution in patients with active gastro-intestinal disorders , such as dysphagia , oesophagus disorders , gastritis , duodenitis , ulcers , or with recent ( within the last year ) , severe gastro-intestinal disorders , such as peptic ulcer , active gastro-intestinal bleeding or upper gastro-intestinal surgery other than pyloroplasty ( see section 4.3 ) .
P-296	-0.8270 -0.0670 -0.1247 -0.7884 -1.6260 -0.1126 -0.0892 -0.1351 -0.1324 -0.5364 -0.0278 -1.3814 -0.1630 -1.3286 -0.1072 -0.1218 -0.0737 -0.1338 -0.3719 -1.2729 -0.8269 -1.5061 -0.1502 -0.2906 -0.1572 -0.0471 -0.0911 -0.1430 -1.0971 -0.1516 -0.1065 -0.0766 -0.3466 -0.0653 -1.3006 -0.1517 -0.1479 -0.0700 -0.0434 -0.1341 -0.0653 -0.1389 -1.0806 -0.0311 -0.1905 -0.1007 -0.1814 -0.4073 -0.0816 -0.1345 -0.2696 -0.0672 -0.0518 -0.1373 -0.1111 -0.1196 -0.0937 -0.1000 -0.0595 -0.1380 -0.1822 -0.5130 -0.1795 -0.1485 -0.2569 -0.3667 -0.0754 -0.4366 -0.3586 -0.2403 -1.1311 -0.1134 -0.1305 -0.8155 -0.6424 -0.1654 -0.1345 -0.4292 -0.1330 -0.0921 -0.0509 -0.1728 -0.0576 -0.4360 -0.1785 -0.1437 -0.1958 -0.1108 -0.0899 -0.1198 -0.1340 -0.1421 -0.0419 -0.3008 -0.1441 -0.5421 -0.1735 -0.0706 -0.0596 -1.2921 -0.1442 -1.0551 -0.2835 -0.1659 -0.1802 -0.3198 -0.1888 -0.0786 -0.0395 -0.1416 -1.3899 -0.1018 -0.1021 -0.0628 -0.0976 -0.2622 -0.2098 -0.1733 -0.0989 -0.0797 -0.1297 -0.1241 -0.1338 -0.1756 -0.1521
S-108	Aufgrund der möglichen Verschlechterung der zugrunde liegenden Erkrankung sollte Alendronat bei Patienten mit aktiven gastrointestinalen Erkrankungen , wie Dysphagie , Erkrankungen des Ösophagus , Gastritis , Duodenitis , Ulzera , oder mit kürzlich aufgetretenen ( innerhalb des letzten Jahres ) , schweren gastrointestinalen Erkrankungen , wie z. B. peptisches Ulkus , aktive gastrointestinale Blutungen oder chirurgische Eingriffe im oberen Gastrointestinaltrakt außer Pyloroplastik , nur unter besonderer Vorsicht gegeben werden ( siehe Abschnitt 4.3 ) .
T-108	Because there is a potential for worsening of the underlying disease , caution should be used when alendronate is given to patients with active upper gastrointestinal problems , such as dysphagia , oesophageal disease , gastritis , duodenitis , ulcers , or with a recent history ( within the previous year ) of major gastrointestinal disease such as peptic ulcer , or active gastrointestinal bleeding , or surgery of the upper gastrointestinal tract other than pyloroplasty ( see section 4.3 ) .
H-108	-0.29420825839042664	Due to the possible worsening of the underlying condition , alendronate should be given with caution in patients with active gastro-intestinal disorders , such as dysphagia , oesophagus disorders , gastritis , duodenitis , ulcers , or with recent ( within the last year ) , severe gastro-intestinal disorders , such as peptic ulcer , active gastro-intestinal bleeding or upper gastro-intestinal surgery other than pyloroplasty ( see section 4.3 ) .
D-108	-0.29420825839042664	Due to the possible worsening of the underlying condition , alendronate should be given with caution in patients with active gastro-intestinal disorders , such as dysphagia , oesophagus disorders , gastritis , duodenitis , ulcers , or with recent ( within the last year ) , severe gastro-intestinal disorders , such as peptic ulcer , active gastro-intestinal bleeding or upper gastro-intestinal surgery other than pyloroplasty ( see section 4.3 ) .
P-108	-0.8270 -0.0670 -0.1247 -0.7884 -1.6260 -0.1126 -0.0892 -0.1351 -0.1324 -0.5364 -0.0278 -1.3814 -0.1630 -1.3286 -0.1072 -0.1218 -0.0737 -0.1338 -0.3719 -1.2729 -0.8269 -1.5061 -0.1502 -0.2906 -0.1572 -0.0471 -0.0911 -0.1430 -1.0971 -0.1516 -0.1065 -0.0766 -0.3466 -0.0653 -1.3006 -0.1517 -0.1479 -0.0700 -0.0434 -0.1341 -0.0653 -0.1389 -1.0806 -0.0311 -0.1905 -0.1007 -0.1814 -0.4073 -0.0816 -0.1345 -0.2696 -0.0672 -0.0518 -0.1373 -0.1111 -0.1196 -0.0937 -0.1000 -0.0595 -0.1380 -0.1822 -0.5130 -0.1795 -0.1485 -0.2569 -0.3667 -0.0754 -0.4366 -0.3586 -0.2403 -1.1311 -0.1134 -0.1305 -0.8155 -0.6424 -0.1654 -0.1345 -0.4292 -0.1330 -0.0921 -0.0509 -0.1728 -0.0576 -0.4360 -0.1785 -0.1437 -0.1958 -0.1108 -0.0899 -0.1198 -0.1340 -0.1421 -0.0419 -0.3008 -0.1441 -0.5421 -0.1735 -0.0706 -0.0596 -1.2921 -0.1442 -1.0551 -0.2835 -0.1659 -0.1802 -0.3198 -0.1888 -0.0786 -0.0395 -0.1416 -1.3899 -0.1018 -0.1021 -0.0628 -0.0976 -0.2622 -0.2098 -0.1733 -0.0989 -0.0797 -0.1297 -0.1241 -0.1338 -0.1756 -0.1521
S-67	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu <unk> EMEA 2007 Reproduction and<unk> or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Menopause ) auf , wenn der Spiegel des weiblichen Hormons Östrogen sinkt , denn das Hormon Östrogen unterstützt die Knochengesundheit . Die arzneilich wirksamen Bestandteile in ADROVANCE sind Alendronat und Vitamin D3 .
T-67	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu <<unk>> EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Vitamin D3 is a nutrient that is found in some foods , but is also made in the skin through exposure to natural sunlight .
H-67	-0.33626312017440796	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 Email : mail/ emea.europa.eu http/ / www.emea 2007 Reproduction and/ or distribution of this document is authorised for non @-@ commercial purposes only provided the EMEA is recognised menopause ) when levels of the female hormone oestrogen decrease because the hormone oestrogen supports bone health . ADROVANCE contains active ingredients alendronate and vitamin D3 .
D-67	-0.33626312017440796	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 Email : mail/ emea.europa.eu http/ / www.emea 2007 Reproduction and/ or distribution of this document is authorised for non @-@ commercial purposes only provided the EMEA is recognised menopause ) when levels of the female hormone oestrogen decrease because the hormone oestrogen supports bone health . ADROVANCE contains active ingredients alendronate and vitamin D3 .
P-67	-0.8073 -0.0927 -0.0501 -0.1144 -0.1257 -0.0791 -0.0968 -0.0555 -0.0989 -0.1071 -0.1421 -0.0797 -0.0530 -0.1112 -0.1200 -0.0803 -0.0963 -0.0452 -0.1296 -0.1994 -1.3788 -0.1446 -0.2483 -0.1904 -0.0492 -1.3752 -0.1075 -0.1902 -0.0947 -0.6945 -0.2311 -0.0868 -0.3681 -1.2172 -0.0235 -0.9823 -0.8185 -0.1817 -0.1534 -0.6151 -0.1404 -0.1855 -0.2080 -0.1243 -0.1252 -0.1266 -0.1829 -0.8524 -0.1872 -0.1270 -0.4226 -1.4521 -0.1638 -0.8287 -0.1377 -0.3055 -0.1636 -0.1688 -0.0748 -0.1165 -0.1478 -1.9264 -0.1229 -0.0981 -0.0367 -0.1321 -0.4014 -0.3476 -0.1269 -0.1564 -0.0837 -0.1009 -0.0771 -0.7302 -0.2405 -0.0565 -0.0411 -1.1480 -0.3895 -1.3709 -0.4994 -0.1412 -0.0778 -0.1092 -0.1967 -0.0640 -0.0444 -0.8784 -0.0444 -1.1571 -0.2523 -1.2899 -0.0608 -0.1257 -0.0892 -0.0472 -1.7435 -0.8819 -1.0881 -1.2442 -0.0836 -0.1312 -0.0497 -0.1341 -0.1248 -0.0797 -0.1460 -0.1324 -0.2440 -0.1644
S-200	Studien mit ADROVANCE Die Wirkung von ADROVANCE ( 70 mg Alendronat<unk> 2.800 I.E. Vitamin D3 ) auf den Vitamin-D- Status wurde in einer 15-wöchigen , multinationalen Studie an 682 postmenopausalen Frauen mit Osteoporose gezeigt ( mittlerer Serum-Ausgangswert von 25-Hydroxyvitamin D : 56 nmol<unk> l <unk> 22,3 ng<unk> ml <unk> ; Bereich : 22,5-225 nmol<unk> l <unk> 9-90 ng<unk> ml <unk> ) .
T-200	ADROVANCE studies The effect of ADROVANCE ( alendronate 70 mg/ vitamin D3 2800 IU ) on vitamin D status was demonstrated in a 15-week , multinational study that enrolled 682 osteoporotic post-menopausal women ( serum 25-hydroxyvitamin D at baseline : mean , 56 nmol/ l <<unk>> 22.3 ng/ ml <<unk>> ; range , 22.5- 225 nmol/ l <<unk>> 9-90 ng/ ml <<unk>> ) .
H-200	-0.257274866104126	trials of ADROVANCE The effect of ADROVANCE ( 70 mg alendronate<unk> 2,800 IU of vitamin D3 ) on vitamin D status was demonstrated in a 15 @-@ week , multinational trial in 682 post-menopausal women with osteoporosis ( mean serum baseline of 25 -hydroxyvitamin D : 56 nmol/ l <unk> 22.3 ng/ ml ; range : 22.5 -225 nmol/ l <unk> 9 -90 ng/ ml <unk> ) .
D-200	-0.257274866104126	trials of ADROVANCE The effect of ADROVANCE ( 70 mg alendronate<unk> 2,800 IU of vitamin D3 ) on vitamin D status was demonstrated in a 15 @-@ week , multinational trial in 682 post-menopausal women with osteoporosis ( mean serum baseline of 25 -hydroxyvitamin D : 56 nmol/ l <unk> 22.3 ng/ ml ; range : 22.5 -225 nmol/ l <unk> 9 -90 ng/ ml <unk> ) .
P-200	-0.9663 -0.4462 -0.0713 -0.0641 -0.1284 -0.1101 -0.0836 -0.6334 -0.1742 -0.1315 -0.0357 -0.0508 -0.1242 -0.1122 -0.0893 -0.1509 -0.5453 -0.0252 -0.2527 -0.0816 -0.1564 -0.4172 -1.0491 -1.7600 -0.1014 -0.0829 -0.1031 -0.1630 -0.7031 -0.1363 -0.0784 -0.1636 -0.1472 -0.1385 -0.1023 -0.3771 -0.0464 -0.1123 -0.0369 -0.2481 -0.3699 -0.1249 -0.1317 -0.1924 -1.0363 -0.0838 -0.5978 -0.1060 -0.0667 -0.2320 -0.7446 -0.8064 -0.1931 -0.0666 -0.0713 -0.3857 -0.0682 -0.1063 -0.0447 -0.1173 -0.0870 -0.1500 -0.1193 -0.0853 -0.1218 -0.1199 -0.0836 -0.0991 -0.1508 -0.1455 -1.2307 -0.1261 -0.0592 -0.0368 -0.1868 -0.6001 -1.4660 -0.0575 -0.1240 -0.1180 -0.1030 -0.0679 -0.1063 -0.2583 -0.1230 -0.1177 -0.3662 -0.2220 -1.5106 -0.8178 -0.0576 -0.1535 -0.0900 -0.2244 -0.1021 -0.0786 -0.3899 -0.1278 -0.4004 -0.1526 -0.3098 -0.1142 -0.1085 -0.1130 -0.1121 -0.1907 -0.1378 -0.1836 -0.1856 -1.2021 -0.2220 -0.0831 -0.0921 -0.1638 -0.1086 -0.0546 -0.2976 -0.1311 -0.3293 -0.1500
S-77	Die häufigsten Nebenwirkungen ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Kopfschmerzen , Schmerzen des Bewegungsapparats ( Muskeln , Knochen oder Gelenke ) und Symptome des Verdauungsapparats wie Bauchschmerzen , Dyspepsie ( Verdauungsstörungen ) , Verstopfung , Diarrhoe ( Durchfall ) , Flatulenz ( Blähungen ) , Geschwüre ( Ulcera ) der Speiseröhre , Dysphagie ( Schluckbeschwerden ) , aufgetriebenes Abdomen ( geblähter Bauch ) sowie saures Aufstoßen .
T-77	The most common side effects ( seen in between 1 and 10 patients in 100 ) are headache , musculoskeletal ( bone , muscle or joint ) pain and gastro-intestinal symptoms such as abdominal ( tummy ) pain , dyspepsia ( indigestion ) , constipation , diarrhoea , flatulence ( wind ) , oesophageal ( gullet ) ulcers , dysphagia ( difficulty swallowing ) , abdominal distension ( swollen tummy ) and acid regurgitation .
H-77	-0.24349051713943481	The most common adverse reactions ( observed in 1 to 10 out of 100 patients ) are headache , musculoskeletal pain ( muscles , bones or joints ) and digestive system symptoms such as abdominal pain , dyspepsia ( indigestion ) , constipation , diarrhoea ( diarrhoea ) , flatulence ( flatulence ) , ulcers ( oesophagus ) , dysphagia ( difficulty swallowing ) , bloated abdomen ( bloated abdomen ) and acid regurgitation .
D-77	-0.24349051713943481	The most common adverse reactions ( observed in 1 to 10 out of 100 patients ) are headache , musculoskeletal pain ( muscles , bones or joints ) and digestive system symptoms such as abdominal pain , dyspepsia ( indigestion ) , constipation , diarrhoea ( diarrhoea ) , flatulence ( flatulence ) , ulcers ( oesophagus ) , dysphagia ( difficulty swallowing ) , bloated abdomen ( bloated abdomen ) and acid regurgitation .
P-77	-0.2203 -0.1289 -0.3438 -0.3587 -0.0294 -0.4532 -0.0262 -0.2117 -0.4096 -0.1357 -0.2291 -0.1729 -0.1283 -1.0945 -0.1237 -0.2502 -0.1415 -0.1295 -0.2299 -0.1784 -0.0312 -0.2035 -0.1545 -0.3520 -0.1441 -0.0401 -0.0545 -0.1342 -0.1130 -0.1467 -0.1354 -0.1307 -0.1408 -0.2854 -0.7355 -0.0307 -0.0172 -0.1234 -0.5219 -0.3549 -0.0822 -0.0366 -1.5839 -0.0790 -0.2482 -0.1618 -0.3732 -0.0543 -0.0503 -0.0589 -0.1442 -0.0986 -0.1296 -0.0813 -0.0431 -0.2658 -0.4866 -0.0829 -0.1566 -0.1269 -0.1333 -0.1009 -0.0298 -0.0666 -0.1510 -0.1367 -0.0915 -0.0637 -0.2217 -0.0479 -0.2294 -0.1531 -0.1236 -0.0781 -0.0455 -0.1338 -0.1314 -0.0403 -0.0090 -0.1027 -0.2808 -0.0502 -0.0138 -0.0829 -0.1429 -0.1378 -0.0240 -0.7625 -0.1613 -0.3588 -0.9439 -0.0075 -0.2494 -0.0134 -0.1512 -0.9322 -0.1318 -0.0564 -0.0409 -0.1219 -0.0693 -0.1468 -0.1466 -0.0191 -0.0372 -0.1612 -0.1339 -2.9555 -0.0538 -0.0900 -0.0812 -0.2017 -0.1820 -1.4051 -0.0601 -0.8817 -0.0418 -0.1362 -0.1280 -0.6771 -0.2338 -2.1010 -0.1929 -0.3752 -0.1410 -0.1745 -0.1537
S-1926	Aerinaze darf auch nicht bei Patienten angewendet werden , die an einem Engwinkelglaukom ( erhöhtem Augeninnendruck ) , Harnverhaltung ( erschwertem Wasserlassen ) , Herz- oder Gefäßerkrankungen einschließlich Hypertonie ( Bluthochdruck ) , Hyperthyreose ( Überfunktion der Schilddrüse ) leiden oder bereits einen hämorrhagischen Schlaganfall ( durch eine Gehirnblutung verursachten Schlaganfall ) hatten oder ein Risiko für einen hämorrhagischen Schlaganfall haben .
T-1926	Aerinaze should also not be taken by people who have narrow- angle glaucoma ( increased pressure inside the eye ) , urinary retention ( difficulty in passing urine ) , heart or blood vessel diseases including hypertension ( high blood pressure ) , hyperthyroidism ( an overactive thyroid gland ) , or a history or risk of haemorrhagic stroke ( stroke caused by bleeding within the brain ) .
H-1926	-0.32840612530708313	Aerinaze should also not be used in patients with narrow @-@ angle glaucoma ( increased intraocular pressure ) , urinary retention ( difficult urination ) , cardiovascular disorders including hypertension ( hypertension ) , hyperthyroidism ( hyperthyroidism ) , or who have had a haemorrhagic stroke ( stroke caused by cerebral haemorrhage ) or are at risk of a haemorrhagic stroke .
D-1926	-0.32840612530708313	Aerinaze should also not be used in patients with narrow @-@ angle glaucoma ( increased intraocular pressure ) , urinary retention ( difficult urination ) , cardiovascular disorders including hypertension ( hypertension ) , hyperthyroidism ( hyperthyroidism ) , or who have had a haemorrhagic stroke ( stroke caused by cerebral haemorrhage ) or are at risk of a haemorrhagic stroke .
P-1926	-1.2914 -0.1354 -0.1485 -0.1628 -0.0697 -1.1389 -0.9801 -0.4144 -0.1534 -0.2592 -0.1486 -0.3560 -0.9346 -0.9570 -1.7902 -0.1364 -0.6133 -0.0833 -0.1240 -0.1682 -0.5174 -0.4057 -0.1524 -0.2760 -0.1785 -0.0608 -0.1322 -0.1498 -0.1514 -0.2410 -0.0703 -0.1613 -0.1505 -1.0769 -0.1509 -0.0672 -0.1359 -0.1348 -0.2025 -0.1294 -0.0581 -0.0741 -1.6531 -0.0615 -0.1018 -0.0166 -0.0262 -0.1973 -0.4647 -0.0588 -0.1280 -0.1365 -0.0590 -0.1134 -0.1378 -0.1373 -0.1656 -0.0375 -0.0926 -0.1512 -1.3601 -0.2064 -0.1456 -0.0368 -0.6117 -0.0122 -0.0547 -0.1296 -0.5821 -0.4162 -0.3835 -0.1823 -1.0647 -0.1732 -0.4318 -0.6568 -0.0957 -0.2259 -0.0754 -0.0944 -0.1315 -0.3050 -0.5287 -0.1269 -2.0236 -0.0966 -0.0907 -0.2049 -0.5100 -0.1055 -0.4360 -0.1252 -0.3671 -0.5085 -0.0431 -0.1347 -0.3896 -1.4225 -0.1344 -0.7226 -0.0966 -0.3549 -0.1044 -0.0674 -0.1979 -0.1618
S-1922	Die häufigsten Nebenwirkungen von Aerinaze ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Tachykardie ( Herzjagen ) , Mundtrockenheit , Schwindel , psychomotorische Hyperaktivität ( Ruhelosigkeit ) , Pharyngitis ( Rachenentzündung ) , Anorexie ( Appetitlosigkeit ) , Verstopfung , Kopfschmerzen , Müdigkeit , Insomnie ( Schlaflosigkeit ) , Somnolenz ( Schläfrigkeit ) , Schlafstörungen und Nervosität .
T-1922	The most common side effects with Aerinaze ( seen in between 1 and 10 patients in 100 ) are tachycardia ( fast heart rate ) , dry mouth , dizziness , psychomotor hyperactivity ( restlessness ) , pharyngitis ( sore throat ) , anorexia ( loss of appetite ) , constipation , headache , fatigue ( tiredness ) , insomnia ( difficulty sleeping ) , somnolence ( sleepiness ) , sleep disorders and nervousness .
H-1922	-0.24402044713497162	The most common adverse reactions of Aerinaze ( observed in 1 to 10 out of 100 patients ) are tachycardia ( heart failure ) , dry mouth , dizziness , psychomotor hyperactivity ( restlessness ) , pharyngitis ( pharyngitis ) , anorexia ( anorexia ) , constipation , headache , tiredness , insomnia ( insomnia ) , somnolence ( somnolence ) , trouble sleeping and nervousness .
D-1922	-0.24402044713497162	The most common adverse reactions of Aerinaze ( observed in 1 to 10 out of 100 patients ) are tachycardia ( heart failure ) , dry mouth , dizziness , psychomotor hyperactivity ( restlessness ) , pharyngitis ( pharyngitis ) , anorexia ( anorexia ) , constipation , headache , tiredness , insomnia ( insomnia ) , somnolence ( somnolence ) , trouble sleeping and nervousness .
P-1922	-0.2412 -0.1532 -0.2965 -1.1007 -0.0359 -0.1960 -0.0295 -1.2887 -0.1411 -0.1237 -0.1608 -0.1470 -0.0884 -0.1538 -0.3783 -0.1321 -0.1894 -0.1513 -0.1378 -1.0633 -0.1255 -0.1761 -0.1579 -0.1325 -0.3149 -0.0376 -0.1007 -0.1521 -0.1127 -0.0490 -0.2141 -1.6898 -3.2192 -0.1353 -0.1665 -0.1219 -0.0727 -0.1546 -0.1289 -0.0373 -0.0669 -0.1411 -0.1286 -0.1041 -0.1897 -0.4155 -0.0419 -0.2051 -0.1391 -0.0300 -0.0574 -0.1092 -0.1326 -0.1357 -0.3630 -0.0258 -0.0468 -0.1472 -0.0631 -0.3110 -0.1222 -0.0140 -0.0086 -0.5665 -0.1644 -0.1505 -0.1336 -0.1518 -0.1160 -0.0893 -0.0521 -0.1535 -1.7196 -0.0601 -0.0187 -0.0397 -0.3165 -0.1326 -0.1064 -0.0341 -0.0695 -0.1357 -0.1469 -0.1074 -0.0192 -0.2266 -0.1381 -0.0791 -0.0502 -0.0756 -0.1373 -0.4507 -0.0577 -0.0798 -1.1991 -0.5875 -0.0475 -0.0573 -0.1279 -0.1346 -0.0649 -0.0897 -0.0320 -0.1397 -0.1887 -0.3522 -0.0577 -0.0485 -0.0769 -0.1290 -0.1349 -2.3475 -0.0443 -0.2355 -0.0309 -0.0711 -0.1562 -0.1546
S-420	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet .
T-420	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet . 5.8 % , a reduction of 50 % ) .
H-420	-0.24929486215114594	In this study , a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % ; reduction of 56 % ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % ; reduction of 50 % ) was observed in analysis of the subgroup of osteoporotic women ( 37 % of the total number suffering from osteoporosis as defined above ) .
D-420	-0.24929486215114594	In this study , a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % ; reduction of 56 % ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % ; reduction of 50 % ) was observed in analysis of the subgroup of osteoporotic women ( 37 % of the total number suffering from osteoporosis as defined above ) .
P-420	-0.3217 -0.1541 -0.3848 -0.1969 -2.5079 -0.1315 -0.2159 -0.3965 -0.9875 -0.0708 -0.0538 -0.1262 -0.0356 -0.5671 -0.1061 -0.1314 -0.1954 -0.0893 -0.1764 -0.0822 -0.1295 -0.1155 -0.1168 -1.0306 -0.0707 -0.1358 -0.1868 -0.1291 -0.1615 -0.1370 -0.1040 -0.2336 -0.1352 -0.3870 -0.1096 -0.1128 -0.1254 -0.1651 -0.7285 -0.1664 -0.0233 -0.0557 -0.1250 -0.2127 -0.1104 -0.1534 -0.1506 -0.1159 -0.0928 -0.3361 -0.0593 -0.0633 -0.1383 -0.1319 -0.1245 -0.1038 -0.1030 -0.0862 -0.1303 -0.1177 -0.1356 -0.1483 -0.1315 -0.1551 -0.1116 -0.2650 -0.2127 -0.4436 -0.1933 -1.1073 -0.1770 -0.2168 -0.5952 -0.8537 -0.4790 -0.0792 -0.0967 -0.1276 -0.1224 -0.2232 -0.1159 -0.1377 -0.0935 -0.1109 -0.1396 -0.2103 -0.1942 -0.1149 -1.7462 -0.1643 -0.0979 -0.0931 -0.1183 -0.1244 -0.0945 -0.0664 -1.2841 -0.0534 -0.2880 -0.1399 -0.1675 -0.1520
S-224	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet .
T-224	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet . 5.8 % , a reduction of 50 % ) .
H-224	-0.24929486215114594	In this study , a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % ; reduction of 56 % ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % ; reduction of 50 % ) was observed in analysis of the subgroup of osteoporotic women ( 37 % of the total number suffering from osteoporosis as defined above ) .
D-224	-0.24929486215114594	In this study , a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % ; reduction of 56 % ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % ; reduction of 50 % ) was observed in analysis of the subgroup of osteoporotic women ( 37 % of the total number suffering from osteoporosis as defined above ) .
P-224	-0.3217 -0.1541 -0.3848 -0.1969 -2.5079 -0.1315 -0.2159 -0.3965 -0.9875 -0.0708 -0.0538 -0.1262 -0.0356 -0.5671 -0.1061 -0.1314 -0.1954 -0.0893 -0.1764 -0.0822 -0.1295 -0.1155 -0.1168 -1.0306 -0.0707 -0.1358 -0.1868 -0.1291 -0.1615 -0.1370 -0.1040 -0.2336 -0.1352 -0.3870 -0.1096 -0.1128 -0.1254 -0.1651 -0.7285 -0.1664 -0.0233 -0.0557 -0.1250 -0.2127 -0.1104 -0.1534 -0.1506 -0.1159 -0.0928 -0.3361 -0.0593 -0.0633 -0.1383 -0.1319 -0.1245 -0.1038 -0.1030 -0.0862 -0.1303 -0.1177 -0.1356 -0.1483 -0.1315 -0.1551 -0.1116 -0.2650 -0.2127 -0.4436 -0.1933 -1.1073 -0.1770 -0.2168 -0.5952 -0.8537 -0.4790 -0.0792 -0.0967 -0.1276 -0.1224 -0.2232 -0.1159 -0.1377 -0.0935 -0.1109 -0.1396 -0.2103 -0.1942 -0.1149 -1.7462 -0.1643 -0.0979 -0.0931 -0.1183 -0.1244 -0.0945 -0.0664 -1.2841 -0.0534 -0.2880 -0.1399 -0.1675 -0.1520
S-265	Mikrokristalline Cellulose ( E 460 ) Lactose Mittelkettige Triglyceride Gelatine Croscarmellose-Natrium Sucrose Hochdisperses Siliciumdioxid Magnesiumstearat ( Ph.Eur. ) ( E 572 ) Butylhydroxytoluol ( Ph.Eur. ) ( E 321 ) Stärke , modifiziert ( Mais ) Aluminiumnatriumsilicat ( E 554 )
T-265	Microcrystalline cellulose ( E460 ) Lactose anhydrous Medium chain triglycerides Gelatin Croscarmellose sodium Sucrose Colloidal silicon dioxide Magnesium stearate ( E572 ) Butyl hydroxytoluene ( E321 ) Modified starch ( maize ) Sodium aluminium silicate ( E554 )
H-265	-0.2603316307067871	Microcrystalline cellulose ( E 460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose Highly dispersed silicon dioxide Magnesium stearate ( Ph.Eur. ) ( E572 ) Butyl hydroxytoluene ( Ph.Eur. ) ( E321 ) Starch , modified ( maize ) Sodium silicate ( E554 )
D-265	-0.2603316307067871	Microcrystalline cellulose ( E 460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose Highly dispersed silicon dioxide Magnesium stearate ( Ph.Eur. ) ( E572 ) Butyl hydroxytoluene ( Ph.Eur. ) ( E321 ) Starch , modified ( maize ) Sodium silicate ( E554 )
P-265	-0.1241 -0.1672 -0.0564 -0.0440 -0.0764 -0.0772 -0.3618 -0.0833 -0.0443 -0.1468 -0.3242 -0.1488 -0.1072 -0.1301 -0.1816 -0.1450 -0.0268 -0.7818 -0.1336 -0.5919 -0.1997 -0.0717 -0.2119 -0.0522 -0.0855 -0.1461 -1.1048 -0.0775 -0.0339 -0.0823 -0.0866 -0.0668 -0.0978 -0.5595 -0.0735 -0.1276 -0.1119 -0.0329 -2.9806 -0.1078 -0.0148 -0.0832 -1.1272 -0.3454 -0.0623 -0.0927 -0.1220 -0.0367 -0.3956 -0.1941 -0.0827 -0.1109 -0.0260 -0.1560 -0.0737 -0.1451 -0.3791 -0.5457 -0.2245 -0.1341 -0.1345 -0.1500 -1.6838 -0.1502 -0.1114 -0.1292 -0.0183 -0.9712 -0.0376 -0.1432 -0.1662 -0.1330 -0.0894 -0.1172 -0.1184 -0.1381 -0.4121 -0.3790 -0.2044 -0.1278 -0.1255 -0.1405 -0.6999 -0.1250 -0.1017 -0.1251 -0.6574 -0.1301 -0.6839 -0.1185 -0.0753 -0.1312 -0.6991 -0.1024 -0.0553 -0.1369 -0.6922 -0.1021 -1.2671 -0.0808 -0.1449 -0.1470 -0.6156 -0.1798 -0.0802 -0.4224 -0.1853
S-461	Mikrokristalline Cellulose ( E 460 ) Lactose Mittelkettige Triglyceride Gelatine Croscarmellose-Natrium Sucrose Hochdisperses Siliciumdioxid Magnesiumstearat ( Ph.Eur. ) ( E 572 ) Butylhydroxytoluol ( Ph.Eur. ) ( E 321 ) Stärke , modifiziert ( Mais ) Aluminiumnatriumsilicat ( E 554 )
T-461	Microcrystalline cellulose ( E460 ) Lactose anhydrous Medium chain triglycerides Gelatin Croscarmellose sodium Sucrose Colloidal silicon dioxide Magnesium stearate ( E572 ) Butyl hydroxytoluene ( E321 ) Modified starch ( maize ) Sodium aluminium silicate ( E554 )
H-461	-0.2603316307067871	Microcrystalline cellulose ( E 460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose Highly dispersed silicon dioxide Magnesium stearate ( Ph.Eur. ) ( E572 ) Butyl hydroxytoluene ( Ph.Eur. ) ( E321 ) Starch , modified ( maize ) Sodium silicate ( E554 )
D-461	-0.2603316307067871	Microcrystalline cellulose ( E 460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose Highly dispersed silicon dioxide Magnesium stearate ( Ph.Eur. ) ( E572 ) Butyl hydroxytoluene ( Ph.Eur. ) ( E321 ) Starch , modified ( maize ) Sodium silicate ( E554 )
P-461	-0.1241 -0.1672 -0.0564 -0.0440 -0.0764 -0.0772 -0.3618 -0.0833 -0.0443 -0.1468 -0.3242 -0.1488 -0.1072 -0.1301 -0.1816 -0.1450 -0.0268 -0.7818 -0.1336 -0.5919 -0.1997 -0.0717 -0.2119 -0.0522 -0.0855 -0.1461 -1.1048 -0.0775 -0.0339 -0.0823 -0.0866 -0.0668 -0.0978 -0.5595 -0.0735 -0.1276 -0.1119 -0.0329 -2.9806 -0.1078 -0.0148 -0.0832 -1.1272 -0.3454 -0.0623 -0.0927 -0.1220 -0.0367 -0.3956 -0.1941 -0.0827 -0.1109 -0.0260 -0.1560 -0.0737 -0.1451 -0.3791 -0.5457 -0.2245 -0.1341 -0.1345 -0.1500 -1.6838 -0.1502 -0.1114 -0.1292 -0.0183 -0.9712 -0.0376 -0.1432 -0.1662 -0.1330 -0.0894 -0.1172 -0.1184 -0.1381 -0.4121 -0.3790 -0.2044 -0.1278 -0.1255 -0.1405 -0.6999 -0.1250 -0.1017 -0.1251 -0.6574 -0.1301 -0.6839 -0.1185 -0.0753 -0.1312 -0.6991 -0.1024 -0.0553 -0.1369 -0.6922 -0.1021 -1.2671 -0.0808 -0.1449 -0.1470 -0.6156 -0.1798 -0.0802 -0.4224 -0.1853
S-438	Resorption Bei gesunden erwachsenen Probanden ( Frauen und Männer ) betrug nach der Gabe von ADROVANCE ( 70 mg<unk> 5.600 I.E. ) nach nächtlichem Fasten und zwei Stunden vor Aufnahme einer Mahlzeit die mittlere Fläche unter der Serum-Konzentration-Zeit-Kurve ( AUC0-80 h ) für Vitamin D3 490,2 ng h<unk> ml ( ohne Berücksichtigung endogener Vitamin-D3-Spiegel ) .
T-438	Absorption In healthy adult subjects ( males and females ) , following administration of ADROVANCE 70 mg/ 5600 IU after an overnight fast and two hours before a meal , the mean area under the serum- concentration-time curve ( AUC0-80 hrs ) for vitamin D3 ( unadjusted for endogenous vitamin D3 levels ) was 490.2 ng hr/ ml .
H-438	-0.305751234292984	In healthy adult subjects ( women and men ) after ADROVANCE ( 70 mg/ 5,600 IU ) after nocturnal fasting and two hours before meal intake , the mean surface area below the serum concentration time curve ( AUC0-80 h ) for vitamin D3 was 490.2 ng h/ ml ( excluding endogenous vitamin D3 levels ) .
D-438	-0.305751234292984	In healthy adult subjects ( women and men ) after ADROVANCE ( 70 mg/ 5,600 IU ) after nocturnal fasting and two hours before meal intake , the mean surface area below the serum concentration time curve ( AUC0-80 h ) for vitamin D3 was 490.2 ng h/ ml ( excluding endogenous vitamin D3 levels ) .
P-438	-1.8154 -0.1152 -0.0374 -0.0234 -0.1411 -1.0102 -0.1717 -0.1321 -0.1273 -1.3506 -1.0265 -0.0653 -0.1290 -0.0966 -0.0728 -0.1331 -0.1309 -0.1233 -0.1498 -0.0712 -0.5148 -0.1038 -0.1153 -0.0780 -0.1590 -2.7155 -0.8969 -0.0844 -0.0258 -0.1534 -0.0216 -0.2886 -0.1642 -0.9448 -0.1018 -0.5930 -0.8581 -0.9229 -0.1143 -0.2448 -0.1341 -0.0289 -0.9475 -0.2957 -1.1984 -0.1812 -0.9508 -0.0947 -0.0943 -0.2080 -0.4935 -0.0904 -0.1308 -0.0560 -0.1529 -1.1059 -0.0914 -0.1821 -0.3020 -0.1281 -0.1920 -0.2090 -0.0721 -0.1446 -0.1351 -0.1102 -0.0394 -0.0699 -0.1348 -0.1009 -0.2805 -0.1741 -0.2341 -0.0646 -0.1439 -0.4374 -0.1892 -0.1468 -0.1057 -0.0359 -0.1357 -0.0738 -0.1332 -0.1399 -0.0599 -0.1352 -0.1653 -0.1525
S-242	Resorption Bei gesunden erwachsenen Probanden ( Frauen und Männer ) betrug nach der Gabe von ADROVANCE nach nächtlichem Fasten und zwei Stunden vor Aufnahme einer Mahlzeit die mittlere Fläche unter der Serum-Konzentration-Zeit-Kurve ( AUC0-120 h ) für Vitamin D3 296,4 ng h<unk> ml ( ohne Berücksichtigung endogener Vitamin-D3-Spiegel ) .
T-242	Absorption In healthy adult subjects ( males and females ) , following administration of ADROVANCE after an overnight fast and two hours before a meal , the mean area under the serum-concentration-time curve ( AUC0-120 hrs ) for vitamin D3 ( unadjusted for endogenous vitamin D3 levels ) was 296.4 ng hr/ ml .
H-242	-0.3510885238647461	Absorption In healthy adult subjects ( women and men ) after nocturnal fasting and two hours before meal intake , the mean surface area below the serum concentration time curve ( AUC0-120 h ) for vitamin D3 was 296.4 ng h/ ml ( excluding endogenous vitamin D3 levels ) .
D-242	-0.3510885238647461	Absorption In healthy adult subjects ( women and men ) after nocturnal fasting and two hours before meal intake , the mean surface area below the serum concentration time curve ( AUC0-120 h ) for vitamin D3 was 296.4 ng h/ ml ( excluding endogenous vitamin D3 levels ) .
P-242	-2.9608 -0.0726 -0.0966 -0.6748 -0.1325 -0.0360 -0.0244 -0.1410 -0.8257 -0.1692 -0.1371 -0.1263 -1.0252 -2.6549 -0.0909 -0.0199 -0.1396 -0.0138 -0.2617 -0.1960 -1.0080 -0.0964 -0.7559 -1.4381 -1.7915 -0.0879 -0.3536 -0.1887 -0.0288 -0.8990 -0.3072 -0.9920 -0.1974 -1.2551 -0.0916 -0.1431 -0.2056 -0.5146 -0.0903 -0.1326 -0.0548 -0.1378 -1.1184 -0.0734 -0.1231 -0.3218 -0.1299 -0.1883 -0.1472 -0.0699 -0.1542 -0.1360 -0.1235 -0.1064 -0.0724 -0.1838 -0.1008 -0.2547 -0.1674 -0.1494 -0.0690 -0.1446 -0.4332 -0.1803 -0.1391 -0.0833 -0.0325 -0.1550 -0.0860 -0.1341 -0.1484 -0.0644 -0.1359 -0.1822 -0.1541
S-96	ADROVANCE soll nach dem Aufstehen des Tages nur mit einem vollen Glas Wasser ( mindestens 200 ml ) geschluckt werden . Die Patienten sollen die Tablette nicht kauen oder die Tablette im Mund zergehen lassen , da ein Risiko für oropharyngeale Ulzera besteht . Die Patienten sollen sich nicht vor der ersten Nahrungsaufnahme des Tages , die frühestens 30 Minuten nach Einnahme der Tablette erfolgen soll , hinlegen .
T-96	ADROVANCE should only be swallowed after getting up for the day with a full glass of water ( not less than 200ml or 7fl . oz . ) .
H-96	-0.3511810302734375	ADROVANCE should be swallowed only with a full glass of water ( at least 200 ml ) after waking up each day . Patients should not chew or allow the tablet to melt in their mouth as there is a risk of oropharyngeal ulcers . Patients should not lie down before their first food intake of the day , which should be 30 minutes after taking the tablet at the earliest .
D-96	-0.3511810302734375	ADROVANCE should be swallowed only with a full glass of water ( at least 200 ml ) after waking up each day . Patients should not chew or allow the tablet to melt in their mouth as there is a risk of oropharyngeal ulcers . Patients should not lie down before their first food intake of the day , which should be 30 minutes after taking the tablet at the earliest .
P-96	-0.1097 -0.0555 -0.1351 -0.1082 -0.0778 -0.3012 -0.6970 -1.0759 -0.2837 -0.0614 -1.4592 -0.4492 -0.1361 -0.0750 -0.0236 -0.2014 -0.1270 -0.1689 -0.5707 -0.1351 -0.1381 -0.0569 -0.1475 -0.5446 -2.0660 -0.0489 -0.6104 -1.7646 -0.2467 -0.3620 -0.5677 -0.1027 -0.1461 -0.2118 -0.0377 -0.1093 -0.7960 -1.9115 -0.2311 -0.1774 -0.1015 -0.1438 -1.2289 -0.1740 -0.5431 -0.7002 -0.4513 -0.8508 -0.3181 -0.1710 -0.2269 -0.1093 -0.5623 -0.1979 -0.1028 -0.0785 -0.1175 -0.0530 -0.0953 -0.1892 -0.3355 -0.1862 -0.2317 -0.1538 -0.0991 -0.1209 -0.1531 -0.0953 -0.0987 -0.5295 -0.7388 -0.0842 -0.2345 -0.3055 -0.1450 -0.1571 -0.1651 -0.1043 -0.2015 -0.5662 -0.5757 -2.2018 -0.8929 -0.1628 -0.2876 -0.2089 -0.1860 -0.1067 -0.1388 -0.2153 -0.1505 -0.0500 -0.2038 -0.1689 -0.1620
S-655	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen . ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-655	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions . ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-655	-0.27056771516799927	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions . ADVATE contains recombinant clotting factor VIII ( Octocog alfa ) , a glycoprotein equivalent to the glycoprotein present in human plasma .
D-655	-0.27056771516799927	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions . ADVATE contains recombinant clotting factor VIII ( Octocog alfa ) , a glycoprotein equivalent to the glycoprotein present in human plasma .
P-655	-0.3905 -0.6418 -0.4250 -0.2415 -0.9215 -0.1793 -1.1922 -0.4935 -0.1303 -0.1772 -0.7139 -0.1549 -0.2949 -0.0929 -0.1331 -0.1651 -0.0678 -0.0719 -0.1588 -0.4124 -0.1681 -0.0979 -0.1734 -0.5712 -0.1227 -0.1356 -0.2151 -0.4221 -0.1333 -0.2633 -1.2481 -0.0806 -0.1846 -0.2079 -0.1647 -0.0349 -0.1564 -0.0831 -0.1084 -0.0847 -0.0987 -0.1025 -0.0835 -0.1243 -1.4704 -0.0557 -0.0590 -0.0394 -0.1599 -0.0711 -0.1458 -1.0029 -0.0960 -0.1197 -0.2093 -0.1285 -0.0629 -0.1308 -0.1578 -0.1754 -0.1664 -0.1291 -0.1967 -0.0310 -0.1748 -0.0689 -0.1484 -1.4644 -0.2653 -0.1119 -0.1625 -0.0359 -0.1814 -1.5468 -0.1283 -0.2733 -0.1010 -0.0620 -0.1273 -0.1694 -0.1630
S-283	ADROVANCE soll nach dem Aufstehen des Tages nur mit einem vollen Glas Wasser ( mindestens 200 ml ) geschluckt werden . Die Patienten sollen die Tablette nicht kauen oder die Tablette im Mund zergehen lassen , da ein Risiko für oropharyngeale Ulzera besteht . Die Patienten sollen sich nicht vor der ersten Nahrungsaufnahme des Tages , die frühestens 30 Minuten nach Einnahme der Tablette erfolgen soll , hinlegen .
T-283	ADROVANCE should only be swallowed after getting up for the day with a full glass of water ( not less than 200ml or 7fl . oz . ) .
H-283	-0.3511810302734375	ADROVANCE should be swallowed only with a full glass of water ( at least 200 ml ) after waking up each day . Patients should not chew or allow the tablet to melt in their mouth as there is a risk of oropharyngeal ulcers . Patients should not lie down before their first food intake of the day , which should be 30 minutes after taking the tablet at the earliest .
D-283	-0.3511810302734375	ADROVANCE should be swallowed only with a full glass of water ( at least 200 ml ) after waking up each day . Patients should not chew or allow the tablet to melt in their mouth as there is a risk of oropharyngeal ulcers . Patients should not lie down before their first food intake of the day , which should be 30 minutes after taking the tablet at the earliest .
P-283	-0.1097 -0.0555 -0.1351 -0.1082 -0.0778 -0.3012 -0.6970 -1.0759 -0.2837 -0.0614 -1.4592 -0.4492 -0.1361 -0.0750 -0.0236 -0.2014 -0.1270 -0.1689 -0.5707 -0.1351 -0.1381 -0.0569 -0.1475 -0.5446 -2.0660 -0.0489 -0.6104 -1.7646 -0.2467 -0.3620 -0.5677 -0.1027 -0.1461 -0.2118 -0.0377 -0.1093 -0.7960 -1.9115 -0.2311 -0.1774 -0.1015 -0.1438 -1.2289 -0.1740 -0.5431 -0.7002 -0.4513 -0.8508 -0.3181 -0.1710 -0.2269 -0.1093 -0.5623 -0.1979 -0.1028 -0.0785 -0.1175 -0.0530 -0.0953 -0.1892 -0.3355 -0.1862 -0.2317 -0.1538 -0.0991 -0.1209 -0.1531 -0.0953 -0.0987 -0.5295 -0.7388 -0.0842 -0.2345 -0.3055 -0.1450 -0.1571 -0.1651 -0.1043 -0.2015 -0.5662 -0.5757 -2.2018 -0.8929 -0.1628 -0.2876 -0.2089 -0.1860 -0.1067 -0.1388 -0.2153 -0.1505 -0.0500 -0.2038 -0.1689 -0.1620
S-1617	Risiko-Management-Plan Der Zulassungsinhaber verpflichtet sich , alle Studien und Pharmakovigilanz-Aktivitäten durchzuführen , die detailliert im Pharmakovigilanz-Plan beschrieben sind . Dieser Pharmakovigilanz- Plan wurde mit der Version 3.0 des Risiko-Management-Plans ( RMP ) festgelegt . Der RMP wurde mit dem CHMP abgestimmt und ist im Kapitel 1.8.2 der Arzneimittelzulassung enthalten .
T-1617	Risk Management Plan The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan , as agreed in version 3.0 of the Risk Management Plan ( RMP ) presented in Module 1.8.2 . of the Marketing Authorisation and any subsequent updates of the RMP agreed by the CHMP .
H-1617	-0.4309273362159729	The Authorisation Holder undertakes to conduct all trials and pharmacovigilance activities detailed in the Pharmacovigilance Plan . This pharmacovigilance plan was established in version 3.0 of the Risk Management Plan ( RMP ) and has been agreed with the CHMP and is included in chapter 1.8.2 of the Marketing Authorisation .
D-1617	-0.4309273362159729	The Authorisation Holder undertakes to conduct all trials and pharmacovigilance activities detailed in the Pharmacovigilance Plan . This pharmacovigilance plan was established in version 3.0 of the Risk Management Plan ( RMP ) and has been agreed with the CHMP and is included in chapter 1.8.2 of the Marketing Authorisation .
P-1617	-1.9285 -0.8605 -0.0914 -0.0318 -0.0151 -0.0786 -1.2674 -0.2168 -0.1666 -1.8234 -0.3170 -1.1139 -0.1297 -0.1766 -0.1200 -0.1051 -0.2326 -0.3019 -0.2571 -0.4904 -0.1215 -0.1863 -0.8889 -0.1241 -0.1855 -0.1493 -0.1173 -0.2068 -0.4086 -0.9471 -1.8722 -0.3867 -0.2667 -0.1503 -0.1448 -0.2824 -0.4019 -0.3303 -1.1329 -1.3222 -0.4920 -1.1553 -0.1051 -0.1076 -0.1370 -0.1513 -0.3005 -0.1016 -0.1141 -0.2826 -0.2132 -0.1621 -0.1196 -0.1248 -0.6687 -0.7306 -0.1328 -1.0530 -0.2053 -0.2995 -0.1112 -0.0650 -0.2007 -0.2305 -1.2627 -0.1228 -1.9262 -0.1582 -0.1020 -0.1323 -0.1403 -0.3015 -1.6324 -0.0312 -0.0618 -0.0275 -0.9396 -0.1599
S-298	Der Arzt soll deshalb aufmerksam auf alle Anzeichen und Symptome achten , die auf mögliche ösophageale Reaktionen hinweisen , und die Patienten sollen darauf hingewiesen werden , beim Auftreten von Symptomen ösophagealer Irritation wie Dysphagie , Schmerzen beim Schlucken oder retrosternale Schmerzen oder neues oder sich verschlimmerndes Sodbrennen das Arzneimittel abzusetzen und ärztliche Beratung einzuholen ( siehe Abschnitt 4.8 ) .
T-298	Physicians should therefore be alert to any signs or symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia , pain on swallowing or retrosternal pain or new or worsening heartburn ( see section 4.8 ) .
H-298	-0.3576052784919739	The doctor should therefore be attentive to all signs and symptoms indicating possible oesophageal reaction and patients should be advised to discontinue the product and seek medical advice if symptoms of oesophageal irritation such as dysphagia , swallowing pain or retrostatic pain or new or worsening heartburn occur ( see section 4.8 ) .
D-298	-0.3576052784919739	The doctor should therefore be attentive to all signs and symptoms indicating possible oesophageal reaction and patients should be advised to discontinue the product and seek medical advice if symptoms of oesophageal irritation such as dysphagia , swallowing pain or retrostatic pain or new or worsening heartburn occur ( see section 4.8 ) .
P-298	-0.3419 -0.8686 -0.1907 -0.2500 -1.1016 -1.2306 -0.1057 -0.1741 -0.7363 -0.1259 -0.1351 -0.0774 -1.9180 -0.1261 -0.2751 -0.4430 -0.0428 -0.2767 -0.0724 -0.0706 -0.1195 -0.7045 -0.4152 -0.6993 -0.1714 -0.1269 -0.1352 -0.4523 -0.2712 -0.0574 -1.6469 -0.9452 -0.5139 -0.0521 -0.4778 -0.0933 -0.3826 -1.1600 -0.1245 -0.2085 -0.1387 -0.3738 -0.0774 -0.0806 -0.1404 -0.0384 -0.1284 -0.3390 -0.1559 -0.0894 -0.0401 -0.1071 -0.0531 -0.1325 -0.3352 -0.0811 -0.3113 -0.2835 -0.1458 -0.0597 -2.7298 -1.6048 -0.0800 -0.7502 -0.2948 -0.1796 -0.2066 -0.0704 -0.1811 -0.0357 -0.0772 -0.8916 -0.2033 -0.1041 -0.0689 -0.1141 -0.1306 -0.1402 -0.1597 -0.1538
S-814	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 4 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-814	During clinical trials with ADVATE in 145 paediatric and adult patients 4 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-814	-0.31358811259269714	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-814	-0.31358811259269714	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-814	-0.1569 -0.3455 -0.1064 -0.3909 -0.0517 -0.1517 -0.0803 -0.0892 -0.3056 -0.0975 -0.1373 -1.1752 -0.4390 -0.7324 -0.0176 -0.0220 -0.1104 -0.0353 -0.4477 -0.7559 -0.2021 -0.4183 -0.1957 -0.3085 -0.1749 -0.0752 -0.0768 -0.1444 -0.1407 -0.1769 -0.1575 -0.1088 -0.1025 -0.1318 -0.1370 -0.2957 -1.0420 -0.0884 -0.1488 -0.5097 -0.6590 -1.5426 -0.7279 -0.1134 -0.1315 -0.0935 -0.0916 -0.1356 -0.2485 -0.1971 -0.1478 -0.0764 -1.5342 -0.0747 -1.3717 -0.3197 -0.1291 -0.1434 -0.0683 -0.9792 -0.1010 -0.4332 -0.8630 -0.1260 -0.1381 -0.5832 -1.3695 -0.7561 -0.7034 -0.0625 -0.0717 -0.1135 -0.1042 -0.1254 -0.5514 -0.2086 -0.3714 -0.1390 -0.3293 -0.1454 -0.3105 -0.2080 -0.0591 -0.1422 -0.0774 -0.0895 -0.1905 -0.1530
S-110	Der Arzt soll deshalb aufmerksam auf alle Anzeichen und Symptome achten , die auf mögliche ösophageale Reaktionen hinweisen , und die Patienten sollen darauf hingewiesen werden , beim Auftreten von Symptomen ösophagealer Irritation wie Dysphagie , Schmerzen beim Schlucken oder retrosternale Schmerzen oder neues oder sich verschlimmerndes Sodbrennen das Arzneimittel abzusetzen und ärztliche Beratung einzuholen ( siehe Abschnitt 4.8 ) .
T-110	Physicians should therefore be alert to any signs or symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia , pain on swallowing or retrosternal pain or new or worsening heartburn ( see section 4.8 ) .
H-110	-0.3576052784919739	The doctor should therefore be attentive to all signs and symptoms indicating possible oesophageal reaction and patients should be advised to discontinue the product and seek medical advice if symptoms of oesophageal irritation such as dysphagia , swallowing pain or retrostatic pain or new or worsening heartburn occur ( see section 4.8 ) .
D-110	-0.3576052784919739	The doctor should therefore be attentive to all signs and symptoms indicating possible oesophageal reaction and patients should be advised to discontinue the product and seek medical advice if symptoms of oesophageal irritation such as dysphagia , swallowing pain or retrostatic pain or new or worsening heartburn occur ( see section 4.8 ) .
P-110	-0.3419 -0.8686 -0.1907 -0.2500 -1.1016 -1.2306 -0.1057 -0.1741 -0.7363 -0.1259 -0.1351 -0.0774 -1.9180 -0.1261 -0.2751 -0.4430 -0.0428 -0.2767 -0.0724 -0.0706 -0.1195 -0.7045 -0.4152 -0.6993 -0.1714 -0.1269 -0.1352 -0.4523 -0.2712 -0.0574 -1.6469 -0.9452 -0.5139 -0.0521 -0.4778 -0.0933 -0.3826 -1.1600 -0.1245 -0.2085 -0.1387 -0.3738 -0.0774 -0.0806 -0.1404 -0.0384 -0.1284 -0.3390 -0.1559 -0.0894 -0.0401 -0.1071 -0.0531 -0.1325 -0.3352 -0.0811 -0.3113 -0.2835 -0.1458 -0.0597 -2.7298 -1.6048 -0.0800 -0.7502 -0.2948 -0.1796 -0.2066 -0.0704 -0.1811 -0.0357 -0.0772 -0.8916 -0.2033 -0.1041 -0.0689 -0.1141 -0.1306 -0.1402 -0.1597 -0.1538
S-640	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 2 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-640	During clinical trials with ADVATE in 145 paediatric and adult patients 2 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-640	-0.31347060203552246	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-640	-0.31347060203552246	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-640	-0.1578 -0.3565 -0.1063 -0.3939 -0.0516 -0.1527 -0.0795 -0.0884 -0.2736 -0.0945 -0.1394 -0.9862 -0.4244 -0.7691 -0.0171 -0.0213 -0.1103 -0.0352 -0.4940 -0.8386 -0.1988 -0.4271 -0.1947 -0.3184 -0.1744 -0.0742 -0.0768 -0.1426 -0.1403 -0.1741 -0.1577 -0.1095 -0.1039 -0.1341 -0.1369 -0.3008 -1.0467 -0.0896 -0.1479 -0.5116 -0.6589 -1.5562 -0.7388 -0.1131 -0.1312 -0.0942 -0.0914 -0.1357 -0.2542 -0.1950 -0.1496 -0.0782 -1.5192 -0.0741 -1.3697 -0.3212 -0.1283 -0.1433 -0.0682 -0.9790 -0.1018 -0.4327 -0.8641 -0.1255 -0.1385 -0.5764 -1.3765 -0.7639 -0.6997 -0.0630 -0.0721 -0.1126 -0.1033 -0.1264 -0.5499 -0.2089 -0.3720 -0.1405 -0.3248 -0.1450 -0.3191 -0.2076 -0.0582 -0.1432 -0.0766 -0.0899 -0.1901 -0.1528
S-267	Etui mit versiegelten Aluminium<unk> Aluminium-Blisterpackungen in Umkartons zu 2 ( 1 Etui mit 2 Tabletten ) , 4 ( 1 Etui mit 4 Tabletten ) , 6 ( 3 Etuis mit 2 Tabletten ) , 12 ( 3 Etuis mit 4 Tabletten ) oder 40 ( 10 Etuis mit 4 Tabletten ) Tabletten .
T-267	Wallet with sealed aluminium/ aluminium blisters , in cartons containing 2 ( 1 wallet x 2 tablets ) , 4 ( 1 wallet x 4 tablets ) , 6 ( 3 wallets x 2 tablets ) , 12 ( 3 wallets x 4 tablets ) or 40 ( 10 wallets x 4 tablets ) tablets .
H-267	-0.2547774016857147	Aluminium sealed blister case in cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 6 ( 3 cases of 2 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
D-267	-0.2547774016857147	Aluminium sealed blister case in cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 6 ( 3 cases of 2 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
P-267	-1.2601 -0.1656 -0.4754 -0.2680 -0.0903 -1.3987 -0.6240 -1.6979 -0.9006 -0.1406 -0.1209 -0.1360 -0.1620 -0.6279 -0.7471 -0.1166 -0.0677 -0.1518 -0.1495 -0.1414 -0.1495 -0.1434 -0.1762 -0.2831 -0.1357 -0.1369 -0.0539 -0.1549 -0.1297 -0.1339 -0.1517 -0.1414 -0.1258 -0.5469 -0.1346 -0.1232 -0.0562 -0.1675 -0.1252 -0.1364 -0.1086 -0.1366 -0.1134 -0.2379 -0.1316 -0.1316 -0.0647 -0.1767 -0.1163 -0.2407 -0.0857 -0.1320 -0.1283 -0.1908 -0.1305 -0.1301 -0.0614 -0.1602 -0.1204 -0.2692 -0.1533 -0.2248 -0.1583
S-990	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 6 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-990	During clinical trials with ADVATE in 145 paediatric and adult patients 6 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-990	-0.3187083899974823	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-990	-0.3187083899974823	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-990	-0.1583 -0.3212 -0.1063 -0.3894 -0.0520 -0.1516 -0.0792 -0.0887 -0.2628 -0.1044 -0.1347 -1.6590 -0.4310 -0.6956 -0.0157 -0.0212 -0.1079 -0.0244 -0.3785 -0.8085 -0.1966 -0.4323 -0.2010 -0.3139 -0.1768 -0.0750 -0.0760 -0.1431 -0.1389 -0.1789 -0.1575 -0.1089 -0.1017 -0.1336 -0.1362 -0.3044 -1.0294 -0.0871 -0.1492 -0.5165 -0.6880 -1.5273 -0.7381 -0.1133 -0.1315 -0.0957 -0.0920 -0.1351 -0.2488 -0.2021 -0.1496 -0.0758 -1.5213 -0.0746 -1.3989 -0.3225 -0.1287 -0.1450 -0.0678 -0.9786 -0.1018 -0.4357 -0.8614 -0.1245 -0.1381 -0.5936 -1.3946 -0.7547 -0.7034 -0.0630 -0.0716 -0.1135 -0.1033 -0.1266 -0.5478 -0.2092 -0.3724 -0.1413 -0.3221 -0.1454 -0.3217 -0.2060 -0.0594 -0.1422 -0.0780 -0.0882 -0.1915 -0.1531
S-1166	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 8 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-1166	During clinical trials with ADVATE in 145 paediatric and adult patients 8 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-1166	-0.313744455575943	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-1166	-0.313744455575943	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-1166	-0.1576 -0.3308 -0.1037 -0.3882 -0.0522 -0.1525 -0.0803 -0.0885 -0.2816 -0.1052 -0.1350 -1.1984 -0.4000 -0.6587 -0.0152 -0.0230 -0.1080 -0.0353 -0.4739 -0.7131 -0.1940 -0.4265 -0.1969 -0.3069 -0.1756 -0.0751 -0.0772 -0.1370 -0.1381 -0.1774 -0.1576 -0.1081 -0.1025 -0.1327 -0.1360 -0.3248 -1.0311 -0.0859 -0.1489 -0.5097 -0.6707 -1.5431 -0.7305 -0.1124 -0.1317 -0.0947 -0.0908 -0.1361 -0.2508 -0.2036 -0.1504 -0.0782 -1.5464 -0.0740 -1.3928 -0.3196 -0.1287 -0.1425 -0.0673 -0.9954 -0.1023 -0.4328 -0.8902 -0.1248 -0.1393 -0.5749 -1.3846 -0.7728 -0.7193 -0.0634 -0.0726 -0.1123 -0.1041 -0.1257 -0.5564 -0.2092 -0.3749 -0.1401 -0.3276 -0.1453 -0.3117 -0.2100 -0.0596 -0.1421 -0.0777 -0.0894 -0.1900 -0.1533
S-1342	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 10 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-1342	During clinical trials with ADVATE in 145 paediatric and adult patients 10 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-1342	-0.31624168157577515	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-1342	-0.31624168157577515	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-1342	-0.1558 -0.4331 -0.0998 -0.3993 -0.0509 -0.1525 -0.0804 -0.0885 -0.2911 -0.1041 -0.1353 -0.5518 -0.4179 -0.7009 -0.0136 -0.0219 -0.1094 -0.0324 -0.6531 -1.1235 -0.1898 -0.5230 -0.2019 -0.3011 -0.1749 -0.0748 -0.0767 -0.1406 -0.1397 -0.1786 -0.1576 -0.1074 -0.1018 -0.1342 -0.1367 -0.3045 -1.0605 -0.0860 -0.1485 -0.5285 -0.6851 -1.5025 -0.7378 -0.1124 -0.1316 -0.0925 -0.0910 -0.1361 -0.2542 -0.2047 -0.1502 -0.0746 -1.5557 -0.0734 -1.4173 -0.3197 -0.1278 -0.1427 -0.0677 -1.0100 -0.1025 -0.4355 -0.8763 -0.1255 -0.1377 -0.5699 -1.3649 -0.7628 -0.7220 -0.0627 -0.0726 -0.1120 -0.1032 -0.1254 -0.5507 -0.2098 -0.3710 -0.1381 -0.3276 -0.1458 -0.3240 -0.2071 -0.0582 -0.1433 -0.0777 -0.0889 -0.1921 -0.1527
S-1519	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 12 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-1519	During clinical trials with ADVATE in 145 paediatric and adult patients 12 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-1519	-0.3129114806652069	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-1519	-0.3129114806652069	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitortiter ( 2.4 B.E. in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-1519	-0.1570 -0.3536 -0.1035 -0.4083 -0.0513 -0.1516 -0.0796 -0.0885 -0.3053 -0.1119 -0.1346 -0.8192 -0.4494 -0.7785 -0.0134 -0.0211 -0.1107 -0.0351 -0.4492 -0.8006 -0.1954 -0.5078 -0.2053 -0.3171 -0.1760 -0.0733 -0.0750 -0.1443 -0.1399 -0.1789 -0.1586 -0.1081 -0.1033 -0.1319 -0.1379 -0.3004 -1.0509 -0.0863 -0.1482 -0.5266 -0.6895 -1.5065 -0.7400 -0.1123 -0.1319 -0.0934 -0.0920 -0.1355 -0.2460 -0.2010 -0.1504 -0.0787 -1.5002 -0.0736 -1.3853 -0.3207 -0.1279 -0.1447 -0.0674 -1.0193 -0.1028 -0.4360 -0.8539 -0.1248 -0.1378 -0.5720 -1.3719 -0.7552 -0.7142 -0.0627 -0.0721 -0.1120 -0.1040 -0.1256 -0.5546 -0.2117 -0.3749 -0.1394 -0.3323 -0.1451 -0.3124 -0.2025 -0.0591 -0.1431 -0.0768 -0.0895 -0.1929 -0.1527
S-1256	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-1256	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-1256	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
D-1256	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
P-1256	-3.8081 -0.0743 -0.1735 -0.1467 -0.2433 -0.1366 -0.1998 -0.3320 -1.4259 -0.9550 -0.0813 -0.0948 -0.1768 -0.1776 -0.0578 -0.0835 -0.1413 -0.5373 -0.6957 -0.7927 -0.9428 -0.1267 -0.3703 -2.8286 -0.1302 -0.5525 -0.8950 -0.1379 -0.5176 -2.2480 -0.2333 -0.0561 -0.1654 -0.2893 -0.1544 -2.1093 -0.0765 -0.0768 -0.9960 -0.4749 -0.1167 -0.0672 -0.1752 -0.0538 -0.7568 -1.6065 -0.8655 -0.4587 -1.2178 -0.0441 -0.0636 -0.0594 -0.1475 -0.0698 -0.8575 -0.9812 -0.1913 -0.0916 -0.0646 -0.1106 -0.0468 -0.0817 -0.1565 -1.1368 -0.2663 -0.1365 -0.3338 -0.1314 -0.2360 -0.2528 -0.1366 -0.1044 -0.1252 -0.1255 -0.2211 -0.1574
S-904	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-904	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-904	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
D-904	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
P-904	-3.8081 -0.0743 -0.1735 -0.1467 -0.2433 -0.1366 -0.1998 -0.3320 -1.4259 -0.9550 -0.0813 -0.0948 -0.1768 -0.1776 -0.0578 -0.0835 -0.1413 -0.5373 -0.6957 -0.7927 -0.9428 -0.1267 -0.3703 -2.8286 -0.1302 -0.5525 -0.8950 -0.1379 -0.5176 -2.2480 -0.2333 -0.0561 -0.1654 -0.2893 -0.1544 -2.1093 -0.0765 -0.0768 -0.9960 -0.4749 -0.1167 -0.0672 -0.1752 -0.0538 -0.7568 -1.6065 -0.8655 -0.4587 -1.2178 -0.0441 -0.0636 -0.0594 -0.1475 -0.0698 -0.8575 -0.9812 -0.1913 -0.0916 -0.0646 -0.1106 -0.0468 -0.0817 -0.1565 -1.1368 -0.2663 -0.1365 -0.3338 -0.1314 -0.2360 -0.2528 -0.1366 -0.1044 -0.1252 -0.1255 -0.2211 -0.1574
S-1432	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-1432	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-1432	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
D-1432	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
P-1432	-3.8081 -0.0743 -0.1735 -0.1467 -0.2433 -0.1366 -0.1998 -0.3320 -1.4259 -0.9550 -0.0813 -0.0948 -0.1768 -0.1776 -0.0578 -0.0835 -0.1413 -0.5373 -0.6957 -0.7927 -0.9428 -0.1267 -0.3703 -2.8286 -0.1302 -0.5525 -0.8950 -0.1379 -0.5176 -2.2480 -0.2333 -0.0561 -0.1654 -0.2893 -0.1544 -2.1093 -0.0765 -0.0768 -0.9960 -0.4749 -0.1167 -0.0672 -0.1752 -0.0538 -0.7568 -1.6065 -0.8655 -0.4587 -1.2178 -0.0441 -0.0636 -0.0594 -0.1475 -0.0698 -0.8575 -0.9812 -0.1913 -0.0916 -0.0646 -0.1106 -0.0468 -0.0817 -0.1565 -1.1368 -0.2663 -0.1365 -0.3338 -0.1314 -0.2360 -0.2528 -0.1366 -0.1044 -0.1252 -0.1255 -0.2211 -0.1574
S-1080	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-1080	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-1080	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
D-1080	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
P-1080	-3.8081 -0.0743 -0.1735 -0.1467 -0.2433 -0.1366 -0.1998 -0.3320 -1.4259 -0.9550 -0.0813 -0.0948 -0.1768 -0.1776 -0.0578 -0.0835 -0.1413 -0.5373 -0.6957 -0.7927 -0.9428 -0.1267 -0.3703 -2.8286 -0.1302 -0.5525 -0.8950 -0.1379 -0.5176 -2.2480 -0.2333 -0.0561 -0.1654 -0.2893 -0.1544 -2.1093 -0.0765 -0.0768 -0.9960 -0.4749 -0.1167 -0.0672 -0.1752 -0.0538 -0.7568 -1.6065 -0.8655 -0.4587 -1.2178 -0.0441 -0.0636 -0.0594 -0.1475 -0.0698 -0.8575 -0.9812 -0.1913 -0.0916 -0.0646 -0.1106 -0.0468 -0.0817 -0.1565 -1.1368 -0.2663 -0.1365 -0.3338 -0.1314 -0.2360 -0.2528 -0.1366 -0.1044 -0.1252 -0.1255 -0.2211 -0.1574
S-728	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-728	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-728	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
D-728	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
P-728	-3.8081 -0.0743 -0.1735 -0.1467 -0.2433 -0.1366 -0.1998 -0.3320 -1.4259 -0.9550 -0.0813 -0.0948 -0.1768 -0.1776 -0.0578 -0.0835 -0.1413 -0.5373 -0.6957 -0.7927 -0.9428 -0.1267 -0.3703 -2.8286 -0.1302 -0.5525 -0.8950 -0.1379 -0.5176 -2.2480 -0.2333 -0.0561 -0.1654 -0.2893 -0.1544 -2.1093 -0.0765 -0.0768 -0.9960 -0.4749 -0.1167 -0.0672 -0.1752 -0.0538 -0.7568 -1.6065 -0.8655 -0.4587 -1.2178 -0.0441 -0.0636 -0.0594 -0.1475 -0.0698 -0.8575 -0.9812 -0.1913 -0.0916 -0.0646 -0.1106 -0.0468 -0.0817 -0.1565 -1.1368 -0.2663 -0.1365 -0.3338 -0.1314 -0.2360 -0.2528 -0.1366 -0.1044 -0.1252 -0.1255 -0.2211 -0.1574
S-553	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-553	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-553	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
D-553	-0.4653160274028778	Activity ( international units ) is determined by the chromogenic assay against an in @-@ house standard referred to as the WHO. Specific activity is approximately 4,000-10,000 IU/ mg protein <unk> / human clotting factor VIII produced by recombinant DNA technology in Chinese hamster ovarian cells ( CHO ) .
P-553	-3.8081 -0.0743 -0.1735 -0.1467 -0.2433 -0.1366 -0.1998 -0.3320 -1.4259 -0.9550 -0.0813 -0.0948 -0.1768 -0.1776 -0.0578 -0.0835 -0.1413 -0.5373 -0.6957 -0.7927 -0.9428 -0.1267 -0.3703 -2.8286 -0.1302 -0.5525 -0.8950 -0.1379 -0.5176 -2.2480 -0.2333 -0.0561 -0.1654 -0.2893 -0.1544 -2.1093 -0.0765 -0.0768 -0.9960 -0.4749 -0.1167 -0.0672 -0.1752 -0.0538 -0.7568 -1.6065 -0.8655 -0.4587 -1.2178 -0.0441 -0.0636 -0.0594 -0.1475 -0.0698 -0.8575 -0.9812 -0.1913 -0.0916 -0.0646 -0.1106 -0.0468 -0.0817 -0.1565 -1.1368 -0.2663 -0.1365 -0.3338 -0.1314 -0.2360 -0.2528 -0.1366 -0.1044 -0.1252 -0.1255 -0.2211 -0.1574
S-390	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( 56 nmol<unk> l <unk> 23 ng<unk> ml <unk> ) als in der Gruppe unter Alendronat allein ( 46 nmol<unk> l <unk> 18,2 ng<unk> ml <unk> ) .
T-390	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<<unk>> 2.800 I.E. ) ( 56 nmol<<unk>> l <<unk>> 23 ng<<unk>> ml <<unk>> ) als in der Gruppe unter Alendronat allein ( 46 nmol<<unk>> l <<unk>> 18,2 ng<<unk>> ml <<unk>> ) . After 15 weeks of treatment , the mean serum 25-hydroxyvitamin D levels were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2800 IU ) group ( 56 nmol/ l <<unk>> 23 ng/ ml <<unk>> ) than in the alendronate-only group ( 46 nmol/ l <<unk>> 18.2 ng/ ml <<unk>> ) .
H-390	-0.2467254102230072	After 15 weeks of treatment , mean levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ 23 ng/ ml ) group than in the alendronate alone group ( 46 nmol/ l / 18.2 ng/ ml ) .
D-390	-0.2467254102230072	After 15 weeks of treatment , mean levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ 23 ng/ ml ) group than in the alendronate alone group ( 46 nmol/ l / 18.2 ng/ ml ) .
P-390	-0.9806 -0.2047 -0.1077 -0.1549 -0.1617 -0.1974 -0.1101 -0.7318 -0.1256 -1.0088 -0.1158 -0.0905 -0.1065 -0.1237 -0.1149 -0.0633 -0.1149 -0.1468 -0.1602 -0.2149 -0.1352 -0.1534 -0.1640 -0.1296 -0.1373 -0.1800 -0.0352 -0.0634 -0.1378 -0.1185 -0.0787 -0.3089 -0.1715 -0.1570 -0.2339 -0.0956 -0.2417 -0.0898 -0.1202 -0.0942 -0.4927 -0.1777 -0.1950 -0.1218 -0.3306 -0.1169 -1.1693 -0.0998 -0.1581 -0.1131 -0.0469 -0.9645 -0.9439 -0.1776 -0.1530 -0.1725 -0.4395 -0.1056 -0.1322 -0.0702 -0.3699 -1.2590 -0.1417 -0.0807 -0.1704 -0.3748 -0.1348 -0.5714 -0.1468 -0.0904 -0.1394 -0.1044 -0.1403 -0.0944 -0.0534 -0.9819 -0.1778 -0.1512
S-202	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( 56 nmol<unk> l <unk> 23 ng<unk> ml <unk> ) als in der Gruppe unter Alendronat allein ( 46 nmol<unk> l <unk> 18,2 ng<unk> ml <unk> ) .
T-202	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<<unk>> 2.800 I.E. ) ( 56 nmol<<unk>> l <<unk>> 23 ng<<unk>> ml <<unk>> ) als in der Gruppe unter Alendronat allein ( 46 nmol<<unk>> l <<unk>> 18,2 ng<<unk>> ml <<unk>> ) . After 15 weeks of treatment , the mean serum 25-hydroxyvitamin D levels were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2800 IU ) group ( 56 nmol/ l <<unk>> 23 ng/ ml <<unk>> ) than in the alendronate-only group ( 46 nmol/ l <<unk>> 18.2 ng/ ml <<unk>> ) .
H-202	-0.2467254102230072	After 15 weeks of treatment , mean levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ 23 ng/ ml ) group than in the alendronate alone group ( 46 nmol/ l / 18.2 ng/ ml ) .
D-202	-0.2467254102230072	After 15 weeks of treatment , mean levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ 23 ng/ ml ) group than in the alendronate alone group ( 46 nmol/ l / 18.2 ng/ ml ) .
P-202	-0.9806 -0.2047 -0.1077 -0.1549 -0.1617 -0.1974 -0.1101 -0.7318 -0.1256 -1.0088 -0.1158 -0.0905 -0.1065 -0.1237 -0.1149 -0.0633 -0.1149 -0.1468 -0.1602 -0.2149 -0.1352 -0.1534 -0.1640 -0.1296 -0.1373 -0.1800 -0.0352 -0.0634 -0.1378 -0.1185 -0.0787 -0.3089 -0.1715 -0.1570 -0.2339 -0.0956 -0.2417 -0.0898 -0.1202 -0.0942 -0.4927 -0.1777 -0.1950 -0.1218 -0.3306 -0.1169 -1.1693 -0.0998 -0.1581 -0.1131 -0.0469 -0.9645 -0.9439 -0.1776 -0.1530 -0.1725 -0.4395 -0.1056 -0.1322 -0.0702 -0.3699 -1.2590 -0.1417 -0.0807 -0.1704 -0.3748 -0.1348 -0.5714 -0.1468 -0.0904 -0.1394 -0.1044 -0.1403 -0.0944 -0.0534 -0.9819 -0.1778 -0.1512
S-1788	Gelegentliche Nebenwirkungen Juckreiz , verstärktes Schwitzen , ungewöhnliches Geschmacksempfinden , Hitzewallungen , Migräne , Gedächtnisstörungen , Schüttelfrost , Durchfall , Übelkeit , Erbrechen , Kurzatmigkeit , rauher Hals , Entzündungen der Lymphgefäße , Blässe , Augenentzündungen , Hautausschläge , extremes Schwitzen ,
T-1788	Uncommon side effects
H-1788	-0.3057192862033844	Uncommon side effects itching , increased sweating , unusual taste sensation , hot flashes , migraine , memory problems , chills , diarrhoea , nausea , vomiting , shortness of breath , rough throat , inflammation of the lymphatic vessels , paleness , eye inflammation , rashes , extreme sweating ,
D-1788	-0.3057192862033844	Uncommon side effects itching , increased sweating , unusual taste sensation , hot flashes , migraine , memory problems , chills , diarrhoea , nausea , vomiting , shortness of breath , rough throat , inflammation of the lymphatic vessels , paleness , eye inflammation , rashes , extreme sweating ,
P-1788	-1.9660 -0.1018 -0.5785 -0.1022 -0.2861 -0.0522 -0.1349 -0.5026 -0.1299 -0.0613 -0.1354 -0.0736 -0.7880 -0.1166 -0.1135 -0.1326 -0.2942 -0.4981 -0.2928 -0.1356 -0.1314 -0.0153 -1.0906 -0.1349 -1.4078 -2.2073 -0.1300 -0.1998 -0.0330 -0.1378 -0.1277 -0.0248 -0.1097 -0.0256 -0.1361 -0.1062 -0.0299 -0.1392 -0.0945 -0.0445 -0.0950 -0.1324 -0.0188 -0.1513 -0.1187 -0.0685 -0.1379 -0.4752 -1.1709 -0.1434 -1.1332 -0.0539 -0.1181 -0.1292 -0.7819 -0.2577 -0.6473 -0.1109 -0.6152 -0.0567 -0.1354 -1.0907 -0.1945 -0.1476 -0.3262 -0.3766 -0.0343 -0.1467 -0.1361 -0.4204 -0.4226 -0.1377 -0.2467 -0.1179 -0.0622 -0.1538 -0.1529
S-391	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant nach 15 Wochen den Anteil an Patienten mit Vitamin-D-Insuffizienz ( Serumwert von 25-Hydroxyvitamin D <unk> 37,5 nmol<unk> l <unk> <unk> 15 ng<unk> ml <unk> ) um 62,5 % im Vergleich zu Alendronat allein ( 12 % vs .
T-391	The percentage of patients with vitamin D insufficiency ( serum 25-hydroxyvitamin D <<unk>> 37.5 nmol/ l <<unk>> <<unk>> 15 ng/ ml <<unk>> ) was significantly reduced by 62.5 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 12 % vs.
H-391	-0.26844194531440735	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 37.5 nmol/ <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs.
D-391	-0.26844194531440735	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 37.5 nmol/ <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs.
P-391	-0.1006 -0.0635 -0.1329 -0.1120 -0.0915 -0.1525 -0.1437 -0.1191 -0.1591 -0.0937 -0.2159 -0.0963 -0.1119 -0.1051 -0.1378 -0.8072 -0.7434 -0.0640 -0.4683 -0.4263 -0.1621 -0.4440 -0.1960 -0.3973 -0.0455 -0.1178 -0.7475 -0.0311 -0.1065 -0.1298 -0.6418 -0.1293 -1.0728 -1.0372 -0.0546 -0.0605 -0.1132 -0.1289 -0.0823 -0.0737 -0.1214 -0.8772 -0.1021 -0.0606 -0.1032 -0.2408 -0.2172 -2.5980 -0.2354 -0.0844 -0.1706 -0.0843 -0.0660 -0.1695 -0.1288 -0.4323 -0.1483 -0.0883 -0.1422 -0.4674 -0.5374 -0.2063 -0.1113 -0.1329 -0.0823 -0.0799 -0.1416 -0.1112 -0.1162 -0.7122 -0.1736
S-203	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant nach 15 Wochen den Anteil an Patienten mit Vitamin-D-Insuffizienz ( Serumwert von 25-Hydroxyvitamin D <unk> 37,5 nmol<unk> l <unk> <unk> 15 ng<unk> ml <unk> ) um 62,5 % im Vergleich zu Alendronat allein ( 12 % vs .
T-203	The percentage of patients with vitamin D insufficiency ( serum 25-hydroxyvitamin D <<unk>> 37.5 nmol/ l <<unk>> <<unk>> 15 ng/ ml <<unk>> ) was significantly reduced by 62.5 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 12 % vs.
H-203	-0.26844194531440735	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 37.5 nmol/ <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs.
D-203	-0.26844194531440735	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 37.5 nmol/ <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs.
P-203	-0.1006 -0.0635 -0.1329 -0.1120 -0.0915 -0.1525 -0.1437 -0.1191 -0.1591 -0.0937 -0.2159 -0.0963 -0.1119 -0.1051 -0.1378 -0.8072 -0.7434 -0.0640 -0.4683 -0.4263 -0.1621 -0.4440 -0.1960 -0.3973 -0.0455 -0.1178 -0.7475 -0.0311 -0.1065 -0.1298 -0.6418 -0.1293 -1.0728 -1.0372 -0.0546 -0.0605 -0.1132 -0.1289 -0.0823 -0.0737 -0.1214 -0.8772 -0.1021 -0.0606 -0.1032 -0.2408 -0.2172 -2.5980 -0.2354 -0.0844 -0.1706 -0.0843 -0.0660 -0.1695 -0.1288 -0.4323 -0.1483 -0.0883 -0.1422 -0.4674 -0.5374 -0.2063 -0.1113 -0.1329 -0.0823 -0.0799 -0.1416 -0.1112 -0.1162 -0.7122 -0.1736
S-974	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-974	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-974	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-974	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-974	-1.4543 -0.0547 -0.0853 -0.6402 -0.2086 -0.2140 -0.8715 -0.6139 -0.0407 -0.2296 -0.1591 -0.1815 -0.2184 -0.1491 -0.1272 -1.0177 -0.3459 -0.1966 -0.1655 -0.6117 -0.1450 -0.0780 -0.0933 -0.2080 -0.1611 -0.4654 -0.1151 -0.2954 -0.1147 -0.1366 -2.4629 -0.1001 -0.1454 -0.0969 -0.1109 -0.3298 -0.1247 -0.3515 -0.1476 -0.1477 -0.1117 -0.1319 -0.0598 -0.1444 -0.0931 -0.1006 -0.3021 -0.1238 -0.4528 -0.2296 -0.2435 -0.1199 -0.1362 -0.2240 -0.0596 -1.1180 -0.2027 -0.1762 -0.2392 -0.1187 -0.1375 -1.2511 -0.1324 -0.4438 -0.0644 -0.9546 -0.1502 -0.9770 -0.5554 -0.1538 -0.2034 -0.1494 -0.1655 -0.1733 -0.1533
S-1502	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-1502	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-1502	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-1502	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-1502	-1.4543 -0.0547 -0.0853 -0.6402 -0.2086 -0.2140 -0.8715 -0.6139 -0.0407 -0.2296 -0.1591 -0.1815 -0.2184 -0.1491 -0.1272 -1.0177 -0.3459 -0.1966 -0.1655 -0.6117 -0.1450 -0.0780 -0.0933 -0.2080 -0.1611 -0.4654 -0.1151 -0.2954 -0.1147 -0.1366 -2.4629 -0.1001 -0.1454 -0.0969 -0.1109 -0.3298 -0.1247 -0.3515 -0.1476 -0.1477 -0.1117 -0.1319 -0.0598 -0.1444 -0.0931 -0.1006 -0.3021 -0.1238 -0.4528 -0.2296 -0.2435 -0.1199 -0.1362 -0.2240 -0.0596 -1.1180 -0.2027 -0.1762 -0.2392 -0.1187 -0.1375 -1.2511 -0.1324 -0.4438 -0.0644 -0.9546 -0.1502 -0.9770 -0.5554 -0.1538 -0.2034 -0.1494 -0.1655 -0.1733 -0.1533
S-624	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-624	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-624	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-624	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-624	-1.4543 -0.0547 -0.0853 -0.6402 -0.2086 -0.2140 -0.8715 -0.6139 -0.0407 -0.2296 -0.1591 -0.1815 -0.2184 -0.1491 -0.1272 -1.0177 -0.3459 -0.1966 -0.1655 -0.6117 -0.1450 -0.0780 -0.0933 -0.2080 -0.1611 -0.4654 -0.1151 -0.2954 -0.1147 -0.1366 -2.4629 -0.1001 -0.1454 -0.0969 -0.1109 -0.3298 -0.1247 -0.3515 -0.1476 -0.1477 -0.1117 -0.1319 -0.0598 -0.1444 -0.0931 -0.1006 -0.3021 -0.1238 -0.4528 -0.2296 -0.2435 -0.1199 -0.1362 -0.2240 -0.0596 -1.1180 -0.2027 -0.1762 -0.2392 -0.1187 -0.1375 -1.2511 -0.1324 -0.4438 -0.0644 -0.9546 -0.1502 -0.9770 -0.5554 -0.1538 -0.2034 -0.1494 -0.1655 -0.1733 -0.1533
S-798	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-798	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-798	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-798	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-798	-1.4543 -0.0547 -0.0853 -0.6402 -0.2086 -0.2140 -0.8715 -0.6139 -0.0407 -0.2296 -0.1591 -0.1815 -0.2184 -0.1491 -0.1272 -1.0177 -0.3459 -0.1966 -0.1655 -0.6117 -0.1450 -0.0780 -0.0933 -0.2080 -0.1611 -0.4654 -0.1151 -0.2954 -0.1147 -0.1366 -2.4629 -0.1001 -0.1454 -0.0969 -0.1109 -0.3298 -0.1247 -0.3515 -0.1476 -0.1477 -0.1117 -0.1319 -0.0598 -0.1444 -0.0931 -0.1006 -0.3021 -0.1238 -0.4528 -0.2296 -0.2435 -0.1199 -0.1362 -0.2240 -0.0596 -1.1180 -0.2027 -0.1762 -0.2392 -0.1187 -0.1375 -1.2511 -0.1324 -0.4438 -0.0644 -0.9546 -0.1502 -0.9770 -0.5554 -0.1538 -0.2034 -0.1494 -0.1655 -0.1733 -0.1533
S-1150	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-1150	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-1150	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-1150	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-1150	-1.4543 -0.0547 -0.0853 -0.6402 -0.2086 -0.2140 -0.8715 -0.6139 -0.0407 -0.2296 -0.1591 -0.1815 -0.2184 -0.1491 -0.1272 -1.0177 -0.3459 -0.1966 -0.1655 -0.6117 -0.1450 -0.0780 -0.0933 -0.2080 -0.1611 -0.4654 -0.1151 -0.2954 -0.1147 -0.1366 -2.4629 -0.1001 -0.1454 -0.0969 -0.1109 -0.3298 -0.1247 -0.3515 -0.1476 -0.1477 -0.1117 -0.1319 -0.0598 -0.1444 -0.0931 -0.1006 -0.3021 -0.1238 -0.4528 -0.2296 -0.2435 -0.1199 -0.1362 -0.2240 -0.0596 -1.1180 -0.2027 -0.1762 -0.2392 -0.1187 -0.1375 -1.2511 -0.1324 -0.4438 -0.0644 -0.9546 -0.1502 -0.9770 -0.5554 -0.1538 -0.2034 -0.1494 -0.1655 -0.1733 -0.1533
S-1126	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-1126	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-1126	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
D-1126	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
P-1126	-1.3320 -0.0950 -0.1869 -0.1734 -0.7281 -0.1361 -0.6781 -0.7823 -0.1283 -0.0583 -0.0258 -0.0385 -1.8914 -0.2493 -0.1512 -0.3714 -0.0659 -0.1385 -0.1531 -0.0498 -0.1395 -0.0963 -0.6698 -0.1076 -0.0763 -0.0897 -0.1406 -0.1605 -0.0909 -0.0083 -0.1191 -0.1116 -0.1376 -0.1210 -0.0574 -0.0653 -0.0949 -0.1481 -0.1732 -0.1016 -0.0501 -0.1125 -0.0350 -0.0882 -0.1669 -0.0955 -0.0832 -0.1445 -0.1383 -0.0946 -0.4060 -0.2140 -0.0481 -0.0551 -0.0616 -0.0779 -1.4126 -0.1931 -0.1607 -0.0599 -0.1222 -0.0508 -0.9035 -0.1850 -0.0769 -0.1985 -0.2011 -0.1502 -0.1380 -1.2959 -0.0135 -0.2056 -0.1339 -0.1663 -0.1534
S-600	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-600	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-600	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
D-600	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
P-600	-1.3320 -0.0950 -0.1869 -0.1734 -0.7281 -0.1361 -0.6781 -0.7823 -0.1283 -0.0583 -0.0258 -0.0385 -1.8914 -0.2493 -0.1512 -0.3714 -0.0659 -0.1385 -0.1531 -0.0498 -0.1395 -0.0963 -0.6698 -0.1076 -0.0763 -0.0897 -0.1406 -0.1605 -0.0909 -0.0083 -0.1191 -0.1116 -0.1376 -0.1210 -0.0574 -0.0653 -0.0949 -0.1481 -0.1732 -0.1016 -0.0501 -0.1125 -0.0350 -0.0882 -0.1669 -0.0955 -0.0832 -0.1445 -0.1383 -0.0946 -0.4060 -0.2140 -0.0481 -0.0551 -0.0616 -0.0779 -1.4126 -0.1931 -0.1607 -0.0599 -0.1222 -0.0508 -0.9035 -0.1850 -0.0769 -0.1985 -0.2011 -0.1502 -0.1380 -1.2959 -0.0135 -0.2056 -0.1339 -0.1663 -0.1534
S-1326	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-1326	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-1326	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-1326	-0.31290915608406067	Frequency categories are defined by the following criteria : Very common ( 1<unk> 10 ) , common ( 1<unk> 100 to 1<unk> 10 ) , occasional ( 1<unk> 1,000 to 1<unk> 100 ) , rare ( 1<unk> 10,000 to 1<unk> 1,000 ) , very rare ( 1<unk> 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-1326	-1.4543 -0.0547 -0.0853 -0.6402 -0.2086 -0.2140 -0.8715 -0.6139 -0.0407 -0.2296 -0.1591 -0.1815 -0.2184 -0.1491 -0.1272 -1.0177 -0.3459 -0.1966 -0.1655 -0.6117 -0.1450 -0.0780 -0.0933 -0.2080 -0.1611 -0.4654 -0.1151 -0.2954 -0.1147 -0.1366 -2.4629 -0.1001 -0.1454 -0.0969 -0.1109 -0.3298 -0.1247 -0.3515 -0.1476 -0.1477 -0.1117 -0.1319 -0.0598 -0.1444 -0.0931 -0.1006 -0.3021 -0.1238 -0.4528 -0.2296 -0.2435 -0.1199 -0.1362 -0.2240 -0.0596 -1.1180 -0.2027 -0.1762 -0.2392 -0.1187 -0.1375 -1.2511 -0.1324 -0.4438 -0.0644 -0.9546 -0.1502 -0.9770 -0.5554 -0.1538 -0.2034 -0.1494 -0.1655 -0.1733 -0.1533
S-774	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-774	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-774	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
D-774	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
P-774	-1.3320 -0.0950 -0.1869 -0.1734 -0.7281 -0.1361 -0.6781 -0.7823 -0.1283 -0.0583 -0.0258 -0.0385 -1.8914 -0.2493 -0.1512 -0.3714 -0.0659 -0.1385 -0.1531 -0.0498 -0.1395 -0.0963 -0.6698 -0.1076 -0.0763 -0.0897 -0.1406 -0.1605 -0.0909 -0.0083 -0.1191 -0.1116 -0.1376 -0.1210 -0.0574 -0.0653 -0.0949 -0.1481 -0.1732 -0.1016 -0.0501 -0.1125 -0.0350 -0.0882 -0.1669 -0.0955 -0.0832 -0.1445 -0.1383 -0.0946 -0.4060 -0.2140 -0.0481 -0.0551 -0.0616 -0.0779 -1.4126 -0.1931 -0.1607 -0.0599 -0.1222 -0.0508 -0.9035 -0.1850 -0.0769 -0.1985 -0.2011 -0.1502 -0.1380 -1.2959 -0.0135 -0.2056 -0.1339 -0.1663 -0.1534
S-950	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-950	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-950	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
D-950	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
P-950	-1.3320 -0.0950 -0.1869 -0.1734 -0.7281 -0.1361 -0.6781 -0.7823 -0.1283 -0.0583 -0.0258 -0.0385 -1.8914 -0.2493 -0.1512 -0.3714 -0.0659 -0.1385 -0.1531 -0.0498 -0.1395 -0.0963 -0.6698 -0.1076 -0.0763 -0.0897 -0.1406 -0.1605 -0.0909 -0.0083 -0.1191 -0.1116 -0.1376 -0.1210 -0.0574 -0.0653 -0.0949 -0.1481 -0.1732 -0.1016 -0.0501 -0.1125 -0.0350 -0.0882 -0.1669 -0.0955 -0.0832 -0.1445 -0.1383 -0.0946 -0.4060 -0.2140 -0.0481 -0.0551 -0.0616 -0.0779 -1.4126 -0.1931 -0.1607 -0.0599 -0.1222 -0.0508 -0.9035 -0.1850 -0.0769 -0.1985 -0.2011 -0.1502 -0.1380 -1.2959 -0.0135 -0.2056 -0.1339 -0.1663 -0.1534
S-1302	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-1302	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-1302	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
D-1302	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
P-1302	-1.3320 -0.0950 -0.1869 -0.1734 -0.7281 -0.1361 -0.6781 -0.7823 -0.1283 -0.0583 -0.0258 -0.0385 -1.8914 -0.2493 -0.1512 -0.3714 -0.0659 -0.1385 -0.1531 -0.0498 -0.1395 -0.0963 -0.6698 -0.1076 -0.0763 -0.0897 -0.1406 -0.1605 -0.0909 -0.0083 -0.1191 -0.1116 -0.1376 -0.1210 -0.0574 -0.0653 -0.0949 -0.1481 -0.1732 -0.1016 -0.0501 -0.1125 -0.0350 -0.0882 -0.1669 -0.0955 -0.0832 -0.1445 -0.1383 -0.0946 -0.4060 -0.2140 -0.0481 -0.0551 -0.0616 -0.0779 -1.4126 -0.1931 -0.1607 -0.0599 -0.1222 -0.0508 -0.9035 -0.1850 -0.0769 -0.1985 -0.2011 -0.1502 -0.1380 -1.2959 -0.0135 -0.2056 -0.1339 -0.1663 -0.1534
S-1478	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-1478	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-1478	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
D-1478	-0.23780444264411926	Patients should be aware of immediate signs of hypersensitivity , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. tightness in the chest , wheezing ) .
P-1478	-1.3320 -0.0950 -0.1869 -0.1734 -0.7281 -0.1361 -0.6781 -0.7823 -0.1283 -0.0583 -0.0258 -0.0385 -1.8914 -0.2493 -0.1512 -0.3714 -0.0659 -0.1385 -0.1531 -0.0498 -0.1395 -0.0963 -0.6698 -0.1076 -0.0763 -0.0897 -0.1406 -0.1605 -0.0909 -0.0083 -0.1191 -0.1116 -0.1376 -0.1210 -0.0574 -0.0653 -0.0949 -0.1481 -0.1732 -0.1016 -0.0501 -0.1125 -0.0350 -0.0882 -0.1669 -0.0955 -0.0832 -0.1445 -0.1383 -0.0946 -0.4060 -0.2140 -0.0481 -0.0551 -0.0616 -0.0779 -1.4126 -0.1931 -0.1607 -0.0599 -0.1222 -0.0508 -0.9035 -0.1850 -0.0769 -0.1985 -0.2011 -0.1502 -0.1380 -1.2959 -0.0135 -0.2056 -0.1339 -0.1663 -0.1534
S-393	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant den Anteil an Patienten mit Vitamin-D-Mangel ( Serumwert von 25-Hydroxyvitamin D <unk> 22,5 nmol<unk> l <unk> <unk> 9 ng<unk> ml <unk> ) um 92 % im Vergleich zu Alendronat allein ( 1 % vs . 13 % ) .
T-393	The percentage of patients with vitamin D deficiency ( serum 25- hydroxyvitamin D <<unk>> 22.5 nmol/ l <<unk>> <<unk>> 9 ng/ ml <<unk>> ) was significantly reduced by 92 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 1 % vs 13 % , respectively ) .
H-393	-0.22059179842472076	ADROVANCE ( 70 mg/ 2,800 IU ) significantly reduced the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 22.5 nmol/ l <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
D-393	-0.22059179842472076	ADROVANCE ( 70 mg/ 2,800 IU ) significantly reduced the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 22.5 nmol/ l <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
P-393	-0.0593 -0.0642 -0.1306 -0.1146 -0.0920 -0.1509 -0.1449 -0.1228 -0.1668 -0.0950 -0.1967 -0.0968 -0.1128 -0.1041 -0.1336 -0.2523 -0.8800 -0.1912 -0.4428 -0.1584 -0.3374 -0.1963 -0.2630 -0.0398 -0.1014 -0.0389 -0.0592 -0.1272 -0.1299 -0.4077 -0.1204 -1.1031 -1.1863 -0.0573 -0.0490 -0.1168 -0.1430 -0.0849 -0.0625 -0.1211 -0.9395 -0.0265 -0.1640 -0.1030 -0.2532 -0.1906 -0.8887 -0.5025 -0.3347 -0.0904 -0.1653 -0.0868 -0.0595 -0.0862 -0.1259 -0.1934 -0.1473 -0.1507 -0.3598 -0.5284 -0.2063 -0.1123 -0.1352 -0.0932 -0.0822 -0.1438 -0.1373 -0.1259 -0.7361 -0.1179 -0.1033 -0.1342 -0.1930 -0.1517
S-205	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant den Anteil an Patienten mit Vitamin-D-Mangel ( Serumwert von 25-Hydroxyvitamin D <unk> 22,5 nmol<unk> l <unk> <unk> 9 ng<unk> ml <unk> ) um 92 % im Vergleich zu Alendronat allein ( 1 % vs . 13 % ) .
T-205	The percentage of patients with vitamin D deficiency ( serum 25-hydroxyvitamin D <<unk>> 22.5 nmol/ l <<unk>> <<unk>> 9 ng/ ml <<unk>> ) was significantly reduced by 92 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 1 % vs 13 % , respectively ) .
H-205	-0.22059179842472076	ADROVANCE ( 70 mg/ 2,800 IU ) significantly reduced the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 22.5 nmol/ l <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
D-205	-0.22059179842472076	ADROVANCE ( 70 mg/ 2,800 IU ) significantly reduced the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 22.5 nmol/ l <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
P-205	-0.0593 -0.0642 -0.1306 -0.1146 -0.0920 -0.1509 -0.1449 -0.1228 -0.1668 -0.0950 -0.1967 -0.0968 -0.1128 -0.1041 -0.1336 -0.2523 -0.8800 -0.1912 -0.4428 -0.1584 -0.3374 -0.1963 -0.2630 -0.0398 -0.1014 -0.0389 -0.0592 -0.1272 -0.1299 -0.4077 -0.1204 -1.1031 -1.1863 -0.0573 -0.0490 -0.1168 -0.1430 -0.0849 -0.0625 -0.1211 -0.9395 -0.0265 -0.1640 -0.1030 -0.2532 -0.1906 -0.8887 -0.5025 -0.3347 -0.0904 -0.1653 -0.0868 -0.0595 -0.0862 -0.1259 -0.1934 -0.1473 -0.1507 -0.3598 -0.5284 -0.2063 -0.1123 -0.1352 -0.0932 -0.0822 -0.1438 -0.1373 -0.1259 -0.7361 -0.1179 -0.1033 -0.1342 -0.1930 -0.1517
S-1927	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Aerinaze bei der symptomatischen Behandlung der saisonalen allergischen Rhinitis mit Nasenschleimhautschwellung gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Aerinaze zu erteilen .
T-1927	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Aerinaze bei der symptomatischen Behandlung der saisonalen allergischen Rhinitis mit Nasenschleimhautschwellung gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Aerinaze zu erteilen . The Committee recommended that Aerinaze be given marketing authorisation .
H-1927	-0.23749352991580963	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that the benefits of Aerinaze in the symptomatic treatment of seasonal allergic rhinitis with nasal swelling outweigh the risks and recommended authorisation for the marketing of Aerinaze .
D-1927	-0.23749352991580963	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that the benefits of Aerinaze in the symptomatic treatment of seasonal allergic rhinitis with nasal swelling outweigh the risks and recommended authorisation for the marketing of Aerinaze .
P-1927	-0.1728 -0.1234 -0.2015 -0.1844 -0.1283 -0.0990 -0.1358 -0.1393 -0.2143 -0.0921 -0.1271 -0.0626 -0.0654 -0.1206 -0.9268 -0.1557 -0.2850 -0.2481 -0.1532 -0.1184 -0.1234 -0.1505 -0.1478 -0.0987 -1.0935 -0.9258 -0.1661 -0.1294 -0.0863 -0.5102 -0.1223 -0.1098 -0.0894 -0.1200 -0.0657 -0.0281 -0.0722 -0.1052 -0.0795 -0.2086 -0.2229 -0.0244 -0.2433 -0.0575 -0.1169 -0.1871 -0.3024 -0.2470 -0.2060 -0.3520 -0.1060 -2.0424 -0.0547 -0.8005 -0.2309 -0.5783 -0.1298 -0.1544 -0.1388 -0.1495 -0.1565 -0.1223 -0.2383 -0.1513
S-463	Etui mit versiegelten Aluminium<unk> Aluminium-Blisterpackungen in Umkartons zu 2 ( 1 Etui mit 2 Tabletten ) , 4 ( 1 Etui mit 4 Tabletten ) , 12 ( 3 Etuis mit 4 Tabletten ) oder 40 ( 10 Etuis mit 4 Tabletten ) Tabletten .
T-463	Wallet with sealed aluminium/ aluminium blisters , in cartons containing 2 ( 1 wallet x 2 tablets ) , 4 ( 1 wallet x 4 tablets ) , 12 ( 3 wallets x 4 tablets ) or 40 ( 10 wallets x 4 tablets ) tablets .
H-463	-0.27399492263793945	Aluminium sealed blister case in cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
D-463	-0.27399492263793945	Aluminium sealed blister case in cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
P-463	-1.2908 -0.1535 -0.5209 -0.2548 -0.0957 -1.5079 -0.6093 -1.4789 -0.8157 -0.1430 -0.1259 -0.1435 -0.1590 -0.5871 -0.7620 -0.1170 -0.0661 -0.1534 -0.1575 -0.1419 -0.1493 -0.1423 -0.1667 -0.2910 -0.1316 -0.1355 -0.0535 -0.1544 -0.1222 -0.1359 -0.1125 -0.1372 -0.1234 -0.4573 -0.1315 -0.1325 -0.0575 -0.1609 -0.1176 -0.2597 -0.0927 -0.1294 -0.1366 -0.3944 -0.1312 -0.1340 -0.0606 -0.1523 -0.1214 -0.1774 -0.1419 -0.2344 -0.1595
S-1679	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1679	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1679	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
D-1679	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
P-1679	-0.0616 -0.0211 -0.0274 -0.0875 -0.1516 -0.0222 -0.0104 -0.0193 -0.0222 -0.0627 -0.0472 -0.0680 -0.6044 -0.0698 -0.0211 -0.0968 -0.0302 -0.0432 -0.0884 -0.2831 -1.2626 -0.0007 -0.0244 -0.2773 -0.0363 -0.0326 -0.0303 -0.0745 -0.0795 -0.0132 -0.0321 -0.0275 -0.0401 -0.5575 -0.0483 -2.3999 -0.2458 -0.9135 -0.0152 -0.0243 -0.0061 -0.0427 -0.0089 -0.0504 -1.7154
S-1662	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1662	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1662	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
D-1662	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
P-1662	-0.0616 -0.0211 -0.0274 -0.0875 -0.1516 -0.0222 -0.0104 -0.0193 -0.0222 -0.0627 -0.0472 -0.0680 -0.6044 -0.0698 -0.0211 -0.0968 -0.0302 -0.0432 -0.0884 -0.2831 -1.2626 -0.0007 -0.0244 -0.2773 -0.0363 -0.0326 -0.0303 -0.0745 -0.0795 -0.0132 -0.0321 -0.0275 -0.0401 -0.5575 -0.0483 -2.3999 -0.2458 -0.9135 -0.0152 -0.0243 -0.0061 -0.0427 -0.0089 -0.0504 -1.7154
S-1629	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1629	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1629	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
D-1629	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
P-1629	-0.0616 -0.0211 -0.0274 -0.0875 -0.1516 -0.0222 -0.0104 -0.0193 -0.0222 -0.0627 -0.0472 -0.0680 -0.6044 -0.0698 -0.0211 -0.0968 -0.0302 -0.0432 -0.0884 -0.2831 -1.2626 -0.0007 -0.0244 -0.2773 -0.0363 -0.0326 -0.0303 -0.0745 -0.0795 -0.0132 -0.0321 -0.0275 -0.0401 -0.5575 -0.0483 -2.3999 -0.2458 -0.9135 -0.0152 -0.0243 -0.0061 -0.0427 -0.0089 -0.0504 -1.7154
S-1695	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1695	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1695	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
D-1695	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
P-1695	-0.0616 -0.0211 -0.0274 -0.0875 -0.1516 -0.0222 -0.0104 -0.0193 -0.0222 -0.0627 -0.0472 -0.0680 -0.6044 -0.0698 -0.0211 -0.0968 -0.0302 -0.0432 -0.0884 -0.2831 -1.2626 -0.0007 -0.0244 -0.2773 -0.0363 -0.0326 -0.0303 -0.0745 -0.0795 -0.0132 -0.0321 -0.0275 -0.0401 -0.5575 -0.0483 -2.3999 -0.2458 -0.9135 -0.0152 -0.0243 -0.0061 -0.0427 -0.0089 -0.0504 -1.7154
S-1711	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1711	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1711	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
D-1711	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
P-1711	-0.0616 -0.0211 -0.0274 -0.0875 -0.1516 -0.0222 -0.0104 -0.0193 -0.0222 -0.0627 -0.0472 -0.0680 -0.6044 -0.0698 -0.0211 -0.0968 -0.0302 -0.0432 -0.0884 -0.2831 -1.2626 -0.0007 -0.0244 -0.2773 -0.0363 -0.0326 -0.0303 -0.0745 -0.0795 -0.0132 -0.0321 -0.0275 -0.0401 -0.5575 -0.0483 -2.3999 -0.2458 -0.9135 -0.0152 -0.0243 -0.0061 -0.0427 -0.0089 -0.0504 -1.7154
S-81	Der Ausschuss für Humanarzneimittel ( CHMP ) entschied , dass die Vorteile von ADROVANCE bei der Behandlung von Osteoporose bei postmenopausalen Patientinnen mit Risiko eines Vitamin-D- Mangels gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von ADROVANCE zu erteilen .
T-81	Der Ausschuss für Humanarzneimittel ( CHMP ) entschied , dass die Vorteile von ADROVANCE bei der Behandlung von Osteoporose bei postmenopausalen Patientinnen mit Risiko eines Vitamin-D- Mangels gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von ADROVANCE zu erteilen . The Committee recommended that ADROVANCE be given marketing authorisation .
H-81	-0.22178280353546143	The Committee for Medicinal Products for Human Use ( CHMP ) decided that the benefits of ADROVANCE in the treatment of osteoporosis in post-menopausal patients at risk of vitamin D deficiency outweigh the risks and recommended authorisation for the marketing of ADROVANCE .
D-81	-0.22178280353546143	The Committee for Medicinal Products for Human Use ( CHMP ) decided that the benefits of ADROVANCE in the treatment of osteoporosis in post-menopausal patients at risk of vitamin D deficiency outweigh the risks and recommended authorisation for the marketing of ADROVANCE .
P-81	-0.1744 -0.1345 -0.2105 -0.1486 -0.1549 -0.1113 -0.1352 -0.1376 -0.1784 -0.0768 -0.1333 -0.0618 -0.0640 -0.1220 -0.9139 -0.1380 -0.3652 -0.3290 -0.1337 -0.0619 -0.0630 -0.1275 -0.1124 -0.0910 -0.2876 -0.4503 -0.1666 -0.1217 -0.1551 -0.0852 -0.0954 -0.1224 -0.0841 -0.1006 -0.1576 -0.1140 -0.5162 -0.0896 -0.0967 -0.0482 -0.1243 -0.3918 -0.1652 -0.1055 -0.1824 -0.3853 -0.0223 -0.1187 -0.0339 -0.0367 -0.1513 -0.2649 -0.5527 -0.2533 -0.2405 -0.5273 -0.0910 -2.2472 -0.0513 -0.6783 -0.2512 -0.8042 -0.1233 -0.0846 -0.0507 -0.1234 -0.1289 -0.0786 -0.2328 -0.1530
S-1645	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1645	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1645	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
D-1645	-0.21771733462810516	SPECIAL PRECAUTIONS FOR THE PRODUCTS OR UNUSED MEDICINAL PRODUCTS OR IF APPROPRIATE
P-1645	-0.0616 -0.0211 -0.0274 -0.0875 -0.1516 -0.0222 -0.0104 -0.0193 -0.0222 -0.0627 -0.0472 -0.0680 -0.6044 -0.0698 -0.0211 -0.0968 -0.0302 -0.0432 -0.0884 -0.2831 -1.2626 -0.0007 -0.0244 -0.2773 -0.0363 -0.0326 -0.0303 -0.0745 -0.0795 -0.0132 -0.0321 -0.0275 -0.0401 -0.5575 -0.0483 -2.3999 -0.2458 -0.9135 -0.0152 -0.0243 -0.0061 -0.0427 -0.0089 -0.0504 -1.7154
S-23	Harnsäurespiegel im Blut senken und auf einem niedrigeren Niveau halten , so dass sich keine Kristalle mehr bilden können . Dadurch können die Symptome der Gicht gelindert werden . Wenn der Harnsäurespiegel lange genug auf niedrigem Niveau gehalten wird , können unter Umständen sogar bereits vorhandene Gichtknoten kleiner werden . Wie wurde Adenuric untersucht ?
T-23	How has Adenuric been studied ?
H-23	-0.5857473611831665	lower uric acid levels in the blood and maintain them at a lower level so that no crystals can form , thus relieving symptoms of gout . If uric acid levels are maintained at a low level for long enough , even existing gout nodes may become smaller . How has Adenuric been investigated ?
D-23	-0.5857473611831665	lower uric acid levels in the blood and maintain them at a lower level so that no crystals can form , thus relieving symptoms of gout . If uric acid levels are maintained at a low level for long enough , even existing gout nodes may become smaller . How has Adenuric been investigated ?
P-23	-4.3197 -1.8302 -0.0765 -0.1049 -0.3240 -0.2446 -0.1893 -0.0867 -0.1991 -0.8848 -0.4142 -0.1918 -0.4184 -0.6341 -0.0762 -1.8229 -0.2152 -1.5034 -0.4392 -0.0217 -0.1968 -0.4794 -0.4799 -0.9374 -1.1100 -1.4837 -0.1387 -1.0885 -0.1256 -0.0396 -0.1684 -0.1595 -0.2368 -0.9299 -0.0787 -0.1262 -0.6056 -0.2976 -1.3510 -0.5020 -0.7601 -0.8957 -0.2316 -1.0709 -0.7036 -0.1485 -0.1547 -1.8032 -0.4459 -1.2729 -0.2107 -0.2946 -0.1886 -0.2988 -0.6611 -0.1807 -0.1715 -1.6602 -1.3002 -0.0697 -0.1803 -0.1030 -0.1254 -0.0941 -1.0135 -0.5135 -0.1598
S-544	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Advate bei der Behandlung und Propyhlaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Mangel an Faktor VIII ) gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Advate zu erteilen .
T-544	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Advate bei der Behandlung und Propyhlaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Mangel an Faktor VIII ) gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Advate zu erteilen . The Committee recommended that Advate be given marketing authorisation .
H-544	-0.2867940068244934	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that the benefits of Advate in the treatment and propyhlaxis of bleeding in patients with haemophilia A ( congenital deficiency of factor VIII ) outweigh the risks and recommended authorisation for the marketing of Advate .
D-544	-0.2867940068244934	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that the benefits of Advate in the treatment and propyhlaxis of bleeding in patients with haemophilia A ( congenital deficiency of factor VIII ) outweigh the risks and recommended authorisation for the marketing of Advate .
P-544	-0.1971 -0.1145 -0.1834 -0.1243 -0.1039 -0.1161 -0.1344 -0.1402 -0.1823 -0.0680 -0.1303 -0.0655 -0.0632 -0.1208 -0.8632 -0.1471 -0.7125 -0.3605 -0.1499 -0.4417 -0.0880 -0.2647 -0.9720 -0.2465 -0.1236 -0.1979 -0.1604 -0.1645 -0.1508 -0.2472 -0.1237 -0.8721 -0.1014 -0.1571 -0.5690 -0.1430 -0.0966 -0.0646 -0.0656 -0.0631 -0.1322 -0.1484 -0.6089 -0.1355 -0.1668 -0.4879 -0.0799 -0.0932 -0.9499 -0.2892 -0.1588 -0.0780 -0.1303 -0.2881 -0.4978 -0.2360 -0.2090 -0.5490 -0.1031 -1.9967 -0.0496 -0.7077 -0.2217 -0.9275 -0.1256 -0.6475 -0.0846 -0.2421 -0.1530
S-26	In der ersten Studie , an der 1 072 Patienten teilnahmen , wurde die Wirksamkeit dreier verschiedener Adenuric-Dosierungen ( einmal täglich 80 , 120 und 240 mg ) mit der eines Placebo ( Scheinmedikaments ) und von Allopurinol ( einem anderen Arzneimittel zur Behandlung der Hyperurikämie ) verglichen .
T-26	The first study , carried out in 1,072 patients , compared the effectiveness of three doses of Adenuric ( 80 , 120 and 240 mg once a day ) with that of placebo ( a dummy treatment ) and of allopurinol ( another medicine used to treat hyperuricaemia ) .
H-26	-0.30573803186416626	In the first trial involving 1,072 patients , the efficacy of three different adenuric doses ( 80 , 120 , and 240 mg once daily ) was compared with placebo ( sham ) and allopurinol ( another hyperuricaemia medicine ) .
D-26	-0.30573803186416626	In the first trial involving 1,072 patients , the efficacy of three different adenuric doses ( 80 , 120 , and 240 mg once daily ) was compared with placebo ( sham ) and allopurinol ( another hyperuricaemia medicine ) .
P-26	-1.3877 -0.1776 -0.0747 -0.2911 -1.0146 -0.8520 -0.0664 -0.1170 -0.2380 -0.1868 -0.2468 -0.2513 -0.0772 -0.0894 -0.1153 -0.1511 -0.9583 -0.7126 -0.1268 -0.1157 -0.2353 -0.1102 -0.1718 -0.5688 -0.1546 -0.0781 -1.1869 -0.2001 -0.0800 -0.0402 -0.6003 -0.2415 -0.1268 -0.2319 -0.0984 -0.6961 -1.0776 -0.1329 -0.1753 -0.1426 -0.2082 -0.6956 -0.1826 -0.1956 -0.1652 -0.1040 -0.1154 -0.1660 -0.0925 -0.2071 -0.0600 -1.0046 -0.0718 -0.3769 -0.0312 -0.1211 -0.5021 -0.1364 -0.1534 -0.1546
S-1876	Wirksamkeit des Arzneimittels wurde mithilfe von Scans bewertet , wobei untersucht wurde , wie die Tumore auf die Behandlung ansprachen . Das Unternehmen legte ferner Ergebnisse mehrerer kleiner Studien vor , in denen die Wirkungen eines Dosisbereichs von Advexin bei verschiedenen Krebsarten untersucht wurden . In welchem Stadium der Beurteilung befand sich der Antrag zum Zeitpunkt der Rücknahme ?
T-1876	How far into the evaluation was the application when it was withdrawn ?
H-1876	-0.5500454306602478	efficacy of the product has been evaluated by scans looking at how tumours responded to treatment , and results from several small trials evaluating the effects of a dose range of Advexin in various cancers , what stage of assessment was the withdrawal request at ?
D-1876	-0.5500454306602478	efficacy of the product has been evaluated by scans looking at how tumours responded to treatment , and results from several small trials evaluating the effects of a dose range of Advexin in various cancers , what stage of assessment was the withdrawal request at ?
P-1876	-0.5356 -0.0652 -0.0800 -0.9376 -0.2626 -0.8005 -0.9757 -0.1682 -0.5859 -0.1181 -1.2740 -0.1100 -0.1776 -2.7505 -0.2459 -0.1907 -0.5926 -0.1083 -0.0867 -0.1487 -0.2686 -0.7915 -0.3946 -1.6755 -0.4688 -0.1985 -0.1482 -1.0580 -1.0844 -0.1156 -0.3988 -0.5156 -0.1419 -0.1910 -0.1259 -0.2298 -0.1402 -0.7625 -0.1780 -0.1306 -0.4894 -1.2902 -1.2645 -0.1336 -0.6806 -1.1550 -0.4378 -1.2817 -0.7859 -0.4375 -0.2293 -0.8014 -1.3688 -0.4941 -0.5548 -0.1651
S-106	Überempfindlichkeit gegen einen der arzneilich wirksamen Bestandteile oder der sonstigen Bestandteile . Erkrankungen des Ösophagus und andere Faktoren , welche die ösophageale Entleerung verzögern , wie Strikturen oder Achalasie . Unfähigkeit , für mindestens 30 Minuten aufrecht zu stehen oder zu sitzen . Hypocalcämie .
T-106	Inability to stand or sit upright for at least 30 minutes .
H-106	-0.32662275433540344	Hypersensitivity to any active substance or ingredients . Oesophagus disorders and other factors that delay oesophageal emptying , such as stricture or achalasia . Inability to stand or sit upright for at least 30 minutes . Hypocalcaemia .
D-106	-0.32662275433540344	Hypersensitivity to any active substance or ingredients . Oesophagus disorders and other factors that delay oesophageal emptying , such as stricture or achalasia . Inability to stand or sit upright for at least 30 minutes . Hypocalcaemia .
P-106	-0.1968 -0.0649 -0.0329 -0.0647 -0.1566 -0.3391 -0.5441 -0.6325 -0.1582 -0.4163 -0.3958 -0.2290 -0.0336 -0.6277 -0.1453 -0.1713 -0.4585 -0.0654 -0.1472 -0.1938 -0.1273 -1.1274 -0.3548 -1.2913 -0.0628 -0.2979 -0.0580 -0.0732 -0.1272 -1.1977 -0.0700 -0.2152 -0.3560 -0.4218 -0.1538 -1.2351 -0.6138 -0.2054 -0.0779 -0.1498 -1.3118 -0.1180 -0.1522 -1.4384 -0.4335 -0.1474 -0.5056 -0.4492 -0.2822 -0.6460 -0.0901 -0.0847 -0.1331 -0.1301 -0.1078 -0.1547 -0.1509 -0.1673 -1.0518 -0.0601 -0.0598 -0.0758 -0.0198 -0.1232 -0.2010 -0.1725
S-138	Colecalciferol Vitamin D3 kann das Ausmaß einer Hypercalcämie und<unk> oder Hypercalciurie verstärken , wenn es an Patienten mit Krankheiten , die mit einer unkontrollierten Überproduktion von Calcitriol in Verbindung stehen , gegeben wird ( z. B. Leukämie , Lymphom , Sarkoidose ) .
T-138	Colecalciferol Vitamin D3 may increase the magnitude of hypercalcaemia and/ or hypercalciuria when administered to patients with disease associated with unregulated overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
H-138	-0.25122249126434326	Colecalciferol Vitamin D3 may increase the extent of hypercalcaemia and/ or hypercalciuria when administered in patients with disorders associated with uncontrolled overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
D-138	-0.25122249126434326	Colecalciferol Vitamin D3 may increase the extent of hypercalcaemia and/ or hypercalciuria when administered in patients with disorders associated with uncontrolled overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
P-138	-0.5662 -0.1128 -0.1949 -0.1234 -0.1814 -0.1558 -0.8365 -0.0668 -0.1478 -0.1416 -0.3291 -0.7394 -0.2688 -1.8479 -0.1706 -0.0393 -0.1009 -0.0420 -0.0201 -0.1665 -0.0468 -0.0765 -0.2648 -0.0261 -0.1450 -0.1628 -0.0723 -0.1532 -0.2930 -1.0297 -0.1033 -0.5539 -0.2543 -0.1743 -1.1026 -0.0577 -0.3576 -0.1474 -0.2277 -0.1788 -0.7531 -0.2161 -0.1384 -0.3183 -0.2074 -0.1187 -0.1746 -0.1520 -0.1217 -0.0885 -0.0602 -0.1243 -0.7918 -0.0101 -0.1429 -0.1394 -0.1210 -0.1099 -0.1456 -0.1024 -0.2434 -0.0957 -0.2103 -0.0904 -0.1457 -0.1736 -0.1563
S-326	Colecalciferol Vitamin D3 kann das Ausmaß einer Hypercalcämie und<unk> oder Hypercalciurie verstärken , wenn es an Patienten mit Krankheiten , die mit einer unkontrollierten Überproduktion von Calcitriol in Verbindung stehen , gegeben wird ( z. B. Leukämie , Lymphom , Sarkoidose ) .
T-326	Colecalciferol Vitamin D3 may increase the magnitude of hypercalcaemia and/ or hypercalciuria when administered to patients with disease associated with unregulated overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
H-326	-0.25122249126434326	Colecalciferol Vitamin D3 may increase the extent of hypercalcaemia and/ or hypercalciuria when administered in patients with disorders associated with uncontrolled overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
D-326	-0.25122249126434326	Colecalciferol Vitamin D3 may increase the extent of hypercalcaemia and/ or hypercalciuria when administered in patients with disorders associated with uncontrolled overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
P-326	-0.5662 -0.1128 -0.1949 -0.1234 -0.1814 -0.1558 -0.8365 -0.0668 -0.1478 -0.1416 -0.3291 -0.7394 -0.2688 -1.8479 -0.1706 -0.0393 -0.1009 -0.0420 -0.0201 -0.1665 -0.0468 -0.0765 -0.2648 -0.0261 -0.1450 -0.1628 -0.0723 -0.1532 -0.2930 -1.0297 -0.1033 -0.5539 -0.2543 -0.1743 -1.1026 -0.0577 -0.3576 -0.1474 -0.2277 -0.1788 -0.7531 -0.2161 -0.1384 -0.3183 -0.2074 -0.1187 -0.1746 -0.1520 -0.1217 -0.0885 -0.0602 -0.1243 -0.7918 -0.0101 -0.1429 -0.1394 -0.1210 -0.1099 -0.1456 -0.1024 -0.2434 -0.0957 -0.2103 -0.0904 -0.1457 -0.1736 -0.1563
S-1786	Sehr häufig : es sind mehr als 1 von 10 Patienten betroffen Häufig : betrifft zwischen 1 und 10 von 100 Patienten Gelegentlich : betrifft zwischen 1 und 10 von 1.000 Patienten Selten : betrifft zwischen 1 und 10 von 10.000 Patienten Sehr selten : betrifft weniger als 1 von 10.000 Patienten Nicht bekannt : ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-1786	Side effects may occur with certain frequencies , which are defined as follows : very common : affects more than 1 user in 10 common : affects 1 to 10 users in 100 uncommon : affects 1 to 10 users in 1,000 rare : affects 1 to 10 users in 10,000 very rare : affects less than 1 user in 10,000 not known : frequency cannot be estimated from the available data .
H-1786	-0.31097811460494995	Very common : more than 1 in 10 patients Common : affects between 1 and 10 in 100 Patients Uncommon : affects between 1 and 10 in 1,000 Patients Rare : affects between 1 and 10 in 10,000 Patients Very rare : affects less than 1 in 10,000 Patients Unknown : ( frequency cannot be estimated based on available data ) .
D-1786	-0.31097811460494995	Very common : more than 1 in 10 patients Common : affects between 1 and 10 in 100 Patients Uncommon : affects between 1 and 10 in 1,000 Patients Rare : affects between 1 and 10 in 10,000 Patients Very rare : affects less than 1 in 10,000 Patients Unknown : ( frequency cannot be estimated based on available data ) .
P-1786	-0.6290 -0.2085 -0.1494 -1.3864 -0.1128 -0.1719 -0.3354 -0.1260 -0.4978 -0.0998 -0.1059 -0.1525 -0.2687 -0.1133 -0.1501 -0.2091 -0.1445 -0.2216 -0.1302 -2.6662 -0.1227 -0.3572 -0.0682 -0.1507 -0.1781 -0.0903 -0.1390 -0.2841 -0.2012 -0.2173 -0.1752 -1.2276 -0.1049 -0.2987 -0.0895 -0.1480 -0.2364 -0.0920 -0.1421 -0.3919 -0.1359 -0.1673 -0.2814 -0.2857 -0.1177 -0.0724 -0.0411 -0.1499 -0.2672 -0.3711 -0.1241 -0.1496 -0.1566 -0.2752 -0.4732 -0.1052 -0.6960 -0.1160 -0.1846 -0.1597 -1.2510 -0.0776 -1.1110 -0.1620 -0.7504 -0.5469 -0.1583 -0.1918 -0.1289 -0.1435 -0.7859 -0.1591
S-294	Überempfindlichkeit gegen einen der arzneilich wirksamen Bestandteile oder der sonstigen Bestandteile . Erkrankungen des Ösophagus und andere Faktoren , welche die ösophageale Entleerung verzögern , wie Strikturen oder Achalasie . Unfähigkeit , für mindestens 30 Minuten aufrecht zu stehen oder zu sitzen . Hypocalcämie .
T-294	Inability to stand or sit upright for at least 30 minutes .
H-294	-0.32662275433540344	Hypersensitivity to any active substance or ingredients . Oesophagus disorders and other factors that delay oesophageal emptying , such as stricture or achalasia . Inability to stand or sit upright for at least 30 minutes . Hypocalcaemia .
D-294	-0.32662275433540344	Hypersensitivity to any active substance or ingredients . Oesophagus disorders and other factors that delay oesophageal emptying , such as stricture or achalasia . Inability to stand or sit upright for at least 30 minutes . Hypocalcaemia .
P-294	-0.1968 -0.0649 -0.0329 -0.0647 -0.1566 -0.3391 -0.5441 -0.6325 -0.1582 -0.4163 -0.3958 -0.2290 -0.0336 -0.6277 -0.1453 -0.1713 -0.4585 -0.0654 -0.1472 -0.1938 -0.1273 -1.1274 -0.3548 -1.2913 -0.0628 -0.2979 -0.0580 -0.0732 -0.1272 -1.1977 -0.0700 -0.2152 -0.3560 -0.4218 -0.1538 -1.2351 -0.6138 -0.2054 -0.0779 -0.1498 -1.3118 -0.1180 -0.1522 -1.4384 -0.4335 -0.1474 -0.5056 -0.4492 -0.2822 -0.6460 -0.0901 -0.0847 -0.1331 -0.1301 -0.1078 -0.1547 -0.1509 -0.1673 -1.0518 -0.0601 -0.0598 -0.0758 -0.0198 -0.1232 -0.2010 -0.1725
S-270	EU<unk> 1<unk> 06<unk> 364<unk> 001 2 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 002 4 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 003 6 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 004 12 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 005 40 Tabletten
T-270	EU/ 1/ 06/ 364/ 001 2 tablets EU/ 1/ 06/ 364/ 002 4 tablets EU/ 1/ 06/ 364/ 003 6 tablets EU/ 1/ 06/ 364/ 004 12 tablets EU/ 1/ 06/ 364/ 005 40 tablets
H-270	-0.29722917079925537	06/ 364/ 001 2 tablets EU/ 06/ 364/ 004 tablets EU/ 06/ 364/ 003 6 tablets EU/ 06/ 364/ 004 12 tablets EU/ 06/ 364/ 005 40 tablets
D-270	-0.29722917079925537	06/ 364/ 001 2 tablets EU/ 06/ 364/ 004 tablets EU/ 06/ 364/ 003 6 tablets EU/ 06/ 364/ 004 12 tablets EU/ 06/ 364/ 005 40 tablets
P-270	-2.1676 -0.1975 -0.4892 -0.1894 -0.1035 -0.1084 -0.8480 -0.1228 -0.1133 -0.0850 -0.3858 -0.1161 -1.1250 -0.1764 -0.1203 -0.1559 -0.0971 -0.0961 -2.1219 -0.1369 -0.1019 -0.1940 -0.1044 -0.7878 -0.1516 -0.1616 -0.1501 -0.0889 -0.1009 -0.3929 -0.1216 -0.0901 -0.0882 -0.1595 -0.0997 -0.7797 -0.5043 -0.0950 -0.1560 -0.0878 -0.0953 -0.1823 -0.1058 -0.1185 -0.0928 -0.2407 -0.0963 -0.8863 -0.5190 -0.1481 -0.1510 -0.0788 -0.1010 -0.3138 -0.2616 -0.1718 -0.1206 -0.1837
S-33	In der ersten Studie hatten 48 % ( 126 von 262 ) der Patienten , die Adenuric in einer Dosis von einmal täglich 80 mg einnahmen , und 65 % ( 175 von 269 ) der Patienten , die einmal täglich 120 mg einnahmen , bei den letzten drei Messungen einen Harnsäurespiegel im Blut von unter 6 mg<unk> dl .
T-33	In the first study , 48 % of the patients taking 80 mg Adenuric once a day ( 126 out of 262 ) and 65 % of the patients taking 120 mg once a day ( 175 out of 269 ) had levels of uric acid below 6 mg/ dl in the final three measurements .
H-33	-0.313869833946228	In the first trial , 48 % ( 126 out of 262 ) of those taking 80 mg once daily of adenuric and 65 % ( 175 out of 269 ) of those taking 120 mg once daily had uric acid levels below 6 mg/ dl in their blood on the last three measurements .
D-33	-0.313869833946228	In the first trial , 48 % ( 126 out of 262 ) of those taking 80 mg once daily of adenuric and 65 % ( 175 out of 269 ) of those taking 120 mg once daily had uric acid levels below 6 mg/ dl in their blood on the last three measurements .
P-33	-0.1604 -0.1508 -0.0866 -0.5369 -0.2391 -0.1063 -0.1257 -0.1512 -0.1556 -0.1374 -1.0153 -0.1248 -0.0622 -0.1526 -0.1323 -0.1232 -0.3971 -0.2997 -1.7464 -0.0558 -1.1548 -0.4032 -0.3864 -0.7534 -0.0669 -0.1374 -0.4947 -0.0963 -0.0814 -0.1424 -0.0580 -0.2270 -0.1224 -0.0576 -0.1112 -0.1308 -0.1217 -0.0395 -0.2947 -0.0484 -0.0424 -0.5808 -0.1308 -0.0575 -1.2053 -0.0824 -0.0733 -0.3214 -0.5160 -0.1499 -0.1772 -0.1364 -0.1565 -0.0694 -0.6475 -0.6611 -0.5649 -1.7391 -0.2312 -0.2843 -0.1448 -1.2353 -0.0920 -0.1901 -0.1863 -0.1519
2021-02-05 13:33:31 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-02-05 13:33:31 | INFO | fairseq_cli.generate | Translated 2001 sentences (60240 tokens) in 18.8s (106.25 sentences/s, 3198.70 tokens/s)
2021-02-05 13:33:31 | WARNING | root | That's 100 lines that end in a tokenized period ('.')
2021-02-05 13:33:31 | WARNING | root | It looks like you forgot to detokenize your test data, which may hurt your score.
2021-02-05 13:33:31 | WARNING | root | If you insist your data is detokenized, or don't care, you can suppress this message with '--force'.
Generate test with beam=5: BLEU = 38.99 72.7/50.5/36.8/27.4 (BP = 0.889 ratio = 0.895 hyp_len = 41352 ref_len = 46222)


###############################################################################
Peregrine Cluster
Job 17839176 for user 's3475743'
Finished at: Fri Feb  5 13:33:33 CET 2021

Job details:
============

Job ID              : 17839176
Name                : g_EMEA_p4_1
User                : s3475743
Partition           : gpu
Nodes               : pg-gpu39
Number of Nodes     : 1
Cores               : 12
State               : COMPLETED
Submit              : 2021-02-05T12:44:22
Start               : 2021-02-05T13:32:03
End                 : 2021-02-05T13:33:33
Reserved walltime   : 23:55:00
Used walltime       : 00:01:30
Used CPU time       : 00:00:54 (efficiency:  5.01%)
% User (Computation): 83.90%
% System (I/O)      : 16.10%
Mem reserved        : 32G/node
Max Mem used        : 2.27G (pg-gpu39)
Max Disk Write      : 40.96K (pg-gpu39)
Max Disk Read       : 2.30M (pg-gpu39)
Average GPU usage   : 47.5% (pg-gpu39)


Acknowledgements:
=================

Please see this page for information about acknowledging Peregrine in your publications:

https://wiki.hpc.rug.nl/peregrine/introduction/scientific_output

################################################################################
